(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 February 2009 (05.02.2009)

PCT

(10) International Publication Number
WO 2009/017838 A2

(51) International Patent Classification:
A61K 45/06 (2006.01) *A61P 35/02* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2008/009360

(22) International Filing Date: 31 July 2008 (31.07.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/962,776 1 August 2007 (01.08.2007) US

(71) Applicant *(for all designated States except US)*: **EXELIXIS, INC.** [US/US]; Post Office Box 511, 210 East Grand Avenue, South San Francisco, CA 94083-0511 (US).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: **LAMB, Peter** [US/US]; 814 Mandana Blvd, Oakland, California 94610 (US).

(74) Agents: **BERNSTEIN, Robert L.** et al.; EXELIXIS, Inc., 210 East Grand Avenue Post Office Box 511, South San Francisco, CA 94083-0511 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

WO 2009/017838 A2

(54) Title: COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS

(57) Abstract: A method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J) as described in the specification, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J) and a pharmaceutically acceptable carrier, in combination with an active agent selected from of a Raf inhibitor, an EGFR inhibitor, a VEGFR inhibitor, a ErbB2 inhibitor, a BCR-Abl, inhibitor, a Flt3 inhibitor, a Src inhibitor, a c Kit inhibitor, an Akt inhibitor, a Ret inhibitor, an IFG1R inhibitor, an m-Tor inhibitor, a PI3K inhibitior, a PI3Kalpha inhibitor, wherein the mammal is in need of the treatment.

COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS

BACKGROUND OF THE INVENTION

Field of the Invention

[0001] This invention relates to methods of using certain inhibitors JAK-2 in combination with other active agents for the treatment of diseases in mammals, especially humans.

State of the Art

[0002] Improvements in the specificity of agents used to treat cancer is of considerable interest because of the therapeutic benefits which would be realized if the side effects associated with the administration of these agents could be reduced. Traditionally, dramatic improvements in the treatment of cancer are associated with identification of therapeutic agents acting through novel mechanisms.

[0003] Protein kinases are enzymes that catalyze the phosphorylation of proteins, in particular, hydroxy groups on tyrosine, serine and threonine residues of proteins. The consequences of this seemingly simple activity are staggering; cell differentiation and proliferation; i.e., virtually all aspects of cell life in one-way or another depend on protein kinase activity. Furthermore, abnormal protein kinase activity has been related to a host of disorders, ranging from relatively non-life threatening diseases such as psoriasis to extremely virulent diseases such as glioblastoma (brain cancer).

[0004] Binding of growth factors and cytokines to their cell surface receptors results in activation of intracellular signaling pathways which control cell proliferation, survival and differentiation. Key components of these pathways are protein kinases, which phosphorylate tyrosine, serine or threonine residues and thereby modulate the activity of substrate proteins. One major signaling pathway which emanate from growth factor and cytokine receptors is the JAK/STAT pathway. Activation of members of the JAK family of cytoplasmic tyrosine kinases results in phosphorylation of members of the STAT family of inducible transcription factors. Phosphorylation of a key regulatory tyrosine residue in STAT proteins by JAKs results in their dimerization, translocation to the nucleus and binding to specific DNA sequences in the promoters and enhancers of regulated genes.

The DNA-bound STATs serve to promote the transcription of these genes, many of which are involved in the control of cellular growth.

[0005] The JAK/STAT pathway intersect at the levels of the STAT proteins. The STATs are substrates for ERK kinases and are phosphorylated by ERKs in their C-terminal transcriptional activation domain. Phosphorylation at this site is required for efficient transcriptional activation by STAT proteins.

[0006] Constitutive STAT activation is a feature of a wide variety of human tumors. In particular, activation of STAT5 is observed in leukemias, including CML, AML and ALL, whereas activation of STAT3 is a common feature of solid tumors including prostate carcinoma, non-small cell lung carcinoma and head and neck tumors. Reduction of STAT3 or STAT5 levels results in a reduction in tumor cell growth and in some case induction of tumor cell apoptosis in preclinical models. It is therefore desirable to develop strategies for pharmacologically inhibiting STAT activity in tumor cells as a method for treating cancers in combination with other active agents.

SUMMARY OF THE INVENTION

[0007] The following only summarizes certain aspects of the invention and is not intended to be limiting in nature. These aspects and other aspects and embodiments are described more fully below. All references cited in this specification are hereby incorporated by reference in their entirety. In the event of a discrepancy between the express disclosure of this specification and the references incorporated by reference, the express disclosure of this specification shall control.

[0008] This invention provides methods that inhibit, regulate and/or modulate the signal transduction of JAK-2 using any of the JAK-2 compounds described hereinbelow in combination with any of the other agents described herein. These methods are useful for treating various diseases as described herein.

[0009] There are many different aspects of the invention as described hereinbelow, and each aspect is non-limiting in regard to the scope of the invention. The term "invention" is meant to be non-limiting such that "invention" refers to an "aspect" or a "non-limiting embodiment" regardless of whether the terms "aspect" or "embodiment" appear in conjunction with the term "invention." The transitional term "comprising" as used herein, which is synonymous with "including," "containing," or "characterized by," is

inclusive or open-ended and does not exclude additional, unrecited elements or method steps.

DETAILED DESCRIPTION OF THE INVENTION

[0010] In aspect (1), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a PI3K inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the PI3K inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof. Non-limiting examples of the PI3K inhibitors in this embodiment include any one of more of the PI3K compounds described hereinbelow that inhibit PI3K, or the pharmaceutically acceptable salts thereof, wherein the mammal is in need of the treatment.

[0011] In aspects (1) – (29) of this invention, a pharmaceutical composition of any of the compounds or inhibitors in each of these aspects is meant to include the compound or inhibitor and a pharmaceutically acceptable carrier. For instance, a pharmaceutical composition of a PI3K inhibitor comprises the PI3K inhibitor and a pharmaceutically acceptable carrier.

[0012] In aspect (2), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a PI3Kα inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the PI3Kα inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof. Non-limiting examples of the PI3Kα inhibitors in this embodiment include any one or more of the

PI3Kα compounds described hereinbelow that inhbit PI3Kα, or the pharmaceutically acceptable salts thereof, wherein the mammal is in need of the treatment.

[0013] In aspect (3), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a Akt inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the Akt inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof. Non-limiting examples of the Akt inhibitors in this embodiment include any one or more of the Akt compounds described hereinbelow that inhibit Akt, or the pharmaceutically acceptable salts thereof, wherein the mammal is in need of the treatment.

[0014] In another aspect (4), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a VEGFR inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the VEGFR inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof. Non-limiting examples of the VEGFR inhibitors in this embodiment include any one or more of the VEGFR compounds described hereinbelow that inhibit VEGFR, or the pharmaceutically acceptable salts thereof, wherein the mammal is in need of the treatment.

[0015] In aspect (5), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or

VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a c-Met inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the c-Met inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof. Non-limiting examples of the c-Met inhibitors in this embodiment include any one or more of the c-Met compounds described hereinbelow that inhibit c-Met, or the pharmaceutically acceptable salts thereof, wherein the mammal is in need of the treatment.

[0016] In aspect (6), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, in combination with a therapeutically effective amount of a c-Kit inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the c-Kit inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof. Non-limiting examples of the c-Kit inhibitors in this embodiment include any one or more of the c-Kit compounds described hereinbelow that inhibibt c-Kit, or the pharmaceutically acceptable salts thereof, wherein the mammal is in need of the treatment.

[0017] In aspect (7), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a Src inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the Src inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof. Non-limiting examples of the Src inhibitors in this embodiment include any one or more of the Src compounds described hereinbelow that inhibit Src, or the pharmaceutically acceptable salts thereof, wherein the mammal is in need of the treatment.

[0018] In aspect (8), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a Flt3 inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the Flt3 inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof. Non-limiting examples of the Flt3 inhibitors in this embodiment include any one or more of the Flt3 compounds described hereinbelow that inhibit Flt3, or the pharmaceutically acceptable salts thereof, wherein the mammal is in need of the treatment.

[0019] In aspect (9), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a BCR-Abl inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the BCR-Abl inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof. Non-limiting examples of the BCR-Abl inhibitors in this embodiment include any one or more of the BCR-Abl compounds described hereinbelow that inhibit BCR-Abl, or the pharmaceutically acceptable salts thereof, wherein the mammal is in need of the treatment.

[0020] In aspect (10), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a ErbB2 inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the ErbB2 inhibitor as

described hereinbelow, or a pharmaceutically acceptable salt thereof. Non-limiting examples of the ErbB2 inhibitors in this embodiment include any one or more of the ErbB2 compounds described hereinbelow that inhibit ErbB2, or the pharmaceutically acceptable salts thereof, wherein the mammal is in need of the treatment.

[0021] In aspect (11), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a EGFR inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the EGFR inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof. Non-limiting examples of the EGFR inhibitors in this embodiment include any one or more of the EGFR compounds described hereinbelow that inhibit EGFR, or the pharmaceutically acceptable salts thereof, wherein the mammal is in need of the treatment.

[0022] In aspect (12), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a raf inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the raf inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof. Non-limiting examples of the raf inhibitors in this embodiment include any one or more of the raf compounds described hereinbelow that inhibit raf, or the pharmaceutically acceptable salts thereof, wherein the mammal is in need of the treatment.

[0023] In aspect (13), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically

effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a mTor inhibitor, such as the rapamycins, or a pharmaceutically acceptable salt thereof (including pharmaceutical compositions thereof), wherein the mammal is in need of the treatment.

[0024] In aspect (14), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a Ret inhibitor as described herein below, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the Ret inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof. Non-limiting examples of the Ret inhibitors in this embodiment include any one or more of the Ret compounds described hereinbelow that inhibit Ret, or the pharmaceutically acceptable salts thereof, wherein the mammal is in need of the treatment.

[0025] In aspect (15), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a IGF1R inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the IGF1R inhibitor as described hereinbelow, or a pharmaceutically acceptable salt thereof. Non-limiting examples of the IGF1R inhibitors in this embodiment include any one or more of the IGF1R compounds described hereinbelow that inhibit IGF1R, or the pharmaceutically acceptable salts thereof, wherein the mammal is in need of the treatment.

[0026] In aspect (16), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically

acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a PI3K compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the PI3K compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, wherein the mammal is in need of the treatment.

[0027] In aspect (17), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a PI3Kα compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the PI3Kα compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, wherein the mammal is in need of the treatment.

[0028] In aspect (18), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a Akt compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the Akt compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, wherein the mammal is in need of the treatment.

[0029] In another aspect (19), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J),

IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a VEGFR compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the VEGFR compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, wherein the mammal is in need of the treatment.

[0030] In aspect (20), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a c-Met compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the c-Met compound as described hereinbelow, or a pharmaceutically acceptable salt thereof. Non-limiting examples of the c-Met inhibitors in this embodiment include any one or more of the c-Met compounds described hereinbelow that inhibit c-Met, or the pharmaceutically acceptable salts thereof, wherein the mammal is in need of the treatment.

[0031] In aspect (21), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, in combination with a therapeutically effective amount of a c-Kit compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the c-Kit compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, wherein the mammal is in need of the treatment.

[0032] In aspect (22), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or

VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a Src compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the Src compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, wherein the mammal is in need of the treatment.

[0033] In aspect (23), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a Flt3 compound described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the Flt3 compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, wherein the mammal is in need of the treatment.

[0034] In aspect (24), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a BCR-Abl compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the BCR-Abl compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, wherein the mammal is in need of the treatment.

[0035] In aspect (25), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a ErbB2 compound as described hereinbelow, or a pharmaceutically

acceptable salt thereof, or a pharmaceutical composition of the ErbB2 compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, wherein the mammal is in need of the treatment.

[0036] In aspect (26), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a EGFR compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the EGFR compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, wherein the mammal is in need of the treatment.

[0037] In aspect (27), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a raf compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the raf compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, wherein the mammal is in need of the treatment.

[0038] In aspect (28), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a Ret compound as described herein below, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the Ret compound as described

hereinbelow, or a pharmaceutically acceptable salt thereof, wherein the mammal is in need of the treatment.

[0039] In aspect (29), the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a IGF1R compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the IGF1R compound as described hereinbelow, or a pharmaceutically acceptable salt thereof, wherein the mammal is in need of the treatment.

[0040] In other embodiments for any of the aspects described above [including any of aspects (1)-(35)], the diseases that can be treated in mammals are selected from myeloproliferative disorder, cancer, cardiovascular disease, and/or hematopoitic abnormality wherein the mammal is in need of the treatment. In other embodiments for any of the aspects described above [including any of aspects (1)-(35)], the diseases that can be treated in mammals are selected from cancer, such as prostate cancer, breast cancer, multiple myeloma, leukemia, lymphoma, lung cancer, colorectal cancer, renal cancer, melanoma, hepatocellular, gastric, GIST, pancreatic carcinoma, and papillary thyroid cancer. In other embodiments for any of the aspects described above [including any of aspects (1)-(35)], the diseases that can be treated are selected from myelofibrosis, thrombocythemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia. In other embodiments for any of the aspects described above, the diseases that can be treated are selected from cancers selected from leukemias, lymphomas, multiple myeoloma, prostate cancers, lung cancers, breast cancers, and ovarian cancers. In other embodiments for any of the aspects described above [including any of aspects (1)-(35)], the diseases that are treated are selected from congestive heart failure and hypertension. In other embodiments for any of the aspects described above [including any of aspects (1)-(35)], the diseases that can be treated include those related to hematopoitic abnormality such as thrombocytosis.

[0041] In other embodiments in any of the aspects described herein [including any of aspects (1)-(35)] , the disease being treated is selected from prostate cancer, breast cancer, multiple myeloma, leukemia, lymphoma, lung cancer, colorectal cancer, renal cancer, melanoma, hepatocellular, gastric, GIST, pancreatic carcinoma, papillary thyroid cancer, myelofibrosis, thrombocythemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, chronic myelogenous leukemia, and thrombocytosis.

JAK-2 COMPOUNDS

[0042] The JAK-2 compounds regulate and/or modulate the signal transduction of JAK-2 aminopyrimidine derivatives. The JAK-2 compounds described below are non-limiting examples of "JAK-2 inhibitors". All of the substituents for the JAK-2 compounds described below are defined separately from any of the other active agents so that every substituent in the JAK-2 compounds that also appears in any of the other active agents has a separate and distinct meaning. For instance, R^1 for the JAK-2 compounds has a separate and distinct meaning from R^1 that appears in any of the other active agents. All of the following JAK-2 compounds are intended to alternatively include the pharmaceutically acceptable salts of these compounds whether it is explicitely stated or not. The JAK-2 compounds that fall within the scope of any of aspects (1)-(15) of the invention (described above) are the following compounds:

[0043] The JAK-2 compound is a compound of Formula I(J):



I(J)

or a pharmaceutically acceptable salt thereof, wherein

D is hydrogen, halo, $-CF_3$, heterocycloalkyl or alkyl;

E is hydrogen, halo, $-CF_3$, heterocycloalkyl or alkyl; or

D and E, together with the carbon atoms to which they are attached, form a 5-7 membered heteroaryl or a 5-7 membered heterocycloalkyl, wherein the 5-7

membered heteroaryl or 5-7 membered heterocycloalkyl are each fused to the pyrimidinyl moiety to which D and E are attached;

L is a bond, -O- or -N(H)-;

Z is selected from alkoxy, cycloalkyl, heteroaryl optionally substituted with alkyl, halo, $-C(O)OR^{26}$, -C(=N-OH)alkyl, $-C(O)R^{8}$, $-C(O)NR^{30}R^{30a}$, $-CH_2R^{2}$, $-(CH_2)_{n5}NR^{26}R^{26a}$, $-CF_3$, -CN, $-SO_2R^{12}$, $-S-R^{12a}$, $-OR^{32a}$, $-NHC(O)R^{32}$, aryl, and heterocycloalkyl optionally substituted with 1 or 2 oxo, or

Z and R^{25}, together with the carbon atoms to which they are attached, join to form a 5 or 6 membered heterocycloalkyl, a 5 or 6 membered heteroaryl, or a 5 or 6 membered cycloalkyl ring, wherein the 5 or 6 membered heterocycloalkyl, 5 or 6 membered heteroaryl, or 5 or 6 membered cycloalkyl ring are fused to the phenyl moiety to which Z and R^{25} are attached, and wherein the 5 or 6 membered heterocycloalkyl, 5 or 6 membered heteroaryl, or 5 or 6 membered cycloalkyl ring are each optionally substituted with 1, 2, or 3 groups independently selected from oxo, alkyl, alkoxy and halo;

n1 is 0, 1, 2, 3, or 4, and each n1 is independently selected when more than one n1 is present;

n2 is 0, 1, 2, 3, or 4, and each n2 is independently selected when more than one n2 is present;

n3 is 0, 1, 2, or 3, and each n3 is independently selected when more than one n3 is present;

n4 is 0, 1, 2, 3 or 4, and each n4 is independently selected when more than one n4 is present;

n5 is 0, 1, 2, 3 or 4, and each n5 is independently selected when more than one n5 is present;

p is 0-3;

r is 1-3;

R^1 is hydrogen;

R^2 is selected from one of the following groups:


(a)


(b)


(c-1)


(c-2)


(d)


(e)


(f)


(g)


(h)


(i)


(j)


(k)


(l)


(m)


(n)


(o)


(p)


(q)

or


(r)

;

or R^2 is selected from one of the following groups:



ring X in Formula (d) of R^2 is a 5 or 6 membered unsaturated heterocyclic ring fused to the two carbon atoms of the phenyl moiety to which ring X is attached, wherein ring X contains 1 or 2 nitrogen atoms;

R^7, $R^{7'}$, R^9, R^{10}, R^{12} and R^{15} are each independently hydrogen, alkyl, alkoxy, or alkoxyalkyl;

R^8 is selected from hydrogen, hydroxy, alkyl, alkenyl, lower alkynyl, hydroxyamino, hydroxyalkyl, alkoxyalkyl, dihydroxyalkyl, alkylamino, dialkylamino, aminoalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, alkylaminoalkyl, dialkylaminoalkyl, $-(CH_2)_r-C(O)OR^7$, $-(CH_2)_r-C(O)NR^7R^{7'}$, aryl, heteroaryl, cycloalkyl, arylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, heteroaryl, cycloalkyl, arylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently optionally substituted at the ring position with one, two, three, four or five groups independently selected from alkyl, alkenyl, lower alkynyl, halo, hydroxy, haloalkyl, haloalkoxy, lower alkoxy, amino, aryl, alkylamino, dialkylamino, heterocyclylalkoxy, oxo and haloalkyl;

each R^{11}, when R^{11} is present, is independently selected from alkyl, alkenyl, lower alkynyl, $-CF_3$, alkoxy, halo, haloalkoxy, haloalkyl, aminoalkyl, aminoalkoxy, alkylaminoalkyl, alkylaminoalkoxy, dialkylaminoalkyl, dialkylaminoalkoxy, oxo, thioalkyl, alkylthioalkyl, $-(CH_2)_p-OR^{17}$, -CN, $-O-CH_2-C(O)-R^{17}$, $-C(O)R^{16}$, $-(CH_2)_p-C(O)OR^{17}$, $-S(O)_2R^{17}$, $-S(O)_2NR^{15}R^{17}$, aryl, heteroaryl, cycloalkyl,

arylalkyl, arylalkoxy, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, heteroaryl, cycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently optionally substituted at any ring position with 1, 2, 3 or 4 R^{21};

R^{12} is hydrogen or alkyl;

R^{12a} is hydrogen or alkyl;

R^{13} is selected from hydrogen, hydroxy, alkyl, alkenyl, lower alkynyl, hydroxyamino, haloalkyl, alkyl substituted with halo and hydroxy, hydroxyalkyl, alkoxyalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, $-(CH_2)_r-C(O)OR^7$, $-(CH_2)_r-C(O)NR^7R^{7'}$, aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently optionally substituted at the ring position with 1, 2, 3, 4 or 5 groups independently selected from alkyl, alkenyl, lower alkynyl, halo, hydroxy, hydroxyalkyl, alkoxycarbonyl, alkylcarbonyl, haloalkyl, haloalkoxy, lower alkoxy, amino, aryl, alkylamino, dialkylamino, heterocyclylalkoxy, oxo and haloalkyl; and wherein the alkyl of cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl are independently optionally substituted with 1, 2, 3, 4, or 5 groups selected from halo and hydroxy;

R^{14} is a bond, heterocycloalkyl or cycloalkyl;

R^{16} is selected from hydrogen, hydroxy, alkyl, alkenyl, lower alkynyl, hydroxyamino, haloalkyl, alkyl substituted with halo and hydroxy, hydroxyalkyl, alkoxyalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, dialkylaminoalkyl, $-(CH_2)_r-C(O)OR^7$, aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently optionally substituted at the ring position with one, two, three, four or five groups independently selected from

alkyl, alkenyl, lower alkynyl, halo, hydroxy, hydroxyalkyl, alkoxycarbonyl, alkylcarbonyl, haloalkyl, haloalkoxy, lower alkoxy, amino, aryl, alkylamino, dialkylamino, heterocyclylalkoxy, oxo and haloalkyl; and wherein the alkyl of cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl is optionally substituted with 1, 2, 3, 4, or 5 groups selected from halo and hydroxy;

R^{17} is selected from hydrogen, hydroxy, alkyl, alkenyl, lower alkynyl, hydroxyamino, haloalkyl, alkyl substituted with halo and hydroxy, hydroxyalkyl, alkoxyalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, dialkylaminoalkyl, $-(CH_2)_r-C(O)OR^7$, $-(CH_2)_r-C(O)NR^7R^{7'}$, aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently optionally substituted at the ring position with one, two, three, four or five groups independently selected from alkyl, alkenyl, lower alkynyl, halo, hydroxy, hydroxyalkyl, alkoxycarbonyl, alkylcarbonyl, haloalkyl, haloalkoxy, lower alkoxy, amino, aryl, alkylamino, dialkylamino, heterocyclylalkoxy, oxo and haloalkyl; and wherein the alkyl of cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl is optionally substituted with 1, 2, 3, 4, or 5 groups selected from halo and hydroxy;

each R^{21}, when R^{21} is present, is independently selected from alkyl, alkenyl, lower alkynyl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, amino, alkylamino, dialkylamino, dialkylaminoalkyl, dialkylaminoalkyloxy, haloalkyl, oxo, $-OR^{13}$, $-NHS(O)_2R^{17}$, $-S(O)_2R^{17}$, $-C(O)R^{17}$, $-C(O)OR^{17}$, $-C(O)NR^{15}R^{17}$, $-NR^{15}C(O)R^{17}$, aryl, arylalkyl, heteroarylalkyl, aryloxy, and heteroaryl; wherein each of the aryl, arylalkyl, heteroarylalkyl, aryloxy, and heteroaryl within R^{21} are optionally substituted at any ring position with 1, 2, or 3 groups selected from alkyl, lower alkoxy halo, phenyl, heteroaryl and alkylheteroalkyl;

R^{25} is selected from alkyl, alkenyl, lower alkyl, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, $-OR^{12}$, cyano, $-CH_2NHC(O)OR^7$, $-CH_2NHC(O)R^7$, $-SR^7$, $-S(O)_2R^7$, $-S(O)_2NR^7R^8$, $-C(O)OR^8$,

-C(O)NR^{7}R^8, cycloalkyl, heterocycloalkyl, aryl and heteroaryl; wherein the cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optionally substituted with one, two or three groups independently selected from alkyl, alkenyl, halo, haloalkoxy, haloalkyl, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, -OR^8, -NHS(O)$_2$R^8, cyano, -C(O)R^8, -CH$_2$NHC(O)OR^7, -CH$_2$NHC(O)R^7, -SR^7, -S(O)$_2$R^7, -S(O)$_2$NR^{7}R^8, -C(O)OR^8, -C(O)NR^{7}R^8, -NR$^{7'}$C(O)-CHR^3-OR^8, -NR$^{7'}$C(O)-CHR^3-NR^7-R^8, and -NR^{7}C(O)R^8;

R^{26} is hydrogen, -C(O)-phenyl or alkyl, wherein the -C(O)-phenyl is optionally substituted at any ring position with 1, 2 or 3 halo;

R^{26a} is hydrogen, alkyl, heteroaryl, -C(O)R^{32}, -C(O)NHR^{32a}, -S(O)$_2$R^9, -SR^9, -C(O)OR^{32}, or -C(O)NR^{32a}R^{32};

R^{27} and R^{28} are each independently selected from alkyl, alkenyl, hydroxy, alkoxy, and alkoxyalkyl;

R^{27a} and R^{28a} are independently selected from hydrogen, alkyl, alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, dialkylaminoalkyl, arylcarbonylalkyl, aryloxyalkyl, dialkylaminoalkyl, alkyl-O-C(O)heterocylcoalkyl, -(CH$_2$)$_{n4}$heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, -(CH$_2$)$_{n4}$-C(O)R^{29}, -(CH$_2$)$_{n4}$NR^{28}R^{28a}, -(CH$_2$)$_{n4}$NHR^{28a}, -CH(phenyl)$_2$, -S(O)$_2$R^{29}, -C(O)R^{29}, -C(O)OR^{29}, and -C(O)NR^{29a}R^{29}, wherein the aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl groups within R^{27a} and R^{28a} are each independently optionally substituted at any ring position with 1, 2, 3, 4, or 5 groups selected from halo, alkyl, alkoxy, alkylcarbonyl, phenyl, phenoxy, arylcarbonyl, -CF$_3$, oxo, -OCF$_3$, alkoxyphenyl, and heteroaryl optionally substituted with alkyl or halo;

or R^{27} and R^{27a}, together with the nitrogen to which they are attached, form heterocycloalkylamino, heterocycloalkyl or heteroaryl, wherein the heterocycloalkylamino and heteroaryl are each independently optionally substituted with 1, 2, 3, 4, or 5 R^{31};

or R^{28} and R^{28a} together with the nitrogen to which they are attached form heterocycloalkyl or heteroaryl, wherein the heterocycloalkyl and heteroaryl are each optionally substituted with 1, 2, 3, 4, or 5 R^{31};

R^{29a} is hydrogen or alkyl;

R^{29} is selected from alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl groups within R^{29} are each optionally substituted at any ring position with 1, 2, 3, 4, or 5 groups selected from halo, alkyl, alkoxy, alkylcarbonyl, phenyl, phenoxy, arylcarbonyl, $-CF_3$, oxo, $-OCF_3$, alkoxyphenyl, and heteroaryl optionally substituted with alkyl or halo;

R^{30a} is hydrogen or alkyl;

R^{30} is selected from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkoxycarbonylalkyl, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aryl, arylalkyl, phenoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, arylheteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, arylalkyl, phenoxyalkyl, cycloalkyl, arylheteroarylalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl groups within R^{30} are each independently optionally substituted at any ring position with 1, 2, 3, 4, or 5 groups selected from halo, alkyl, alkoxy, alkoxyalkyl, $-C(O)OCH_3$, $-CF_3$, $-OCF_3$, alkylcarbonyl, phenyl, phenoxy, alkylphenoxy, dialkylaminoalkoxy and heteroaryl;

R^{31} is selected from alkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, alkylthioalkyl, $-C(O)R^{30}$, $-C(O)NR^{30}R^{30a}$, $-C(O)OR^{30}$, $-S(O)_2R^{30}$, amino, dihydroxyalkyl, arylcarbonyl, alkylcarbonylamino, alkoxyphenyl, phenylalkoxyalkyl, arylheteroarylalkyl, alkylamino, -O-dialkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, dialkylaminoalkoxy, oxo, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, spirocyclic cycloalkyl, spirocyclic heterocycloalkyl, and heterocycloalkylalkyl, wherein the aryl, arylalkyl, cycloalkyl, arylheteroarylalkyl, arylalkoxyalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl groups within R^{31} are each independently optionally substituted at any ring position with 1, 2, 3, 4, or 5 groups selected from halo, alkyl, $-CF_3$, $-OCF_3$, cyano, alkoxy,

alkoxyalkyl, -C(O)OCH_3, alkylcarbonyl, phenyl optionally substituted at any ring position with halo, phenoxy, alkylphenoxy, arylalkoxyalkyl, dialkylaminoalkoxy and heteroaryl;

R^{32a} is hydrogen, -OCF_3, -CF_3, or alkyl;

R^{32} is selected from aryl, arylalkyl, arylalkoxy, arylcycloalkyl, alkoxycarbonylalkoxy, cycloalkyl, cycloalkylalkyl, cycloalkylhydroxyalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl, wherein the aryl, arylalkyl, cycloalkyl, arylcycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently optionally substituted at any ring position with 1, 2, 3, 4, or 5 groups selected from hydroxy, oxo, alkyl, alkoxy, amino, hydroxyalkyl, alkylcarbonyl, alkoxycarbonyl, halo, -CF_3, -OCF_3, aminoalkyl, alkylaminoalkyl, aryl and dialkylaminoalkyl, and wherein the alkyl portion of the heteroarylalkyl can be substituted with amino;

or R^{32} is alkyl optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from hydroxy, alkoxycarbonyl, alkoxy, -CF_3, halo, aminocarbonyl, alkylaminocarbonyl, alkoxycarbonylalkylamino, dialkylaminocarbonyl, -$NR^{34}R^{34a}$ and phenyl optionally substituted with 1, 2, or 3 halo;

or R^{32} is alkylamino or arylalkylamino;

R^{34} is hydrogen or alkyl;

R^{34a} is selected from hydrogen, alkyl, heteroaryl, aryl, aminoalkyl, aminocarbonylalkyl, heteroarylalkyl, arylalkoxy and arylalkyloxycarbonylalkyl; wherein the heteroaryl, aryl, heteroarylalkyl, arylalkoxy or arylalkyloxycarbonylalkyl are each independently optionally substituted at any ring position with 1, 2, 3, 4, or 5 groups selected from hydroxy, oxo, alkyl, amino, hydroxyalkyl, alkylcarbonyl, alkoxycarbonyl, halo, aminoalkyl, alkylaminoalkyl, and dialkylaminoalkyl; and

R^{35} is selected from halo, -$(CH_2)_pC(O)OR_{17}$, cycloalkyl, heterocycloalkyl, and heterocycloalklylalkyl; wherein the heterocycloalkyl and heterocycloalklylalkyl are each optionally substituted with 1, 2, 3, 4, or 5 groups each independently selected from alkyl, alkoxy, and halo.

Abbreviations and Definitions

[0044] The following abbreviations and terms have the indicated meanings throughout:

Abbreviation	Meaning
Ac	Acetyl
Br	Broad
°C	degrees Celsius
CBZ	CarboBenZoxy = benzyloxycarbonyl
D	Doublet
Dd	doublet of doublet
Dt	doublet of triplet
DAST	(diethylamino)sulfur trifluoride
DCM	Dichloromethane
DIPEA	*N,N*-diisopropylethylamine
DMAP	4-dimethylaminopyridine
DMF	*N,N*-dimethylformamide
DMSO	dimethyl sulfoxide
DPPA	Diphenylphosphoryl azide
EDCI	1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
EI	Electron Impact ionization
Et	Ethyl
G	gram(s)
GC	gas chromatography
H or hr	hour(s)
HBTU	2-(1*H*-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
HOAc	acetic acid
HOBt	Hydroxybenzotriazole
HPLC	high pressure liquid chromatography
L	liter(s)
LDA	lithium diiospropylamide
LHMDS	lithium hexamethyldisilazide
M	molar or molarity
M	Multiplet
MCPBA	meta-chloroperbenzoic acid
Me	Methyl
Mg	milligram(s)
MHz	megahertz (frequency)
Min	minute(s)
mL	milliliter(s)
mM	Millimolar
Mmol	millimole(s)
Mol	mole(s)
MS	mass spectral analysis
N	normal or normality

Abbreviation	Meaning
nM	Nanomolar
NMM	*N*-methylmorpholine
NMR	nuclear magnetic resonance spectroscopy
PyBOP	benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate
Q	Quartet
RT	room temperature
S	Singlet
s-	Secondary
t-	Tertiary
T or tr	Triplet
THF	Tetrahydrofuran
μL	microliter(s)
μM	micromole(s) or micromolar

[0045] The compounds of the invention and their pharmaceutically acceptable salts may exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. The compounds may also exist as geometric isomers. All such single stereoisomers, racemates and mixtures thereof, and geometric isomers are intended to be within the scope of this invention.

[0046] It is assumed that when considering generic descriptions of compounds of the invention for the purpose of constructing a compound, such construction results in the creation of a stable structure. That is, one of ordinary skill in the art would recognize that there can theoretically be some constructs which would not normally be considered as stable compounds (that is, sterically practical and/or synthetically feasible, *supra*).

[0047] The atom numbering convention for the quinazoline structure is as follows:



[0048] The symbol "-" means a single bond, "=" means a double bond, "≡" means a triple bond. The symbol "〰" refers to a group on a double-bond as occupying either position on the terminus of a double bond to which the symbol is attached; that is, the geometry, *E*- or *Z*-, of the double bond is ambiguous. When a group is depicted removed from its parent Formula, the "〜" symbol will be used at the end of the bond which was theoretically cleaved in order to separate the group from its parent structural Formula.

[0049] If a group "R" is depicted as "floating" on a ring system, as for example in the Formula:



then, unless otherwise defined, a substituent "R" may reside on any atom of the ring system, assuming replacement of a depicted, implied, or expressly defined hydrogen from one of the ring atoms, so long as a stable structure is formed.

[0050] If a group "R" is depicted as floating on a fused ring system, as for example in the Formulae:



then, unless otherwise defined, a substituent "R" may reside on any atom of the fused ring system, assuming replacement of a depicted (for example the -NH- in the Formula above), implied (for example as in the Formula above, where the hydrogens are not shown but understood to be present), or expressly defined hydrogen (for example where in the Formula above, "X" equals -CH-) from one of the ring atoms, so long as a stable structure is formed. In the example depicted, the "R" group may reside on either the 5-membered or the 6-membered ring of the fused ring system. In the Formula depicted above, when y is 2 for example, then the two "R's" may reside on any two atoms of the ring system, again assuming each replaces a depicted, implied, or expressly defined hydrogen on the ring.

[0051] When there are more than one such depicted "floating" groups, as for example in the Formulae:



where there are two groups, namely, the "R" and the bond indicating attachment to a parent structure; then, unless otherwise defined, the "floating" groups may reside on any atoms of the ring system, again assuming each replaces a depicted, implied, or expressly defined hydrogen on the ring.

[0052] When a group "R" is depicted as existing on a ring system containing saturated carbons, as for example in the Formula:



where, in this example, "y" can be more than one, assuming each replaces a currently depicted, implied, or expressly defined hydrogen on the ring; then, unless otherwise defined, where the resulting structure is stable, two "R's" may reside on the same carbon. A simple example is when R is a methyl group; there can exist a geminal dimethyl on a carbon of the depicted ring (an "annular" carbon). In another example, two R's on the same carbon, including that carbon, may form a ring, thus creating a spirocyclic ring (a "spirocyclyl" group) structure with the depicted ring as for example in the Formula:



[0053] "Spiro", "Spirocyclyl" or "spiro ring" refers to a ring originating from a particular annular carbon of another ring. For example, as depicted below, a ring atom of a saturated bridged ring system (rings B and B'), but not a bridgehead atom, can be a shared atom between the saturated bridged ring system and a spirocyclyl (ring A) attached thereto.



[0054] "Yield" for each of the reactions described herein is expressed as a percentage of the theoretical yield.

[0055] "Patient" for the purposes of the present invention includes humans and other animals, particularly mammals, and other organisms. Thus the methods are applicable to both human therapy and veterinary applications. In a specific embodiment the patient is a mammal, and in a more specific embodiment the patient is human.

[0056] "Therapeutically effective amount" is an amount of a compound of the invention, that when administered to a patient, ameliorates a symptom of the disease. The amount of a compound of the invention which constitutes a "therapeutically effective amount" will vary depending on the compound, the disease state and its severity, the age

of the patient to be treated, and the like. The therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to their knowledge and to this disclosure.

[0057] "Cancer" refers to cellular-proliferative disease states, including but not limited to: Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hanlartoma, inesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinorna, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinorna, lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis defornians), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastorna multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified

carcinoma], granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma], fallopian tubes (carcinoma); Hematologic: blood (myeloid leukemia [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma [malignant lymphoma]; Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; and Adrenal Glands: neuroblastoma. Thus, the term "cancerous cell" as provided herein, includes a cell afflicted by any one of the above-identified conditions.

[0058] A "pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in *Remington's Pharmaceutical Sciences*, 17th ed., Mack Publishing Company, Easton, PA, 1985, which is incorporated herein by reference or S. M. Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977;66:1-19 both of which are incorporated herein by reference.

[0059] Examples of pharmaceutically acceptable acid addition salts include those formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; as well as organic acids such as acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, 3-(4-hydroxybenzoyl)benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid,

lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, p-toluenesulfonic acid, and salicylic acid and the like.

[0060] Examples of a pharmaceutically acceptable base addition salts include those formed when an acidic proton present in the parent compound is replaced by a metal ion, such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferable salts are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins. Examples of organic bases include isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, tromethamine, *N*-methylglucamine, polyamine resins, and the like. Exemplary organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.

[0061] "Prodrug" refers to compounds that are transformed (typically rapidly) *in vivo* to yield the parent compound of the above Formulae, for example, by hydrolysis in blood. Common examples include, but are not limited to, ester and amide forms of a compound having an active form bearing a carboxylic acid moiety. Examples of pharmaceutically acceptable esters of the compounds of this invention include, but are not limited to, alkyl esters (for example with between about one and about six carbons) the alkyl group is a straight or branched chain. Acceptable esters also include cycloalkyl esters and arylalkyl esters such as, but not limited to benzyl. Examples of pharmaceutically acceptable amides of the compounds of this invention include, but are not limited to, primary amides, and secondary and tertiary alkyl amides (for example with between about one and about six carbons). Amides and esters of the compounds of the present invention may be prepared according to conventional methods. A thorough discussion of prodrugs is provided in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche,

American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference for all purposes.

[0062] "Metabolite" refers to the break-down or end product of a compound or its salt produced by metabolism or biotransformation in the animal or human body; for example, biotransformation to a more polar molecule such as by oxidation, reduction, or hydrolysis, or to a conjugate (see Goodman and Gilman, "The Pharmacological Basis of Therapeutics" 8.sup.th Ed., Pergamon Press, Gilman et al. (eds), 1990 for a discussion of biotransformation). As used herein, the metabolite of a compound of the invention or its salt may be the biologically active form of the compound in the body. In one example, a prodrug may be used such that the biologically active form, a metabolite, is released *in vivo*. In another example, a biologically active metabolite is discovered serendipitously, that is, no prodrug design *per se* was undertaken. An assay for activity of a metabolite of a compound of the present invention is known to one of skill in the art in light of the present disclosure.

[0063] "Treating" or "treatment" of a disease, disorder, or syndrome, as used herein, includes (i) preventing the disease, disorder, or syndrome from occurring in a human, i.e., causing the clinical symptoms of the disease, disorder, or syndrome not to develop in an animal that may be exposed to or predisposed to the disease, disorder, or syndrome but does not yet experience or display symptoms of the disease, disorder, or syndrome; (ii) inhibiting the disease, disorder, or syndrome, *i.e.*, arresting its development; and (iii) relieving the disease, disorder, or syndrome, *i.e.*, causing regression of the disease, disorder, or syndrome. As is known in the art, adjustments for systemic versus localized delivery, age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by one of ordinary skill in the art.

[0064] "Mammal" is intended to mean any various warm-blooded vertebrate animals of the class Mammalia, including humans, dogs, cats, and the like, characterized by a covering of hair on the skin and, in the female, milk-producing mammary glands for nourishing the young.

[0065] "JAK-2 inhibitors" are intended to include all JAK-2 inhibitors including the JAK-2 compounds of Formula I(J), II(J), III(J), IV(J), V(J) and VI(J) defined hereinbelow.

JAK-2 inhibitors, including the JAK-2 compounds, include pharmaceutically acceptable salts or solvates throughout this application whether it is explicitly stated or not.

[0066] In one specific embodiment of the JAK compound of Formula I(J) is a compound of Formula II(J):



II(J)

wherein E, D, L, Z, R^1, R^2 and R^{25} are as defined above for the compound of Formula I(J).

[0067] In another specific embodiment of the the JAK compound of Formula I(J) is a compound of Formula III(J):



III(J)

wherein E, D, L, Z, R^1, R^2 and R^{25} are as defined above for the compound of Formula I(J).

[0068] Another specific embodiment of the JAK compound of Formula I is a compound of Formula IV(J):



IV(J)

wherein D, E, R^{25} and R^{32} are as defined above for Formula I, and R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the

heterocycloalkyl is optionally substituted with one or two R^{31}, and wherein R^{31} is as defined above in Formula I(J).

[0069] Another specific embodiment of the JAK-2 compound of Formula I is a compound of Formula V(J):



wherein D, E, R^{25} and R^{32} are as defined above for Formula I, and R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}, and wherein R^{31} is as defined above in Formula I(J).

[0070] Another specific embodiment of the JAK compound of Formula I(J) is a compound of Formula VI(J):



wherein D, E, R^{25} and R^{32} are as defined above for Formula I, and R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}, and wherein R^{31} is as defined above in Formula I(J).

[0071] In other embodiments of the JAK-2 compound, D, E and R^{25} for Formula IV(J), Formula V(J) or Formula VI(J) are each hydrogen.

[0072] In other embodiments of the JAK-2 compound, R^{32} for Formula IV(J), Formula V(J) or Formula VI(J) is heterocycloalkyl.

[0073] In other embodiments of the JAK-2 compound, R^{32} for Formula IV(J), Formula V(J) or Formula VI(J) is alkyl optionally substituted with alkoxy, hydroxy, amino, alkylamino, or dialkylamino.

[0074] In other embodiments of the JAK-2 compound, R^2 in Formula I(J), II(J) or III(J) is



(f)

wherein R^{27a}, R^{11} and n2 are as defined above for the compound of Formula I(J).

[0075] In other embodiments of the JAK-2 compound, R^2 in Formula I(J), II(J) or III(J) is



wherein R^{28}, R^{11} and n2 are as defined above for the compound of Formula I(J), and R^{28a} is arylalkyl or heteroarylalkyl, wherein the arylalkyl or heteroarylalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halo or lower alkyl.

[0076] In other embodiments of the JAK compound, R^2 in Formula I(J), II(J) or III(J) is



(a) or (b),

wherein R^{28}, R^{28a}, R^{11} and n2 are as defined above for the compound of Formula I(J).

[0077] In the embodiments of the JAK-2 compound, R^2 in Formula I(J), II(J) or III(J) is



(a) or (b),

wherein R^{28}, R^{11} and n2 are as defined above for the compound of Formula I(J), and R^{28a} is selected from lower alkyl, dialkylaminoalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, and hetercycloalkylalkyl.

[0078] In other embodiments of the JAK-2 compound, R^2 in Formula I(J), II(J) or III(J) is



,

wherein R^{11} and n2 are as defined above for the compound of Formula I(J), and R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, join together to form a ring structure selected from thiazolidinyl, piperazinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyrimidinyl, and pyridinyl, wherein the ring structure is optionally substituted with 1, 2, 3, 4 or 5 subsituents selected from halo, lower alkyl or alkoxy.

[0079] In other embodiments of the JAK-2 compound, R^2 in Formula I(J), II(J) or III(J) is



wherein R^{27a}, R^{11} and $_{n2}$ are as defined above for the compound of Formula I(J).

[0080] Other embodiments of the JAK compound are of Formula I(J), II(J) or III(J), wherein L is a bond, and Z is 

.

[0081] Other embodiments of the JAK-2 compound are of Formula I(J), II(J) or III(J) , wherein Z is 

and R^{25} is hydrogen.

[0082] Other embodiments of the JAK-2 compound are of Formula I(J), II(J) or III(J), wherein Z is 

, R^{25} is hydrogen and E and D are hydrogen.

[0083] Other embodiments of the JAK-2 compound are of Formula I(J), II(J) or III(J), wherein R^{25} is on the 3 position.

[0084] Other embodiments of the JAK-2 compound are of Formula I(J), II(J) or III(J),



wherein Z is , and R^{26a} is $-C(O)R^{32}$.

[0085] Other embodiments of the JAK-2 compound are of Formula I(J), II(J) or III(J),



wherein Z is , R^{26a} is $-C(O)R^{32}$, and R^{32} is selected from lower alkyl, cylcoalkyl, diaminoalkyl, aminoalkyl, arylalkyl, heterocycloalkyl, alkoxyalkyl, alkylamino, and hydroxyalkyl optionally substituted with amino.

[0086] Other embodiments of the JAK-2 compound are of Formula I(J), II(J) or III(J),



wherein Z is , R^{26a} is $-C(O)R^{32}$, and R^{32} is cycloalkyl.

[0087] Other embodiments of the JAK-2 compound are of Formula I(J), II(J) or III(J),



wherein Z is , R^{26a} is $-C(O)R^{32}$, and R^{32} is lower alkyl.

[0088] Other embodiments of the JAK-2 compound are of Formula I(J), II(J) or III(J)



wherein Z is , R^{26a} is $-C(O)R^{32}$, R^{26} is hydrogen, wherein R^{32} selected from aryl, arylalkyl, cycloalkyl, alkoxycarbonylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl, wherein R^{32} optionally substituted with 1, 2, 3, 4 or 5 groups selected from hydroxyl, oxo, alkyl, alkoxy, amino, hydroxyalkyl or halo.

[0089] Other embodiments of the JAK compound are of Formula I(J), II(J) or III(J),



wherein Z is , R^{26a} is $-C(O)R^{32}$, R^{26} is hydrogen, wherein R^{32} selected from tetrahydrofuran, pyrrolidinyl or pryimidinyl, wherein R^{32} optionally substituted with 1, 2, 3, 4 or 5 groups selected from hydroxyl, oxo, alkyl, alkoxy, amino, hydroxyalkyl or halo.

[0090] Other embodiments of the JAK compound are of Formula I(J), II(J) or III(J),



wherein Z is , R^{26a} is $-C(O)R^{32}$, R^{26} is hydrogen, wherein R^{32} is lower alkyl

optionally substituted with 1, 2, 3, 4 or 5 groups selected from dialkylaminocarbonyl, hydroxy and -$NR^{34}R^{34a}$, wherein R^{34} and R^{34a} are as defined above for Formula I(J).

[0091] Other embodiments of the JAK-2 compound are of Formula I(J), II(J) or III(J), wherein R^2 is  .

[0092] In another embodiment of the JAK-2 compound, R^{32} is methyl.

[0093] In another embodiment of the JAK-2 compound, R^{32} is alkyl substituted with -$NR^{34}R^{34a}$.

[0094] Other embodiments of the JAK-2 compound are of Formula I(J), II(J) or III(J), wherein R^{32} is U or -CH_2-U, wherein U is selected from pyrolidinyl, thiazolidinyl, morpholinyl, azetidinyl, cyclobutyl, cyclopropyl, tetrahydofuranyl, pyrazinyl, imidazolyl, piperazinyl, thienyl, thienylmethyl, furanyl, phenyl, prolinamidyl, pyridinyl, tetrahydronaphthalene, tetrazolyl, isoindolinyl, pyranyl, cyclopentyl, and octahydro-1H-indolyl.

[0095] Other embodiments of the JAK-2 compound are of Formula I(J), II(J) or III(J), wherein R^{11}, when present, is halo or lower alkyl.

[0096] Other embodiments of the JAK-2 compound are of Formula I(J), II(J) or III(J), wherein R^{11}, when present, is lower alkyl.

[0097] Other embodiments of the JAK-2 compound are of Formula I(J), II(J) or III(J), wherein R^{35} is heterocycloalkylalkyl, wherein the heterocyloalkyl is selected from piperazinyl, piperidinyl, morpholinyl and dioxanyl.

[0098] Other embodiments of the JAK-2 compound are of Formula I(J), II(J) or III(J), wherein n2 is 0.

[0099] Other embodiments of the JAK-2 compound are of Formula I(J), II(J) or III(J), wherein R^2 is  .

[00100] Other embodiments of the JAK-2 compound are of Formula I(J), II(J) or III(J), wherein R^2 is  , and wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl.

[00101] Other embodiments of the JAK-2 compound are of Formula I(J), II(J) or III(J), IV(J) or V(J), wherein R^{25} is hydrogen.

[00102] Representative JAK-2 compounds of Formula I(J) are the compounds depicted below in Table 1(J), or the pharmaceutically acceptable salts of any of these compounds. The examples are merely illustrative and do not limit the scope of the JAK-2 compounds or JAK-2 inhibitors in any way.

5

TABLE 1(J)

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
1	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2,6-dichlorobenzamide	27
2	2,6-dichloro-*N*-(3-{[4-(2,4-dichlorophenyl)pyrimidin-2-yl]amino}propyl)benzamide	27
3	2,6-dichloro-*N*-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]benzamide	27
4	2,6-dichloro-*N*-(3-{[4-(2,3-dihydro-1-benzofuran-6-yl)pyrimidin-2-yl]amino}propyl)benzamide	27
5	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2-fluoro-6-iodobenzamide	27
6	*N*-(3-{[4-(4-aminophenyl)pyrimidin-2-yl]amino}propyl)-2,6-dichlorobenzamide	27
7	*N*-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,6-dichlorobenzamide	2
8	*N*-{4-[2-({3-[(4-ethylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	29

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
9	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[2-(dimethylamino)ethyl]benzamide	29
10	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2-fluorobenzamide	39
11	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2-fluoro-6-iodobenzamide	39
12	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,6-dimethylbenzamide	39
13	*N*-(4-{2-[(3-aminophenyl)amino]pyrimidin-4-yl}phenyl)acetamide	28
14	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]pyridine-4-carboxamide	39
15	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,3,4,5,6-pentafluorobenzamide	39
16	4-(4-chlorophenyl)-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine	9
17	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,6-dichlorobenzamide	39
18	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	3
19	4-(2,4-dichlorophenyl)-*N*-{3-[(2-piperidin-1-ylethyl)oxy]phenyl}pyrimidin-2-amine	33
20	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2-chlorobenzamide	39

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
21	*N*-(4-{2-[(3-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	3
22	*N*-(4-{2-[(3-piperidin-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	3
23	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2-bromobenzamide	39
24	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-3-fluorobenzamide	39
25	*N*-[3-({4-[4-(acetylamino)phenyl]-5-methylpyrimidin-2-yl}amino)phenyl]-2,6-dichlorobenzamide	39
26	*N*-(4-{2-[(3-{[(2,6-dichlorophenyl)sulfonyl]amino}phenyl)amino]-5-methylpyrimidin-4-yl}phenyl)acetamide	36
27	2,6-dichloro-*N*-(3-{[4-(1*H*-indol-5-yl)pyrimidin-2-yl]amino}phenyl)benzamide	39
28	*N*-[3-({4-[4-(acetylamino)phenyl]-5-fluoropyrimidin-2-yl}amino)phenyl]-2,6-dichlorobenzamide	36
29	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2-methylbenzamide	39
30	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,4-dichlorobenzamide	39
31	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,3-dichlorobenzamide	39
32	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,5-dichlorobenzamide	39
33	*N*-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	3

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
34	*N*-(4-{2-[(4-piperidin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	34
35	*N*-(4-{2-[(2-methyl-4-piperazin-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	34
36	*N*-(4-{2-[(3-aminophenyl)amino]pyrimidin-4-yl}phenyl)thiophene-2-carboxamide	1
37	*N*-(4-{5-methyl-2-[(3-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	3
38	*N*-(4-{2-[(3-aminophenyl)amino]pyrimidin-4-yl}phenyl)-2-(phenyloxy)acetamide	1
39	*N*-(4-{6-methyl-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	5
40	*N*-(4-{2-[(3-aminophenyl)amino]pyrimidin-4-yl}phenyl)-2-morpholin-4-ylacetamide	1
41	*N*-[3-({4-[4-(acetylamino)-2-chlorophenyl]pyrimidin-2-yl}amino)phenyl]-2,6-dichlorobenzamide	39
42	2,6-dichloro-*N*-{3-[(4-phenylpyrimidin-2-yl)amino]phenyl}benzamide	39
43	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,6-difluorobenzamide	39
44	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,4,5-trifluorobenzamide	39
45	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]benzamide	39
46	*N*-(4-{6-morpholin-4-yl-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	37

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
47	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-3,5-difluorobenzamide	39
48	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2-chloro-6-fluoro-3-(methyloxy)benzamide	39
49	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2-chloro-6-fluoro-4-methylbenzamide	39
50	*N*-(4-{2-[(3-{[(2,6-dimethylphenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	28
51	4-(2,4-dichlorophenyl)-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine	9
52	4-(2,4-dichlorophenyl)-*N*-{3-[(4-ethylpiperazin-1-yl)carbonyl]phenyl}pyrimidin-2-amine	29
53	*N*-(3-{[4-(4-aminophenyl)pyrimidin-2-yl]amino}phenyl)-2,6-dichlorobenzamide	39
54	4-(4-aminophenyl)-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine	8
55	4-[4-(ethylamino)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine	49
56	*N*-[4-(2-{[3-(methyloxy)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	3
57	*N*-(4-{2-[(4-aminophenyl)amino]pyrimidin-4-yl}phenyl)acetamide	1
58	*N*-[4-(2-{[4-(methyloxy)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	3
59	N-{4-[2-({3-[4-(pyridin-4-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
60	*N*-[5-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-2-morpholin-4-ylphenyl]-2,6-dichlorobenzamide	30
61 63	*N*-(4-{5-fluoro-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	5
62	*N*-(4-{2-[(4-{[2-(4-ethylpiperazin-1-yl)-2-oxoethyl]oxy}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	33
63	*N*-[4-(2-{[3-(morpholin-4-ylcarbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	29
64	*N*-{3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-5-[(4-ethylpiperazin-1-yl)carbonyl]phenyl}-2,6-dichlorobenzamide	31
65	4-[4-(dimethylamino)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine	9
66	2,6-dichloro-*N*-(3-{[4-(2,4-dichlorophenyl)pyrimidin-2-yl]amino}phenyl)benzamide	39
67	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]-5-(trifluoromethyl)pyrimidin-4-yl}phenyl)acetamide	5
68	*N*-(3-{2-[(3-aminophenyl)amino]pyrimidin-4-yl}phenyl)thiophene-2-carboxamide	1
69	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-1-methylpiperidine-4-carboxamide	39
70	*N*-{4-[2-({3-[(phenylmethyl)amino]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	28
71	*N*-(4-{2-[(3-aminophenyl)amino]-5-methylpyrimidin-4-yl}phenyl)acetamide	1
72	*N*-(4-{2-[(3-aminophenyl)amino]-5-fluoropyrimidin-4-yl}phenyl)acetamide	5

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
73	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(2-ethylphenyl)benzamide	29
74	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(phenylmethyl)benzamide	29
75	*N*-{4-[2-({3-[(4-cyclopentylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	29
76	*N*-{4-[2-({3-[(4-phenylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	29
77	*N*-(3-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	9
78	*N*-(2-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	9
79	*N*-{4-[2-({3-[(4-pyrazin-2-ylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	29
80	*N*-(4-{2-[(3-{[4-(3-chlorophenyl)piperazin-1-yl]carbonyl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	46
81	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(1-methyl-1*H*-benzimidazol-2-yl)methyl]benzamide	46
82	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-propylbenzamide	29
83	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-cyclopropylbenzamide	29
84	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(3-fluorophenyl)methyl]benzamide	29
85	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(naphthalen-1-ylmethyl)benzamide	29

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
86	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[2-(dimethylamino)ethyl]-*N*-methylbenzamide	29
87	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(2-methylphenyl)methyl]benzamide	29
88	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(3-chlorophenyl)methyl]benzamide	29
89	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(2-phenylethyl)benzamide	29
90	*N*-{4-[2-({3-[(4-methylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	29
91	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(tetrahydrofuran-2-ylmethyl)benzamide	29
92	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]benzamide	29
93	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(3s,5s,7s)-tricyclo[3.3.1.1~3,7~]dec-1-yl]benzamide	29
94	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[2-(methyloxy)ethyl]benzamide	29
95	*N*-[4-(2-{[3-(1,3-thiazolidin-3-ylcarbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	29
96	*N*-{4-[2-({3-[(4-pyridin-2-ylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	29
97	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-{[2-(methyloxy)phenyl]methyl}benzamide	29
98	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-{[3-(methyloxy)phenyl]methyl}benzamide	29

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
99	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(2-fluorophenyl)methyl]benzamide	29
100	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(4-fluorophenyl)methyl]benzamide	29
101	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(3,3-dimethylbutyl)benzamide	29
102	*N*-[4-(2-{[3-(thiomorpholin-4-ylcarbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	29
103	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(2-thienylmethyl)benzamide	29
104	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[3-(dimethylamino)propyl]benzamide	29
105	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-{[2-(trifluoromethyl)phenyl]methyl}benzamide	29
106	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-{[3-(trifluoromethyl)phenyl]methyl}benzamide	29
107	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-{[4-(trifluoromethyl)phenyl]methyl}benzamide	29
108	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(2,4-difluorophenyl)methyl]benzamide	29
109	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-ethyl-*N*-methylbenzamide	29
110	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-({4-[(trifluoromethyl)oxy]phenyl}methyl)benzamide	29
111	*N*-{4-[2-({3-[(4-acetylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	29

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
112	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(cyclopropylmethyl)benzamide	29
113	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[2-(2-fluorophenyl)ethyl]benzamide	29
114	*N*-[4-(2-{[3-(pyrrolidin-1-ylcarbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	29
115	*N*-{4-[2-({3-[(4-pyrimidin-2-ylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	29
116	*N*-methyl-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	32
117	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)benzamide	9
118	*N*-[4-(2-{[3-(1,3-dioxan-2-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	3
119	*N*-[4-(2-{[3-(morpholin-4-ylmethyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	22
120	*N*-{4-[2-({3-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	29
121	*N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-3-[(2-morpholin-4-ylethyl)oxy]benzamide	39
122	4-[4-(methylamino)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine	29
123	*N*-[4-(2-{[4-(4-acetylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	7
124	*N*-(4-{2-[(3-amino-2,4,5,6-tetrafluorophenyl)amino]pyrimidin-4-yl}phenyl)acetamide	1

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
125	*N*-(4-{2-[(3-{[4-(2-fluorophenyl)piperazin-1-yl]carbonyl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	Made according to the examples described herein
126	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[2-(phenyloxy)ethyl]benzamide	29
127	methyl 1-{[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]carbonyl}piperidine-4-carboxylate	29
128	*N*-[4-(2-{[3-({4-[3-(methyloxy)phenyl]piperazin-1-yl}carbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	29
129	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-{2-[2-(methyloxy)phenyl]ethyl}benzamide	29
130	*N*-[4-(2-{[3-(1,3-dihydro-2*H*-isoindol-2-ylcarbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	29
131	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(biphenyl-4-ylmethyl)benzamide	29
132	*N*-(4-{2-[(3-{[4-(phenylcarbonyl)piperazin-1-yl]carbonyl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	29
133	*N*-[4-(2-{[3-({4-[4-(methyloxy)phenyl]piperazin-1-yl}carbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	29
134	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-methyl-*N*-{[2-(methyloxy)phenyl]methyl}benzamide	29
135	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(2-fluorophenyl)methyl]-*N*-methylbenzamide	29
136	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(diphenylmethyl)benzamide	29
137	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(2-pyridin-2-ylethyl)benzamide	29

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
138	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(pyridin-2-ylmethyl)benzamide	29
139	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[2-(2-chlorophenyl)ethyl]benzamide	29
140	*N*-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}-5-fluoropyrimidin-4-yl)phenyl]acetamide	5
141	N^2-[3-(1*H*-imidazol-1-yl)propyl]-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)glycinamide	23
142	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-N^2-(2-pyridin-3-ylethyl)glycinamide	23
143	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(pyridin-3-ylmethyl)benzamide	29
144	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(pyridin-4-ylmethyl)benzamide	29
145	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-methyl-*N*-(phenylmethyl)benzamide	29
146	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-cyclopentylbenzamide	29
147	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(2-chlorophenyl)methyl]benzamide	29
148	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(4-chlorophenyl)methyl]benzamide	29
149	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(furan-2-ylmethyl)benzamide	29
150	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-{[4-(methyloxy)phenyl]methyl}benzamide	29

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
151	*N*-[4-(2-{[3-({4-[2-(methyloxy)phenyl]piperazin-1-yl}carbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	29
152	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[3-(methyloxy)propyl]benzamide	29
153	*N*-(4-{2-[(3-{[(2*R*,6*S*)-2,6-dimethylmorpholin-4-yl]carbonyl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	29
154	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(6-chloropyridin-3-yl)methyl]benzamide	29
155	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-butylbenzamide	29
156	*N*-(4-{2-[(3-{[4-(2-chlorophenyl)piperazin-1-yl]carbonyl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	29
157	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-ethyl-*N*-[2-(methyloxy)ethyl]benzamide	29
158	*N*-(4-(2-(3-(3-morpholinopropoxy)phenylamino)pyrimidin-4-yl)phenyl)acetamide	35
159	*N*-(4-(2-(3-(2-(dimethylamino)ethoxy)phenylamino)pyrimidin-4-yl)phenyl)acetamide	33
160	*N*-[3-({4-[4-(acetylamino)phenyl]-5-methylpyrimidin-2-yl}amino)phenyl]-2,6-dimethylbenzamide	39
161	*N*-[4-(2-{[4-(phenyloxy)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	3
162	4-(4-aminophenyl)-*N*-[4-(phenyloxy)phenyl]pyrimidin-2-amine	8
163	*N*-{4-[2-({4-[(phenylmethyl)oxy]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	3

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
164	4-(4-aminophenyl)-*N*-[3-(morpholin-4-ylsulfonyl)phenyl]pyrimidin-2-amine	8
165	*N*-(4-{2-[(3,5-dimorpholin-4-ylphenyl)amino]-5-fluoropyrimidin-4-yl}phenyl)acetamide	6
166	*N*-{4-[2-({4-[4-(phenylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49
167	*N*-(4-{2-[(4-{4-[(5-methyl-3-phenylisoxazol-4-yl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
168	*N*-(4-{2-[(4-{4-[(5-methyl-1-phenyl-1*H*-pyrazol-4-yl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
169	*N*-(4-{2-[(4-{4-[(2-phenyl-1,3-thiazol-4-yl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
170	*N*-[4-(2-{[4-(4-{[6-(phenyloxy)pyridin-3-yl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	49
171	*N*-{4-[2-({4-[4-(cyclohexylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49
172	*N*-(4-{2-[(4-{4-[(1*S*,4*S*)-bicyclo[2.2.1]hept-5-en-2-ylmethyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
173	*N*-[4-(2-{[4-(4-pentylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	49
174	*N*-(4-{2-[(4-{4-[(2-chlorophenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
175	*N*-[4-(2-{[4-(4-{[3,5-bis(methyloxy)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	49
176	*N*-(4-{2-[(4-{4-[(4-fluorophenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
177	*N*-(4-{2-[(4-{4-[(1-methyl-1*H*-pyrrol-2-yl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
178	*N*-(4-{2-[(4-{4-[(2,4-dichlorophenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
179	*N*-{4-[2-({4-[4-(9*H*-fluoren-2-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49
180	*N*-(4-{2-[(4-{4-[(3-methyl-2-thienyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
181	*N*-(4-{2-[(4-{4-[(5-ethylfuran-2-yl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
182	*N*-(4-{2-[(4-{4-[(3-{[4-(1,1-dimethylethyl)phenyl]oxy}phenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
183	*N*-{4-[2-({4-[4-(3-thienylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49
184	methyl 4-({4-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}methyl)benzoate	49
185	*N*-(4-{2-[(4-{4-[3-(methylthio)propyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
186	*N*-(4-{2-[(4-{4-[(4-{[3-(dimethylamino)propyl]oxy}phenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
187	*N*-[4-(2-{[4-(4-{2-[(phenylmethyl)oxy]ethyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	49
188	*N*-(4-{2-[(4-{4-[(2-chloroquinolin-3-yl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
189	*N*-(4-{2-[(4-{4-[(4-chloro-2,6-dimethylphenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
190	*N*-{1-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]pyrrolidin-3-yl}acetamide	3
191	N^2-[3-(4-methylpiperazin-1-yl)propyl]-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)glycinamide	23
192	N^2-(1-methylpiperidin-4-yl)-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)glycinamide	23
193	*N*-{4-[2-({4-[(pyridin-4-ylmethyl)oxy]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	33
194	*N*-(4-{2-[(4-{[2-(methyloxy)ethyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	28
195	2-(dimethylamino)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)acetamide	12
196	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)furan-2-carboxamide	12
197	2-(methyloxy)-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	12
198	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)cyclobutanecarboxamide	12
199	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)azetidine-3-carboxamide	13
200	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)piperidine-2-carboxamide	13
201	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)piperidine-3-carboxamide	13
202	*N*-[4-(2-{[4-(dimethylamino)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	3

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
203	*N*-(4-{2-[(4-chlorophenyl)amino]pyrimidin-4-yl}phenyl)acetamide	3
204	*N*-(4-{2-[(3-{[(2-fluorophenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	28
205	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)piperidine-4-carboxamide	13
206	2-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide	14
207	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)glycinamide	14
208	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)morpholine-2-carboxamide	13
209	N^2-methyl-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)glycinamide	13
210	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-beta-alaninamide	13
211	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)phenylalaninamide	13
212	*N*-[4-(2-{[4-(3-oxopiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	34
213	*N*-[4-(2-{[4-(4-{[5-(3-chlorophenyl)furan-2-yl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	49
214	*N*-[4-(2-{[4-(4-{[4-fluoro-2-(trifluoromethyl)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	49
215	*N*-[4-(2-{[4-(4-{[4-(1*H*-imidazol-1-yl)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	49

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
216	*N*-[4-(2-{[4-(4-{[2,5-bis(trifluoromethyl)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	49
217	*N*-(4-{2-[(4-{4-[(2,6-dimethylphenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
218	*N*-(4-{2-[(4-{4-[(2,3-dimethylphenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
219	*N*-[4-(2-{[4-(4-{[2,4-bis(ethyloxy)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	49
220	*N*-[4-(2-{[4-(4-{[3-(ethyloxy)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	49
221	*N*-{4-[2-({4-[4-(2,2'-bithien-5-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49
222	*N*-[4-(2-{[4-(4-{[4-(2-thienyl)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	49
223	*N*-(4-{2-[(4-{4-[(4-cyanophenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
224	*N*-[4-(2-{[4-(4-{[2,5-bis(methyloxy)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	49
225	*N*-{4-[2-({4-[4-(2,2-diphenylethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49
226	*N*-{4-[2-({4-[4-(1*H*-pyrrol-2-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49
227	*N*-{4-[2-(1*H*-indazol-6-ylamino)-5-methylpyrimidin-4-yl]phenyl}acetamide	3
228	*N*-{4-[2-(1*H*-indol-5-ylamino)-5-methylpyrimidin-4-yl]phenyl}acetamide	3

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
229	*N*-[4-(2-{[4-(morpholin-4-ylmethyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	22
230	*N*-(4-{2-[(3-{[(3-fluorophenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	28
231	*N*-(4-{2-[(3-{[(4-fluorophenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	28
232	4-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-*N*-ethylpiperazine-1-carboxamide	7
233	*N*-{4-[2-({4-[4-(ethylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	36
234	*N*-{4-[2-(1*H*-indazol-5-ylamino)-5-methylpyrimidin-4-yl]phenyl}acetamide	3
235	*N*-[4-(2-{[4-(4-propylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	49
236	*N*-[4-(2-{[4-(4-butylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	49
237	*N*-{4-[2-({4-[4-(cyclopropylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49
238	4-[4-(methylsulfonyl)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine	16
239	ethyl *N*-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-*N*-methylglycinate	3
240	4-[3-(methylsulfonyl)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine	9
241	4-[4-(methylthio)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine	9

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
242	*N*-(4-{2-[(4-cyclohexylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	3
243	*N*-{4-[2-({4-[(tetrahydrofuran-2-ylmethyl)amino]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	28
244	*N*-{4-[2-({4-[(phenylmethyl)amino]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	28
245	*N*-[4-(2-{[4-(acetylamino)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	3
246	methyl (4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)carbamate	17
247	1-ethyl-3-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)urea	17
248	ethyl 1-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]piperidine-3-carboxylate	3
249	ethyl [4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]acetate	3
250	4-[4-(methyloxy)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine	9
251	4-[3-(methyloxy)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine	9
252	4-(1*H*-indol-5-yl)-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine	9
253	2-[(2-amino-2-oxoethyl)amino]-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	23
254	2-morpholin-4-yl-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	12

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
255	2,6-dichloro-*N*-{3-[(4-{4-[(cyclopropylcarbonyl)amino]phenyl}pyrimidin-2-yl)amino]phenyl}benzamide	2
256	N^2-(2-aminoethyl)-N^2-methyl-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)glycinamide	1
257	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-N^2-1*H*-pyrazol-5-ylglycinamide	23
258	phenylmethyl *N*-{2-[(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)amino]-2-oxoethyl}-L-alaninate	23
259	4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}benzamide	9
260	1,1-dimethylethyl [(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)methyl]carbamate	9
261	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)propanamide	12
262	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-phenylacetamide	12
263	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-3-phenylpropanamide	12
264	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)tetrahydrofuran-2-carboxamide	12
265	5-methyl-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyrazine-2-carboxamide	12
266	2-(ethyloxy)-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	23
267	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-(phenyloxy)acetamide	23

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
268	*N*-[4-(2-{[4-(1*H*-pyrrol-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	3
269	*N*-[4-(2-{[4-(2,6-dimethylmorpholin-4-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	3
270	ethyl 1-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]piperidine-4-carboxylate	3
271	2-cyclopentyl-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	12
272	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-3-pyridin-3-ylpropanamide	12
273	6-(methyloxy)-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridine-3-carboxamide	12
274	methyl 4-[(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)amino]-4-oxobutanoate	12
275	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)butanamide	12
276	*N*-(4-{2-[(4-{bis[2-(methyloxy)ethyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	3
277	*N*-[4-(2-{[4-(morpholin-4-ylsulfonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	3
278	4-(4-(aminomethyl)phenyl)-*N*-(4-morpholinophenyl)pyrimidin-2-amine	47
279	*N*-[(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)methyl]acetamide	48
280	*N*-(4-morpholin-4-ylphenyl)-4-{4-[(propylamino)methyl]phenyl}pyrimidin-2-amine	47

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
281	*N*-(4-{2-[(4-piperidin-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	3
282	*N*-(4-{2-[(3,5-dimorpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	6
283	2-(2-methylphenyl)-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	12
284	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)cyclopentanecarboxamide	12
285	*N*,*N*-dimethyl-*N*'-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)butanediamide	12
286	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-N^2-pyrimidin-4-ylglycinamide	12
287	3-chloro-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridine-4-carboxamide	12
288	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-piperidin-1-ylacetamide	12
289	N^2-ethyl-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)glycinamide	12
290	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-pyrrolidin-1-ylacetamide	11
291	2-(1*H*-imidazol-1-yl)-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	11
292	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-piperazin-1-ylacetamide	11

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
293	*N*-[4-(2-{[4-(4-phenylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	3
294	*N*-(4-{2-[(3-chloro-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	15
295	*N*-(4-{2-[(4-piperazin-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	34
298	2,6-dichloro-N-(3-{[4-(4-fluorophenyl)pyrimidin-2-yl]amino}propyl)benzamide	27
299	'*N*-[6-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)pyridin-2-yl]-2,6-dichlorobenzamide	38
300	'*N*-[6-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)pyrimidin-4-yl]-2,6-dichlorobenzamide	38
301	'*N*-(4-{2-[(6-aminopyridin-2-yl)amino]pyrimidin-4-yl}phenyl)acetamide	38
302	'*N*-(4-{2-[(6-aminopyrimidin-4-yl)amino]pyrimidin-4-yl}phenyl)acetamide	38
303	'5-fluoro-N^4-[2-(methyloxy)phenyl]-N^2-[3-(methyloxy)phenyl]pyrimidine-2,4-diamine	50
304	'2,6-dichloro-*N*-{3-[(4-{[3-chloro-4-(methyloxy)phenyl]oxy}pyrimidin-2-yl)amino]phenyl}benzamide	41
305	'4-{[2-chloro-4-(methyloxy)phenyl]oxy}-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine	41
306	'*N*-[4-({2-[(4-morpholin-4-ylphenyl)amino]-7*H*-pyrrolo[2,3-d]pyrimidin-4-yl}amino)phenyl]acetamide	35
307	'*N*-[4-({2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}oxy)phenyl]acetamide	41

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
308	*N*-{4-[2-({4-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
309	*N*-{4-[2-({4-[(2*R*,6*S*)-2,6-dimethylmorpholin-4-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	3
310	*N*-(4-{2-[(4-{4-[(2-methylphenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
311	*N*-{4-[2-({4-[4-(1*H*-pyrazol-4-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
312	*N*-(4-{2-[(3-piperazin-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	34
313	*N*-[4-(2-{[3-(4-{[2-(methyloxy)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	49
314	*N*-{4-[2-({3-[4-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49
315	*N*-(4-{2-[(3-bromo-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	3
316	*N*-[4-(2-{[4-{[2-(diethylamino)ethyl]oxy}-3-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	3
317	4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}benzoic acid	9
318	4-(4-furan-2-ylphenyl)-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine	9
319	4-[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine	10
320	4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}benzonitrile	9

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
321	methyl 4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}benzoate	9
322	4-(4-fluorophenyl)-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine	9
323	*N*-[3-({2-[(4-morpholin-4-ylphenyl)amino]-7*H*-pyrrolo[2,3-d]pyrimidin-4-yl}amino)phenyl]acetamide	35
324	*N*-(4-morpholin-4-ylphenyl)-4-[4-(pyridin-3-ylamino)phenyl]pyrimidin-2-amine	9
325	*N*-(4-morpholin-4-ylphenyl)-4-[4-(pyridin-2-ylamino)phenyl]pyrimidin-2-amine	9
326	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)methanesulfonamide	10
327	1-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-3-(phenylmethyl)urea	17
328	4-(2,3-dihydro-1,4-benzodioxin-6-yl)-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine	9
329	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]-7*H*-pyrrolo[2,3-d]pyrimidin-4-yl}phenyl)acetamide	43
330	*N*-(4-morpholin-4-ylphenyl)-4-quinolin-6-ylpyrimidin-2-amine	9
331	4-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine	9
332	*N*-(4-morpholin-4-ylphenyl)-4-(4-pyrimidin-5-ylphenyl)pyrimidin-2-amine	9
333	*N*-(4-morpholin-4-ylphenyl)-4-quinoxalin-6-ylpyrimidin-2-amine	9

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
334	2-chloro-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)benzamide	12
335	2-(2-fluorophenyl)-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	12
336	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyrimidine-5-carboxamide	12
337	(2*S*)-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)azetidine-2-carboxamide	45
338	*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-N^2-phenylglycinamide	23
339	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-prolinamide	14
340	*N*-(4-(2-(3-methoxy-4-morpholino-phenylamino)pyrimidin-4-yl)phenyl)acetamide	15
341	*N*-(4-(2-(4-(4-isobutyrylpiperazin-1-yl)phenylamino)-pyrimidin-4-yl)phenyl)acetamide	7
342	*N*-(4-(2-(4-(4-(3-methylbutanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	7
343	*N*-(4-(2-(4-(4-(cyclopropanecarbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	7
344	*N*-(4-(2-(4-(4-(cyclobutanecarbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	7
345	*N*-(4-(2-(4-(4-(cyclopentanecarbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	7
346	*N*-(4-(2-(4-(4-(2-methoxybenzoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	7

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
347	*N*-(4-(2-(4-(4-pentanoylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	7
348	*N*-(4-(2-(4-(4-picolinoylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	7
349	*N*-(4-(2-(4-(4-isonicotinoylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	7
350	*N*-(4-(2-(4-(4-(1-acetylpiperidine-4-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	7
351	*N*-(4-(2-(4-(4-(2-cyclopropylacetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	7
352	*N*-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	7
353	*N*-(4-(2-(4-(4-(2-(2-methoxyethoxy)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	7
354	*N*-(4-(2-(4-(4-(2-(pyridin-3-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	7
355	*N*-(4-(2-(4-(4-(3-(pyridin-3-yl)propanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	7
356	*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide	12
357	*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-2-(pyridin-3-yl)acetamide	12
358	*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)isonicotinamide	12
359	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-prolinamide	45

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
360	N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]-D-prolinamide	45
361	O-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-serinamide	14
362	(*S*)-3-hydroxy-*N*-(4-(2-(4-morpholino-phenylamino)-pyrimidin-4-yl)-phenyl)-butanamide	18
363	(*R*)-3-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide	20
364	(*R*)-2-amino-3-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide	21
365	2-*H*ydroxy-2-methyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide	11
366	2-methyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	44
367	(*R*)-*N*-(4-(2-(4-((*R*)-3-(dimethylamino)pyrrolidin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
368	4-amino-1,1-dioxo-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)tetrahydro-2*H*-thiopyran-4-carboxamide	44
369	(*R*)-4-(4-aminophenyl)-*N*-(4-(3-(dimethylamino)-pyrrolidin-1-yl)phenyl)-pyrimidin-2-amine	8
370	(*R*)-*N*-(4-(2-(4-(3-(dimethylamino)pyrrolidin-1-yl)phenylamino)-pyrimidin-4-yl)phenyl)-3-methoxy-propanamide	12
371	*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)piperazine-2-carboxamide	12
372	2-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-1,2,3,4-tetrahydronaphthalene-2-carboxamide	44

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
373	4-(4-(1,1-dioxo-isothiazolidin-2-yl)phenyl)-*N*-(4-morpholinophenyl)-pyrimidin-2-amine	25
374	4-(4-(1*H*-tetrazol-1-yl)phenyl)-*N*-(4-morpholinophenyl)-pyrimidin-2-amine	25
375	(*R*)-*N*-(4-(2-(3-(benzyloxy)-4-morpholino-phenylamino)-pyrimidin-4-yl)phenyl)-pyrrolidine-2-carboxamide	45
376	(*S*)-2-amino-3-hydroxy-*N*-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide	21
377	*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-2-(1*H*-tetrazol-1-yl)acetamide	24
378	(*R*)-*N*-(4-(2-(3-ethoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-pyrrolidine-2-carboxamide	45
379	(*R*)-*N*-(4-(2-(1,2,3,4-tetrahydroquinolin-6-ylamino)-pyrimidin-4-yl)phenyl)-pyrrolidine-2-carboxamide	45
380	3-hydroxy-*N*-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-3-methylbutanamide	18
381	(3*S*,7*S*)-7-(hydroxymethyl)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)quinuclidine-3-carboxamide	18
382	1-hydroxy-*N*-(4-(2-(4-morpholino-phenylamino)-pyrimidin-4-yl)phenyl)cyclopropanecarboxamide	18
383	(*S*)-2-amino-*N*-(4-(2-(3-methyl-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide	14
384	(*R*)-*N*-(4-(2-(3-methyl-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
385	(*R*)-*N*-(4-(2-(4-morpholino-3-(trifluoromethyl)-phenylamino)pyrimidin-4-yl)-phenyl)-pyrrolidine-2-carboxamide	45

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
386	(*R*)-*N*-(4-(2-(4-(4-((*S*)-tetrahydrofuran-2-carbonyl)-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl)phenyl)-pyrrolidine-2-carboxamide	45
387	(*R*)-*N*-(4-(2-(4-(4-((*R*)-tetrahydrofuran-2-carbonyl)-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl)phenyl)-pyrrolidine-2-carboxamide	45
388	4-methyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)piperazine-1-carboxamide	12
389	3-methoxy-*N*-(4-(2-(4-morpholino-3-(trifluoromethyl)phenylamino)pyrimidin-4-yl)phenyl)propanamide	12
390	3-methoxy-*N*-(4-(2-(4-morpholino-phenylamino)pyrimidin-4-yl)phenyl)-propane-1-sulfonamide	16
391	2-methoxy-*N*-(4-(2-(4-morpholino-phenylamino)pyrimidin-4-yl)phenyl)-ethanesulfonamide	16
392	(*S*)-3-hydroxy-*N*-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide	18
393	(*R*)-3-hydroxy-*N*-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide	20
394	*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-2,5-dihydro-1*H*-pyrrole-2-carboxamide	13
395	1-(3-(dimethylamino)propyl)-3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)urea	17
396	(*R*)-*N*-(4-(2-(4-(4-((*S*)-pyrrolidin-2-ylmethyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
397	(*R*)-2-amino-*N*-(4-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)-5-methylpyrimidin-4-yl)phenyl)propanamide	14
398	1-(3-methoxypropyl)-3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)urea	17

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
399	(*R*)-*N*-(4-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)-5-methylpyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
400	(*S*)-*N*-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)-3-fluorophenylamino)pyrimidin-4-yl)phenyl)-5-oxopyrrolidine-2-carboxamide	45
401	(*R*)-*N*-(4-(2-(3-chloro-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
402	1-(2-morpholinoethyl)-3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)urea	17
403	1-(2-(dimethylamino)ethyl)-3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)urea	17
404	(*S*)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-2-(pyrrolidin-2-yl)acetamide	12
405	2,3-dihydroxy-*N*-(4-(2-(4-morpholino-phenylamino)pyrimidin-4-yl)phenyl)-propanamide	18
406	(*S*)-2-amino-4-methyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pentanamide	14
407	(*R*)-2-amino-4-methyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pentanamide	14
408	*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)isoindoline-1-carboxamide	13
409	*N*-ethyl-4-(4-(4-(4-(tetrahydrofuran-2-carboxamido)phenyl)pyrimidin-2-ylamino)phenyl)piperazine-1-carboxamide	12
410	*N*-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-2-carboxamide	12
411	(*R*)-*N*-(4-(2-(4-(4-((*R*)-2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
412	(*R*)-*N*-(4-(2-(4-(4-((*S*)-2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
413	*N*-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide	12
414	3-methoxy-*N*-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide	12
415	*N*-(4-(2-(4-(4-pivaloylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide	12
416	(*R*)-*N*-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-1-methylpyrrolidine-2-carboxamide	12
417	(*R*)-*N*-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
418	(*R*)-4-(4-(4-(4-(2-aminopropanamido)phenyl)-pyrimidin-2-ylamino)phenyl)-*N*-ethylpiperazine-1-carboxamide	14
419	(*R*)-2-amino-*N*-(4-(2-(4-(4-((*R*)-pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide	14
420	(*R*)-2-amino-*N*-(4-(2-(4-(4-((*S*)-pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide	14
421	(*R*)-2-amino-*N*-(4-(2-(4-(4-((*S*)-2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide	14
422	(*R*)-*N*-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
423	(*S*)-*N*-(4-(2-(4-(4-(pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide	11
424	*N*-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide	11

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
425	(*R*)-*N*-(4-(2-(4-(4-(pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide	11
426	1-ethyl-3-(4-(5-methyl-2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)urea	17
427	(*S*)-*N*-(4-(2-(4-(4-(2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide	11
428	(*R*)-*N*-(4-(2-(4-(4-(2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-methoxypropanamide	12
429	(*S*)-3-methoxy-*N*-(4-(2-(4-(4-(pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide	12
430	(*R*)-*N*-(4-(2-(4-(4-(2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide	1
431	*N*-(4-(2-(4-(4-(cyclobutanecarbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide	11
432	*N*-(4-(2-(4-(4-isobutyrylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide	11
433	*N*-(4-(2-(4-(1-butyryl-1,2,4-triazinan-4-yl)phenylamino)pyrimidin-4-yl)phenyl)butyramide	11
434	1-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-ethylurea	17
435	*N*-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-methoxypropanamide	11
436	*N*-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide	11
437	*N*-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)butyramide	11

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
438	1-ethyl-3-(4-(2-(4-(4-pivaloylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)urea	17
439	1-(4-(2-(4-(4-(cyclobutanecarbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-ethylurea	17
440	1-ethyl-3-(4-(2-(4-(4-isobutyrylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)urea	17
441	*N*-ethyl-4-(4-(4-(4-(3-ethylureido)phenyl)pyrimidin-2-ylamino)phenyl)piperazine-1-carboxamide	17
442	(*S*)-1-ethyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
443	(*R*)-1-(2-hydroxyethyl)-*N*-(4-(2-(4-morpholinobenzyl)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	47
444	(*R*)-1-isopropyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	42
445	(*S*)-2-(dimethylamino)-*N*-(4-(2-(4-(4-(pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	12
446	1-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-ethylurea	17
447	(*R*)-1-ethyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
448	4-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)tetrahydro-2*H*-pyran-4-carboxamide	44
449	(*R*)-2-amino-*N*-(4-(2-(4-(4-isobutyrylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide	14
450	(*R*)-2-amino-*N*-(4-(2-(4-(4-((*R*)-2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide	14

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
451	(*R*)-*N*-(4-(5-methyl-2-(4-(4-((1-methyl-1*H*-imidazol-2-yl)methyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
452	(*R*)-2-amino-*N*-(4-(5-methyl-2-(4-(4-((1-methyl-1*H*-imidazol-2-yl)methyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide	14
453	(*R*)-2-(dimethylamino)-*N*-(4-(2-(4-(4-(pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	12
454	(*R*)-*N*-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
455	(*S*)-*N*-(4-(5-methyl-2-(4-(4-((1-methyl-1*H*-imidazol-2-yl)methyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
456	(*R*)-2-amino-*N*-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide	14
457	(2*R*)-*N*-(4-(2-(4-(4-(tetrahydrofuran-3-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
458	(*S*)-1-ethyl-3-(4-(2-(4-(4-(pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)urea	17
459	(*S*)-1-(4-(2-(4-(4-(2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-ethylurea	17
460	*N*-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)butyramide	11
461	(*S*)-*N*-(4-(2-(4-(4-(2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)butyramide	11
462	3-methoxy-*N*-(4-(5-methyl-2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide	12
463	(*R*)-2-amino-*N*-(4-(5-methyl-2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide	14

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
464	2-(dimethylamino)-*N*-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	12
465	1-ethyl-3-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)urea	17
466	3-methoxy-*N*-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide	12
467	(*R*)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-5-oxopyrrolidine-2-carboxamide	45
468	(*S*)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-5-oxopyrrolidine-2-carboxamide	45
469	(*S*)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-3-carboxamide	42
470	(2*R*,3*S*)-2-amino-3-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide	18
471	(*R*)-2-amino-*N*-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide	14
472	*N*-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide	11
473	*N*-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butyramide	12
474	*N*-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)butyramide	12
475	*N*-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide	12

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
476	(*R*)-2-amino-*N*-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide	14
477	(2*S*,3*R*)-2-amino-3-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide	14
478	(*R*)-*N*-(4-(2-(4-((2*S*,6*R*)-2,6-dimethylmorpholino)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
479	(*R*)-*N*-(4-(2-(4-(4-(3-hydroxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
480	1-ethyl-3-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)urea	12
481	(*R*)-1-ethyl-3-(4-(2-(4-(4-(pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)urea	12
482	3,3,3-trifluoro-2-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide	18
483	(*R*)-1-(4-(2-(4-(4-(2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-ethylurea	17
484	2-(dimethylamino)-*N*-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	12
485	(*R*)-2-amino-*N*-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide	20
486	(*R*)-*N*-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
487	(*R*)-2-amino-*N*-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide	14
488	*N*-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-methoxypropanamide	12

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
489	*N*-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)butyramide	12
490	*N*-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide	11
491	*N*-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide	11
492	(*R*)-*N*-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-2-carboxamide	11
493	2-(dimethylamino)-*N*-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	12
494	(*R*)-*N*-(4-(2-(4-(4-(piperidine-4-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
495	3-methoxy-*N*-(4-(2-(4-(4-(piperidine-4-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide	12
496	1-ethyl-3-(4-(2-(4-(4-(piperidine-4-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)urea	17
497	*N*-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropanoyl)piperazin-1-yl)benzyl)pyrimidin-4-yl)phenyl)acetamide	49
498	(*S*)-*N*-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-2-carboxamide	12
499	(*R*)-*N*-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-2-carboxamide	12
500	(4*S*)-4-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	21
501	(*R*)-*N*-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-2-carboxamide	12

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
502	(*S*)-*N*-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-2-carboxamide	12
503	*N*-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide	11
504	*N*-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide	11
505	(*S*)-*N*-(4-(2-(4-(4-(pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)butyramide	11
506	(2*R*)-*N*-(4-(2-(4-(4-(tetrahydrofuran-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
507	(*R*)-*N*-(4-(5-chloro-2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
508	*N*-(4-(2-(4-(4-(3-(diethylamino)propanoyl)piperazin-1-yl)benzyl)pyrimidin-4-yl)phenyl)acetamide	7
509	(*S*)-1-(2-hydroxyethyl)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-3-carboxamide	42
510	(*S*)-2-amino-*N*1-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pentanediamide	14
511	(*R*)-2-amino-*N*1-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pentanediamide	18
512	(*R*)-2-amino-*N*1-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)succinamide	20
513	(*R*)-*N*-(4-(2-(4-(4-((4-chloro-1-methyl-1*H*-pyrazol-3-yl)methyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
514	(*S*)-1-ethyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-3-carboxamide	42

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
515	(*R*)-*N*-(4-(2-(4-(4-(2-ethoxyacetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
516	(*R*)-*N*-(4-(2-(4-(4-(2-(pyrrolidin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
517	(*R*)-*N*-(4-(2-(4-(4-(2-morpholinoacetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
518	*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-1*H*-imidazole-4-carboxamide	12
519	2-(dimethylamino)-*N*-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	12
520	(*S*)-*N*-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-2-carboxamide	12
521	(*R*)-2-hydroxy-2-methyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide	18
522	(*S*)-2-hydroxy-2-methyl-*N*-(4-(2-(4-morpholinobenzyl)pyrimidin-4-yl)phenyl)butanamide	18
523	(*R*)-2-methoxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide	11
524	(*S*)-2-methoxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide	11
525	(*R*)-*N*-(4-(2-(4-(4-(2-methoxyacetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	49
526	(*R*)-*N*-(4-(2-(4-(4-acetylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	49
527	(*S*)-2-amino-*N*-(4-(5-methyl-2-(4-(4-((1-methyl-1*H*-imidazol-2-yl)methyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide	14

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
528	*N*-(4-(2-(4-(4-(piperidine-4-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide	12
529	(2*R*,4*S*)-4-hydroxy-*N*-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	21
530	1-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)cyclopentanecarboxamide	44
531	(*R*)-*N*-(4-(2-(4-(4-formylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
532	(*R*)-1-(2-hydroxyethyl)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-3-carboxamide	42
533	1-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide	12
534	*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-1*H*-pyrrole-2-carboxamide	12
535	*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-1*H*-imidazole-2-carboxamide	12
536	(*S*)-2-hydroxy-3,3-dimethyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide	20
537	(*R*)-2-cyclohexyl-2-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)acetamide	18
538	(*S*)-2-cyclohexyl-2-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)acetamide	20
539	(*S*)-2-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide	20
540	1-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)cyclobutanecarboxamide	14

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
541	(*R*)-*N*-(4-(2-(6-morpholinopyridin-3-ylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
542	(*S*)-*N*-(4-(2-(3-chloro-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
543	(2*R*,3*R*)-2-amino-3-methyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pentanamide	14
544	1-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)cyclopentanecarboxamide	18
545	(*R*)-*N*-(4-(2-(4-(4-(4-(dimethylamino)butanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
546	(*R*)-*N*-(4-(2-(4-(2-methoxyethyl)-3,4-dihydro-2*H*-benzo[b][1,4]oxazin-7-ylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
547	(*R*)-2-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide	14
548	(*R*)-2-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pentanamide	14
549	(*R*)-2-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)hexanamide	14
550	(*R*)-2-amino-3-methoxy-*N*-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide	14
551	(2*S*,3*R*)-2-amino-3-methyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pentanamide	14
552	(*R*)-*N*-(4-(2-(3-fluoro-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
553	*N*-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-2-(1*H*-tetrazol-1-yl)acetamide	24

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
554	(*S*)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)indoline-2-carboxamide	45
555	(*R*)-tert-butyl 2-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenylcarbamoyl)pyrrolidine-1-carboxylate	45
556	1-acetyl-4-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)piperidine-4-carboxamide	44
557	(*R*)-2-amino-3-methoxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide	14
558	(*S*)-*N*-(4-(2-(3-fluoro-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
559	(*R*)-2-amino-*N*-(4-(2-(3-fluoro-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide	14
560	2-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)acetamide	18
561	(*R*)-*N*-(4-(2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
562	(*R*)-*N*-(4-(2-(4-(4-((1-methyl-1*H*-pyrrol-2-yl)methyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
563	(*R*)-*N*-(4-(2-(4-(4-((*R*)-pyrrolidin-2-ylmethyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide	45
564	(2*S*,3a*S*,7a*S*)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)octahydro-1*H*-indole-2-carboxamide	45
565	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)cyclopropanecarboxamide	12
566	N-(4-{5-methyl-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)cyclopropanecarboxamide	12

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
567	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)valinamide	14
568	N-(4-{2-[(4-{4-[(1-methyl-1H-imidazol-2-yl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
569	N-(4-{2-[(3,5-dimorpholin-4-ylphenyl)amino]-5-methylpyrimidin-4-yl}phenyl)acetamide	6
570	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-alaninamide	14
571	N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
572	2-amino-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-phenylacetamide	4
573	N-(4-{5-methyl-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	5
574	3-(methyloxy)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)propanamide	12
575	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)prolinamide	13
576	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-alaninamide	14
577	N-(4-{2-[(4-{4-[3-(dimethylamino)-2,2-dimethylpropyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
578	N-(4-{2-[(4-{4-[3-(methyloxy)propanoyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
579	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-1,3-thiazole-4-carboxamide	12

Cmpd No.	Name	Can Be Made According To Synthetic Example #:
580	2,6-dichloro-N-(3-{[4-(2,3-dihydro-1,4-benzodioxin-6-yl)pyrimidin-2-yl]amino}propyl)benzamide	27
581	N-(4-{2-[(2-methyl-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	3
582	N-(4-{2-[(4-pyrrolidin-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	3
583	N-[4-(2-{[4-(diethylamino)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	3
584	N-(4-{2-[(4-azepan-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	3
585	N-{4-[2-({4-[methyl(2-phenylethyl)amino]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	3
586	N-[4-(2-{[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	3
587	N-[4-(2-{[4-(2-oxopiperidin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	3
588	N-[4-(2-{[4-(2-methylpiperidin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	3
589	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-valinamide	45
590	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-valinamide	45
591	2-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)alaninamide	14
592	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)tryptophanamide	14

593	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamide	14
594	O-(1,1-dimethylethyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-serinamide	45
595	3-amino-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)tetrahydrofuran-3-carboxamide	14
596	bis(1,1-dimethylethyl) (2R)-2-{[(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)amino]carbonyl}piperazine-1,4-dicarboxylate	14
597	N-(4-{2-[(4-{4-[2-(2-fluorophenyl)acetyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
598	N-(4-{2-[(4-{4-[2-(2-methylphenyl)acetyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
599	N-(4-{2-[(4-{4-[2-(3-fluorophenyl)acetyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
600	N-{4-[2-({4-[4-(3-thienylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
601	N-(4-{2-[(4-{4-[(6-chloropyridin-3-yl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
602	N-(4-{2-[(4-{4-[(3-methylfuran-2-yl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
603	N-(4-(2-(4-(4-(3-fluoro-2-methylbenzoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	7
604	N-(4-(2-(4-(4-(1H-imidazole-4-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	7
605	N-(4-(2-(4-(4-(2-methoxynicotinoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	7

606	N-(4-(2-(4-(4-(4-fluoro-3-methylbenzoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide	7
607	N-{4-[2-({4-[4-(naphthalen-2-ylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	36
608	N-{4-[2-({4-[4-(quinolin-8-ylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	36
609	N-[4-(2-{[4-(4-{[4-(1,1-dimethylethyl)phenyl]sulfonyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	36
610	N-[4-(2-{[4-(4-{[5-bromo-2-(methyloxy)phenyl]sulfonyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	36
611	N-(4-{2-[(4-{4-[(phenylmethyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	36
612	N-[4-(2-{[4-(4-{[3-(trifluoromethyl)phenyl]sulfonyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	36
613	N-(4-{2-[(4-{4-[(2-methylphenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	36
614	N-(4-{2-[(4-{4-[(3-fluorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	36
615	N-(4-{2-[(4-{4-[(2,4-difluorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	36
616	N-{4-[2-({3-[4-({4-[(trifluoromethyl)oxy]phenyl}methyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49
617	N-(4-{2-[(3-{4-[(1-methyl-1H-imidazol-2-yl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
618	N-{4-[2-({3-[4-({2-[(trifluoromethyl)oxy]phenyl}methyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49
619	N-(4-{2-[(3-{4-[(3-chlorophenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
620	N-{4-[2-({3-[4-(2,3-dihydroxypropyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49

621	N-{4-[2-({3-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49
622	N-{4-[2-({3-[4-(pyridin-2-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49
623	N-{4-[2-({3-[4-(pyridin-3-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49
624	N-{4-[2-({3-[4-(1H-pyrrol-2-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49
625	4-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-N-(phenylmethyl)piperazine-1-carboxamide	53
626	N-[4-(2-{[3-(4-{[2-(methyloxy)phenyl]carbonyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	7
627	N-{4-[2-({3-[4-(1H-pyrazol-4-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
628	N-{4-[2-({3-[4-(3-pyridin-3-ylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
629	N-(4-{2-[(3-{4-[3-(methyloxy)propanoyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
630	N-[4-(2-{[3-(4-{2-[(4-fluorophenyl)oxy]acetyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	7
631	N-{4-[2-({3-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
632	N-{4-[2-({3-[4-(pyridin-4-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
633	N-{4-[2-({3-[4-(pyridin-2-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
634	N-(4-{2-[(3-{4-[(2-methylphenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
635	N-{4-[2-({3-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
636	N-{4-[2-({3-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
637	N-{4-[2-({3-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
638	N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-3-carboxamide	12

639	(2R)-N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-2-carboxamide	12
640	(2S)-N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-2-carboxamide	12
641	N-(4-{2-[(4-{4-[(2-fluorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	36
642	N-(4-{2-[(3-{4-[(3,5-dichlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
643	ethyl 3-[(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)amino]-3-oxopropanoate	12
644	N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}tetrahydrofuran-3-carboxamide	7
645	N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}tetrahydrofuran-3-carboxamide	7
646	N-ethyl-4-{4-[(4-{4-[(tetrahydrofuran-3-ylcarbonyl)amino]phenyl}pyrimidin-2-yl)amino]phenyl}piperazine-1-carboxamide	53
647	N-[4-(2-{[4-(4-D-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-3-carboxamide	7
648	N-[4-(2-{[4-(4-L-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-3-carboxamide	7
649	N-[4-(2-{[4-(4-D-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-3-carboxamide	7
650	N-[4-(2-{[4-(4-L-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-3-carboxamide	7
651	N-{4-[2-(1H-benzimidazol-6-ylamino)-5-methylpyrimidin-4-yl]phenyl}acetamide	5
652	4-(4-furan-2-ylphenyl)-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine	9
653	N-(4-morpholin-4-ylphenyl)-4-[4-(pyrimidin-2-ylamino)phenyl]pyrimidin-2-amine	9
654	N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}-5-methylpyrimidin-4-yl)phenyl]cyclopropanecarboxamide	51

655	N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]cyclopropanecarboxamide	51
656	N-(4-{2-[(3,5-dimorpholin-4-ylphenyl)amino]-5-methylpyrimidin-4-yl}phenyl)-N^2,N^2-dimethylglycinamide	6
657	N^2,N^2-dimethyl-N-(4-{5-methyl-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)glycinamide	12
658	N-(4-{5-methyl-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-prolinamide	45
659	N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-prolinamide	52
660	N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-prolinamide	52
661	N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-prolinamide	52
662	N-ethyl-4-[4-({4-[4-(D-prolylamino)phenyl]pyrimidin-2-yl}amino)phenyl]piperazine-1-carboxamide	53
663	N-[4-(2-{[4-(4-D-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-D-prolinamide	52
664	N-[4-(2-{[4-(4-L-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-D-prolinamide	52
665	1-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)piperidine-2-carboxamide	12
666	N-{4-[2-({4-[4-(piperidin-4-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
667	1-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-prolinamide	12
668	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-pyridin-4-ylacetamide	12

669	2-(3-fluorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	12
670	3-(4-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)propanamide	12
671	2-(3-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	12
672	2-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-3-phenylpropanamide	12
673	(1R,2R)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-phenylcyclopropanecarboxamide	12
674	2-(4-fluorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	12
675	3-(2-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)propanamide	12
676	3-(3-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)propanamide	12
677	3-(2-fluorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)propanamide	Made according to the examples described herein
678	Nalpha,Nalpha-dimethyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-phenylalaninamide	12
679	2-(2-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	12
680	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-pyridin-2-ylacetamide	12
681	2-(4-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	12
682	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-{4-[(trifluoromethyl)oxy]phenyl}acetamide	12

683	2-[2-(methyloxy)phenyl]-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	12
684	2-[3-(methyloxy)phenyl]-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	12
685	2-[4-(methyloxy)phenyl]-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	12
686	N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-D-alaninamide	51
687	N-{4-[2-({4-[4-(N,N-dimethylglycyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
688	N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-3-(methyloxy)propanamide	51
689	(2R)-2-amino-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-phenylethanamide	45
690	N^2,N^2-dimethyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-alaninamide	12
691	1-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-prolinamide	12
692	N^2,N^2-dimethyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-alaninamide	12
693	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-1-phenylcyclopropanecarboxamide	12
694	2-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)butanamide	12
695	(2S)-1-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)azetidine-2-carboxamide	12
696	2,4,6-trichloro-N-(3-{[4-(4-methyl-2-thienyl)pyrimidin-2-yl]amino}propyl)benzamide	27

697	N-[3-({4-[3,4-bis(methyloxy)phenyl]pyrimidin-2-yl}amino)propyl]-2,6-dichlorobenzamide	27
698	2,6-dichloro-N-[3-({4-[(4-morpholin-4-ylphenyl)amino]pyrimidin-2-yl}amino)propyl]benzamide	27
699	2,6-dichloro-N-(3-{[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-fluoropyrimidin-2-yl]amino}propyl)benzamide	27
700	2,6-dichloro-N-{3-[(4-{3-[(dimethylamino)methyl]phenyl}pyrimidin-2-yl)amino]propyl}benzamide	27
701	2,6-dichloro-N-[3-({4-[3-(1-methylethyl)phenyl]pyrimidin-2-yl}amino)propyl]benzamide	27
702	2,6-dichloro-N-{3-[(4-{4-[(1-methylethyl)oxy]phenyl}pyrimidin-2-yl)amino]propyl}benzamide	27
703	N-[3-({4-[3-(acetylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2,6-dichlorobenzamide	27
704	2,6-dichloro-N-[3-({4-[(E)-2-phenylethenyl]pyrimidin-2-yl}amino)propyl]benzamide	27
705	phenyl (4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)carbamate	27
706	phenylmethyl (4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)carbamate	17
707	N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-3-(methyloxy)propanamide	7
708	N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}cyclopropanecarboxamide	7
709	4-{4-[(4-{4-[(cyclopropylcarbonyl)amino]phenyl}pyrimidin-2-yl)amino]phenyl}-N-ethylpiperazine-1-carboxamide	7
710	N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-3-(methyloxy)propanamide	7

711	3-(methyloxy)-N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}propanamide	7
712	N-ethyl-4-(4-{[4-(4-{[3-(methyloxy)propanoyl]amino}phenyl)pyrimidin-2-yl]amino}phenyl)piperazine-1-carboxamide	53
713	N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-2-phenylacetamide	51
714	1-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyrrolidin-2-one	25
715	N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-alaninamide	52
716	N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-alaninamide	52
717	(2S)-2-hydroxy-3-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)butanamide	18
718	(2R)-2-hydroxy-3-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)butanamide	18
719	N-{4-[2-({4-[4-(cyclopropylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-alaninamide	52
720	(2S)-2-amino-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-phenylethanamide	45
721	2-amino-2-(4-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	14
722	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)morpholine-3-carboxamide	14
723	1-ethyl-3-[4-(2-{[4-(4-ethylpiperazin-1-yl)-3-(methyloxy)phenyl]amino}pyrimidin-4-yl)phenyl]urea	53
724	N-[4-(2-{[4-(4-ethylpiperazin-1-yl)-3-(methyloxy)phenyl]amino}pyrimidin-4-yl)phenyl]-D-prolinamide	24

725	N-[4-(2-{[4-(4-ethylpiperazin-1-yl)-3-(methyloxy)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	3
726	1-(2,6-dichlorophenyl)-3-(3-{[4-(4-methyl-2-thienyl)pyrimidin-2-yl]amino}propyl)urea	27
727	1-[2-fluoro-5-(trifluoromethyl)phenyl]-3-(3-{[4-(4-methyl-2-thienyl)pyrimidin-2-yl]amino}propyl)urea	27
728	2,6-dichloro-N-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]benzenesulfonamide	36
729	N-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2,6-difluorobenzenesulfonamide	36
730	N-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]naphthalene-2-sulfonamide	36
731	N-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]-3,4-bis(methyloxy)benzenesulfonamide	36
732	3-chloro-N-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]propane-1-sulfonamide	36
733	N-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]propane-1-sulfonamide	17
734	methyl (3-{[4-(2,4-dichlorophenyl)pyrimidin-2-yl]amino}propyl)carbamate	17
735	1-methylethyl (3-{[4-(2,4-dichlorophenyl)pyrimidin-2-yl]amino}propyl)carbamate	17
736	phenylmethyl (3-{[4-(2,4-dichlorophenyl)pyrimidin-2-yl]amino}propyl)carbamate	17
737	N-{4-[2-({[3-(3-chlorophenyl)isoxazol-5-yl]methyl}amino)pyrimidin-4-yl]phenyl}acetamide	3
738	ethyl 4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)piperidine-1-carboxylate	17
739	1,1-dimethylethyl 4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)piperidine-1-carboxylate	1

740	N-(4-{2-[(4-cyanophenyl)amino]pyrimidin-4-yl}phenyl)acetamide	3
741	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyridin-4-yl}phenyl)acetamide	51
742	1,1-dimethylethyl {1-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]piperidin-4-yl}carbamate	1
743	N-{4-[2-({4-[4-(cyclopropylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}cyclopropanecarboxamide	52
744	N-{1-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]piperidin-4-yl}acetamide	1
745	4-(4-aminophenyl)-N-[4-(4-aminopiperidin-1-yl)phenyl]pyrimidin-2-amine	1
746	N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}-5-methylpyrimidin-4-yl)phenyl]-3-(methyloxy)propanamide	51
747	N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}tetrahydrofuran-2-carboxamide	52
748	N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}tetrahydrofuran-2-carboxamide	52
749	N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}tetrahydrofuran-2-carboxamide	52
750	N-cyclopropyl-4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}benzamide	9
751	N-[2-(methyloxy)ethyl]-4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}benzamide	9
752	2,6-dichloro-N-{3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]propyl}benzamide	27

753	2,6-dichloro-N-(3-{[4-(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)pyrimidin-2-yl]amino}propyl)benzamide	27
754	2,6-dichloro-N-(3-{[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-methylpyrimidin-2-yl]amino}propyl)benzamide	27
755	N-(4-{2-[(3-{[(2,6-dichlorophenyl)carbonyl]amino}propyl)amino]pyrimidin-4-yl}phenyl)morpholine-4-carboxamide	27
756	2,6-dichloro-N-{3-[(4-{4-[(cyclopropylcarbonyl)amino]phenyl}pyrimidin-2-yl)amino]propyl}benzamide	27
757	N-(4-{2-[(3-{[(2,6-dichlorophenyl)carbonyl]amino}propyl)amino]pyrimidin-4-yl}phenyl)thiophene-2-carboxamide	27
758	2,6-dichloro-N-(3-{[4-(4-{[N-(2-morpholin-4-ylethyl)glycyl]amino}phenyl)pyrimidin-2-yl]amino}propyl)benzamide	27
759	1-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)ethanone	9
760	(1E)-1-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)ethanone oxime	9
761	N-{4-[2-({4-[4-(cyclopropylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-2-phenylacetamide	7
762	N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2-bromobenzamide	27
763	N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2-fluorobenzamide	27
764	N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2-chlorobenzamide	27
765	N-[4-(2-{[3-(morpholin-4-ylsulfonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	36
766	N-{4-[2-({3-[(cyclohexylmethyl)amino]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	28

767	N-(4-{2-[(3-{[(5-bromo-2-fluorophenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	28
768	N-(4-{2-[(3-{[(2,5-dimethylphenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	28
769	N-(4-{2-[(3,4-dimorpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	6
770	N-{4-[2-({4-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}cyclopropanecarboxamide	52
771	N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}butanamide	52
772	N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}butanamide	52
773	N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}butanamide	52
774	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridine-2-carboxamide	12
775	2-hydroxy-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)benzamide	12
776	3-(methyloxy)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)benzamide	12
777	4-(methyloxy)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)benzamide	12
778	4-chloro-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)benzamide	12
779	(2R)-N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-2-carboxamide	51
780	(2S)-N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-2-carboxamide	51

781	1-(2-hydroxyethyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-prolinamide	42
782	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)thiophene-2-carboxamide	12
783	N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-3-carboxamide	51
784	2-phenyl-N-{4-[2-({4-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	52
785	3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-(diphenylmethyl)benzamide	3
786	N-[4-(2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	51
787	N-{4-[2-({4-[4-(phenylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
788	N-{4-[2-({4-[4-(2-cyclopentylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
789	N-{4-[2-({4-[4-(cyclohexylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
790	N-(4-{2-[(4-{4-[(2-chlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
791	N-(4-{2-[(4-{4-[(3-fluorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
792	N-(4-{2-[(4-{4-[(3-fluoro-4-methylphenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
793	N-(4-{2-[(4-{4-[(3,4-dichlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7

794	N-(4-{2-[(4-{4-[(3,5-dichlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
795	N-[4-(2-{[4-(4-{[3-(methyloxy)phenyl]carbonyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	7
796	N-(4-{2-[(4-{4-[(4-chlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
797	N-(4-{2-[(4-{4-[(4-methylphenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
798	N-(4-{2-[(4-{4-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
799	N-{4-[2-({4-[4-(furan-2-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
800	N-[4-(2-{[4-(4-{2-[(4-fluorophenyl)oxy]acetyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	7
801	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)furan-3-carboxamide	12
802	N-{4-[2-({4-[4-(phenylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	36
803	N-{4-[2-({4-[4-(2-thienylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	36
804	N-(4-{2-[(4-{4-[(4-fluorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	36
805	N-[4-(2-{[4-(4-{[4-(methyloxy)phenyl]sulfonyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	36
806	N-(4-{2-[(4-{4-[(4-chlorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	36
807	N-(4-{2-[(4-{4-[(3-chlorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	36

808	N-{4-[2-({4-[4-(biphenyl-4-ylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	36
809	N-{4-[2-({4-[4-(naphthalen-1-ylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	36
810	N-(4-{2-[(3-{4-[(2-chlorophenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
811	N-[4-(2-{[3-(4-{[3-(methyloxy)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	49
812	N-{4-[2-({3-[4-(3-methylbutyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49
813	N-{4-[2-({3-[4-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49
814	N-{4-[2-({3-[4-(cyclopropylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49
815	N-(4-{2-[(3-{4-[3-(methylthio)propyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
816	N-(4-{2-[(3-{4-[(4-{[3-(dimethylamino)propyl]oxy}phenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	49
817	N-{4-[2-({3-[4-({3-[(trifluoromethyl)oxy]phenyl}methyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	49
818	4-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-N-phenylpiperazine-1-carboxamide	53
819	N-[4-(2-{[3-(4-propanoylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	7
820	N-{4-[2-({3-[4-(phenylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
821	N-{4-[2-({3-[4-(2-phenylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
822	N-{4-[2-({3-[4-(cyclopentylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7

823	N-{4-[2-({3-[4-(2-pyridin-3-ylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
824	N-{4-[2-({3-[4-(2-cyclopentylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
825	N-(4-{2-[(3-{4-[(2-chlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
826	N-(4-{2-[(3-{4-[(4-chlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
827	N-(4-{2-[(3-{4-[(3,4-dichlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
828	N-(4-{2-[(3-{4-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	7
829	N^2,N^2-dimethyl-N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]glycinamide	24
830	3-(methyloxy)-N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]propanamide	24
831	N-(4-{2-[(4-{4-[(2-chlorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide	36
832	N-{4-[2-({3-[4-(cyclopropylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
833	N-{4-[2-({3-[4-(2-cyclopropylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
834	N-[4-(2-{[3-(4-{[3-(methyloxy)phenyl]carbonyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	7
835	N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
836	1-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]piperidine-3-carboxylic acid	3

837	1,1-dimethylethyl methyl{2-[(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)amino]-2-oxoethyl}carbamate	14
838	1,1-dimethylethyl [4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]carbamate	51
839	N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-N^2,N^2-dimethylglycinamide	51
840	4-(4-aminophenyl)-N-[4-(4-ethylpiperazin-1-yl)phenyl]pyrimidin-2-amine	51
841	Nalpha-{[(1,1-dimethylethyl)oxy]carbonyl}-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-phenylalaninamide	45
842	Nalpha-{[(1,1-dimethylethyl)oxy]carbonyl}-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-phenylalaninamide	45
843	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-phenylalaninamide	45
844	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-phenylalaninamide	45
845	N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-L-valinamide	45
846	N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-D-valinamide	45
847	1-ethyl-3-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]urea	53
848	(2R)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)piperidine-2-carboxamide	45
849	N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}-5-methylpyrimidin-4-yl)phenyl]acetamide	51
850	4-{4-[(4-{4-[(N,N-dimethylglycyl)amino]phenyl}pyrimidin-2-yl)amino]phenyl}-N-ethylpiperazine-1-carboxamide	53
851	N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-N^2,N^2-dimethylglycinamide	52

852	N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-N^2,N^2-dimethylglycinamide	52
853	N^2,N^2-dimethyl-N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}glycinamide	52
854	N-{4-[2-({4-[4-(cyclopropylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-N^2,N^2-dimethylglycinamide	52
855	N-[4-(2-{[4-(4-D-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-N^2,N^2-dimethylglycinamide	52
856	N-[4-(2-{[4-(4-L-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-N^2,N^2-dimethylglycinamide	52
857	N-(4-{2-[({1-[(2,6-dichlorophenyl)carbonyl]azetidin-3-yl}methyl)amino]pyrimidin-4-yl}phenyl)acetamide	41
858	N-(4-{2-[(3-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	3
859	N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)cyclohexyl]-2,6-dichlorobenzamide	2
860	N-{4-[2-({[4-(4-methylpiperazin-1-yl)phenyl]methyl}amino)pyrimidin-4-yl]phenyl}acetamide	3
861	N-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,6-dichlorobenzamide	2
862	N-{4-[2-(piperidin-4-ylamino)pyrimidin-4-yl]phenyl}acetamide	1
863	N-{4-[2-({1-[(2,6-dichlorophenyl)carbonyl]piperidin-4-yl}amino)pyrimidin-4-yl]phenyl}acetamide	2
864	N-{4-[2-({4-[(2-hydroxyethyl)oxy]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	33

865	1-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-3-phenylurea	53
866	N-[5-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-2-(4-ethylpiperazin-1-yl)phenyl]-2,6-dichlorobenzamide	30
867	1-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-3-(phenylmethyl)urea	53
868	N^2,N^2-dimethyl-N-{4-[2-({4-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}glycinamide	52
869	N-(3-fluoro-4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)cyclopropanecarboxamide	9
870	N-(4-{2-[(4-{4-[(1-methyl-1H-imidazol-2-yl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)cyclopropanecarboxamide	52
871	N-[4-(2-{[4-(4-L-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	52
872	N-[4-(2-{[4-(4-L-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	7
873	N-[4-(2-{[4-(4-D-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	7
874	N-[4-(2-{[4-(4-D-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide	7
875	N-{4-[2-({4-[4-(2-piperazin-1-ylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide	7
876	N-[4-(2-{[4-(4-L-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-2-carboxamide	52
877	N-[4-(2-{[4-(4-L-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-2-carboxamide	52

878	N-[4-(2-{[4-(4-D-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-2-carboxamide	52
879	N-[4-(2-{[4-(4-D-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-2-carboxamide	52
880	1-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-1H-pyrrole-2-carboxamide	12
881	3-fluoro-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridine-4-carboxamide	12
882	6-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridine-3-carboxamide	12
883	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridazine-4-carboxamide	12
884	2-cyclopropyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide	12
885	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)isoxazole-5-carboxamide	12
886	N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridine-3-carboxamide	12
887	4-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)benzamide	12
888	N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-D-prolinamide	52
889	N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]butanamide	51
890	1-ethyl-3-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]urea	53

JAK-2 Definitions

[00103] The following definitions apply to the JAK-2 compounds described above only. These definitions are not to be considered when determining the scope and meaning of any of the compounds that are not JAK-2 compounds. To the same extent, the definitions for the compounds described herein that are not JAK-2 compounds are not to be considered when determining the scope and meaning of the JAK-2 compounds.

[00104] "Alkyl" is intended to include C_1-C_{20}, more typically, C_1-C_{12} linear or branched structures and combinations thereof, inclusively. "Lower alkyl" is intended to include C_1-C_6 linear or branched structures and combinations thereof, inclusively. For example, "C_6 alkyl" can refer to an *n*-hexyl, *iso*-hexyl, cyclobutylethyl, and the like. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, *s*-butyl, *t*-butyl, isobutyl, pentyl, hexyl and the like. Higher alkyl refers to alkyl groups containing more that six carbon atoms. In this application, alkyl refers to alkanyl, alkenyl, and alkynyl residues (and combinations thereof); it is intended to include cyclohexylmethyl, vinyl, allyl, isoprenyl, and the like. Thus when an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be encompassed; thus, for example, either "butyl" or "C_4 alkyl" is meant to include *n*-butyl, *sec*-butyl, isobutyl, *t*-butyl, isobutenyl and but-2-ynyl groups; and for example, "propyl" or "C_3 alkyl" each include *n*-propyl, propenyl, and isopropyl.

[00105] "Cycloalkyl" means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 14 carbon atoms, 5 to 10 carbon atoms, or 5 to about 7 ring atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Non-limiting examples of multicyclic cycloalkyls include 1-decalin, norbornyl, adamantyl and the like. Cycloalkyls can be fused or bridge ring systems or spirocyclic systems.

[00106] "Alkyl substituted with halo and hydroxy" means an alkyl group substituted with 1, 2, or 3 hydroxy and 1, 2, 3, 4, or 5 halo.

[00107] "Alkylene" refers to straight or branched chain divalent group consisting solely of carbon and hydrogen atoms, containing no unsaturation and having from one to ten carbon atoms, for example, methylene, ethylene, propylene, *n*-butylene and the like. Alkylene is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, fully saturated. Examples of alkylene include ethylene (-CH_2CH_2-), propylene (-$CH_2CH_2CH_2$-), dimethylpropylene (-$CH_2C(CH_3)_2CH_2$-), and cyclohexylpropylene (-$CH_2CH_2CH(C_6H_{13})$).

[00108] "Alkylidene" refers to a straight or branched chain unsaturated divalent group consisting solely of carbon and hydrogen atoms, having from two to ten carbon atoms, for example, ethylidene, propylidene, *n*-butylidene, and the like. Alkylidene is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and,

specifically, double bond unsaturation. The unsaturation present includes at least one double bond.

[00109] "Alkylidyne" refers to a straight or branched chain unsaturated divalent group consisting solely of carbon and hydrogen atoms having from two to ten carbon atoms, for example, propylid-2-ynyl, *n*-butylid-1-ynyl, and the like. Alkylidyne is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, triple bond unsaturation. The unsaturation present includes at least one triple bond.

[00110] Any of the above groups, "alkylene," "alkylidene" and "alkylidyne," when optionally substituted, can contain alkyl substitution which itself contains unsaturation. For example, 2-(2-phenylethynyl-but-3-enyl)-naphthalene (IUPAC name) contains an *n*-butylid-3-ynyl group with a vinyl substituent at the 2-position of said group.

[00111] "Alkoxy" or "alkoxyl" refers to the group -O-alkyl, wherein the term "alkyl" is as defined hereinabove. Examples include methoxy, ethoxy, propoxy, isopropoxy, and the like. Lower alkoxy refers to groups containing one to six carbons.

[00112] "Substituted alkoxy" refers to the group -O-(substituted alkyl), the substitution on the alkyl group generally containing more than only carbon (as defined by alkoxy). Another exemplary substituted alkoxy group is hydroxyalkoxy or –O-alkyl-OH.

[00113] "Aryl" means a monovalent six - to fourteen-membered mono- or multicyclic ring, wherein the monocyclic ring is aromatic and at least one of the rings in the multicyclic ring is aromatic. An aryl can also be six- to ten membered, or six membered. Representative non-limiting examples of aryl include phenyl, naphthyl, and the like.

[00114] "Arylalkyl" means a residue in which an aryl moiety, as defined above, is attached to a parent structure via one of an alkylene, alkylidene, or alkylidyne group. Examples include benzyl, phenethyl, phenylvinyl, phenylallyl and the like. The "alkyl" portion of the group can be one to ten carbons, and in another embodiment, one to six carbons; the latter can also be referred to as C_{1-6} arylalkyl. When a group is referred to as or "-(C_1-C_6)alkylaryl," an aryl moiety is attached to a parent structure via an alkylene group. Examples include benzyl, phenethyl, and the like.

[00115] In some examples, as appreciated by one of ordinary skill in the art, two adjacent groups on an aromatic system can be fused together to form a ring structure. The fused ring structure can contain heteroatoms and can be optionally substituted with one or

more groups. It should additionally be noted that saturated carbons of such fused groups (*i.e.* saturated ring structures) can contain two substitution groups.

[00116] "Fused-polycyclic" or "fused ring system" refers to a polycyclic ring system that contains bridged or fused rings; that is, where two rings have more than one shared atom in their ring structures. In this application, fused-polycyclics and fused ring systems includes non-aromatic and aromatic systems. Typically, but not necessarily, fused-polycyclics share a vicinal set of atoms, for example naphthalene or 1,2,3,4-tetrahydro-naphthalene. A spiro ring system is not a fused-polycyclic by this definition, but fused polycyclic ring systems of the invention can themselves have spiro rings attached thereto via a single ring atom of the fused-polycyclic.

[00117] "Halogen" or "halo" refers to fluorine, chlorine, bromine or iodine. "Haloalkyl" and "haloaryl" refer generically to alkyl and aryl groups that are substituted with one or more halogens, respectively. Non-limiting examples of "haloalkyl" include -CH_2F, -$CHCl_2$ or -CF_3.

[00118] "Heteroatom" refers to O, S, N, or P.

[00119] "Heterocyclyl" refers to a stable three- to fifteen-membered ring substituent that consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, phosphorus, oxygen and sulfur. For purposes of this invention, the heterocyclyl substituent can be a monocyclic, bicyclic or tricyclic ring system, which can include fused or bridged ring systems as well as spirocyclic systems. The terms "heterocycloalkyl" and "heteroaryl" are groups that are encompassed by the broader term "heterocyclyl." The nitrogen, phosphorus, carbon or sulfur atoms in the heterocyclyl group can be optionally oxidized to various oxidation states. In a specific example, the group -$S(O)_{0-2}$-, refers to -S- (sulfide), -S(O)- (sulfoxide), and -SO_2- (sulfone) respectively. For convenience, nitrogens, particularly but not exclusively, those defined as annular aromatic nitrogens, are meant to include their corresponding *N*-oxide form, although not explicitly defined as such in a particular example. Thus, for a compound of the invention having, for example, a pyridyl ring; the corresponding pyridyl-*N*-oxide is meant to be included as another compound of the invention. In addition, annular nitrogen atoms can be optionally quaternized; and the ring substituent can be partially or fully saturated or aromatic. Examples of heterocyclyl groups include, but are not limited to, azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofuranyl, carbazoyl, cinnolinyl, dioxolanyl,

indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrazoyl, tetrahydroisoquinolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, dihydropyridinyl, tetrahydropyridinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolinyl, oxazolidinyl, triazolyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl, quinolyl, isoquinolyl, decahydroisoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, dioxaphospholanyl, oxadiazolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, and tetrahydroquinolinyl.

[00120] "Heterocycloalkyl" refers to a stable 4-12 membered monocyclic, bicyclic or tricyclic ring containing one or more heteroatoms.

[00121] "Heterocycloalkylalkyl" refers to a heterocycloalkyl, as defined herein, attached to the parent moiety through an "alkyl," as defined herein. One non-limiting example of heterocycloalkyl includes piperadinyl. Another non-limiting example of heterocycloalkyl includes piperadinyl. Another non-limiting example of heterocycloalkyl includes piperazinyl. Another non-limiting example of heterocycloalkyl includes furanyl. Another non-limiting example of heterocycloalkyl includes pyrrolidinyl. Another non-limiting example of heterocycloalkyl includes morpholinyl.

[00122] "Amino" refers to $-NH_2$.

[00123] "Alkylamino" refers to –NH(alkyl), wherein "alkyl" is as defined above, and wherein the the parent moiety is attached to the nitrogen atom.

[00124] "Dialkylamino" refers to $-N(alkyl)_2$, wherein "alkyl" is as defined above, and wherein the parent moiety is attached to the nitrogen atom.

[00125] "Dialkylaminoalkyl refers to $-(alkyl)N(alkyl)_2$, wherein "alkyl" is as defined above. One such non-limiting example of "dialkylaminoalkyl" includes $-CH_2C(CH_3)_2CH_2N(CH_3)_2$.

[00126] "Aminoalkyl" refers to -(alkyl)NH, wherein "alkyl" is as defined above, and wherein the the parent moiety is attached to the alkyl group.

[00127] "Aminoalkyl" refers to -(alkyl)NH_2, wherein "alkyl" is as defined above, and wherein the the parent moiety is attached to the alkyl group. The amino group can be attached at any point along the alkyl group. Non-limiting examples of aminoalkyl include $-CH(NH_2)CH_3$,

[00128] Phenoxy refers to a -alkyl-O-phenyl group, wherein "alkyl" is as defined above, and the parent moiety is attached to the alkyl group.

[00129] "Heteroaryl" means a 5- to 12-membered, monocyclic aromatic heterocyclyl (where heterocyclyl is defined herein) or bicyclic heterocyclyl ring system (where at least one of the rings in the bicyclic system is aromatic) where the monocyclic ring and at least one of the rings in the bicyclic ring system contains one, two, three, four, or five heteroatom(s) selected from nitrogen, oxygen, phosphorous, and sulfur. The ring containing the heteroatom can be aromatic or non-aromatic. Representative examples include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzdioxolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl, thiadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. Fused, bridged, and spiro moieties are also included within the scope of this definition.

[00130] "Carbonyl" refers to the group "-C(O)-", which is bivalent.

[00131] "Aminocarbonyl" refers to the group "-C(O)-NH_2," wherein the parent moiety is attached to the amino group.

[00132] "Alkoxycarbonyl" refers to the group "-C(O)alkoxy," wherein alkoxy is as defined above, and the parent moiety is attached to the carbonyl. A non-limiting example includes $-C(O)-OC(CH_3)_3$.

[00133] When a group is referred to as "-C_1-C_6 alkyl heterocyclyl" the heterocyclyl is attached to a parent structure via one of an alkylene, alkylidene, or alkylidyne group. Examples include (4-methylpiperazin-1-yl) methyl, (morpholin-4-yl) methyl, (pyridine-4-yl) methyl, 2-(oxazolin-2-yl) ethyl, 4-(4-methylpiperazin-1-yl)-2-butenyl, and the like.

Both the heterocyclyl and the corresponding alkylene, alkylidene, or alkylidyne portion of a heterocyclylalkyl group can be optionally substituted.

[00134] "Hydroxyalkyl" means –alkyl-OH, wherein alkyl is as defined hereinabove.

[00135] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. One of ordinary skill in the art would understand that with respect to any molecule described as containing one or more optional substituents, only sterically practical and/or synthetically feasible compounds are meant to be included. "Optionally substituted" refers to all subsequent modifiers in a term. So, for example, in the term "optionally substituted arylalkyl," both the "alkyl" portion and the "aryl" portion of the molecule may or may not be substituted. A list of exemplary optional substitutions is presented below in the definition of "substituted."

[00136] Unless otherwise specified, the term "optionally substituted" applies to the chemical moiety immediately preceding it. For instance, if a variable group (such as R) is defined as aryl, optionally substituted alkyl, or cycloalkyl, then only the alkyl group is optionally substituted.

[00137] In the case where there is a point of attachment for a monovalent substituent, such as $-CH_3$, $-NH_2$, or -OH, the indication of where the point of attachment is is not necessary. That is, $-CH_3$ has the same meaning as CH_3, $-NH_2$ has the same meaning as NH_2, and -OH has the same meaning as OH.

[00138] In Table I(J), where there appears to be an empty valence for oxygen or nitrogen for any of the compounds listed in this table, where the name of the structure requires that the empty valence is filled with hydrogen, it is assumed that the missing valence is filled with hydrogen for each of these cases.

[00139] The term "other active agents" or "other active agents described herein" as used in the combination of JAK-2 inhibitors with other active agents, means any of the Raf inhibitors, PI3K inhibitors, PI3Kα inhibitors, mTor inhibitors, Akt inhibitors, EGFR inhibitors, ErbB2 inhibitors, VEGFR inhibitors, c-Met inhibitors, c-Kit inhibitors, Ret inhibitors, IFG1R inhibitors, BCR-Abl inhibitors, Flt3 inhibitors, Src inhibitors, described within this application, as well as any of the chemotherapeutic agents described herein, such as the taxanes.

[00140] "Saturated bridged ring system" refers to a bicyclic or polycyclic ring system that is not aromatic. Such a system can contain isolated or conjugated unsaturation, but not aromatic or heteroaromatic rings in its core structure (but can have aromatic substitution thereon). For example, hexahydro-furo[3,2-b]furan, 2,3,3a,4,7,7a-hexahydro-1H-indene, 7-aza-bicyclo[2.2.1]-heptane, and 1,2,3,4,4a,5,8,8a-octahydro-naphthalene are all included in the class "saturated bridged ring system.

[00141] "Spirocyclyl" or "spirocyclic ring" refers to a ring originating from a particular annular carbon of another ring. For example, as depicted below, a ring atom of a saturated bridged ring system (rings B and B'), but not a bridgehead atom, can be a shared atom between the saturated bridged ring system and a spirocyclyl (ring A) attached thereto. A spirocyclyl can be carbocyclic or heteroalicyclic.



[00142] "Substituted" alkyl, aryl, and heterocyclyl, refer respectively to alkyl, aryl, and heterocyclyl, one or more (for example up to about five, in another example, up to about three) hydrogen atoms are replaced by a substituent independently selected from: alkyl (for example, fluoromethyl), aryl (for example, 4-hydroxyphenyl), arylalkyl (for example, 1-phenyl-ethyl), heterocyclylalkyl (for example, 1-pyridin-3-yl-ethyl), heterocyclyl (for example, 5-chloro-pyridin-3-yl or 1-methyl-piperidin-4-yl), alkoxy, alkylenedioxy (for example methylenedioxy), amino (for example, alkylamino and dialkylamino), amidino, aryloxy (for example, phenoxy), arylalkyloxy (for example, benzyloxy), carboxy (-CO_2H), carboalkoxy (that is, acyloxy or -OC(=O)R), carboxyalkyl (that is, esters or -CO_2R), carboxamido, benzyloxycarbonylamino (CBZ-amino), cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, thiol, halogen, hydroxy, oxo, carbamyl, acylamino, and sulfonamido. Thus, an optionally substituted moiety is one that may or may not have one or more substituents, and each of the substituents may or may not have one or more substituents. But where a first optionally substituted group can be substituted by a second optionally substituted group, the second substituent cannot be further substituted.

[00143] Some of the compounds described herein can have imino, amino, oxo or hydroxy substituents off aromatic heterocyclyl systems. For purposes of this disclosure, it

is understood that such imino, amino, oxo or hydroxy substituents can exist in their corresponding tautomeric form, *i.e.*, amino, imino, hydroxy or oxo, respectively.

UTILITY OF JAK-2 COMPOUNDS

[00144] The compounds of Formula I(J) are useful for treating diseases, particularly myeloproliferative disorders, for example, myelofibrosis, thrombocythemia, polycythemia vera (PV), essential thrombocythemia (ET), agnogenic myeloid metaplasia (AMM), also referred to as idiopathic myelofibrosis (IMF), and chronic myelogenous leukemia (CML); and cancer, for example, ovarian cancer, cervical cancer, breast cancer, colorectal cancer, glioblastomas, prostrate, colon, melanoma, leukemia and haematopoietic malignancies, as described above, in which JAK-2 activity contributes to the pathology and/or symptomatology of the disease.

[00145] Suitable *in vitro* assays for measuring JAK-2 activity and the inhibition thereof by compounds are known. For further details of an *in vitro* assay for measuring JAK-2 activity see Biological Examples.

[00146] Assays for measurement of efficacy in treatment of various cancers are described in Biological Examples.

[00147] Suitable *in vivo* models of various cancers are known to those of ordinary skill in the art. For further details of *in vivo* assays see Biological Examples.

Synthetic Procedures for JAK-2 Compounds

[00148] The JAK-2 compounds described herein, or their pharmaceutically acceptable salts, can have asymmetric carbon atoms, oxidized sulfur atoms or quaternized nitrogen atoms in their structure.

[00149] The JAK-2 compounds described herein and their pharmaceutically acceptable salts can exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. The compounds can also exist as geometric isomers. All such single stereoisomers, racemates and mixtures thereof, and geometric isomers are intended to be within the scope of this invention.

[00150] It is assumed that when considering generic descriptions of JAK-2 compounds for the purpose of constructing a compound, such construction results in the creation of a stable structure. That is, one of ordinary skill in the art would recognize that theoretically some constructs which would not normally be considered as stable compounds (that is, sterically practical and/or synthetically feasible, *supra*).

[00151] Methods for the preparation and/or separation and isolation of single stereoisomers from racemic mixtures or non-racemic mixtures of stereoisomers are well known in the art. For example, optically active (R)- and (S)- isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. Enantiomers (R- and S-isomers) can be resolved by methods known to one of ordinary skill in the art, for example by: formation of diastereoisomeric salts or complexes which can be separated, for example, by crystallization; via formation of diastereoisomeric derivatives which can be separated, for example, by crystallization, selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where a desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step can be required to liberate the desired enantiomeric form. Alternatively, specific enantiomer can be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents or by converting on enantiomer to the other by asymmetric transformation. For a mixture of enantiomers, enriched in a particular enantiomer, the major component enantiomer can be further enriched (with concomitant loss in yield) by recrystallization.

[00152] In addition, the JAK-2 compounds can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the present invention.

[00153] In addition, it is intended that the JAK-2 compounds are made either using standard organic synthetic techniques, including combinatorial chemistry or by biological methods, such as bacterial digestion, metabolism, enzymatic conversion, and the like.

[00154] Scheme 1 for the JAK-2 compounds below depicts the general synthetic procedure for the JAK-2 compounds. Synthesis of the JAK-2 compounds is not limited by the procedure of Scheme 1. One skilled in the art will know that other procedures can be used to synthesize the JAK-2 compounds, and that the procedure described in Scheme 1 is only one such procedure. In the descriptions below, one of ordinary skill in the art would recognize that specific reaction conditions, added reagents, solvents, and reaction

temperatures can be modified for the synthesis of the JAK-2 compounds described herein. Thus, the general synthetic procedure depicted in Scheme 1 in conjunction with the specific examples that follow provide sufficient information and guidance to allow one of ordinary skill in the art to synthesize the JAK-2 compounds.

[00155] Compounds of Formula I(J) can be prepared according to Scheme 1:

Scheme 1



[00156] The synthesis of compounds of Formula **I(J)** proceeds from commercially available reagents and employs standard techniques. Standard Suzuki coupling reactions conditions can be used to convert dichloropyrimindines of Formula **A** (commercially available from Sigma Aldrich) and boronic acids of Formula **B** (commercially available from Sigma Aldrich, Fisher Scientific, or Combi-Blocks Inc.), where R^{25}, Z and and n1 are as defined in the Detailed Description of the Invention, to 4-substituted-2-chloropyrimidines of Formula **C**. Compounds of Formula **D1** and **I** can be generated by

reaction of **C** with the corresponding amines (**F1**, available from Fluka) or anilines (**F2**, available from Sigma Aldrich). Compounds of Formula **D1** can be further transformed to amides of Formula **E** using standard peptide coupling conditions with carboxylic acids or reaction with acid chlorides. For instance, **D1** ca be reacted with an intermediate of Formula $LG^1C(O)R^4$ where LG^1 is a leaving group under acylation conditions and R^4 is phenyl optionally substituted with 1, 2, 3, 4, or 5 R^{11} groups, wherein R^{11} is as defined in the Detailed Description of the Invention to yield a compound of Formula **E**.

Synthetic Examples for JAK-2 Compounds

[00157] The following examples serve to more fully describe the manner of making the JAK-2 compounds described herein. These examples in no way serve to limit the scope of the JAK-2 compounds or the JAK-2 inhibitors, but rather are presented for illustrative purposes. All references cited herein are incorporated by reference in their entirety. Generally, each example is set out below with a corresponding multi-step synthesis procedure. Following the specific examples is a list of compounds that were made in a similar way.

Example 1

N-(4-{2-[(3-aminophenyl)amino]pyrimidin-4-yl}phenyl)acetamide (Compound 58)

a) N-(4-(2-chloropyrimidin-4-yl)phenyl)acetamide (C_1)



A_1 B_1 C_1

[00158] A flask was charged with 2,4-dichloropyrimindine A_1 (650 mg, 4.4 mmol), 4-acetoamidophenylboronic acid B_1 (820 mg, 4.6 mmol), dicholor[1,1'-bis(diphenyl-phosphino)ferrocenepalladium (480 mg, 0.56 mmol, 15 mol %), and triethylamine (1.5 mL, 11 mmol). Ethyleneglycoldimethylether (30 mL) was added to the flask and the mixture was purged with N_2 for 5 minutes. The reaction mixture was stirred under an N_2 atmosphere at 80 °C for 12 hours, after which time, ether was added and the reaction mixture was filtered. The product, C_1, was isolated by removal of the solvent with a rotary evaporator and used without further purification. LCMS: m/z 248 $(M+H)^+$.

b) N-(4-{2-[(3-aminophenyl)amino]pyrimidin-4-yl}phenyl)acetamide (58)



C_1 F1 58

[00159] A flask containing a solution of C_1 (500 mg, 2.0 mmol) and 3-boc-amino-aniline **F** (687 mg, 3.3 mmol) in nBuOH (5 mL) was immersed in an oil bath at 180 °C for 30 mins. The mixture was cooled to ambient temperature and to the black residue was added aqueous HCl and MeOH. The aqueous layer was twice washed with ethylacetate. The aqueous layer was then basified with NaOH and extracted twice with ethylacetate. The organic layer was washed with brine and dried with sodium sulfate. The solvent was removed on a rotary evaporator and the product was purified by HPLC with TFA/ACN as eluent. The TFA salt was removed by extraction with sodium hydroxide and ethylacetate to afford the title compound **58.**

Example 2

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,6-dichlorobenzamide (Compound 7)



58 G 7

[00160] A flask was charged with **58** (638 mg, 2.0 mmol), 2,6-dichlorobenzoylchloride **G** (350 µL, 2.4 mmol), diispropylethylamine (1.1 mL, 6 mmol) and THF (50 mL). The reaction mixture was stirred at 70 °C for 6 hours. The crude mixture was concentrated on a rotary evaporator and the crude product was purified by HPLC with TFA/ACN as eluent. The title compound **7** was isolated by precipitation from ACN and washed with ether. ^{1}H-NMR (400MHz, d_6-DMSO): 10.718 ppm (s, 1H), 10.269 ppm (s, 1H), 9.678 ppm (s, 1H), 8.507 ppm (d, 1H), 8.419 ppm (s, 1H), 8.215 ppm (d, 2H), 7.758 ppm (d, 2H), 7.608 ppm (d, 2H), 7.532 ppm (t, 1H), 7.472 ppm (d, 1H), 7.380 ppm (d, 1H), 7.301 ppm (t, 1H), 7.216 ppm (d, 1H), 2.085 ppm (s, 3H); MS (EI) $C_{25}H_{19}Cl_2N_5O_2$: 492.2 (MH^+).

Example 3

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide (18)



C_1 H 18

[00161] A flask was charged with C_1 (500 mg, 2.0 mmol), 4-morpholinoaniline **H** (540 mg, 3.0 mmol) and *n*BuOH (10 mL). The flask was immersed in a 180 °C oil bath for 30 minutes. The reaction mixture was cooled to ambient temperature and the black residue dissolved in DMF and MeOH. The product was purified by HPLC with TFA/ACN as eluent. The TFA salt was removed by extracting with sodium hydroxide and ethylacetate to afford the title compound (**18**).

^{1}H-NMR (400MHz, d_6-DMSO): 10.533 ppm (s, 1H), 9.408 ppm (s, 1H), 8.447 ppm (d, 1H), 8.114 ppm (d, 2H), 7.813 ppm (d, 2H), 7.705 ppm (d, 2H), 7.288 ppm (d, 1H), 6.982 ppm (br s, 2H), 4.65 ppm (br s, 4H), 3.072 ppm (br s, 2H), 2.108 ppm (s, 3H); MS (EI) $C_{22}H_{23}N_5O_2$: 390.3 (MH^+).

Example 4

N-{1-[(2,6-dichlorophenyl)carbonyl]piperidin-4-yl}-4-(4-methyl-2-thienyl)pyrimidin-2-amine



I G G2

[00162] To a solution of {4-[4-(5-Methyl-thiophen-2-yl)-phenyl]-pyrimidin-2-yl}-piperidin-4-yl-amine hydrochloride **I** (274mg, 1 mmoL) and TEA (0.69mL, 5 mmo) in DMF (5 mL) was added 2,6-dichlorobenzoyl chloride **G** (0.21mL, 1.5 mmol) and the

solution was stirred for 4 h. To the resulting solution was added ethyl acetate (100mL) and the organic layer was washed with 5% LiCl (3 x 50mL), dried over anhydrous sodium sulfate, filtered, and concentrated to yield a residue. This residue was purified by reverse phase HPLC to yield the product **G2** (195mg, 38.9% yield, acetate salt) as a tan solid.

^{1}H NMR (400 MHz, d_6-DMSO): 8.28 (m, 1H), 7.73 (m, 1H), 7.58-7.54 (m, 2H), 7.48-7.46 (m, 1H), 7.32 (s, 1H), 7.27 (m, 1H), 7.01 (m, 1H), 4.47 (m, 1H), 4.03 (m, 1H), 3.30-3.05 (m, 2H), 2.25 (s, 3H), 2.03 (m, 1H), 1.88 (m, 1H), 1.58-1.48 (m, 3H); MS (EI) for $C_{21}H_{20}Cl_2N_4OS$: 447 (MH^+).

Example 5

N-(4-{5-methyl-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide (Compound 574)

a) N-(4-(2-chloro-5-methylpyrimidin-4-yl)phenyl)acetamide (C_2)



A_2 B_1 C_2

[00163] A flask was charged with 5-methly-2,4-dichloropyrimindine C_2 (2.45g, 15.0mmol), 4-acetoamidophenylboronic acid (2.95g, 16.5mmol), dicholor[1,1'-bis(diphenyl-phosphino)ferrocenepalladium B_1 (1.22g, 1.5mmol, 10 mol %), and triethylamine (5.23mL, 37.5mmol). Ethyleneglycoldimethylether (20 mL) and H_2O (5ml) were added to the flask and the mixture was purged with N_2 for 5 minutes. The reaction mixture was stirred under an N_2 atmosphere at 90 °C for 2hours, after which time, ether was added and the reaction mixture was filtered. The product, C_2, was isolated by removal of the solvent with a rotary evaporator and used without further purification. LCMS: m/z 262 $(M+H)^+$.

b) N-(4-{5-methyl-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide



[00164] A flask containing a solution of C_2 (523 mg, 2.0 mmol) and **H** (392 mg, 2.2mmol) in *n*-BuOH (6 mL) was immersed in an oil bath at 180 °C for 3hr. The mixture was cooled to ambient temperature and concentrated in vacuo. The residue was purified by HPLC with Ammonium acetate/ACN as eluent to afford the title compound **574** (531mg, 66%).

^{1}H-NMR (400MHz, d_6-DMSO): 10.15 ppm (s, 1H), 9.27 ppm (s, 1H), 8.31 ppm (s, 1H), 7.72 ppm (d, J = 8.8Hz, 2H), 7.66-7.62 ppm (m, 4H), 6.88 ppm (d, J = 8.8Hz, 2H), 3.73 (t, J = 4.8Hz, 4H), 3.01 (t, J = 4.8Hz, 4H), 2.21 ppm (s, 3H), 2.09 (s, 3H); MS (EI) $C_{23}H_{25}N_5O_2$: 404 $(M+H)^+$.

Example 6

N-(4-(2-(3,5-dimorpholinophenylamino)-5-methylpyrimidin-4-yl)phenyl)acetamide (Compound 570)



[00165] A flask containing a solution of C_2 (288 mg, 1.1 mmol) and H_1 (263 mg, 1.0mmol) in n-BuOH (3 mL) was immersed in an oil bath at 180 °C for 4hr. The mixture was cooled to ambient temperature and concentrated *in vacuo*. The residue was purified

by HPLC with ammonium acetate/acetonitrile (ACN) as eluent to afford the title compound **570** (205mg, 42%).

^{1}H-NMR (400MHz, d_6-DMSO): 10.15 ppm (s, 1H), 9.22 ppm (s, 1H), 8.34 ppm (s, 1H), 7.72 ppm (d, J = 9.2Hz, 2H), 7.69 ppm (d, J = 8.8Hz, 2H), 7.10 ppm (d, J = 2.0Hz, 2H), 6.09 ppm (s, 1H), 3.71 (t, J = 4.8Hz, 8H), 3.03 (t, J = 4.8Hz, 8H), 2.26 ppm (s, 3H), 2.07 (s, 3H); MS (EI) $C_{27}H_{32}N_6O_3$: 489 $(M+H)^+$.

Example 7

'N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide



[00166] A solution of N-(4-(2-(4-(piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl) acetamide (300mg, 0.6mmol) and DIPEA (261ul, 1.50mmol) was treated with isobutyryl chloride at room temperature. After stirring for 10 minutes, the reaction mixture was directly concentrated *in vacuo* and the residue was purified by HPLC TFA/ACN as eluent. TFA salt was removed by using basic resin to afford 111mg (40%) of the title compound **572**.

^{1}H-NMR (400MHz, d_6-DMSO): 10.21 ppm (s, 1H), 9.40 ppm (s, 1H), 8.44 ppm (d, J = 4.8Hz, 1H), 8.11 ppm (d, J = 9.2Hz, 2H), 8.10 ppm (s, 1H), 7.74 ppm (d, J = 8.8Hz, 2H), 7.68 ppm (d, J = 8.8Hz, 1H), 7.28 ppm (d, J = 5.6Hz, 1H), 6.97 (d, J = 9.6Hz, 2H), 3.65-3.61 (m, 4H), 3.08-3.02 (m, 4H), 2.92 ppm (penth, J = 6.8Hz, 1H), 2.09 ppm (s, 3H), 1.03 ppm (s, 3H), 1.01 ppm (s, 3H); MS (EI) $C_{26}H_{30}N_6O_2$: 459 $(M+H)^+$.

Example 8

Methyl (4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)carbamate (Compound 248)



55 248

[00167] To a solution of 4-(4-aminophenyl)-N-(4-morpholinophenyl)pyrimidin-2-amine **55** (100 mg, 0.29 mmol) and DIEA (0.435 mmol, 75 µl) in THF (50 mL) was added methyl chloroformate (0.348 mmol, 27 µl) and the solution was stirred at room temperature for 2 hours. The solution mixture was concentrated, redissolved with MeOH and purified using reverse phase HPLC. The product obtained from the reverse phase HPLC was free base **248**, converted to HCl salt using 3 N HCl and lyophilized to yield the product **248** (60mg, 47% yield) as a yellow solid.

^{1}H-NMR (400MHz, d_6-DMSO): 10.063 ppm (s, 1H), 9.976 ppm (s, 1H), 8.521 ppm (d, 1H), 8.153 ppm (d, 2H), 7.878 ppm (d, 2H), 7.661 ppm (d, 2H), 7.554 ppm (bs, 2H), 7.432 ppm (d, 1H), 3.983 ppm (bs, 4H), 3.707 ppm (s, 3H), 4.435 ppm (bs, 4H); MS (EI) $C_{22}H_{23}N_5O_3HCl$: 475.4 (MH^+).

Example 9

4-[4-(dimethylamino)phenyl]-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine (67)

a) 4-(2-chloropyrimidin-4-yl)-N,N-dimethylaniline (C_3)



B_2 A_1 C_3

[00168] A flask was charged with A_1 (650 mg, 4.4 mmol), 4-(dimethylamino)phenylboronic acid B_2 (797 mg, 4.8 mmol), dicholor[1,1'-bis(diphenylphosphino)ferrocenepalladium (480 mg, 0.56 mmol, 15 mol %), and triethylamine (1.5 mL, 11 mmol). Ethyleneglycoldimethylether (30 mL) was added to the flask and the mixture was purged with N_2 for 5 minutes. The reaction mixture was stirred

under an N_2 atmosphere at 80 °C for 12 hours, after which time, ether was added and the reaction mixture was filtered. The product, C_3, was isolated by removal of the solvent with a rotary evaporator and used without further purification. LCMS: m/z 234 $(M+H)^+$.

b) 4-[4-(dimethylamino)phenyl]-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine (67)



C_3 67

[00169] A flask was charged with C_3 (500 mg, 2.1 mmol), 4-morpholinoaniline (573 mg, 3.2 mmol) and nBuOH (10 mL). The flask was immersed in a 180 °C oil bath for 30 minutes. The reaction mixture was cooled to ambient temperature and the black residue dissolved in DMF and MeOH. The product **67** was purified by HPLC with TFA/ACN as eluent. The TFA salt was removed by extracting with sodium hydroxide and ethylacetate to afford the free base of **67**.

^{1}H-NMR (400MHz, d_6-DMSO): 9.24 ppm (s, 1H), 8.33 (d, 1H), 8.03 (d, 2H), 7.68 (d, 2H), 7.18 (d, 1H), 6.92 (d, 2H), 6.81 (d, 2H), 3.72-3.77 (m, 4H), 3.04-3.08 (m, 4H), 3.00 (s, 6H). MS (EI) $C_{22}H_{25}N_5O$: 376.1 (MH^+).

Example 10

4-[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine (Compound 319)

a) 4-(2-chloropyrimidin-4-yl)benzonitrile



A_1 B_3 C_4

[00170] A flask was charged with A_1 (763 mg, 5.16 mmol), 4-cyanophenylboronic acid B_3 (848 mg, 5.77 mmol), dicholoro[1,1'-bis(diphenylphosphino)ferrocenepalladium (375

mg, 0.437 mmol, 10 mol %), and triethylamine (1.76 mL, 12.9 mmol). Ethylene glycol dimethyl ether (5.0 mL) was added to the flask and the mixture was purged with N_2. The reaction mixture was stirred under an N_2 atmosphere at 90 °C for 1 hour, after which time, it was cooled to ambient temperature and filtered. The product, C_4, was isolated by removal of the solvent with a rotary evaporator and used without further purification. LCMS: m/z 216 $(M+H)^+$.

b) 4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzonitrile (S)



[00171] A flask containing a solution of C_4 (400 mg, 1.85 mmol) and 4-morphilinoaniline (362 mg, 2.04 mmol) in 1-butanol (10 mL) was immersed in an oil bath at 180 °C for 2 h. The mixture was cooled to ambient temperature, concentrated, and the crude product **S** was used without further purification. LCMS: m/z 358 $(M+H)^+$.

c) 4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzoic acid



[00172] A flask containing a solution of **S** (600 mg, 1.68 mmol) and 10 N HCl (aq., 20 mL) was immersed in an oil bath at 100 °C for 5 hours. The mixture was cooled to ambient temperature, after which time, 5 N LiOH was added until the reaction mixture was pH 6. The white precipitate was filtered and dried to give the product **T**, which was used without further purification. LCMS: m/z 377 $(M+H)^+$.

d) 4-[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine (323)



[00173] To a flask containing a solution of **T** (570 mg, 1.47 mmol) and THF (10 mL) was added 1,1'-carbonyldiimidazole (475 mg, 2.93 mmol). The reaction mixture was immersed in an oil bath at 60 °C for 2 h, after which time, it was cooled to ambient temperature. A mixture of acetamide oxime (120 mg, 1.62 mmol) and NaH (39 mg, 1.6 mmol) in DMF (5 mL) was added to the reaction mixture, after which time, the reaction mixture was immersed in an oil bath at 80 °C for 2 hours. The reaction mixture was then cooled to ambient temperature, quenched with saturated NH_4Cl (aq., 10 mL), extracted with ethyl acetate (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to yield a residue. The residue was purified by reverse phase HPLC to yield the product **319** (49.6 mg, 8.10% yield) as a light brown solid.

^{1}H-NMR (400MHz, d_6-DMSO): 9.57 ppm (s, 1H), 8.57 ppm (d, 1H), 8.38 ppm (d, 2H), 8.25 ppm (d, 2H), 7.67 ppm (d, 2H), 7.44 ppm (d, 1H), 6.95 ppm (d, 2H), 3.75 ppm (t, 4H), 3.06 ppm (t, 4H), 2.46 ppm (s, 3H); MS (EI) $C_{23}H_{22}N_6O_2$: 415.0 (MH^+).

Example 11

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-pyrrolidin-1-ylacetamide (Compound 292)

a) 2-chloro-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)acetamide



[00174] To a flask charged with 4-(4-aminophenyl)-N-(4-morpholinophenyl)pyrimidin-2-amine (100 mg, 0.286 mmol) and THF (1 mL) was added chloroacetyl chloride (0.0230

mL, 0.286 mmol). The solution was stirred at ambient temperature for 1 hour. The crude mixture was then concentrated and used without further purification. LCMS: m/z 424 $(M+H)^+$.

b) N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-pyrrolidin-1-ylacetamide (292)



[00175] To a flask charged with **U** (100 mg, 0.236 mmol), diisopropylethylamine (0.2 mL, 1 mmol), and dimethylacetimide (1 mL) was added pyrrolidine (0.021 mL, 1.3 mmol). The reaction mixture was stirred at 80 °C for 1 hour. The crude mixture was concentrated on a rotary evaporator and the product **292** was purified by reverse phase HPLC.

^{1}H-NMR (400MHz, d_6-DMSO): 10.90 ppm (s, 1H), 10.20 ppm (br. s, 1H), 9.64 ppm (s, 1H), 8.50 ppm (d, 1H), 8.19 ppm (d, 2H), 7.78 ppm (d, 2H), 7.74 ppm (d, 2H), 7.36 ppm (d, 1H), 7.11 ppm (d, 2H), 4.32 ppm (s, 2H), 3.80 ppm (t, 4H), 3.70-3.65 ppm (m, 2H), 3.19-3.06 ppm (m, 6H), 2.10-1.86 (m, 4H); MS (EI) $C_{26}H_{30}N_6O_2$: 459.4 (MH^+).

Example 12

3-methoxy-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide (Compound 575)



249(a)

[00176] To a solution of **249(a)** (0.18 g, 0.05 mmol), HATU (0.4 g, 1.1 mmol), and DIEA (0.5 mL, 4.0 mmol) in DMA (5 mL) was added 3-methoxypropanoic acid (0.1 mL, 1.05 mmol) and the solution was stirred at 60 °C for 2 hours. The solution mixture was diluted with ethyl acetate and the mixture was extracted with 10% LiCL (3X) and brine (1X). The resulting organic layer was dried with sodium sulfate and concentrated *in vacuo*. The product was purified by silica column chromatography (5% MeOH/DCM as eluent) to afford 0.1 g of the title compound **575** (49% yield) as a white solid.

^{1}H-NMR (400MHz, d_6-DMSO): 10.20 ppm (s, 1H), 9.37 ppm (s, 1H), 8.42 ppm (d, 1H), 8.10 ppm (d, 2H), 7.74 ppm (d, 2H), 7.65 ppm (d, 2H), 7.25pm (d, 1H), 6.91 ppm (d, 2H), 3.72 ppm (m, 4H), 3.61 ppm (t, 2H), 3.23 ppm (s, 3H), 3.03 ppm (m, 4H), 2.57 ppm (t, 2H); MS (EI) $C_{22}H_{23}N_5O_3HCl$: 434.3 (MH^+).

Example 13
N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)prolinamide (576)



249(a) Z

[00177] To a solution of **249(a) (5HCl)** (0.2 g, 0.37 mmol) in DMA (5 mL) was added a solution of 1-(*tert*-butoxycarbonyl)pyrrolidine-2-carboxylic acid, (*d,l*-boc-proline) (0.1 g, 0.46 mmol), Hunigs base (0.5 mL, 2.5 mmol), HATU (0.2 g, 0.52 mmol) and the solution was stirred at RT for 14 hours. The resulting solution was loaded on the silica gel and was purified by silica gel column chromatography (10-100% gradient of ethyl acetate/hexanes) to yield **Z** (160 mg) in 79% yield as yellow solid. LCMS: m/z 545 $(M+H)^+$.

*d) **N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide (Compound 585)***



Z 576

[00178] A flask containing a solution of **Z** (160 mg, 0.29 mmol) in 4M HCl in 1,4-dioxane (5 mL) and MeOH (5 mL) was stirred at 50 C for 1 hour. Concentration of the solvent gave a yellow solid that was purified by reverse phase HPLC using an ammonium acetate buffer to yield 105 mg (68%) of **576** as a yellow solid.

^{1}H NMR (400 MHz, d_4-MeOD): 8.36 (m, 1H), 8.14 (m, 2H), 7.78 (m, 2H), 7.62 (m, 2H), 7.22 (m, 1H), 6.98 (m, 2H), 4.15 (m, 1H), 3.83 (m, 4H), 3.21 (m, 2H), 3.13 (m, 4H), 2.41 (m, 1H), 2.06-1.91 (m, 3H); LCMS: for $C_{25}H_{28}N_6O_2$: 445 $(M + H)^+$.

Example 14

2-amino-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide (Compound 208)



249(a) 208

[00179] A flask was charged with **249(a)** (140 mg, 0.3 mmol), *N*-(*tert*-butoxycarbonyl)-alanine (57 mg, 0.3 mmol, purchased from Chem-Impex International), HATU (140 mg, 0.37 mmol), diispropylethylamine (0.6 mL, 3.0 mmol) and DMA (5 mL). The reaction mixture was stirred at RT for 12 hours. The crude mixture was concentrated on a rotary evaporator and the residue was dissolved in 10 mL of MeOH and 5 mL of 4N HCl in dioxane. The reaction mixture was stirred at 70 °C for 1 hour. The crude mixture was concentrated on a rotary evaporator and the product was purified by HPLC with NH_4OAc/ACN as eluent. The resulting solution was concentrated on a rotary evaporator and the final product, **208**, was dried by lyophilization.

^{1}H-NMR (400MHz, d_6-DMSO): 9.387 ppm (s, 1H), 8.443 ppm (d, 1H), 8.127 ppm (d, 2H), 7.825 ppm (d, 2H), 7.676 ppm (d, 2H), 7.287 ppm (d, 1H), 6.939 ppm (d, 2H), 3.747 ppm (m, 4H), 3.457 ppm (q, 1H), 3.050 ppm (m, 4H), 1.896 ppm (s, 3H (AcOH)) 1.243 ppm (d, 3H); MS (EI) $C_{23}H_{26}N_6O_2$: 419.1 (MH^+).

Example 15

N-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)acetamide (Compound 341)

a) *4-(2-methoxy-4-nitrophenyl)morpholine (AA)*



[00180] A pressure bottle was charged with 1-chloro-2-methoxy-4-nitrobenzene (10.0 g mg, 53.3 mmol, purchased from TCI America) and morpholine (15 mL, 172.0 mmol). The reaction mixture was stirred at 120 °C for 15 hours and it was allowed to cool to room temperature by itself. The resulting solid was suspended in 20 mL of ethyl acetate, filtered, and washed with 20 mL of *tert*-butyl methyl ether. 8.8 g of yellow solid as the desired product **AA** was collected (69% yield). ^{1}H-NMR (400MHz, d_6-DMSO): 7.83 (dd, 1H), 7.67 (d, 1H), 6.98 (d, 1H), 3.88 (s, 3H), 3.71 (m, 4H), 3.16 (m, 4H). MS (EI) $C_{11}H_{14}N_2O_4$: 239 $(M+H)^+$.

b) 3-methoxy-4-morpholinoaniline



[00181] To a solution of **AA** (8.8 g, 37.0 mmol) in ethyl acetate (30 mL) and methanol (10 mL) in a Parr bottle was added 1 g 10% palladium on carbon. The reaction mixture was hydrogenated at 40 PSI H_2 for 1 hour, filtered and concentrated. 8.0 g of a pink solid as the product **BB** was obtained as a crude product and used without further purification. MS (EI) $C_{11}H_{16}N_2O_2$: 209 $(M+H)^+$.

c) N-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)acetamide



[00182] A flask was charged with **BB** (51 mg, 0.24 mmol), N-(4-(2-chloropyrimidin-4-yl)phenyl)acetamide (50 mg, 0.2 mmol) and nBuOH (2 mL). The flask was immersed in a 180 °C oil bath for 30 minutes, and then cooled to ambient temperature. The residue was suspended in 5 mL of ethyl acetate, stirred for 1 hour, filtered, and washed with 10 mL of ethyl acetate. 50 mg of an off-white powder was obtained as the title compound (**341**) (60% yield).

^{1}H-NMR (400MHz, d_6-DMSO): 10.33 (s, 1H), 9.50 (br, 1H), 8.54 (d, 1H), 8.15 (d, 2H), 7.95 (br, 1H), 7.77 (d, 2H), 7.42 (m, 2H), 3.94 (s, 3H), 3.77 (br, 4H), 3.40 (br, 2H), 2.15 (s, 2H). MS (EI) $C_{23}H_{25}N_5O_3$: 420 $(M+H)^+$.

Example 16

N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)methanesulfonamide (Compound 326)



[00183] **82** (500 mg, 0.94 mmol) was dissolved in 4 mL of pyridine. Methanesulfonyl chloride (730 µL, 9.4 mmol) was added dropwise to the vigorously stirred pyridine solution. The addition of the sulfonyl chloride was exothermic and caused a significant

increase in the temperature of the reaction. The reaction was maintained at 80 °C for several hours. After cooling, the solvent was removed under vacuum and the residue was purified by reverse phase HPLC to afford 200 mg (52% yield) of the title compound (**326**). ^{1}H-NMR (400MHz, d_6-DMSO): 10.16 ppm (s, 1H), 9.41 ppm (s, 1H), 8.45 ppm (d, 1H), 8.13 ppm (d, 2H), 7.67 ppm (d, 2H), 7.33 ppm (d, 2H), 7.28 ppm (d, 1H), 6.94 ppm (d, 2H), 3.74 ppm (br s, 4H), 3.09 ppm (s, 3H), 3.05 ppm (br s, 4H); MS (EI) $C_{21}H_{23}N_5O_3S$: 426 (MH^+).

Example 17

Methyl (4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)carbamate (Compound 248)



249(a) **248**

[00184] To a solution of 4-(4-aminophenyl)-N-(4-morpholinophenyl)pyrimidin-2-amine **249(a)** (100 mg, 0.29 mmol) and DIEA (0.435 mmol, 75 µl) in THF (50 mL) was added methyl chloroformate (0.348 mmol, 27 µl) and the solution was stirred at room temperature for 2 hours. The solution mixture was concentrated, redissolved with MeOH and purified using reverse phase HPLC. The product obtained from the reverse phase HPLC was free base **248**, converted to HCl salt using 3 N HCl and lyophilized to yield the product **248** (60mg, 47% yield) as a yellow solid.

^{1}H-NMR (400MHz, d_6-DMSO): 10.063 ppm (s, 1H), 9.976 ppm (s, 1H), 8.521 ppm (d, 1H), 8.153 ppm (d, 2H), 7.878 ppm (d, 2H), 7.661 ppm (d, 2H), 7.554 ppm (bs, 2H), 7.432 ppm (d, 1H), 3.983 ppm (bs, 4H), 3.707 ppm (s, 3H), 4.435 ppm (bs, 4H); MS (EI) $C_{22}H_{23}N_5O_3HCl$: 475.4 (MH^+).

Example 18

(*S*)-3-hydroxy-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide (Compound 363)



[00185] To a solution of (*S*)-3-hydroxybutyrate (0.180 g, 1.73 mmol), HATU (0.602 g, 1.58 mmol), DIEA (1.0 mL, 5.4 mmol) in DMF (3.0 mL) was added a solution of 4-(4-aminophenyl)-*N*-(4-morpholinophenyyl)pyrimidin-2-amine (0.500 g, 1.44 mmol) in DMF (1.0 mL). The reaction mixture was stirred at rt for 2 hours, at which time it was quenched with saturated $NaHCO_3$ (10 mL, aq.), extracted into DCM (3X), and washed with brine (1X). The organic layers were dried with sodium sulfate and concentrated. The product was purified by reverse phase HPLC to afford (*S*)-3-hydroxy-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide (0.136 g, 22% yield) as a light brown solid. (**363**) ^{1}H-NMR (400MHz, DMSO-d_6): 10.14 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.27 (d, 1H), 6.94 (d, 2H), 4.79 (d, 1H), 4.11 (m, 1H), 3.74 (m, 4H), 3.05 (m, 4H), 2.47 (dd, 1H), 2.35 (dd, 1H)), 1.15 (d, 3H); MS (EI) m/z for $C_{24}H_{28}N_5O_3$: 434.3 (MH^+).

Example 19

2-Hydroxy-2-methyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide (Compound 366)



[00186] To a solution of 4-(4-aminophenyl)-*N*-(4-morpholinophenyyl)pyrimidin-2-amine (1.0 g, 2.8 mol) **249(a)** and DIPEA (0.5 mL, 1 eq.) in anhydrous DMA (5 mL) was added dropwise 2-acetoxy-2-methylpropionyl chloride (3 mol, 1.05 eq., 0.44 mL) at 0 °C. The mixture was stirred for 20 min at room temperature. The solution was diluted with

water and EtOAc. The organic layer was concentrated in vacuo. The residue **366(a)** was suspended in MeOH (10 mL) and a solution of $LiOH\text{-}H_2O$ (8.3 mmol, 3 eq. 0.35 g) in water (3 mL) was added. The reaction was complete within 20 min and then was neutralized. The organic solvent was removed *in vacuo*. The residue was purified to afford 2-hydroxy-2-methyl-*N*-(4-(2-(4-morpholino-phenylamino)pyrimidin-4-yl)phenyl)-propanamide (**366**) (1.0 g, 85% yield) as a pale yellow solid. ^{1}H-NMR (400MHz, DMSO-d_6): 9.86 (s, 1H), 9.41 (s, 1H), 8.47 (d, 1H), 8.12 (d, 2H), 7.94 (d, 2H), 7.68 (d, 2H), 7.30 pm (d, 1H), 6.94 (d, 2H), 5.82 (s, 1H), 3.75 (m, 4H), 3.08 (m, 4H), 1.38 (s, 6H); MS (EI) m/z for $C_{22}H_{23}N_5O_3HCl$: 434.2 (MH^+).

Example 20

(*R*)-3-hydroxy-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide (Compound 364)



[00187] To a solution of (*R*)-3-hydroxybutyrate (0.180 g, 1.73 mmol), HATU (0.602 g, 1.58 mmol), DIEA (1.0 mL, 5.4 mmol) in DMF (3.0 mL) was added and a solution of 4-(4-aminophenyl)-*N*-(4-morpholinophenyyl)pyrimidin-2-amine (**249(a)**) (0.500 g, 1.44 mmol) in DMF (1.0 mL). The reaction mixture was stirred at room temperature for 2 hours, at which time it was quenched with saturated $NaHCO_3$ (10 mL, aq.), extracted into DCM (3X), washed with brine (1X), and the organic layers were dried with sodium sulfate. The solution was concentrated and the product was purified by reverse phase HPLC to afford (*R*)-3-hydroxy-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide (**364**) (0.129 g, 21% yield) as a light brown solid. ^{1}H-NMR (400MHz, DMSO)-d_6: 10.14 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.27 (d, 1H), 6.94 (d, 2H), 4.79 (d, 1H), 4.11 (m, 1H), 3.74 (m, 4H), 3.05 (m, 4H), 2.47 (dd, 1H), 2.35 (dd, 1H), 1.15 (d, 3H); MS (EI) m/z for $C_{24}H_{28}N_5O_3$: 434.3 (MH^+).

Example 21

(*R*)-2-amino-3-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-propanamide (Compound 365)



[00188] To a solution of 4-(4-aminophenyl)-*N*-(4-morpholinophenyyl)pyrimidin-2-amine **249(a)** (521mg, 1.5 mmol), N-CBZ-D-Serine (359mg, 1.5mmol), and DIEA (0.653mL, 3.75mol) in DMA (4mL) was added HATU (855mg, 2.25mmol) and the solution was stirred at room temperature for 0.5 hour. Excess H_2O was added to the reaction mixture. The precipitate was collected and were redissolved in CH_2Cl_2, washed with $NaHCO_3$ (aq) (2X), brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue was purified by silica column chromatography (1% MeOH/DCM as eluent) to afford (*R*)-benzyl 3-hydroxy-1-(4-(2-(4-morpholino-phenylamino)pyrimidin-4-yl)phenylamino)-1-oxopropan-2-ylcarbamate **365(a)** (668 mg, 78% yield).

[00189] To a stirred solution of (*R*)-benzyl 3-hydroxy-1-(4-(2-(4-morpholinophenylamino)-pyrimidin-4-yl)phenylamino)-1-oxopropan-2-ylcarbamate from the step above in MeOH (10 mL) was added $Pd(OH)_2$ (134 mg) and ammonium formate (369 mg, 5.85). The mixture was heated at 60 °C for 2 hours, cooled down to room temperature, and filtered on Celite by eluting with MeOH. The filtrate was concentrated *in vacuo* and the residue was purified by prepatory HPLC (TFA). The TFA salt was removed by using basic resin to afford (*R*)-2-amino-3-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)-henyl)ropanamide **365** (346 mg, 68%). ^{1}H-NMR (400MHz, DMSO-d_6): 9.39 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.83 (d, 2H), 7.67 (d, 2H), 7.29 (d, 1H), 6.94pm (d, 2H), 4.94 (m, 1H), 3.75 (m, 4H), 3.60 (m, 2H), 3.46 (m, 1H), 3.05 (m, 4H); MS (EI) m/z for $C_{23}H_{26}N_6O_3$: 435.4 (MH^+).

Example 22

N-{4-[2-({3-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]phenyl}-acetamide (Compound 122)



[00190] Intermediate **A** (0.5g) was dissolved in THF (5 ml), 20% aqueous H_2SO_4 solution (5ml) was then added to the solution. The mixture was stirred at 50^0 C for 2 hours and monitored by LC/MS (MH+, 333). The solution was then neutralized with 2N NaOH solution and extracted with ethyl acetate. The organic layer was washed with brine, dried over Na_2SO_4, and concentrated to afford 0.38g of the aldehyde **B**. (90% yield).

[00191] A flask was charged with aldehyde **B** (0.1g, 0.3 mmol), dichloromethane (10 ml), sodiumtriacetoxyborohydride (0.32g, 1.5mmol), and 1-ethylpiperazine (0.19 ml, 1.5mmol). The reaction mixture was stirred at room temperature overnight and checked with LC/MS. The product **122** was isolated by removal of the solvent with a rotary evaporator and then purified with a preparative HPLC.

^{1}H NMR (400 MHz, d_6-DMSO): 10.23 (s, 1H), 9.6 (s, 1H), 8.5 (d, 1H), 8.14 (d, 2H), 7.9 (s, 1H), 7.76 (d, 2H), 7.65 (d, 1H), 7.36 (d, 1H), 7.24 (t, 1H), 6.89 (d, 1H), 3.43 (s, 2H), 2.4 (br, 6H), 2.3 (q, 2H), 2.1 (s, 3H), 0.96 (t, 3H). MS (EI) for $C_{25}H_{30}N_6O$: 431 (MH^+).

Example 23

2-(3-(1H-imidazol-1-yl)propylamino)-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)acetamide (Compound 143)



143

[00192] A flask was charged with aniline A_1 (100 mg, 0.29 mmol), and THF (1.0 mL). Chloroacetylchloride (23 μL, 0.29 mmol) was added and the mixture was stirred at ambient temperature for 1 hr, after which time it was concentrated. The product, B_1, was isolated by removal of the solvent with a rotary evaporator and used without further purification.

[00193] A flask was charged with alkyl chloride B_1 (20 mg, 0.047 mmol), Na_2CO_3 (30 mg, 0.28 mmol), 1-(3-Aminopropyl)imidazole (5.6 μL, 0.047 mmol), and DMF (1.0 mL). The mixture was stirred at 150 °C for 1 hr, after which time it was concentrated. The product **143** was purified by reverse phase HPLC to afford 9.7 mg (40% yield from B_1) as a white solid.

^{1}H-NMR (400MHz, d6-DMSO): 8.35 (d, 1H), 8.13 (d, 2H), 7.78-7.63 (m, 3H), 7.61 (d, 2H), 7.22 (d, 1H), 7.17 (s, 1H), 7.05-6.95 (m, 2H), 4.62 (s, br, 1H), 4.16 (t, 2H), 3.87-3.77

(m, 4H), 3.49 (s, 1H), 3.34 (s, 1H), 3.15-3.07 (m, 4H), 2.67 (t, 2H), 2.11-2.01 (m, 2H), 1.95 (s, 2H). MS (EI) $C_{28}H_{32}N_8O_2$: 513.1 (MH+).

Example 24

N-chloro-N-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-2-(1H-tetrazol-1-yl)acetamide (Compound 554)



[00194] 4-(4-aminophenyl)-N-(3-methoxy-4-morpholinophenyl)pyrimidin-2-amine hydrochloride: A flask was charged with tert-butyl 4-(2-chloropyrimidin-4-yl)phenylcarbamate **A** (12.2 g, 40.0 mmol), 3-Methoxy-4-morpholinoaniline (9.7 g, 40.76 mmol) and 50 mL n-butanol. The reaction mixture was stirred under an N_2 atmosphere at 100 °C for 12 hours, after which time, then, cooled to room temperature. 25 mL of 4N HCl in dioxane was added, the reaction mixture was stirred at 50 °C for 5 hours. After cooled to room temperature, it was filtered, washed with ethyl acetate, dried in the air to collect 16 g of yellow-green solid as the desired product. NMR (400 MHz, d6-DMSO): 10.40 (s, 1H), 8.60 (d, 1H), 8.20 (s, 2H), 7.94 (s, 1H), 7.84 (d, 1H), 7.54 (d, 1H), 7.41 (d, 1H), 7.30 (m, 2H), 4.10 (m, 2H), 3.99 (s, 3H), 3.60 (br, 2H), 3.39 (m, 2H), 1.25 – 1.42 (m, 4H). MS (EI) for $C_{21}H_{23}N_5O_2$: 378 (MH+).

[00195] A flask was charged with 4-(4-aminophenyl)-N-(3-methoxy-4-morpholinophenyl)pyrimidin-2-amine hydrochloride **B** (471.0 mg, 0.84 mmol), 2-(1H-

tetrazol-1-yl)acetic acid (216.0 mg, 1.69 mmol), HATU (1276.0 mg, 3.38 mmol) and 2 mL of DMA. The reaction mixture was stirred at room temperature for 24 hours, and then quenched with 50 mL of water, extracted with ethyl acetate (3X50 mL). The combined organics were washed with water and then brine (50 mL each), dried over anhydrous sodium sulfate, and then concentrated. The crude product was purified with a silica gel column (ethyl acetate to 10% methanol in ethyl acetate), 345.0 mg of the desired product **554** was obtained as yellowish powder. NMR (400 MHz, d6-DMSO): 10.85 (s, 1H), 9.50 (s, 1H), 9.43 (s, 1H), 8.47 (s, 1H), 8.19 (d, 2H), 7.75 (d, 2H), 7.63 (s, 1H), 7.20 (m, 3H), 6.84 (d, 1H), 5.56 (s, 2H), 3.80 (s, 3H), 3.74 (m, 4H), 2.94 (m, 4H). MS (EI) for $C_{24}H_{25}N_9O_3$: 488 (MH+).

Example 25

4-[4-(1,1-Dioxidoisothiazolidin-2-yl)phenyl]-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine (Compound 374)



A 374

[00196] Aniline **A** (300 mg, 0.78 mmol) was dissolved in 4 mL of dry pyridine. 3-Chloropropanesulfonyl chloride (950 uL, 7.8 mmol) was added dropwise. The reaction mixture was heated to 80 °C and stirred overnight under a nitrogen atmosphere. The solvent was removed under vacuum and the residue was re-dissolved in 25 mL of ethyl acetate. The reaction mixture was washed one time each with 10 mL portions of water, 0.1 M HCl, and saturated aqueous NaCl. The organic layer was dried with $MgSO_4$ and concentrated under vacuum. The residue was taken up in DMF (4 mL) and triethylamine (1100 uL, 7.9 mmol). The reaction mixture was heated to 80 °C and stirred overnight. The product was purified by preparative HPLC to give 85 mg of **374**. ^1H NMR (400 MHz, d_6-DMSO): 9.78 (s, 1H), 8.49 (d, 1H), 8.20 (d, 2H), 7.78 (d, 2H), 7.39 (d, 1H), 7.33 (d, 2H), 7.25 (br s, 2H), 3.84 (br s, 4H), 3.73 (t, 2H), 3.60 (t, 2H), 2.54 (m, 2H), 2.45 (m, 2H) 2.01 (m, 2H); MS (EI) for $C_{23}H_{25}N_5O_3S$: 452 (MH^+).

Example 26

N-(4-Morpholin-4-ylphenyl)-4-[4-(1H-tetrazol-1-yl)phenyl]pyrimidin-2-amine



A **375**

[00197] Aniline **A** (200 mg, 0.52 mmol), sodium azide (45 mg, 0.69 mmol), triethylorthoformate (280 uL, 1.7 mmol) and acetic acid (480 uL, 8.4 mmol) were combined in a 25 mL round bottom flask. The reaction mixture was stirred for 2 hours at 80 °C. The reaction mixture was allowed to cool to room temperature and then it was cooled further in an ice bath. A solution of 670 uL of 6.0 M HCl in 1.25 mL of water was added to the reaction mixture. After stirring in the ice bath for 5 minutes, another solution of sodium nitrite (50 mg, 0.72 mmol) in water (200 uL) was added slowly. The precipitate was filtered off and purified by reverse phase HPLC to give 24 mg of **375**. ^{1}H NMR (400 MHz, d_6-DMSO): 10.19 (s, 1H), 9.51 (s, 1H), 8.53 (d, 1H), 8.40 (dd, 2H), 8.10 (d, 2H), 7.65 (d, 2H), 7.43 (d, 1H), 6.92 (d, 2H), 3.73 (m, 4H), 3.03 (m, 4H); MS (EI) for $C_{21}H_{20}N_8O$: 401 (MH^+).

Example 27

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2-fluoro-6-iodobenzamide (Compound 289)



[00198] A flask was charged with **C1** (5.0 g, 20.2388 mmol) and (3-aminopropyl)-carbamicacid-t-butyl ester (6 mL, 30.3582 mmol). n-butanol (40 mL) were added to the flask and heated to 175 °C for an hour. Solvent was evaporated and reaction mixture was checked with LC/MS. The reaction mixture was cooled to room temperature and ethyl acetate was added. The precipitate, **B**, was filtered and used without further purification. LC/MS: m/z 386 $(M+H)^+$.

[00199] A flask was charged with **B**. 4 N HCl in dioxane was added and stirred at room temperature for 3 hours. The reaction mixture was checked with LC/MS. The product, **E**, was isolated by removal of the solvent with a rotary evaporation and used without further purification. LC/MS; m/z 286 $(M+H)^+$.

[00200] A flask was charged with **E** (254 mg, 0.8902 mmol), 2-fluoro-6-idobenzoyl chloride (90 μL, 0.6231 mmol), tetrahydrofuran (25 mL), and n-ethyldiisopropylamine (108 μL, 0.6231 mmol). The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was monitored with LC/MS. The product, **289**, was isolated by removal of the solvent with a rotary evaporator and purified with a TFA preparative HPLC (10:90, 11 min run).

^{1}H-NMR (400MHz, d_6-DMSO): 10.16 ppm (s, 1H), 8.64 ppm (t, 1H), 8.30 ppm (d, 1H), 8.06 ppm (d, 2H), 7.70 ppm (m, 3H), 7.30 ppm (m, 1H), 7.20 ppm (m, 1H), 7.13 ppm (m, 1H), 7.07 ppm (m, 1H), 3.34 ppm (m, 4H), 2.08 ppm (s, 3H), 1.83 ppm (m, 2H); MS (EI) $C_{22}H_{21}FIN_5O_2$: 533.9 (MH^+).

Example 28

N-(4-{2-[(3-{[(2,6-dimethylphenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide (Compound 51)



C1 D

[00201] A flask was charged with **C1** (5.0 g, 20.2388 mmol) and tert-butyl 3-aminophenylcarbamate (4.6 g, 22.2627 mmol). n-butanol (40 mL) were added to the flask and heated to 175 °C for 4 hours. Solvent was evaporated and reaction mixture was checked with LC/MS. The reaction mixture was cooled to room temperature and ethyl acetate was added. The precipitate, **D**, was filtered and used without further purification. LC/MS: m/z 320 $(M+H)^+$.

[00202] A flask was charged with **D** (463 mg, 1.4514 mmol), dichloromethane/tetrahydrofuran (2;1, 15 mL), sodium triacetoxyborohydride (615 mg, 2.9028 mmol), and 2,6-dimethylbenzaldehyde (196 μL, 1.4514 mmol) The reaction mixture was stirred at room temperature for 12 hours and monitored with LC/MS. The product, **51**, was isolated by removal of the solvent with a rotary evaporator and purified with a TFA preparative HPLC (10:90, 11 min run). ^{1}H-NMR (400MHz, d_6-DMSO): 10.20 ppm (s, 1H), 9.36 ppm (s, 1H), 8.47 ppm (d, 1H), 8.16 ppm (d, 2H), 7.72 ppm (d, 2H), 7.35 ppm (s, 1H), 7.31 ppm (d, 1H), 7.12 ppm (m, 1H), 7.07 ppm (m, 2H), 6.99 ppm (m, 3H), 6.38 ppm (d, 1H), 5.46 ppm (t, 1H), 4.14 ppm (d, 2H), 2.36 ppm (s, 6H), 2.08 ppm (s, 3H); MS (EI) $C_{27}H_{27}N_5O$: 438.1 (MH^+).

Example 29

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[2-(dimethylamino)ethyl]benzamide (Compound 9)



[00203] A flask was charged with 2,4-dichloropyrimindine (22.7 g, 152.38 mmol), 4-acetoamidophenylboronic acid (30.0 g, 167.62 mmol), dicholor[1,1'-bis(dipheny-phosphino)-ferrocenepalladium (16.726 g, 22.86 mmol, 15 mol %), and triethylamine (53 mL, 380.95 mmol). Ethyleneglycoldimethylether (500 mL) and H_2O (20 mL) was added to the flask. The reaction mixture was stirred at 80 °C for 4 hours. The product, Intermediate **A**, was isolated by removal of the solvent with a rotary evaporator and purified using glass column chromatography and eluted with ethyl acetate to afford 30.5 g (123.14 mmol, 81% yield) of intermediate **A** as a yellow solid.

[00204] A seal tube was charged with intermediate **A** (400 mg, 1.62 mmol) and 3-aminobenzoic acid (222 mg, 1.62 mmol). N-butanol (15 mL) was added to the seal tube and stirred at 180°C. The reaction was done in 1hour according to LCMS to afford intermediate **B** as a yellow solid. Intermediate **B** was placed on a rotary evaporator to remove excess n-butanol. Intermediate **B** was carried on to the next step without further purification.

[00205] A flask was charged with intermediate **B** (282 mg, 0.81 mmol), HATU (464 mg, 1.22 mmol), DMF (15 mL) and DIEA (212 µL, 1.22 mmol). The reaction mixture was stirred at rt and completed in 30 min. to afford the final product (**9**). The final product

was purified using Preperative HPLC and ammonium acetate buffer and lyophilized to afford the product as ACE salt (170 mg, 0.41 mmol). ^{1}H-NMR (400MHz, d_6-CD_3OD): 8.523 ppm (t, 1H), 8.45 ppm (d, 1H), 8.176 ppm (m, 2H), 7.828 ppm (m, 1H), 7.2 ppm (d, 2H), 7.475-7.404 ppm (m, 2H), 7.326 ppm (d, 1H), 3.738 ppm (t, 2H), 3.244 ppm (t, 2H), 2.877 ppm (s, 6H), 2.162 ppm (s, 3H), 1.955 (s, 3H, ACE). MS (EI) $C_{23}H_{26}N_6O_2$: 419.1 (MH^+).

Example 30

N-[5-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-2-morpholin-4-ylphenyl]-2,6-dichlorobenzamide (Compound 62)



[00206] A seal tube was charged with intermediate **A** (500 mg, 2.02 mmol) and 4-morpholinobenzene-1,3-diamine (400 mg, 2.02 mmol, Zerenex Limited). N-butanol (15 mL) was added to the seal tube and stirred at 180^{0}C. The reaction was done in 1h according to LCMS to afford intermediate **C** as a yellow solid. Intermediate **C** was placed on a rotary evaporator to remove excess n-butanol. Intermediate **C** was carried on to the next step without further purification.

[00207] A flask was charged with intermediate **C** (816 mg, 2.02 mmol), THF (100 mL), DIEA (705 µL, 4.04mmol), and 2,6-dichlorobenzoyl chloride (290 µL, 2.02 mmol). The reaction mixture was stirred at rt over night to afford the final product **62**. The final

product was purified using Preperative HPLC and TFA buffer, then was free-based and lyophilized (165 mg, 0.28 mmol, 14% Yield).

^{1}H NMR (400 MHz, DMSO): 10.194 (s, 1H), 9.8 (s, 1H), 9.607 (s, 1H), 8.585 (s, 1H), 8.484 (d, 1H), 8.235 (d, 2H), 7.711 (d, 2H), 7.592 (d, 2H), 7.496 (m, 2H), 7.356 (d, 1H), 7.183 (d, 1H), 3.74 (t, 4H)), 2.89 (t, 4H), 2.07 (s, 3H). MS (EI) for $C_{29}H_{26}Cl_2N_6O_3$: 579.1 (MH^+).

Example 31

N-{3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-5-[(4-ethylpiperazin-1-yl)carbonyl]phenyl}-2,6-dichlorobenzamide (Compound 66)



[00208] A seal tube was charged with intermediate **A** (300 mg, 1.21mmol) and 3,5-diaminobenzoic acid (204 mg, 1.34 mmol). N-butanol (15 mL) was added to the seal tube and stirred at 180^{0}C. The reaction was done in 1h according to LCMS to afford intermediate **D** as a yellow solid. Intermediate **D** was placed on a rotary evaporator to remove excess n-butanol. Intermediate **D** was carried on to the next step without further purification.

[00209] A flask was charged with intermediate **D** (439 mg, 1.21 mmol), THF (30 mL), DMF(5 mL), DIEA (632 µL, 3.63 mmol), and 2,6-dichlorobenzoyl chloride (174 µL, 1.21

mmol). The reaction mixture was stirred at rt over night. The reaction mixture was quenched with 2 M NaOH (100 mL) and extracted with ethyl acetate (3x) and the organic layer was discarded. The aqueous NaOH layer was neutralized with conc. HCl. The solid formed was collected via filtration and washed with excess water to afford intermediate **E** (274 mg, 0.51 mmol, 62% yield) as a yellow solid. Intermediate **E** was carried on to the next step without further purification.

[00210] A flask was charged with intermediate **E** (274 mg, 0.51 mmol), HATU (291 mg, 0.765 mmol), DMF (25 mL), ethylpiperazine (78 μL, 0.61 mmol) and DIEA (133 μL, 0.765 mmol). The reaction was stirred at rt and completed in 15 min. The final product **66** was purified using Preperative HPLC and TFA buffer, free-based and lyophilized to afford the product (166 mg, 52% yield).

^{1}H NMR (400 MHz, DMSO): 10.896 (s, 1H), 10.33 (s, 1H), 9.881 (s, 1H), 8.533 (d, 1H), 8.374 (s, 1H), 8.202 (d, 2H), 7.776 (d, 2H), 7.636-7.6 (m, 3H), 7.529 (m, 1H), 7.419 (d, 1H), 7.296 (s, 1H), 3.628 (br s, 2H), 3.415 (br s, 2H), 2.427-2.314 (m, 6H), 2.091 (s, 3H), 0.996 (t, 3H). MS (EI) for $C_{32}H_{31}Cl_2N_7O_3$: 634.1(MH^+).

Example 32

***N*-methyl-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide (Compound 118):**



Intermediate A Intermediate F 118

[00211] A flask was charged with intermediate **A** (250 mg, 1.01 mmol), DMF (10 mL), NaH (30.0 g, 167.62 mmol), dicholor[1,1'-bis(diphenylphosphino)ferrocenepalladium (60 mg, 1.5 mmol), and methyl iodide (94 μL, 1.5 mmol). The reaction mixture was stirred at rt and completed in 30 min. The reaction mixture was quenched with H_2O and extracted with ethyl acetate (3X) and washed with 10% LiCl solution (1X), brine (1X), dried over sodium sulfate, and filtered. The organic layer was removed with a rotary evaporator to afford intermediate **F** (200 mg, 0.766 mmol) as a yellow gelatin. Intermediate **F** was carried on to the next step without further purification.

[00212] A seal tube was charged with intermediate **F** (200 mg, 0.766 mmol), anhydrous DMA (15 mL), cesium carbonate (374 mg, 1.15 mmol), racemic-2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl (70 mg, 0.115 mmol), and tris(dibenzylideneacetone)dipalladium(0). The reaction was flushed with N_2 gas for five minutes and the seal tube was sealed and stirred at 80^0C over night. The reaction was filtered and washed with ethyl acetate and the solid was discarded. The organic solvent was removed using the rotary evaporator. The final product **66** was purified using Preperative HPLC and TFA buffer, free-based and lyophilized to afford the product (95 mg, 0.235 mmol, 28% Yield).

^{1}H-NMR (400MHz, d_6-DMSO): 9.464 ppm (s, 1H), 8.511 ppm (d, 1H), 8.209 ppm (d, 2H), 7.67 ppm (m , 2H), 7.516 ppm (d, 2H), 7.366 ppm (d, 1H), 6.926 ppm (m, 2H), 3.743 ppm (t, 4H), 3.22 ppm (s, 3H), 3.048 ppm (t, 4H). MS (EI) $C_{23}H_{25}N_5O_2$: 404.3 (MH^+).

Example 33

N-(4-(2-(3-(3-morpholinopropoxy)phenylamino)pyrimidin-4-yl)phenyl)acetamide (Compound 160)



[00213] A seal tube was charged with intermediate **A** (500 mg, 2.02 mmol) and 3-benzyloxyaniline (404 mg, 2.02 mmol). N-butanol (15 mL) was added to the seal tube and stirred at 180^0C. The reaction was done in 1h according to LCMS to afford

intermediate **G** as a yellow solid. Intermediate **G** was placed on a rotary evaporator to remove excess n-butanol. Intermediate **G** was carried on to the next step without further purification. A flask was charged with intermediate **G** and HBr/Acetic acid (33%, 10 mL) and stirred at rt over night. The reaction was done and the solid was collected via filtration and washed with ether to afford intermediate **H** as a yellow and HBr salt solid (800 mg, 1.66 mmol, 82% yield).

[00214] A flask was charged with intermediate **H** (250 mg, 0.52 mmol), DMF (15mL), Cs_2CO_3 (847mg, 2.6 mmol) and 4-(3-chloropropyl)morpholine HCl salt (135 mg, 0.676 mmol, purchased from Apin Chemicals, Ltd.) and stirred at 80^0C over night. The reaction mixture had approximately 85% desired product and 15% bis-alkylated by-product. The solid was filtered and washed with ethyl acetate and discarded. The filtrate was concentrated using the rotary evaporator. The final product was purified using Preperative HPLC and TFA buffer, free-based, converted to HCl salt and lyophilized to afford the product (115mg, 0.237 mmol, 46% Yield).

^{1}H NMR (400 MHz, DMSO): 11.058 (s, 1H), 10.403 (s, 1H), 9.761 (s, 1H), 8.532 (d, 1H), 8.158 (d, 2H), 7.81 (d, 2H), 7.677 (s, 1H), 7.4-7.345 (m, 2H), 7.231 (t, 1H), 6.569 (m, 1H), 4.081 (t, 2H), 3.962 (m, 2H), 3.82 (t, 2H), 3.46 (m, 2H), 3.267 (m, 2H), 3.123 (m, 2H), 2.254 (m, 2H), 2.104 (s, 3H). MS (EI) for $C_{25}H_{29}N_5O_3$: 448.3 (MH^+).

Example 34

N-(4-{2-[(2-methyl-4-piperazin-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide (Compound 35):



[00215] A flask was charged with 5-fluoro-2-nitrotoluene (1 mL, 8.2 mmol), DMF (15 mL), Bocpiperazine (1.68 g, 9.02 mmol), and K_2CO_3 (2.27 g, 16.4 mmol). The reaction mixture was stirred at 50 ^{0}C for about 25 h. The reaction was quenched with H_2O and the solid precipitated out of the solution and collected via filtration and washed with excess H_2O to obtain intermediate **I** (1.765g, 5.4 mmol). Intermediate **I** was carried on to the next step without further purification. A flask was charged with intermediate **I** (290 mg, 0.9 mmol), ethanol (18 mL), ammonium formate (340 mg, 5.4 mmol) and Pt/S (10.2 mg, 0.04 mmol). The reaction mixture was stirred at 70^{0}C for 3 h and 78^{0}C for 4 h. The reaction mixture was filtered through celite and washed with ethanol. The filtrate was removed using the rotary evaporator and then treated with ethyl acetate and washed with H_2O, dried over sodium sulfate, and filtered. The ethyl acetate layer was concentrated using rotary evaporator to afford intermediate **J**.

[00216] A seal tube was charged with intermediate **A** (200 mg, 0.81 mmol), and intermediate **J** (235 mg, 0.81 mmol). N-butanol (15 mL) was added to the seal tube and stirred at 180^{0}C. The reaction was done in 1h and concentrated to remove excess n-butanol and then treated with 4N HCl/dioxane. The reaction mixture was stirred at rt for 1h to afford the final product **35**. The final product was purified using Preperative HPLC and ammonium acetate buffer, then free-based and lyophilized (90 mg, 0.22 mmol, 27% Yield).

^{1}H-NMR (400MHz, d_6-DMSO): 10.31 ppm (s, 1H), 8.569 ppm (s, 1H), 8.323 ppm (d, 1H), 8.022 ppm (d, 2H), 7.715 ppm (d, 2H), 7.271 ppm (d, 1H), 7.186 ppm (d, 1H), 6.8 ppm (m, 2H), 3.023 ppm (t, 4H), 2.844 ppm (t, 4H), 2.175 ppm (s, 3H), 2.077 ppm (s, 3H), 1.605 ppm (s, 2H); MS (EI) $C_{23}H_{26}N_6O$: 403.1 (MH^+).

Example 35

***N*-[4-({2-[(4-morpholin-4-ylphenyl)amino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl}amino)-phenyl]acetamide (Compound 306)**



[00217] A flask was charged with methylsulfide (2.1g, 11.6mmol) and THF (50mL). To this, m-CPBA (7.9g, 46mmol) was added and the mixture was stirred at ambient temperature for 20 hours. Volatiles were removed under *vacuo*. The crude mixture was

partitioned between EtOAc and DI H_2O. The aqueous layer was extracted with EtOAc (3x15mL). The combined organics were washed with 1N $NaHCO_3$ (x2), DI H_2O (x2), brine, (x1), dried over sodium sulfate, filtered and concentrated under *vacuo*. The product (1.8g, 75%) was used without further purification. LCMS: m/z 214$(M+H)^+$.



[00218] A pressure tube was charged with methylsulfone (1.15g, 5.4mmol) and aniline (2.8g, 16.2mmol). The tube was sealed and the mixture heated at 140°C for 30 minutes. The mixture was cooled. Methanol was added and the resulting solid collected via filtration then washed with methanol. The product (270mg, 8.7%) was used without further purification. LCMS: 312 $(M+H)^+$.



[00219] A flask was charged with pyrrolopyrimidinone (250mg, 0.8mmol) and toluene (5mL). Phosphorous oxychloride (218µL, 2.41mmol) and DIPEA (165µL, 0.96mmol) were added and the mixture stirred at 110°C for 6 hours. The volatiles were removed under *vacuo* and the product used without further purification. LCMS: 330 $(M+H)^+$.



[00220] A flask was charged with pyrrolopyrimidine (100mg, 0.3mmol) and isopropanaol (1mL). Aniline (55mg, .036mmol) and two drops of conc. HCl were added and the mixture heated to reflux for 6 hours. Volatiles were removed under *vacuo*. The

product was purified by preparative HPLC to afford the title compound (**306**) (12.8mg, 9.6%).

^{1}H NMR (400MHz, d6-DMSO): 11.13 (s, 1H), 9.95 (s, 1H), 9.04 (s, 1H), 8.56 (s, 1H), 7.86 (d, 2H), 7.66 (d, 2H), 7.54 (d, 2H), 6.88-6.82 (m, 3H), 6.65-6.61 (m, 1H), 3.78-3.71 (m, 4H), 3.05-2.99 (m, 4H), 2.04 (s, 3H). MS (EI) for $C_{24}H_{25}N_7O_2$: 444 (MH+).

Example 36

(N-(4-{2-[(3-{[(2,6-dichlorophenyl)sulfonyl]amino}phenyl)amino]-5-methyl-pyrimidin-4-yl}phenyl)acetamide) (Compound 26)



[00221] To a mixture of 2,4-dichloro-5-methylpyrimidine (4.17g, 25.6mmol) and 4-acetamidophenylboronic acid (5.0g, 27.9mmol) in DME (40ml) was added Et_3N (8.92ml, 64.0mmol), H_2O (4ml), and dichloro[1,1'-bis(diphenylphosphino)ferrocenepalladium (2.81g, 3.44mmol, 13%). The mixture was allowed to stir at reflux for 5hours. After the mixture was cooled down to rt, the crude mixture was directly filtered on silica gel and eluted with EtOAc. The filtrate was concentrated in vacuo. Further purification was conducted by flash chromatography to afford Intermediate 1 (5.94g, 89%) as a white solid. LCMS: m/z 262 $(M+H)^+$.



[00222] To a stirred solution of chloropyrimidine (1.05g, 4.0mmol) in 1-butanol (10ml) was added N-Boc-amino-3-aniline (920mg, 4.4mmol) and the mixture was heated in the sealed tube at 180°C for 1.5 hours. The mixture was cooled down to rt and acidified with

1N HCl (20ml). The aqueous layer was washed with EtOAc (50ml). The separated aqueous layer was basified with 2N NaOH to pH 8-9 and extracted with EtOAc (50ml*3). The combined organic layer was dried over Na_2SO_4, concentrated in vacuo, and purified by flash chromatography to afford product **Intermediate K** (943mg, 71% as a light yellow solid. LCMS: m/z 334 $(M+H)^+$.



[00223] To a stirred suspension of aniline (250mg, 0.75mmol) in THF (5ml) was added DIPEA (157ml, 0.90mmol) and 2,6-dichlorobenzenesulfonyl chloride (203mg, 0.83mmol) and the mixture containing intermediate K was stirred at reflux for 2hrs. After cooling down to rt, the mixture was diluted with EtOAc, washed with H_2O, brine, and dried over Na_2SO_4. After concentrated in vacuo, the residue was purified by flash chromatography to give product **26** (299mg, 73%) as a light pink solid.

^{1}H-NMR (400MHz, d_6-DMSO): 10.71 (s, 1H), 10.16 (s, 1H), 9.54 (s, 1H), 8.34 (s, 1H), 7.75-7.69 (m, 5H), 7.60 (dd, 2H), 7.51 (dd, 1H), 7.31 (dd, 1H), 7.09 (t, 1H), 6.66 (dd, 1H), 2.25 (s, 3H), 2.08 (s, 3H); MS (EI) $C_{25}H_{21}Cl_2N_5O_3S$: 542.2 $(M+H)^+$.

Example 37

N-(4-{6-morpholin-4-yl-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide (Compound 47)



Intermediate L

[00224] The mixture of 2,4,6-trichloropyrimidine (1.72ml, 15mmol) 4-acetamidophenyl-boronic acid (1.79g, 10mmol) in DME (20ml) was added Et_3N (3.5ml,

25.0mmol), H_2O (2ml), and dichloro[1,1'-bis(diphenylphosphino)ferrocenepalladium (1.22g, 1.5mmol, 15%). The mixture was allowed to stir at reflux for 2hrs. After the mixture was cooled down to rt, the crude mixture was directly filtered on silica gel and eluted with EtOAc. The filtrate was concentrated in vacuo. Further purification was conducted by flash chromatography to afford intermediate L (1.91g, 68%) as a white solid. LCMS: m/z 282 $(M+H)^+$.



Intermediate M

[00225] To a stirred suspension of pyrimidine (282mg, 1.0mmol) in 1-butanol (5ml) was added morpholine (96ml, 1.10mmol) and DIPEA (209µl, 1.2mmol). The mixture was heated at 120°C for 1hr, cooled down to rt, and concentrated in vacuo. The residue was purified by flash chromatography to afford intermediate M (176mg, 53%) as well as isomer (108mg, 32%). LCMS: m/z 333 $(M+H)^+$.



47

[00226] The mixture of chloropyrimidine (176mg, 0.53mmol) and 4-morpholinoaniline (104mg, 0.58mmol) in 1-butanol (5ml) was heated in the sealed tube at 160°C for 3hrs. The reaction mixture was cooled down to rt and the crude mixture was directly subjected on silica gel to afford product **47** (122mg, 49%) as a pale pink solid. LCMS: m/z 475 $(M+H)^+$.

^{1}H-NMR (400MHz, d_6-DMSO): 10.13 (s, 1H), 8.87 (s, 1H), 8.07 (d, 2H), 7.70-7,64 (m, 4H), 6.90 (d, 2H), 6.71 (d, 1H), 3.74-3.68 (m, 12H), 3.03 (t, 4H), 2.08 (s, 3H); MS (EI) $C_{26}H_{30}N_6O_3$: 475 (MH+).

Example 38

N-[6-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)pyridin-2-yl]-2,6-dichlorobenzamide (Compound 299)



A B C

[00227] To a mixture of 2,6-diaminopyridine **A** (9.2 mmol, 1.0 g), and diisopropylethylamine (6.9mmol, 1.2ml) in 20ml of THF, was added 2,6-dichlorobenzoylchloride **B** (4.6mmol, 0.67ml) dropwise. The mixture was stirred at room temperature for 1 hour and LCMS indicated it was done (M+H: 283). THF was removed and replaced with ethyl acetate. The reaction mixture was then extracted with water, brine, and dried over sodium sulfate. The product, **C** , was isolated by removal of the solvent with a rotary evaporator and used without further purification. LCMS: 283 (M+H).



A_1 C 299

[00228] A seal tube was charged with intermediate A_1 (0.2g, 0.81 mmol), compound **C** from the previous step (0.56g, 2.0mmol), tris(dibenzylideneacetone)dipalladium(0) (0.15g, 0.16 mmol), racemic-2,2'-bis(diphenylphosphino)-1,1'binaphthyl (0.12g, 0.2mmol), cesium carbonate (0.4g, 1.22mmol). Dimethylacetamide (10ml) was added and the

mixture was purged with N_2 for 5 minutes. The tube was sealed and the reaction mixture was stirred at 80^0C overnight. LCMS showed the reaction was done (M+H: 493). The reaction mixture was partitioned between ethyl acetate and water, the organic layer extracted with 10% LiCl solution, followed by brine, dried over Na_2SO_4, and then evaporated. The crude product 299 was then purified via prep HPLC.

^{1}H NMR (400 MHz, d_6-DMSO): 11.12 (s, 1H), 10.25 (s, 1H), 9.43 (s, 1H), 8.58 (d, 1H), 8.2-8.13 (m, 3H), 7.9 (t, 1H), 7.83 (d, 1H), 7.78 (d, 2H), 7.55 (d, 2H), 7.52-7.45 (m, 2H), 2.1 (s, 3H). MS (EI) for $C_{24}H_{18}Cl_2N_6O_2$: 493 (MH^+).

Example 39

N-(3-(4-(4-acetamidophenyl)pyrimidin-2-ylamino)phenyl)-3-(2-morpholinoethoxy)-benzamide (Compound 123)





[00229] A flask was charged with 2,4-dichloropyrimindine (22.7 g, 152.38 mmol), 4-acetoamido-phenylboronic acid (30.0 g, 167.62 mmol), dicholor[1,1'-bis(diphenylphosphino)-ferrocene-palladium (16.726 g, 22.86 mmol, 15 mol %), and triethylamine (53 mL, 380.95 mmol). Ethyleneglycoldimethylether (500 mL) and H_2O (20 mL) were added to the flask. The reaction mixture was stirred at 80 °C for 4 hours. The product, Intermediate **A**, was isolated by removal of the solvent with a rotary evaporator and purified using glass column chromatography and eluted with ethyl acetate to afford 30.5 g (123.14 mmol, 81% yield) of intermediate **A** as a yellow solid.

[00230] A seal tube was charged with intermediate **A** (400 mg, 1.62 mmol) and 3-(tert-butoxycarbonylamino)aniline (1.99g, 9.57 mmol). N-butanol (50 mL) was added to the seal tube and stirred at 180^{0}C. The reaction was stopped after 2.5h, monitored by LCMS. The reaction mixture was diluted with methanol and the solid precipitate was filtered to afford intermediate **B** as a yellow solid. The filter pad was washed with ethyl-acetate, 72% yield. Intermediate **B** was carried on to the next step without further purification.

[00231] A flask was charged with intermediate **B** (159mg, 0.5 mmol), 3-(2-morpholinoethoxy)benzoyl chloride (169mg, 0.63 mmol), and Pyridine (8 mL). The reaction mixture was stirred at RT under nitrogen. Reaction was complete after 1hour. The final product **123** was purified using Preperative HPLC and trifluoroacetic acid buffer then free based with hydroxide resin in methanol. The filtrate was then concentrated, the yellow oil was then freezed and lyophilized.

1H-NMR (400MHz, d6-DMSO): 10.206(s, br, 2H), 9.665(s, br, 1H), 8.512(d, 1H), 8.502(s, 1H), 8.440(d, 2H), 7.755(d, 2H), 7.582(m, 2H), 7.483(m, 2H), 7.375(d, 1H), 7.287(m, 2H), 7.163(d, 1H), 4.188(m, 2H), 3.595 (m, 4H), 3.174(m, 4H), 2.732(m, 2H), 2.083(s, 3H). MS(EI) for $C_{31}H_{32}N_6O_4$: 553 (MH+).

Example 40

4-[4-(methylamino)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine (Compound 124)



A_1 B C

[00232] A flask was charged with 2,4-dichloropyrimidine (810 mg, 5.5 mmol), 4-(tert-butoxycarbonyl(methyl)amino)phenylboronic acid **B** (4.93 g, 15 mmol), dicholoro[1,1'-bis(diphenylphosphino)ferrocenepalladium (590 mg, 0.81 mmol, 15 mol %), triethylamine (1.8 mL, 13 mmol), and water (2 mL). Ethylene glycol dimethyl ether (5.0 mL) was added to the flask and the mixture was purged with N_2. The reaction mixture was stirred under an N_2 atmosphere at 90 °C for 1 hour, after which time, it was cooled to ambient

temperature and filtered. The product, **C**, was isolated by removal of the solvent with a rotary evaporator and used without further purification. LCMS: m/z 319 $(M+H)^+$.



C **124**

[00233] A flask containing a solution of **C** (1.9 g, 5.8 mmol) and 4-morphilinoaniline (1.5 g, 8.2 mmol) in 1-butanol (10 mL) was immersed in an oil bath at 180 °C for 4 h. The mixture was cooled to ambient temperature, concentrated, and the residue was dissolved in dichloromethane (10 mL) and 4N HCl in dioxane (10 mL). A portion of this crude product (200 mg) was purified by reverse phase HPLC to yield the product **124** (20 mg) in > 99% purity.

^{1}H-NMR (400MHz, d_6-DMSO): 9.92-9.99 ppm (bs, 1H), 8.20-8.29 (bs, 1H), 8.02 (d, 2H), 7.52-7.68 (bs, 2H), 7.33 (d, 1H), 7.04-7.17 (bs, 1H), 6.67 (d, 2H), 3.71-3.82 (bs, 4H), 3.14-3.24 (bs, 4H), 2.78 (s, 3H). MS (EI) $C_{21}H_{23}N_5O$: 362.1 (MH^+).

Example 41

2,6-dichloro-N-{3-[(4-{[3-chloro-4-(methyloxy)phenyl]oxy}pyrimidin-2-yl)amino]phenyl}-benzamide (Compound 304)



A **B**

[00234] A flask was charged with 2,4-dichloropyrimidine (500 mg, 3.4 mmol), 2-chloro-4-methoxyphenol (580 mg, 3.7 mmol), and diisopropylethylamine (1.2 mL, 6.9 mmol). Dimethylformamide (20 mL) was added to the flask and the mixture was stirred at 70 °C for 15 hours. The reaction mixture was diluted with water and the mixture was extracted with dichloromethane 2X and 5% LiCL 3X. The crude product, **B**, was isolated

by removal of the solvent with a rotary evaporator and the resultant brown oil was used without further purification. LCMS: m/z 272 $(M+H)^+$.



B C

[00235] A flask containing a solution of intermediate **B** (910 mg, 3.4 mmol) and benzene-1,3-diamine (540 mg, 5.0 mmol) in nBuOH (5 mL) was immersed in an oil bath at 180 °C for 30 mins. The intermediate, **C**, was isolated by removal of the solvent with a rotary evaporator and used without further purification. LCMS: m/z 343 $(M+H)^+$.



C 304

[00236] A flask was charged with intermediate **C** (1.1 g, 3.4 mmol), 2,6-dichlorobenzoylchloride (1.2 mL, 8.3 mmol), diispropylethylamine (1.8 mL, 10 mmol) and THF (50 mL). The reaction mixture was stirred at 60 °C for 15 hours. The reaction mixture was diluted with ethylacetate, extracted with 5% LiCl 3X, and the organic fraction was concentrated on a rotary evaporator. The crude product was purified by silica column chromatography (1:1 ethylacetate:hexanes as eluent) followed by reverse phase HPLC (TFA/ACN as eluent) to yield the product, **304** (24 mg, 1% yield).

^{1}H-NMR (400MHz, d6-DMSO): 10.7 (s, 1H), 9.65 (s, 1H), 8.36 (d, 1H), 7.77 (s, 1H), 7.58-7.47 (m, 3H), 7.36-7.28 (m, 3H), 7.23 (d, 1H), 7.04-6.98 (m, 2H), 6.47 (d, 1H), 3.83 (s, 3H). MS (EI) $C_{24}H_{17}C_{l3}N_4O_3$: 514.8 (MH-).

Example 42

(3S)-1-(2-hydroxyethyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyrrolidine-3-carboxamide (Compound 510)



249 (a) B C

[00237] To a solution of **249(a)** (300 mg, 0.78 mmol) in DMA (10 mL) was added a solution of (S)-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid (350 g, 1.6 mmol) diisopropyl-ethylamine (0.5 mL, 2.7 mmol), and HATU (600 mg, 1.6 mmol) in DMA (10 mL) and the solution was stirred at room temperature 15 hours. The solution was diluted with ethyl acetate (100 mL), washed with 10% LiCl (2X) and brine. The resultant solution was dried over Na_2SO_4, filtered and concentrated to yield a residue that was purified by silica gel column chromatography (3:1 ethyl acetate/hexanes). The Boc intermediate was isolated as a solid (340 mg, 78% yield). LC/MS: m/z 545 $(M+H)^+$. A flask containing the Boc-intermediate was dissolved in 4N HCl in dioxane (10 mL) and dichloromethane (10 mL) and the mixture was stirred at room temperature for 15 hours. Intermediate **C** was isolated as a yellow solid after filtration and used without purification.



C 510

[00238] A flask was charged with intermediate C (450 mg, 0.78 mmol), 2-hydroxy-acetaldehyde (45 mg, 0.75 mmol), sodium triacetoxyborohydride (150 mg, 0.71 mmol), diisopropylethylamine (0.7 mL, 3.8 mmol) and dichloromethane (20 mL) and the mixture was stirred at room temperature for 4 hours. The reaction mixture was diluted with water and the solution was extracted with saturated $NaHCO_3$ (2X) and brine. The residue was purified by reverse phase HPLC (ammonium acetate/ACN as eluent) to afford the product **510** (120 mg, 31% yield).

^{1}H-NMR (400MHz, d6-DMSO): 10.2 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.75 (d, 2H), 7.67 (d, 2H), 7.28-7.27 (m, 1H), 6.93 (d, 2H), 4.47 (br 1H), 3.76-3.73 (m, 4H), 3.49 (t, 2H), 3.06-3.03 (m, 4H), 2.91 (t, 1H), 2.70-2.65 (m, 1H), 2.58-2.56 (m, 1H), 2.54-2.49 (m, 4H), 1.99 (t, 2H). MS (EI) $C_{27}H_{32}N_6O_3$: 489.2 (MH+).

Example 43

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}phenyl)acetamide (Compound 329)



A B

[00239] A mixture of 2-[(4-morpholin-4-ylphenyl)amino]-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one A (312 mg, 1 mmol), phosphorous oxybromide (717 mg, 2.5 mmol), and diisopropylethylamine (130 mg, 1 mmol) in anhydrous toluene (15 ml) was heated at reflux under N_2 overnight. The mixture was cooled down to room temperature, and the solid was filtered, washed with sat. $NaHCO_3$, water, and dried over $MgSO_4$. The solvent was removed in vacuo to give the product 4-bromo-N-(4-morpholin-4-ylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine B (284 mg, 76%) as a black solid. This was clean and used as such without further purification.



B C **329**

[00240] A mixture of 4-bromo-N-(4-morpholin-4-ylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine B (284 mg, 0.76 mmol), 4-acetoamidophenylboronic acid C (340 mg, 2.5 eq), tetrakis(triphenyl-phosphine)palladium(0) (120 mg, 0.1 mmol), and 1M Na_2CO_3 (1ml, 1 mmol) in 1,4-dioxane (15 ml) was heated at reflux overnight. The mixture was cooled, extracted with 3N HCl. The aqueous layer was washed with ethylacetate, and

then basified with 6N NaOH. The solid was filtered, and the crude product was purified by preparative HPLC to give the product N-(4-{2-[(4-morpholin-4-ylphenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}phenyl)acetamide D (0.8 mg, 0.25%) as a yellow solid. ^{1}H NMR (400 MHz, CD_3OD): 8.10 (d, 2H), 7.75 (d, 2H), 7.68 (d, 2H), 7.12 (d, 1H), 6.98 (d, 2H), 6.70 (d, 1H), 3.85 (t, 4H), 3.09 (t, 4H), 2.17 (s, 3H). MS (EI) for $C_{24}H_{24}N_6O_2$: 429 (MH^+).

Example 44

2-Methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)prolinamide (Compound 367)

Preparation of *tert*-butyl 2-methyl-2-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenylcarbamoyl)pyrrolidine-1-carboxylate



[00241] An oven dried 50 ml round bottomed flask fitted with a Teflon stirrer and gas inlet was flushed with dry nitrogen and allowed to cool to room temperature. The flask was charged with 4-(4-aminophenyl)-N-(4-morpholinophenyl)pyrimidin-2-amine pentahydrochloride (1 equiv., 0.52 g, 0.9631 mmoles) and anhydrous dimethylacetamide (15 ml). The mixture was stirred for 10 minutes to allow for the complete dissolution of the amine. Diisoproplyethylamine (10 equiv., 1.24 g, 1.67 ml, 9.631 mmoles) was added in one lot and the reaction mixture was stirred for 5 minutes. 1-(tert-Butoxycarbonyl)-2-methylpyrrolidine-2-carboxylic acid (4 equiv., 3.852 mmoles, 0.883 g, purchased from Fluka-Sigma Aldrich) was added to the reaction mixture in one lot, followed by 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU, 4 equiv., 3.852 mmoles, 1.464 g, purchased from Oakland Products). The reaction mixture was stirred at room temperature and the progress of the reaction was monitored by LC/MS. After 72 hours, the reaction mixture was quenched with ethyl acetate (20ml), and

transferred to separatory funnel. The reaction flask was further rinsed with ethyl acetate (20 ml), transferred to the separatory funnel, shaken and the layered separated off. The aqueous layer was further washed with ethyl acetate (3 x 50 ml). The combined ethyl acetate solutions were washed with cold water (2 x 50 ml) and saturated sodium chloride solution (2 x 50 ml). The ethyl acetate solution was dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure to give orange oil. The resulting crude material was purified by silica phase flash chromatography (45 mm x 250 mm) using 3:1 ethyl acetate -hexane to give 0.147 g of *tert*-butyl 2-methyl-2-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenylcarbamoyl)-pyrrolidine-1-carboxylate as a white solid (27% yield). 1H NMR (400 MHz, d6-DMSO) 10.01 (br s, 1H), 9.45 (br s 1H), 8.19 (d, 1H), 7.70 (d, 2H), 7.46 (d, 2H), 6.74 (d, 1H), 6.66 (d, 2H), 6.28 (d, 2H), 3.67 (m, 4H), 3.40 (m, 1H), 3.30 (m, 1H), 2.29 (m, 4H), 1.76 (m, 1H), 1.64 (m, 1H), 1.58 (s, 3H), 1.54 (m, 1H), 1.40 (s, 9H). MS (EI) for C31H38N6O4: 559 (M+).

Preparation of 2-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)prolinamide



[00242] *tert*-Butyl 2-methyl-2-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl-carbamoyl)pyrrolidine-1-carboxylate (0.140 g, 0.250 mmoles), was dissolved in an ethyl acetate (5 ml) and methanol (1 ml) mixture. 4 M hydrogen chloride in 1,4-dioxane (0.625 ml, 2.5 mmoles, 10 equivalents, purchased from Sigma-Aldrich) was then added in a drop wise fashion over 5-10 minutes. Upon completion of addition, the reaction mixture was stirred at room temperature, and the progress of the reaction monitored by LC/MS. After 16 hours, additional 4M hydrogen chloride in 1,4-dioxane (0.312 ml, 1.25 mmoles, 5 equivalents) was added. After a total of 48 hours the reaction was complete and the resulting slurry was filtered off. The reaction flask was rinsed with ethyl acetate to ensure

complete transfer of product. The resulting solid was washed with ethyl acetate (3 x 10 ml) and diethyl ether (2 x 25 ml) and dried under reduced pressure to give of 0.061 mg 2-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)prolinamide **367** as its hydrochloride salt (53% yield).

1H NMR (400 MHz, d6-DMSO): 10.88 (s, 1H), 9.79 (br s, 1H), 8.47 (d, 1H), 8.12 (d, 1H), 8.10 (d, 1H), 7.80 (br d, 2H), 7.75 (d, 2H), 7.37 (d, 2H), 5.26 (br s, 3H), 3.72 (br s, 4H), 3.27 (br s, 4H), 2.80 (m , 1H), 2.70 (m, 1H), 2.01 (m, 1H), 1.76 (m, 1H), 1,64 (m, 1H), 1.54 (m, 1H), 1.38 (s, 3H). MS (EI) for $C_{26}H_{30}N_6O_2$: 459 (MH+).

Example 45

2-Methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]-pyrimidin-4-yl}phenyl)prolinamide (Compound 360)



[00243] An oven dried 50 ml round bottomed flask fitted with a Teflon stirrer and gas inlet was flushed with dry nitrogen and allowed to cool to room temperature. The flask was charged with 4-(4-aminophenyl)-N-(4-morpholinophenyl)pyrimidin-2-amine pentahydrochloride (1 equiv., 0.4 g, 0.756 mmoles) and anhydrous dimethylacetamide (15 ml). The mixture was stirred for 10 minutes to allow for the complete dissolution of the amine. Diisoproplyethylamine (10 equiv., 0.977 g, 1.31 ml, 7.561 mmoles) was added in one lot and the reaction mixture was stirred for 5 minutes. N-Boc-D-proline (4 equiv., 3.204 mmoles, 0.65 g, purchased from Fluka-Sigma Aldrich) was added to the reaction mixture in one lot, followed by 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyl-uronium hexafluorophosphate (HATU, 4 equiv., 3.024 mmoles, 1.149 g, purchased from Oakland Products). The reaction mixture was stirred at room temperature and the progress of the reaction was monitored by LC/MS. After 72 hours, the reaction mixture was quenched with ethyl acetate (20ml), and transferred to separatory funnel. The reaction flask was further rinsed with ethyl acetate (20 ml), transferred to the separatory funnel,

shaken and the layer separated off. The aqueous layer was further washed with ethyl acetate (3 x 50 ml). The combined ethyl acetate solutions were washed with chloride solution (2 x 50 ml). The ethyl acetate solution was dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure to give an orange oil. The resulting crude material was purified by silica phase flash chromatography (45 mm x 250 mm) using 3:1 ethyl acetate -hexane to give 0.39 g of 1,1-dimethylethyl (2R)-2-{[(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)amino]carbonyl}pyrrolidine-1-carboxylate as a white solid (94 % yield).

1H NMR (400 MHz, d6-DMSO): 10.26 (br s ,1H), 9.38 (br s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.78 (d, 2H)< 7.68 (d, 2H), 7.28 (d, 1H), 6.94 (d, 2H), 4.22 (m, 1H), 3.74 (m, 4H), 3.43 (m, 1H), 3.34 (m, 1H), 3.04 (m, 4H), 2.20 (m, 1H), 1.90 (m, 1H), 1.81 (m, 1H)< 1.40 (s, 3H), 1.27 (s, 6H). MS (EI) for $C_{30}H_{36}N_6O_4$: 545 (MH+).



[00244] 1,1-Dimethylethyl (2R)-2-{[(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)amino]carbonyl}pyrrolidine-1-carboxylate (0.38 g, 0.698 mmoles), was dissolved in an ethyl acetate (10 ml) and methanol (2 ml) mixture. 4 M hydrogen chloride in 1,4-dioxane (1.75 ml, 6.98 mmoles, 10 equivalents, purchased from Sigma-Aldrich) was then added in a drop wise fashion over 5-10 minutes. Upon completion of addition, the reaction mixture was stirred at room temperature, and the progress of the reaction monitored by LC/MS. After 16 hours, additional 4M hydrogen chloride in 1,4-dioxane (0.87, 1.25 mmoles, 5 equivalents) was added. After a total of 48 hours the reaction was complete and the resulting slurry was filtered off. The reaction flask was rinsed with ethyl acetate to ensure complete transfer of product. The resulting solid was washed with ethyl acetate (3 x 10 ml), followed by diethyl ether (3 x 25 ml) and dried under reduced

pressure to give of 0.264 mg 2-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]-pyrimidin-4-yl}phenyl)prolinamide (68 % yield).

1H NMR (400 MHz, d6-DMSO): 11.43 (br s, 1H), 10.07 (br s, 2H), 8.73 (d, 1H), 8.57 (d, 1H), 8.21 (d, 2H), 7.91 (d, 2H), 7.98 (d, 2H), 7.71 (br s, 2H), 7.48 (d, 1H), 4.48 (m, 1H), 4.08 (s, 4H), 3.74 (m, 4H), 3.42 (m, 1H), 3.36 (m, 1H), 3.04 (m, 4H), 2.22 (m 1H), 1.90 (m, 2H), 1.82 (m, 2H). MS (EI) for $C_{25}H_{28}N_6O_2$: 445 (MH+).

Example 46

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[(1-methyl-1H-benzimidazol-2-yl)methyl]benzamide (Compound 83)



[00245] 7.9 grams (11.04 mmol, 1.9 eq) of PL-TFP Resin (source: *Polymer Laboratories*) was weighed into a pressure tube. 60 ml of DCM was added. 2 g (5.74 mmol) of 3-(4-(3-acetamidophenyl)pyrimidin-2-ylamino)benzoic acid was dissolved in 15 ml of DMF and After 10 min, this solution was added to the pressure tube. Dimethylaminopyridine (4.41 mmol, .6 eq, source: *Acros*) was added to the pressure tube as a solid, followed by 1,3-diisopropylcarbodiimide (33.08 mmol, 4.5 eq, source: *Acros*). The pressure tube was sealed and the reaction was placed on a vertical shaker overnight. The resin was filtered, and then washed 3 times with DMF, followed by three times with THF, followed by three times with DCM. The resin was then dried overnight by vaccum.

[00246] 300 mg of resin prepared above (loading = 0.6 mmol/g, .18 mmol) was added to a 1 dram vial. 2 ml of DMA were added. 1 ml of (1-methyl-1H-benzo[d]imidazol-2-yl)methanamine (0.12 mmol, 0.67 eq) dissolved in DMA was added to the vial. The reaction was stirred overnight at room temperature. The reaction was filtered and rinsed twice with 4 ml of MeOH. The solution was further purified by HPLC to yield (3-(4-(4-acetamidophenyl)pyrimidin-2-ylamino)-N-((1-methyl-1H-benzo[d]imidazol-2-yl)methyl) benzamide **83** (10.2 mg, 17%).

^{1}H-NMR (400MHz, d_6-DMSO): 10.23 (s, 1H), 9.80 (s, 1H), 9.01 (t, 1H), 8.52 (t, 2H), 8.17-8.19 (m, 2H), 7.91-7.93 (m, 1H), 7.75 (d, 2H), 7.50-7.59 (m, 3H), 7.39-7.43 (m, 2H),

7.16-7.26 (m, 2H), 4.80 (d, 2H), 3.86 (s, 3H), 2.10 (s, 3H). MS (EI) for $C_{28}H_{25}N_7O_2$: 492.4 (MH^+).

Example 47

N-(4-morpholin-4-ylphenyl)-4-{4-[(propylamino)methyl]phenyl} pyrimidin-2-amine (Compound 283)



Intermediate A Intermediate B



283

[00247] A flask was charged with 2,4-dichloropyrimindine (1.5 g, 10 mmol), 4-formylphenyl boronic acid (1.65 g, 11 mmol), dicholor[1,1'-bis(diphenylphosphino)-ferrocenepalladium (731 mg, 1 mmol, 10 mol %), and triethylamine (2.6 mL, 15 mmol). Ethyleneglycoldimethylether (50 mL) and H_2O (2mL) was added to the flask. The reaction mixture was stirred at 80 °C for 4 hours. The product, Intermediate **A**, was isolated by removal of the solvent with a rotary evaporator and purified using glass column chromatography and eluted with ethyl acetate to afford 1.0 g (4.58 mmol, 46% yield) of intermediate **A** as a yellow solid.

[00248] A flask was charged with intermediate **A** (150 mg, 0.668 mmol), sodium triacetoxy-borohydride (220 mg, 1.032 mmol), propylamine (63 µl, 0.756 mmol). Dichloromethane (50 mL) was added to the flask and the reaction mixture was stirred at room temperature for 48 h. The reaction was quenched with 2 N NaOH and extracted with ethyl acetate, washed with brine, dried over sodium sultate, and filtered. The solvent

was removed using the rotary evaporator to afford intermediate **B** as a yellow solid (140 mg, 0.536 mmol, 80% Yield). Intermediate **B** was carried on without further purification.

[00249] A seal tube was charged with intermediate **B** (140 mg, 0.536 mmol) and 4-morpholinoaniline (95 mg, 0.536 mmol). N-butanol (15 mL) was added to the seal tube and stirred at 180^{0}C. The reaction was done in 1h according to LCMS to afford 283 as a yellow solid. **Compound 283** was purified using preperative HPLC and TFA buffer. **Compound 283** was free-based, converted to HCl salt, and lyophilized (20mg, 0.455 mmol).

^{1}H NMR (400 MHz, DMSO): 9.93 (br s, 1H), 9.396 (br s, 2H), 8.607 (d, 1H), 8.233 (d, 2H), 7.905 (d, 2H), 7.767 (d, 2H), 7.571-7.494 (m, 3H), 4.226 (br s, 2H), 3.998 (br s, 4H), 3.436 (br s, 4H), 2.865 (m, 2H), 1.708 (m, 2H), 0.914 (t, 3H). MS (EI) for $C_{24}H_{29}N_5O$: 404.4 (MH^+).

Example 48

N-[(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)methyl]acetamide (Compound 282)



Compound A **282**

[00250] In a 20 ml round bottomed flask, 36 mg (1 mmol) of compound A was dissolved in 5 ml of dichloromethane and 0.5 ml of triethylamine was added. It was cooled in ice bath and 10 mg (1.2 mmol) of acetyl chloride was added and stirred for 30 min. Compound **282** precipitated out and purified in a Waters prep column. Yield 40 mg (90%).

^{1}H NMR (400MHz, CD_3CN):11.20-11.22(b,1H), 8.40 (d, 2H), 8.05(d,2H), 7.80(d,2H), 7.50 (d, 2H), 7.45 (s, 1H), 7.20 (d, 1H), 7.05-7.10 (b, 1H), 4.40-4.44 (b, 2H), 3.90 (t, 4H), 3.40 (t, 4H),2.01(s,3H); MS (EI) for $C_{23}H_{25}N_5O_2$: 404 (MH^+).

Example 49

N-(4-{2-[(4-{4-[(2,4-dichlorophenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide (Compound 180)



[00251] To a 1 ml vial was added N-(4-{2-[(4-piperazin-1-ylphenyl)amino]pyrimidin-4-yl}-phenyl)acetamide (38.85 mg, 0.1 mmol), 2,4-dichlorobenzaldehyde (350 mg, 2.0 mmol, 20 eq, source: Aldrich) and 1 ml of DMF. To this mixture was added sodium triacetoxyborohydride (106 mg, 0.5 mmol, 5 eq). The mixture was stirred over night at room temperature. Upon completion of the reaction as determined by LC/MS, 0.1 ml of 2M HCl was added. The residue was purified via reverse phase HPLC (ammonium acetate/ACN) to yield N-(4-{2-[(4-{4-[(2,4-dichlorophenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide **180** (20.2 mg, 37 %) .
^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.80 (s, 1H), 9.10 (t, 1H), 8.53 (d, 2H), 8.18 (d, 2H), 7.94-7.91 (m, 1H), 7.75 (d, 1H), 7.69-7.57 (m, 4H), 7.48-7.39 (m, 2H), 4.58 (d, 6H), 2.50 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{29}H_{28}C_{l2}N_6O$: 548.5 (MH+).

Example 50

5-fluoro-N^4-[2-(methyloxy)phenyl]-N^2-[3-(methyloxy)phenyl] pyrimidine-2,4-diamine (Compound 306)



[00252] A round-bottomed flask was charged with 2,4-dichloro-5-fluoropyrimidine (0.84 g, 5 mmol), 2-methoxylaniline (0.61 g, 5 mmol) and dioxane (5 mL). The reaction

mixture was heated at 85 °C overnight. The reaction was cooled down and diluted with acetonitrile/water, stirred for 30 min. and filtered. The collected solid was re-suspended in acetonitrile/water, stirred and filtered to give a 2-chloro-5-fluoro-N-(2-methoxyphenyl)pyrimidin-4-amine (0.9 g, 70% yield). To a seal tube was added 2-chloro-5-fluoro-N-(2-methoxyphenyl)pyrimidin-4-amine (254 mg), 3-methoxyaniline (500 mg, 4 eq.) and dioxane (5 mL). The mixture was heated to 130 °C overnight. The reaction mixture was cooled and partitioned between EtOAc and water. The organic layer was concentrated; the residue was triturated with a 1:1 mixture of dichloromethane and acetonitrile, then filtered to give the title product as a white solid (150 mg).

^{1}H NMR (400 MHz, d6-DMSO): 9.16 (s, 1H), 8.37 (s, 1H), 8.09 (s, 1H), 7.88 (d, 1H), 7.26 (t, 2H), 7.22-7.16 (m, 2H), 7.12-7.08 (m, 1H), 7.08-6.93 (m, 2H), 3.81 (s, 3H), 3.62 (s, 3H). MS (EI) for $C_{18}H_{17}FN_4O_2$: 341 (MH+).

Example 51

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}phenyl)-acetamide (Compound 329)





[00253] To a flask containing a solution of **1** (0.25g, 1 mmol), 4-(4-ethylpiperazin-1-yl)aniline (0.23g, 1.1 mmol), cesium carbonate (0.5g, 1.5 mmol), *racemic*-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (95mg, 0.15 mmol) in N,N-dimethylacetamide (5mL) purged with N_2 was added tris(dibenzylideneacetone)dipalladium(0) (0.14g, 0.15 mmol). This reaction was heated to 90 °C for 16 h under N_2. At this time the reaction was concentrated and the residue was purified via silica gel column chromatography. The column was eluted with ethyl acetate to remove the impurities and then with 85:10:5 (ethyl acetate/methanol/7M ammonia in methanol) to elute the desired product. The solid obtained was sonicated first in acetone (5mL) and then in ether (10mL) to yield intermediate **2** (0,23g, 48% yield) as a yellow solid. LCMS: m/z 417 (MH+). To a flask containing **2** (0.23g, 0.45 mmol) was added 4N HCl in dioxane (5mL) and the solution was heated at 50 °C for 4 h. To the cooled solution was added a 2N aqueous solution of sodium hydroxide (10mL) and the resulting precipitate was filtered and dried to yield **3** (0.2g, 99% yield) as a yellow solid. LCMS: m/z 375 $(M+H)^+$. To a flask with **3** (0.3g, 0.8 mmol), phenylacetic acid (0.125mL, 1 mmol), triethylamine (0.97mL, 7 mmol), and DMF (5mL) was added O-(7-azabenzotriazole-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (HATU) (0.46g, 1.2 mmol). The reaction mixture was stirred at

ambient temperature for 1 h then diluted with 5% aqueous solution of lithium chloride (100mL) and extracted with ethyl acetate (3 x 50mL). The combined organic layers were washed with an aqueous 5% sodium bicarbonate solution, a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, filtered and concentrated. The residue obtained was purified by silica gel column chromatography (98:2 ethylacetate/methanol) to provide Compound **329** (0.25g, 63% yield) as an off-white solid.

Example 52

N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-prolinamide (Compound 662)



[00254] A solution of chloropyrimidine (**1**) (0.28g, 0.64 mmol) and tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate (0.18g, 0.6 mmol) in *n*-butanol (5ml) was heated at 180 °C in a sealed tube for 7 h. The reaction mixture was concentrated, the residue dissolved in methanol (5ml) and treated with HCl (3ml, 4M in dioxane) for 1 hour at room temperature. After concentration, the residue was dissolved in H_2O (200mL) and the pH adjusted to ca. 8-9 with 1N NaOH. The aqueous layer was extracted with CH_2Cl_2 (2 x 10ml) and the combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (85:15 ethyl acetate/methanol) to afford **2** (0.26g, 69%). $C_{33}H_{35}N_7O_3$: 578 (MH^+).



2 3

[00255] To a solution of **2** (0.41g, 0.7 mmol) and DIPEA (0.31ml, 1.75 mmol) in CH_2Cl_2 (7ml) was added cyclobutylcarbonyl chloride (0.80ml, 0.7 mmol) at room temperature. After 10 min, the reaction mixture was diluted with H_2O (10mL) and CH_2Cl_2 (10mL). The aqueous layer was extracted with CH_2Cl_2 (3 x 5mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue obtained was purified by silica gel column chromatography (98:2 ethyl acetate/methanol) to afford **3** (0.31g, 68%) as a white powder. $C_{38}H_{41}N_7O_4$: 660 (MH^+).



3 662

[00256] The mixture of **3** (0.31g, 0.47 mmol) and Pd/C (0.94g) AcOH (1mL) and MeOH (5mL) was stirred at room temperature for 24 h under a H_2 balloon. The palladium was filtered through celite and the filtrate was concentrated. The residue was purified by silica gel column chromatography (90:10 ethyl acetate/methanol) to afford product which was then washed with acetonitrile several times to afford Compound **662** (0.14g, 59% yield).

Example 53

N-ethyl-4-[4-({4-[4-(D-prolylamino)phenyl]pyrimidin-2-yl}amino)phenyl]piperazine-1-carboxamide (Compound 663)



2 4

[00257] To a stirred solution of **2** (0.58g, 1 mmol) in DMF (4ml) was added ethyl isocyanate (3mL) at room temperature. After stirring for 30 min, the mixture was diluted with H_2O (5mL) and CH_2Cl_2 (5mL). The separated aqueous layer was extracted with CH_2Cl_2 (3 x 5mL). The combined extracts were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (98:2 ethyl acetate/methanol) to afford **4** (0.46g, 71%). $C_{36}H_{40}N_8O_4$: 649 $(M+H)^+$.



4 663

[00258] A solution of **4** (0.46g, 0.71 mmol) and Pd/C (0.14g) in AcOH (1mL) and MeOH (5mL) was stirred for 24 h under a H_2 balloon. The palladium was filtered through celite and the filtrate was concentrated. The residue obtained was purified by silica gel column chromatography (90:10 ethyl acetate/methanol) to afford product which was then washed with acetonitrile several times to afford N-ethyl-4-[4-({4-[4-(D-prolylamino)phenyl]-pyrimidin-2-yl}amino)phenyl]piperazine-1-carboxamide (663) (0.19g, 51%) as a white powder.

2-{[2-(dimethylamino)ethyl]oxy}-3-(4-ethylpiperazin-1-yl)aniline



[00259] To a solution of 2-(diethylamino)ethanol (0.59g, 5mmol) in DMA (5ml), sodium hydride (0.24g, 10mmol) was added in one portion. Fifteen minute later 2-bromo-4-nitroaniline (1.1g, 5mmol) was added and the content was stirred for 4 hr. Water (50ml) was added to the reaction mixture followed by chloroform. The organic layer was separated, washed with saturated sodium bicarbonate follow by brine. The organic layer was dried over sodium sulfate and concentrated to oil. The oil was dissolved in methanol and saturated with HCl gas. The resulting solution was concentrated and diethyl ester was added. The resulting precipitate was washed with ether and dried to yield 0.8g of 2-[(2-bromo-4-nitrophenyl)0xy]-N,N-diethylethanamine hydrochloride as a solid. LCMS: m/z 318 $(M+H)^+$.

[00260] A mixture of 2-[(2-bromo-4-nitrophenyl)0xy]-N,N-diethylethanamine hydrochloride (0.5g, 1.4mmol), $Pd(dba)_2$ (0.192g, 021mmol), BINAP (0.139g, 0.21mmol), 1-ethylpiperazine (0.182g, 1.68mmol), and cesium carbonate (0.91g, 2.8mmol) in DMA was heated at 80 ^{0}C with stirring for 72 hr. Saturated aqueous sodium bicarbonate and ethyl acetate was added, the phases separated, the solvent was removed under vacuum and the residue chromatographed on silica with ethyl acetate/methanol to give 0.32g of N,N-diethyl-2-{[2-(4-ethylpiperazin-1-yl)-4-nitrophenyl]oxy}ethanamine. LCMS: m/z 351 $(M+H)^+$.

[00261] A solution of N,N-diethyl-2-{[2-(4-ethylpiperazin-1-yl)-4-nitrophenyl]oxy}ethanamine (0.280mg, 0.8mmol) in methanol (10ml) was added 10% Pd/C and stirred in hydrogen atmosphere at ambient temperature for 2hours. The reaction mixture was filtered through a pad of Celite and concentrated in vacuum. The residue was

taken up in methanol, ether/HCl was added and the hydrochloride (0.270 mg) was precipitated. LCMS: m/z 321 $(M+H)^+$.

Example 54

(*R*)-*N*-(4-(2-(3-(benzyloxy)-4-morpholino-phenylamino)-pyrimidin-4-yl)phenyl)-pyrrolidine-2-carboxamide (Compound 376)

[00262] *R*)-*N*-(4-(2-(3-(benzyloxy)-4-morpholino-phenylamino)-pyrimidin-4-yl)phenyl)-pyrrolidine-2-carboxamide was synthesized in an analogous fashion to Example 3, wherein 4-morpholinoaniline was substituted with 3-(benzyloxy)-4-morpholinoaniline to afford the title compound.

3-(benzyloxy)-4-morpholinoaniline



[00263] 4-(2-(Benzyloxy)-4-nitrophenyl)morpholine: A flask was charged with 2-chloro-5-nitrophenol (3.5 g, 20.2 mmol), potassium carbonate (4.0g, 30.3 mmol), benzyl bromide (2.9 mL, 24.24 mmol,) and acetonitrile (25 mL). The reaction mixture was stirred under an N_2 atmosphere at room temperature for 12 hours, after which time, the reaction mixture was filtered through Celite pat and washed with ethyl acetate (50 mL). The product was isolated by removal of the solvent with a rotary evaporator and used without further purification. NMR (400 MHz, $CDCl_3$): 7.80 (m, 2H), 7.27 – 7.58 (m, 6H), 5.24 (s, 2H). MS (EI) for $C_{13}H_{10}ClNO_3$: 264 (MH+).

Example 55

(*S*)-2-amino-*N*-(4-(2-(3-methyl-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide (Compound 384) was synthesized in an analogous fashion to Example 3, wherein 4-morpholinoaniline was substituted with 3-methyl-4-morpholino-aniline to afford the title compound.

3-Methyl-4-morpholinoaniline



Intermediate 1

[00264] A flask was charged with 2-fluoro-5-nitrotuloene (3.0 mL, 20.2388 mmol). Exess amount of morpholine (10 mL) were added to the flask and heated to 40 °C for 6 hours. The reaction mixture was checked with LC/MS. Water was added to the reaction mixture and the precipitate, intermediate 1, was filtered and used without further purification. LC/MS: m/z 223 $(M+H)^+$.

[00265] A hydrogenation flask was charged with intermediate 1 (1.0 g, 4.4209 mmol) and palladium/carbon (200 mg). Ethyl alcohol (50 mL) was added to the flask and hydrogenation technique was used. The reaction mixture was checked with LC/MS. The reaction mixture was filtered through a celite plug and washed with methanol. The product, 3-methyl-4-morpholinoaniline, was isolated by removal of the solvent with a rotary evaporator and used without further purification. LC/MS: m/z 197 $(M+H)^+$.

Example 56

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2-chloro-6-fluoro-3-(methyloxy)benzamide

[00266] (Compound 49) was synthesized in an analogous fashion to Example 2, wherein benzoylchloride was substituted with 2-chloro-3-methoxy-6-fluorobenzoylchloride (JRD Fluroochemicals) to afford the title compound.

Example 57

***N*-(4-{2-[(3-chloro-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide**

[00267] (Compound 296) was synthesized in an analogous fashion to Example 3, wherein aniline was substituted with 3-chloro-4-morpholinoaniline (Pfaltz and Bauer, Inc.) to afford the title compound.

Example 58

***N*-(4-{2-[(3-bromo-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide**

[00268] (Compound 315) was synthesized in an analogous fashion to Example 3, wherein aniline was substituted with 3-bromo-4-morpholinoaniline (Ryan Scientific, Inc.) to afford the title compound.

Example 59

(*R*)-*N*-(4-(2-(4-morpholino-3-(trifluoromethyl)-phenylamino)pyrimidin-4-yl)-phenyl)-pyrrolidine-2-carboxamide was synthesized in an analogous fashion to Example 3, wherein aniline was substituted with 3-trifluoromethyl-4-morpholinoaniline (Zerenex Limited) to afford the title compound.

Example 60

(*R*)-*N*-(4-(2-(3-fluoro-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide was synthesized in an analogous fashion to Example 3, wherein aniline was substituted with 3-fluoro-4-morpholinoaniline (Astatech, Inc.) to afford the title compound.

Example 61

***N*-[4-(2-{[3-(1,3-dioxan-2-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide** was synthesized in an analogous fashion to Example 3, wherein aniline was substituted 3-(1,3-dioxan-2-yl)aniline (Oakwood Products, Inc.) to afford the title compound.

Example 62

***N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]-5-(trifluoromethyl)pyrimidin-4-yl}phenyl)acetamide** was synthesized in an analogous fashion to Example 5, wherein pyrimidine was substituted with 5-trifluoromethyl-2,4-dichloropyrimidine (Astatech, Inc.) to afford the title compound.

[00269] Using the same or analogous techniques as illustrated in the preceding examples the following compounds herein below were made. The skilled artisan would be able to make the necessary modifications and/or substitutions in the above synthetic procedures to arrive at the following compounds:

***N*-(4-{2-[(3-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide** (Compound 21): ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 ppm (s, 1H), 9.511 ppm (s, 1H), 8.504 ppm (d, 1H), 8.154 ppm (d, 2H), 7.76 ppm (d, 3H), 7.343 ppm (d, 1H), 7.215-7.153 ppm (m, 2H), 6.584 ppm (d, 1H), 3.775 ppm (t, 4H), 3.14 ppm (t, 4H), 2.094 ppm (s, 3H); MS (EI) $C_{22}H_{23}N_5O_2$: 390.1 (MH^+).

***N*-(4-{2-[(3-piperidin-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide** (Compound 22): ^{1}H-NMR (400MHz, d_6-DMSO): 10.231 ppm (s, 1H), 9.466 ppm (s, 1H), 8.497 ppm (d, 1H), 8.16 ppm (d, 2H), 7.765 ppm (d, 3H), 7.337 ppm (d, 1H), 7.119 ppm (d, 2H), 6.553 ppm (m, 1H), 3.176 ppm (t, 4H), 2.092 ppm (s, 3H), 1.658 ppm (m, 4H), 1.571 ppm (m, 2H); MS (EI) $C_{23}H_{25}N_5O$: 388.1 (MH^+).

***N*-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide** (Compound 33): ^{1}H-NMR (400MHz, d_6-DMSO): 10.269 ppm (s, 1H), 9.317 ppm (s, 1H), 8.411 ppm (d, 1H), 8.089 ppm (d, 2H), 7.743 ppm (d, 2H), 7.638 ppm (d, 2H), 7.243 ppm (d, 1H), 6.908 ppm (d, 2H), 3.048 ppm (br s, 4H), 2.350 ppm (q, 2H), 2.07 ppm (s, 3H), 1.027 ppm (t, 3H); MS (EI) $C_{24}H_{28}N_6O$: 417.4 (MH^+).

***N*-(4-{2-[(4-piperidin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide** (Compound 34): ^{1}H-NMR (400MHz, d_6-DMSO): 10.229 ppm (s, 1H), 9.53 ppm (s, 1H), 8.481 ppm (d, 1H), 8.135 ppm (d, 2H), 7.76 ppm (t, 4H),l 7.325 ppm (d, 1H), 7.178 ppm (d, 2H), 3.025 ppm (br d, 2H), 2.59 ppm (m, 2H), 2.094 ppm (s, 3H), 2.08 ppm (br d, 2H), 1.54-1.439 ppm (m, 2H); MS (EI) $C_{23}H_{25}N_5O$: 388.3 (MH^+).

***N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,6-dichlorobenzamide** (Compound 17): ^{1}H-NMR (400MHz, d_6-DMSO): 10.718 ppm (s, 1H), 10.269 ppm (s, 1H), 9.678 ppm (s, 1H), 8.507 ppm (d, 1H), 8.419 ppm (s, 1H), 8.215 ppm (d, 2H), 7.758 ppm (d, 2H), 7.608 ppm (d, 2H), 7.532 ppm (t, 1H), 7.472 ppm (d, 1H), 7.380 ppm (d, 1H), 7.301 ppm (t, 1H), 7.216 ppm (d, 1H), 2.085 ppm (s, 3H); MS (EI) $C_{25}H_{19}Cl_2N_5O_2$: 492.2 (MH^+).

***N*-{4-[2-({3-[(4-ethylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide** (Compound 8): ^{1}H-NMR (400MHz, d_6-MEOD): 8.455 ppm (d, 1H),

8.15 ppm (m, 3H), 7.76-7.7 ppm (m, 3H), 7.435 ppm (t, 1H), 7.311 ppm (d, 1H), 7.1 ppm (d, 1H), 3.832 ppm (br s, 4H), 3.13 ppm (br s, 4H), 3.016 ppm (q, 2H), 2.162 ppm (s, 3H), 1.975 ppm (s, 3H, ACE), 1.299 ppm (t, 3H); MS (EI) $C_{25}H_{28}N_6O_2$: 445.4 (MH^+).

***N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2-fluorobenzamide** (Compound 10): ^{1}H NMR (DMSO-d_6) 10.40 (s, 1H), 10.21 (s, 1H), 9.66 (s, 1H), 8.49 (d, 1H), 8.41 (s, 1H), 8.20 (d, 2H), 7.74 (d, 2H), 7.69 (m, 1H), 7.58 (m, 1H), 7.48 (m, 1H), 7.37 (m, 3H), 7.28 (m, 2H), 2.09 (s, 3H). LCMS: m/z 442 $(M+H)^+$.

***N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2-fluoro-6-iodobenzamide** (Compound 11): ^{1}H NMR (DMSO-d_6) 10.65 (s, 1H), 10.19 (s, 1H), 9.67 (s, 1H), 8.50 (d, 1H), 8.41 (s, 1H), 8.21 (d, 2H), 7.76 (m, 3H), 7.41 (m, 3H), 7.28 (m, 3H), 2.08 (s, 3H). LCMS: m/z 567 $(M+H)^+$.

***N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2-bromobenzamide** (Compound 23): ^{1}H NMR (DMSO-d_6) 10.48 (s, 1H), 10.20 (s, 1H), 9.66 (s, 1H), 8.49 (d, 1H), 8.42 (s, 1H), 8.20 (d, 2H), 7.73 (d, 3H), 7.55 (m, 2H), 7.45 (m, 2H), 7.36 (m, 1H), 7.37 (d, 1H), 7.25 (m, 2H), 2.08 (s, 3H). LCMS: m/z 502, 503, 504, 505 $(M+H)^+$.

***N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-3-fluorobenzamide** (Compound 24): ^{1}H NMR (DMSO-d_6) 10.33 (s, 1H), 10.23 (s, 1H), 9.69 (s, 1H), 8.50 (d, 1H), 8.44 (s, 1H), 8.21 (d, 2H), 7.85 (m, 1H), 7.79 (m, 1H), 7.73 (d, 2H), 7.61 (m, 1H), 7.50 (m, 1H), 7.36 (m, 1H), 7.29 (m, 2H), 2.09 (s, 3H). LCMS: m/z 442 $(M+H)^+$.

***N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,6-dimethylbenzamide** (Compound 12): ^{1}H NMR (DMSO-d_6) 10.37 (s, 1H), 10.20 (s, 1H), 8.55 (s, 1H), 8.49 (d, 1H), 8.22 (d, 2H), 7.72 (d, 2H), 7.36 (d, 2H), 7.22 (m, 3H), 7.12 (d, 2H), 2.33 (s, 6H), 2.08 (s, 3H). LCMS: m/z 452 $(M+H)^+$.

***N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]pyridine-4-carboxamide** (Compound 14): ^{1}H NMR (DMSO-d_6) 10.59 (s, 1H), 10.34(s, 1H), 9.71 (s, 1H), 8.80 (dd, 2H), 8.50 (m, 2H), 8.21 (d, 2H), 7.90 (dd, 2H), 7.75 (d, 2H), 7.51 (m, 1H), 7.37 (d, 1H), 7.31 (m, 2H), 2.09 (s, 3H). LCMS: m/z 425 $(M+H)^+$.

***N*-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,3,4,5,6-pentafluorobenzamide** (Compound 15): ^{1}H NMR (DMSO-d_6) 10.97 (s, 1H), 10.20 (s,

1H), 9.75 (s, 1H), 8.50 (d, 1H), 8.33 (s, 1H), 8.17 (d, 2H), 7.72 (d, 2H), 7.55 (m, 1H), 7.38 (d, 1H), 7.32 (t, 1H), 7.24 (d, 1H), 2.08 (s, 3H). LCMS: m/z 514 $(M+H)^+$.

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2,6-dichlorobenzamide (Compound 1): ^{1}H NMR (DMSO-d_6) 10.15 (s, 1H), 8.68 (t, 1H), 8.27 (d, 1H), 8.04 (d, 2H), 7.67 (d, 2H), 7.49 (d, 2H), 7.41 (m, 1H), 7.13 (t, 1H), 7.06 (d, 1H), 3.41 (m, 2H), 3.30 (m, 2H), 2.06 (s, 3H), 1.80 (m, 2H). LCMS: m/z 458 $(M+H)^+$.

2,6-dichloro-N-(3-{[4-(2,4-dichlorophenyl)pyrimidin-2-yl]amino}propyl)benzamide (Compound 2): ^{1}H NMR (DMSO-d_6) 8.63 (s, 1H), 8.36 (d, 1H), 7.73 (s, 1H), 7.58 (d, 1H), 7.52 (d, 1H), 7.47 (m, 2H), 7.40 (m, 2H), 6.79 (d, 2H), 3.37 (m, 2H), 3.27 (m, 2H), 1.75 (t, 2H). LCMS: m/z 471 $(M+H)^+$.

4-(2,4-dichlorophenyl)-*N*-{3-[(2-piperidin-1-ylethyl)oxy]phenyl}pyrimidin-2-amine (Compound 19): ^{1}H NMR (DMSO-d_6) 9.79 (s, 1H), 8.58 (d, 1H), 7.77 (d, 1H), 7.68 (d, 1H), 7.58 (m, 2H), 7.24 (d, 1H), 7.10 (m, 2H), 6.50 (dd, 1H), 3.98 (t, 2H), 2.60 (t, 2H), 2.47 (m, 4H), 1.46 (m, 4H), 1.36 (m, 2H). LCMS: m/z 443 $(M+H)^+$

N-(3-{[4-(4-aminophenyl)pyrimidin-2-yl]amino}propyl)-2,6-dichlorobenzamide (Compound 6): ^{1}H NMR (400 MHz, DMSO): δ 8.76-8.79 (m, 1H), 8.45 (d, 6.0 Hz, 1H), 7.94-8.06 (m, 3H), 7.56 (m. 1H), 7.52-7.51 (m, 1H), 7.50 (s, 2H), 7.43-7.52 (m, 2H), 7.36-7.42 (m, 1H), 7.22-7.34 (bs, 1H), 3.44-3.64 (bs, 2H), 3.32-3.40 (m, 2H), 1.02-1.52 (bs, 2H). LC/MS MH=416.

2,6-dichloro-N-(3-{[4-(2,3-dihydro-1-benzofuran-6-yl)pyrimidin-2-yl]amino}-propyl)benzamide (Compound 4): ^{1}H NMR (400 MHz, DMSO): δ 8.724 (t, 5.6Hz, 1H), 8.29 (d, 5.6 Hz, 1H), 8.41-8.18 (bs, 1H), 7.92-8.15 (bs, 1H), 7.49-7.52 (m, 2H), 7.41-7.45 (m, 2H), 7.14-7.23 (bs, 1H), 6.88 (d, 8.4Hz, 1H), 4.61-4.65 (m, 2H), 3.62-3.93 (bs, 1H), 3.39-3.51 (bs, 1H), 3.33-3.36 (m, 2H), 3.23-3.27 (m, 2H), 1.80-1.87 (bs, 2H). LC/MS MH=443.

2,6-dichloro-N-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]-benzamide (Compound 3): ^{1}H NMR (400 MHz, DMSO): δ 8.66 (t, 5.6Hz, 1H), 8.17 (d, 5.2 Hz, 1H), 7.95 (d, 8.8 Hz, 2H), 7.47-7.49 (m, 2H), 7.38-7.42 (m, 1H), 6.95-6.97 (m, 2H), 6.72-6.75 (m, 2H), 3.37-3.43 (m, 2H), 3.26-3.32 (m, 2H), 2.96 (s, 6H), 1.79 (t, 6.8Hz, 2H). LC/MS M-H=442.

***N*-[3-({4-[4-(acetylamino)phenyl]-5-methylpyrimidin-2-yl}amino)phenyl]-2,6-dichlorobenzamide** (Compound 25): ^{1}H NMR (400MHz, DMSO-d_6) δ 10.67 (s, 1H),

10.15 (s, 1H), 9.57 (s, 1H), 8.38 (s, 1H), 8.16 (s, 1H), 7.72 (s, 4H), 7.60-7.50 (m, 4H), 7.26-7.23 (m, 2H), 2.26 (s, 3H), 2.09 (s, 3H). LCMS (EI) $C_{26}H_{22}Cl_2N_5O_2$: 506 (M+H).

***N*-[3-({4-[4-(acetylamino)phenyl]-5-fluoropyrimidin-2-yl}amino)phenyl]-2,6-dichlorobenzamide** (Compound 28): ^{1}H NMR (400MHz, DMSO-d_6) δ 10.72 (s, 1H), 10.25 (s, 1H), 9.78 (s, 1H), 8.59 (d, J = 4.0Hz, 1H), 8.32 (s, 1H), 8.12 (d, J = 8.4Hz, 2H), 7.77 (d, J = 8.8Hz, 2H), 7.61-7.58 (m, 2H), 7.51 (dd, J = 8.8, 6.8Hz, 1H), 7.44 (d, J = 8.4Hz, 1H), 7.28 (t, J = 8.0Hz, 1H), 7.23 (t, J = 8.0Hz, 1H), 2.09 (s, 3H). LCMS (EI) $C_{25}H_{18}Cl_2FN_5O_2$: 510 (M+H).

***N*-(4-{2-[(4-{[2-(4-ethylpiperazin-1-yl)-2-oxoethyl]oxy}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide** (Compound 64): ^{1}H-NMR (400MHz, d_6-DMSO): 10.222 ppm (s, 1H), 9.445 ppm (s, 1H), 8.457 ppm (d, 1H), 8.119 ppm (d, 2H), 7.75 ppm (d, 2H), 7.686 ppm (d, 2H), 7.299 ppm (d, 1H), 6.922 ppm (d, 2H), 4.76 ppm (s, 2H), 3.465 ppm (bs, 4H), 2.4 ppm (m, 4H), 2.31 ppm (m, 2H), 2.091 ppm (s, 3H), 1.02 ppm (t, 3H); MS (EI) $C_{26}H_{30}N_6O_3$: 475.4 (MH^+).

1-ethyl-3-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)urea (Compound 250·HCl) (Compound 250): ^{1}H-NMR (400MHz, d_6-DMSO): 10.064 ppm (s, 1H), 9.305 ppm (s, 1H), 8.483 ppm (d, 1H), 8.105 ppm (d, 2H), 7.832 ppm (bd, 2H), 7.603 ppm (d, 2H), 7.54 ppm (bs, 2H), 7.431 ppm (d, 1H), 6.55 ppm (bs, 1H), 3.89 ppm (bs, 4H), 3.426 ppm (bs, 4H), 3.15 ppm (m, 2H), 1.08 ppm (t, 3H)); MS (EI) $C_{23}H_{26}N_6O_2HCl$: 419.3 (MH^+).

***N*-[6-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)pyrimidin-4-yl]-2,6-dichlorobenzamide** (Compound 301): ^{1}H NMR (400MHz, d_6-DMSO): 11.55 (s, 1H), 10.5 (s, 1H), 10.2 (s, 1H), 9.32 (s, 1H), 8.68 (d, 1H), 8.6 (s, 1H), 8.4 (d, 2H), 7.74 (d, 2H), 7.64 (d, 1H), 7.62-7.5 (m, 3H), 2.03 (s, 3H); MS (EI) for $C_{23}H_{17}Cl_2N_7O_2$: 494 (MH^+).

***N*-[4-(2-{[4-(morpholin-4-ylmethyl)phenyl]amino}pyrimidin-4-yl)phenyl]-acetamide** (Compound 232): ^{1}H NMR (400MHz, d_6-DMSO): 10.3 (s, 1H), 9.6 (s, 1H), 8.46 (d, 1H), 8.13 (d, 2H), 7.78 (t, 4H), 7.35 (d, 1H), 7.47 (d, 1H), 7.23 (d, 2H), 3.58 (t, 4H), 3.4 (s, 2H), 2.33 (t, 4H), 2.1 (s, 3H); MS (EI) for $C_{23}H_{25}N_5O_2$: 404 (MH^+).

4-(1*H*-indol-5-yl)-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine (Compound 254): ^{1}H-NMR (400MHz, d_6-DMSO): 11.35 ppm (s, 1H), 9.33 ppm (s, 1H), 8.41 ppm (m, 2H), 7.94 ppm (dd, 1H), 7.71 ppm (d, 2H), 7.50 ppm (d, 1H), 7.44 ppm (t, 1H), 7.33 ppm

(d, 1H), 6.94 ppm (d, 2H), 6.57 ppm (s,1H), 3.75 ppm (m, 4H), 3.05 ppm (m, 4H), 2.09 ppm (s, 3H); MS (EI) $C_{24}H_{25}N_5O_2$: 372.3 (MH^+).

***N*-(3-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide** (Compound 79): ^{1}H-NMR (400MHz, d_6-DMSO): 10.14 ppm (s, 1H), 9.45 ppm (s, 1H), 8.49 ppm (d, 1H), 8.40 ppm (s, 1H), 7.77 ppm (d, 1H), 7.70 ppm (d, 3H), 7.45 ppm (t, 1H), 7.20 ppm (d, 1H), 6.93 ppm (d, 2H), 3.74 ppm (m, 4H), 3.04 ppm (m, 4H), 2.09 ppm (s, 3H); MS (EI) $C_{24}H_{25}N_5O_2$: 390.1 (MH^+).

4-[4-(methyloxy)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine (Compound 252): ^{1}H-NMR (400MHz, d_6-DMSO): 9.37 ppm (s, 1H), 8.42 ppm (d, 1H), 8.13 ppm (d, 2H), 7.67 ppm (d, 2H), 7.27 ppm (d, 1H), 7.08 ppm (d, 2H), 6.92 ppm (d, 2H), 3.84 ppm (s, 3H), 3.74 ppm (m, 4H), 3.04 ppm (m, 4H); MS (EI) $C_{24}H_{25}N_5O_2$: 363.1 (MH^+).

***N*-(4-{2-[(3-piperazin-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide** (Compound 312): ^{1}H-NMR (400MHz, d_6-DMSO): 10.32 ppm (s, 1H), 9.55 ppm (s, 1H), 8.50 ppm (d, 1H), 8.13 ppm (d, 2H), 7.78 ppm (d, 2H), 7.68 ppm (s, 1H), 7.35 ppm (dd, 2H), 7.20 ppm (t, 1H), 6.63 (dd, 1H), 3.38 (m, 4H), 3.25 (m, 4H), 2.13 ppm (s, 3H); MS (EI) $C_{22}H_{24}N_6O$: 389.1 (MH^+)

2-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-2-phenyl-acetamide (Compound 573): ^{1}H-NMR (400MHz, d_6-DMSO): 11.93 ppm (s, 1H), 10.18 (s, 1H), 9.08 ppm (s, 2H), 8.58 ppm (d, 1H), 8.18 ppm (d, 2H), 7.98-7.88 ppm (m, 2H), 7.82-7.75 ppm (m, 2H), 7.60-7.40 ppm (m, 6H), 7.30 ppm (s, 2H), 5.52-5.46 (m, 1H), 4.10 (t, 4H), 3.57 (t, 4H); MS (EI) $C_{28}H_{28}N_6O_2$: 481.3 (MH^+).

***N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-alaninamide** (Compound 577): ^{1}H-NMR (400MHz, d_6-DMSO): 9.387 ppm (s, 1H), 8.443 ppm (d, 1H), 8.127 ppm (d, 2H), 7.825 ppm (d, 2H), 7.676 ppm (d, 2H), 7.287 ppm (d, 1H), 6.939 ppm (d, 2H), 3.747 ppm (m, 4H), 3.457 ppm (q, 1H), 3.050 ppm (m, 4H), 1.896 ppm (s, 3H (AcOH)), 1.243 ppm (d, 3H); MS (EI) $C_{23}H_{26}N_6O_2$: 419.1 (MH^+).

***N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)valinamide** (Compound 575): ^{1}H-NMR (400MHz, d_6-DMSO): 9.390 ppm (s, 1H), 8.449 ppm (d, 1H), 8.124 ppm (d, 2H), 7.815 ppm (d, 2H), 7.686 ppm (d, 2H), 7.284 ppm (d, 1H), 6.939 ppm (d, 2H), 3.747 ppm (m, 4H), 3.147 ppm (d, 1H), 3.051 ppm (m, 4H), 1.953 ppm (m,

1H), 1.864 ppm (s, 3H (AcOH)), 0.943 ppm (d, 3H), 0.871 ppm (d, 3H); MS (EI) $C_{25}H_{30}N_6O_2$: 446.2 (MH^+).

2-(dimethylamino)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)-phenyl)-acetamide (Compound 197): ^{1}H-NMR (400MHz, d_6-DMSO): 10.001 ppm (s, 1H), 9.384 ppm (s, 1H), 8.440 ppm (d, 1H), 8.118 ppm (d, 2H), 7.836 ppm (d, 2H), 7.673 ppm (d, 2H), 7.287 ppm (d, 1H), 6.939 ppm (d, 2H), 3.745 ppm (m, 4H), 3.114 ppm (s, 2H), 3.049 ppm (m, 4H), 2.290 ppm (s, 6H); MS (EI) $C_{24}H_{28}N_6O_2$: 432.5 (MH^+).

***N*-(4-{2-[(4-{4-[3-(dimethylamino)-2,2-dimethylpropyl]piperazin-1-yl}phenyl)-amino]pyrimidin-4-yl}phenyl)acetamide** (Compound 578): ^{1}H-NMR (400MHz, d_6-DMSO):): 10.208 ppm (s, 1H), 9.358 ppm (s, 1H), 8.433 ppm (d, 1H), 8.106 ppm (d, 2H), 7.741 ppm (d, 2H), 7.648 ppm (d, 2H), 7.262 ppm (d, 1H), 6.909 ppm (d, 2H), 3.050 ppm (m, 4H), 2.595 ppm (m, 4H), 2.212 ppm (s, 6H), 2.172 ppm (s, 2H), 2.091 ppm (m, 5H), 0.843 ppm (s, 6H); MS (EI) $C_{29}H_{39}N_70$: 502.2 (MH^+).

***N*-(4-{2-[(4-{4-[(1-methyl-1*H*-imidazol-2-yl)methyl]piperazin-1-yl}phenyl)-amino]-pyrimidin-4-yl}phenyl)acetamide** (Compound 576): ^{1}H-NMR (400MHz, d_6-DMSO): 10.23 ppm (s, 1H), 9.37 ppm (s, 1H), 8.43 ppm (d, 1H), 8.106 ppm (d, 2H), 7.74 ppm (d, 2H), 7.65 ppm (d, 2H), 7.26 ppm (d, 1H), 7.10 ppm (s, 1H), 6.92 ppm (d, 2H), 6.78 ppm (s, 1H), 3.67 ppm (s, 3H), 3.58 ppm (s, 2H), 3.39-3.34 ppm (m, 4H), 3.02-3.08 ppm (M, 4H), 2.10 ppm (s, 3H); MS (EI) $C_{27}H_{30}N_8O$ 482.6 (MH^+).

***N*-(4-(2-(4-(4-(cyclopropanecarbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide** (Compound 349): ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 ppm (s, 1H), 9.41 ppm, (s, 1H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.74 ppm (d, 2H), 7.69 ppm (d, 2H), 7.28 ppm (d, 1H), 6.97 ppm (d, 2H), 3.83 ppm (s, 2H), 3.62 ppm (s, 2H), 3.15 ppm (s, 2H), 3.03 ppm (s, 2H), 2.09 ppm (s, 3H), 2.02-2.05 ppm (m, 1H), 0.74-0.76 ppm (m, 4H); MS (EI) $C_{26}H_{28}N_6O_2$: 456.5 (MH^+).

***N*-{4-[2-({3-[(4-phenylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide** (Compound 78): ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 ppm (s,1H), 9.83 ppm (s,1H), 8.53 ppm (d, 1H), 8.13 ppm (d, 2H), 8.05 ppm (s, 1H), 7.95 ppm (s, 1H), 7.87 ppm (d, 1H), 7.75 ppm (d, 2H), 7.38-7.43 (m, 2H), 7.20-7.242 (m, 2H), 7.02 ppm (d, 2H) 6.95 ppm (d, 2H), 6.81 ppm (t, 1H), 3.68-3.88 ppm (m, 2H), 3.44-3.65 ppm (m, 2H), 3.02-3.11 ppm (m, 4H), 2.09 ppm (s, 3H); MS (EI) $C_{29}H_{28}N_6O_2$: 492.6 (MH^+).

***N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-alaninamide** (Compound 578): ^{1}H-NMR (400MHz, d_6-DMSO): 11.13 ppm (s, 1H), 9.89 ppm (s, 1H), 8.53 ppm (d, 1H), 8.35 ppm (d, 3H), 8.20 ppm (d, 2H), 7.85 ppm (d, 4H), 7.49 ppm (br s, 2H), 7.43 ppm (d, 1H), 4.14 ppm (m, 1H), 3.96 ppm (br s, 4H), 3.40 ppm (br s, 4H), 1.50 ppm (s, 3H); MS (EI) $C_{23}H_{26}N_6O_2$: 419 (MH^+).

(N-(4-{5-methyl-2-[(3-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl-acetamide): ^{1}H-NMR (400MHz, d_6-DMSO): 10.17 (s, 1H), 9.41 (s, 1H), 8.38 (s, 1H), 7.84 (s, 1H), 7.72 (s, 4H), 7.09 (d, 2H), 6.51 (dd, 1H), 3.74 (t, 4H), 3.07 (t, 4H), 2.26 (s, 3H), 2.09 (s, 3H); MS (EI) $C_{23}H_{25}N_5O_2$: 404.3 $(M+H)^+$.

(N-(4-{6-methyl-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-acetamide): ^{1}H-NMR (400MHz, d_6-DMSO): 10.18 (s, 1H), 9.31 (s, 1H), 8.09 (d, 2H), 7.74-7,70 (m, 4H), 7.19 (s, 1H), 6.93 (d, 2H), 3.74 (t, 4H), 3.04 (t, 4H), 2.38 (s, 3H), 2.09 (s, 3H); MS (EI) $C_{23}H_{25}N_5O_2$: 404.3 $(M+H)^+$.

(N-(4-{2-[(4-morpholin-4-ylphenyl)amino]-5-(trifluoromethyl)pyrimidin-4-yl}-phenyl)acetamide): ^{1}H-NMR (400MHz, $CDCl_3$): 8.66 (s, 1H), 7.65-7.59 (m, 4H), 7.51 (d, 2H), 7.33 (d, 2H), 6.93 (d, 2H), 3.87 (t, 4H), 3.14 (t, 4H); MS (EI) $C_{26}H_{30}N_6O_3$: 458.1 $(M+H)^+$.

(N-(4-{2-[(3-aminophenyl)amino]-5-methylpyrimidin-4-yl}phenyl)acetamide): ^{1}H-NMR (400MHz, d_6-DMSO): 10.14 (s, 1H), 9.19 (s, 1H), 8.33 (d, 1H), 7.72 (d, 2H), 7.67 (dd, 2H), 7.03 (t, 1H), 6.94 (dd, 1H), 6.87 (t, 1H), 6.17-6.14 (m, 1H), 4.92 (s, 2H), 2.23 (s, 3H), 2.08 (s, 3H); MS (EI) $C_{19}H_{19}N_5O$: 334.0 $(M+H)^+$.

(N-(4-{2-[(3-aminophenyl)amino]-5-fluoropyrimidin-4-yl}phenyl)acetamide): ^{1}H-NMR (400MHz, d_6-DMSO): 10.26 (s, 1H), 9.41 (s, 1H), 8.54 (d, 1H), 8.04 (d, 2H), 7.78 (d, 2H), 7.03 (s, 1H), 6.95-6.91 (m, 2H), 6.20 (d, 1H), 5.00 (s, 2H), 2.10 (s, 3H); MS (EI) $C_{18}H_{16}FN_5O$: 338.3 $(M+H)^+$.

(N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}-5-fluoropyrimidin-4-yl)phenyl]acetamide): ^{1}H-NMR (400MHz, d_6-DMSO): 10.26 (s, 1H), 9.45 (s, 1H), 8.52(d, 1H), 8.02 (d, 2H), 7.78 (d, 2H), 7.59 (d, 2H), 6.91 (d, 2H), 3.35 (bs, 4H), 3.07 (bs, 4H), 2.50 (q, 2H), 2.10 (s, 3H), 1.04 (t, 3H); MS (EI) $C_{24}H_{27}FN_6O$: 435.3 $(M+H)^+$.

(N-[3-({4-[4-(acetylamino)phenyl]-5-methylpyrimidin-2-yl}amino)phenyl]-2,6-dimethylbenzamide): ^{1}H-NMR (400MHz, d_6-DMSO): 10.32 (s, 1H), 10.15 (s, 1H), 9.51 (s, 1H), 8.37(s, 1H), 8.29 (s, 1H), 7.76-7.70 (m, 4H), 7.42-7.41 (m, 1H), 7.25-7.17 (m,

3H), 7.11 (d, 2H), 2.29 (s, 6H), 2.26 (s, 3H), 2.09(s, 3H); MS (EI) $C_{28}H_{27}N_5O_2$: 466.3 $(M+H)^+$.

(N-(4-{2-[(3,5-dimorpholin-4-ylphenyl)amino]-5-fluoropyrimidin-4-yl}-phenyl)-acetamide): ^{1}H-NMR (400MHz, d_6-DMSO): 10.27 (s, 1H), 9.45 (s, 1H), 8.58(d, 1H), 8.07 (d, 2H), 7.77 (d, 2H), 7.06 (s, 2H), 6.17 (s, 1H), 3.75 (t, 8H), 3.10 (t, 8H), 2.10 (s, 3H); MS (EI) $C_{26}H_{29}FN_6O_3$: 493.4 $(M+H)^+$.

(N-{4-[2-(1H-indazol-6-ylamino)-5-methylpyrimidin-4-yl]phenyl}acetamide): ^{1}H-NMR (400MHz, d_6-DMSO): 12.80 (s, 1H), 10.18 (s, 1H), 9.72 (s, 1H), 8.44(d, 1H), 8.37 (d, 1H), 7.90 (s, 1H), 7.77-7.70 (m, 4H), 7.59 (d, 1H), 7.28 (dd, 1H), 2.27 (s, 3H), 2.10 (s, 3H); MS (EI) $C_{20}H_{18}N_6O$: 359.3 $(M+H)^+$.

(N-{4-[2-(1H-indol-5-ylamino)-5-methylpyrimidin-4-yl]phenyl}acetamide): ^{1}H-NMR (400MHz, d_6-DMSO): 10.90 (s, 1H), 10.15 (s, 1H), 9.21 (s, 1H), 8.32(d, 1H), 8.00 (d, 1H), 7.72 (dd, 2H), 7.66 (dd, 2H), 7.36 (dd, 1H), 7.28-7.25 (m, 2H), 6.33 (t, 1H), 2.22 (s, 3H), 2.09 (s, 3H); MS (EI) $C_{21}H_{19}N_5O$: 358.3 $(M+H)^+$.

(N-(4-{5-fluoro-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-acetamide): ^{1}H-NMR (400MHz, d_6-DMSO): 10.26 (s, 1H), 9.48 (s, 1H), 8.52 (d, 1H), 8.02 (d, 2H), 7.77 (d, 2H), 7.61 (d, 2H), 6.93 (d, 2H), 3.74 (t, 4H), 3.03 (t, 4H); MS (EI) $C_{22}H_{22}FN_5O_2$: 408.3 $(M+H)^+$.

N-(4-{5-methyl-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-cyclopropanecarboxamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.41 (s, 1H), 9.28 (s, 1H), 8.31(d, 1H), 7.73 (d, 2H), 7.66-7.62 (m, 4H), 6.89 (d, 2H), 3.73 (bs, 4H), 3.02 (bs, 4H), 2.22 (s, 3H), 1.85-1.79 (m, 1H), 0.84-0.81 (m, 4H); MS (EI) $C_{25}H_{27}N_5O_2$: 430 (MH+).

N-{4-[2-(1H-indazol-5-ylamino)-5-methylpyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 12.88 (s, 1H), 10.16 (s, 1H), 9.49 (s, 1H), 8.37(s, 1H), 8.29 (d, 1H), 7.97 (s, 1H), 7.73 (d, 2H), 7.67 (d, 2H), 7.59 (dd, 1H), 7.44 (d, 1H), 2.24 (s, 3H), 2.10 (s, 3H); MS (EI) $C_{20}H_{18}N_6O$: 359 (MH+).

N-(4-{2-[(3,5-dimorpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 (s, 1H), 9.36 (s, 1H), 8.48 (d, 1H), 8.15 (d, 2H), 7.74 (d, 2H), 7.32 (d, 1H), 7.12 (d, 2H), 6.17 (s, 1H), 3.75 (t, 4H), 3.11 (t, 4H), 2.09 (s, 3H); MS (EI) $C_{26}H_{30}N_6O_3$: 475 (MH+).

4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}benzonitrile: ^{1}H-NMR (400MHz, d_6-DMSO): 9.60 (s, 1H), 8.57 (d, 1H), 8.32 (d, 2H), 8.03 (d, 2H), 7.65 (d, 2H), 7.44 (d, 1H), 6.94 (d, 2H), 3.75 (t, 4H), 3.05 (t, 4H), ; MS (EI) $C_{21}H_{19}N_50$: 358 (MH+).

4-(4-fluorophenyl)-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine: ^{1}H-NMR (400MHz, d_6-DMSO): 9.46 (s, 1H), 8.49 (d, 1H), 8.22 (dd, 2H), 7.66 (d, 2H), 7.38 (t, 2H), 7.33 (d, 1H), 6.93 (dd, 2H), 3.74 (t, 4H), 3.05 (t, 4H), ; MS (EI) $C_{20}H_{19}FN_40$: 358.3 $(M+H)^+$.

N-(4-morpholin-4-ylphenyl)-4-(4-pyrimidin-5-ylphenyl)pyrimidin-2-amine: ^{1}H-NMR (400MHz, d_6-DMSO): 9.50 (s, 1H), 9.26 (s, 2H), 9.24 (s, 1H), 8.53 (d, 1H), 8.32 (d, 2H), 8.02 (d, 2H), 7.69 (d, 2H), 7.44 (s, 1H), 6.94 (d, 2H), 3.75 (t, 4H), 3.06 (t, 4H); MS (EI) $C_{24}H_{22}N_60$: 411 (MH+).

N-(4-morpholin-4-ylphenyl)-4-[4-(pyridin-2-ylamino)phenyl]pyrimidin-2-amine: ^{1}H-NMR (400MHz, d_6-DMSO): 9.42 (s, 1H), 9.33 (s, 1H), 8.40 (d, 1H), 8.23 (dd, 1H), 8.09 (dd, 2H), 7.86 (d, 2H), 7.70 (d, 2H), 7.65-7.61 (m, 1H), 7.25 (d, 1H), 6.96-6.90 (m, 3H), 6.84-6.81 (m, 1H). 3.75 (t, 4H), 3.05 (t, 4H) ; MS (EI) $C_{25}H_{24}N_60$: 425 (MH+).

N-(4-morpholin-4-ylphenyl)-4-[4-(pyridin-3-ylamino)phenyl]pyrimidin-2-amine: ^{1}H-NMR (400MHz, d_6-DMSO): 9.33 (s, 1H), 8.81 (s, 1H), 8.45 (d, 1H), 8.40 (d, 1H), 8.14 (dd, 1H), 8.08 (d, 2H), 7.68 (d, 2H), 7.63-7.60 (m, 1H), 7.32 (dd, 1H), 7.23 (d, 1H), 7.19 (dd, 2H), 6.93 (d, 2H), 3.74 (t, 4H), 3.05 (t, 4H); MS (EI) $C_{25}H_{24}N_60$: 425 (MH+).

N-[4-(2-{[4-(4-D-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-D-prolinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.23 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.31 (s, 1H), 8.13 (d, 2H), 7.84 (d, 2H), 7.69 (d, 2H), 7.30 (d, 1H), 6.97 (d, 2H), 4.09-4.04 (m, 1H), 3.77-3.73 (m, 1H), 3.67-3.61 (m, 4H), 3.09-3.03 (m, 4H), 2.92 (t, 2H), 2.10-2.03 (m, 1H), 1.85-1.77 (m, 1H), 1.71-1.64 (m, 2H), 1.19 (d, 3H); MS (EI) $C_{28}H_{34}N_80_2$: 515 (MH+).

N-[4-(2-{[4-(4-L-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-D-prolinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.23 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.34 (s, 1H), 8.13 (d, 2H), 7.84 (d, 2H), 7.69 (d, 2H), 7.30 (d, 1H), 6.97 (d, 2H), 4.06-4.01 (m, 1H), 3.77-3.73 (m, 1H), 3.67-3.61 (m, 4H), 3.09-3.02 (m, 4H), 2.92 (t, 2H), 2.10-2.03 (m, 1H), 1.85-1.77 (m, 1H), 1.71-1.64 (m, 2H), 1.18 (d, 3H); MS (EI) $C_{28}H_{34}N_80_2$: 515 (MH+).

N-{4-[2-({4-[4-(piperazin-1-ylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-prolinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.28 (s, 1H), 8.13 (d, 2H), 7.84 (d, 2H), 7.68 (d, 2H), 7.30 (d, 1H), 6.96 (d, 2H), 3.76-3.73 (m, 1H), 3.69-3.59 (m, 4H), 3.19 (s, 2H), 3.10-3.02 (m, 4H), 2.91 (t, 2H), 2.81 (bs, 4H), 2.44 (bs, 4H), 2.10-2.04 (m, 1H), 1.85-1.77 (m, 1H), 1.71-1.64 (m, 2H); MS (EI) $C_{31}H_{39}N_9O_2$: 570 (MH+).

N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-alaninamide: ^{1}H-NMR (400MHz, d_6-DMSO): 9.43 (s, 1H), 8.47 (d, 1H), 8.17 (d, 2H), 7.80 (d, 2H), 7.69 (d, 2H), 7.31 (d, 1H), 6.98 (d, 2H), 3.82-3.78 (m, 4H), 3.66-3.62 (m, 4H), 3.09-3.03 (m, 4H), 2.97-2.90 (m, 1H), 1.39 (d, 3H), 1.03 (d, 6H); MS (EI) $C_{27}H_{33}N_7O_2$: 488 (MH+).

N-[4-(2-{[4-(4-D-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-D-alaninamide: ^{1}H-NMR (400MHz, d_6-DMSO): 9.42 (s, 1H), 8.45 (d, 1H), 8.33 (s, 1H), 8.13 (d, 2H), 7.82 (d, 2H), 7.69 (d, 2H), 7.30 (d, 1H), 6.98 (d, 2H), 4.13-4.07 (m, 1H), 3.70-3.59 (m, 5H), 3.11-3.01 (m, 4H), 1.27 (d, 3H), 1.21 (d, 3H); MS (EI) $C_{26}H_{32}N_8O_2$: 489 (MH+).

N-{4-[2-({4-[4-(tetrahydrofuran-3-ylcarbonyl)piperazin-1-yl]phenyl}amino)-pyrimidin-4-yl]phenyl}-D-prolinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.19 (s, 1H), 9.42 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.84 (d, 2H), 7.68 (d, 2H), 7.30 (d, 1H), 6.96 (d, 2H), 3.89 (t, 1H), 3.74-3.69 (m, 4H), 3.67-3.63 (m, 4H), 3.45-3.37 (m, 1H), 3.09-3.02 (m, 4H), 2.90 (t, 2H), 2.08-1.99 (m, 3H), 1.84-1.76 (m, 1H), 1.70-1.64 (m, 2H); MS (EI) $C_{30}H_{35}N_7O_3$: 542 (MH+).

N-{4-[2-({4-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]phenyl}amino)-pyrimidin-4-yl]phenyl}-D-prolinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.83 (d, 2H), 7.68 (d, 2H), 7.30 (d, 1H), 6.96 (d, 2H), 4.72 (dd, 1H), 3.82-3.72 (m, 3H), 3.69-3.58 (m, 4H), 3.08-3.02 (m, 4H), 2.91 (t, 2H), 2.11-1.99 (m, 3H), 1.88-1.79 (m, 3H), 1.71-1.66 (m, 2H); MS (EI) $C_{30}H_{35}N_7O_3$: 542 (MH+).

N-(4-{5-chloro-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-prolinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.30 (s, 1H), 9.67 (s, 1H), 8.52 (s, 1H), 7.82 (s, 4H), 7.59 (d, 2H), 6.90 (dd, 2H), 3.84 (dd, 1H), 3.74-3.72 (m, 4H), 3.04-3.02 (m,

4H), 2.97 (t, 2H), 2.15-2.09 (m, 1H), 1.86-1.79 (m, 1H), 1.75-1.69 (m, 2H); MS (EI) $C_{25}H_{27}ClN_6O_2$: 479 (MH+).

(R)-N-(4-(2-(4-(4-(2-(pyrrolidin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.84 (d, 2H), 7.68 (d, 2H), 7.30 (d, 1H), 6.95 (d, 2H), 3.75-3.71 (m, 1H), 3.69-3.59 (m, 4H), 3.07-3.01 (m, 4H), 2.91 (t, 2H), 2.50 (t, 4H), 2.48 (s, 2H), 2.11-2.02 (m, 1H), 1.86-1.78 (m, 1H), 1.72-1.63 (m, 6H); MS (EI) $C_{31}H_{38}N_8O_2$: 555 (MH+).

(R)-N-(4-(2-(4-(4-(2-morpholinoacetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.19 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.84 (dd, 2H), 7.68 (d, 2H), 7.30 (d, 1H), 6.96 (d, 2H), 3.74-3.69 (m, 3H), 3.61-3.57 (m, 6H), 3.19 (s, 2H), 3.11-3.09 (m, 2H), 33.04-3.01 (m, 2H), 2.90 (t, 2H), 2.41 (bs, 4H), 2.11-2.02 (m, 1H), 1.84-1.76 (m, 1H), 1.70-1.63 (m, 2H); MS (EI) $C_{31}H_{38}N_8O_3$: 571 (MH+).

N-{4-[2-({4-[2-(methyloxy)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}amino)-pyrimidin-4-yl]phenyl}-D-prolinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.19 (s, 1H), 9.25 (s, 1H), 8.42 (d, 1H), 8.11 (d, 2H), 7.83 (d, 2H), 7.28-7.25 (m, 2H), 7.17 (dd, 1H), 6.68 (d, 1H), 4.15 (t, 2H), 3.72 (dd, 1H), 3.52 (t, 2H)), 3.41-3.36 (m, 4H), 3.27 (s, 3H), 2.90 (t, 2H), 2.10-2.01 (m, 1H), 1.84-1.75 (m, 1H), 1.70-1.63 (m, 2H); MS (EI) $C_{26}H_{30}N_6O_3$: 475 (MH+).

N-(4-{2-[(4-{4-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)-D-prolinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.20 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.84 (d, 2H), 7.68 (d, 2H), 7.30 (d, 1H), 6.96 (d, 2H), 4.72 (dd, 1H), 3.82-3.72 (m, 3H), 3.69-3.58 (m, 4H), 3.08-3.03 (m, 4H), 2.90 (t, 2H), 2.11-1.98 (m, 3H), 1.88-1.75 (m, 3H), 1.70-1.65 (m, 2H); MS (EI) $C_{30}H_{35}N_7O_3$: 542 (MH+).

N-(4-{2-[(4-{4-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperazin-1-yl}phenyl)-amino]pyrimidin-4-yl}phenyl)-D-prolinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.20 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.84 (d, 2H), 7.68 (d, 2H), 7.30 (d, 1H), 6.96 (d, 2H), 4.72 (dd, 1H), 3.82-3.72 (m, 3H), 3.69-3.58 (m, 4H), 3.08-3.03 (m, 4H), 2.91 (t, 2H), 2.09-1.98 (m, 3H), 1.88-1.75 (m, 3H), 1.70-1.63 (m, 2H); MS (EI) $C_{30}H_{35}N_7O_3$: 542 (MH+).

N-{4-[2-(1,2,3,4-tetrahydroquinolin-6-ylamino)pyrimidin-4-yl]phenyl}-D-prolinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.17 (s, 1H), 9.05 (s, 1H), 8.38 (d, 1H), 8.10 (dd, 2H), 7.84-7.81 (m, 2H), 7.29 (s, 1H), 7.21-7.18 (m, 2H), 6.40 (d, 1H), 5.36 (s, 1H), 3.72 (dd, 1H), 3.15 (t, 2H), 2.90 (t, 2H), 2.67 (t, 2H), 2.10-2.01 (m, 1H), 1.84-1.76 (m, 3H), 1.69-1.63 (m, 2H) ; MS (EI) $C_{24}H_{26}N_60$: 415 (MH+).

N-{4-[2-({4-[(phenylmethyl)oxy]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.42 (s, 1H), 8.42 (d, 1H), 8.06 (d, 2H), 7.75-7.65 (m, 4H), 7.42-7.24 (m, 6H), 6.95 (d, 2H), 5.04 (s, 2H), 2.04 (s, 3H). MS (EI) for $C_{25}H_{22}N_4O_2$: 411 (MH+).

4-(4-aminophenyl)-N-[4-(phenyloxy)phenyl]pyrimidin-2-amine: ^{1}H-NMR (400 MHz, d6-DMSO): 10.42 (s, 1H), 8.43 (d, 1H), 8.08 (d, 2H), 7.72 (d, 2H), 7.43-7.37 (m, 3H), 7.26-7.15 (m, 3H), 7.07-6.95 (m, 3H). MS (EI) for C22H18N4O: 355 (MH+).

N-[4-(2-{[4-(phenyloxy)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.64 (s, 1H), 8.49 (d, 1H), 8.11 (d, 2H), 7.85 (d, 2H), 7.75 (d, 2H), 7.38-7.32 (m, 3H), 7.10-7.03 (m, 3H), 6.97 (d, 1H). MS (EI) for $C_{24}H_{20}N_4O_2$: 397 (MH+).

N-(4-{2-[(4-{[2-(methyloxy)ethyl]amino}phenyl)amino]pyrimidin-4-yl}-phenyl)acetamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.18 (s, 1H), 9.08 (s, 1H), 8.38 (d, 1H), 8.05 (d, 2H), 7.73 (d, 2H), 7.43 (d, 2H), 7.19 (d, 1H), 6.58 (d, 2H), 5.20 (t, 1H), 3.43 (t, 2H), 3.25 (s, 3H), 3.16 (t, 2H), 2.04 (s, 3H). MS (EI) for $C_{21}H_{23}N_5O_2$: 378 (MH+).

N-{4-[2-({4-[(pyridin-4-ylmethyl)oxy]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.43 (s, 1H), 8.60 (s, 2H), 8.43 (d, 1H), 8.10 (d, 2H), 7.79-7.72 (m, 4H), 7.43 (d, 1H), 7.30 (d, 1H), 7.01 (d, 2H), 5.08 (s,1H), 2.03 (s, 3H). MS (EI) for $C_{24}H_{21}N_5O_2$: 412 (MH+).

N-(4-{2-[(4-cyclohexylphenyl)amino]pyrimidin-4-yl}phenyl) acetamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.53 (s, 1H), 8.45 (d, 1H), 8.15 (d, 2H), 7.78-7.70 (m, 4H), 7.35 (d, 1H), 7.18 (d, 1H), 2.43-2.40 (m, 1H), 2.08 (s, 3H), 1.82-1.68 (m, 4H), 1.42-1.20 (m, 6H). MS (EI) for $C_{24}H_{26}N_4O$: 387 (MH+).

N-{4-[2-({4-[(tetrahydrofuran-2-ylmethyl)amino]phenyl}amino) pyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.18 (s, 1H), 8.39 (d, 1H), 8.08 (d, 2H), 7.76 (d, 2H), 7.45 (d, 2H), 7.20 (d, 1H), 6.60 (d, 2H), 5.23 (t, 1H),

4.02-3.97 (m, 1H), 3.80-3.77 (m, 1H), 3.65-3.60 (m, 1H), 3.08-3.00 (m, 2H), 2.07 (s, 3H), 2.00-1.80 (m, 3H), 1.62-1.57 (m, 1H). MS (EI) for $C_{23}H_{25}N_5O_2$: 404 (MH+).

N-{4-[2-({4-[(phenylmethyl)amino]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.17 (s, 1H), 8.05 (d, 2H), 7.72 (d, 2H), 7.44-7.27 (m, 5H), 7.22-7.17 (m, 2H), 6.57 (d, 2H), 6.00 (t, 1H), 4.25 (d, 2H), 2.08 (s, 3H). MS (EI) for $C_{25}H_{23}N_5O$: 410 (MH+).

ethyl [4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl] acetate: ^{1}H-NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.53 (s, 1H), 8.45 (d, 1H), 8.15 (d, 2H), 7.78-7.70 (m, 4H), 7.32 (d, 1H), 7.17 (d, 2H), 4.05 (q, 2H), 3.45 (s, 2H), 1.35 (t, 3H). MS (EI) for $C_{22}H_{22}N_4O_3$: 391 (MH+).

N-(4-{2-[(3-chloro-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-acetamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.25 (s, 1H), 9.73 (s, 1H), 8.55 (d, 1H), 8.12 (d, 2H), 8.05 (s, 1H), 7.80-7.70 (m, 3H), 7.37 (d, 2H), 7.20 (d, 2H), 3.75 (t, 4H), 2.95 (t, 4H), 2.05 (s, 3H). MS (EI) for $C_{22}H_{22}ClN_5O_2$: 425 (MH+).

N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]-L-serinamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.50 (s, 1H), 8.45 (d, 1H), 8.18 (d, 2H), 7.83 (d, 2H), 7.70 (s, 1H), 7.37-7.30 (m, 2H), 6.90 (d, 1H), 3.82 (s, 3H), 3.72 (t, 4H), 3.60-3.57 (m, 2H), 3.43 (t, 1H), 2.92 (t, 4H). MS (EI) : 465 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-(1H-tetrazol-1-yl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.90 (s, 1H), 9.47 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.18 (d, 2H), 7.77 (d, 2H), 7.67 (d, 2H), 7.30 (d, 1H), 6.95 (d, 2H), 5.58 (s, 2H), 3.77 (t, 4H), 3.03 (t, 4H). MS (EI): 458 (MH+).

(3S)-3-hydroxy-N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]butanamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.19 (s, 1H), 9.48 (s, 1H), 8.48 (s, 1H), 8.17 (d, 2H), 7.78 (d, 2H), 7.65 (s, 1H), 7.31 (d, 2H), 6.88 (d, 1H), 4.80 (s, 1H), 4.15- 4.07 (m, 1H), 3.81 (s, 3H), 3.75 (t, 4H), 2.96 (t, 4H), 2.44-2.37 (m, 2H), 1.14 (d, 3H). MS (EI): 464 (MH+).

(3R)-3-hydroxy-N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]butanamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.19 (s, 1H), 9.48 (s, 1H), 8.48 (s, 1H), 8.17 (d, 2H), 7.78 (d, 2H), 7.65 (s, 1H), 7.31 (d, 2H), 6.88 (d, 1H), 4.80 (s, 1H), 4.15-4.07 (m, 1H), 3.83 (s, 3H), 3.75 (t, 4H), 2.96 (t, 4H), 2.44-2.37 (m, 2H), 1.14 (d, 3H). MS (EI): 464 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.19 (s, 1H), 9.40 (s, 1H), 8.43 (s, 1H), 8.17 (d, 2H), 7.83 (d, 2H), 7.68 (d, 2H), 7.30 (s, 1H), 6.96 (d, 2H), 6.02-5.98 (m, 1H), 5.93-5.89 (m, 1H), 4.60 (s, 1H), 3.82 (s, 2H), 3.75 (t, 4H), 3.05 (t, 4H). MS (EI): 443 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-[(2S)-pyrrolidin-2-yl]acetamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.86 (s, 1H), 10.10 (s, 1H), 9.37 (s, br, 1H), 9.28 (s, br, 1H), 8.55 (d, 1H), 8.20 (d, 2H), 7.95-7.85 (m, 4H), 7.70 (s, 2H), 7.45 (d, 1H), 4.10 (t, 4H), 3.83-3.78 (m, 2H), 3.73 (t, 4H), 3.25-3.18 (m, 1H), 3.03-2.95 (m, 2H), 2.20-2.10 (m, 1H), 2.00-1.80 (m, 2H), 1.68-1.56 (m, 1H). MS (EI): 459 (MH+).

2,3-dihydroxy-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)propanamide: ^{1}H-NMR (400 MHz, d6-DMSO): 9.95 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.12 (d, 2H), 7.90 (d, 2H), 7.68 (d, 2H), 7.25 (s, 1H), 6.96 (d, 2H), 5.95 (s, br, 1H), 4.95 (s, br, 1H), 4.08 (t, 1H), 3.78-3.60 (m, 6H), 3.03 (t, 4H). MS (EI) : 436 (MH+).

1-{4-[2-({4-[4-(N,N-dimethylglycyl)piperazin-1-yl]phenyl}amino) pyrimidin-4-yl]phenyl}-3-ethylurea: ^{1}H-NMR (400 MHz, d6-DMSO): 9.37 (s, 1H), 9.19 (s, 1H), 9.40 (d, 1H), 8.03 (d, 2H), 7.70 (d, 2H), 7.58 (d, 2H), 7.23 (d, 2H), 6.95 (d, 2H), 6.75 (t, 1H), 3.58 (t, 4H), 3.60 (t, 3H), 3.15-3.00 (m, 8H), 2.18 (s, 6H), 1.05 (t, 3H). MS (EI) : 503 (MH+).

N-{4-[2-({4-[4-(N,N-dimethylglycyl)piperazin-1-yl]phenyl}amino) pyrimidin-4-yl]phenyl}-3-(methyloxy)propanamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.78 (d, 2H), 7.67 (d, 2H), 7.27 (d, 1H), 6.95 (d, 2H), 3.73-3.58 (m, 6H), 3.24 (s, 3H), 3.14-3.00 (m, 6H), 2.60 (t, 3H), 2.20 (s, 6H). MS (EI): 518 (MH+).

N-{4-[2-({4-[4-(N,N-dimethylglycyl)piperazin-1-yl]phenyl}amino) pyrimidin-4-yl]phenyl}cyclopropanecarboxamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.26 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.14 (d, 2H), 7.78 (d, 2H), 7.67 (d, 2H), 7.27 (d, 1H), 6.95 (d, 2H), 3.70-3.58 (m, 4H), 3.10-3.00 (m, 6H), 2.20 (s, 6H), 1.84-1.80 (m, 1H), 0.83-0.80 (m, 4H). MS (EI): 500 (MH+).

N-{4-[2-({4-[4-(N,N-dimethylglycyl)piperazin-1-yl]phenylamino) pyimidin-4-yl]-phenyl}butanamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.18 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.12-8.05 (m, 3H), 7.80-7.68 (m, 3H), 7.28 (d, 1H), 6.99 (d, 2H), 2H), 3.70-3.60 (m, 4H), 3.28 (s, 2H), 3.14-3.00 (m, 4H), 2.35-2.20 (m, 8H), 1.64-1.58 (m, 2H), 0.95-0.88 (m, 3H). MS (EI): 502 (MH+).

N-{4-[2-({4-[4-(N,N-dimethylglycyl)piperazin-1-yl]phenyl}amino) pyrimidin-4-yl]phenyl}-N^2,N^2-dimethylglycinamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.00 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.82 (d, 2H), 7.65 (d, 2H), 7.25 (d, 1H), 6.95 (d, 2H), 3.65-3.57 (m, 4H), 3.23 (s, 2H), 3.12-3.00 (m, 6H), 2.28 (s, 6H), 2.20 (s, 6H). MS (EI): 517 (MH+).

N-{4-[2-({4-[4-(N,N-dimethylglycyl)piperazin-1-yl]phenyl}amino) pyrimidin-4-yl]phenyl}-D-alaninamide: ^{1}H-NMR (400 MHz, d6-DMSO): 9.40 (s, 1H), 8.43 (d, 1H), 8.15 (d, 2H), 7.85 (d, 2H), 7.70 (d, 2H), 7.30 (d, 1H), 6.95 (d, 2H), 3.70-3.57 (m, 4H), 3.50 (q, 1H), 3.18-3.00 (m, 6H), 1.83 (s, 6H), 1.21 (d, 3H). MS (EI): 503 (MH+).

N-{4-[2-({4-[4-(N,N-dimethylglycyl)piperazin-1-yl]phenyl}amino) pyrimidin-4-yl]phenyl}tetrahydrofuran-3-carboxamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.30 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.15 (d, 2H), 7.78 (d, 2H), 7.68 (d, 2H), 7.25 (d, 1H), 6.95 (d, 2H), 3.97 (t, 1H), 3.82-3.70 (m, 3H), 3.67-3.60 (m, 4H), 3.22-3.17 (m, 1 H), 3.12-3.00 (m, 4H), 2.35 (s, 6H), 2.12-2.05 (m, 2H). MS (EI): 530 (MH+).

(2R)-N-{4-[2-({4-[4-(N,N-dimethylglycyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}tetrahydrofuran-2-carboxamide: ^{1}H-NMR (400 MHz, d6-DMSO): 9.95 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.16 (d, 2H), 7.88 (d, 2H), 7.70 (d, 2H), 7.30 (d, 1H), 6.97 (d, 2H), 4.44-4.41 (m, 1H), 4.02-3.98 (m, 1H), 3.85-3.80 (m, 1H), 3.68-3.57 (m, 4H), 3.18-3.00 (m, 6H), 2.20 (s, 6H), 2.05-1.85 (m, 4H). MS (EI): 530 (MH+).

(2S)-N-{4-[2-({4-[4-(N,N-dimethylglycyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}tetrahydrofuran-2-carboxamide: ^{1}H-NMR (400 MHz, d6-DMSO): 9.95 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.16 (d, 2H), 7.88 (d, 2H), 7.70 (d, 2H), 7.30 (d, 1H), 6.98 (d, 2H), 4.45-4.42 (m, 1H), 4.02-3.98 (m, 1H), 3.85-3.80 (m, 1H), 3.70-3.57 (m, 4H), 3.20 (s, 2H), 3.10-3.00 (m, 6H), 2.22 (s, 6H), 2.05-1.85 (m, 4H). MS (EI): 530 (MH+).

N-(4-{2-[(6-morpholin-4-ylpyridin-3-yl)amino]pyrimidin-4-yl}phenyl)-D-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.38 (s, 1H), 10.10 (s, 2H), 9.03 (s, br, 1H), 8.75 (s, br, 1H), 8.60 (d, 2H), 8.30-8.20 (m, 3H), 7.85 (d, 2H), 7.55 (d, 2H), 4.48-4.42 (m, 1H), 3.82-3.70 (m, 8H), 3.37-3.20 (m, 2H), 2.43-2.40 (m, 1H), 2.10-1.95 (m, 3H). MS (EI): 446 (MH+).

1-hydroxy-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-cyclopentanecarboxamide: ^{1}H-NMR (400 MHz, d6-DMSO): 9.95 (s, 1H), 9.45 (s, 1H), 8.42 (d, 1H), 8.10 (d, 2H), 7.95 (d, 2H), 7.70 (d, 2H), 7.30 (d, 1H), 7.05-6.95 (m, 2H), 5.68 (s, br, 1H), 3.80-3.70 (m, 4H), 3.15-3.05 (m, 4H), 2.10-1.97 (m, 3H), 1.87-1.68 (m, 5H). MS (EI) : 460 (MH+).

2-hydroxy-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.95 (s, 1H), 9.39 (s, 1H), 8.43 (d, 1H), 8.12 (d, 2H), 7.90 (d, 2H), 7.70 (d, 2H), 7.28 (d, 1H), 6.95 (d, 2H), 5.75 (t, 1H), 4.03 (d, 2H), 3.78-3.70 (m, 4H), 3.10-3.00 (m, 4H). MS (EI): 406 (MH+).

3-chloro-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridine-4-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.68 (s, 1H), 11.00 (s, 1H), 9.43 (s, 2H), 8.83 (s, 1H), 8.70 (d, 1H), 8.50 (d, 1H), 8.20 (d, 2H), 7.87 (d, 2H), 7.75-7.65 (m, 3H), 7.32 (d, 1H), 6.95 (d, 2H), 3.75 (t, 4H), 3.05 (t, 4H). MS (EI): 487 (MH+).

N-{4-[2-({4-[4-(N,N-dimethylglycyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.24 (s, br, 1H), 9.41 (s, 1H), 8.44 (d, 2H), 8.13 (d, 2H), 7.82 (d, 2H), 7.68 (d, 2H), 7.27 (d, 1H), 6.95 (d, 2H), 3.78-3.57 (m, 5H), 3.15-3.00 (m, 6H), 2.93 (t, 2H), 2.18 (s, 6H), 2.08-2.00 (m, 1H), 1.93-1.88 (m, 1H), 1.90-1.80 (m, 2H). MS (EI) : 529 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)propanamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.18 (s, br, 1H), 9.18 (s, 1H), 8.40 (d, 1H), 8.13 (d, 2H), 7.78 (d, 2H), 7.63 (d, 2H), 7.25 (d, 1H), 6.93 (d, 2H), 3.77 (t, 4H), 3.07 (t, 4H), 2.16 (q, 2H), 1.10 (t, 3H). MS (EI): 404 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-pyridin-3-ylacetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.90 (s, 1H), 9.40 (s, 1H), 8.43 (s, 1H), 8.18 (d, 2H), 7.88 (d, 2H), 7.73-7.45 (m, 5H), 7.32 (d, 1H), 6.95 (d, 2H), 3.77 (t, 4H), 3.03 (t, 4H). MS (EI): 467 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyrimidine-5-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.82 (s, 1H), 9.42 (s, 1H), 9.38 (s, 1H), 9.31 (s, 2H), 8.45 (d, 1H), 8.20 (d, 2H), 7.97 (d, 2H), 7.70 (d, 2H), 7.33 (d, 1H), 6.95 (d, 2H), 3.77 (t, 4H), 3.03 (t, 4H). MS (EI): 454 (MH+).

N-[4-(2-{[3-(morpholin-4-ylmethyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide: ^{1}H NMR (400MHz, d_6-DMSO): 10.25 (s, 1H), 9.62 (s, 1H), 8.5 (d, 1H), 8.16 (d, 2H), 7.94 (s, 1H), 7.76 (d, 2H), 7.62 (d, 1H), 7.36 (d,1H), 7.26 (t, 1H), 6.9 (d, 1H), 3.6 (t, 4H), 3.45 (s, 2H), 2.39 (t, 4H), 2.1 (s, 3H), 1.86 (s, 3H). MS (EI) for $C_{23}H_{25}N_5O_2$: 404 (MH^+).

N-[4-(2-{[3-(1,3-dioxan-2-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 (s, 1H), 9.68 (s, 1H), 8.5 (d, 1H), 8.32 (s, 1H), 8.21 (d, 2H), 7.77 (d, 2H), 7.58 (d, 1H), 7.39 (d, 1H), 7.28 (t, 1H), 6.98 (d, 1H), 5,52 (s, 1H), 4.2 (dd, 2H), 4.0 (t, 2H), 2.1 (s, 3H), 2.05 (m, 1H), 1.5 (dd, 1H). MS (EI) for $C_{22}H_{22}N_4O_3$: 391 (MH^+).

N-(4-{2-[(6-aminopyridin-2-yl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 (s, 1H), 8.93 (s, 1H), 8.55 (d, 1H), 8.14 (d, 2H), 7.75 (d, 2H), 7.57 (d, 1H), 7.45-7.4 (m, 2H), 6.12 (d, 1H), 5.78 (s, 2H), 2.08 (s, 3H). MS (EI) for $C_{17}H_{16}N_6O$: 321 (MH^+).

N-(4-{2-[(6-aminopyrimidin-4-yl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.25 (s, 1H), 9.72 (s, 1H), 8.6 (d, 1H), 8.2-8.15 (m, 3H), 7.8 (d, 2H), 7.52 (d, 1H), 7.42 (s, 1H), 6.8 (br,2H), 2.08 (s, 3H). MS (EI) for $C_{16}H_{15}N_7O$: 322 (MH^+).

N-(4-morpholin-4-ylphenyl)-4-quinolin-6-ylpyrimidin-2-amine: ^{1}H NMR (400MHz, d_6-DMSO): 9.57 (s, 1H), 9.0 (d,1H), 8.8 (s, 1H), 8.58 (d, 1H), 8.52 (d, 2H), 8.18 (d, 1H), 7.72 (d, 2H), 7.63 (q, 1H), 7.51 (d, 1H), 6.96 (d, 2H), 3.75 (t, 4H), 3.07 (4H). MS(EI) for $C_{23}H_{21}N_5O$: 384 (MH^+).

N-(4-morpholin-4-ylphenyl)-4-quinoxalin-6-ylpyrimidin-2-amine: ^{1}H NMR (400MHz, d_6-DMSO): 9.6 (s, 1H), 9.04 (d, 2H), 8.88 (s, 1H), 8.63 (d, 1H), 8.6 (d, 1H), 8.27 (d, 1H), 7.7 (d, 2H), 7.63 (d, 1H), 6.95 (d, 2H), 3.75 (t, 4H), 3.06 (t, 4H). MS (EI) for $C_{22}H_{20}N_6O$: 385 (MH^+).

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}-5-methylpyrimidin-4-yl)phenyl]-D-alaninamide: ^{1}H NMR (400MHz, d_6-DMSO): 9.25 (s, 1H), 8.3 (s, 1H), 7.7

(d, 2H), 7.66 (d, 2H), 7.6 (d, 2H), 6.85 (d, 2H), 3.5 (q, 1H), 3.03 (t, 4H), 2.5 (t, 4H), 2.35 (q, 2H), 2.21 (s, 3H), 1.23 (d, 3H), 1.02 (t, 3H). MS (EI) for $C_{26}H_{33}N_7O$: 460.5 (MH^+).

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}-5-methylpyrimidin-4-yl)phenyl]-D-prolinamide: ^{1}H NMR (400MHz, d_6-DMSO): 10.27 (s, 1H), 9.25 (s, 1H), 8.3 (s, 1H), 7.8 (d, 2H), 7.65 (d, 2H), 7.61 (d, 2H), 6.86 (d, 2H), 3.73 (m, 1H), 3.03 (t, 4H), 2.9 (t, 2H), 2.5 (t, 4H), 2.36 (q, 2H), 2.2 (s, 3H), 2.1-2.0 (m, 1H), 1.85-1.75 (m, 1H), 1.67 (p,2H), 1.02 (t, 3H). MS (EI) for $C_{28}H_{35}N_7O$: 486 (MH^+).

N-ethyl-4-{4-[(4-{4-[(tetrahydrofuran-2-ylcarbonyl)amino]phenyl}pyrimidin-2-yl)amino]phenyl}piperazine-1-carboxamide: ^{1}H NMR (400MHz, d_6-DMSO): 9.93 (s, 1H), 9.4 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.88 (d, 2H), 7.67 (d, 2H), 7.3 (d, 1H), 6.96 (d, 2H), 6.6 (t, 1H), 4.43 (t, 1H), 4.0 (q, 1H), 3.86 (q, 1H), 3.42 (t, 4H), 3.05 (p, 2H), 3.01 (t, 4H), 2.27-2.17 (m, 1H), 2.06-1.97 (m, 1H), 1.88 (p, 2H), 1.02 (t, 3H). MS (EI) for $C_{28}H_{33}N_7O_3$: 516 (MH^+).

N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-1H-imidazole-4-carboxamide: ^{1}H NMR (400MHz, d_6-DMSO): 12.76 (br, 1H), 10.12(s, 1H), 9.39 (s, 1H), 8.43 (d, 1H), 8.13 (d, 2H), 8.01 (d, 2H), 7.87 (s, 2H), 7.7 (d, 2H), 7.3 (d, 1H), 6.93 (d, 2H), 3.74 (t, 4H), 3.05 (t, 4H). MS (EI) for $C_{24}H_{23}N_7O_2$: 442 (MH^+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-1H-pyrrole-2-carboxamide: ^{1}H NMR (400MHz, d_6-DMSO): ^{1}H NMR (400MHz, d_6-DMSO): 11.75 (s, 1H), 10.0 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.15 (d, 2H), 7.92 (d, 2H), 7.7 (d, 2H), 7.3 (d, 1H), 7.12 (s, 1H), 7.0 (s, 1H), 6.93 (d, 2H), 6.2 (d, 1H), 3.74 (t, 4H), 3.05 (t, 4H). MS (EI) for $C_{25}H_{24}N_6O_2$: 441 (MH^+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-1H-imidazole-2-carboxamide: ^{1}H NMR (400MHz, d_6-DMSO): 13.2 (br, 1H), 10.65 (s, 1H), 9.4 (s, 1H), 8.44 (d, 1H), 8.15 (d, 2H), 8.04 (d, 2H), 7.68 (d, 2H), 7.4-7.2 (m, 3H), 6.95 (d, 2H), 3.74 (t, 4H), 3.05 (t, 4H). MS (EI) for $C_{24}H_{23}N_7O_2$: 442 (MH^+).

N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-2-(2-(pyridin-3-yl)-ethylamino)acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.00 (s, 1H), 8.92 (d, 1H), 8.64 (d, 1H), 8.35 (d, 1H), 8.17-8.14 (m, 3H), 7.75 (d, 2H), 7.61 (d, 2H), 7.22 (d, 1H), 7.00 (d, 2H), 3.89-3.79 (m, 4H), 3.33-3.21 (m, 2H), 3.15-3.07 (m, 4H), 1.92 (s, 2H); MS (EI): 510.4 (MH+).

2-(3-(4-methylpiperazin-1-yl)propylamino)-N-(4-(2-(4-morpholinophenyl-amino)pyrimidin-4-yl)phenyl)acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 8.36 (d, 1H), 8.14 (d, 2H), 7.75 (d, 2H), 7.61 (d, 2H), 7.22 (d, 1H), 6.99 (d, 2H), 3.87-3.81 (m, 4H), 3.68 (s, 2H), 3.13-3.07 (m, 4H), 2.98-2.88 (m, 2H), 2.82-2.62 (m, 8H), 2.39 (s, 3H), 1.93 (s, 3H), 1.89-1.79 (m, 2H); MS (EI): 512.6 (MH+).

2-(1-methylpiperidin-4-ylamino)-N-(4-(2-(4-morpholinophenylamino)-pyrimidin-4-yl)phenyl)acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 8.35 (d, 1H), 8.14 (d, 2H), 7.75 (d, 2H), 7.61 (d, 2H), 7.22 (d, 1H), 6.99 (d, 2H), 3.87-3.81 (m, 4H), 3.47 (s, 2H), 3.15-3.09 (m, 4H), 3.06-2.95 (m, 2H), 2.69-2.55 (m, 1H), 2.39 (s, 3H), 2.38-2.22 (m, 2H), 2.03-1.93 (m, 2H), 1.90 (s, 2H), 1.63-1.43 (m, 2H); MS (EI): 545.2 (MH+).

2-(2-amino-2-oxoethylamino)-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 8.27 (d, 1H), 8.04 (d, 2H), 7.68 (d, 2H), 7.53 (d, 2H), 7.13 (d, 1H), 6.91 (d, 2H), 4.54 (s, 2H), 3.79-3.73 (m, 4H), 3.39 (s, 2H), 3.06-3.00 (m, 4H), 1.86 (s, 2H); MS (EI): 462.1 (MH+).

2-morpholino-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.0 (s, 1H), 9.40 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.82 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.94 (d, 2H), 3.78-3.70 (m, 4H), 3.69-3.61 (m, 4H), 3.08-3.02 (m, 4H), 2.56-2.46 (m, 4H); MS (EI): 475.3 (MH+).

2-((2-aminoethyl)(methyl)amino)-N-(4-(2-(4-morpholinophenylamino)-pyrimidin-4-yl)phenyl)acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 8.36 (d, 1H), 8.13 (d, 2H), 7.76 (d, 2H), 7.62 (d, 2H), 7.22 (d, 1H), 7.00 (d, 2H), 3.89-3.81 (m, 4H), 3.51 (s, 2H), 3.14-3.07 (m, 4H), 3.03-3.96 (m, 2H), 2.94-2.88 (m, 2H), 2.67 (s, 3H); MS (EI) $C_{25}H_{31}N_7O_2$: 462.4 (MH+).

2-(1H-pyrazol-5-ylamino)-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)-phenyl)acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 8.35 (d, 2H), 8.12 (d, 2H), 7.74 (d, 2H), 7.61 (d, 2H), 7.40 (s, 1H), 7.21 (d, 1H), 6.99 (d, 2H), 5.69 (s, 1H), 3.95 (s, 2H), 3.86-3.80 (m, 4H), 3.14-3.07 (m, 4H), 1.96 (s, 2H); MS (EI): 471.1 (MH+).

N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-2-(piperazin-1-yl)-acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.39 (s, 1H), 9.53 (s, 1H), 8.87 (s, 2H), 8.48 (d, 1H), 8.17 (d, 1H), 7.80 (d, 2H), 7.10 (d, 2H), 7.33 (d, 1H), 7.04 (d, 2H), 3.82-3.74 (m, 4H), 3.32-3.24 (m, 2H), 3.19-3.09 (m, 4H), 3.08-3.02 (m, 2H), 2.95 (s, 2H), 2.79 (s, 2H), 1.96 (s, 2H); MS (EI): 474.2 (MH+).

(S)-benzyl 2-(2-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenylamino)-2-oxoethylamino)propanoate: ^{1}H-NMR (400MHz, CD3OD): 8.25 (d, 2H), 8.01 (d, 2H), 7.61 (d, 2H), 7.51 (d, 2H), 7.30-7.08 (m, 5H), 7.12 (d, 1H), 6.90 (d, 2H), 5.15-5.05 (m, 2H), 3.78-3.73 (m, 4H), 3.43 (q, 1H), 3.33 (d, 2H), 3.05-2.97 (m, 4H), 1.28 (d, 3H); MS (EI): 567.2 (MH+).

N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-2-(pyrimidin-4-yl-amino)acetamide: ^{1}H-NMR (400MHz, CD3OD): 10.90 (s, 1H), 9.63 (s, 1H), 9.18 (d, 2H), 8.78 (s, 1H), 8.50 (s, 1H), 8.26 (d, 1H), 8.18 (d, 2H), 7.82-7.68 (m, 4H), 7.36 (d, 1H), 7.11 (d, 2H), 6.84 (s, 1H), 5.16 (s, 2H), 3.83-3.77 (m, 4H), 2.54-2.47 (m, 4H); MS (EI): 483.2 (MH+).

N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-2-(piperidin-1-yl)-acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.98 (s, 1H), 9.84 (s, 1H), 9.65 (s, 1H), 8.50 (d, 1H), 8.20 (d, 2H), 7.90-7.70 (m, 4H), 7.36 (d, 1H), 7.11 (d, 2H), 4.12-4.07 (m, 2H), 3.87-3.77 (m, 4H), 3.62-3.42 (m, 2H), 3.23-3.13 (m, 4H), 2.51 (s, 2H), 1.94-1.64 (m, 6H), 1.45-1.38 (m, 2H); MS (EI): 473.4 (MH+).

2-(ethylamino)-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.78 (s, 1H), 9.45 (s, 1H), 8.87 (s, 2H), 8.48 (d, 1H), 8.17 (d, 2H), 7.77 (d, 2H), 7.71 (d, 2H), 7.33 (d, 1H), 7.04 (d, 2H), 4.04-3.97 (m, 2H), 3.82-3.74 (m, 4H), 3.19-3.02 (m, 6H), 1.12 (t, 3H); MS (EI): 433.3 (MH+).

2-(1H-imidazol-1-yl)-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.87 (s, 1H), 9.56 (s, 1H), 9.11 (s, 1H), 8.45 (d, 1H), 8.15 (d, 2H), 7.76 (d, 2H), 7.70 (d, 2H), 7.32 (d, 1H), 7.05 (d, 2H), 5.26 (s, 2H), 3.82-3.72 (m, 4H), 3.18-3.08 (m, 4H); MS (EI): 456.3 (MH+).

4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzoic acid: ^{1}H-NMR (400MHz, d6-DMSO): 9.56 (s, 1H), 8.55 (d, 1H), 8.27 (d, 2H), 8.09 (d, 2H), 7.68 (d, 2H), 7.41 (d, 1H), 6.97 (d, 2H), 3.80-3.72 (m, 4H), 3.11-3.03 (m, 4H); MS (EI): 377.3 (MH+).

N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-2-(phenylamino)-acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.29 (s, 1H), 9.59 (s, 1H), 8.46 (d, 1H), 8.14 (d, 2H), 7.79 (d, 2H), 7.73 (d, 2H), 7.33 (d ,1H), 7.19-7.00 (m, 4H), 6.70-6.50 (m, 3H), 3.96-3.88 (m, 4H), 3.22-3.12 (m, 4H); MS (EI): 481.1 (MH+).

4-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)-N-(4-morpholinophenyl)-pyrimidin-2-amine: ^{1}H-NMR (400MHz, d6-DMSO): 9.53 (s, 1H), 8.54 (d, 1H), 8.35 (d,

2H), 8.12 (d, 2H), 7.65 (d, 2H), 7.40 (d, 1H), 6.92 (d, 1H), 3.76-3.70 (m, 4H), 3.06-3.00 (m, 4H), 2.59 (s, 3H); MS (EI): 415.3 (MH+).

(R)-4-(4-(4-(4-(2-aminopropanamido)phenyl)pyrimidin-2-ylamino)phenyl)-N-ethylpiperazine-1-carboxamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.41 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.82 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.96 (d, 2H), 6.59 (t, 1H), 3.54-3.46 (m, 1H), 3.44-3.36 (m, 4H), 3.12-2.97 (m, 6H), 1.24 (d, 3H), 1.02 (t, 2H), 0.95 (t, 2H); MS (EI): 487.1 (MH-).

(R)-2-amino-N-(4-(2-(4-(4-((R)-pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.82 (d, 2H), 7.69 (d, 2H), 7.29 (d, 1H), 6.97 (d, 2H), 3.97-3.92 (m, 1H), 3.72-3.58 (m, 4H), 3.51-3.42 (m, 2H), 3.14-2.99 (m, 4H), 2.68-2.62 (m, 1H), 2.12-2.00 (m, 1H), 1.74-1.70 (m, 1H), 1.70-1.56 (m, 2H), 1.24 (d, 3H); MS (EI): 513.2 (MH-).

(R)-2-amino-N-(4-(2-(4-(4-((S)-pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.83 (d, 2H), 7.69 (d, 2H), 7.29 (d, 1H), 6.97 (d, 2H), 4.65 (t, 1H), 3.89-3.81 (m, 1H), 3.75-3.58 (m, 3H), 3.54-3.28 (m, 2H), 3.15-2.98 (m, 4H), 2.72-2.58 (m, 1H), 2.06-1.97 (m, 2H), 1.74-1.54 (m, 2H), 1.24 (d, 3H); MS (EI): 515.4 (MH+).

N-[4-(2-{[4-(4-L-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-D-alaninamide: 1H-NMR (400MHz, d6-DMSO): 9.40 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.83 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.97 (d, 2H), 3.57 (dd, 1H), 3.68-3.58 (m, 4H), 3.46 (dd, 1H), 3.12-2.98 (m, 4H), 1.23 (d, 3H), 1.12 (d, 3H); MS (EI): 489.4 (MH+).

(R)-2-amino-N-(4-(2-(4-(4-((S)-2-aminopropanoyl)piperazin-1-yl)phenylamino)-pyrimidin-4-yl)phenyl)propanamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.40 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.83 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.97 (d, 2H), 3.17 (s, 2H), 3.12-3.07 (m, 1H), 3.05-2.98 (m, 1H), 2.70-2.64 (m, 4H), 2.36-2.28 (m, 4H), 1.23 (d, 3H); MS (EI): 544.4 (MH+).

3,3,3-trifluoro-2-hydroxy-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.42 (br s, 1H), 9.41 (s, 1H), 8.46 (d, 1H), 8.15 (d, 2H), 7.89 (d, 2H), 7.68 (d, 2H), 7.57 (br s, 1H), 7.31 (d, 1H), 6.94 (d, 2H), 4.83-4.74 (m, 1H), 3.78-3.70 (m, 4H), 3.09-3.01 (m, 4H); MS (EI): 474.3(MH+).

(R)-2-hydroxy-2-methyl-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.72 (s, 1H), 9.34 (s, 1H), 8.41 (d, 1H), 8.08 (d, 2H), 7.89 (d, 2H), 7.64 (d, 2H), 7.27 (d, 1H), 6.91 (d, 2H), 5.66 (s, 1H), 4.21-4.13 (m, 1H), 3.72 (q, 1H), 3.15 (d, 3H), 3.12-3.02 (m, 4H), 1.80-1.72 (m, 1H), 1.59-1.51 (m, 1H), 1.32 (s, 3H), 0.82 (t, 3H); MS (EI): 448.4 (MH+).

(S)-2-hydroxy-2-methyl-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)-phenyl)butanamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.72 (s, 1H), 9.34 (s, 1H), 8.41 (d, 1H), 8.08 (d, 2H), 7.89 (d, 2H), 7.64 (d, 2H), 7.27 (d, 1H), 6.91 (d, 2H), 5.66 (s, 1H), 4.21-4.13 (m, 1H), 3.72 (q, 1H), 3.19-3.11 (d, 3H), 3.07-3.02 (m, 4H), 1.81-1.71 (m, 1H), 1.60-1.50 (m, 1H), 1.32 (s, 3H), 0.82 (t, 3H); MS (EI): 448.1 (MH+).

(R)-2-methoxy-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-propanamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.07 (s, 1H), 9.35 (s, 1H), 8.41 (d, 1H), 8.11 (d, 2H), 7.84 (d, 2H), 7.64 (d, 2H), 7.26 (d, 1H), 6.90 (d, 2H), 3.89 (q, 1H), 3.75-3.67 (m, 4H), 3.30 (s, 3H), 3.04-2.96 (m, 4H), 1.31 (d, 3H); MS (EI): 434.3 (MH+).

(S)-2-methoxy-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-propanamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.07 (s, 1H), 9.35 (s, 1H), 8.41 (d, 1H), 8.11 (d, 2H), 7.84 (d, 2H), 7.64 (d, 2H), 7.26 (d, 1H), 6.90 (d, 2H), 3.89 (q, 1H), 3.75-3.67 (m, 4H), 3.30 (s, 3H), 3.04-2.96 (m, 4H), 1.31 (d, 3H); MS (EI): 434.3 (MH+).

1-amino-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-cyclopentanecarboxamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.39 (s, 1H), 8.44 (d, 1H), 8.14 (d, 2H), 7.87 (d, 2H), 7.68 (d, 2H), 7.30 (d, 1H), 6.94 (d, 2H), 3.78-3.70 (m, 4H), 3.08-3.00 (m, 4H), 2.10-2.00 (m, 2H), 1.86-1.75 (m, 2H), 1.74-1.62 (m, 2H), 1.60-1.50 (m, 2H); MS (EI): 459.4 (MH+).

(S)-2-hydroxy-3,3-dimethyl-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.83 (s, 1H), 9.39 (s, 1H), 8.45 (d, 1H), 8.11 (d, 2H), 7.89 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.95 (d, 2H), 5.85 (d, 1H), 3.78-3.70 (m, 4H), 3.47 (q, 1H), 3.09-3.01 (m, 4H), 0.97 (d, 9H); MS (EI): 462.4 (MH+).

(R)-2-cyclohexyl-2-hydroxy-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.91 (s, 1H), 9.39 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.89 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.94 (d, 2H), 5.76 (br s, 1H), 3.85 (d, 1H), 3.77-3.69 (m, 4H), 3.10-3.02 (m, 4H), 1.80-1.51 (m, 6H), 1.30-1.02 (m, 5H); MS (EI): 488.1 (MH+).

(S)-2-cyclohexyl-2-hydroxy-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.91 (s, 1H), 9.39 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.89 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.94 (d, 2H), 5.76 (br s, 1H), 3.85 (d, 1H), 3.77-3.69 (m, 4H), 3.07-2.98 (m, 4H), 1.78-1.50 (m, 6H), 1.25-1.00 (m, 5H); MS (EI): 488.1 (MH+).

(S)-2-hydroxy-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-propanamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.95 (s, 1H), 9.39 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.90 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.94 (d, 2H), 5.87 (br s, 1H), 4.23-4.15 (m, 1H), 3.79-3.71 (m, 4H), 3.08-3.00 (m, 4H), 2.51 (d, 3H); MS (EI): 420.4 (MH+).

1-amino-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-cyclobutanecarboxamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.39 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.87 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.94 (d, 2H), 3.79-3.71 (m, 4H), 3.09-3.00 (m, 4H), 2.00-1.85 (m, 4H), 1.84-1.76 (m, 2H); MS (EI): 445.4 (MH+).

4-(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)-N-(4-morpholinophenyl)pyrimidin-2-amine: ^{1}H-NMR (400MHz, d6-DMSO): 9.57 (s, 1H), 8.57 (d, 1H), 8.39 (d, 2H), 8.26 (d, 2H), 7.67 (d, 2H), 7.44 (d, 1H), 6.95 (d, 2H), 3.78-3.72 (m, 4H), 3.09-3.03 (m, 4H), 2.46 (s, 3H); MS (EI): 415.0 (MH+).

N-(4-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-2-phenylacetamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.45 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.12 (d, 2H), 7.76 (d, 2H), 7.64 (d, 2H), 7.38-7.33 (m, 3H), 7.27 (d, 1H), 6.92 (d, 2H), 3.69 (s, 2H), 3.10-3.04 (m, 4H), 2.35 (q, 3 H), 1.89 (s, 2H), 1.03 (t, 2H); MS (EI): 493.1 (MH+).

1-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidin-2-one: ^{1}H-NMR (400MHz, d6-DMSO): 8.26 (d, 1H), 8.14 (d, 2H), 7.77 (d, 2H), 7.65 (d, 2H), 7.36 (d, 1H), 7.25 (d, 2H), 3.92-3.84 (m, 5H), 3.82-3.74 (m, 1H), 3.74-3.60 (m, 1H), 3.42-3.30 (m, 4H), 3.06-3.02 (m, 1H), 2.16-2.06 (m, 2H); MS (EI): 416.1 (MH+).

(S)-2-hydroxy-3-methyl-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.90 (s, 1H), 9.39 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.90 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.94 (d, 2H), 5.76 (d, 1H), 3.86 (dd, 1H), 3.78-3.73 (m, 4H), 3.08-3.02 (m, 4H), 0.96 (d, 3H), 0.87 (d, 3H); MS (EI): 448.3 (MH+).

(R)-2-hydroxy-3-methyl-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.90 (s, 1H), 9.39 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.90 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.94 (d, 2H), 5.76 (d, 1H), 3.86 (dd, 1H), 3.78-3.73 (m, 4H), 3.08-3.02 (m, 4H), 0.96 (d, 3H), 0.87 (d, 3H); MS (EI): 448.3 (MH+).

(R)-2-amino-N-(4-(2-(4-(4-(cyclobutanecarbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.41 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.82 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.95 (d, 2H), 3.63-3.56 (m, 2H), 3.43-3.37 (m, 3H), 3.18 (d, 1H), 3.07-2.98 (m, 4H), 2.25-2.02 (m, 4H), 1.98-1.83 (m, 1H), 1.82-1.70 (m, 1H), 1.23 (d, 3H); MS (EI): 500.2 (MH+).

(R)-2-amino-N-(4-(2-(4-(4-pivaloylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.82 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.95 (d, 2H), 3.73-3.67 (m, 4H), 3.52-4.42 (m, 1H), 3.08-3.02 (m, 4H), 1.25 (s, 3H), 1.23 (d, 3H); MS (EI): 502.4 (MH+).

4-[4-(ethylamino)phenyl]-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine: ^{1}H-NMR (400 MHz, DMSO): 9.202 (s, 1H), 8.3 (d, 2H), 7.948 (d, 2H), 7.689 (q, 2H), 7.134 (d, 1H), 6.93 (d, 2H), 6.657(d, 2H), 6.285 (t, 1H), 3.754 (t, 4H), 3.132-3.113 (m, 2H), 3.04 (t, 4H), 1.187 (t, 3H). MS (EI) for $C_{22}H_{25}N_5O$: 376.3 (MH^+).

N-{4-[2-(phenylamino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, DMSO): 10.233 (s, 1H), 9.63 (s, 1H), 8.513 (d, 1H), 8.147 (d, 2H), 7.854 (d, 2H), 7.774 (d, 2H), 7.362-7.305 (m, 3H), 6.961 (t, 1H), 2.098 (s, 3H). MS (EI) for $C_{18}H_{16}N_4O$: 305.3 (MH^+).

N-{4-[2-({4-[(4-ethylpiperazin-1 yl)carbonyl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H NMR (400 MHz, DMSO): 10.236 (s, 1H), 9.889 (s, 1H), 8.549 (d, 1H), 8.167-8.134 (m, 2H), 7.93-7.903 (m, 2H), 7.782 (d, 2H), 7.418-7.369 (m, 3H), 3.509 (br s, 4H), 2.378-2.324 (m, 6H), 2.097 (s, 3H), 1.025 (t, 3H). MS (EI) for $C_{25}H_{28}N_6O_2$: 445.4 (MH^+).

N-[4-(2-{[3-(morpholin-4-ylcarbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]-acetamide: ^{1}H NMR (400 MHz, DMSO): 10.237 (s, 1H), 9.823 (s, 1H), 8.541 (d, 1H), 8.152 (d, 2H), 8.026 (t, 1H), 7.847 (d, 1H), 7.772 (d, 2H), 7.392 (m, 2H), 6.996 (d, 1H), 3.76-3.36 (br s, 8H), 2.094 (s, 3H). MS (EI) for $C_{23}H_{23}N_5O_3$: 418.3 (MH^+).

N-(4-(2-(3-(2-(dimethylamino)ethoxy)phenylamino)pyrimidin-4-yl)phenyl)-acetamide: ^{1}H NMR (400 MHz, DMSO): 10.471 (br s, 1H), 10.42 (s, 1H), 9.816 (s, 1H), 8.534 (d, 1H), 8.158 (d, 2H), 7.804 (d, 2H), 7.7 (t, 1H), 7.413-7.383 (m, 2H), 7.29 (t, 1H), 6.636 (m, 1H), 4.381 (t, 2H), 3.531 (q, 2H), 2.883 (d, 6H), 2.106 (s, 3H). MS (EI) for $C_{22}H_{25}N_5O_2$: 392.3 (MH^+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)benzamide: ^{1}H-NMR (400 MHz, DMSO): 10.532 (s, 1H), 9.407 (s, 1H), 8.47 (d, 1H) 8.189 (d, 2H), 7.982 (m, 4H), 7.7-7.54 (m, 5H), 7.325 (d, 1H), 6.959 (d, 2H), 3.747 (t, 4H), 3.054 (t, 4H). MS (EI) for $C_{27}H_{25}N_5O_2$: 452.1 (MH^+).

N-[4-(2-{[4-(methyloxy)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400 MHz, DMSO): 10.222 (s, 1H), 9.433 (s, 1H), 8.455 (s, 1H), 8.121 (d, 2H), 7.725 (q, 4H), 7.293 (d, 1H), 6.91 (d, 2H), 3.739 (s, 3H), 2.093 (s, 3H). MS (EI) for $C_{19}H_{18}N_4O_2$: 335 (MH^+).

4-(4-chlorophenyl)-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine: ^{1}H-NMR (400 MHz, DMSO): 9.488 (s, 1H), 8.514 (d, 1H), 8.185 (d, 2H), 7.665-7.606 (q, 4H), 7.354 (d, 1H), 6.918 (d, 2H), 3.757 (t, 4H), 3.048 (t, 4H). MS (EI) for $C_{20}H_{19}ClN_4O$: 367 (MH^+).

N-[4-(2-{[3-(methyloxy)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400 MHz, DMSO): 10.235 (s, 1H), 9.633 (s, 1H), 8.52 (d, 1H), 8.15 (d, 2H), 7.65 (t, 1H), 7.369 (d, 2H), 7.209 (t, 1H), 6.535 (q, 1H), 3.77 (s, 3H), 2.092 (s, 3H). MS (EI) for $C_{19}H_{18}N_4O_2$: 335 (MH^+).

1-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-3-(phenylmethyl)urea: ^{1}H NMR (400 MHz, DMSO): 9.347 (s, 1H), 9 (s, 1H), 8.414 (d, 1H), 8.067 (d, 2H), 7.688 (d, 2H), 7.583 (d, 2H), 7.351-7.31 (m, 4H), 7.237 (d, 2H), 6.943 (d, 2H), 6.831 (t, 1H), 4.33 (d, 2H), 3.742 (t, 4H), 3.044 (t, 4H). MS (EI) for $C_{28}H_{28}N_6O_2$: 481.4 (MH^+).

N-(4-{2-[(4-{4-[(2S)-pyrrolidin-2-ylmethyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)-D-prolinamide: ^{1}H NMR (400 MHz, DMSO): 10.231 (br s, 1H), 9.376 (s, 1H), 8.443 (d, 1H), 8.134 (d, 2H), 7.848 (d, 2H), 7.663 (d, 2H), 7.29 (d, 1H), 6.936 (d, 2H), 3.74 (m, 1H), 3.505 (m, 1H), 3.08-2.89 (m, 6H), 2.64 (m, 2H), 2.374 (m, 1H), 2.069 (m, 1H), 1.938-1.648 (m, 9H), 1.452 (m, 1H). MS (EI) for $C_{30}H_{38}N_8O$: 527.3 (MH^+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2,3-dihydro-1H-isoindole-1-carboxamide: ^{1}H NMR (400 MHz, DMSO): 11.345 (s, 1H), 10.326 (br s, 1H), 9.525 (s, 1H), 9.479 (br s, 1H), 8.474 (d, 1H), 8.19 (d, 2H), 7.799 (d, 2H), 7.7-7.627 (m, 3H), 7.469-7.415 (m, 3H), 7.323 (d, 1H), 7.025 (d, 2H), 5.688 (br s, 1H), 4.578 (m, 2H), 3.757 (s, 4H), 3.105 (s, 4H). MS (EI) for $C_{29}H_{28}N_6O_2$: 492.58 (MH^+).

N-{4-[2-({4-[4-(2-piperazin-1-ylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}tetrahydrofuran-2-carboxamide: ^{1}H NMR (400 MHz, DMSO): 9.938 (s, 1H), 9.412 (s, 1H), 8.456 (d, 1H), 7.135 (d, 2H), 7.886 (d, 2H), 7.691 (d, 2H), 7.304 (d, 1H), 6.975 (d, 2H), 4.45 (m, 1H), 4.01 (q, 1H), 3.878 (q, 1H), 3.705 (br s, 4H), 3.592 (br s, 4H), 3.148 (s, 2H), 3.1 (br s, 2H), 3.02 (br s, 2H), 2.719 (br s, 4H), 2.354 (br s, 4H), 2.21 (m, 1H), 2.021 (m, 1H), 1.862 (m, 2H). MS (EI) for $C_{31}H_{38}N_8O_3$: 571 (MH^+).

N-(4-{2-[(4-{4-[(4-chloro-1-methyl-1H-pyrazol-3-yl)methyl]piperazin-1-yl}-phenyl)amino]pyrimidin-4-yl}phenyl)-D-prolinamide: ^{1}H NMR (400 MHz, DMSO): 10.215 (s, 1H), 9.363 (s, 1H), 8.439 (d, 1H), 8.131 (d, 2H), 7.901 (s, 1H), 7.841 (d, 2H), 7.651 (d, 2H), 7.286 (d, 1H), 6.916 (d, 2H), 3.802 (s, 3H), 3.7 (m, 1H), 3.47 (s, 2H), 3.048 (br s, 4H), 2.92 (t, 2H), 2.568 (t, 4H), 2.08 (m, 1H), 1.816 (m, 1H), 1.691 (m, 2H). MS (EI) for $C_{30}H_{34}ClN_9O$: 572.4 (MH^+).

N-{4-[2-({4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}-D-prolinamide: ^{1}H NMR (400 MHz, DMSO): 10.176 (s, 1H), 9.927 (s, 1H), 8.374 (d, 1H), 8.065 (d, 2H), 7.773 (d, 2H), 7.587 (d, 2H), 7.219 (d, 1H), 6.857 (d, 2H), 4.396 (br s, 1H), 3.715 (t, 1H), 3.468 (br s, 4H), 2.996-2.954 (m, 6H), 2.873 (t, 2H), 2.74 (s, 1H0, 2.368 (t, 2H) 2.369 (t, 2H) 2.368 (t, 2H), 2.038 (m, 1H), 1.749 (m, 1H), 1.61 (m, 2H). MS (EI) for $C_{27}H_{33}N_7O_2$: 488.3 (MH^+).

N-(4-{2-[(4-{4-[(1-methyl-1H-pyrrol-2-yl)methyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)-D-prolinamide: ^{1}H NMR (400 MHz, DMSO): 10.194 (s, 1H), 9.349 (s, 1H), 8.42 (d, 1H), 8.11 (d, 2H), 7.822 (d, 2H), 7.636 (d, 2H), 7.267 (d, 1H), 7.076 (s, 1H), 6.902 (d, 2H), 6.75 (s, 1H), 3.738 (m, 1H), 3.701 (s, 3H), 3.553 (s, 2H), 3.306 (m, 4H), 3.031 (br s, 4H), 2.892 (t, 2H), 2.728 (s, 1H), 2.054 (m, 1H), 1.803 (m, 1H), 1.647 (m, 2H). MS (EI) for $C_{31}H_{36}N_8O$: 538.3 (MH^+).

N-(4-{2-[(4-{4-[(2R)-pyrrolidin-2-ylmethyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)-D-prolinamide: ^{1}H NMR (400 MHz, DMSO): 8.319-8.251 (m, 3H), 7.86 (d, 2H), 7.636 (d, 2H), 7.56 (d, 1H), 7.282 (d, 2H), 4.479 (t, 1H), 4.106 (m, 1H),

3.514 (br s, 4H), 3.496-3.303 (m, 11H),. 2.252 (m, 1H), 2.342 (m, 1H), 2.19-2.094 (m, 6H), 1.835 (m, 1H). MS (EI) for $C_{30}H_{36}N_8O$: 528.5 (MH^+).

(2S,3aS,7aS)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-octahydro-1H-indole-2-carboxamide: ^{1}H NMR (400 MHz, DMSO): 10.857 (s, 1H), 9.84 (s, 1H), 9.714 (br s, 1H), 8.531 (d, 1H), 8.207 (m, 3H), 7.816 (d, 4H), 7.42 (d, 1H), 4.448 (m, 1H), 3.874 (t, 4H), 3.681 (br s, 1H), 3.322 (t, 4H), 2.504 (m, 2H), 2.09 (m, 1H), 1.913 (m, 1H), 1.615 (m, 4H), 1.371-1.259 (m, 3H). MS (EI) for $C_{29}H_{34}N_6O_2$: 499.5 (MH^+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-cyclopropane-carboxamide: ^{1}H NMR (400 MHz, DMSO): 10.476 (s, 1H), 9.383 (s, 1H), 8.443 (d, 1H), 8.123 (d, 2H), 7.768 (d, 2H), 7.686 (d, 2H), 7.279 (d, 1H), 6.946 (d, 2H), 3.74 (t, 4H), 3.046 (t, 4H), 1.824 (m, 1H), 0.829 (m, 4H). MS (EI) for $C_{24}H_{25}N_5O_2$: 416 (MH^+).

N-[4-(2-{[4-(dimethylamino)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.38 (s, br, 1H), 9.92 (s, br, 1H), 8.85 (d, 2H), 8.11 (d, 2H), 7.92 (d, 2H), 7.79 (d, 2H), 7.67 (s, 2H), 7.42 (d, 1H), 3.10 (s, 6H), 2.10 (s, 3H). MS (EI): 348 (MH+).

N-(4-{2-[(4-chlorophenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.30 (s, 1H), 9.88 (s, 1H), 8.53 (d, 1H), 8.14 (d, 2H), 7.87 (d, 2H), 7.75 (d, 2H), 7.41 (d, 2H), 7.37 (1H), 2.10 (s, 3). MS (EI): 339 (MH+).

N-[4-(2-{[4-(1H-pyrrol-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.26 (br s, 1H), 9.78 (br s, 1H), 8.52 (d, 1H), 8.15 (d, 2H), 7.92 (d, 2H), 7.77 (d, 2H), 7.54 (d, 2H), 7.38 (d, 1H), 7.31 (m, 2H), 6.24 (m, 2H). 2.09 (s, 3H). MS (EI): 370 (MH+).

ethyl 1-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-piperidine-4-carboxylate: ^{1}H NMR (400 MHz, d6-DMSO): 10.25 (s, 1H), 9.49 (br s, 1H), 8.45 (d, 1H), 8.11 (d, 2H), 7.75 (d, 4H0, 7.30 (d, 1H), 4.10 (q, 2H), 3.56 (d, 2H), 2.86 (br s, 2H), 2.09 (s, 3H), 1.97 (br d, 2H), 1.35 (m, 2H), 1.30 (m, 2H), 0.88 (t, 3H). MS (EI): 460 (MH+).

N-[4-(2-{[4-(4-phenylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.28 (s, 1H), 9.68 (br s 1H), 9.49 (d, 1H),

8.14 (d, 2H), 7.82 (br s 1H), 7.70 (d, 2H), 7.35 (d, 1H), 7.28 (t, 2H), 7.08 (d, 2H), 6.88 (t, 1H), 3.45 (br s, 8H), 2.09 (s, 3H). MS (EI): 465 (MH+).

N-{4-[2-({4-[(2R,6S)-2,6-dimethylmorpholin-4-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.28 (s, 1H), 9.79 (br s, 1H), 8.47 (d, 1H), 8.12 (d, 1H), 8.10 (d, 1H), 7.80 (br d, 2H), 7.75 (d, 2H), 7.37 (d, 2H), 3.69 (br s, 4H), 3.54 (d, 2H), 2.07 (s, 3H), 1.16 (s, 3H), 1.14 (s, 3H) MS (EI): 418 (MH+).

4-amino-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide: 1H NMR (400 MHz, d6-DMSO):11.06 (br s, 1H), 9.97 (br s, 1H), 9,29 (s, 2H0), 8.56 (d, 1H), 8.21 (d, 2H), 7.94 (d, 2H), 7.89 (d, 1H), 7.58 (s, 1H), 7.47 (d, 1H), 5.32 (br s, 3H), 3.99 (s, 4H), 3.48 (m, 4H), 3.38 (m, 4H), 2.84 (m, 2H), 2.46 (m, 2H). MS (EI): 523 (MH+).

(2R)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-piperazine-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.33 (br s, 1H), 10.31 (br s, 1H), 8.58 (d, 1H), 8.22 (d, 2H), 7.94 (d, 2H), 7.89 (d, 2H), 7.77 (d, 2H), 7.53 (d, 1H), 4.55 (d, 1H), 4.08 (s, 5H), 3.54 (s, 5H), 3.43 (m, 2H), 3.28 (m, 2H). MS (EI): 460 (MH+).

2-amino-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-1,2,3,4-tetrahydronaphthalene-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.10 (br s, 1H), 10.07 (br s, 1H), , 8.89 (d, 2H), 8.56 (d, 1H), 8.20 (d, 2H), 7.98 (d, 2H), 7.92 (d, 2H), 7.70 (d, 2H), 7.48 (d, 1H), 7.10 (m, 4H), 6.10 (br s, 3H), 4.40 (s, 4H), 3.70 (d, 1H), 3.50 (s, 4H), 3.39 (d, 4H), 2.89 (m, 1H), 2.71 (m, 1H), 2.1 (m, 1H), 1.26 (m, 1H), 1.17 (m, 1H). MS (EI): 521 (MH+).

4-amino-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-tetrahydro-2H-pyran-4-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO):10.85 (br s, 1H), 9.85 (br s , 1H), 8.97 (s, 2H), 8.53 (d, 1H), 8.20 (d, 2H), 7.94 (d, 2H), 7.83 (d, 2), 7.43 (d, 2H), 4.39 (br s, 3H), 3.94 (s, 4H), 3.87 (d, 4H), 3.72 (m, 4H), 2.45 (m, 2H), 1.97 (d, 2H). MS (EI): 475 (MH+).

(4S)-4-hydroxy-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.38 (s, 1H), 10.25 (m, 1H), 10.31 (s, 1H), 8.84 (m, 1H), 8.57 (d, 1H), 8.21 (d, 2H), 7.93 (d, 2H), 7.87 (d, 2H), 7.75 (d, 2H), 7.49 (d, 1H), 6.62 (m, 1H), 4.50 (s, 1H), 4.06 (s, 4H), 3.53 (s, 4H), 3.42 (m, 1H)< 3.17 (m, 1H), 2.45 (t, 1H), MS (EI): 461 (MH+).

1-acetyl-4-amino-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)piperidine-4-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.72 (s, 1H), 8.51 (d, 1H), 8.14 (dd, 2H), 8.12 (d, 1H), 8.08 (d, 1H), 7.00 (dd, 1H), 7.39 (d, 1H), 7.17 (d, 1H), 4.15 (d, 1H), 3.70 (m, 4H), 3.68 (d, 1H), 4.41(m, 4H),3.41 (m, 4H), 3.01 (m,1H), 2.93 (m, 4H), 2.02 (s, 3H), 1.98 (m, 1H), 1.84 (m, 1H). MS (EI): 516 (MH+).

O-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-serinamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.51 (br s, 1H), 9.99 (br s, 1H), 8.55 (d, 1H), 8.50 (br s, 2H), 8.19 (d, 2H), 7.88 (m, 4H), 7.46 (d, 1H), 5.19 (br s, 3H), 4.36 M, 1H), 4.02 (br s, 4H), 3.88 (m, 1H), 3.46 br s, 4H), 3.33 (s, 3H). MS (EI): 449 (MH+).

N-[4-(2-{[4-(2,6-dimethylmorpholin-4-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.30 (br s, 1H), 9.83 (br s, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.81 (br s, 1H), 7.77 (d, 2H), 7.39 (d, 1H),4.10 (br s, 4H), 3.56 (d, 2H), 2.10 (s, 3H), 1.18 (s, 3H), 1.71 (s, 3H). MS (EI): 418 (MH+).

N-(4-{2-[(4-piperidin-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400 MHz, d6-DMSO): 10.32 (br s, 1H), 9.89 (br s, 1H), 8.52 (d, 1H), 8.11 (d, 2H), 7.94 (d, 2H), 7.76 (d, 4H), 7.40 (d, 1H), 3.45 (Br s, 4H), 3.36 (6H), 2.07 (s, 3H). MS (EI): 388 (MH+).

O-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-serinamide: ^{1}H NMR (400 MHz, d6-DMSO):11.51 (br s, 1H), 9.99 (br s, 1H), 8.55 (d, 1H), 8.50 (br s, 2H), 8.19 (d, 2H), 7.88 (m, 4H), 7.46 (d, 1H), 5.19 (br s, 3H), 4.36 M, 1H), 4.02 (br s, 4H), 3.88 (m, 1H), 3.46 br s, 4H), 3.33 (s, 3H). MS (EI): 449 (MH+).

1,1-dimethylethyl (2R)-2-{[(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)amino]carbonyl}pyrrolidine-1-carboxylate: ^{1}H NMR (400 MHz, d6-DMSO): 10.26 (brs ,1H), 9.38 (br s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.78 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.94 (d, 2H), 4.22 (m, 1H), 3.74 (m, 4H), 3.43 (m, 1H), 3.34 (m, 1H), 3.04 (m, 4H), 2.20 (m, 1H), 1.90 (m, 1H), 1.81 (m, 1H), 1.40 (s, 3H), 1.27 (s, 6H). (MS (EI) 4: 545 (MH+).

4-[4-(methylsulfonyl)phenyl]-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine: ^{1}H-NMR (400 MHz, d6-DMSO): 9.62 (s,1H), 8.59 (d, 1H), 8.39 (d, 2H), 8.09 (d, 2H), 7.68 (d, 2H), 7.45 (d, 1H), 7.0 (s, br, 1H), 3.81-3.71 (m, 4H), 3.29 (s, 3H), 3.04-3.14 (m, 4H). MS (EI): 411 (MH+).

4-[3-(methylsulfonyl)phenyl]-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine: ^{1}H-NMR (400 MHz, d6-DMSO): 9.60 (s,1H), 8.72 (s, 1H), 8.57 (d, 1H), 8.47 (d, 1H), 8.10 (d, 1H), 7.85 (d, 1H), 7.66 (d, 1H), 7.46 (d, 1H), 6.92 (d, 1H), 3.81-3.71 (m, 4H), 3.31 (s, 3H), 3.0-3.11 (m, 4H). MS (EI): 411 (MH+).

4-[4-(methylthio)phenyl]-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine: ^{1}H-NMR (400 MHz, d6-DMSO): 9.42 (s,1H), 8.46 (d, 1H), 8.09 (d, 2H), 7.66 (d, 2H), 7.40 (d, 2H), 7.31 (d, 1H), 6.92 (d, 2H), 3.79-3.69 (m, 4H), 3.1-3.0 (m, 4H), 2.55 (s, 3H). MS (EI): 379 (MH+).

N-(4-{2-[(3-bromo-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.23 (s,1H), 9.72 (s, 1H), 8.52 (d, 1H), 8.27 (d, 1H), 8.13 (d, 2H), 7.81-7.71 (m, 3H), 7.42-7.32 (m, 1H), 7.18 (d, 1H), 3.78-3.69 (m, 4H), 2.97-2.87 (m, 4H), 2.09 (s, 3H). MS (EI): 469 (MH+).

N-[4-(2-{[4-{[2-(diethylamino)ethyl]oxy}-3-(4-ethylpiperazin-1-yl)phenyl]-amino}pyrimidin-4-yl)phenyl]acetamide: ^{1}H NMR (400 MHz, d6-DMSO):10.21 (s, 1H), 9.36 (s,1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.73 (d, 2H), 7.54 (s, 1H), 7,36-7.26 (m, 2H), 6,88 (d, 1H), 4.02-3.92 (m, 2H), 2.81-2.71 (m, 2H), 2.59-2.49 (m, 4H), 2.45-2.35 (m, 2H), 1.04 (t, 3H), 0.98 (t, 6H). MS (EI): 533 (MH+).

N^2,N^2-dimethyl-N-(4-{2-[(4-{4-[3-(methyloxy)propanoyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)glycinamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.99 (s,1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.11 (d, 2H), 7.84 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.95 (d, 2H), 3.63-3.59 (m, 4H), 3.25 (s, 3H), 3.11 (s, 2H), 3.10-3.05 (m, 2H, 3.04-2.99 (m, 2H), 2.65 (t, 2h), 2.29 (s, 6H). MS (EI): 519 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-cyclobutane-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.99 (s, 1H), 9.37 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.77 (d, 2H), 7.67 (d, 2H), 7.27 (d, 1H), 6.93 (d, 2H), 3.75 (m, 4H), 3.32 (m, 1H), 3.05 (m, 4H), 2.24 (m, 2H), 2.12 (m, 2H), 1.93 (m, 1H), 1.82 (m, 1H). MS (EI): 430 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)azetidine-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.10 (s, 1H), 9.36 (s, 1H), 8.42 (d, 1H), 8.09 (d, 2H), 7.74 (d, 2H), 7.64 (d, 2H), 7.24 (d, 1H), 6.91 (d, 2H), 3.71 (m, 4H), 3.61 (m, 1H), 3.52 (m, 4H), 3.02 (m, 4H). MS (EI): 431 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)piperidine-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.35 (s, 1H), 8.40 (d, 1H), 8.08 (d, 2H), 7.73 (d, 2H), 7.64 (d, 2H), 7.24 (d, 1H), 6.90 (d, 2H), 3.72 (m, 4H), 3.41 (m, 4H), 3.02 (m, 4H), 2.83 (m, 1H), 2.62 (m, 1H), 1.58 (m, 2H), 1.37 (m, 1H),. MS (EI): 459 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)piperidine-4-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.12 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.76 (d, 2H), 7.67 (d, 2H), 7.27 (d, 1H), 6.93 (d, 2H), 3.74 (m, 4H), 3.37 (m, 1H), 3.03 (m, 4H), 3.00 (m, 1H), 2.50 (m, 2H), 2.47 (m, 1H), 1.73 (m, 2H), 1.54 (m, 2H). MS (EI): 459 (MH+).

2-(methyloxy)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.05 (s, 1H), 9.36 (s, 1H), 8.42 (d, 1H), 8.09 (d, 2H), 7.82 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H), 6.91 (d, 2H), 4.02 (s, 2H), 3.72 (m, 4H), 3.38 (s, 3H), 3.02 (m, 4H). MS (EI): 420 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)piperidine-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.85 (s, br, 1H), 9.31 (s, 1H), 8.36 (d, 1H), 8.04 (d, 2H), 7.75 (d, 2H), 7.60 (d, 2H), 7.21 (d, 1H), 6.87 (d, 2H), 3.67 (m, 4H), 3.21 (m, 1H), 2.98 (m, 4H), 2.93 (m, 1H), 2.47 (m, 1H), 1.70 (m, 2H), 1.37 (m, 4H). MS (EI) 2: 459 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)glycinamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.37 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.82 (d, 2H), 7.66 (d, 2H), 7.27 (d, 1H), 6.93 (d, 2H), 3.75 (m, 4H), 3.62 (br s, 2H), 3.32 (m, 2H), 3.05 (m, 4H). MS (EI): 405 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)furan-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.44 (s, 1H), 9.40 (s, 1H), 8.46 (d, 1H), 8.16 (d, 2H), 7.98 (m, 1H), 7.93 (m, 2H), 7.68 (d, 2H), 7.39 (d, 1H), 7.30 (d, 1H), 6.93 (d, 2H), 6.74 (d, 1H), 3.75 (m, 4H), 3.05 (m, 4H). MS (EI): 3: 442 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)tetra-hydrofuran-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.91 (s, 1H), 9.36 (s, 1H), 8.41 (d, 1H), 8.09 (d, 2H), 7.84 (d, 2H), 7.67 (d, 2H), 7.22 (d, 1H), 6.91 (d, 2H), 4.41 (dd, 1H), 3.96 (q, 1H), 3.83 (q, 1H), 3.72 (m, 4H), 3.02 (m, 4H), 2.19 (m, 1H), 1.99 (m, 1H), 1.88 (m, 2H). MS (EI): 446 (MH+).

5-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-pyrazine-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.90 (s, 1H), 9.38 (s, 1H), 9.17 (s, 1H), 8.71 (s, 1H), 8.43 (d, 1H), 8.16 (d, 2H), 8.08 (d, 2H), 7.66 (d, 2H), 7.31 (d, 1H), 6.92 (d, 2H), 3.71 (m, 4H), 3.03 (m, 4H), 2.62 (s, 3H),. MS (EI): 468 (MH+).

2-(ethyloxy)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.94 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.80 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H), 6.91 (d, 2H), 4.05 (s, 2H), 3.72 (m, 4H), 3.55 (q, 2H), 3.02 (m, 4H), 1.17 (t, 3H). MS (EI): 434 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-(phenyloxy)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.37 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.14 (d, 2H), 7.82 (d, 2H), 7.67 (d, 2H), 7.31 (m, 3H), 6.98 (m, 4H), 4.75 (s, 2H), 3.73 (m, 4H), 3.04 (m, 4H). MS (EI): 482 (MH+).

methyl 4-[(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)amino]-4-oxobutanoate: ^{1}H NMR (400 MHz, d6-DMSO): 10.28 (s, 1H), 9.37 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.67 (d, 2H), 7.27 (d, 1H), 6.93 (d, 2H), 3.74 (m, 4H), 3.60 (s, 3H), 3.06 (m, 4H), 2.65 (m, 4H). MS (EI): 462 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)butanamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.15 (s, 1H), 9.37 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.75 (d, 2H), 7.67 (d, 2H), 7.26 (d, 1H), 6.93 (d, 2H), 3.73 (m, 4H), 3.04 (m, 4H), 2.33 (t, 2H), 1.63 (q, 2H), 0.93 (t, 3H). MS (EI): 418 (MH+).

2-(2-methylphenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.44 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.76 (d, 2H), 7.67 (d, 2H), 7.27 (m, 2H), 7.16 (m, 3H), 6.93 (d, 2H), 3.75 (m, 6H), 3.03 (m, 4H), 2.31 (m, 3H). MS (EI): 480 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-cyclopentane-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.14 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.77 (d, 2H), 7.67 (d, 2H), 7.27 (d, 1H), 6.93 (d, 2H), 3.75 (m, 4H), 3.04 (m, 4H), 2.80 (m, 1H), 1.87 (m, 2H), 1.72 (m, 4H), 1.55 (m, 2H). MS (EI): 444 (MH+).

(2S)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-azetidine-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.09 (br s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.86 (d, 2H), 7.67 (d, 2H), 7.29 (d, 1H), 6.94 (d, 2H), 4.32

(t, 1H), 3.73 (m, 4H), 3.62 (m, 1H), 3.06 (m, 4H), 2.58 (m, 1H), 2.29 (m, 1H), 0.99 (m, 1H). MS (EI): 431 (MH+).

N-{4-[2-({4-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.19 (s, 1H), 9.19 (s, 1H), 8.40 (d, 1H), 8.11 (d, 2H), 7.83 (d, 2H), 7.56 (d, 2H), 7.22 (d, 1H), 6.53 (d, 2H), 3.72 (m, 1H), 3.41 (m, 1H), 3.33 (m, 1H), 3.22 (m, 1H), 3.02 (m, 1H), 2.90 (m, 2H), 2.78 (m, 1H), 2.20 (s, 6H), 2.05 (m, 2H), 1.75 (m, 2H), 1.66 (m, 2H). MS (EI): 472 (MH+).

4-(4-aminophenyl)-N-{4-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]phenyl}-pyrimidin-2-amine: ^{1}H NMR (400 MHz, d6-DMSO): 8.99 (s, 1H), 8.25 (s, 1H), 7.87 (d, 2H), 7.57 (d, 2H), 7.05 (d, 1H), 6.63 (d, 2H), 6.52 (d, 2H), 5.70 (s, 2H), 3.41 (m, 1H), 3.31 (m, 1H), 3.21 (m, 1H), 3.01 (m, 1H), 2.77 (m, 1H), 2.20 (s, 6H), 2.15 (m, 1H), 1.77 (m, 1H). MS (EI): 375 (MH+).

N-{4-[2-({4-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-3-(methyloxy)propanamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.19 (s, 1H), 8.40 (d, 1H), 8.10 (d, 2H), 7.75 (d, 2H), 7.58 (d, 2H), 7.23 (d, 1H), 6.54 (d, 2H), 3.63 (t, 2H), 3.41 (m, 1H), 3.25 (m, 3H), 3.21 (m, 1H), 3.01 (m, 1H), 2.77 (m, 1H), 2.59 (t, 2H), 2.52 (m, 1H) 2.20 (s, 6H), 2.13 (m, 1H), 1.79 (m, 1H). MS (EI): 461 (MH+).

1-ethyl-3-(4-{2-[(4-{4-[3-(methyloxy)propanoyl]piperazin-1-yl}phenyl)-amino]pyrimidin-4-yl}phenyl)urea: ^{1}H NMR (400 MHz, d6-DMSO): 9.35 (s, 1H), 8.76 (s, 1H), 8.41 (d, 1H), 8.04 (d, 2H), 7.68 (d, 2H), 7.54 (d, 2H), 7.23 (d, 1H), 6.95 (d, 2H), 6.26 (t, 1H), 3.59 (m, 4H), 3.56 (q, 2H), 3.23 (s, 3H), 3.14 (m, 2H), 3.07 (m, 2H), 3.01 (m, 2H), 2.61 (t, 2H), 1.06 (t, 3H). MS (EI): 504 (MH+).

3-(methyloxy)-N-(4-{2-[(4-{4-[3-(methyloxy)propanoyl]piperazin-1-yl}phenyl)-amino]pyrimidin-4-yl}phenyl)propanamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.76 (d, 2H), 7.68 (d, 2H), 7.27 (d, 1H), 6.95 (d, 2H), 3.60 (m, 8H), 3.25 (s, 3H), 3.23 (s, 3H), 3.08 (m, 2H), 3.01 (m, 2H), 2.61 (m, 4H). MS (EI): 519 (MH+).

N-{4-[2-({4-[4-(3-hydroxypropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.19 (s, 1H), 9.40 (s, 1H), 8.42 (d, 1H), 8.10 (d, 2H), 7.84 (d, 2H), 7.67 (d, 2H), 7.28 (d, 1H), 6.95 (d, 2H), 3.74

(dd, 1H), 3.66 (t, 2H), 3.62 (m, 4H), 3.09 (m, 2H), 3.03 (m, 2H), 2.91 (t, 2H), 2.52 (m, 2H), 2.05 (m, 1H), 1.79 (m, 1H), 1.66 (m, 2H). MS (EI): 516 (MH+).

N-(4-{2-[(4-{4-[3-(methyloxy)propanoyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)-D-alaninamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.40 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.82 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.95 (d, 2H), 3.59 (m, 4H), 3.57 (t, 2H), 3.46 (m, 1H), 3.23 (s, 3H), 3.07 (m, 2H), 3.02 (m, 2H), 2.61 (t, 2H), 1.24 (d, 3H). MS (EI): 504 (MH+).

N-(4-{2-[(4-{4-[3-(methyloxy)propanoyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)-D-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.11 (d, 2H), 7.83 (d, 2H), 7.66 (d, 2H), 7.28 (d, 1H), 6.95 (d, 2H), 3.75 (dd, 1H), 3.60 (m, 4H), 3.56 (t, 2H), 3.23 (s, 3H), 3.08 (m, 2H), 3.03 (m, 2H), 2.91 (t, 2H), 2.61 (t, 2H), 2.17 (m, 1H), 1.80 (m, 1H), 1.67 (m, 2H). MS (EI): 530 (MH+).

N-2-,N-2-dimethyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)glycinamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.98 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.83 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.93 (d, 2H), 3.74 (m, 4H), 3.11 (s, 2H), 3.05 (m, 4H), 2.29 (s, 6H). MS (EI): 433 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.18 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.13 (d, 2H), 7.83 (d, 2H), 7.67 (d, 2H), 7.27 (d, 1H), 6.93 (d, 2H), 3.74 (m, 4H), 3.71 (m, 1H), 3.04 (m, 4H), 2.90 (t, 2H), 2.05 (m, 1H), 1.80 (m, 1H), 1.66 (m, 2H). MS (EI): 445 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-3-phenyl-propanamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.12 (s, 1H), 9.31 (s, 1H), 8.37 (d, 1H), 8.05 (d, 2H), 7.67 (d, 2H), 7.60 (d, 2H), 7.21 (m, 5H), 7.12 (m, 1H), 6.83 (d, 2H), 3.67 (m, 4H), 2.98 (m, 4H), 2.86 (t, 2H), 2.61 (t, 2H). MS (EI): 480 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-phenyl-acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.44 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.77 (d, 2H), 7.67 (d, 2H), 7.34 (m, 4H), 7.26 (m, 2H), 6.93 (d, 2H), 3.75 (m, 4H), 3.69 (m, 2H), 3.04 (m, 4H). MS (EI): 466 (MH+).

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2-fluoro-6-iodobenzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.16 ppm (s, 1H), 8.64 ppm (t, 1H), 8.30 ppm (d, 1H), 8.06 ppm (d, 2H), 7.70 ppm (m, 3H), 7.30 ppm (m, 1H), 7.20 ppm (m,

1H), 7.13 ppm (m, 1H), 7.07 ppm (m, 1H), 3.34 ppm (m, 4H), 2.08 ppm (s, 3H), 1.83 ppm (m, 2H); MS (EI) $C_{22}H_{21}FIN_5O_2$: 533.9 (MH^+).

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,6-difluoro-benzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.78 ppm (s, 1H), 10.12 ppm (s, 1H), 9.70 ppm (s, 1H), 8.50 ppm (d, 1H), 8.39 ppm (s, 1H), 8.12 ppm (d, 2H), 7.73 ppm (d, 2H), 7.61 ppm (m, 1H), 7.47 ppm (m, 1H), 7.40 ppm (m, 1H), 7.27 ppm (m, 4H), 2.09 ppm (s, 3H); MS (EI) $C_{25}H_{19}F_2N_5O_2$: 460 (MH^+).

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,4,5-trifluoro-benzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.52 ppm (s, 1H), 10.29 ppm (s, 1H), 9.71 ppm (s, 1H), 8.50 ppm (d, 1H), 8.36 ppm (s, 1H), 8.20 ppm (d, 2H), 7.87 ppm (m, 1H), 7.75 ppm (d, 3H), 7.51 ppm (m, 1H), 7.37 ppm (d, 1H), 7.28 ppm (m, 2H), 2.09 ppm (s, 3H); MS (EI) $C_{25}H_{18}F_3N_5O_2$: 478 (MH^+).

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]benzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.27 ppm (s, 1H), 10.21 ppm (s, 1H), 9.67 ppm (s, 1H), 8.51 ppm (d, 1H), 8.47 ppm (s, 1H), 8.13 ppm (d, 2H), 8.00 ppm (m, 2H), 7.75 ppm (m, 2H), 7.58 ppm (m, 3H), 7.48 ppm (m, 1H), 7.37 ppm (d, 1H), 7.29 ppm (m, 2H), 2.09 ppm (s, 3H); MS (EI) $C_{25}H_{21}N_5O_2$: 424(MH^+).

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-3,5-difluoro-benzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.37 ppm (s, 1H), 10.20 ppm (s, 1H), 9.70 ppm (s, 1H), 8.51 ppm (d, 1H), 8.41 ppm (s,1H), 8.21 ppm (d, 2H), 7.73 ppm (m, 4H), 7.55 ppm (m, 2H), 7.37 ppm (d, 1H), 7.29 ppm (m, 2H), 2.08 ppm (s, 3H); MS (EI) $C_{25}H_{19}F_2N_5O_2$: 468.0 (MH^+).

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2-chloro-6-fluoro-4-methylbenzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.72 ppm (s, 1H), 10.20 ppm (s, 1H), 9.69 ppm (s, 1H), 8.50 ppm (d, 1H), 8.41 ppm (s,1H), 8.21 ppm (d, 2H), 7.74 ppm (d, 2H), 7.50 ppm (m, 2H), 7.37 ppm (d, 1H), 7.28 ppm (m, 8H), 2.38 ppm (s, 3H), 2.08 ppm (s, 3H); MS (EI) $C_{26}H_{21}ClFN_5O_2$: 490.0 (MH^+).

N-(4-{2-[(3-{[(2,6-dimethylphenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}-phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.20 ppm (s, 1H), 9.36 ppm (s, 1H), 8.47 ppm (d, 1H), 8.16 ppm (d, 2H), 7.72 ppm (d, 2H), 7.35 ppm (s, 1H), 7.31 ppm (d, 1H), 7.12 ppm (m, 1H), 7.07 ppm (m, 2H), 6.99 ppm (m, 3H), 6.38 ppm (d, 1H), 5.46

ppm (t, 1H), 4.14 ppm (d, 2H), 2.36 ppm (s, 6H), 2.08 ppm (s, 3H); MS (EI) $C_{27}H_{27}N_5O$: 438.1 (MH^+).

N-(3-{2-[(3-aminophenyl)amino]pyrimidin-4-yl}phenyl)thiophene-2-carboxamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.66 ppm (s, 1H), 10.28 ppm (s, br, 2H), 10.10 ppm (s, 1H), 8.74 ppm (s, 1H), 8.63 ppm (d, 1H), 8.25 ppm (m, 2H), 7.94 ppm (m, 3H), 7.75 ppm (t, 1H), 7.55 ppm (t, 1H), 7.45 ppm (m, 2H), 7.26 ppm (m, 1H), 6.97 ppm (m,1H); MS (EI) $C_{21}H_{17}N_5O_2S$: 388.0 (MH^+).

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-1-methylpiperidine-4-carboxamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 ppm (s, 1H), 9.84 ppm (s, 1H), 9.60 ppm (s, 1H), 8.49 ppm (d, 1H), 8.29 ppm (s, 1H), 8.20 ppm (d, 2H), 7.74 ppm (d, 2H), 7.36 ppm (m, 2H), 7.18 ppm (m, 2H), 2.84 ppm (m, 2H), 2.31 ppm (m, 1H), 2.17 ppm (s, 3H), 2.09 ppm (s, 3H), 1.87 ppm (m, 2H), 1.72 ppm (m, 4H); MS (EI) $C_{25}H_{28}N_5O_2$: 445 (MH^+).

4-(4-aminophenyl)-N-[3-(morpholin-4-ylsulfonyl)phenyl]pyrimidin-2-amine: ^{1}H-NMR (400MHz, d_6-DMSO): 9.94 ppm (s, 1H), 8.76 ppm (s, 1H), 8.42 ppm (d, 1H), 7.98 ppm (d, dH), 7.90 ppm (m, 1H), 7.57 ppm (t, 1H), 7.28 ppm (m, 2H), 6.65 ppm (d, 2H), 5.81 ppm (s, 2H), 3.64 ppm (m, 4H), 2.90 ppm (m, 4H); MS (EI) $C_{20}H_{21}N_5O_3S$: 412 (MH^+).

N-(4-{2-[(3-{[(2-fluorophenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 ppm (s, 1H), 9.35 ppm (s, 1H), 8.45 ppm (d, 1H), 8.12 ppm (d, 2H), 7.74 ppm (d, 2H), 7.43 ppm (m, 2H), 7.29 ppm (m, 2H), 7.16 ppm (m, 3H), 6.99 ppm (m, 2H), 6.21 ppm (m, 2H), 4.33 ppm (d, 2H), 2.09 ppm (s, 3H); MS (EI) $C_{25}H_{22}FN_5O$: 428 (MH^+).

N-(4-{2-[(3-aminophenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 ppm (s, 1H), 9.31 ppm (s, 1H), 8.46 ppm (d, 1H), 8.13 ppm (d, 2H), 7.75 ppm (d, 2H), 7.30 ppm (d, 1H), 7.13 ppm (s, 1H), 6.94 ppm (m, 2H), 6.20 ppm (d, 1H), 5.01 ppm (s, 2H), 2.10 ppm (s, 3H); MS (EI) $C_{18}H_{17}IN_5O$: 320 (MH^+).

N-(4-{2-[(3-{[(4-fluorophenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}-phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.26 ppm (s, 1H), 9.33 ppm (s, 1H), 8.45 ppm (d, 1H), 8.13 ppm (d, 2H), 7.75 ppm (d, 2H), 7.37 ppm (m, 2H), 7.31 ppm (m, 3H), 7.21 ppm (m, 2H), 6.97 ppm (m, 2H), 6.23 ppm (m, 2H), 4.48 ppm (d, 2H), 2.09 ppm (s, 3H); MS (EI) $C_{25}H_{23}N_5O$: 410 (MH^+).

N-(4-{2-[(3-{[(3-fluorophenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}-phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.36 ppm (s, 1H), 9.35 ppm (s, 1H), 8.45 ppm (d, 1H), 8.12 ppm (d, 2H), 7.76 ppm (d, 2H), 7.33 ppm (m, 2H), 7.19 ppm (m, 3H), 6.99 ppm (m, 3H), 6.32 ppm (t, 1H), 6.20 ppm (m, 2H), 4.30 ppm (d, 2H), 2.09 ppm (s, 3H); MS (EI) $C_{25}H_{22}FN_5O$: 428 (MH^+).

N-(4-{2-[(3-{[(4-fluorophenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}-phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.20 ppm (s, 1H), 9.33 ppm (s, 1H), 8.45 ppm (d, 1H), 8.12 ppm (d, 2H), 7.74 ppm (d, 2H), 7.39 ppm (m, 2H), 7.30 ppm (d, 1H), 7.21 ppm (s, 1H), 7.13 ppm (t, 2H), 6.96 ppm (m, 2H), 6.22 ppm (m, 2H), 2.09 ppm (s, 3H); MS (EI) $C_{25}H_{22}FN_5O$: 428 (MH^+).

4-[4-({4-[4-(butanoylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-N-ethyl-piperazine-1-carboxamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 ppm (s, 1H), 9.39 ppm (s, 1H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.77 ppm (d, 2H), 7.68 ppm (d, 2H), 7.28 ppm (d, 1H), 6.96 ppm (d, 2H), 6.59 ppm (t, 1H), 3.43 ppm (t, 4H), 3.07 ppm (m, 2H), 3.02 ppm (t, 4H), 2.34 ppm (t, 2H), 1.63 ppm (m, 2H), 1.02 ppm (t, 3H), 0.98 ppm (t, 3H); MS (EI) $C_{27}H_{33}N_7O_2$: 488 (MH^+).

N-{4-[2-({4-[4-(2-piperazin-1-ylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}butanamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.18 ppm (s, 1H), 9.40 ppm (s, 1H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.77 ppm (d, 2H), 7.68 ppm (d, 2H), 7.28 ppm (d, 1H), 6.97 ppm (d, 2H), 3.72 ppm (m, 2H), 3.59 ppm (m, 2H), 3.13 ppm (m, 4H), 3.01 ppm (m, 2H), 2.67 ppm (m, 4H), 2.33 ppm (m, 4H), 1.63 ppm (m, 2H), 0.93 ppm (t, 3H); MS (EI) $C_{30}H_{38}N_8O_2$: 543 (MH^+).

N-[4-(2-{[4-(4-L-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-butanamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.15 ppm (s, 1H), 9.40 ppm (s, 1H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.76 ppm (d, 2H), 7.69 ppm (d, 2H), 7.28 ppm (d, 1H), 6.97 ppm (d, 2H), 3.79 ppm (m, 1H), 3.62 ppm (m, 4H), 3.06 ppm (m, 4H), 2.33 ppm (t, 2H), 1.91 ppm (br. s, 2H), 1.63 ppm (m, 2H), 1.09 ppm (d, 3H), 0.93 ppm (t, 3H); MS (EI) $C_{27}H_{33}N_7O_2$: 488 (MH^+).

N-[4-(2-{[4-(4-L-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-butanamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 ppm (s, 1H), 9.41 ppm (s, 1H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.77 ppm (d, 2H), 7.69 ppm (d, 2H), 7.28 ppm (d, 1H), 6.97 ppm (d, 2H), 3.85 ppm (m, 1H), 3.62 ppm (m, 4H), 3.04 ppm (m, 5H), 2.62 ppm (m,

1H), 2.34 ppm (t, 2H), 2.00 ppm (m, 1H), 1.62 ppm (m, 6H), 0.93 ppm (t, 3H); MS (EI) $C_{29}H_{35}N_7O_2$: 514 (MH^+).

(3R)-1-(2-hydroxyethyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyrrolidine-3-carboxamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 ppm (s, 1H), 9.38 ppm (s, 1H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.76 ppm (d, 2H), 7.67 ppm (d, 2H), 7.28 ppm (d, 1H), 6.94 ppm (d, 2H), 4.50 ppm (m, 1H), 3.75 ppm (m, 4H), 3.49 ppm (m, 2H), 3.05 ppm (m, 6H), 2.91 ppm (t, 1H), 2.67 ppm (m, 1H), 2.56 ppm (m, 3H), 1.98 ppm (m, 2H); MS (EI) $C_{27}H_{32}N_6O_3$: 489 (MH^+).

N-(4-{2-[(3-fluoro-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-prolinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 ppm (s, 1H), 9.69 ppm (s, 1H), 8.51 ppm (d, 1H), 8.13 ppm (d, 2H), 7.85 ppm (d, 2H), 7.79 ppm (m, 1H), 7.52 ppm (m, 1H), 7.37 ppm (d, 1H), 7.03 ppm (t, 1H), 3.74 ppm (m, 5H), 3.14 ppm (br.s, 1H), 2.95 ppm (m, 4H), 2.91 ppm (m, 2H), 2.06 ppm (m, 1H), 1.80 ppm (m, 1H), 1.66 ppm (m, 2H); MS (EI) $C_{25}H_{27}FN_6O_2$: 463 (MH^+).

N-(4-{2-[(3-fluoro-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-alaninamide: ^{1}H-NMR (400MHz, d_6-DMSO): 9.69 ppm (s, 1H), 8.51 ppm (d, 1H), 8.13 ppm (d, 2H), 7.84 ppm (d, 2H), 7.79 ppm (m, 1H), 7.54 ppm (m, 1H), 7.37 ppm (m, 1H), 7.37 ppm (m, 1H), 7.03 ppm (t, 1H), 3.74 ppm (m, 4H), 3.47 ppm (m, 1H), 2.95 ppm (m, 4H), 1.23 ppm (d, 3H); MS (EI) $C_{23}H_{25}FN_6O_2$: 437 (MH^+).

N-(4-{2-[(3-methyl-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-prolinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 ppm (s, 1H), 9.45 ppm (s, 1H), 8.46 ppm (d, 1H), 8.14 ppm (d, 2H), 7.85 ppm (d, 2H), 7.63 ppm (d, 2H), 7.32 ppm (d, 1H), 7.32 ppm (d, 1H), 3.73 ppm (m, 5H), 3.08 ppm (br.s., 1H), 2.90 ppm (t, 2H), 2.80 ppm (m, 4H), 2.27 ppm (s, 3H), 2.06 ppm (m, 1H), 1.80 ppm (m, 1H), 1.66 ppm (m, 2H); MS (EI) $C_{26}H_{30}N_6O_2$: 459 (MH^+).

N-(4-{2-[(3-methyl-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-alaninamide: ^{1}H-NMR (400MHz, d_6-DMSO): 9.44 ppm (s, 1H), 8.47 ppm (d, 1H), 8.14 ppm (d, 2H), 7.83 ppm (d, 2H), 7.64 ppm (m, 2H), 7.32 ppm (d, 1H), 7.02 ppm (m, 1H), 3.73 ppm (m, 4H), 3.46 ppm (m, 1H), 2.80 ppm (m, 4H), 2.28 ppm (m, 4H), 1.23 ppm (d, 3H); MS (EI) $C_{24}H_{28}N_6O_2$: 433 (MH^+).

1-hydroxy-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-cyclopropanecarboxamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.14 ppm (s, 1H), 9.39

ppm (s, 1H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.94 ppm (d, 2H), 7.68 ppm (d, 2H), 7.29 ppm (d, 1H), 6.94 ppm (d, 2H), 6.81 ppm (s, 1H), 3.74 ppm (m, 4H), 3.05 ppm (m., 4H), 1.18 ppm (m, 2H), 1.00 ppm (m, 2H); MS (EI) $C_{24}H_{25}N_5O_3$: 432 (MH^+).

N-(4-(2-(4-(4-(4-chloro-2,6-dimethylphenylsulfonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.42 (s, 1H), 8.41 (m, 1H), 8.08 (d, 2H), 7.77 (s, 1H), 7.71 (d, 2H), 7.64 (m, 2H), 7.57 (s, 1H), 7.27 (m, 1H), 6.93 (m, 2H), 3.41 (m, 4H), 3.15 (m, 4H), 2.53 (s, 3H), 2.37 (s, 3H), 2.06 (s, 3H). MS (EI): 591 (MH+).

N-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.31 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.96 (d, 2H), 3.96 (t, 1H), 3.75 (m, 5H), 3.60 (m, 2H), 3.32 (m, 1H), 3.19 (m, 1H), 3.12 (s, 2H), 3.10 (m, 2H), 3.01 (m, 2H), 2.68 (m, 4H), 2.32 (m, 4H), 2.10 (m, 2H). MS (EI): 571 (MH+).

N-(4-(2-(4-(4-pivaloylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-tetrahydrofuran-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.30 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.95 (d, 2H), 3.96 (t, 1H), 3.74 (m, 6H), 3.19 (m, 2H), 3.05 (m, 4H), 2.10 (q, 2H), 1.23 (s, 9H). MS (EI): 529 (MH+).

1-ethyl-3-(4-(5-methyl-2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)urea: ^{1}H NMR (400 MHz, d6-DMSO): 9.24 (s, 1H), 8.87 (s, 1H), 8.29 (s, 1H), 7.64 (d, 2H), 7.59 (m, 2H), 7.53 (m, 2H), 6.88 (d, 2H), 6.41 (m, 1H), 3.73 (m, 4H), 3.12 (m, 2H), 3.02 (m, 4H), 2.23 (s, 3H), 1.06 (t, 3H). MS (EI): 433 (MH+).

3-methoxy-N-(4-(5-methyl-2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.17 (s, 1H), 9.30 (s, 1H), 8.31 (s, 1H), 7.74 (m, 2H), 7.66 (m, 4H), 6.90 (m, 2H), 3.74 (m, 4H), 3.64 (t, 2H), 3.26 (s, 3H), 3.03 (m, 4H), 2.59 (m, 2H), 2.22 (s, 3H). MS (EI): 448 (MH+).

N-(4-(2-(4-(4-(ethylsulfonyl)piperazine-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.38 (s, 1H), 8.42 (d, 1H), 8.08 (d, 2H), 7.72 (d, 2H), 7.66 (d, 2H), 7.26 (d, 1H), 6.95 (d, 2H), 3.36 (m, 4H), 3.12 (m, 4H), 2.48 (m, 2H), 2.07 (s, 3H), 1.22 (t, 3H). MS (EI): 481 (MH+).

4-(4-(4-(4-acetamidophenyl)pyrimidin-2-ylamino)phenyl)-N-ethylpiperazine-1-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.41 (d, 1H), 8.08 (d, 2H), 7.72 (d, 2H), 7.64 (d, 2H), 7.25 (d, 1H), 6.94 (d, 2H), 6.57 (d, 1H), 3.50 (m, 2H), 3.39 (m, 4H), 2.99 (m, 4H), 2.07 (s, 3H), 1.00 (t, 3H). MS (EI): 460 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)morpholine-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.87 (s, 1H), 9.37 (s, 1H), 8.43 (s, 1H), 8.04-8.16 (d, 2H), 7.81-7.93 (d, 2H), 7.60-7.72 (d, 2H), 7.27 (s,1H), 6.85-6.99 (d, 2H), 4.08-4.69 (s, br, 1H), 4.00-4.07 (d, 1H), 3.85-3.94 (d, 1H), 3.72 (s, 3H), 3.51-3.63 (d, 1H), 2.58-2.80 (m, 3H), 1.86 (s, 6H). MS (EI): 461 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-beta-alaninamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.38 (s, 1H), 10.65 (d, 1H), 8.07-8.16 (d, 2H), 7.72-7.81 (d, 2H), 7.62-7.72 (d,2H), 7.28 (s, 1H), 6.89-6.98 (d, 2H). MS (EI): 419 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)phenylalaninamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.39 (s, 1H), 8.42-8.46 (d, 1H), 8.09-8.14 (d, 2H), 7.75-7.81 (d, 2H), 7.64-7.70 (d, 2H), 7.23-7.32 (m, 6H), 7.16-7.22 (m, 2H), 6.90-6.97 (d, 2H), 3.71-3.78 (m, 4H), 3.57-3.63 (m, 1H), 3.02-3.08 (m, 4H), 2.98-3.02 (m, 1H), 2.71-2.79 (m, 1H). MS (EI): 495 (MH+).

N^2-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-glycinamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.39 (s, 1H), 8.45 (s, 1H), 8.09-8.17 (d, 2H), 7.78-7.86 (d, 2H), 7.65-7.73 (d, 2H), 7.29 (s, 1H), 6.90-7.00 (d, 2H), 3.74 (s, 4H), 3.05 (s, 4H), 2.33 (s, 3H), 1.92 (s, 1H). MS (EI):419 (MH+).

2-cyclopentyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.13 (s, 1H), 9.37 (s, 1H), 8.42-8.45 (d, 1H), 8.07-8.14 (d, 2H), 7.73-7.79 (d, 2H), 7.65-7.71 (d, 2H), 7.25-7.28 (d, 1H), 6.90-6.97 (d, 2H), 3.71-3.77 (m, 4H), 3.02-3.07 (m, 4H), 2.33-2.37 (d, 2H), 2.20-2.30 (m, 1H), 1.71-1.82 (m, 2H), 1.48-1.66 (m, 4H), 1.14-1.25 (m, 2H). MS (EI): 458 (MH+).

6-(methyloxy)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)pyridine-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.50 (s, 1H), 9.44 (s, 1H), 8.80-8.83 (d, 1H), 8.44-8.49 (d, 1H), 8.24-8.28 (m, 1H), 8.15-8.21 (d, 2H), 7.92-7.97 (d, 2H), 7.67-7.72 (d, 2H), 7.30-7.34 (d, 1H), 6.93-7.02 (m, 3H), 3.94-3.96 (s, 3H), 3.72-3.79 (m, 4H), 3.04-3.11 (m, 4H). MS (EI): 483 (MH+).

N,N-dimethyl-N'-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)butanediamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.36 (s, 1H), 8.43 (s, 1H), 8.05-8.17 (d, 2H), 7.71-7.79 (d, 2H), 7.61-7.71 (d, 2H), 7.26-7.31 (d, 1H), 6.89-7.00 (d, 2H), 3.68-3.79 (m, 4H), 3.02-3.08 (m, 4H), 3.00 (s, 3H), 2.82 (s, 3H), 2.56-2.66 (m, 4H). MS (EI): 475 (MH+).

N-[4-(2-{[4-morpholin-4-yl-3-(trifluoromethyl)phenyl]amino} pyrimidin-4-yl)-phenyl]-D-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.31 (s, 1H), 9.94 (s, 1H), 8.53-8.57 (d, 1H), 8.48 (s, 1H), 8.14-8.21 (d, 2H), 7.93-7.98 (m, 1H), 7.82-7.88 (d, 2H), 7.56-7.61 (d, 1H), 7.42-7.46 (d, 1H), 3.79-3.86 (m, 1H), 3.67-3.75 (m, 4H), 2.93-3.00 (m, 2H), 2.79-2.86 (m, 4H), 2.05-2.17 (m, 1H), 1.79-1.89 (m, 1H), 1.65-1.75 (m, 2H). MS (EI): 513 (MH+).

3-(methyloxy)-N-[4-(2-{[4-morpholin-4-yl-3-(trifluoromethyl)phenyl]amino}-pyrimidin-4-yl)phenyl]propanamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.24 (s, 1H), 9.94 (s, 1H), 8.53-8.56 (d, 1H), 8.47 (s, 1H), 8.13-8.19 (d, 2H), 7.94-8.00 (d, 1H), 7.76-7.81 (d, 1H), 7.56-7.62 (d, 1H), 7.41-7.45 (d, 1H), 3.67-3.74 (m, 4H), 3.60-3.67 (m, 2H), 3.35 (s, 3H), 2.80-2.86 (d, 4H), 2.57-2.63 (m, 2H). MS (EI): 502 (MH+).

N-(4-{2-[(4-{4-[3-(dimethylamino)-2,2-dimethylpropyl]piperazin-1-yl}phenyl)-amino]pyrimidin-4-yl}phenyl)-5-oxo-L-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.34 (s, 1H), 9.37 (s, 1H), 8.43-8.46 (d, 1H), 8.12-8.16 (d, 2H), 7.94 (s, 1H), 7.77-7.81 (d, 2H), 7.62-7.67 (d, 2H), 7.26-7.30 (d, 1H), 6.88-6.94 (d, 2H), 4.20-4.26 (m, 1H), 3.02-3.08 (m, 4H), 2.57-2.64 (m, 4H), 2.21 (s, 6H), 2.17 (s, 2H), 2.10 (s, 2H), 1.89 (s, 4H), 0.84 (s, 6H). MS (EI): 571 (MH+).

(2R)-N-(4-{2-[(4-{4-[3-(methyloxy)propanoyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)tetrahydrofuran-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.94 (s, 1H), 9.41 (s, 1H), 8.43-8.46 (d, 1H), 8.09-8.15 (d, 2H), 7.85-7.90 (d, 2H), 7.65-7.71 (d, 1H), 6.92-6.98 (d, 2H), 4.39-4.48 (m, 1H), 3.95-4.05 (m, 1H), 3.79-3.89 (m, 1H), 3.52-3.64 (m, 6H), 3.32 (s, 1H), 3.23 (s, 2H), 2.98-3.11 (m, 4H), 2.58-2.65 (m, 2H), 2.15-2.25 (m, 1H), 1.96-2.07 (m, 1H), 1.83-1.93 (m, 2H). MS (EI): 531 (MH+).

(2S)-N-(4-{2-[(4-{4-[3-(methyloxy)propanoyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)tetrahydrofuran-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.94 (s, 1H0, 9.41 (s, 1H), 8.42-8.47 (d, 2H), 8.09-8.16 (d, 2H), 7.84-7.91 (d, 2H), 7.64-7.72 (d, 2H), 7.27-7.37 (d, 1H), 6.93-6.99 (d, 2H), 4.40-4.47 (m, 1H), 3.95-4.05

(m, 1H), 3.80-3.89 (m, 1H), 3.53-3.65 (m, 6H), 3.32 (s, 1H), 3.23 (s, 2H), 2.98-3.10 (m, 4H), 2.59-2.65 (m, 2H), 2.15-2.27 (m, 1H), 1.95-2.07 (m, 1H), 1.83-1.93 (m, 2H). MS (EI): 531 (MH+).

(2R,4S)-4-hydroxy-N-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.42-8.46 (d, 1H), 8.09-8.15 (d, 2H), 7.80-7.86 (d, 2H), 7.65-7.71 (d, 2H), 7.27-7.31 (d, 1H), 6.93-6.98 (d, 1H), 4.20-4.26 (m, 1H), 3.88-3.94 (m, 1H), 3.53-3.64 (m, 6H), 3.17 (s, 1H), 2.99-3.10 (m, 4H), 2.89-2.93 (m, 1H), 2.77-2.84 (m, 1H), 2.58-2.64 (m, 3H), 1.99-2.07 (m, 2H), 1.73-1.83 (m, 2H). MS (EI): 546 (MH+).

N-(4-{2-[(3-fluoro-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.07 (s, 1H), 9.89 (s, 1H), 8.46-8.56 (d, 1H), 8.08-8.21 (d, 2H), 7.74-7.91 (m, 3H), 7.47-7.57 (d, 1H), 7.35-7.41 (d, 1H), 6.98-7.08 (m, 1H), 3.70-3.82 (m, 5H), 2.87-3.03 (m, 5H), 2.01-2.16 (m, 1H), 1.92 (s, 2H), 1.75-1.87 (m, 1H), 1.61-1.74 (m, 2H). MS (EI): 463 (MH+).

N-(4-{2-[(4-{4-[3-(methyloxy)propanoyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)tetrahydrofuran-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.30 (s, 1H), 9.40 (s, 1H), 8.42-8.47 (d, 1H), 8.09-8.15 (d, 2H), 7.74-7.80 (d, 2H), 7.64-7.71 (d, 2H), 7.27-7.30 (d, 1H), 6.92-7.00 (d, 2H), 3.92-3.99 (m, 1H), 3.68-3.84 (m, 4H), 3.53-3.64 (m, 5H), 3.32 (s, 1H), 3.23 (s, 2H), 3.16-3.22 (m, 1H), 2.98-3.10 (m, 4H), 2.59-2.65 (m, 1H), 2.06-2.15 (m, 2H). MS (EI): 531 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-3-pyridin-3-ylpropanamide: ^{1}H NMR (400 MHz, d6-DMSO):10.21 (s, 1H), 9.37 (s, 1H), 8.39-8.51 (m, 3H), 8.08-8.13 (d, 2H), 7.64-7.76 (m, 5H), 7.25-7.35 (m, 2H), 6.91-6.98 (d, 2H), 3.72-3.77 (m, 4H), 3.01-3.08 (m, 4H), 2.91-2.98 (m, 2H), 2.65-2.75 (m, 2H). MS (EI): 481 (MH+).

N-(3-(4-(4-acetamidophenyl)pyrimidin-2-ylamino)phenyl)-2-chlorobenzamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.497(s, 1H), 10.201 (s, 1H), 9.668 (s, 1H), 8.505 (d, 1H), 8.505 (d, 1H), 8.427 (s, 1H), 8.223 (d, 2H), 7.748 (d, 2H), 7.59 (m, 2H), 7.477 (m, 3H), 7.374 (d, 1H), 7.253 (m, 2H), 2.083 (s, 3H). MS (EI): 458 (MH+).

N-(3-(4-(4-acetamidophenyl)pyrimidin-2-ylamino)phenyl)-2-methylbenzamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.284(d, 2H), 9.622 (s, 1H),

8.487(m, 2H), 8.235(d, 2H), 7.749 (d, 2H), 7.352(m, 8H), 2.084(s, 3H). MS (EI): 438 (MH+).

N-(3-(4-(4-acetamidophenyl)pyrimidin-2-ylamino)phenyl)-2,4-dichlorobenzamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.533 (s, 1H), 10.198(s, 1H), 9.687(s, 1H), 8.506(d, 1H), 8.406(s, br, 1H), 8.220(d, 2H), 7.787(d, 1H), 7.747(d, 2H), 7.659(d, 1H), 7.591(d, 1H), 7.464 (d, 1H), 7.377(d, 1H), 7.247(m, 2H), 2.085(s, 3H). MS (EI): 492 (MH+).

N-(3-(4-(4-acetamidophenyl)pyrimidin-2-ylamino)phenyl)-2,5-dichlorobenzamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.510(s, 1H), 10.198(s, 1H), 9.696(s, 1H), 8.507(s, 1H), 8.389(s, 1H), 8.220(d, 2H), 7.744(m, 3H), 7.617(m, 2H), 7.487(d, 1H), 7.379(d, 1H), 7.282(m, 2H), 2.081(s, 3H). MS (EI): 492 (MH+).

N-(3-(4-(4-acetamidophenyl)pyrimidin-2-ylamino)phenyl)-2-chloro-6-fluoro-3-methoxybenzamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.726(s, 1H), 10.204(s, 1H), 9.709(s, 1H), 8.509(d, 1H), 8.402(s, 1H), 8.217(d, 2H), 7.743(d, 2H), 7.488(d, 1H), 7.386(m, 2H), 7.282(m, 2H), 7.221(d, 1H), 3.904(s, 3H), 2.082(s, 3H). MS (EI): 506 (MH+).

N-(3-(4-(4-acetamidophenyl)pyrimidin-2-ylamino)phenyl)-2,3-dichlorobenzamide: ^{1}H-NMR(400MHz, d6-DMSO): 10.6 (s,1H), 10.2(s, 1H), 9.7(s, 1H), 8.5(d, 1H), 8.4(s, 1H), 8.2(d, 2H), 7.8(m, 3H), 7.6(d, 1H), 7.5(m, 2H), 7.4(d, 1H), 7.2(m, 2H), 2.081(s,3H). MS (EI): 492 (MH+).

(R)-N-(4-(2-(4-(4-(pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)-pyrimidin-4-yl) phenyl)cyclopropanecarboxamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.476(s, 1H), 9.406(s, 1H), 8.448(d, 1H), 8.124(d, 2H), 7.767(m, 4H), 7.287(d, 1H), 6.977(d, 2H), 3.85(m, 1H), 3.65(m, 4H), 3.0(m, 4H), 2.95(m, 1H), 2.6(m, 1H), 2.0(m, 1H), 1.8(m, 1H), 1.613(m, 3H), 0.84(m, 4H). MS (EI): 512 (MH+).

N-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.480(s, 1H), 9.399(s,1H), 8.447(d, 1H), 8.124(d, 2H), 7.769(d, 2H), 7.692(d, 2H), 7.285(d, 1H), 6.975(d, 2H), 3.170(m, 2H), 3.592(m, 2H), 3.134(s, 2H), 3.099(m, 2H), 3.028(m, 2H), 2.694(m, 4H), 2.331(m, 4H), 0.842(m, 4H). MS (EI): 541 (MH+).

4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.5(s, 1H), 8.5(d, 1H), 8.2(d, 2H), 8.15(s, 1H), 8(d, 2H), 7.7(d, 1h), 7.5(s, 1H), 7.4(d, 1H), 6.9(d, 1H), 4.8(m, 4h), 3.0(m, 4H). MS (EI): 376 (MH+).

(R)-N-(4-(2-(4-(4-(pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide: ^{1}H-NMR (400MHz, d6-MeOD): 8.355(d, 1H), 8.114(d, 2H), 7.177(d, 2H), 7.639(d, 2H), 7.217(d, 1H), 7.028(d, 2H), 4.394(m, 1H), 3.797 (m, 2H), 3.692(m, 2H), 3.137(m, 4H), 3.1(m, 1H), 2.410(m, 1H), 1.992(m, 2H), 1.827(m, 2H), 0.981(m, 2H), 0.85(m, 2H). MS (EI): 512 (MH+).

(S)-N-(4-(2-(4-(4-(2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide: ^{1}H-NMR (400MHz, MeOD): 8.357(d, 1H), 8.116(d, 2H), 7.718(d, 2H), 7.642(d, 2H), 7.221(d, 1H), 7.033(d, 2H), 4.1(m, 1H), 3.85(m, 1H), 3.7(m, 4H), 3.2(m, 4H), 1.8(m, 1H), 1.4(d, 3H), 0.9(m, 2H), 0.85(m, 2H). MS (EI): 486 (MH+).

(R)-N-(4-(2-(4-(4-(2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide: ^{1}H-NMR (400MHz, MeOD): 8.4(d, 1H), 8.15(d, 2H), 7.8(d, 2H0, 7.6(d, 2H), 7.2(d,1H), 7.0(d, 2H), 4.0(m, 1H), 3.7(m, 4H), 3.2(m, 4H), 1.8(m, 1H), 1.3(d, 3H), 0.9(m, 2H), 0.85(m, 2H). MS (EI): 486 (MH+).

(R)-N-(4-(2-(4-(4-acetylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-pyrrolidine-2-carboxamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.193(s, 1H), 9.411(s, 1H), 8.452-8.439(d, 1H), 8.136-8.144(d, 2H), 7.849-7.828 ((d, 2H), 7.690-7.688(d, 2H), 7.302-7.289(d, 1H), 6.971-6.948(d, 2H), 3.743(m, 1H), 3.588(m, 4H), 3.085-3.016(m, 4H), 2.905(t, 2H), 2.046(s, 3H), 1.808(m, 1H), 1.663(m, 2H). MS (EI): 486 (MH+).

(R)-N-(4-(2-(4-(4-(2-methoxyacetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.198(s, 1H), 9.414(s, 1H), 8.452(d, 1H), 8.136(d, 2H), 7.850(d, 2H), 7.691(d, 2H), 7.302(d, 1H), 6.970(d, 2H), 4.136(s, 2H), 3.744(m, 1H), 3.599-3.535(m, 4H), 3.302(s, 3H), 3.078(m, 4H), 2.905(t, 2H), 2.079(m, 1H), 1.791(m, 1H), 1.646((m, 2H). MS (EI): 516 (MH+).

N-{1-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]pyrrolidin-3-yl}acetamide: NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.20 (s, 1H), 8.60 (s, 1H), 8.15-8.20 (m, 3H), 7.79-7.86 (m, 4H), 7.20 (s, 1H), 6.58 (d, 2H), 4.39 (m, 1H), 3.43 (m,

1H), 3.23 (m, 1H), 3.10 (m, 1H), 2.18 (m, 1H), 2.07 (s, 3H), 1.85 (m, 1H), 1.80 (s, 3H). MS (EI): 431 (MH+).

N-[4-(2-{[4-(3-oxopiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide: NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.41 (s, 1H), 8.06 (d, 2H), 8.02 (s, 1H), 7.65 – 7.80 (m, 4H), 7.25 (s, 1H), 6.97 (d, 2H), 3.64 (s, 2H), 3.35 – 3.40 (m, 4H), 2.05 (s, 3H). MS (EI): 403 (MH+).

ethyl N-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-N-methylglycinate: MS (EI): 420 (MH+).

ethyl 1-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]piperidine-3-carboxylate: NMR (400 MHz, d6-DMSO): 10.40 (s, 1H), 10.00 (s, 2H), 8.65 (d, 1H), 8.14 (d, 2H), 7.78 (d, 2H), 7.50 – 7.62 (m, 4H), 7.40 (d, 1H), 2.09 (s, 3H), 2.00 (s, 3H). MS (EI): 362 (MH+).

ethyl 1-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]piperidine-3-carboxylate: MS (EI): 460 (MH+).

N-(4-{2-[(4-{bis[2-(methyloxy)ethyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: MS (EI) for $C_{24}H_{29}N_5O_3$: 436 (MH+).

N-[4-(2-{[4-(morpholin-4-ylsulfonyl)phenyl]amino}pyrimidin-4-yl)phenyl]-acetamide: MS (EI) for $C_{22}H_{23}N_5O_4S$: 454 (MH+).

3-hydroxy-3-methyl-N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}-pyrimidin-4-yl)phenyl]butanamide: NMR (400 MHz, d6-DMSO): 10.04 (s, 1H), 9.46 (s, 1H), 8.45 (d, 1H), 8.11 (d, 2H), 7.75 (d, 2H), 7.65 (s, 1H), 7.29 (d, 1H), 6.91 (d, 1H), 3.79 (s, 3H), 3.68 (m, 4H), 2.89 (m, 4H), 2.44 (s, 2H), 1.23 (s, 6H). MS (EI) for $C_{26}H_{31}N_5O_4$: 478 (MH+).

1-methyl-N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]-D-prolinamide: NMR (400 MHz, d6-DMSO): 10.0 (s, 1H), 9.44 (s, 1H), 8.42 (d, 1H), 8.18 (d, 2H), 7.82 (d, 2H), 7.62 (s, 1H), 7.30 (m, 2H), 6.81 (d, 1H), 3.80 (s, 3H), 3.68 (m, 4H), 2.85 – 3.10 (m, 6H), 2.37 – 2.48 (m, 5H), 2.20 (m, 1H), 1.80 (m, 2H). MS (EI) for $C_{27}H_{32}N_6O_3$: 489 (MH+).

N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]-D-alaninamide: NMR (400 MHz, d6-DMSO): 11.40 (s, 1H), 10.10 (s, 1H), 8.57 (d, 1H), 8.45(d, 2H), 8.02 (d, 2H), 7.87 (m, 3H), 7.47 (m, 2H), 4.15 (m, 1H), 3.95 – 4.10 (m, 7H), 3.58 (m, 4H), 1.48 (d, 3H). MS (EI) for $C_{24}H_{28}N_6O_3$: 449 (MH+).

N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]-cyclopropanecarboxamide: NMR (400 MHz, d6-DMSO): 10.45 (s, 1H), 9.43 (s, 1H), 8.42 (d, 1H), 8.17 (d, 2H), 7.75 (d, 2H), 7.64 (s, 1H), 7.15 (m, 2H), 6.84 (d, 1H), 3.80 (s, 3H), 3.75 (m, 4H), 2.96 (m, 4H), 2.52 (m, 2H), 0.80 (m, 2H). MS (EI) for $C_{25}H27N_5O_3$: 446 (MH+).

N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]-butanamide: NMR (400 MHz, d6-DMSO): 10.18 (s, 1H), 9.43 (s, 1H), 8.44 (d, 1H), 8.17 (m, 2H), 7.75 (d, 2H), 7.64 (s, 1H), 7.25 (m, 2H), 6.84 (d, 1H), 3.80 (s, 3H), 3.75 (m, 4H), 2.96 (m, 4H), 2.35 (q, 2H), 1,62 (m, 2H), 0.92 (q, 3H). MS (EI) for $C_{25}H_{29}N_5O_3$: 448 (MH+).

N-(4-{2-[(4-{4-[3-(methyloxy)propanoyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)butanamide: NMR (400 MHz, d6-DMSO): 10.18 (s, 1H), 9.40 (s, 1H), 8.41 (d, 1H), 8.17 (d, 2H), 7.78 (d, 2H), 7.68 (d, 2H), 7.24 (s, 1H), 6.94 (d, 2H), 3.60 (m, 6H), 3.21 (s, 3H), 3.0 – 3.09 (m, 4H), 2.60 (q, 2H), 2.35 (m, 2H), 1,60 (m, 2H), 0.95 (q, 3H). MS (EI) for $C_{28}H_{34}N_6O_3$: 503 (MH+).

O-methyl-N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]-L-serinamide: NMR (400 MHz, d6-DMSO): 11.60 (s, 1H), 10.1 (s, 1H), 8.60 (s, 1H), 8.55 (m, 2H), 8.20 (m, 2H), 7.98 (s, 1H), 7.90 (d, 2H), 7.80 (s, 1H), 7.48 (m, 2H), 4.35 (m, 1H), 4.04 (m, 5H), 3.98 (s, 3H), 3.85 (m, 4H), 3.60 (m, 4H). MS (EI) for $C_{25}H_{30}N_6O_4$: 479 (MH+).

N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]-D-prolinamide: NMR (400 MHz, d6-DMSO): 11.57 (s, 1H), 10.25 (br, 1H), 10.06 (s, 1H), 8.76 (br, 1H), 8.60 (d, 1H), 8.22 (d, 2H), 8.05 (s, 1H), 7.87 (m, 3H), 7.50 (m, 2H), 4.18 – 4.52 (m, 5H), 4.08 (m, 2H), 3.99 (s, 3H), 3.62 (m, 4H), 3.30 (m, 2H), 1.95 (m, 2H). MS (EI) for $C_{26}H_{30}N_6O_3$: 475 (MH+).

N-(4-{2-[(4-{4-[3-(methyloxy)propanoyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)cyclopropanecarboxamide: NMR (400 MHz, d6-DMSO): 10.45 (s, 1H), 9.40 (s, 1H), 8.41 (s, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.98 (d, 2H), 3.60 (m, 6H), 3.22 (s, 3H), 3.0 – 3.11 (m, 4H), 6.62 (q, 2H), 0.82 (m, (4H). MS (EI) for $C_{28}H_{32}N_6O_3$: 501 (MH+).

N-{4-[2-({4-[4-(Piperidin-4-ylcarbonyl)piperazin-1-yl]phenyl}amino)-pyrimidin-4-yl]phenyl}-D-prolinamide: ^{1}H NMR (400 MHz, d_6-DMSO): 11.40 (s, 1H),

10.0 (m, 1H), 9.96 (s, 1H), 9.11 (br d, 1H), 8.7-8.8 (m, 2H), 8.55 (d, 1H), 8.20 (d, 2H), 7.87 (m, 4H), 7.59 (br s, 2H), 7.45 (d, 1H), 4.48 (m, 1H), 3.4-3.5 (m, 4H), 3.25-3.30 (m, 4H) 3.0-3.1 (m, 1H), 2.9-3.0 (m, 2H), 2.4-2.5 (m, 1H), 1.9-2.0 (m, 3H), 1.7-1.9 (m, 4H); MS (EI) for $C_{31}H_{38}N_8O_2$: 555 (MH^+).

3-(Methyloxy)-N-{4-[2-({4-[4-(piperidin-4-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}propanamide: ^{1}H NMR (400 MHz, d_6-DMSO): 10.49 (s, 1H), 9.93 (s, 1H), 9.07 (m, 1H), 8.72 (m, 1H), 8.50 (d, 1H), 8.13 (d, 2H), 7.85 (d, 2H), 7.79 (d, 2H), 7.56 (br s, 2H), 7.42 (d, 1H), 3.61 (t, 2H), 3.3-3.5 (m, 4H), 3.2-3.30 (m, 5H) 3.0-3.1 (m, 1H), 2.85-3.0 (m, 2H), 2.59 (t, 2H), 1.7-1.9 (m, 4H); MS (EI) for $C_{30}H_{37}N_7O_3$: 544 (MH^+).

1-Ethyl-3-{4-[2-({4-[4-(piperidin-4-ylcarbonyl)piperazin-1-yl]phenyl}amino)-pyrimidin-4-yl]phenyl}urea: ^{1}H NMR (400 MHz, d_6-DMSO): 9.96 (s, 1H), 9.20 (s, 1H), 8.93 (m, 1H), 8.65 (m, 1H), 8.46 (d, 1H), 8.09 (d, 2H), 7.79 (m, 2H), 7.58 (d, 2H), 7.41 (m, 3H), 6.51 (br s, 1H), 3.2-3.4 (m, 6H), 3.13 (q, 2H) 3.0-3.1 (m, 1H), 2.9-3.0 (m, 2H), 1.7-1.9 (m, 4H), 1.06 (t, 3H); MS (EI) for $C_{29}H_{36}N_8O_2$: 529 (MH^+).

N-(4-{2-[(4-{4-[3-(Dimethylamino)-2,2-dimethylpropanoyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d_6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.28 (d, 1H), 6.96 (d, 2H), 6.57 (br s, 1H), 3.70 (m, 4H), 3.07 (m, 4H) 2.60 (br s, 2H), 2.28 (br s, 6H), 2.09 (s, 3H), 1.23 (s, 6H); MS (EI) for $C_{29}H_{37}N_7O_2$: 516 (MH^+).

2-(Methyloxy)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-ethanesulfonamide: ^{1}H NMR (400 MHz, d_6-DMSO): 9.39 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.67 (d, 2H), 7.31 (d, 2H), 7.26 (d, 1H), 6.94 (d, 2H), 3.74 (m, 4H), 3.67 (t, 2H) 3.43 (t, 2H), 3.18 (s, 3H), 3.05 (m, 4H); MS (EI) for $C_{23}H_{27}N_5O_4S$: 470 (MH^+).

3-(Methyloxy)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)propane-1-sulfonamide: MS (EI) for $C_{24}H_{29}N_5O_4S$: 484 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-(tetrahydrofuran-2-ylmethyl)benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.23 (s, 1H), 9.77 (s, 1H), 8.52 (d, 1H), 8.45 (d, 1H), 8.43 (d, 1H), 8.19 (d, 1H), 8.17 (d,1H), 7.88-7.86 (m,1H), 7.76 (s, 1H), 7.74 (s, 1H), 7.43-7.38 (m, 3H), 4.01-3.98 (m, 1H), 3.81-3.76 (m, 2H), 3.65-3.62 (m, 2H), 2.09 (s, 3H), 1.85-1.80 (m, 3H), 1.64-1.61 (m, 1H). MS (EI): 432.5 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[3-(2-oxopyrrolidin-1-yl)propyl]benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.23 (s, 1H), 9.78 (s, 1H), 8.52 (d, 1H), 8.49 (s, 1H), 8.41 (t, 1H), 8.19 (dd, 2H), 7.87-7.84 (m,1H), 7.76 (s, 1H), 7.74 (s, 1H), 7.40-7.38 (m, 3H), 3.27-3.23 (m, 6H), 2.22 (t, 2H), 2.09 (s, 3H), 1.96-1.88 (m, 2H), 1.73-1.70 (m, 2H). MS (EI): 473.5 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[(3s,5s,7s)-tricyclo-[3.3.1.1~3,7~]dec-1-yl]benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.73 (s, 1H), 8.52 (d, 1H), 8.35 (s, 1H), 8.16 (d, 2H), 7.84-7.81 (m, 1H), 7.76 (d, 2H), 7.55 (s, 1H), 7.39-7.31 (m, 3H), 2.09 (s, 3H), 1.67 (m, 15H). MS (EI): 482.6 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[2-(methyloxy)ethyl]-benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.23 (s, 1H), 9.77 (s, 1H), 8.52 (d, 1H), 8.46 (d, 2H), 8.19 (d, 1H), 8.18 (d, 1H), 7.88-7.85 (m,1H), 7.77 (s, 1H), 7.75 (s, 1H), 7.43-7.39 (m, 3H), 3.48-3.41 (m, 4H), 3.29-3.27 (m, 3H), 2.09 (s, 3H). MS (EI): 406.3 (MH+).

N-[4-(2-{[3-(1,3-thiazolidin-3-ylcarbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]-acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.23 (s, 1H), 9.84 (s, 1H), 8.52 (d, 1H), 8.19-8.12 (m, 3H), 7.90-7.87 (m, 1H), 7.77-7.75 (m, 2H), 7.43-7.38 (m, 2H), 7.11 (d, 1H), 4.64 (m, 2H), 3.77 (m, 2H), 3.06 (m, 2H), 2.09 (s, 3H). MS (EI): 420.6 (MH+).

N-{4-[2-({3-[(4-pyridin-2-ylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.83 (s, 1H), 8.53 (d, 1H), 8.14-8.11 (m, 3H), 8.04 (t, 1H), 7.89-7.86 (m, 1H), 7.73 (d, 2H), 7.57-7.53 (m, 1H), 7.43-7.39 (m, 2H), 7.03-7.01 (m, 1H), 6.83 (d, 1H), 6.69-6.66 (m, 1H), 3.74 (m, 4H), 3.49 (m, 4H), 2.08 (s, 3H). MS (EI): 494.5 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-{[2-(methyloxy)phenyl]-methyl}benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.79 (s, 1H), 8.80 (d, 1H), 8.53-8.49 (m, 2H), 8.19 (dd, 2H), 7.94-7.91 (m, 1H), 7.74 (d, 2H), 7.52-7.49 (m, 1H), 7.44-7.39 (m, 1H), 7.26-7.19 (m, 2H), 6.99 (dd, 1H), 6.93-6.89 (m, 1H), 4.46 (d, 2H), 3.84 (s, 3H), 2.09 (s, 3H). MS (EI): 468.5 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-{[3-(methyloxy)phenyl]-methyl}benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.79 (s, 1H), 8.97 (t, 1H), 8.53-8.49 (m, 2H), 8.20-8.18 (m, 2H), 7.93-7.90 (m, 1H), 7.75 (d, 2H), 7.48-7.46 (m, 1H), 7.43-7.39 (m, 1H), 7.27-7.23 (m, 1H), 6.92-6.90 (m, 2H), 6.83-6.80 (m, 1H), 4.47 (d, 2H), 3.71 (s, 3H), 2.09 (s, 3H). MS (EI): 468.4 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[(2-fluorophenyl)methyl]-benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.79 (s, 1H), 8.97 (t, 1H), 8.53-8.49 (m, 2H), 8.19-8.17 (m, 2H), 7.93-7.90 (m, 1H), 7.75 (d, 2H), 7.50-7.47 (m, 1H), 7.43-7.37 (m, 2H), 7.32-7.29 (m, 1H), 7.22-7.16 (m, 2H), 4.40 (d, 2H), 2.09 (s, 3H). MS (EI): 456.4 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[(4-fluorophenyl)methyl]-benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.79 (s, 1H), 9.00 (t, 1H), 8.53-8.50 (m, 2H), 8.19-8.17 (m, 2H), 7.90-7.88 (m, 1H), 7.75 (d, 2H), 7.47-7.36 (m, 4H), 7.19-7.13 (m, 2H), 4.47 (d, 2H), 2.09 (s, 3H). MS (EI): 456.5 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-(3,3-dimethylbutyl)-benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.76 (s, 1H), 8.53-8.51 (d, 1H), 8.41 (s, 1H), 8.33 (t, 1H), 8.18-8.17 (m, 2H), 7.88-7.85 (m, 1H), 7.75 (d, 2H), 7.39-7.37 (m, 2H), 3.30-3.26 (m, 2H), 2.08 (s, 3H), 1.48-1.44 (m, 2H), 0.94 (s, 9H). MS (EI): 432.4 (MH+).

N-[4-(2-{[3-(thiomorpholin-4-ylcarbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]-acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.23 (s, 1H), 9.82 (s, 1H), 8.53 (d, 1H), 8.15-8.20 (m, 2H), 7.99 (t, 1H), 7.85-7.82 (m, 1H), 7.76 (d, 2H), 7.41-7.37 (m, 2H), 6.98-6.96 (m, 1H), 3.88 (m, 4H), 3.60 9m, 4H), 2.09 (s, 3H). MS (EI): 434.5 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-(2-thienylmethyl)benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.79 (s, 1H), 9.09 (t, 1H), 8.53-8.50 (m, 2H), 8.18 (d, 2H), 7.89-7.86 (m, 1H), 7.75 (d, 2H), 7.44-7.38 (m, 3H), 7.03 (m, 1H), 6.98-6.96 (m, 1H), 4.64 (d, 2H), 2.09 (s, 3H). MS (EI): 444.4 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[3-(dimethylamino)-propyl]benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.79 (s, 1H), 8.74 (m, 1H), 8.55-8.50 (m, 2H), 8.21-8.18 (m, 2H), 7.95-7.87 (m, 1H), 7.75 (d, 2H), 7.45-7.40 (m, 2H), 3.05 (s, 2H), 2.75 (s, 6H), 2.55-2.54 (m, 2H), 2.09 (s, 3H), 1.25-1.21 (m, 2H). MS (EI): 433.4 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[2-(2-chlorophenyl)-ethyl]benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.77 (s, 1H), 8.54-8.51 (m, 2H), 8.44 (m, 1H), 8.18 (d, 2H), 7.88-7.86 (m, 1H), 7.75 (d, 2H), 7.45-7.36 (m, 4H),

7.28-7.25 (m, 2H), 3.55-3.50 (m, 2H), 3.01-2.98 (m, 2H), 2.08 (s, 3H). MS (EI): 486.8 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-{[2-(trifluoromethyl)-phenyl]methyl}benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.81 (s, 1H), 9.07 (t, 1H), 8.53-8.49 (m, 2H), 8.19-8.17 (m, 2H), 7.96-7.94 (m, 1H), 7.75-7.72 (m, 2H), 7.55-7.39 (m, 6H), 4.68 (d, 2H), 2.08 (s, 3H). MS (EI): 506.5 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-{[3-(trifluoromethyl)-phenyl]methyl}benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.80 (s, 1H), 9.10 (t, 1H), 8.53-8.49 (m, 2H), 8.19-8.17 (m, 2H), 7.94-7.91 (m, 1H), 7.74 (d, 2H), 7.68-7.58 (m, 3H), 7.48-7.39 (m, 3H), 4.58 (d, 2H), 2.09 (s, 3H). MS (EI): 506.4 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-{[4-(trifluoromethyl)-phenyl]methyl}benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.80 (s, 1H), 9.10 (t, 1H), 8.52 (m, 2H), 8.18 (d, 2H), 7.91-7.89 (m, 1H), 7.75-7.69 (m, 4H), 7.55 (d, 2H), 7.49-7.38 (m, 3H), 4.58 (d, 2H), 2.08 (s, 3H). MS (EI): 506.5 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[(2,4-difluorophenyl)-methyl]benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.79 (s, 1H), 8.98 (t, 1H), 8.52 (m, 2H), 8.18 (d, 2H), 7.91-7.89 (m, 1H), 7.54 (d, 2H), 7.47-7.38 (m, 4H), 7.27-7.22 (m, 1H), 7.09-7.04 (m, 1H), 4.48 (d, 2H), 2.09 (s, 3H). MS (EI): 474.4 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-ethyl-N-methylbenzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.23 (s, 1H), 9.80 (s, 1H), 8.53 (d, 1H), 8.13 (d, 2H), 7.76-7.74 (m, 2H), 7.40-7.32 (m, 3H), 6.94 (m,2H), 3.28-3.24 (m, 2H), 2.94 (m, 3H), 2.09 (s, 3H), 1.15-1.08 (m, 3H). MS (EI): 390.4 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-({4-[(trifluoromethyl)-oxy]phenyl}methyl)benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.79 (s, 1H), 9.04 (t, 1H), 8.52 (m, 2H), 8.18 (d, 2H), 7.91-7.88 (m, 1H), 7.75 (d, 2H), 7.48-7.39 (m, 4H), 7.34-7.32 (m, 2H), 4.51 (d, 2H), 2.09 (s, 3H). MS (EI): 522.5 (MH+).

N-{4-[2-({3-[(4-acetylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.82 (s, 1H), 8.53 (t, 1H), 8.19 (d, 2H), 8.14-8.12 (m, 2H), 7.84-7.84 (m, 1H), 7.75 (d, 2H), 7.40-7.38 (m, 2H), 3.53-3.44 (m, 8H), 2.09 (s, 6H). MS (EI): 459.5 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-(cyclopropylmethyl)-benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.77 (s, 1H), 8.53-8.50 (m,

2H), 8.48 (d, 1H), 8.19(dd, 2H), 7.86-7.84 (m, 1H), 7.75 (d, 2H), 7.41-7.38 (m, 2H), 3.17-3.14 (m, 2H), 2.09 (s, 3H), 1.06 (m, 1H), 0.45-0.42 (m, 2H), 0.25-0.23 (m, 2H). MS (EI): 402.5 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[2-(2-fluorophenyl)-ethyl]benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.77 (s, 1H), 8.54-8.51 (m, 2H), 8.44 (m, 1H), 8.20-8.17 (m, 2H), 7.88-7.86 (m, 1H), 7.75 (d, 2H), 7.40-7.26 (m, 4H), 7.18-7.13 (m, 2H), 3.52-3.49 (m, 2H), 2.92-3.88 (m, 2H), 2.09 (s, 3H). MS (EI): 470.4 (MH+).

N-[4-(2-{[3-(pyrrolidin-1-ylcarbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]-acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.78 (s, 1H), 8.53 (d, 1H), 8.20-8.12 (m, 4H), 7.83 (d, 1H), 7.76-7.73 (m, 2H), 7.39-7.35 (m, 2H), 3.50-3.40 (m, 4H), 2.09 (s, 3H), 1.95-1.80 (m, 4H). MS (EI): 402.5 (MH+).

N-{4-[2-({3-[(4-pyrimidin-2-ylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.83 (s, 1H), 8.53 (d, 2H), 8.39 (d, 1H), 8.14-8.12 (m, 2H), 8.04 (t, 1H), 7.89-7.87 (m, 1H), 7.74 (d, 1H), 7.43-7.38 (m, 2H), 7.03-7.01 (m, 1H), 6.67 (t, 2H), 3.81 (m, 4H), 3.73 (m, 4H), 2.08 (s, 3H). MS (EI): 495.6 (MH+).

N-{4-[2-({4-[4-(9H-fluoren-2-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.87 (t, 2H), 7.73 (d, 2H), 7.65 (d, 2H), 7.59-7.56 (m, 2H), 7.37-7.25 (m, 4H), 6.92 (d, 2H), 3.92 (s, 2H), 3.60 (s, 2H), 3.10 (m, 4H), 2.56 (m, 4H), 2.08 (s, 3H). MS (EI): 567.7 (MH+).

N-(4-{2-[(4-{4-[(3-methyl-2-thienyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.73 (d, 2H), 7.65 (d, 2H), 7.33 (d, 1H), 7.26 (d, 1H), 6.92 (d, 2H), 6.85 (d, 1H), 3.63 (s, 2H), 3.07 (m, 4H), 2.56 (m, 4H), 2.17 (s, 3H), 2.08 (s, 3H). MS (EI): 499.5 (MH+).

N-(4-{2-[(4-{4-[(5-ethylfuran-2-yl)methyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.73 (d, 2H), 7.64 (d, 2H), 7.26 (d, 1H), 6.92 (d, 2H), 6.18 (d, 1H), 6.01 (d, 1H), 3.48 (s, 2H), 3.07 (m, 4H), 2.62-2.56 (m, 6H), 2.09 (s, 3H), 1.16 (t, 3H). MS (EI): 497.6 (MH+).

N-(4-{2-[(4-{4-[(3-{[4-(1,1-dimethylethyl)phenyl]oxy}phenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.64 (d, 2H), 7.42-7.38 (m, 2H), 7.33 (t, 1H), 7.26 (d, 1H), 7.08 (d, 1H), 6.97-6.86 (m, 6H), 3.52 (s, 2H), 3.06 (m, 4H), 2.52 (m, 4H), 2.09 (s, 3H), 1.27 (s, 9H). MS (EI): 627.7 (MH+).

N-{4-[2-({4-[4-(3-thienylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.73 (d, 2H), 7.64 (d, 2H), 7.51-7.45 (m, 1H), 7.35 (d, 1H), 7.29-7.25 (m, 1H), 7.08-7.04 (m, 1H), 6.91 (d, 2H), 3.53 (s, 2H), 3.07 (m, 4H), 2.52 (m, 4H), 2.09 (s, 3H). MS (EI): 485.6 (MH+).

methyl 4-({4-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-phenyl]piperazin-1-yl}methyl)benzoate: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.94 (d, 2H), 7.73 (d, 2H), 7.65 (d, 2H), 7.50 (d, 2H), 7.26 (d, 1H), 6.92 (d, 2H), 3.85 (s, 3H), 3.61 (s, 2H), 3.09 (m, 4H), 2.54 (m, 4H), 2.09 (s, 3H). MS (EI): 537.7 (MH+).

N-(4-{2-[(4-{4-[3-(methylthio)propyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H), 6.92 (d, 2H), 3.34 (m, 4H), 3.07 (m, 4H), 2.39 (m, 4H), 2.09 (s, 3H), 2.03 (m, 3H), 1.75-1.68 (m, 2H). MS (EI): 477.5 (MH+).

N-(4-{2-[(4-{4-[(4-{[3-(dimethylamino)propyl]oxy}phenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.73 (d, 2H), 7.64 (d, 2H), 7.26-7.21 (m, 3H), 6.92-6.87 (m, 4H), 3.97 (t, 2H), 3.44 (m, 6H), 3.06 (m, 4H), 2.37 (t, 2H), 2.16 (s, 6H), 2.09 (s, 3H), 1.87-1.82 (m, 2H). MS (EI): 580.7 (MH+).

N-[4-(2-{[4-(4-{2-[(phenylmethyl)oxy]ethyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.38-7.26 (m, 6H), 6.92 (d, 2H), 4.50 (s, 2H), 3.59 (m, 3H), 3.07 (m, 3H), 2.58 (m, 6H), 2.09 (s, 3H). MS (EI): 523.5 (MH+).

N-(4-{2-[(4-{4-[(2-chloroquinolin-3-yl)methyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.37

(s, 1H), 8.49 (s, 1H), 8.44 (d, 1H), 8.13-8.09 (m, 3H), 7.96 (d, 1H), 7.83-7.79 (m, 1H), 7.74 (d, 1H), 7.69-7.65 (m, 3H), 7.26 (d, 2H), 6.95 (d, 2H), 3.78 (s, 2H), 3.15 (m, 4H), 2.69 (m, 4H), 2.09 (s, 3H). MS (EI): 565.1 (MH+).

N-{4-[2-({4-[4-(2,2'-bithien-5-ylmethyl)piperazin-1-yl]phenyl}amino)-pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.49 (dd, 1H), 7.27-7.25 (m, 2H), 7.15 (d, 1H), 7.09-7.07 (m, 1H), 6.96-6.92 (m, 3H), 3.73 (s, 2H), 3.10 (m, 4H), 2.59 (m, 4H), 2.09 (s, 3H). MS (EI): 567.6 (MH+).

N-[4-(2-{[4-(4-{[4-(2-thienyl)phenyl]methyl}piperazin-1-yl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.73 (d, 2H), 7.66-7.62 (m, 4H), 7.54-7.50 (m, 2H), 7.38 (d, 2H), 7.26 (d, 1H), 7.15-7.13 (m, 1H), 6.92 (d, 2H), 3.54 (s, 2H), 3.09 (m, 4H), 2.55-2.52 (m, 4H), 2.09 (s, 3H). MS (EI): 561.6 (MH+).

N-(4-{2-[(4-{4-[(4-cyanophenyl)methyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.82 (d, 2H), 7.73 (d, 2H), 7.65 (d, 2H), 7.56 (d, 2H), 7.26 (d, 1H), 6.92 (d, 2H), 3.63 (s, 2H), 3.10-3.08 (m, 4H), 2.54-2.52 (m, 4H), 2.09 (s, 3H). MS (EI): 504.5 (MH+).

N-[4-(2-{[4-(4-{[2,5-bis(methyloxy)phenyl]methyl}piperazin-1-yl)phenyl]-amino}pyrimidin-4-yl)phenyl]acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H), 6.95-6.90 (m, 4H), 6.81-6.78 (m, 1H), 3.74 (s, 3H), 3.70 (s, 3H), 3.50 (s, 2H), 3.09 (m, 4H), 2.55 (m, 4H), 2.09 (s, 3H). MS (EI): 539.7 (MH+).

N-{4-[2-({4-[4-(2,2-diphenylethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.82 (d, 2H), 7.65-7.59 (m, 6H), 7.50-7.46 (m, 4H), 7.26 (d, 1H), 7.21 (d, 2H), 6.92 (d, 2H), 4.45 (t, 1H), 3.61 (t, 2H), 3.09 (m, 4H), 2.54 (m, 4H), 2.09 (s, 3H). MS (EI): 569.6 (MH+).

N-{4-[2-({4-[4-(1H-pyrrol-2-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.71 (s, 1H), 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.73 (d, 2H), 7.64 (d, 2H), 7.26 (d, 1H), 6.91 (d,

2H), 6.65-6.63 (m, 1H), 5.94-5.90 (m, 2H), 3.44 (s, 2H), 3.06 (m, 4H), 2.48 (m, 4H), 2.09 (s, 3H). MS (EI): 468.6 (MH+).

N-[4-(2-{[4-(4-propylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.73 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H), 6.92 (d, 2H), 3.06 (m, 4H), 2.27 (m, 4H), 2.08 (s, 3H), 1.80 (s, 2H), 1.48 (m, 2H), 0.88 (t, 3H). MS (EI): 431.6 (MH+).

N-[4-(2-{[4-(4-butylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.12 (d, 2H), 7.74 (d, 2H), 7.64 (d, 2H), 7.25 (d, 1H), 6.92 (d, 2H), 3.07 (m, 4H), 2.31 (m, 4H), 2.09 (s, 3H), 1.87 (m, 2H), 1.44 (m, 2H), 1.30 (m, 2H), 0.90 (t, 3H). MS (EI): 445.6 (MH+).

N-{4-[2-({4-[4-(cyclopropylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.73 (d, 2H), 7.65 (d, 2H), 7.25 (d, 1H), 6.92 (d, 2H), 3.08 (m, 4H), 2.58 (m, 4H), 2.22 (d, 2H), 2.09 (s, 3H), 1.86 (s, 1H), 0.49 (m, 2H), 0.09 (m, 2H). MS (EI): 443.6 (MH+).

N-[4-(2-{[4-(4-pentanoylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.96 (d, 2H), 3.60 (m, 4H), 3.07 (m, 2H), 3.02 (m, 2H), 2.35 (t, 2H), 2.09 (s, 3H), 1.49 (m, 2H), 1.31 (m, 2H), 0.89 (t, 3H). MS (EI): 473.6 (MH+).

N-{4-[2-({4-[4-(pyridin-2-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.62 (d, 1H), 8.44 (d, 1H), 8.10 (d, 2H), 7.95 (t, 1H), 7.74 (d, 2H), 7.69 (d, 2H), 7.61 (d, 1H), 7.27 (d, 1H), 6.97 (d, 2H), 3.82 (t, 2H), 3.57 (t, 2H), 3.18 (t, 2H), 3.06 (t, 2H), 2.09 (s, 3H). MS (EI): 494.6 (MH+).

N-{4-[2-({4-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.68 (m, 2H), 8.44 (d, 1H), 8.10 (d, 2H), 7.89 (d, 1H), 7.74 (d, 2H), 7.69 (d, 2H), 7.51 (m, 1H), 7.28 (d, 2H), 3.80 (m, 2H), 3.49 (m, 2H), 3.18 (m, 2H), 3.09 (m, 2H), 2.09 (s, 3H). MS (EI): 494.6 (MH+).

N-{4-[2-({4-[4-(pyridin-4-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.69 (d, 2H), 8.44 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.44 (d, 2H), 7.28 (d, 1H), 6.96 (d, 2H), 3.79 (m, 2H), 3.41 (m, 2H), 3.18 (m, 2H), 3.07 (m, 2H), 2.09 (s, 3H). MS (EI): 494.6 (MH+).

N-{4-[2-({4-[4-(1H-pyrazol-4-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.10 (d, 2H), 7.75-7.68 (m, 4H), 7.28 (d, 2H), 6.97 (d, 3H), 3.75 (m, 4H), 3.11 (m, 4H), 2.09 (s, 3H). MS (EI): 483.5 (MH+).

N-(4-{2-[(4-{4-[(1-acetylpiperidin-4-yl)carbonyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.26 (d, 1H), 6.97 (d, 2H), 3.65 (m, 4H), 3.02 (m, 8H), 2.62 (m, 1H), 2.09 (s, 3H), 1.99 (s, 3H), 1.66 (m, 2H), 1.56 (m, 2H). MS (EI): 542.7 (MH+).

N-(4-(2-(4-(4-(2-cyclopropylacetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.10 (d, 2H), 7.54 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.96 (d, 2H), 3.59 (m, 4H), 3.04 (m, 4H), 2.30 (d, 2H), 2.09 (s, 3H), 0.97 (m, 1H), 0.45 (m, 2H), 0.14 (m, 2H). MS (EI): 471.6 (MH+).

N-(4-{2-[(4-{4-[3-(methyloxy)propanoyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.68 (d, 2H), 7.27 (d, 1H), 6.95 (d, 2H), 3.58 (m, 6H), 3.23 (s, 3H), 3.08 (m, 2H), 3.02 (m, 2H), 2.62 (t, 2H), 2.09 (s, 3H). MS (EI): 475.6 (MH+).

N-{4-[2-({4-[4-(2-{[2-(methyloxy)ethyl]oxy}acetyl)piperazin-1-yl]phenyl}amino)-pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.23 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.68 (d, 1H), 7.27 (d, 1H), 6.96 (d, 2H), 4.20 (s, 2H), 3.58 (m, 6H), 3.47 (m, 2H), 3.25 (s, 3H), 3.06 (m, 4H), 2.09 (s, 3H). MS (EI): 505.6 (MH+).

N-(4-(2-(4-(4-(2-(pyridin-3-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.44 (m, 3H), 8.10 (d, 2H), 7.75 (d, 2H), 7.68 (d, 2H), 7.64 (m, 1H), 7.34 (m, 1H), 7.28 (d, 1H),

6.96 (d, 1H), 3.83 (s, 2H), 3.70 (m, 2H), 3.63 (m, 2H), 3.05 (m, 4H), 2.09 (s, 3H). MS (EI): 508.6 (MH+).

(2R,4S)-4-hydroxy-N-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.48 (d, 1H), 8.44 (d, 1H), 8.39 (dd, 1H), 8.11 (d, 1H), 7.74 (d, 2H), 7.69 (m, 3H), 7.28 (m, 3H), 6.94 (d, 2H), 3.59 (m, 4H), 3.01 (m, 4H), 2.86 (t, 2H), 2.73 (t, 2H), 2.09 (s, 3H). MS (EI): 522.6 (MH+).

N-{4-[2-({3-[4-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]phenyl}amino)-pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.19 (s, 1H), 9.45 (s, 1H), 8.47 (d, 1H), 8.11 (d, 2H), 7.73 (d, 2H), 7.66 (d, 1H), 7.60 (s, 1H), 7.31 (d, 1H), 7.21 (d, 1H), 7.12 (t, 1H), 6.55 (dd, 1H), 3.90 (s, 2H), 3.17 (m, 4H), 2.66 (m, 4H), 2.07 (s, 3H). MS (EI): 486.6 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-5-oxo-L-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.33 (s, 1H), 9.40 (s, 1H), 8.45 (d, 1H), 8.14 (d, 2H), 7.93 (s, 1H), 7.79 (d, 2H), 7.67 (d, 2H), 7.29 (d, 1H), 6.93 (d, 2H), 4.23 (dd, 1H), 3.75 (m, 4H), 3.06 (m, 4H), 2.35 (m, 1H), 2.21 (m, 2H), 2.02 (m, 1H). MS (EI): 459.5 (MH+).

(3S)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyrrolidine-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.75 (s, 1H), 9.84 (s, 1H), 9.34 (m, 1H), 9.14 (m, 1H), 8.51 (d, 1H), 8.16 (d, 2H), 7.82 (d, 3H), 7.41 (d, 2H), 3.93 (m, 4H), 3.82 (m, 6H), 3.36 (m, 2H), 3.24 (m, 1H), 2.33-2.24 (m, 1H), 2.11-2.04 (m, 2H). MS (EI): 445.5 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-threoninamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.53 (s, 1H), 10.11 (s, 1H), 8.51 (d, 1H), 8.31 (d, 2H), 8.15 (d, 2H), 7.86 (t, 3H), 7.73 (d, 2H), 7.44 (d, 2H), 4.01 (m, 6H), 3.48 (m, 4H), 1.18 (s, 3H). MS (EI): 449.5 (MH+).

N-{4-[2-({4-[4-(N,N-diethyl-beta-alanyl)piperazin-1-yl]phenyl}amino)-pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.38 (s, 1H), 8.42 (d, 1H), 8.09 (d, 2H), 7.73 (d, 2H), 7.67 (d, 2H), 7.25 (d, 1H), 6.95 (d, 2H), 3.58 (m, 4H), 3.05 (m, 4H), 2.81 (t, 2H), 2.66-2.55 (m, 6H), 1.93 (s, 3H), 0.99 (t, 6H). MS (EI): 516.7 (MH+).

N^1-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-glutamamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.36 (s, 1H), 8.42 (d, 2H), 8.11 (d, 3H), 7.80 (d, 2H), 7.66 (d, 2H), 7.26 (d, 2H), 6.92 (d, 3H), 3.72 (m, 4H), 3.32 (m, 1H), 3.02 (m, 4H), 1.93 (s, 2H), 1.82 (s, 2H). MS (EI): 476.6 (MH+).

(S)-1-ethyl-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.19 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.94 (d, 2H), 3.04 (m, 4H), 2.90 (m, 2H), 2.65 (m, 2H), 2.43 (m, 3H), 1.98 (m, 6H), 1.03 (t, 3H). MS (EI): 473.6 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-norvalinamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.50 (s, 1H), 10.15 (s, 1H), 8.56 (m, 3H), 8.24 (d, 2H), 7.94 (d, 2H), 7.76 (m, 3H), 7.51 (d, 2H), 4.08 (m, 4H), 3.67 (d, 1H), 1.97 (m, 4H), 1.43 (m, 2H), 1.19 (m, 2H), 0.94 (m, 3H). MS (EI): 447.6 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-norleucinamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.55 (s, 1H), 10.19 (s, 1H), 8.57 (d, 2H), 8.26 (d, 1H), 8.01 (m, 4H), 7.80 (m, 3H), 7.53 (d, 2H), 4.05 (m, 4H), 3.68 (d, 1H), 1.92 (m, 4H), 1.36 (m, 4H), 1.19 (m, 2H), 0.99 (d, 3H). MS (EI): 461.6 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-alloisoleucinamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.32 (s, 1H), 10.01 (s, 1H), 8.56 (d, 2H), 8.44 (d, 3H), 8.21 (d, 2H), 7.89 (m, 3H), 7.46 (d, 2H), 4.02 (m, 4H), 3.56 (d, 1H), 1.99 (m, 4H), 1.63 (m, 1H), 1.17 (m, 2H), 1.00 (d, 3H), 0.91 (d, 3H). MS (EI): 461.6 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-leucinamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.32 (s, 1H), 9.97 (s, 1H), 8.56 (d, 2H), 8.45 (d, 3H), 8.21 (d, 2H), 7.89 (m, 3H), 7.46 (d, 2H), 4.02 (m, 4H), 3.57 (d, 1H), 1.99 (m, 4H), 1.91 (m, 1H), 1.71 (t, 2H), 1.17 (t, 3H), 0.95 (t, 3H). MS (EI): 461.6 (MH+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-(2-ethylphenyl)benzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 (s, 1H), 9.85 (d, 2H), 8.59 (s, 1H), 8.53 (d, 1H), 8.18 (d, 2 H), 7.93 (m, 1H), 7.73 (d, 2H), 7.57 (d, 1H), 7.46 (t, 1H), 7.40 (d, 1H), 7.30-7.34 (m, 2H), 7.24-7.27 (m, 2H), 2.62-2.67 (m, 2H), 2.08 (s, 3H), 1.13-1.7 (t, 3H). MS (EI) for $C_{27}H_{25}N_5O_2$: 452.58 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-(phenylmethyl)-benzamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.22 (s, 1H), 9.80 (s, 1H), 8.98-9.01 (t, 1H), 8.52 (d, 1H), 8.50 (s, 1H), 8.18 (d, 2H), 7.9 (dd, 1H), 7.76 (s,1H), 7.74 (s, 1H), 7.47 (d, 1H), 7.39-7.43 (m, 2H), 7.43 (s, 2H), 7.34 (d, 2H), 7.23-7.25 (m, 1H), 4.50(d, 2H), 2.09 (s, 3H). MS (EI) for $C_{26}H_{23}N_5O_2$: 438.48 (MH^+).

N-{4-[2-({3-[(4-cyclopentylpiperazin-1-yl) carbonyl] phenyl}amino) pyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.23 (s, 1H), 9.82 (s, 1H), 8.53 (d, 1H), 8.12 (s, 2H), 8.05 (s, 1H), 7.81 (dd, 1H), 7.76 (d, 2H), 7.38 (t, 2H), 6.95 (d, 1H), 2.89 (s, 2H), 2.73 (s, 2H), 2.34-2.45 (m, 5H), 2.09 (s, 3H), 2.73-2.75 (m, 2H), 1.52-1.59 (m, 2H), 1.46-1.50 (m, 2H), 1.27-1.33 (m, 2H): MS (EI) for $C_{28}H_{32}N_6O_2$: 485.8 (MH^+).

N-{4-[2-({3-[(4-pyrazin-2-ylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.17 (s, 1H), 9.84 (s, 1H), 8.54 (d, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 8.06-8.10 (m, 2H), 7.86-7.88 (m, 2H), 7.73 (d, 2H), 7.42 (d, 1H), 7.39 (d, 1H), 7.02-7.04 (m, 1H), 3.69 (m, 4H), 3.57 (m, 4H), 2.08 (s, 3H). MS (EI) for $C_{27}H_{26}N_8O_2$: 495.7 (MH^+).

N-(4-{2-[(3-{[4-(3-chlorophenyl)piperazin-1-yl]carbonyl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.20 (s,1H), 9.84 (s, 1H), 8.53 (d, 1H), 8.13 (dd, 2H), 8.064 (t, 1H), 7.85-7.87 (m, 1H), 7.74 (d, 2H), 7.39-7.43 (m, 2H), 7.22 (t, 1H), 7.01-7.03 (m, 1H), 6.96 (t, 1H), 6.90 (dd, 1H), 6.81 (dd, 1H), 3.76 (m, 4H), 3.52 (m, 4H), 2.08 (s, 3H). MS (EI) for $C_{29}H_{27}ClN_6O_2$: 528.1 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[(1-methyl-1H-benzimidazol-2-yl)methyl]benzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.23 (s, 1H), 9.80 (s, 1H), 9.01 (t, 1H), 8.52 (t, 2H), 8.17-8.19 (m, 2H), 7.91-7.93 (m, 1H), 7.75 (d, 2H), 7.50-7.59 (m, 3H), 7.39-7.43 (m, 2H), 7.16-7.26 (m, 2H), 4.80 (d, 2H), 3.86 (s, 3H), 2.10 (s, 3H). MS (EI) for $C_{28}H_{25}N_7O_2$: 492.4 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-propylbenzamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.22 (s. 1H), 9.77 (s, 1H), 8.52 (d, 1H), 8.46 (s, 1H), 8.40 (t, 1H), 8.18 (d, 2H), 7.83-7.86 (m, 1H), 7.75 (d, 2H), 7.38-7.40 (m, 3H), 3.21-3.26 (m, 2H), 2.09 (s, 3H), 1.52-1.58 (m, 2H), 089-0.93 (t, 3H). MS (EI) for $C_{22}H_{23}N_5O_2$: 390.7 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-cyclopropylbenzamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.24 (s 1H), 9.77 (s, 1H), 8.52 (d, 1H), 8.47 (s, 1H), 8.40 (d, 1H), 8.18 (d, 2H), 7.82-7.85 (m, 1H), 7.76 (d, 2H), 7.39 (d, 1H), 7.36-7.37 (m, 2H), 2.84-2.89 (m, 1H), 2.09 (s, 3H), 0.69-0.73 (m, 2H), 0.56-0.60 (m, 2H). MS (EI) for $C_{22}H_{21}N_5O_2$: 388.7 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[(3-fluorophenyl)-methyl]benzamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.22 (s, 1H), 9.80 (s, 1H), 9.04 (t, 1H), 8.53 (d, 1H), 8.50 (s, 1H), 8.17-8.20 (m, 2H), 7.90-7.93 (m, 1H), 7.74 (d, 2H), 7.46-7.50 (m, 1H), 7.36-7.43 (m, 3H), 7.08-7.19 (m, 3H), 4.51 (d, 2H), 2.09 (s, 3H). MS (EI) for $C_{26}H_{22}FN_5O_2$: 456.5 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-(naphthalen-1-ylmethyl)-benzamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.21 (s, 1H), 9.79 (s, 1H), 9.03 (t, 1H), 8.52 (d, 2H), 8.15-8.23 (m, 3H), 7.95-7.97 (m, 1H), 7.90-7.93 (m, 1H), 7.85-7.87 (dd, 1H), 7.75 (d, 2H), 7.55-760 (m, 2H), 7.48-7.50 (m, 3H), 7.38-7.42 (m, 2H), 4.97 (d, 2H), 2.08 (s, 3H). MS (EI) for $C_{30}H_{25}N_6O_2$: 488.6 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[2-(dimethylamino)ethyl]-N-methylbenzamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.23 (s, 1H), 9.80 (s, 1H), 8.53 (d, 1H), 8.13 (d, 2H), 8.00 (d, 1H), 7.82 (s, 1H), 7.75 (d, 2H), 7.35-7.39 (m, 2H)6.93 (d, 1H), 3.39-3.419 (m, 2H), 2.94 (s, 3H), 2.21 (m, 2H), 2.09 (s, 6H), 1.95 (s, 3H). MS (EI) for $C_{24}H_{28}N_6O_2$: 433.7 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[(2-methylphenyl)-methyl]benzamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.22 (s, 1H), 9.79 (s, 1H), 8.56 (t, 1H), 8.52 (d,1H), 8.50 (s, 1H), 8.17-8.19 (m, 2H), 7.90-7.90 (m, 1H), 7.75 (d, 2H), 7.45-7.50 (s, 1H), 7.39-7.43 (m, 2H), 7.25-7.27 (1H), 7.14-7.18 (m, 3H), 4.47 (d, 2H), 2.34 (s, 3H), 2.09(s, 3H). MS (EI) for $C_{27}H_{25}N_5O_2$: 452.6 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[(3-chlorophenyl)methyl]-benzamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.25 (s, 1H), 9.80 (s, 1H), 9.05 (t, 1H), 8.53 (d, 1H), 8.50 (s, 1H), 8.17-8.20 (m, 2H), 7.91-7.94 (m, 1H), 7.60 (s, 1H), 7.40 (s, 1H), 7.46-7.48 (m, 1H), 7.43 (d, 1H), 7.36-7.40 (m, 3H), 7.30-7.32 (m, 2H), 4.95 (d, 2H), 2.09 (s, 3H). MS (EI) for $C_{26}H_{22}ClN_5O_2$: 472.8 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-(2-phenylethyl)-benzamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.22 (s, 1H), 9.78 (s, 1H), 8.51-8.53 (m,

2H), 8.46 (s, 1H), 8.19 (d, 2H), 7.85-7.88 (m, 1H), 7.76 (d, 2H), 7.37-7.38 (m, 3H), 7.27-7.32 (m, 4H), 7.19-7.23 (m, 1H), 3.47-3.52 (m, 2H), 2.84-2.88 (m, 2H), 2.08 (s, 3H). MS (EI) for $C_{27}H_{25}N_5O_2$: 452.6 (MH^+).

N-{4-[2-({3-[(4-methylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.24 (s, 1H), 9.82 (s, 1H), 8.53 (d, 1H), 8.12-8.15(m, 2H), 8.04(s, 1H), 7.80-7.82 (m, 1H), 7.76 (d, 2H), 7.36-7.40 (m, 2H), 6.94-6.96 (m, 1H), 2.94 (s, 2H), 2.78 (s, 2H), 2.37 (s, 2H), 2.27 (s, 2H), 2.18 (s, 3H), 2.09 (s, 3H). MS (EI) for $C_{24}H_{26}N_6O_2$: 431.6 (MH^+).

N-(4-{2-[(3-{[4-(2-fluorophenyl)piperazin-1-yl]carbonyl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.22 (s, 1H), 9.84 (s, 1H), 8.53 (d, 1H), 8.14 (d, 2H), 8.08 (m, 1H), 7.85 (d, 1H), 7.77 (d, 2H), 7.39-7.43 (m, 2H), 7.05-7.17 (m, 2H), 6.99-7.05 (m, 4H), 3.81(s, 2H), 3.55 (s, 2H), 3.09 (s, 2H), 2.98 (s, 2H), 2.09 (s, 3H). MS (EI) for $C_{29}H_{27}FN_6O_2$: 511.7 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[2-(phenyloxy)ethyl]-benzamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.22 (s, 1H), 9.79 (s, 1H), 8.65 (t, 1H), 8.2 (d, 2H), 8.50 (s br, 1H), 8.9 (d, 2H), 7.88-7.90 (m, 1H), 7.76 (d, 2H), 7.38-7.45 (m, 3H), 7.27-7.30 (m, 2H), 6.91-6.98 (m, 3H), 4.11-4.14 (m, 2H), 3.63-3.78 (m, 2H), 2.09 (s, 3H). MS (EI) for $C_{27}H_{25}N_5O_3$: 468.4 (MH^+).

methyl 1-{[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]carbonyl}-piperidine-4-carboxylate: ^{1}H-NMR (400MHz, d_6-DMSO):10.23 (s, 1H), 9.82 (s, 1H), 8.53 (d, 1H), 8.14 (d, 2H), 7.97 (t, 1H), 7.86-7.88 (m, 1H), 7.75 (d, 2H), 7.36-7.70 (m, 2H), 6.94-6.96 (m, 1H), 3.61 (s, 3H), 3.30-3.36 (m, 2H), 2.77-3.29 (m, 2H), 2.65-2.70 (m, 1H), 2.09 (s, 3H), 1.99-2.19 (m, 2H), 1.79-1.88 (m, 2H). MS (EI) for $C_{26}H_{27}N_5O_4$: 474.6 (MH^+).

N-[4-(2-{[3-({4-[3-(methyloxy)phenyl]piperazin-1-yl}carbonyl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.21 (s, 1H), 9.83 (s, 1H), 8.53 (d, 1H), 8.14 (d, 2H), 8.04 (m, 1H), 7.86-7.89 (m, 1H), 7.75 (d, 2H), 7.39-7.43 (m, 2H), 7.12 (t, 1H), 7.00-7.03 (m, 1H), 6.53 (dd, 1H), 6.47 (t, 1H), 6.40 (dd, 1H), 3.78-3.80 (m, 2H), 3.71 (s, 3H), 3.20-3.24 (m, 2H), 3.12-3.19(m, 2H), 2.09 (s, 3H). MS (EI) for $C_{30}H_{30}N_6O_3$: 523.5 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-{2-[2-(methyloxy)phenyl]-ethyl}benzamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.22 (s, 1H),

9.78 (s, 1H), 8.52-8.53 (m, 1H), 8.45 (s, 2H), 8.19 (d, 2H), 7.88 (s, 1H), 7.75 (d, 2H), 7.38-7.39(m, 3H), 7.17-7.23 (m, 2H), 6.97 (d, 1H), 6.87 (t, 1H), 3.78 (s, 3H), 3.45-3.47 (m, 2H), 2.84-2.87 (m, 2H), 2.09 (s, 3H). MS (EI) for $C_{28}H_{27}N_5O_3$: 482.7 (MH^+).

N-[4-(2-{[3-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)phenyl]amino}pyrimidin-4-yl)-phenyl]acetamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.21 (s, 1H), 9.82 (s, 1H), 8.53 (d, 1H), 8.16 (s, 1H), 8.12-8.14 (m, 2H), 7.94-7.97 (m, 1H), 7.74 (s, 1H), 7.72 (s, 1H), 7.39-7.45 (m, 3H), 7.27-7.32 (m, 1H), 7.26 (d, 2H), 7.19-7.21 (m, 1H), 7.89 (s, 2H), 4.82 (s, 2H), 2.09 (s, 3H). MS (EI) for $C_{27}H_{23}N_5O_2$: 450.7 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-(biphenyl-4-ylmethyl)-benzamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.23 (s, 1H), 9.80 (s, 1H), 9.04 (s br, 1H), 8.53 (d, 2H), 8.19 (d, 2H), 7.89 (d, 1H), 7.76 (d, 2H), 7.64 (m, 4H), 7.35-7.50 (m, 8H), 4.55 (s, 2H), 2.08 (s, 3H). MS (EI) for $C_{32}H_{27}N_5O_2$: 514.8 (MH^+).

N-(4-{2-[(3-{[4-(phenylcarbonyl)piperazin-1-yl]carbonyl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.25 (s, 1H), 9.83 (s, 1H), 8.53 (d, 1H), 8.14 (d, 2H), 8.04 (s, 1H), 7.86 (d, 1H), 7.76 (d, 2H), 7.44 (m, 5H), 7.39 (d, 2H), 7.00 (d, 1H), 3.56 (m, 8H) 2.09 (s, 3H). MS (EI) for $C_{30}H_{28}N_6O_3$: 521.6 (MH^+).

N-[4-(2-{[3-({4-[4-(methyloxy)phenyl]piperazin-1-yl}carbonyl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 (s, 1H), 9.83 (s, 1H), 8.53 (d, 1H), 8.13 (m, 2H), 8.05 (m, 1H), 7.86 (m, 1H), 7.75 (d, 2H), 7.37-7.43 (m, 2H), 7.01 (m, 1H), 6.90 (m, 2H), 6.82 (m, 2H), 3.77 (m, 2H), 3.68 (s, 3H), 3.53 (m, 2H), 3.08 (m, 2H), 2.97 (m, 2H), 2.09 (s, 3H). MS (EI) for $C_{30}H_{30}N_6O_3$: 523.7 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-methyl-N-{[2-(methyloxy)-phenyl]methyl}benzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.23 (s, 1H), 9.80 (s, 1H), 8.37 (m, 1H), 8.14 (d, 2H), 7.76 (m, 3H), 7.39 (d, 2H), 7.25-7.32 (m, 2H), 7.14-7.18 (m, 1H), 7.04 (m, 1H), 6.95 (d, 2H), 4.57 (d, 2H), 3.76 (d, 3H), 2.88 (s, 3H), 2.09 (s, 3H). MS (EI) for $C_{28}H_{27}N_5O_3$: 482.7 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[(2-fluorophenyl)methyl]-N-methylbenzamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.23 (s, 1H), 9.08 (s, 1H), 8.52 (m, 1H), 8.14 (d, 2H), 8.01 (m, 1H), 7.89 (m, 1H), 7.75 (d, 2H), 7.38 (m, 4H), 7.21 (m, 2H), 7.01 (m, 1H), 4.67 (d, 2H), 2.91 (s, 3H), 2.09 (s, 3H). MS (EI) for $C_{27}H_{24}FN_5O_2$: 470.6 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-(2-pyridin-2-ylethyl)-benzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 (s, 1H), 9.78 (s, 1H), 8.51-8.54 (m, 3H), 8.46 (s, 1H), 8.18 (d, 2H), 7.86-7.88 (m, 1H), 7.76 (d, 2H), 7.69-7.73 (m, 1H), 7.37-7.40 (m, 3H), 7.31 (m, 1H), 7.21-7.24 (m, 1H), 3.61-3.66 (m, 2H), 3.02 (m, 2H), 2.09 (s, 3H). MS (EI) for $C_{26}H_{24}N_6O_2$: 453.6 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-(pyridin-2-ylmethyl)-benzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 (s, 1H), 9.81 (s, 1H), 9.06 (m, 1H), 8.52 (m, 2H), 8.19 (d, 2H), 7.91 (m, 1H), 7.73-7.79 (m, 3H), 7.51 (d, 1H), 7.40 (m, 2H), 7.30 (d, 1H), 7.25-7.27 (m, 1H), 4.59 (d, 2H), 2.09 (s, 3H). MS (EI) for $C_{25}H_{22}N_6O_2$: 439.8 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-(pyridin-3-ylmethyl)-benzamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.22 (s, 1H), 9.78 (s, 1H), 8.52 (d, 1H), 8.45 (s br, 1H), 8.25 (d, 1H), 7.18 (d, 3H), 7.82-7.85 (m, 1H), 7.76 (d, 3H), 7.35-7.41 (m, 4H), 4.25 (m, 2H), 2.09 (s, 3H). MS (EI) for $C_{25}H_{22}N_6O_2$: 438.6 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-(pyridin-4-ylmethyl)-benzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 (s, 1H), 9.80 (s, 1H), 9.08 (t, 1H), 8.50-8.54 (m, 4H), 8.18 (d, 2H), 7.92 (d, 1H), 7.74 (d, 2H), 7.49 (d, 1H), 7.42 (t, 1H), 7.40 (d, 1H), 7.31 (d, 2H), 4.51 (d, 2H), 2.09 (s, 3H). MS (EI) for $C_{25}H_{22}N_6O_2$: 438.5 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-methyl-N-(phenylmethyl)-benzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.23 (s, 1H), 9.81 (s, 1H), 8.53 (s br, 1H), 8.14 (d, 2H), 7.46 (d, 2H), 7.23-7.46 (m, 8H), 7.21 (s br, 1H), 7.02 (s br, 1H), 4.56 (d, 2H), 2.95 (s, 3H), 2.09 (s, 3H). MS (EI) for $C_{27}H_{25}N_5O_2$: 452.7 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-cyclopentylbenzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 (s, 1H), 9.75 (s, 1H), 8.52 (d, 1H), 8.45 (s br, 1H), 8.25 (d, 1H), 8.17 (d, 2H), 7.84 (d, 1H) 7.75 (d, 2H), 7.35-7.42 (m, 3H), 4.22-4.27 (m, 1H), 2.09 (s, 3H), 1.88-1.93 (m, 2H), 1.70 (m, 2H), 1.49-1.59 (m, 4H). MS (EI) for $C_{24}H_{25}N_5O_2$: 416.8 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[(2-chlorophenyl)methyl]-benzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 (s, 1H), 9.80 (s, 1H), 9.00 (t, 1H), 8.53 (d, 1H), 8.50 (s br, 1H), 8.18 (d, 2H), 7.93 (d, 1H), 7.63 (d, 2H), 7.52 (d, 1H), 7.28-7.48 (m, 6H), 4.56 (d, 2H), 2.09 (s, 3H). MS (EI) for $C_{26}H_{22}ClN_5O_2$: 473.0 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[(4-chlorophenyl)methyl]-benzamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.22 (s, 1H), 9.79 (s, 1H), 9.02 (t, 1H), 8.52 (d, 1H), 8.50 (s br, 1H), 8.18 (d, 2H), 7.90 (d, 1H), 7.74 (d, 2H), 7.46 (d, 1H), 7.41 (m, 2H), 7.38 (s, 2H), 7.36 (m, 2H), 4.48 (d, 2H), 2.09 (s, 3H). MS (EI) for $C_{26}H_{22}ClN_5O_2$: 473.1 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-(furan-2-ylmethyl)-benzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 (s, 1H), 9.78 (s, 1H), 8.91 (t, 1H), 8.52 (d, 1H), 8.48 (s br, 1H), 8.17 (d, 2H), 7.88 (d, 1H), 7.76 (d, 2H), 7.58 (m, 1H), 7.44 (d, 1H), 7.37-7.41 (m, 2H), 6.41 (m, 1H), 6.28 (dd, 1H), 4.48 (d, 2H), 2.09 (s, 3H). MS (EI) for $C_{24}H_{21}N_5O_3$: 428.6 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-{[4-(methyloxy)phenyl]-methyl}benzamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.22 (s, 1H), 9.77 (s, 1H), 8.92 (t, 1H), 8.52 (d, 1H), 8.49 (s br, 1H), 8.19 (d, 2H), 7.88 (d, 1H), 7.76 (d, 2H), 7.45 (d, 1H), 7.37-7.41 (m, 2H), 7.27 (d, 2H), 6.89 (d, 2H), 4.42 (d, 2H), 3.72 (s, 3H), 2.08 (s, 3H). MS (EI) for $C_{27}H_{25}N_5O_3$: 468.4 (MH^+).

N-[4-(2-{[3-({4-[2-(methyloxy)phenyl]piperazin-1-yl}carbonyl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 (s, 1H), 9.82 (s, 1H), 8.53 (d, 1H), 8.14 (d, 2H), 8.06 (s, 1H) 7.86 (d, 1H), 7.76 (d, 2H), 7.40 (m, 2H), 7.01 (d, 1H), 6.59 (m, 2H), 6.88 (s, 2H), 3.78 (s, 3H), 3.55 (m, 2H), 3.03 (m, 2H), 2.94 (s, 2H), 2.79 (s, 2H), 2.09 (s, 3H). MS (EI) for $C_{30}H_{30}N_6O_3$: 523.5 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[3-(methyloxy)propyl]-benzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 (s, 1H), 9.76 (s, 1H), 8.52 (d, 1H), 8.46 (s br, 1H), 8.40 (t, 1H), 8.18 (d, 2H), 7.85-7.88 (m, 1H), 7.75 (d, 2H), 7.38-7.40 (m, 3H), 3.40 (m, 2H), 3.30 (m, 2H), 3.24 (s, 3H), 2.09 (s, 3H), 1.74-1.80 (m, 2H). MS (EI) for $C_{23}H_{25}N_5O_3$: 420.5 (MH^+).

N-(4-{2-[(3-{[(2R,6S)-2,6-dimethylmorpholin-4-yl]carbonyl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.23 (s, 1H), 9.81 (s, 1H), 8.53 (d, 1H), 8.13 (d, 2H), 7.99 (m, 1H), 7.86 (d, 1H), 7.76 (d, 2H), 7.37-7.41 (m, 2H), 6.98 (d, 1H), 2.94 (s, 2H), 2.79 (s, 2H), 2.09 (s, 3H), 1.96 (s, 1H), 1.16 (m, 3H), 0.99 (m, 3H). MS (EI) for $C_{25}H_{27}N_5O_3$: 445.5 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-[(6-chloropyridin-3-yl)methyl]benzamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.22 (s, 1H), 9.79 (s, 1H), 9.06

(t, 1H), 8.52 (d, 1H), 8.49 (s, 1H), 8.40 (d, 1H), 8.18 (d, 2H), 7.91 (m, 2H), 7.81 (dd, 1H), 7.74 (d, 2H), 7.49 (d, 1H), 7.41-7.46 (m, 2H), 7.39 (d, 1H), 4.50 (d, 2H), 2.09 (s, 3H). MS (EI) for $C_{25}H_{21}ClN_6O_2$: 474.1 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-butylbenzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.24 (s, 1H), 9.80 (s, 1H), 8.53 (d, 1H), 8.13 (d, 2H), 8.02 (s br, 1H), 7.78 (m, 1H), 7.75 (d, 2H), 7.39 (d, 1H), 7.35 (d, 1H), 6.91 (d, 2H), 3.26 (m, 2H), 2.09 (s, 3H), 1.62 (m, 2H), 1.32 (m, 2H), 1.08 (m, 3H). MS (EI) for $C_{23}H_{25}N_5O_2$: 404.5 (MH^+).

N-(4-{2-[(3-{[4-(2-chlorophenyl)piperazin-1-yl]carbonyl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 (s, 1H), 9.83 (s, 1H), 8.53 (d, 1H), 8.14 (d, 2H), 7.90 (s br, 1H), 7.85 (d, 1H), 7.76 (d 2H), 7.38-7.43 (m, 3H), 7.28 (m, 1H), 7.13 (dd, 1H), 7.07 (dd, 1H), 7.03 (m, 1H), 3.81 (m, 4H), 3.58 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{29}H_{27}ClN_6O_2$: 528.1 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-ethyl-N-[2-(methyloxy)-ethyl]benzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 (s, 1H), 9.80 (s, 1H), 8.53 (d, 1H), 8.13 (d, 2H), 7.99 (m, 2H), 7.82 (m, 1H), 7.76 (d, 2H), 7.39 (d, 2H), 7.36 (d, 2H), 6.92 (d, 1H), 3.57 (m, 2H), 3.12 (m, 2H), 2.94 (s, 3H), 2.09 (s, 3H), 1.10 (m, 3H). MS (EI) for $C_{24}H_{27}N_5O_3$: 434.4 (MH^+).

N-{4-[2-({4-[4-(phenylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.35 (d, 4H), 7.27 (d, 2H), 6.92 (d, 2H), 3.54 (s, 2H), 3.9 (m, 4H), 2.53 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{29}H_{30}N_6O$: 479.7 (MH^+).

N-(4-{2-[(4-{4-[(5-methyl-3-phenylisoxazol-4-yl)methyl]piperazin-1-yl}phenyl)-amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.20 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.93-7.96 (m, 2H), 7.74 (d, 2H), 7.66 (d, 2H), 7.50-7.53 (m, 3H), 7.26 (d, 1H), 6.93 (d, 2H), 3.43 (s, 2H), 3.09 (m, 4H), 2.56 (m, 4H), 2.48 (s, 3H), 2.09 (s, 3H). MS (EI) for $C_{33}H_{33}N_7O_2$: 560.4 (MH^+).

N-(4-{2-[(4-{4-[(5-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]piperazin-1-yl}-phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.56 (s, 1H), 7.53 (d, 4H), 7.40-7.45 (m, 1H), 7.26 (d, 1H), 6.92 (d, 2H), 3.43 (s, 2H), 3.09 (m, 4H), 2.56 (m, 4H), 2.31 (s, 3H), 2.09 (s, 3H). MS (EI) for $C_{33}H_{34}N_8O$: 559.7 (MH^+).

N-(4-{2-[(4-{4-[(2-phenyl-1,3-thiazol-4-yl)methyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.94 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.57 (s, 1H), 7.48-7.53 (m, 3H), 7.26 (d, 1H), 6.93 (d, 1H), 3.73 (s, 2H), 3.11 (m, 4H), 2.65 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{32}H_{31}N_7OS$: 562.5 (MH^+).

N-[4-(2-{[4-(4-{[6-(phenyloxy)pyridin-3-yl]methyl}piperazin-1-yl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.23 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 8.07 (d, 1H), 7.81 (dd, 1H), 7.74 (d, 2H), 7.65 (d, 2H), 7.43 (t, 2H), 7.26 (d, 1H), 7.19-7.23 (m, 1H), 7.14 (d, 2H), 7.01 (d, 1H), 6.92 (d, 2H), 3.21 (s, 2H), 3.08 (m, 4H), 2.48 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{34}H_{33}N_7O_2$: 572.4 (MH^+).

N-{4-[2-({4-[4-(cyclohexylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H), 6.92 (d, 2H), 3.06 (m, 4H), 2.47 (m, 4H), 2.13 (d, 2H), 2.09 (s, 3H), 1.76 (d, 2H), 1.65 (m, 3H), 1.49-1.54 (m, 1H), 1.12-1.17 (m, 3H), 080-0.89 (m, 2H). MS (EI) for $C_{29}H_{36}N_6O$: 485.8 (MH^+).

N-(4-{2-[(4-{4-[(1S,4S)-bicyclo[2.2.1]hept-5-en-2-ylmethyl]piperazin-1-yl}phenyl)-amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H), 6.92 (d, 2H), 6.14-6.16 (m, 1H), 5.95-5.97 (m, 1H), 3.07 (m, 4H), 2.79 (d, 2H), 2.45 (m, 4H), 2.32-2.39 (m, 2H), 2.09 (s, 3H), 1.95-1.99 (m, 1H), 1.81-1.87 (m, 1H), 1.31 (m, 1H), 1.23 (m, 1H), 0.51 (m, 1H). MS (EI) for $C_{30}H_{34}N_6O$: 495.7 (MH^+)

N-[4-(2-{[4-(4-pentylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H), 6.92 (d, 2H), 3.07 (m, 4H), 2.55 (m, 4H), 2.307 (t, 2H), 2.09 (s, 3H), 1.43-1.49 (m, 2H), 1.22-1.34 (m, 4H), 0.88 (t, 3H). MS (EI) for $C_{27}H_{34}N_6O$: 459.7 (MH^+).

N-(4-{2-[(4-{4-[(2-chlorophenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.21 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.66 (d, 2H), 7.54 (dd, 1H), 7.45 (dd, 1H), 7.29-7.39 (m, 2H), 7.26 (d, 1H), 6.93 (d, 2H), 3.64 (s, 2H), 3.10 (m, 4H), 2.60 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{29}H_{29}ClN_6O$: 514.1 (MH^+).

N-[4-(2-{[4-(4-{[3,5-bis(methyloxy)phenyl]methyl}piperazin-1-yl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H), 6.93 (d, 2H), 6.51 (d, 2H), 6.39 (t, 1H), 3.75 (s, 6H), 3.46 (s, 2H), 3.09 (m, 4H), 2.61 (m, 4H), 2.09 (s. 3H). MS (EI) for $C_{31}H_{34}N_6O_3$: 539.8 (MH^+).

N-(4-{2-[(4-{4-[(4-fluorophenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.36-7.39 (m, 2H), 7.26 (d, 1H), 7.16 (t, 2H), 6.92 (d, 2H), 3.51 (S, 2H), 3.08 (m, 4H), 2.28 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{29}H_{29}FN_6O$: 497.8 (MH^+).

N-(4-{2-[(4-{4-[(1-methyl-1H-pyrrol-2-yl)methyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H), 6.92 (d, 2H), 6.68 (t, 1H), 5.88-5.91 (m, 2H), 3.61 (s, 2H), 3.4 (s, 3H), 3.06 (m, 4H), 2.58 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{28}H_{31}N_7O$: 482.8 (MH^+).

N-[4-(2-{[4-(4-{[5-(3-chlorophenyl)furan-2-yl]methyl}piperazin-1-yl)phenyl]-amino}pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.20 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.72-7.76 (m, 3H), 7.63-7.66 (m, 3H), 7.45 (t, 1H), 7.33 (d, 1H), 7.26 (d, 1H), 7.06 (d, 1H), 6.92 (d, 2H), 6.48 (d, 1H), 3.64 (s, 2H), 3.10 (m, 4H), 2.60 (m, 4H), 20.9 (s, 3H). MS (EI) for $C_{33}H_{31}ClN_6O$: 580.3 (MH^+).

N-[4-(2-{[4-(4-{[4-fluoro-2-(trifluoromethyl)phenyl]methyl}piperazin-1-yl)phenyl]-amino}pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 (s, 1H), 9.37 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.84-7.88 (m, 1H), 7.74 (d, 2H), 7.66 (d, 2H), 7.54-7.72 (m, 2H), 7.26 (d, 1H), 6.93 (d, 2H), 3.66 (s, 2H), 3.10 (m, 4H), 2.56 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{30}H_{28}F_4N_6O$: 565.3 (MH^+).

N-[4-(2-{[4-(4-{[4-(1H-imidazol-1-yl)phenyl]methyl}piperazin-1-yl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400MHz, d_6-DMSO):10.21 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.25 (t, 1H), 7.11 (d, 2H), 7.74 (d, 3H), 7.61-7.67 (m, 4H), 7.48 (d, 2H), 7.26 (d, 1H), 7.11 (t, 1H), 6.93 (d, 2H), 3.58 (s, 2H), 3.10 (m, 4H), 2.55 (m, 4H), 20.9 (s, 3H). MS (EI) for $C_{32}H_{32}N_8O$: 545.8 (MH^+).

N-[4-(2-{[4-(4-{[2,5-bis(trifluoromethyl)phenyl]methyl}piperazin-1-yl)phenyl]-amino}pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.20 (s,

1H), 9.37 (s, 1H), 8.43 (d, 1H), 8.17 (s, 1H), 8.10 (d, 2H), 8.00 (d, 1H), 7.89 (d, 1H), 7.74 (d, 2H), 7.67 (d, 2H), 7.26 (d, 1H), 6.94 (d, 2H), 3.79 (s, 2H), 3.12 (m, 4H), 2.60 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{31}H_{28}F_6N_6O$: 615.7 (MH^+).

N-(4-{2-[(4-{4-[(2,6-dimethylphenyl)methyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.20 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.24 (d, 2H), 7.64 (d, 2H), 7.26 (d, 1H), 7.00-7.08 (m, 3H), 6.90 (d, 2H), 3.50 (s, 2H), 3.02 (m, 4H), 2.54 (m, 4H), 2.37 (s, 6H), 2.09 (s, 3H). MS (EI) for $C_{31}H_{34}N_6O$: 507.7 (MH^+).

N-(4-{2-[(4-{4-[(2,3-dimethylphenyl)methyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.74 (d 2H), 7.65 (d, 2H), 7.26 (d, 1H), 7.01-7.09 (m, 3H), 6.91 (d, 2H), 3.45 (s, 2H), 3.05 (m, 4H), 2.53 (m, 4H), 2.24 (d, 6H), 2.09 (s, 3H). MS (EI) for $C_{31}H_{34}N_6O$: 507.8 (MH^+).

N-[4-(2-{[4-(4-{[2,4-bis(ethyloxy)phenyl]methyl}piperazin-1-yl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 (s, 1H), 9.35 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.64 (d, 2H), 7.26 (d, 1H), 7.19 (d, 1H), 6.91 (d, 2H), 6.47-6.51 (m, 2H), 3.97-4.04 (m, 4H), 3.46 (s, 2H), 3.06 (m, 4H), 2.52 (m, 4H), 2.09 (s, 3H), 1.30-1.35 (m, 6H). MS (EI) for $C_{33}H_{38}N_6O_3$: 567.8 (MH^+).

N-[4-(2-{[4-(4-{[3-(ethyloxy)phenyl]methyl}piperazin-1-yl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 (s, 1H), 9.36 (s, 1H), 8.45 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.24 (t, 1H), 7.11-7.19 (m, 3H), 7.02-7.09 (m, 3H), 6.91 (d, 2H), 3.96-4.00 (m, 2H), 3.40 (s, 2H), 3.07 (m, 4H), 2.59 (m, 4H), 2.09 (s, 3H), 1.32-1.38 (m, 3H). MS (EI) for $C_{31}H_{34}N_6O_2$: 523.8 (MH^+).

N-{4-[2-({4-[4-(3-methylbutanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.23 (s, 1H), 9.04 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.27 (d, 1H), 6.96 (d, 2H) 3.67 (m, 4H), 3.06 (m, 2H), 3.02 (m, 2H), 2.24 (d, 2H), 2.09 (s, 3H), 1.97-2.09 (m, 1H), 0.92 (d, 6H). MS (EI) for $C_{27}H_{32}N_6O_2$: 473.8 (MH^+).

N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.27 (d, 1H), 6.95 (d, 2H), 3.59 (m, 2H),

3.46 (m, 2H), 3.39 (t, 1H), 3.02 (m, 4H), 2.11-2.23 (m, 4H), 2.09 (s, 3H), 1.89-1.92 (m, 1H), 1.72-1.78 (m, 1H). MS (EI) for $C_{27}H_{30}N_6O_2$: 470.7 (MH^+).

N-{4-[2-({4-[4-(cyclopentylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.27 (d, 1H), 6.96 (d, 2H), 3.63 (m, 4H), 3.04 (m, 4H), 2.98 (m, 1H), 2.09 (s, 3H), 1.74-2.09 (m, 2H), 1.51-1.72 (m, 6H). MS (EI) for $C_{28}H_{32}N_6O_2$: 485.5 (MH^+).

N-[4-(2-{[4-(4-{[2-(methyloxy)phenyl]carbonyl}piperazin-1-yl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.68 (d, 2H), 7.42 (m, 1H), 7.27 (d, 1H), 7.22 (dd, 1H), 7.10 (d, 1H), 7.02 (m, 1H), 6.96 (d, 2H), 3.81 (s, 3H), 3.77 (m, 2H), 3.27 (m, 2H), 3.12 (m, 2H), 3.01 (m, 2H), 2.09 (s, 3H). MS (EI) for $C_{30}H_{30}N_6O_3$: 523.7 (MH^+).

N-(4-{2-[(4-{4-[(2-methylphenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.30-7.36 (m, 2H), 7.28 (d, 2H), 7.19-7.24 (m, 1H), 6.96 (d, 2H), 3.82 (m, 2H), 3.28 (m, 2H), 3.16 (m, 2H), 3.00 (m, 2H), 2.25 (s, 3H), 2.09 (s, 3H). MS (EI) for $C_{30}H_{30}N_6O_2$: 507.8 (MH^+).

N-[4-(2-{[3-(4-{[2-(methyloxy)phenyl]methyl}piperazin-1-yl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.21 (s, 1H), 9.46 (s, 1H), 8.49 (d, 1H), 8.12 (d, 2H), 7.73 (d, 2H), 7.63 (s, 1H), 7.36 (d, 1H), 7.32 (d, 1H), 7.21 (m, 2H), 7.10 (t, 1H), 6.98 (m, 2H), 6.55 (d, 1H), 3.80 (s, 3H), 3.54 (s, 2H), 3.16 (m, 4H), 2.57 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{30}H_{32}N_6O_2$: 509.6 (MH+).

N-{4-[2-({4-[(2R,6S)-2,6-dimethylmorpholin-4-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.44 (s, 1H), 10.07 (s, 1H), 8.74 (s, 1H), 8.57 (d, 1H), 8.21 (s, 2H), 7.90 (m, 4H), 7.73 (s, 2H), 7.48 (d, 1H), 4.49 (m, 1H), 4.24 (m, 2H), 4.02 (m, 1H), 3.57 (m, 3H), 3.29 (m, 2H), 1.99 (m, 4H), 1.18 (m, 7H). MS (EI) for $C_{27}H_{32}N_6O_2$: 473.5 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-5-oxo-D-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.33 (s, 1H), 9.39 (s, 1H), 8.45 (d, 1H), 8.14 (d, 2H), 7.93 (s, 1H), 7.79 (d, 2H), 7.67 (d, 2H), 7.28 (d, 1H), 6.93 (d, 2H), 4.23 (m,

1H), 3.75 (m, 4H), 3.05 (m, 4H), 2.35 (m, 1H), 2.21 (m, 2H), 2.03 (m, 1H). MS (EI) for $C_{25}H_{26}N_6O_3$: 459.5 (MH+).

N^1-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-aspartamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.71 (s, 1H), 10.09 (s, 1H), 8.94 (s, 3H), 8.58 (d, 1H), 8.23 (d, 2H), 7.91 (m, 4H), 7.73 (s br, 2H), 7.49 (d, 1H), 4.52 (m, 4H), 4.05 (m, 5H), 3.33 (d, 1H), 3.29 (d, 1H). MS (EI) for $C_{24}H_{27}N_7O_3$: 462.5 (MH+).

N^1-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-glutamamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.39 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.83 (d, 2H), 7.67 (d, 2H), 7.35 (s, 1H), 7.29 (d, 1H), 6.93 (d, 2H), 6.77 (s, 1H), 3.75 (m, 4H), 3.37 (t, 1H), 3.05 (m, 4H), 1.88 (m, 2H), 1.70 (m, 1H). MS (EI) for $C_{25}H_{29}N_7O_3$: 476.5 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-threoninamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.26 (s, 1H), 9.89 (s, 1H), 8.54 (d, 1H), 8.31 (s, 2H), 8.19 (d, 2H), 7.86 (d, 3H), 7.44 (m, 3H), 4.11 (m, 2H), 3.96 (m, 4H), 3.39 (m, 4H), 1.23 (d, 3H) . MS (EI) for $C_{24}H_{28}N_6O_3$: 449.5 (MH+).

N-(4-{2-[(3-chloro-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.43 (s, 1H), 9.99 (s, 1H), 8.55 (d, 1H), 8.20 (d, 2H), 8.03 (s, 1H), 7.89 (2H), 7.71 (dd, 1H), 7.46 (d, 2H), 7.20 (d, 1H), 4.49 (m, 1H), 3.76 (m, 4H), 3.28 (m, 2H), 2.96 (m, 4H), 1.97 (m, 4H). MS (EI) for $C_{25}H_{27}ClN_6O_2$: 479.9 (MH+).

N-(4-{2-[(3-chloro-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.55 (s, 1H), 10.15 (s, 1H), 8.56 (d, 1H), 8.21 (d, 2H), 8.01 (s, 1H), 7.89 (d, 2H), 7.71 (dd, 1H), 7.49 (d, 2H), 7.23 (d, 1H), 4.51 (m, 1H), 3.76 (m, 4H), 3.29 (m, 2H), 2.97 (m, 4H), 1.97 (m, 4H). MS (EI) for $C_{25}H_{27}ClN_6O_2$: 479.9 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-leucinamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.41 (s, 1H), 10.05 (s, 1H), 8.56 (d, 1H), 8.60 (m, 3H), 8.25 (d, 2H), 7.96 (m, 3H), 7.69 (m, 2H), 7.47 (d, 1H),4.14 (m, 1H), 4.04 (m, 4H), 3.57 (m, 4H), 1.71 (m, 2H), 1.19 (m, 1H), 1.00 (s, 6H). MS (EI) for $C_{26}H_{32}N_6O_2$: 461.5 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-isoleucinamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.41 (s, 1H), 10.10 (s, 1H), 8.56 (d,

1H), 8.47 (m, 2H), 8.20 (d, 2H), 7.92 (m, 3H), 7.73 (m, 2H), 7.47 (d, 1H), 4.12 (m, 4H), 3.57 (m, 4H), 1.65 (m, 2H), 1.18 (m, 2H), 1.00 (d, 3H), 0.89 (t, 3H). MS (EI) for $C_{26}H_{32}N_6O_2$: 461.5 (MH+).

(2R)-2-amino-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-butanamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.57 (s, 1H), 10.20 (s, 1H), 8.56 (m, 3H), 8.24 (m, 2H), 7.97 (m, 4H), 7.82 (s, 1H), 7.54 (s, 1H), 4.05 (m, 5H), 1.96 (m, 4H), 1.10 (m, 5H). MS (EI) for $C_{24}H_{28}N_6O_2$: 433.5 (MH+).

N-(4-{2-[(3-aminophenyl)amino]pyrimidin-4-yl}phenyl)thiophene-2-carboxamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.5 (s, 1H), 9.40 (br s, 1H), 8.55 (d, 1H), 8.23 (d, 2H), 8.09 (dd, 1H), 7.96-7.91 (m, 5H), 7.53 (m, 1H), 7.45 (d, 1H), 7.32-7.25 (m, 3H), 6.74 (br s, 1H). MS (EI): 388.0 (MH+).

N-(3-{[4-(4-aminophenyl)pyrimidin-2-yl]amino}phenyl)-2,6-dichlorobenzamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.7 (s, 1H), 9.67 (s, 1H), 8.37-8.35 (m, 2H), 8.01 (d, 2H), 7.61-7.58 (m, 2H), 7.51-7.49 (m, 1H), 7.44 (dt, 1H), 7.31-7.22 (m, 3H), 6.69 (d, 2H), 5.95 (br, 2H)); MS (EI): 450.0 (MH+).

4-{[2-chloro-4-(methyloxy)phenyl]oxy}-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine: ^{1}H-NMR (400MHz, d6-DMSO): 9.37 (s, 1H), 8.31 (d, 1H), 7.33-7.23 (m, 4H), 7.02 (dd, 1H), 7.00 (br d, 2H), 6.41 (d, 1H), 3.83 (s, 3H), 3.73-3.71 (m, 4H), 2.98-2.96 (m, 4H). MS (EI): 412.8 (MH+).

N-[4-({2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}oxy)phenyl]acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.2 (s, 1H), 9.92 (br s, 1H), 8.33 (d, 1H), 7.66 (d, 2H), 7.42 (br s, 2H), 7.17 (d, 2H), 7.10 (br s, 2H), 6.50 (d, 1H), 3.86 (br s, 4H), 3.24 (br s, 4H), 2.08 (s, 3H); MS (EI): 406.1 (MH+).

N-[4-(2-{[4-(4-D-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-3-(methyloxy)propanamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.3 (s, 1H), 9.61 (br s, 1H), 8.46 (d, 1H), 8.16-8.12 (m, 4H), 7.78 (d, 2H), 7.72 (d, 2H), 7.34 (d, 1H), 7.12 (br s, 2H), 4.47-4.44 (m, 1H), 3.80 (br s, 4H), 3.64 (t, 2H), 3.64 (s, 3H), 3.07 (br s, 4H), 2.60 (t, 2H), 1.34 (d, 3H); MS (EI): 504.2 (MH+).

3-(methyloxy)-N-[4-(2-{[4-(4-L-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]propanamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.3 (s, 1H), 9.51 (s, 1H), 8.54 (m, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.77 (d, 2H), 7.71 (d, 2H), 7.31 (d, 1H), 7.04 (br

d, 2H), 4.68 (m, 1H), 4.07 (br s, 4H), 3.64 (t, 2H), 3.25 (s, 3H), 3.17 (br s, 4H), 2.60 (t, 2H), 2.43-2.39 (m, 2H), 1.94-1.81 (m, 4H); MS (EI): 530.2 (MH+).

N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}cyclopropanecarboxamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.5 (s, 1H), 9.60 (br s, 1H), 8.46 (d, 1H), 8.12 (d, 2H), 7.78-7.76 (m, 4H), 7.34 (m, 1H), 7.13 (br s, 2H), 3.70 (m, 1H), 3.54 (br s, 4H), 3.41 (m, 1H), 3.16 (br s, 4H), 2.23-2.08 (m, 3H), 1.95-1.74 (m, 3H), 0.84-0.83 (m, 4H); MS (EI): 497.2 (MH+).

N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}cyclopropanecarboxamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.5 (s, 1H), 9.69 (br s, 1H), 8.47 (d, 1H), 8.13 (d, 2H), 7.77 (d, 4H), 7.36 (d, 2H), 7.23 (br s, 1H), 3.76 (br s, 4H), 3.25 (br s, 4H), 2.94 (septet, 1H), 1.84 (p, 1H), 1.03 (d, 6H), 0.84-0.83 (m, 4H). MS (EI): 485.1 (MH+).

2,6-dichloro-N-{3-[(4-{4-[(cyclopropylcarbonyl)amino]phenyl}pyrimidin-2-yl)-amino]phenyl}benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.7 (s, 1H), 10.5 (s, 1H), 9.74 (s, 1H), 8.50 (d, 1H), 8.40 (s, 1H), 8.21 (d, 2H), 7.76 (d, 2H), 7.61-7.59 (m, 2H), 7.53-7.49 (m, 1H), 7.47-7.45 (m, 1H), 7.39 (d, 1H), 7.31-7.22 (m, 2H), 1.83 (p, 1H), 0.83-0.81 (m, 4H); MS (EI): 518.1 (MH+).

2,6-dichloro-N-(3-{[4-(1H-indol-5-yl)pyrimidin-2-yl]amino}phenyl)benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 11.3 (s, 1H), 10.7 (s, 1H), 9.56 (s, 1H), 8.45 (s, 1H), 8.39 (d, 1H), 8.31 (s, 1H), 7.96 (dd, 1H), 7.54-7.52 (m, 2H), 7.46-7.41 (m, 3H), 7.37-7.34 (m, 2H), 7.21 (d, 2H), 6.48-6.48 (m, 1H). MS (EI): 474.0 (MH+).

N-(4-{2-[(3-aminophenyl)amino]pyrimidin-4-yl}phenyl)-2-morpholin-4-ylacetamide: ^{1}H-NMR (400MHz, d6-DMSO): 11.0 (s, 1H), 10.4 (br, 2H), 9.89 (s, 1H), 8.56 (d, 1H), 8.23 (d, 2H), 7.82-7.79 (m, 3H), 7.62 (br, 1H), 7.44 (d, 1H), 7.34 (br, 1H), 6.8 (br, 1H), 4.24 (s, 2H), 3.96-3.84 (m, 8H); MS (EI): 405.3 (MH+).

N-(4-phenylpyrimidin-2-yl)benzene-1,3-diamine: ^{1}H-NMR (400MHz, d6-DMSO): 9.37 (s, 1H), 8.51 (d, 1H), 8.19-8.16 (m, 2H), 7.57-7.53 (m, 3H), 7.37-7.36 (d, 1H), 7.10 (t, 1H), 7.00-6.91 (m, 2H), 6.22-6.20 (m, 1H), 5.00 (s, 2H). MS (EI): 263.3 (MH+).

N-[3-({4-[4-(acetylamino)-2-chlorophenyl]pyrimidin-2-yl}amino)phenyl]-2,6-dichlorobenzamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.7 (s, 1H), 10.3 (s, 1H), 9.78 (s,

1H), 8.52 (d, 1H), 8.13-8.12 (m, 1H), 7.93 (s, 1H), 7.71 (d, 1H), 7.30-7.21 (m, 5H), 7.30-7.21 (m, 2H), 7.11 (d, 1H), 2.07 (s, 3H). MS (EI): 527.9 (MH+).

2,6-dichloro-N-{3-[(4-phenylpyrimidin-2-yl)amino]phenyl}benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.7 (s, 1H), 9.76 (s, 1H), 8.56 (d, 1H), 8.39 (s, 1H), 8.26-8.23 (m, 2H), 7.61-7.59 (m, 2H), 7.55-7.48 (m, 5H), 7.44 (d, 1H), 7.31-7.24 (m, 2H); MS (EI): 437.0 (MH+).

4-(2,4-dichlorophenyl)-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine: ^{1}H-NMR (400MHz, d6-DMSO): 9.59 (s, 1H), 8.52 (d, 1H), 7.80 (d, 1H), 7.66 (d, 1H), 7.63-7.58 (m, 3H), 7.00 (d, 1H), 6.88 (d, 2H), 3.74-3.72 (m, 4H), 3.04-3.01 (m, 4H); MS (EI): 401.0 (MH+).

4-(2,4-dichlorophenyl)-N-{3-[(4-ethylpiperazin-1-yl)carbonyl]phenyl}pyrimidin-2-amine: ^{1}H-NMR (400MHz, d6-DMSO): 10.0 (s, 1H), 8.62 (d, 1H), 7.92 (s, 1H), 7.82 (d, 1H), 7.76 (dd, 1H), 7.70-7.68 (m, 1H), 7.62-7.59 (m, 1H), 7.34 (t, 1H), 7.13 (d, 1H), 6.96-6.94 (m, 1H), 3.59 (br s, 2H), 3.32 (br s, 2H), 2.37 (br s, 2H), 2.30 (q, 2H), 2.22 (br s, 2H), 0.99 (t, 3H); MS (EI): 456.0 (MH+).

2,6-dichloro-N-(3-{[4-(2,4-dichlorophenyl)pyrimidin-2-yl]amino}phenyl)benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.7 (s, 1H), 9.89 (s, 1H), 8.59 (d, 1H), 8.14-8.13 (m, 1H), 7.80 (d, 1H), 7.77 (d, 1H), 7.59-7.48 (m, 5H), 7.32-7.23 (m, 2H), 7.14 (d, 1H); MS (EI): 504.9 (MH+).

N-(2-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 11.3 (s, 1H), 9.61 (s, 1H), 8.53 (d, 1H), 8.19 (d, 1H), 7.79 (d, 1H), 7.50 (d, 2H), 7.48-7.44 (m, 1H), 7.22 (td, 1H), 7.14 (d, 1H), 6.94 (d, 2H), 3.75-3.73 (m, 4H), 3.06-3.03 (m, 4H), 1.69 (s, 3H). MS (EI): 390.1 (MH+).

4-[3-(methyloxy)phenyl]-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine: ^{1}H-NMR (400MHz, d6-DMSO): 9.45 (s, 1H), 8.49 (d, 1H), 7.73-7.66 (m, 4H), 7.45 (t, 1H), 7.34 (d, 1H), 7.13-7.10 (m, 1H), 6.92 (d, 2H), 3.86 (s, 3H), 3.75-3.35 (m, 4H), 2.51-2.50 (m, 4H). MS (EI): 363.1 (MH+).

4-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine: ^{1}H-NMR (400MHz, d6-DMSO): 9.36 (s, 1H), 8.41 (d, 1H), 7.69-7.64 (m, 4H), 7.25 (d, 1H), 6.99 (d, 1H), 6.92 (d, 2H), 4.33-4.30 (m, 4H), 3.75-3.73 (m, 4H), 3.06-3.03 (m, 4H); MS (EI): 391.1 (MH+).

3-(methyloxy)-N-{4-[2-({4-[4-(piperazin-1-ylacetyl)piperazin-1-yl]phenyl}amino)-pyrimidin-4-yl]phenyl}propanamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.2 (s, 1H), 9.43 (s, 1H), 8.79 (br, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.77 (d, 2H), 7.69 (d, 2H), 7.29 (d, 1H), 6.98 (d, 2H), 3.64 (t, 2H), 3.59 (br s, 2H), 3.25 (s, 3H), 3.22 (br m, 8H), 3.13 (br m, 4H), 3.07 (br m, 4H), 2.60 (t, 2H). MS (EI): 559.3 (MH+).

N^2,N^2-dimethyl-N-[4-(2-{[4-(4-L-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]glycinamide • 1.3 AcOH: ^{1}H-NMR (400MHz, d_6-DMSO): 10.00 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.84 (d, 2H), 7.69 (d, 2H), 7.29 (d, 1H), 6.97 (d, 2H), 3.90 (m, 1H), 3.64 (m, 4H), 3.11 (s, 2H), 3.10-2.98 (m, 5H), 2.66 (m, 1H), 2.29 (s, 6H), 2.07-1.99 (m, 1H), 1.89 (s, 4H), 1.73-1.54 (m, 3H); MS (EI) $C_{29}H_{36}N_8O_2$: 529.2 (MH^+).

N^2,N^2-dimethyl-N-[4-(2-{[4-(4-D-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]glycinamide • 1.4 AcOH: ^{1}H-NMR (400MHz, d_6-DMSO): 10.00 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.84 (d, 2H), 7.69 (d, 2H), 7.29 (d, 1H), 6.97 (d, 2H), 3.97 (m, 1H), 3.64 (m, 4H), 3.12 (s, 2H), 3.11-3.0 (m, 5H), 2.70 (m, 1H), 2.29 (s, 6H), 2.07-1.99 (m, 1H), 1.90 (s, 4H), 1.75-1.55 (m, 3H); MS (EI) $C_{29}H_{36}N_8O_2$: 529.2 (MH^+).

2-(dimethylamino)-N-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide • 3 AcOH: ^{1}H-NMR (400MHz, d_6-DMSO): 10.01 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.84 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.96 (d, 1H), 3.71 (m, 2H), 3.59 (m, 2H), 3.15 (s, 2H), 3.12 (s, 2H), 3.10 (m, 2H), 3.02 (m, 2H), 2.71 (m, 4H), 2.35 (m, 4H), 2.29 (s, 6H), 1.84 (s, 9H); MS (EI) $C_{30}H_{39}N_9O_2$: 558.5 (MH^+).

1,1-dimethylethyl [(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)methyl]carbamate: ^{1}H NMR (400MHz, CDCl3): 8.20-8.22 (b, 1H), 8.05 (d, 2H), 7.65(d,1H), 7.50 (d, 2H), 7.25 (s, 1H), 7.23 (d, 2H), 7.05 (d, 2H), 5.01 (d, 1H), 4.40-4.44 (b, 2H), 3.90 (t, 4H), 3.20 (t, 4H), 1.50 (s, 9H); MS (EI) for $C_{26}H_{31}N_5O_3$: 462 (MH^+).

4-(4-(aminomethyl)phenyl)-N-(4-morpholinophenyl)pyrimidin-2-amine: ^{1}H NMR (400MHz, CD3CN): 10.10-10-20(b,1H), 8.40 (d, 1H), 8.20(d,2H), 7.80 (d, 2H), 7.60 (d, 2H), 7.50 (d, 2H), 7.45(d,1H),7.20-7.22 (b, 2H), 4.40-4.44 (b, 2H), 3.90 (t, 4H), 3.20 (t, 4H); MS (EI) for $C_{21}H_{23}N_5O$: 362 (MH^+).

methyl 4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}benzoate: ^{1}H NMR (400MHz, CDCl3):8.45(s,1H), 8.20-8.30 (m, 4H), 7.65(d,1H), 7.25 (d, 2H), 7.15 (d, 2H), 6.85 (d, 1H), 4.01(s,3H), 3.90 (t, 4H), 3.20 (t, 4H),; MS (EI) for $C_{22}H_{22}N_4O_3$: 391 (MH^+).

1-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-3-ethylurea: ^{1}H NMR (400MHz, d6-DMSO): 9.50-9.45 (b, 1H), 8.80(s,1H), 8.40(s,1H), 8.05 (d, 2H), 7.75-7.70 (m,4H), 7.30 (d, 1H), 7.05 (d, 2H),, 6.01 (d, 1H), 4.01(q,2H), 3.90 (m, 2H), 3.20 (m, 6H), 1.20 (s, 9H),1.10(t,3H); MS (EI) for $C_{28}H_{35}N_7O_2$: 502 (MH^+).

1-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-3-ethylurea: ^{1}H NMR (400MHz, d6-DMSO): 9.45 (s, 1H), 8.80(s,1H), 8.40(s,1H), 8.05 (d, 2H), 7.75-7.70 (m, 4H), 7.30 (d, 1H), 7.05 (d, 2H),, 6.01 (d, 1H), 3.80 (m, 4H),3.50(q, 2H), 3.40 (m, 4H),3.30 (m, 1H),3.20 (m, 6H),1.10(t,3H); MS (EI) for $C_{28}H_{33}N_7O_2$: 500 (MH^+).

1-ethyl-3-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}urea: ^{1}H NMR (400MHz, d6-DMSO): 9.45 (s, 1H), 8.80(s,1H), 8.40(s,1H), 8.05 (d, 2H), 7.75-7.70 (m, 4H), 7.30 (d, 1H), 7.05 (d, 2H),, 6.01 (d, 1H), 3.80 (m, 4H),3.30(q, 2H), 3.20 (m, 4H),3.10 (m, 1H),1.20 (m, 6H),1.10(t,3H); MS (EI) for $C_{27}H_{33}N_7O_2$: 488 (MH^+).

N-ethyl-4-(4-{[4-(4-{[(ethylamino)carbonyl]amino}phenyl)pyrimidin-2-yl]amino}-phenyl)piperazine-1-carboxamide: ^{1}H NMR (400MHz, d6-DMSO): 9.45 (s, 1H), 8.80(s,1H), 8.40(m,1H), 8.05 (d, 2H), 7.75-7.70 (m, 4H), 7.30 (d, 1H), 7.05 (d, 2H),6.50 (s, 1H), 6.20 (d, 1H),3.40-3.50(m, 4H),3.00-3.15 (m, 8H),1.10-1.20(m,6H); MS (EI) for $C_{26}H_{32}N_8O_2$: 489 (MH^+).

1-ethyl-3-[4-(2-{[4-(4-L-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-urea: ^{1}H NMR (400MHz, d6-DMSO): 10.20-10.25 (b, 1H), 9.45 (s, 1H), 8.40(m,1H), 8.05 (d, 2H), 7.75-7.60 (m, 6H), 7.30 (d, 1H), 7.00-6.90 (m, 2H),3.80-3.81 (m, 1H), 3.70-3.65(m, 4H),3.20-3.25 (m, 2H), 3.15-3.10 (m, 4H), 1.60-1.50 (m, 6H),1.10-1.20(m,3H); MS (EI) for $C_{28}H_{34}N_8O_2$: 515 (MH^+).

1-[4-(2-{[4-(4-L-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-3-ethyl-urea: ^{1}H NMR (400MHz, d6-DMSO): 9.70-9.65 (b, 1H), 9.25 (s, 1H), 8.40(m,1H), 8.05 (d, 2H), 7.75-7.60 (m, 4H), 7.30 (d, 1H), 7.00-6.90 (m, 2H), 6.80-6.75 (m, 1H),3.80-

3.81 (m, 1H), 3.70-3.65(m, 4H),3.60-3.55 (b, 2H), 3.25-3.20 (m, 6H),,1.10-1.20(m,6H); MS (EI) for $C_{26}H_{32}N_8O_2$: 489 (MH^+).

1-ethyl-3-{4-[2-({4-[4-(piperazin-1-ylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}urea: ^{1}H NMR (400MHz, d4-MeOH): 8.40 (m, 1H), 8.05 (d, 2H), 7.75-7.60 (m, 4H), 7.30 (d, 1H), 7.00-6.90 (m, 2H), 3.80-3.81 (m, 4H), 3.30-3.10(m, 16H), 2.80-2.90 (m, 4H),1.20(t,3H); MS (EI) for $C_{29}H_{37}N_9O_2$: 544 (MH^+).

1-ethyl-3-[4-(2-{[4-(4-D-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-urea: ^{1}H NMR (400MHz, d6-DMSO): 10.20-10.25 (b, 1H), 9.40-9.35 (b, 1H), 9.20 (s, 1H), 8.40(m,1H), 8.05 (d, 2H), 7.75-7.60 (m, 4H), 7.30 (d, 1H), 7.00-6.90 (m, 2H),6.80-6.75 (b, 1H), 3.80-3.81 (m, 1H), 3.70-3.65(m, 4H),3.20-3.25 (m, 2H), 3.15-3.10 (m, 4H), 1.60-1.50 (m, 6H),1.10-1.20(m,3H); MS (EI) for $C_{28}H_{34}N_8O_2$: 515 (MH^+).

1-[4-(2-{[4-(4-D-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-3-ethyl-urea: ^{1}H NMR (400MHz, d6-DMSO): 11.00-10.90 (b, 1H), 9.25 (s, 1H), 8.40(m,1H), 8.05 (d, 2H), 7.75-7.60 (m, 4H), 7.30 (d, 1H), 7.00-6.90 (m, 2H), 6.80-6.75 (m, 1H),3.80-3.81 (m, 1H), 3.70-3.65(m, 4H),3.60-3.55 (b, 2H), 3.25-3.20 (m, 6H),,1.10-1.20(m,6H); MS (EI) for $C_{26}H_{32}N_8O_2$: 489 (MH^+).

(R)-N-(4-(2-(4-(4-(2-ethoxyacetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)-phenyl)pyrrolidine-2-carboxamide: ^{1}H NMR (400MHz, d6-DMSO): 10.20-10.25 (b, 1H), 9.40 (s, 1H), 8.50 (d, 1H), 8.05 (d, 2H), 7.75-7.60 (m, 4H), 7.30 (d, 1H), 7.00-6.90 (m, 2H), 4.20 (s, 2H), 3.80-3.81 (m, 2H), 3.70-3.65(m, 1H),3.20-3.25 (m, 2H), 3.25-2.85 (m, 6H), 2.20 (m, 1H),1.80-1.60 (m, 6H),1.20(t, 3H); MS (EI) for $C_{29}H_{35}N_7O_3$: 530 (MH^+).

N-[4-(2-{[4-(4-formylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-D-prolinamide: ^{1}H NMR (400MHz, CDCl3): 10.10-10.00 (b, 1H), 8.30 (d, 2H), 8.05 (s, 1H), 8.00 (d, 2H), 7.75-7.60 (m, 4H), 7.30 (d, 1H), 7.00-6.90 (m, 2H), 6.10-6.00 (b, 1H), 4.20 (m, 1H), 3.80-3.60 (m, 4H), 3.20-3.25 (m, 6H), 2.20 (m, 2H),1.90-1.80 (m, 2H); MS (EI) for $C_{26}H_{29}N_7O_2$: 472 (MH^+).

N-(4-{2-[(4-{4-[4-(dimethylamino)butanoyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)-D-prolinamide: ^{1}H NMR (400MHz, d6-DMSO): 10.20-10.25 (b, 1H), 9.40 (s, 1H), 8.50 (d, 1H), 8.05 (d, 2H), 7.75-7.60 (m, 4H), 7.30 (d, 1H), 7.00-6.90 (m, 2H), 4.20 (m, 1H), 3.80-3.60 (m, 4H), 3.20-3.25 (m, 6H), 2.90-

2.85 (m, 4H), 2.40 (s, 3H), 2.30-2.22 (m, 2H), 2.20 (m, 3H), 2.05 (s, 3H), 1.90-1.80 (m, 2H); MS (EI) for $C_{31}H_{40}N_8O_2$: 557 (MH^+).

N-(4-(2-(3-aminophenylamino)pyrimidin-4-yl)phenyl)-2-phenoxyacetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.41 (s, 1H), 12.4 (s, br, 1H), 8..56 (s, 1H), 8.19 (s, 1h), 7.97-7.82 (m, 3H), 7.61-7.26 (m, 5H), 7.07-7.02 (m, 3H), 6.98 (m, 1H), 4.79 (s, 2H). MS (EI): 412 (MH+).

N-(4-(2-(4-(4-acetylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide: ^{1}H NMR (400 MHz, d4-MeOH): 10.22 (s, 1H), 9.41 (m, 1H), 8.12 (m, 2H), 7.75 (m, 2H), 7.68 (m, 2H), 7.27 (m, 1H), 3.72 (m, 4H), 6.94 (m, 2H), 3.58 (m, 4H), 3.09 (m, 2H), 3.02 (m, 2H), 2.09 (s, 3H), 2.03 (s, 3H). MS (EI): 431 (MH+).

N-(4-(2-(3-amino-2,4,5,6-tetrafluorophenylamino)pyrimidin-4-yl)phenyl)acetamide: ^{1}H NMR (400 MHz, d4-MeOH): 8.26 (m, 1H), 8.07 (m, 2H), 7.82 (m, 2H), 7.41 (m, 1H), 2.18 (s, 3H). MS (EI): 392 (MH+).

N-(4-(2-(4-(piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide: MS (EI) for $C_{22}H_{24}N_6O$: 389 (MH+).

1-amino-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)cyclopropane-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.27 (s 1H), 10.19 (s, 1H), 9.23 (m, 3H), 8.60 (m, 1H), 8.09 (m, 2H), 7.95 (m, 3H), 7.79 (m, 2H), 7.54 (m, 1H), 4.11 (m, 4H), 3.65 (m, 4H), 1.71 (m, 2H), 1.42 (m, 2H). MS (EI): 431 (MH+).

(S)-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)indoline-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.18 (s, 1H), 9.50 (m, 1H), 8.43 (m, 1H), 8.08 (m, 2H), 7.92 (m, 2H), 7.84 (m, 2H), 7.31 (m, 1H), 7.10-6.88 (m, 4H), 6.61 (m, 2H), 6.07 (m, 1H), 4.42 (m, 1H), 3.75 (m, 4H), 3.18-2.99 (m, 6H). MS (EI): 493 (MH+).

N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.34 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.77 (d, 2H), 7.67 (d, 2H), 7.28 (d, 1H), 6.93 (d, 2H), 3.95 (t, 1H), 3.82-3.69 (m, 7H), 3.25-3.16 (m, 1H), 3.05 (t, 4H), 2.13-2.06 (m, 2H). MS (EI): 446 (MH+).

N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-2-(pyridin-3-yl)-acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.53 (s, 1H), 9.34 (s, 1H), 8.54 (s, 1H), 8.47 (d, 1H), 8.33 (d,1H), 8.12 (d, 2H), 7.76 (d,3H), 7.67 (d, 2H), 7.37 (m, 1H), 7.28 (d, 1H), 6.93 (d, 2H), 3.76-3.73 (m, 6H), 3.06-3.03 (m,4H). MS (EI): 467 (MH+).

1-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-ethylurea: ^{1}H NMR (400 MHz, d6-DMSO): 9.33 (s, 1H), 9.00 (s, 1H), 8.40 (d,1H), 8.04 (d, 2H), 7.66 (d, 2H), 7.55 (d, 2H), 7.23 (d, 1H), 6.93 (d, 2H), 6.39 (t, 1H), 3.17-3.08 (m, 10H), 2.85 (s, 6H), 2.74 (s, 4H), 1.08-1.04 (m, 9H). MS (EI): 531 (MH+).

(R)-N-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 12.64 (s, 1H), 9.35 (s, 1H), 8.42 (d,1H), 8.10 (d, 2H), 7.69-7.63 (m, 4H), 7.28 (d, 1H), 6.89 (d, 2H), 3.30-3.23 (m, 1H), 3.15 (d, 2H), 3.10-3.04 (m, 4H), 2.62-2.58 (m, 4H), 2.34-2.28 (m, 1H), 2.21 (s, 6H), 2.18 (s, 2H), 2.10 (s, 2H), 1.82-1.64 (m, 4H), 0.84 (s, 6H). MS (EI): 557 (MH+).

(R)-2-amino-N-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.35 (s, 1H), 8.42 (d,1H), 8.10 (d, 2H), 7.80 (d, 2H), 7.63 (d, 2H), 7.27 (d, 1H), 6.89 (d, 2H), 3.49-3.43 (m, 1H), 3.05-3.01 (m, 4H), 2.62-2.58 (m, 4H), 2.19 (s, 6H), 2.15 (s, 2H), 2.07 (s, 2H), 1.21 (d, 3H), 0.82 (s, 6H). MS (EI): 531 (MH+).

N-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-methoxypropanamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.31 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.78 (d, 2H), 7.66 (d, 2H), 7.27 (d, 1H), 6.93 (d, 2H), 3.63 (t, 2H), 3.34 (s, 4H), 3.25 (s, 3H), 3.13 (s, 4H), 2.84 (s, 6H), 2.74 (s, 4H), 2.60 (t, 2H), 1.05 (s, 6H). MS (EI): 546 (MH+).

2-(dimethylamino)-N-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.98 (s, 1H), 9.33 (s, 1H), 8.41 (d, 1H), 8.08 (d, 2H), 7.81 (d, 2H), 7.62 (d, 2H), 7.24 (d, 1H) 6.88 (d, 2H), 3.09 (s, 2H), 3.05-3.02 (m, 4H), 2.60-2.45 (m, 4H), 2.27 (s, 6H), 2.20 (s, 6H), 2.15 (s, 2H), 2.09 (s, 2H), 0.82 (s, 6H). MS (EI): 545 (MH+).

N-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)butyramide: ^{1}H NMR (400 MHz, d6-DMSO): 10.18 (s, 1H), 9.36 (s, 1H), 8.41 (d, 1H), 8.08 (d, 2H), 7.75 (d, 2H), 7.64 (d, 2H), 7.26 (d, 1H), 6.92 (d, 2H), 3.12 (s, 4H), 3.07 (s, 4H), 2.84 (s, 6H), 2.73 (s, 4H), 2.31 (t, 2H), 1.66-1.58 (m, 2H), 1.03 (s, 6H), 0.91 (t, 3H). MS (EI): 530 (MH+).

(3S,7S)-7-(hydroxymethyl)-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)quinuclidine-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.25 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.27 (d, 1H), 6.93 (d, 2H), 3.74 (t, 4H), 3.65-3.58 (m, 2H), 3.45-3.37 (m, 3H), 3.05 (t, 4H), 2.94-2.88 (m, 3H), 2.71-2.67 (m, 1H), 2.17 (s, 1H), 1.68-1.63 (m, 2H), 1.50-1.46 (m, 1H), 1.27-1.21 (m, 1H). MS (EI): 515 (MH+).

(R)-N-(4-(2-(3-ethoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-pyrrolidine-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.45 (s, 1H), 10.04 (s, 1H), 8.59 (d, 1H), 8.21 (d, 2H), 7.87 (d, 2H), 7.49 (d, 1H), 7.44-7.41 (m, 2H), 7.32 (s, 1H), 7.19 (s, 1H), 4.51-4.45 (m, 2H), 4.28-4.25 (m, 4H), 4.09-4.01 (m, 4H), 3.68-3.52 (m, 3H), 3.33-3.23 (m, 2H), 2.49-2.42 (m, 1H), 2.03-1.91 (m, 3H), 1.49 (t, 3H). MS (EI): 489 (MH+).

N-{4-[2-({4-morpholin-4-yl-3-[(phenylmethyl)oxy]phenyl}amino)pyrimidin-4-yl]-phenyl}-D-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO):11.57 (s, 1H), 10.17 (s, 1H), 8.59 (d, 1H), 8.23 (d, 2H), 8.09 (s, 1H), 7.90 (m, 3H), 7.59 (m, 2H), 7.48 (m, 5H), 5.34 (s, 2H), 4.51 (m, 4H), 4.06 (m, 5H), 3.29 (m, 3H), 1.98 (m, 3H). MS (EI) for $C_{32}H_{34}N_6O_3$: 551.7 (MH+).

4-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-piperazine-1-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.35 (s, 1H), 8.88 (s, 1H), 8.41 (d, 1H), 8.15 (s, 1H), 8.06 (d, 1H), 7.66 (m, 3H), 7.25 (d, 1H), 6.93 (d, 2H), 3.74 (m, 4H), 3.53 (m, 8H), 3.04 (m, 4H), 3.32 (m, 3H). MS (EI) for $C_{26}H_{31}N_7O_2$: 474.6 (MH+).

1-[3-(dimethylamino)propyl]-3-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)urea: ^{1}H NMR (400 MHz, d6-DMSO): 9.34 (s, 1H), 9.22 (s, 1H), 8.40 (d, 1H), 8.05 (d, 2H), 7.67 (d, 2H), 7.57 (d, 2H), 7.24 (d, 1H), 6.93 (d, 2H), 6.66 (t, 1H), 3.74 (m, 4H), 3.17 (m, 2H), 3.05 (m, 4H), 2.90 (t, 2H), 2.62 (s, 6H), 1.78 (m, 2H). MS (EI) for $C_{26}H_{33}N_7O_2$: 476.6 (MH+).

1-[3-(methyloxy)propyl]-3-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)urea: ^{1}H NMR (400 MHz, d6-DMSO): 9.3 (s, 1H), 8.87 (s, 1H), 8.40 (d, 1H), 8.05 (d, 2H), 7.67 (d, 2H), 7.55 (d, 2H), 7.24 (d, 1H), 6.93 (d, 2H), 6.37 (t, 1H), 3.74 (m, 4H), 3.38 (d, 2H), 3.25 (s, 3H), 3.15 (m, 2H), 3.04 (m, 4H), 1.68 (m, 2H). MS (EI) for $C_{25}H_{30}N_6O_3$: 463.6 (MH+).

1-(2-morpholin-4-ylethyl)-3-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)urea: ^{1}H NMR (400 MHz, d6-DMSO): 9.34 (s, 1H), 9.00 (s, 1H), 8.40 (d, 1H), 8.17 (s, 1H), 8.05 (d, 2H), 7.68 (d, 2H), 7.55 (d, 2H), 7.24 (d, 1H), 6.93 (d, 2H), 6.25 (t, 1H), 3.74 (m, 4H), 3.60 (m, 4H), 3.22 (m, 2H), 3.04 (m, 4H), 2.40 (m, 5H). MS (EI) for $C_{27}H_{33}N_7O_3$: 504.5 (MH+).

1-[2-(dimethylamino)ethyl]-3-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)urea: ^{1}H NMR (400 MHz, d6-DMSO): 9.33 (s, 1H), 9.06 (s, 1H), 8.40 (d, 1H), 8.21 (s, 1H), 8.04 (d, 2H), 7.67 (d, 2H), 7.55 (d, 2H), 7.23 (d, 1H), 6.93 (d, 2H), 6.33 (t, 1H), 3.74 (d, 4H), 3.21 (m , 2H), 3.05 (m, 1H), 2.38 (t, 2H), 2.12 (s, 6H). MS (EI) for $C_{25}H_{31}N_7O_2$: 462.5 (MH+).

1-ethyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.53 (s, 1H), 9.40 (s, 1H), 8.45 (d, 1H), 8.14 (d, 2H), 7.85 (d, 2H), 7.67 (d, 2H), 7.29 (d, 1H), 6.93 (d, 1H), 3.75 (m, 4H), 3.21 (m, 1H), 3.09 (m, 4H), 2.65 (m, 1H), 2.54 (m, 2H), 2.35 (m, 1H), 2.14 (m, 1H), 1.79 (m, 3H), 1.08 (t, 3H). MS (EI) for $C_{27}H_{32}N_6O_2$: 473.6 (MH+).

1-(2-hydroxyethyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)-D-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.31 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.81 (d, 2H), 7.67 (d, 2H), 7.30 (d, 1H), 6.93 (d, 1H), 5.05 (s, br, 1H), 3.75 (m, 4H), 3.05 (m, 4H), 2.75 (m, 2H), 2.63 (m, 1H), 2.40 (m, 2H), 2.18 (m, 2H), 1.80 (m, 3H). MS (EI) for $C_{27}H_{32}N_6O_3$: 489.5 (MH+).

N-(4-{2-[(4-{4-[3-(dimethylamino)-2,2-dimethylpropyl]piperazin-1-yl}phenyl)-amino]pyrimidin-4-yl}phenyl)tetrahydrofuran-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.39 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.79 (d, 2H), 7.66 (d, 2H), 7.28 (d, 1H), 6.93 (d, 2H), 3.94 (t, 1H), 3.75 (m, 4H), 3.15 (m, 8H), 2.80 (m, 9H), 2.09 (m, 2H), 1.03 (s, 7H). MS (EI) for $C_{32}H_{43}N_7O_2$: 558.7 (MH+).

(2R)-N-(4-{2-[(4-{4-[3-(dimethylamino)-2,2-dimethylpropyl]piperazin-1-yl}-phenyl)amino]pyrimidin-4-yl}phenyl)tetrahydrofuran-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.88 (s, 1H), 9.34 (s, 1H), 8.52 (s, 1H), 8.38 (s, 1H), 8.00 (s, 1H), 7.56 (m, 2H), 7.22 (d, 1H), 6.96 (d, 2H), 4.43 (m, 1H), 4.00 (m, 1H), 3.86 (m, 1H), 3.05 (m, 7H), 2.60 (m, 7H), 2.20 (m, 10H), 0.85 (s, 6H). $C_{32}H_{43}N_7O_2$. MS (EI) for $C_{32}H_{43}N_7O_2$: 558.7 (MH+).

N-(4-{2-[(4-{4-[3-(dimethylamino)-2,2-dimethylpropyl]piperazin-1-yl}phenyl)-amino]pyrimidin-4-yl}phenyl)cyclopropanecarboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.47 (s, 1H), 9.36 (s, 1H), 8.42 (d, 1H), 8.10 (d, 2H), 7.75 (d, 2H), 7.64 (d, 2H), 7.26 (d, 1H), 6.90 (d, 2H), 3.05 (m, 4H), 2.61 (m, 4H), 2.21 (s, 6H), 2.17 (s, 2H), 2.10 (s, 2H), 1.90 (s, 1H), 1.82 (m, 1H), 0.84 (m, 9H). MS (EI) for $C_{31}H_{41}N_7O$: 528.6 (MH+).

(S)-N-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenyl-amino)pyrimidin-4-yl)phenyl)tetrahydrofuran-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.95 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.88 (d, 2H), 7.67 (d, 2H), 7.29 (d, 1H), 6.93 (d, 2H), 4.44 (t, 1H), 4.01 (m, 1H), 3.85 (m, 1H), 3.14 (m, 6H), 2.86 (s, 6H), 2.77 (m, 4H), 2.21 (m, 2H), 2.01 (m, 2H), 1.90 (m, 2H), 1.05 (s, 6H). MS (EI) for $C_{32}H_{43}N_7O_2$: 558.7 (MH+).

N-(4-(2-(4-(4-(piperidine-4-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)-phenyl)tetrahydrofuran-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.35 (s, 1H), 9.41 (s, 1H), 8.44 (s, 1H), 8.14 (d, 2H), 7.78 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.96 (d, 2H), 3.96 (m, 1H), 3.73 (m, 3H), 3.62 (m, 4H), 3.20 (m, 1H), 3.04 (m, 5H), 2.79 (m, 1H), 2.62 (t, 2H), 2.11 (m, 2H), 2.79 (m, 3H), 1.55 (m, 3H). MS (EI) for $C_{31}H_{37}N_7O_3$: 556.6 (MH+).

1-(1-methylethyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.98 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.84 (d, 2H), 7.67 (d, 2H), 7.29 (d, 1H), 6.93 (d, 2H), 3.74 (m, 4H), 3.14 (m, 1H), 3.05 (m, 4H), 2.81 (1H), 2.54 (m, 2H), 2.08 (m, 1H), 1.77 (m, 1H), 1.75 (m, 2H), 1.05 (m, 6H). MS (EI) for $C_{28}H_{34}N_6O_2$: 487.6 (MH+).

1-ethyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.95 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.85 (d, 2H), 7.67 (d, 2H), 7.29 (d, 1H), 6.95 (d, 2H), 3.74 (m, 4H), 3.20 (m, 1H), 3.07 (m, 5H), 2.64 (m, 1H), 2.54 (m, 1H), 2.35 (m, 1H), 2.14 (m, 1H), 1.79 (m, 3H), 1.08 (t, 3H). MS (EI) for $C_{27}H_{32}N_6O_2$: 473.5 (MH+).

2-(2-fluorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.50 (s, 1H), 9.32 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.76 (d, 2H), 7.67 (d, 1H), 7.41 (m , 1H), 7.34 (m, 1H), 7.28 (d, 1H), 7.18 (m, 2H), 6.93 (d, 2H), 3.79 (s, 2H), 3.74 (m, 4H), 3.05 (m, 4H). MS (EI) for $C_{28}H_{26}FN_5O_2$: 484.5 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridine-4-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.76 (s, 1H), 9.42 (s, 1H), 8.82 (d, 2H), 8.47 (d, 1H), 8.20 (d, 2H), 7.96 (s, 2H), 7.89 (d, 2H), 7.68 (d, 2H), 7.32 (d, 1H), 6.95 (d, 2H), 3.75 (m, 4H), 3.07 (m, 4H). MS (EI) for $C_{26}H_{24}N_6O_2$: 453.5 (MH+).

(R)-N-(4-(5-methyl-2-(4-(4-((1-methyl-1H-imidazol-2-yl)methyl)piperazin-1-yl)-phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.19 (s, br, 1H), 9.25 (s, br, 1H), 8.31 (s, 1H), 7.81-7.58 (m, 6H), 7.09-6.76 (br m, 3H), 3.79 (m, 3H), 3.66 (s, 3H), 3.02-2.92 (m, 4H), 2.20 (m, 4H), 2.09 (m, 2H), 2.00 (m, 1H), 1.82 (m, 1H), 1.70 (m, 1H), 12.4 (s, 3H). MS (EI): 552 (MH+).

(R)-2-amino-N-(4-(5-methyl-2-(4-(4-((1-methyl-1H-imidazol-2-yl)methyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, br, 1H), 9.24 (s, br, 1H), 8.31 (s, 1H), 7.80 (d, 2H), 7.66-7.69 (m, 4H), 7.09 (s, 1H), 6.85 (m, 2H), 6.76 (s, 1H), 3.80 (m, 3H), 3.66 (m, 3H), 3.00 (m, 4H), 2.95 (m, 4H), 2.22 (s, 3H), 1.24 (s, 3H). MS (EI): 526 (MH+).

(S)-2-amino-N-(4-(5-methyl-2-(4-(4-((1-methyl-1H-imidazol-2-yl)methyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide: ^{1}H NMR (400 MHz, d6-DMSO):): 10.20 (s, br, 1H), 9.24 (s, br, 1H), 8.31 (s, 1H), 7.79 (d, 2H), 7.67-7.58 (m, 4H), 7.09 (s, 1H), 6.86 (m, 2H), 6.76 (s, 1H), 3.80 (m, 3H), 3.66 (m, 3H), 3.01 (m, 4H), 2.95 (m, 4H), 2.22 (s, 3H), 1.23 (s, 3H). MS (EI) for C29H35N9O: 526 (MH+).

***N*-[3-({2-[(4-morpholin-4-ylphenyl)amino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl}-amino)phenyl]acetamide:** ^{1}H NMR (400MHz, d6-DMSO): 11.14 (s, 1H), 9.87 (s, 1H), 9.15 (s, 1H), 8.47 (s, 1H), 8.04 (s, 1H), 7.80-7.73 (m, 1H), 7.70-7.63 (m, 2H), 7.25-7.18 (m, 2H), 6.89-6.81 (m, 3H), 6.67-6.64 (m, 1H), 3.77-3.71 (m, 4H), 3.04-2.98 (m,4H), 2.06 (s, 3H). MS (EI) for C24H25N7O2: 444 (MH+).

N-(4-{2-[(2-methyl-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-acetamide: ^{1}H NMR (400 MHz, *d*6-DMSO): 10.36 (br s, 1H), 9.51 (br s, 1H), 8.34 (d, 1H), 8.08 (d, 2H), 7.74 (d, 2H), 7.39 (d, 2H), 7.05 (br d, 2H), 3.80 (s, 4H), 3.22 (s, 4H), 2.21 (s, 3H), 2.07 (s, 3H). MS (EI): (MH+).

N-(4-{2-[(4-pyrrolidin-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, *d*6-DMSO): 10.33 (br s, 1H), 9.72 (br s, 1H), 8.44 (d, 1H), 8.13 (d,

2H), 7.77 (d, 2H), 7,69 (br s, 2H), 7.34 (d, 1H), 3.37 (m, 4H), 2.10 (s, 3H), 2.03 (s, 4H). MS (EI): 374 (MH+).

N-[4-(2-{[4-(diethylamino)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide: ^{1}H NMR (400 MHz, *d*6-DMSO): 10.34 (br s), 9.99 (br s, 1H), 8.56 (d, 1H), 8.12 (d, 2H), 8.06 (d, 2H), 7.79 (d, 2H), 7.72 (d, 2H), 7.44 (d, 1H), 3.49 (q, 4H), 2.10 (s, 3H), 1.05 (dt, 6H). MS (EI): 376 (MH+).

N-(4-{2-[(4-azepan-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, *d*6-DMSO): 10.34 (br s), 9.99 (br s, 1H), 8.56 (d, 1H), 8.12 (d, 2H), 8.06 (d, 2H), 7.79 (d, 2H), 7.72 (d, 2H), 7.44 (d, 1H), 3.54 (m, 4H), 2.09 (s, 3H), 1.91 (m, 2H), 1.70 (m,2H), 1.64 (m, 4H), 1.44 (m, 2H), 1.37 (m, 2H). MS (EI): 402 (MH+).

N-{4-[2-({4-[methyl(2-phenylethyl)amino]phenyl}amino)pyrimidin-4-yl]phenyl} acetamide: ^{1}H NMR (400 MHz, *d*6-DMSO): 10.34 (br s, 1H), 9.95 (br s, 1H), 8.54 (d, 1H), 8.15 (d, 2H), 7.98 (m, 1H), 7.79 (d, 2H), 7.43 (d, 1H), 7.31 (m, 3H), 7.23 (m, 4H), 3.71 (m, 2H), 3.13 (m, 2H), 2.10 (s, 1H), 1.99 (s, 3H). MS (EI): 438 (MH+).

N-[4-(2-{[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)phenyl]amino}pyrimidin-4-yl)phenyl] acetamide: ^{1}H NMR (400 MHz, *d*6-DMSO): 10.34 (br s), 9.99 (br s, 1H), 8.56 (d, 1H), 8.12 (d, 2H), 8.06 (d, 2H), 7.79 (d, 2H), 7.72 (d, 2H), 7.44 (d, 1H),3.90 (s, 4H), 2.70 (t, 4H), (2.10 (s, 3H), 1.76 (t, 4H). MS (EI): 446 (MH+).

N-[4-(2-{[4-(2-oxopiperidin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.32 (br s, 1H), 9.86 (br s 1H), 8.51 (d, 1H), 8.14 (d, 2H), 7.85 (t, 4H), 7.40 (d, 1H), 7.22 (d, 2H), 3.59 (m, 2H), 2.38 (t, 2H), 2.09 (s, 3H), 1.85 (m, 4H). MS (EI): 402 (MH+).

N-[4-(2-{[4-(2-methylpiperidin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (br s, 1H), 9.36 (br s, 1H), 8.43 (s, 1H), 8.27 (s, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.26 (s, 1H), 6.92 (d, 2H), 2.09 (s, 3H), 3.41 (m, 3H), 1.60 (m, 6H), 0.88 (d, 3H). MS (EI): 402 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-valinamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.51 (br s, 1H), 10.16 (br s, 1H), 8.57 (s, 1H), 8.48 (m, 2H), 8.20 (m, 2H), 7.93 (m, 3H), 7.78 (m, 1H), 7.50 (s, 1H), 5.45 (br s, 4H), 4.07 (s, 4H), 3.53 (s, 4H), 3.35 (m, 1H), 2.25 (m, 1H), 1.03 (m, 6H). MS (EI): 447 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-valinamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.51 (br s, 1H), 10.16 (br s, 1H), 8.57 (s, 1H), 8.48 (m, 2H), 8.20 (m, 2H), 7.93 (m, 3H), 7.78 (m, 1H), 7.50 (s, 1H), 5.45 (br s, 4H), 4.07 (s, 4H), 3.53 (s, 4H), 3.35 (m, 1H), 2.25 (m, 1H), 1.03 (m, 6H). MS (EI): 447 (MH+).

2-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-alaninamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.68 (br s,1H), 10.02 (br s, 1H), 8.53 (m, 2H), 8.18 (d, 2H), 7.95 (d, 2H), 7.89 (d, 2H), 7.66 (m, 1H), 7.47 (d, 1H), 5.20 (br s, 4H), 4.01 (s, 4H), 3.44 (s,4H), 1.66 (6H). MS (EI): 433 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)tryptophanamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.37 (s, 1H), 10.07 (s, 1H), 10.03 (s, 1H), 8.56 (d, 1H), 8.42 (d, 2H), 8.19 (d, 2H), 7.91 (d, 2H), (d, 2H), 7.73 (d, 1H), 7.66 (1H), 7.46 (d, 1H), 7.35 (d, 1H), 7.28 (d, 1H), 7.07 (t, 1H), 6.95 (t, 1H), 4.70 (br s, 4H), 4.34 (m, 1H), 4.03 (s, 4H), 3.49 (s, 4H), 3.36 (dq, 2H). MS (EI): 534 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.43 (br s, 1H), 10.07 (br s, 2H), 8.73 (d, 1H), 8.57 (d, 1H), 8.21 (d, 2H), 7.91 (d, 2H), 7.98 (d, 2H), 7.71 (br s, 2H), 7.48 (d, 1H), 4.48 (m, 1H), 4.08 (s, 4H), 3.74 (m, 4H), 3.42 (m, 1H), 3.36 (m, 1H), 3.04 (m, 4H), 2.22 (m 1H), 1.90 (m, 2H), 1.82 (m, 2H). MS (EI): 445 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-1,2,3,4-tetrahydro-isoquinoline-1-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO):11.30 (br d, 1H), 10.04 (br s, 1H), 8.56 (d, 1H), 8.39 (s, 3H), 8.20 (d, 2H), 7.90 (m, 2H), 7.87 (m, 2H), 7.67 (m, 3H), 7.47 (d, 1H), 5.00 (br s, 3H), 4.65 (s, 1H), 4.20 (m, 2H), 4.03 (s, 4H), 3.97 (m, 1H), 3.94 (m, 2H), 3.80 (m, 1H), 3.49 (s, 4H). MS (EI): 507 (MH+).

O-(1,1-dimethylethyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)-L-serinamide: ^{1}H NMR (400 MHz, d6-DMSO): 12.11 (br s, 1H), 10.65 (br s, 1H), 10.12 (s, 1H), 9.60 (s, 1H), 8.58 (d, 1H), 8.23 (d, 2H), 7.95 (d, 2H),, 7.79 (s, 1H), 7.56 (d, 1H), 7.49 (d, 1H), 7.31 (s, 2H), 5.14 (br s, 4H), 4.06 (s, 4H), 3.79 (m, 1H), 3.54 (s, 4H), 3.45 (m, 1H), 3.15 (q, 1H), 1.21 (s, 9H). MS (EI): 491 (MH+).

3-amino-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl) tetrahydro-furan-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.89 (br s, 1H), 9.92 (br s , 1H), 8.83 (s, 2H), 8.55 (d, 1H), 8.21 (d, 2H), 7.94 (d, 2H), 7.87 (d, 1H), 7.53 (s,

1H), 7.43 (d, 1H), 4.30 (br s, 4H), 4.21 (d, 1H), 4.07 (d, 1H), 4.05 (m, 1H), 4.02 (m, 1H), 3.97 (s, 4H), 3.42 (s, 4H), 2.79 (m, 1H), 2.28 (m, 1H). MS (EI): 461 (MH+).

bis(1,1-dimethylethyl) (2R)-2-{[(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)amino]carbonyl}piperazine-1,4-dicarboxylate: ^{1}H NMR (400 MHz, d6-DMSO): 10.41 (br s, 1H), 9.35 (s, 1H), 8.42 (d, 1H), 8.14 (d, 2H), 8.76 (d, 2H), 7.67 (d, 2H), 7.28 (d, 1H), 6.93 (d, 2H), 4.51 (m, 1H), 3.90 (m, 2H), 3.74 (m, 4H), 3.66 (t, 4H), 3.04 (t, 4H), 1.41 (s, 3H), 1.33 (s, 9H), 1.17 (s, 6H). MS (EI): 660 (MH+).

N-(4-{2-[(4-{4-[2-(2-fluorophenyl)acetyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.70 (d, 2H), 7.29 (m, 3H), 7.16 (m, 2H), 6.98 (d, 2H), 3.80 (s, 2H), 3.69 (m, 2H), 3.63 (m, 2H), 3.09 (m, 2H), 3.04 (m, 2H), 2.09 (s, 3H). MS (EI): 525.5 (MH+).

N-(4-{2-[(4-{4-[2-(2-methylphenyl)acetyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.69 (d, 2H), 7.28 (d, 1H), 7.12 (m, 4H), 6.97 (d, 2H), 3.74 (s, 2H), 3.65 (m, 4H), 3.05 (m, 4H), 2.20 (s, 3H), 2.09 (s, 3H). MS (EI): 521.6 (MH+).

N-(4-{2-[(4-{4-[2-(3-fluorophenyl)acetyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.69 (d, 2H), 7.35 (m, 1H), 7.28 (d, 1H), 7.08 (m, 3H), 6.96 (d, 2H), 3.81 (s, 2H), 3.64 (m, 4H), 3.02 (m, 4H), 2.09 (s, 3H). MS (EI): 525.4 (MH+).

N-{4-[2-({4-[4-(3-thienylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.83 (m, 1H), 7.75 (d, 2H), 7.70 (d, 2H), 7.64 (m, 1H), 7.25 (m, 2H), 6.98 (d, 2H), 3.68 (m, 4H), 3.11 (m, 4H), 2.09 (s, 3H). MS (EI): 499.4 (MH+).

N-(4-{2-[(4-{4-[(6-chloropyridin-3-yl)carbonyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.53 (m, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.98 (dd, 1H), 7.75 (d, 2H), 7.70 (d, 2H), 7.65 (d, 1H), 7.28 (d, 1H), 6.98 (d, 2H), 3.78 (m,2H), 3.48 (m, 2H), 3.17 (m, 2H), 3.08 (m, 2H), 2.09 (s, 3H). MS (EI): 529.1 (MH+).

N-(4-{2-[(4-{4-[(3-methylfuran-2-yl)carbonyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.75-7.68 (m, 5H), 7.28 (d, 1H), 6.98 (d, 2H), 6.52 (d, 1H), 3.73 (m, 4H), 3.11 (m, 4H), 2.17 (s, 3H), 2.09 (s, 3H). MS (EI): 497.6 (MH+).

N-(4-{2-[(4-{4-[(3-fluoro-2-methylphenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: MS (EI) for $C_{30}H_{29}FN_6O_2$: 525.5 (MH+).

N-(4-{2-[(4-{4-[(imidazol-4-yl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: MS (EI) for $C_{26}H_{26}N_8O_2$: 483.5 (MH+).

N-(4-{2-[(4-{4-[(2-methoxypyridin-3-yl)carbonyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.26 (dd, 1H), 8.12 (d, 2H), 7.75-7.67 (m, 5H), 7.28 (d, 1H), 7.09 (dd, 1H), 6.97 (d, 2H), 3.90 (s, 3H), 3.77 (m, 2H), 3.29 (m, 2H), 3.14 (m, 2H), 3.04 (m, 2H), 2.09 (s, 3H). MS (EI): 524.6 (MH+).

N-(4-{2-[(4-{4-[(4-fluoro-3-methylphenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: MS (EI) for $C_{30}H_{29}FN_6O_2$: 525.5 (MH+).

N-{4-[2-({4-[4-(naphthalen-2-ylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.37 (s, 1H), 8.50 (d, 1H), 8.42 (d, 1H), 8.22 (dd, 2H), 8.09 (dd, 3H), 7.82-7.71 (m, 5H), 7.64 (d, 2H), 7.26 (d, 1H), 6.89 (d, 2H), 3.14 (m, 4H), 3.11 (m, 4H), 2.08 (s, 3H). MS (EI): 579.6 (MH+).

N-{4-[2-({4-[4-(quinolin-8-ylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.37 (s, 1H), 9.10 (dd, 1H), 8.56 (dd, 1H), 8.42 (m, 2H), 8.34 (dd, 1H), 8.10 (d, 2H), 7.79 (m, 1H), 7.73 (m, 3H), 7.65 (d, 2H), 7.27 (d, 1H), 6.90 (d, 2H), 3.45 (m, 4H), 3.08 (m, 4H), 2.09 (s, 3H). MS (EI): 580.8 (MH+).

N-[4-(2-{[4-(4-{[4-(1,1-dimethylethyl)phenyl]sulfonyl}piperazin-1-yl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.20 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.70 (m, 4H), 7.66 (d,

2H), 7.27 (d, 1H), 6.91 (d, 2H), 3.16 (m, 4H), 3.01 (m, 4H), 2.08 (s, 3H), 1.32 (s, 9H). MS (EI): 585.5 (MH+).

N-[4-(2-{[4-(4-{[5-bromo-2-(methyloxy)phenyl]sulfonyl}piperazin-1-yl)phenyl]-amino}pyrimidin-4-yl)phenyl]acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.09 (dd, 2H), 7.84 (m, 2H), 7.74 (d, 2H), 7.68 (d, 2H), 7.28 (d, 2H), 6.94 (d, 2H), 3.92 (s, 3H), 3.27 (m, 4H), 3.11 (m, 4H), 2.09 (s, 3H). MS (EI) for C29H29BrN6O4S: 638.6 (MH+).

N-(4-{2-[(4-{4-[(phenylmethyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.69 (d, 2H), 7.42 (m, 5H), 7.28 (d, 1H), 6.96 (d, 2H), 4.50 (s, 2H), 3.20 (m, 4H), 3.06 (m, 4H), 2.08 (s, 3H). MS (EI): 543.6 (MH+).

N-[4-(2-{[4-(4-{[3-(trifluoromethyl)phenyl]sulfonyl}piperazin-1-yl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.18-8.08 (m, 4H), 8.02 (s, 1H), 7.97 (d, 1H), 7.74 (d, 2H), 7.67 (d, 2H), 7.27 (d, 1H), 6.92 (d, 2H), 3.15 (m, 4H), 3.10 (m, 4H), 2.09 (s, 3H). MS (EI): 597.7 (MH+).

N-(4-{2-[(4-{4-[(2-methylphenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.09 (dd, 2H), 7.85 (dd, 1H), 7.74 (d, 2H), 7.67-7.59 (m, 3H), 7.47 (m, 2H), 7.27 (d, 1H), 6.94 (d, 2H), 3.17 (m, 4H), 3.13 (m, 4H), 2.61 (s, 3H), 2.09 (s, 3H). MS (EI): 543.7 (MH+).

N-(4-{2-[(4-{4-[(3-fluorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.39 (s, 1H), 8.43 (d, 1H), 8.10 (dd, 2H), 7.73 (m, 3H), 7.67-7.62 (m, 5H), 7.27 (d, 1H), 6.92 (d, 2H), 3.14 (m, 4H), 3.08 (m, 4H), 2.09 (s, 3H). MS (EI): 547.7 (MH+).

N-(4-{2-[(4-{4-[(2,4-difluorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: MS (EI) for $C_{28}H_{26}F_2N_6O_3S$: 565.6 (MH+).

N-{4-[2-({3-[4-({4-[(trifluoromethyl)oxy]phenyl}methyl)piperazin-1-yl]phenyl}-amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.47 (s, 1H), 8.49 (d, 1H), 8.14 (dd, 2H), 7.75 (d, 2H), 7.64 (s, 1H), 7.48

(dd, 2H), 7.33 (m, 3H), 7.22 (m, 1H), 7.13 (m, 1H), 6.56 (dd, 1H), 3.57 (s, 2H), 3.16 (m, 4H), 2.54 (m, 4H), 2.09 (s, 3H). MS (EI): 563.6 (MH+).

N-(4-{2-[(3-{4-[(1-methyl-1H-imidazol-2-yl)methyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.45 (s, 1H), 8.49 (d, 1H), 8.13 (dd, 2H), 7.75 (d, 2H), 7.58 (s, 1H), 7.33 (d, 1H), 7.25 (dd, 1H), 7.15-7.09 (m, 2H), 6.77 (d, 1H), 6.56 (dd, 1H), 3.68 (s, 3H), 3.58 (s, 2H), 3.12 (m, 4H), 2.54 (m, 4H), 2.09 (s, 3H). MS (EI): 483.5 (MH+).

N-{4-[2-({3-[4-({2-[(trifluoromethyl)oxy]phenyl}methyl)piperazin-1-yl]phenyl}-amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.47 (s, 1H), 8.50 (d, 1H), 8.13 (dd, 2H), 7.75 (d, 2H), 7.64-7.62 (m, 2H), 7.44-7.36 (m, 4H), 7.23 (dd, 1H), 7.14 (m, 1H), 6.55 (dd, 1H), 3.62 (s, 2H), 3.16 (m, 4H), 2.57 (m, 4H), 2.09 (s, 3H). MS (EI): 563.6 (MH+).

N-(4-{2-[(3-{4-[(3-chlorophenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.69 (d, 2H), 7.44-7.38 (m, 4H), 7.28 (d, 1H), 6.96 (d, 2H), 4.48 (s, 2H), 3.27 (m, 4H), 3.09 (m, 4H), 2.09 (s, 3H). MS (EI): 514.1 (MH+).

N-{4-[2-({3-[4-(2,3-dihydroxypropyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.23 (s, 1H), 9.46 (s, 1H), 8.49 (d, 1H), 8.14 (d, 2H), 7.75 (d, 2H), 7.63 (s, 1H), 7.33 (d, 1H), 7.22 (d, 1H), 7.13 (m, 1H), 6.56 (dd, 1H), 3.67 (s, 2H), 3.14 (m, 5H), 2.60 (m, 4H), 2.45 (m, 1H), 2.30 (m, 1H), 2.09 (s, 3H). MS (EI): 463.6 (MH+).

N-{4-[2-({3-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.46 (s, 1H), 8.49 (d, 1H), 8.12 (m, 2H), 7.75 (d, 2H), 7.62 (s, 1H), 7.33 (d, 1H), 7.23 (dd, 1H), 7.12 (t, 1H), 6.90-6.85 (m, 2H), 6.79 (m, 1H), 6.55 (dd, 1H), 5.99 (s, 2H), 3.44 (s, 2H), 3.15 (m, 4H), 2.52 (m, 4H), 2.09 (s, 3H). MS (EI): 523.5 (MH+).

N-{4-[2-({3-[4-(pyridin-2-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.47 (s, 1H), 8.52-8.49 (m, 2H), 8.13 (m, 2H), 7.81-7.72 (m, 3H), 7.63 (s, 1H), 7.50 (d, 1H), 7.33 (d, 1H), 7.30-7.21 (m, 2H), 7.13 (t, 1H), 6.57 (dd, 1H), 3.67 (s, 2H), 3.17 (m, 4H), 2.60 (m, 4H), 2.09 (s, 3H). MS (EI): 480.6 (MH+).

N-{4-[2-({3-[4-(pyridin-3-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.47 (s, 1H), 8.54 (d, 1H), 8.49 (d, 2H), 8.12 (m, 2H), 7.78-7.73 (m, 3H), 7.63 (s, 1H), 7.40-7.37 (m, 1H), 7.33 (d, 1H), 7.23 (d, 1H), 7.13 (t, 1H), 6.55 (dd, 1H), 3.58 (s, 2H), 3.16 (m, 4H), 2.55 (m, 4H), 2.10 (s, 3H). MS (EI): 480.5 (MH+).

N-{4-[2-({3-[4-(pyridin-4-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.47 (s, 1H), 8.53 (dd, 2H), 8.49 (d, 1H), 8.14 (d, 2H), 7.75 (d, 2H), 7.64 (s, 1H), 7.38 (dd, 2H), 7.33 (d, 1H), 7.23 (d, 1H), 7.13 (t, 1H), 6.56 (dd, 1H), 3.59 (s, 2H), 3.18 (m, 4H), 2.56 (m, 4H), 2.09 (s, 3H). MS (EI): 480.7 (MH+).

N-{4-[2-({3-[4-(1H-pyrrol-2-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.45 (s, 1H), 8.49 (d, 1H), 8.12 (m, 2H), 7.75 (d, 2H), 7.61 (s, 1H), 7.33 (d, 1H), 7.21 (d, 1H), 7.12 (t, 1H), 6.64 (m, 1H), 6.55 (dd, 1H), 5.92 (m, 2H), 3.46 (s, 2H), 3.14 (m, 4H), 2.51 (m, 4H), 2.09 (s, 3H). MS (EI): 468.6 (MH+).

4-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-N-(phenylmethyl)-piperazine-1-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.62 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.70 (d, 2H), 7.48 (dd, 2H), 7.28-7.21 (m, 3H), 7.00 (d, 2H), 6.94 (t, 1H), 4.41 (s, 2H), 3.60 (m, 4H), 310 (m, 4H), 2.09 (s, 3H). MS (EI): 522.4 (MH+).

N-[4-(2-{[3-(4-{[2-(methyloxy)phenyl]carbonyl}piperazin-1-yl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.50 (s, 1H), 8.50 (d, 1H), 8.13 (d, 2H), 7.74 (d, 2H), 7.64 (s, 1H), 7.41 (m, 1H), 7.34 (d, 1H), 7.29 (d, 1H), 7.23 (dd, 1H), 7.16 (t, 1H), 7.10 (d, 1H), 7.01 (t, 1H), 6.59 (dd, 1H), 3.79 (s, 3H), 3.21 (m, 4H), 3.07 (m, 4H), 2.09 (s, 3H). MS (EI): 523.5 (MH+).

N-{4-[2-({3-[4-(1H-pyrazol-4-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 13.22 (s, 1H), 10.22 (s, 1H), 9.51 (s, 1H), 8.50 (d, 1H), 8.14 (d, 3H), 7.76 (d, 3H), 7.66 (s, 1H), 7.34 (d, 1H), 7.29 (d, 1H), 7.17 (t, 1H), 6.59 (dd, 1H), 3.78 (m, 4H), 3.20 (m, 4H), 2.09 (s, 3H). MS (EI): 483.5 (MH+).

N-{4-[2-({3-[4-(3-pyridin-3-ylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO):

10.24 (s, 1H), 9.50 (s, 1H), 8.50 (d, 2H), 8.39 (dd, 1H), 8.14 (d, 2H), 7.76 (d, 2H), 7.69 (dd, 2H), 7.34-7.24 (m, 3H), 7.15 (t, 1H), 6.58 (dd, 1H), 3.61 (m, 4H), 3.10 (m, 4H), 2.86 (t, 2H), 2.74 (t, 2H), 2.09 (s, 3H). MS (EI): 522.7 (MH+).

N-(4-{2-[(3-{4-[3-(methyloxy)propanoyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.50 (s, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.76 (d, 2H), 7.66 (s, 1H), 7.34 (d, 1H), 7.27 (d, 1H), 7.16 (t, 1H), 6.59 (dd, 1H), 3.63 (m, 4H), 3.58 (t, 2H), 3.23 (s, 3H), 3.12 (m, 4H), 2.63 (t, 2H), 2.09 (s, 3H). MS (EI): 475.6 (MH+).

N-[4-(2-{[3-(4-{2-[(4-fluorophenyl)oxy]acetyl}piperazin-1-yl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.23 (s, 1H), 9.51 (s, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.76 (d, 2H), 7.66 (s, 1H), 7.34 (d, 1H), 7.29 (d, 1H), 7.19-7.10 (m, 3H), 6.96 (m, 2H), 6.60 (dd, 1H), 4.88 (s, 2H), 3.64 (m, 4H), 3.17 (m, 4H), 2.09 (s, 3H). MS (EI): 541.5 (MH+).

N-{4-[2-({3-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.24 (s, 1H), 9.50 (s, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.76 (d, 2H), 7.69 (s, 1H), 7.34 (d, 1H), 7.24 (d, 1H), 7.15 (t, 1H), 6.58 (dd, 1H), 3.61 (m, 2H), 3.48 (m, 2H), 3.41 (t, 1H), 3.10 (m, 4H), 2.18 (m, 2H), 2.09 (s, 3H) 1.92 (m, 2H), 1.75 (m, 2H). MS (EI): 471.4 (MH+).

N-{4-[2-({3-[4-(pyridin-4-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.51 (s, 1H), 8.69 (dd, 2H), 8.50 (d, 1H), 8.14 (d, 2H), 7.74 (d, 2H), 7.66 (s, 1H), 7.45 (dd, 2H), 7.34 (d, 1H), 7.28 (d, 1H), 7.16 (t, 1H), 6.60 (d, 1H), 3.81 (m, 2H), 3.43 (m, 2H), 3.27 (m, 2H), 3.14 (m, 2H), 2.10 (s, 3H). MS (EI): 494.6 (MH+).

N-{4-[2-({3-[4-(pyridin-2-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.50 (s, 1H), 8.61 (d, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.95 (t, 1H), 7.74 (d, 2H), 7.66 (d, 2H), 7.50 (t, 1H), 7.34 (d, 1H), 7.29 (d, 1H), 7.16 (t, 1H), 6.60 (d, 1H), 3.84 (m, 2H), 3.59 (m, 2H), 3.26 (m, 2H), 3.14 (m, 2H), 2.09 (s, 3H). MS (EI): 494.6 (MH+).

N-(4-{2-[(3-{4-[(2-methylphenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.23 (s, 1H), 9.49 (s, 1H), 8.49 (d, 1H), 8.13 (d, 2H), 7.74 (d, 2H), 7.63 (s, 1H), 7.34-7.16

(m, 7H), 6.59 (d, 1H), 3.84 (m, 2H), 3.28 (m, 2H), 3.25 (m, 2H), 3.06 (m, 2H), 2.24 (s, 3H), 2.09 (s, 3H). MS (EI): 507.6 (MH+).

N-{4-[2-({3-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.51 (s, 1H), 8.50 (dd, 1H), 8.14 (d, 2H), 7.76 (d, 2H), 7.68 (s, 1H), 7.34 (d, 1H), 7.26 (d, 1H), 7.16 (t, 1H), 6.59 (d, 1H), 3.72 (m, 4H), 3.13 (m, 4H), 2.09 (s, 3H), 1.23 (s, 9H). MS (EI): 473.5 (MH+).

N-{4-[2-({3-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.23 (s, 1H), 9.51 (s, 1H), 8.67 (m, 2H), 8.50 (d, 1H), 8.13 (m, 2H), 7.90 (m, 1H), 7.75 (d, 2H), 7.66 (s, 1H), 7.50 (m, 1H), 7.34 (d, 1H), 7.29 (dd, 1H), 7.17 (t, 1H), 6.60 (dd, 1H), 3.82 (m, 2H), 3.50 (m, 2H), 3.29 (m, 2H), 3.16 (m, 2H), 2.09 (s, 3H). MS (EI): 494.7 (MH+).

N-{4-[2-({3-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.24 (s, 1H), 9.51 (s, 1H), 8.50 (d, 1H), 8.14 (dd, 2H), 7.76 (d, 2H), 7.69 (s, 1H), 7.34 (d, 1H), 7.26 (dd, 1H), 7.16 (t, 1H), 6.60 (dd, 1H), 3.66 (m, 4H), 3.11 (m, 4H), 2.90 (m, 1H), 2.09 (s, 3H), 1.03 (s, 6H). MS (EI): 459.6 (MH+).

N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]-tetrahydrofuran-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.32 (s, 1H), 9.48 (s, 1H), 8.48 (d, 1H), 8.16 (d, 2H), 7.78 (d, 2H), 7.67 (s, 1H), 7.32 (d, 1H), 7.29 (dd, 1H), 6.87 (d, 1H), 3.95 (t, 2H), 3.81 (s, 3H), 3.78 (m, 2H), 3.71 (m, 4H), 3.29-3.17 (m, 1H), 2.91 (m, 4H), 2.13-2.07 (m, 2H). MS (EI): 476.5 (MH+).

(2R)-N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)-phenyl]tetrahydrofuran-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.94 (s, 1H), 9.48 (s, 1H), 8.48 (d, 1H), 8.16 (d, 2H), 7.89 (d, 2H), 7.66 (s, 1H), 7.33 (d, 1H), 7.30 (dd, 1H), 6.87 (d, 1H), 4.43 (dd, 1H), 4.01 (m, 1H), 3.86 (m, 1H), 3.81 (s, 3H), 3.72 (m, 4H), 2.91 (m, 4H), 2.22-2.19 (m, 1H), 2.03-1.98 (m, 1H), 1.89 (m, 2H). MS (EI): 476.4 (MH+).

(2S)-N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)-phenyl]tetrahydrofuran-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.94 (s, 1H), 9.48 (s, 1H), 8.48 (d, 1H), 8.16 (d, 2H), 7.89 (d, 2H), 7.66 (s, 1H), 7.33 (d, 1H), 7.30 (dd, 1H), 6.87 (d, 1H), 4.43 (dd, 1H), 4.01 (m, 1H), 3.86 (m, 1H), 3.81 (s, 3H), 3.72 (m, 4H), 2.91 (m, 4H), 2.24-2.19 (m, 1H), 2.03-1.98 (m, 1H), 1.89 (m, 2H). MS (EI): 476.5 (MH+).

N-(4-{2-[(4-{4-[(2-fluorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.85-7.77 (m, 2H), 7.74 (d, 2H), 7.68 (d, 2H), 7.56-7.46 (m, 2H), 7.28 (d, 1H), 6.93 (d, 2H), 3.18-3.16 (m, 8H), 2.09 (s, 3H). MS (EI): 547.7 (MH+).

N-(4-{2-[(3-{4-[(3,5-dichlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.24 (s, 1H), 9.51 (s, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.73 (m, 3H), 7.64 (s, 1H), 7.54 (d, 2H), 7.34 (d, 1H), 7.29 (d, 1H), 7.16 (t, 1H), 6.60 (dd, 1H), 3.79 (m, 2H), 3.46 (m, 2H), 3.26 (m, 2H), 3.15 (m, 2H), 2.09 (s, 3H). MS (EI): 562.5 (MH+).

ethyl 3-(4-(2-(4-morpholinophenylamino(pyrimidin-4-yl)phenylamino)-3-oxopropanoate: ^{1}H NMR (400 MHz, d6-DMSO): 10.46 (s, 1H), 9.35 (s, 1H), 8.42 (d, 1H), 8.11 (d, 2H), 7.71 (d, 2H), 7.64 (d, 2H), 7.26 (d, 1H), 6.92 (d, 2H), 4.11 (q, 2H), 3.72 (m, 2H), 3.37 (m, 4H), 3.02 (m, 4H), 1.19 (t, 3H). MS (EI): 462 (MH+).

N-(4-(2-(4-(4-isobutyrylpiperazin-1-yl)penylamino)pyrimidin-4-yl)phenyl)-tetrahydrofuran-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.30 (s, 1H), 9.43 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.97 (m, 2H), 3.96 (t, 1H), 3.76 (m, 2H), 3.63 (m, 4H), 3.19 (m, 2H), 3.06 (m, 4H), 2.93 (m, 1H), 2.10 (m, 2H), 1.02 (d, 6H). MS (EI): 515 (MH+).

N-(4-(2-(4-(4-(cyclobutanecarbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.30 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.96 (d, 2H), 3.96 (t, 1H), 3.76 (m, 3H), 3.59 (m, 2H), 3.41 (m, 3H), 3.19 (m, 1H), 3.03 (m, 4H), 2.41 (m, 6H), 1.90 (m, 1H), 1.75 (m, 1H). MS (EI): 527 (MH+).

N-ethyl-4-(4-(4-(4-(tetrahydrofuran-3-carboxamido)phenyl)pyrimidin-2-yl-amino(phenyl)piperazine-1-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.30 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.77 (d, 2H), 7.67 (d, 2H), 7.28 (d, 1H), 6.96 (d, 2H), 6.59 (t, 1H), 3.96 (t, 1H), 3.75 (m, 3H), 3.42 (m, 4H), 3.19 (m, 1H), 3.05 (m, 6H), 2.10 (q, 2H), 1.02 (t, 3H). MS (EI): 516 (MH+).

N-(4-(2-(4-(4-((R)-2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.31 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.77 (d, 2H), 7.69 (d, 2H), 7.29 (d, 1H),

6.97 (d, 2H), 3.96 (dd, 1H), 3.89 (m, 1H), 3.76 (m, 4H), 3.63 (m, 4H), 3.18 (m, 2H), 3.07 (m, 4H), 2.09 (m, 2H), 1.13 (d, 3H). MS (EI): 516 (MH+).

N-(4-(2-(4-(4-((S)-2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.31 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.97 (d, 2H), 3.96 (t, 1H), 3.85 (q, 1H), 3.76 (m, 3H), 3.63 (m, 4H), 3.19 (m, 1H), 3.07 (m, 4H), 2.10 (m, 2H), 1.11 (d, 3H). MS (EI): 516 (MH+).

N-(4-(2-(4-(4-((R)-pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.31 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.77 (d, 2H), 7.69 (d, 2H), 7.29 (d, 1H), 6.97 (d, 2H), 3.97 (m, 2H), 3.76 (m, 3H), 3.64 (m, 4H), 3.19 (m, 1H), 3.06 (m, 6H), 2.73 (m, 1H), 2.09 (m, 2H), 1.67 (m, 4H). MS (EI): 542 (MH+).

N-(4-(2-(4-(4-((S)-pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.31 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.77 (d, 2H), 7.69 (d, 2H), 7.29 (d, 1H), 6.97 (d, 2H), 3.96 (t, 1H), 3.86 (m, 1H), 3.76 (m, 3H), 3.64 (m, 4H), 3.18 (m, 1H), 3.05 (m, 6H), 2.64 (m, 1H), 2.10 (m, 1H), 2.00 (m, 1H), 1.62 (m, 4H). MS (EI): 542 (MH+).

N-{4-[2-(1H-benzimidazol-6-ylamino)-5-methylpyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.25 (s, 1H), 8.97 (s, 1H), 8.78 (s, 1H), 8.21(d, 2H), 7.86 (d, 2H), 7.80 (d, 2H), 6.96 (s, 1H), 6.78 (dd, 2H), 2.44 (s, 3H), 2.11 (s, 3H); MS (EI) $C_{20}H_{18}N_60$: 359.3 $(M+H)^+$.

4-(4-furan-2-ylphenyl)-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine: ^{1}H-NMR (400MHz, d_6-DMSO): 9.46 (s, 1H), 8.49 (d, 1H), 8.22 (d, 2H), 7.87 (d, 2H), 7.84 (dd, 1H), 7.68 (d, 2H), 7.37 (d, 1H), 7.12 (t, 1H), 6.94 (d, 2H), 6.66 (dd, 1H), 3.75 (t, 4H), 3.05 (t, 4H) ; MS (EI) $C_{24}H_{22}N_40_2$: 399.3 $(M+H)^+$.

N-(4-morpholin-4-ylphenyl)-4-[4-(pyrimidin-2-ylamino)phenyl]pyrimidin-2-amine: ^{1}H-NMR (400MHz, d_6-DMSO): 10.01 (s, 1H), 9.35 (s, 1H), 8.56 (d, 2H), 8.42 (d, 1H), 8.11 (dd, 2H), 7.95 (dd, 2H), 7.69 (d, 2H), 7.27 (d, 1H), 6.96-6.92 (m, 3H), 3.75 (t, 4H), 3.06 (t, 4H); MS (EI) $C_{24}H_{23}N_70$: 426.3 $(M+H)^+$.

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}-5-methylpyrimidin-4-yl)phenyl]-cyclopropanecarboxamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.40 (s, 1H), 9.41 (bs, 1H), 9.30 (s, 1H), 8.30 (s, 1H), 7.23-7.70 (m, 2H), 7.65-7.62 (m, 3H), 6.91 (d, 2H), 3.70-3.50 (bs, 2H), 3.21-2.87 (m, 8H), 2.20 (s, 3H), 1.80 (p, 1H), 1.18 (bs, 3H), 0.81 (d, 4H); MS (EI) $C_{24}H_{23}N_70$: 457.4 $(M+H)^+$.

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-cyclopropanecarboxamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.48 (s, 1H), 9.37 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.76 (d, 2H), 7.65 (d, 2H), 7.27 (d, 1H), 6.93 (d, 2H), 3.09 (bs, 4H), 2.60-2.35 (m, 6H), 1.83 (p, 1H), 1.06 (t, 3H), 0.84-0.82 (m, 4H); MS (EI) $C_{26}H_{30}N_60$: 443.4 $(M+H)^+$.

N-(4-{2-[(3,5-dimorpholin-4-ylphenyl)amino]-5-methylpyrimidin-4-yl}phenyl)-N^2,N^2-dimethylglycinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.04 (s, 1H), 9.25 (s, 1H), 8.37 (s, 1H), 7.81 (d, 2H), 7.74 (d, 2H), 7.12 (s, 2H), 6.11 (s, 1H), 3.73 (t, 8H), 3.20 (bs, 2H), 3.06 (t, 8H), 2.34 (s, 6H), 2.28 (s, 3H); MS (EI) $C_{29}H_{37}N_70_3$: 532.4 $(M+H)^+$.

N^2,N^2-dimethyl-N-(4-{5-methyl-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)glycinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.43 (s, 1H), 9.28 (s, 1H), 8.33 (s, 1H), 7.77 (d, 2H), 7.69 (d, 2H), 7.63 (d, 2H), 6.88 (d, 2H), 3.73 (t, 4H), 3.35 (bs, 2H), 3.01 (t, 4H), 2.65 (s, 6H), 2.21 (s, 3H); MS (EI) $C_{25}H_{30}N_60_2$: 447.4 $(M+H)^+$.

N-(4-{5-methyl-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-prolinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.15 (s, 1H), 9.28 (s, 1H), 8.32 (s, 1H), 7.82-7.79 (m, 2H), 7.64 (t, 4H), 6.88 (d, 2H), 3.75-3.72 (t, 5H), 3.01 (t, 4H), 2.91 (t, 2H), 2.22 (s, 3H), 2.11-2.02 (m, 1H), 1.84-1.75 (m, 1H), 1.70-1.63 (m, 2H); MS (EI) $C_{26}H_{30}N_60_2$: 459.4 $(M+H)^+$.

N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}-D-prolinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.25 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.83 (d, 2H), 7.68 (d, 2H), 7.30 (d, 1H), 6.96 (d, 2H), 3.80-3.77 (m, 1H), 3.65-3.41 (m, 4H), 3.08-3.02 (m, 4H), 2.96-2.89 (m, 3H), 2.13-2.08 (m, 1H), 1.84-1.78 (m, 1H), 1.73-1.68 (m, 2H), 1.02 (d, 6H); MS (EI) $C_{29}H_{35}N_70_2$: 514.4 $(M+H)^+$.

N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-prolinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.85 (s, 1H), 9.41 (s, 1H), 8.47 (d, 1H), 8.18 (d, 2H), 7.78 (d, 2H), 7.68 (d, 2H),

7.31 (d, 1H), 6.96 (d, 2H), 4.40-4.34 (m, 1H), 3.70 (t, 4H), 3.32-3.25 (m, 2H), 3.05 (t, 4H), 2.44-2.38 (m, 1H), 2.05-1.94 (m, 3H), 1.23 (s, 9H); MS (EI) $C_{30}H_{37}N_7O_2$: 528.4 $(M+H)^+$.

N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}-D-prolinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.19 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.84 (d, 2H), 7.67 (d, 2H), 7.30 (d, 1H), 6.95 (d, 2H), 3.74-3.70 (m, 1H), 3.60-3.46 (m, 4H), 3.04-3.00 (m, 4H), 2.91 (t, 2H), 2.22-2.02 (m, 6H), 1.95-1.87 (m, 1H), 1.82-1.73 (m, 2H), 1.70-1.64 (m, 2H); MS (EI) $C_{30}H_{35}N_7O_2$: 526.2 $(M+H)^+$.

N-ethyl-4-[4-({4-[4-(D-prolylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-piperazine-1-carboxamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.19 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.84 (d, 2H), 7.67 (d, 2H), 7.29 (d, 1H), 6.96 (d, 2H), 6.59 (t, 1H), 3.74-3.71 (m, 1H), 3.42 (t, 4H), 3.10-3.05 (m, 2H), 3.01 (t, 4H), 2.91 (t, 2H), 2.22 (s, 3H), 2.09-2.02 (m, 1H), 1.84-1.76 (m, 1H), 1.70-1.63 (m, 2H), 1.02 (t, 3H); MS (EI) $C_{28}H_{34}N_8O_2$: 515.5 $(M+H)^+$.

N-[4-(2-{[4-(4-D-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-D-prolinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.20 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.84 (d, 2H), 7.68 (d, 2H), 7.30 (d, 1H), 6.97 (d, 2H), 3.92-3.89 (m, 1H), 3.75-3.71 (m, 1H), 3.65-3.59 (m, 4H), 3.09-2.98 (m, 5H), 2.91 (t, 2H), 2.69-2.63 (m, 1H), 2.09-2.02 (m, 2H), 1.84-1.76 (m, 1H), 1.70-1.54 (m, 5H); MS (EI) $C_{30}H_{36}N_8O_2$: 541.4 $(M+H)^+$.

N-[4-(2-{[4-(4-L-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-D-prolinamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.20 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.84 (d, 2H), 7.68 (d, 2H), 7.30 (d, 1H), 6.96 (d, 2H), 3.92-3.89 (m, 1H), 3.75-3.71 (m, 1H), 3.65-3.59 (m, 4H), 3.09-2.98 (m, 5H), 2.91 (t, 2H), 2.69-2.63 (m, 1H), 2.09-2.02 (m, 2H), 1.84-1.76 (m, 1H), 1.70-1.56 (m, 5H); MS (EI) $C_{30}H_{36}N_8O_2$: 541.4 $(M+H)^+$.

1-Methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-prolinamide: ^{1}H NMR (400 MHz, d_6-DMSO): 9.93 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.87 (d, 2H), 7.67 (d, 2H), 7.29 (d, 1H), 6.93 (d, 2H), 3.74 (m, 4H), 3.12 (m, 1H), 3.05 (m, 4H), 2.95 (m, 1H), 2.36 (m, 4H) 2.17 (m, 1H), 1.80 (m, 3H); MS (EI) for $C_{26}H_{30}N_6O_2$: 459 (MH^+).

1-Methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)piperidine-2-carboxamide: ^{1}H NMR (400 MHz, d_6-DMSO): 9.97 (s, 1H),

9.39 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.85 (d, 2H), 7.67 (d, 2H), 7.28 (d, 1H), 6.93 (d, 2H), 3.74 (m, 4H), 3.05 (m, 4H), 2.92 (m, 1H), 2.60 (dd, 1H), 2.16 (s, 3H) 2.03 (m, 1H), 1.76 (m, 2H), 1.60 (m, 3H), 1.25 (m, 1H); MS (EI) for $C_{27}H_{32}N_6O_2$: 473 (MH^+).

N-{4-[2-({4-[4-(Piperidin-4-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, d_6-DMSO): 10.25 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.36 (s, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.28 (d, 1H), 6.97 (d, 2H), 3.64 (m, 4H), 3.17 (m, 2H), 3.06 (m, 4H), 2.93 (m, 1H), 2.81 (m, 2H), 2.09 (s, 3H) 1.60-1.75 (m, 4H); MS (EI) for $C_{28}H_{33}N_7O_2$: 500 (MH^+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-pyridin-4-ylacetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.53 (s, 1H), 9.38 (s, 1H), 8.53 (d, 2H), 8.44 (d, 1H), 8.12 (d, 2H), 7.95 (d, 1H), 7.76 (d, 2H), 7.67 (d, 2H), 7.35 (d, 1H), 6.92 (d, 2H), 3.75 (m, 6H), 3.04 (m, 4H). MS (EI): 467 (MH+).

2-(3-fluorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.44 (s, 1H), 9.36 (s, 1H), 8.42 (m, 1H), 8.09 (d, 2H), 7.74 (d, 2H), 7.64 (d, 2H), 7.35 (m, 1H), 7.24 (m, 1H), 7.15 (d, 2H), 7.07 (m, 1H), 6.90 (d, 2H), 3.71 (m, 6H), 3.04 (m, 4H). MS (EI): 484 (MH+).

3-(4-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)propanamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.19 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.73 (d, 2H), 7.68 (d, 2H), 7.35 (d, 2H), 7.26 (m, 3H), 6.93 (d, 2H), 3.74 (m, 4H), 3.04 (m, 4H), 2.92 (t, 2H), 2.67 (t, 2H). MS (EI): 515 (MH+).

2-(3-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.47 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.66 (d, 2H), 7.43 (s, 1H), 7.32 (m, 4H), 6.93 (d, 2H), 3.74 (m, 6H), 3.04 (m, 4H). MS (EI): 500 (MH+).

2-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-3-phenyl-propanamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.12 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.09 (d, 2H), 7.72 (d, 2H), 7.67 (d, 2H), 7.25 (m, 4H), 7.17 (m, 2H), 6.93 (d, 2H), 3.74 (m, 4H), 3.06 (m, 4H), 2.99 (m, 1H), 2.81 (m, 1H), 2.64 (m, 1H), 1.12 (d, 3H). MS (EI): 494 (MH+).

trans-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-phenyl-cyclopropanecarboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.53 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.77 (d, 2H), 7.67 (d, 2H), 7.28 (m, 3H), 7.21 (m, 3H),

6.93 (d, 2H), 3.74 (m, 4H), 3.04 (m, 4H), 2.39 (m, 1H), 2.11 (m, 1H), 1.53 (m, 1H), 1.42 (m, 1H). MS (EI): 492 (MH+).

2-(4-fluorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.44 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.65 (d, 2H), 7.38 (m, 2H), 7.27 (d, 1H), 7.18 (dd, 2H), 6.93 (d, 2H), 3.71 (m, 4H), 3.69 (s, 2H), 3.04 (m, 4H). MS (EI): 484 (MH+).

3-(2-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)propanamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.23 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.67 (d, 2H), 7.45 (dd, 1H), 7.40 (dd, 1H), 7.25 (m, 3H), 6.93 (d, 2H), 3.74 (m, 4H), 3.04 (m, 6H), 2.70 (t, 2H). MS (EI): 515 (MH+).

3-(3-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)propanamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.19 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.67 (d, 2H), 7.27 (m, 5H), 6.93 (d, 2H), 3.74 (m, 4H), 3.04 (m, 4H), 2.94 (t, 2H), 2.69 (t, 2H). MS (EI): 515 (MH+).

3-(2-fluorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)propanamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.73 (d, 2H), 7.67 (d, 2H), 7.35 (t, 1H), 7.26 (d, 2H), 7.11 (m, 2H), 6.93 (d, 2H), 3.74 (m, 4H), 3.04 (m, 4H), 2.95 (t, 2H), 2.68 (t, 2H). MS (EI): 498 (MH+).

Nalpha,Nalpha-dimethyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]-pyrimidin-4-yl}phenyl)-L-phenylalaninamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.04 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.09 (d, 2H), 7.74 (d, 2H), 7.67 (d, 2H), 7.24 (m, 5H), 7.17 (m, 1H), 6.93 (d, 2H), 3.74 (m, 4H), 3.48 (dd, 1H), 3.06 (m, 5H), 2.86 (dd, 1H), 2.49 (s, 6H). MS (EI): 523 (MH+).

2-(2-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.54 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.76 (d, 2H), 7.67 (d, 2H), 7.46 (m, 2H), 7.33 (m, 2H), 7.29 (d, 1H), 6.93 (d, 2H), 3.89(s, 2H), 3.74 (m, 4H), 3.04 (m, 4H). MS (EI): 500 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-pyridin-2-yl-acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.51 (s, 1H), 9.35 (s, 1H), 8.49 (d, 1H), 8.41 (d, 1H), 8.10 (d, 2H), 7.77 (m, 3H), 7.64 (d, 2H), 7.39 (d, 1H), 7.26 (m, 2H), 6.92 (d, 2H), 3.87 (s, 2H), 3.71 (m, 4H), 3.02 (m, 4H). MS (EI): 467 (MH+).

2-(4-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.47 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.66 (d, 2H), 7.39 (m, 4H), 7.26 (m, 1H), 6.93 (d, 2H), 3.74 (m, 4H), 3.70 (s, 2H), 3.04 (m, 4H). MS (EI): 500 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-{4-[(trifluoro-methyl)oxy]phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.50 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.12 (d, 2H), 7.75 (d, 2H), 7.66 (d, 2H), 7.47 (d, 2H), 7.35 (d, 2H), 7.27(d, 1H), 6.93 (d, 2H), 3.74 (m, 6H), 3.04 (m, 4H). MS (EI): 550 (MH+).

2-[2-(methyloxy)phenyl]-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.34 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.76 (d, 2H), 7.67 (d, 2H), 7.26 (m, 3H), 7.00 (d, 1H), 6.91 (m, 3H), 3.77 (s, 3H), 3.74 (m, 4H), 3.67 (s, 2H), 3.04 (m, 4H). MS (EI): 496 (MH+).

2-[3-(methyloxy)phenyl]-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.44 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.76 (d, 2H), 7.67 (d, 2H), 7.26 (m, 2H), 6.93 (m, 4H), 6.82 (dd, 1H), 3.74 (m, 7H), 3.55 (s, 2H), 3.04 (m, 4H). MS (EI): 496 (MH+).

2-[4-(methyloxy)phenyl]-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.38 (s, 1H), 9.38 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.75 (d, 2H), 7.67 (d, 2H), 7.26 (m, 3H), 6.93 (m, 4H), 3.74 (m, 7H), 3.60 (s, 2H), 3.04 (m, 4H). MS (EI): 496 (MH+).

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-D-alaninamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.35 (s, 1H), 8.43 (d, 1H), 8.13 (d, 2H), 7.82 (d, 2H), 7.63 (d, 2H), 7.28 (d, 1H), 6.92 (d, 2H), 3.48 (m, 1H), 2.35 (q, 2H), 1.86 (br s, 8H), 1.24 (d, 3H), 1.03 (t, 3H). MS (EI): 446 (MH+).

N-{4-[2-({4-[4-(N,N-dimethylglycyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.21 (s, 1H), 9.39 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.75 (d, 2H), 7.67 (d, 2H), 7.28 (d, 1H), 6.96 (d, 2H), 3.68 (m, 4H), 3.10 (s, 2H), 3.07 (m, 4H), 2.18 (s, 6H), 2.09 (s, 3H). MS (EI): 474 (MH+).

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-3-(methyloxy)propanamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.23 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.11 (d, 2H), 7.75 (d, 2H), 7.65 (d, 2H), 7.25 (d, 1H), 6.92 (d, 2H), 3.63 (t,

2H), 3.25 (s, 3H), 3.09 (m, 4H), 2.60 (t, 2H), 2.58 (m, 6H), 1.05 (t, 3H). MS (EI): 461 (MH+).

(2R)-2-amino-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-phenylethanamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.37 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.80 (d, 2H), 7.66 (d, 2H), 7.49 (d, 2H), 7.34 (t, 2H), 7.26 (m, 2H), 6.92 (d, 2H), 4.56 (s, 1H), 3.75 (m, 4H), 3.04 (m, 4H). MS (EI): 481 (MH+).

N'2',N'2'-dimethyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)-D-alaninamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.02 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.84 (d, 2H), 7.66 (d, 2H), 7.28 (d,1H), 6.92 (d, 2H), 3.75 (m, 4H), 3.21 (q, 1H), 3.04 (m, 4H), 2.25 (s, 6H), 1.19 (d, 3H). MS (EI): 447 (MH+).

1-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.94 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.87 (d, 2H), 7.67 (d, 2H), 7.30(d,1H), 6.94 (d, 2H), 3.76 (m, 4H), 3.12 (m, 1H), 3.05 (m, 4H), 2.95 (m, 1H), 2.36 (s, 3H), 2.30 (m, 1H), 2.18 (m, 1H), 1.78 (m, 3H). MS (EI): 459 (MH+).

N'2',N'2'-dimethyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)-L-alaninamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.03 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.84 (d, 2H), 7.67 (d, 2H), 7.28 (d,1H), 6.92 (d, 2H), 3.75 (m, 4H), 3.21 (q, 1H), 3.05 (m, 4H), 2.25 (s, 6H), 1.19 (d, 3H). MS (EI): 447 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-1-phenylcyclopropanecarboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.38 (s, 1H), 8.43 (d, 1H), 8.09 (d, 2H), 7.72 (d, 2H), 7.65 (d, 2H), 7.40 (m, 4H), 7.28 (m, 2H), 6.92 (d, 2H), 3.74 (m, 4H), 3.04 (m, 4H), 1.74 (dd, 2H), 1.15 (dd, 2H). MS (EI): 492 (MH+).

2-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-butanamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.12 (s, 1H), 9.38 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.78 (d, 2H), 7.67 (d, 2H), 7.27 (d,1H), 6.93 (d, 2H), 3.75 (m, 4H), 3.04 (m, 4H), 2.46 (q, 1H), 1.65 (m, 1H), 1.41 (m, 1H), 1.10 (d, 3H), 0.87 (t, 3H). MS (EI): 432 (MH+).

(2S)-1-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-azetidine-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.88 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.89 (d, 2H), 7.67 (d, 2H), 7.29 (d,1H), 6.93 (d,

2H), 3.74 (m, 4H), 3.56 (t, 1H), 3.36 (m, 1H), 3.04 (m, 4H), 2.93 (q, 1H), 2.33 (s, 3H), 2.30 (m, 1H), 2.12 (m, 1H). MS (EI): 445 (MH+).

2,4,6-trichloro-N-(3-{[4-(4-methyl-2-thienyl)pyrimidine-2-yl]amino}propyl)-benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 8.68 (br s, 1H), 8.24 (d, 1H), 7.72-7.70 (m, 3H), 7.29 (s, 1H), 7.17 (t, 1H), 6.98 (d, 1H), 3.37-3.35 (m, 2H), 3.28-3.27 (m, 2H), 2.22 (s, 3H), 1.77 (br t, 2H). MS (EI): 457.0 (MH+).

N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}cyclopropanecarboxamide: MS (EI) $C_{29}H_{34}N_6O_2$: 499 (MH+).

4-{4-[(4-{4-[(cyclopropylcarbonyl)amino]phenyl}pyrimidin-2-yl)amino]phenyl}-N-ethylpiperazine-1-carboxamide: MS (EI) $C_{27}H_{31}N_7O_2$: 486 (MH+).

N-[3-({4-[3,4-bis(mehtyloxy)phenyl]pyrimidine-2-yl}amino)propyl]-2,6-dichloro-benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 8.67 (br s, 1H), 8.26 (d, 1H), 7.69-7.67 (m, 2H), 7.49-7.35 (m, 3H), 7.14-7.09 (m, 2H), 7.03 (d, 1H), 3.82 (s, 3H), 3.80 (s, 3H), 3.42 (m, 2H), 3.32 (m, 2H), 1.80 (m, 2H). MS (EI): 461.2 (MH+).

2,6-dichloro-N-[3-({4-[(4-morpholino-4-ylphenyl)amino]pyrimidin-2-yl}amino)-propyl]benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 8.85 (br s, 1H), 8.63 (t, 1H), 7.69 (d, 1H), 7.48 (d, 2H), 7.44 (d, 1H), 7.42 (s, 1H), 7.37-7.33 (m, 1H), 6.81 (d, 2H), 6.59 (br s, 1H), 5.83 (d, 1H), 3.67-3.65 (m, 4H), 3.23-3.20 (m, 4H), 2.97-2.94 (m, 4H), 1.70 (t, 2H). MS (EI): 501.2 (MH+).

2,6-dichloro-N-(3-{[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-fluoropyrimidin- 2-yl]amino}proypyl)benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 8.62 (t, 1H), 8.29 (d, 1H), 7.49-7.42 (m, 4H), 7.37-7.33 (m, 1H), 7.15 (t, 1H), 6.94-6.92 (m, 1H), 4.27-4.21 (m, 4H), 3.33-3.22 (m, 4H), 1.74 (t, 2H); MS (EI): 477.1 (MH+).

2,6-dichloro-N-{3-[(4-{3-[(dimethylamino)methyl]phenyl}pyrimidin-2-yl)amino]propyl}benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 8.68 (t, 1H), 8.31 (d, 1H), 8.01-7.95 (m, 2H), 7.49-7.38 (m, 5H), 7.23 (br s, 1H), 7.10 (d, 1H), 3.43 (m, 2H), 3.33-3.29 (m, 4H), 2.14 (s, 6H), 1.82 (t, 2H); MS (EI): 460.2 (MH+).

2,6-dichloro-N-[3-({4-[3-(1-methylethyl)phenyl]pyrimidin- 2-yl}amino)-propyl]-benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 8.66 (t, 1H), 8.31 (d, 1H), 7.95-7.88 (m, 2H), 7.55 (br s, 1H), 7.45-7.43 (m, 2H), 7.40-7.34 (m, 3H), 7.20 (br s, 1H), 3.30

(br s, 2H), 3.29-3.25 (m, 2H), 2.92 (septet, 1H), 1.78 (m, 2H), 1.18 (d, 6H); MS (EI): 443.0 (MH+).

2,6-dichloro-N-{3-[(4-{4-[(1-methylethyl)oxy]phenyl}pyrimidin-2-yl)amino]propyl}-benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 8.68 (t, 1H), 8.25 (d, 1H), 8.03 (d, 2H), 7.49-7.47 (m, 2H), 7.42-7.38 (m, 1H), 7.10 (t, 1H), 7.03 (d, 1H), 6.98 (d, 2H), 4.69 (septet, 1H), 3.42 (m, 2H), 3.30 (m, 2H), 1.80 (t, 2H), 1.27 (d, 6H); MS (EI): 459.0 (MH+).

N-[3-({4-[3-(acetylamino)phenyl]pyrimidin- 2-yl}amino)propyl]-2,6-dichloro-benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.1 (s, 1H), 8.70 (t, 1H), 8.33-8.27 (m, 2H), 7.70 (m, 2H), 7.49-7.46 (m, 2H), 7.42-7.37 (m, 2H), 7.37 (br s, 1H), 7.01 (d, 1H), 3.43 (m, 4H), 2.02 (s, 3H), 1.97 (m, 2H). MS (EI): 458.2 (MH+).

2,6-dichloro-N-[3-({4-[(E)-2-phenylethenyl]pyrimidin-2-yl}amino)propyl]-benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 8.71 (t, 1H), 8.27 (d, 1H), 7.76 (d, 1H), 7.67-7.65 (m, 2H), 7.51-7.49 (m, 2H), 7.44-7.34 (m, 4H), 7.12-7.06 (m, 2H), 6.72 (d, 1H), 3.36 (m, 2H), 3.33 (m, 2H), 1.81 (t, 2H). MS (EI): 427.0 (MH+).

phenyl (4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)carbamate: ^{1}H-NMR (400MHz, d6-DMSO): 8.59 (d, 1H), 7.90 (d, 2H), 7.69 (d, 1H), 7.44-7.40 (m, 2H), 7.28-7.20 (m, 5H), 6.97 (d, 2H), 6.62 (d, 2H), 5.90 (s, 2H), 3.74-3.72 (m, 4H), 3.13-3.11 (m, 4H). MS (EI): 468.1 (MH+).

phenylmethyl (4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-carbamate: ^{1}H-NMR (400MHz, d6-DMSO): 8.55 (d, 1H), 7.85 (d, 2H), 7.64 (d, 1H), 7.33-7.30 (m, 5H), 7.13 (d, 2H), 6.92 (d, 2H), 6.62 (d, 2H), 5.88 (s, 2H), 5.88 (s, 2H), 3.74-3.71 (m, 4H), 3.11-3.09 (m, 4H). MS (EI): 428.3 (MH+).

N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-3-(methyloxy)propanamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.2 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.95 (d, 2H), 3.71-3.69 (m, 4H), 3.65 (t, 2H), 3.25 (s, 3H), 3.06-3.03 (m, 4H), 2.59 (t, 2H), 1.23 (s, 9H). MS (EI): 517.4 (MH+).

N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-3-(methyloxy)propanamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.2 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.96 (d,

2H), 3.65-3.60 (m, 4H), 3.47-3.37 (m, 4H), 3.25 (s, 3H), 3.03-3.02 (m, 3H), 2.60 (t, 2H), 2.21-2.07 (m, 4H), 1.94-1.87 (m, 1H), 1.78-1.73 (m, 1H). MS (EI): 515.2 (MH+).

3-(methyloxy)-N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)-pyrimidin-4-yl]phenyl}propanamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.2 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.76 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.96 (d, 2H), 3.65-3.62 (m, 6H), 3.25 (s, 3H), 3.08-3.02 (m, 4H), 2.92 (m, 1H), 2.59 (t, 2H), 1.02 (d, 6H). MS (EI): 503.4 (MH+).

N-ethyl-4-(4-{[4-(4-{[3-(methyloxy)propanoyl]amino}phenyl)pyrimidin-2-yl]-amino}phenyl)piperazine-1-carboxamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.2 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.12 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.28 (d, 1H), 6.97 (d, 2H), 6.59 (t, 1H), 3.64 (t, 2H), 3.43 (m, 4H), 3.25 (s, 3H), 3.10-3.03 (m, 6H), 2.61 (t, 2H), 1.02 (t, 3H). MS (EI): 504.4 (MH+).

N-(4-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-2-phenyl-acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.45 (s, 1H), 9.36 (s, 1H), 8.43 (d, 1H), 8.12 (d, 2H), 7.76 (d, 2H), 7.64 (d, 2H), 7.38-7.33 (m, 3H), 7.27 (d, 1H), 6.92 (d, 2H), 3.69 (s, 2H), 3.10-3.04 (m, 4H), 2.35 (q, 3 H), 1.89 (s, 2H), 1.03 (t, 2H); MS (EI): 493.1 (MH+).

1-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidin-2-one: ^{1}H-NMR (400MHz, d6-DMSO): 8.26 (d, 1H), 8.14 (d, 2H), 7.77 (d, 2H), 7.65 (d, 2H), 7.36 (d, 1H), 7.25 (d, 2H), 3.92-3.84 (m, 5H), 3.82-3.74 (m, 1H), 3.74-3.60 (m, 1H), 3.42-3.30 (m, 4H), 3.06-3.02 (m, 1H), 2.16-2.06 (m, 2H); MS (EI): 416.1 (MH+).

(R)-2-amino-N-(4-(2-(4-(4-(cyclobutanecarbonyl)piperazin-1-yl)phenylamino)-pyrimidin-4-yl)phenyl)propanamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.41 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.82 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.95 (d, 2H), 3.63-3.56 (m, 2H), 3.43-3.37 (m, 3H), 3.18 (d, 1H), 3.07-2.98 (m, 4H), 2.25-2.02 (m, 4H), 1.98-1.83 (m, 1H), 1.82-1.70 (m, 1H), 1.23 (d, 3H); MS (EI): 500.2 (MH+).

(R)-2-amino-N-(4-(2-(4-(4-pivaloylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.41 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.82 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.95 (d, 2H), 3.73-3.67 (m, 4H), 3.52-4.42 (m, 1H), 3.08-3.02 (m, 4H), 1.25 (s, 3H), 1.23 (d, 3H); MS (EI): 502.4 (MH+).

(S)-2-hydroxy-3-methyl-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)-phenyl)butanamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.90 (s, 1H), 9.39 (s, 1H), 8.45 (d,

1H), 8.12 (d, 2H), 7.90 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.94 (d, 2H), 5.76 (d, 1H), 3.86 (dd, 1H), 3.78-3.73 (m, 4H), 3.08-3.02 (m, 4H), 0.96 (d, 3H), 0.87 (d, 3H); MS (EI): 448.3 (MH+).

(R)-2-hydroxy-3-methyl-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)-phenyl)butanamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.90 (s, 1H), 9.39 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.90 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.94 (d, 2H), 5.76 (d, 1H), 3.86 (dd, 1H), 3.78-3.73 (m, 4H), 3.08-3.02 (m, 4H), 0.96 (d, 3H), 0.87 (d, 3H); MS (EI): 448.3 (MH+).

N-{4-[2-({4-[4-(cyclopropylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}-D-alaninamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.17 (s, 1H), 10.04 (s, 1H), 8.58 (s, 1H), 8.40 (s, 2H), 8.11-8.09 (m, 2H), 7.96-7.82 (m, 3H), 7.76-7.65 (m, 1H), 7.45 (d, 1H), 4.05 (t, 4H), 3.75-3.70 (m, 1H), 3.50 (t, 4H), 2.10-2.00 (m, 1H), 1.45 (d, 3H), 0.82-0.72 (m, 4H). MS (EI): 486 (MH+).

(2S)-2-amino-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-phenylethanamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.73 (s, 1H), 10.08 (s, 1H), 8.99 (s, br, 3H), 8.58 (s, 1H), 8.19 (d, 2H), 7.96-7.83 (m, 3H), 7.76-7.65 (m, 3H), 7.45-7.40 (m, 3H), 5.40 (s, br, 1H), 3.85 (s, br, 4H), 3.50 (s, br, 4H). MS (EI): 481 (MH+).

2-amino-2-(4-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.80 (s, 1H), 10.00 (s, 1H), 9.00 (s, 2H), 8.57 (d, 1H), 8.20 (d, 2H), 7.95-7.83 (m, 4H), 7.80-7.60 (m, 3H), 7.58 (d, 2H), 7.43 (d, 1H), 5.50 (s, 1H), 4.00 (t, 4H), 3.50 (t, 4H). MS (EI): 515 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)morpholine-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.60 (s, 1H), 10.20 (s, 1H), 10.00 (s, 1H), 9.40 (s, br, 1H), 8.58 (d, 1H), 8.20 (d, 2H), 7.95-7.88 (m, 3H), 7.60-7.20 (m, 4H), 4.42-4.30 (m, 2H), 4.05-3.90 (m, 2H), 3.85-3.70 (m, 4H), 3.60-3.45 (m, 4H), 3.25-3.10 (m, 3H). MS (EI): 461 (MH+).

1-ethyl-3-[4-(2-{[4-(4-ethylpiperazin-1-yl)-3-(methyloxy)phenyl]amino}pyrimidin-4-yl)phenyl]urea: ^{1}H NMR (400 MHz, d6-DMSO): 9.40 (s, 1H), 8.90 (s, 1H), 8.42 (d, 1H), 8.20 (s, 1H), 8.05 (d, 2H), 7.56 (d, 2H), 7.28 (d, 2H), 6.83 (d, 1H), 6.36 (t, 1H), 3.80 (s, 3H), 3.12 (q, 2H), 2.98 (s, br, 4H), 2.58 (s, br, 4H), 2.42 (q, 2H), 1.08-1.00 (m, 6H). MS (EI): 476 (MH+).

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)-3-(methyloxy)phenyl]amino} pyrimidin-4-yl)-phenyl]-D-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.23 (s, 1H), 11.05 (s, 1H), 10.18 (s, br, 1H), 10.00 (s, 1H), 8.75 (s, br, 1H), 8.57 (d, 1H), 8.21 (d, 2H), 7.85 (d, 2H), 7.63 (s, 1H), 7.44 (d, 1H), 7.33 (dd, 1H), 7.03 (d, 1H), 4.55-4.50 (m, 1H), 3.82 (s, 3H), 3.80-3.60 (m, 4H), 3.35-3.05 (m, 7H), 2.50-2.45 (m, 2H), 2.02-1.95 (m, 3H), 1.30 (t, 3H). MS (EI): 502 (MH+).

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)-3-(methyloxy)phenyl]amino} pyrimidin-4-yl)-phenyl]acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.44 (s, 1H), 8.15 (d, 2H), 7.80-7.60 (m, 3H), 7.33 (d, 2H), 6.85 (d, 1H), 3.80 (s, 3H), 2.90 (s, br, 4H), 2.35 (q, 2H), 2.05 (s, 4H), 1.95 (s, 3H), 1.00 (s, 3H). MS (EI): 447 (MH+).

1-(2,6-dichlorophenyl)-3-(3-{[4-(4-methyl-2-thienyl)pyrimidin-2-yl]amino}propyl)-urea: ^{1}H NMR (400 MHz, d_6-DMSO): 8.26 (d, 1H), 8.02 (br, 1H), 7.71 (s, 1H), 7.48 (d, 2H), 7.31 (s, 1H), 7.26 (t, 1H), 7.16 (t, 1H), 6.99 (d, 1H), 6.39 (t, 1H), 3.38 (t, 2H), 3.15 (t, 2H), 2.21 (s, 3H), 1.65 (m, 2H). MS (EI) for $C_{19}H_{19}Cl_2N_5OS$: 436 (MH^+).

1-[2-fluoro-5-(trifluoromethyl)phenyl]-3-(3-{[4-(4-methyl-2-thienyl)pyrimidin-2-yl]amino}propyl)urea: ^{1}H NMR (400 MHz, d_6-DMSO): 8.65 (d, 2H), 8.23 (s, 1H), 7.7 (s, 1H), 7.4 (t, 1H), 7.38-7.15 (m, 3H), 7.0 (s, 1H), 6.8 (t, 1H), 3.38 (t, 2H), 3.2 (t, 2H), 2.21 (s, 3H), 1.75 (m, 2H). MS (EI) for $C_{20}H_{19}F_4N_5OS$: 454 (MH^+).

2,6-dichloro-N-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]-benzenesulfonamide: ^{1}H NMR (400 MHz, d_6-DMSO): 8.16 (d, 1H), 8.12 (t, 1H), 7.94 (d, 2H), 7.58 (d, 2H), 7.48 (t,1H), 6.97 (d, 1H), 6.92 (t, 6.76 (d, 2H)3.28 (m, 2H), 3.022.96 (m, 8H), 1.68 (m, 2H). MS (EI) for $C_{21}H_{23}Cl_2N_5O_2S$: 480 (MH^+).

N-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2,6-difluoro-benzenesulfonamide: ^{1}H NMR (400 MHz, d_6-DMSO): 8.25 (T, 1H), 8.16 (d, 1H), 7.94 (d, 2H), 7.66 (m, 1H), 7.24 (t, 2H), 6.98 (d, 1H), 6.95 (t, 1H), 6.76 (d, 2H), 3.33(t, 2H), 3.0 (t, 2H), 2.98 (s, 6H), 1.68 (m, 2H). MS (EI) for $C_{21}H_{23}F_2N_5O_2S$: 448 (MH^+).

N-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]naphthalene-2-sulfonamide: ^{1}H NMR (400 MHz, d_6-DMSO): 8.42 (br, 1H), 8.15-8.06 (m, 3H), 8.02 (d, 1H), 7.94 (d, 2H), 7.8 (dd, 1H), 7.74-7.62 (m, 3H), 6.96

(d, 1H), 6.92 (t, 1H), 6.74 (d, 2H), 3.3 (t, 2H), 2.98 (s, 6H), 2.83 (t, 2H), 1.63 (m, 2H). MS (EI) for $C_{25}H_{27}N_5O_2S$: 462 (MH^+).

N-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]-3,4-bis(methyloxy)benzenesulfonamide: ^{1}H NMR (400 MHz, d_6-DMSO): 8.17 (d, 1H), 7.94 (d, 2H), 7.46 (t, 1H), 7.34 (dd, 1H), 7.27 (d, 1H), 7.06 (d, 1H), 6.97 (d, 1H), 6.93 (t, 1H), 6.76 (d, 2H), 3.8 (s, 6H), 3.3 (t, 2H), 2.98 (s, 6H), 2.8 (t, 2H), 1.65 (m, 2H). MS (EI) for $C_{23}H_{29}N_5O_4S$: 472 (MH^+).

3-chloro-N-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]propane-1-sulfonamide: ^{1}H NMR (400 MHz, d_6-DMSO): 8.2 (s, 1H), 7.98 (d, 2H), 7.2 (t, 1H), 7.0 (t, 2H), 6.8-6.7 (m, 2H), 3.7 (t, 2H), 3.1-2.9 (m, 10H), 2.05 (t, 2H), 1.7 (m, 2H), 1.2 (m, 2H). MS (EI) for $C_{18}H_{26}ClN5O_2S$: 412 (MH^+).

N-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]propane-1-sulfonamide: ^{1}H NMR (400 MHz, d_6-DMSO): 8.2 (d, 1H), 7.96 (d, 2H), 7.0-6.95 (m, 3H), 6.76 (d, 2H), 3.38 (t, 2H), 3.0-2.9 (m, 10H), 1.75 (t, 2H), 1.6 (q, 2H), 0.95 (t, 3H). MS (EI) for $C_{18}H_{27}N_5O_2S$: 378 (MH^+).

methyl (3-{[4-(2,4-dichlorophenyl)pyrimidin-2-yl]amino}propyl)carbamate: ^{1}H MR (400 MHz, d_6-DMSO): 8.4 (d, 1H), 7.75 (s, 1H), 7.63-7.55 (m, 2H), 7.35 (t, 1H), 7.12 (t, 1H), 6.8 (d, 1H), 3.5 (s, 3H), 3.28 (t, 2H), 3.03 (t, 2H), 1.65 (m, 2H). MS (EI) for $C_{15}H_{16}Cl_2N_4O_2$: 355 (MH^+).

1-methylethyl (3-{[4-(2,4-dichlorophenyl)pyrimidin-2-yl]amino}propyl)-arbamate: ^{1}H NMR (400 MHz, d_6-DMSO): 8.38 (d, 1H), 7.75 (s, 1H), 7.63-7.55 (m, 2H),7.35 (t, 1H), 7.0 (t, 1H), 6.8 (d, 1H), 4.72 (m, 1H), 3.28 (q, 2H), 3.0 (q, 2H), 1.65 (p, 2H), 1.12 (d, 6H). MS (EI) for $C_{17}H_{20}Cl_2N_4O_2$: 383 (MH^+).

phenylmethyl (3-{[4-(2,4-dichlorophenyl)pyrimidin-2-yl]amino}propyl)carbamate: ^{1}H NMR (400 MHz, d_6-DMSO): 8.46 (d, 1H), 8.2 (br, 1H), 7.8 (d, 1H), 7.66 (br, 1H), 7.6 (dd, 1H), 7.4-7.28 (m, 5H), 7.04 (br, 1H), 5.0 (s, 2H), 3.4 (t, 2H), 3.1 (t, 2H), 1.7 (m, 2H). MS (EI) for $C_{21}H_{20}Cl_2N_4O_2$: 431 (MH^+).

N-{4-[2-({[3-(3-chlorophenyl)isoxazol-5-yl]methyl}amino)pyrimidin-4-yl]-henyl}acetamide: ^{1}H NMR (400 MHz, d_6-DMSO): 10.18 (s, 1H), 8.37 (d, 1H), 8.06 (d, 2H), 7.92 (t, 1H), 7.88-7.82 (m, 2H), 7.7 (d, 2H), 7.56-7.48 (m, 2H), 7.2 (d, 1H), 7.0 (s, 1H), 4.7 (s, 2H), 2.05 (s, 3H). MS (EI) for $C_{22}H_{18}ClN_5O_2$: 420 (MH^+).

ethyl 4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)piperidine-1-carboxylate: ^{1}H MR (400 MHz, d_6-DMSO): 10.18 (s, 1H), 8.3 (d, 1H), 8.04 (d, 2H), 7.7 (d, 2H), 7.13 (d, 1H), 7.06 (d, 1H), 4.05 (q, 3H), 3.95 (br, 2H), 2.96 (br, 2H), 2.08 (s, 3H), 1.9 (br, 2H), 1.4 (q, 2H), 1.2 (t, 3H). MS (EI) for $C_{20}H_{25}N_5O_3$: 384 (MH^+).

1,1-dimethylethyl 4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)piperidine-1-carboxylate: ^{1}H NMR (400 MHz, d_6-DMSO): 10.18 (s, 1H), 8.3 (d, 1H), 8.05 (d, 2H), 7.7 (d, 2H), 7.2 (br, 1H), 7.1 (d, 1H), 3.92 (br, 3H), 2.9 (br, 2H), 2.08 (s, 3H), 1.87 (br, 2H), 1.46-1.36 (m, 11H). MS (EI) for $C_{22}H_{29}N_5O_3$: 412 (MH^+).

N-{4-[2-(3,5-diamino-1H-1,2,4-triazol-1-yl)pyrimidin-4-yl]phenyl}acetamide: ^{1}H MR (400 MHz, d_6-DMSO): 10.28 (s, 1H), 8.7 (d, 1H), 8.16 (d, 2H), 7.78 (d, 2H), 7.7 (d, 1H), 7.58 (s, 2H), 2.03(s, 3H). MS (EI) for $C_{14}H_{14}N_8O$: 311 (MH^+).

N-{4-[2-({5-[(4-ethylpiperazin-1-yl)carbonyl]pyridin-2-yl}amino)pyrimidin-4-yl]-henyl}acetamide: ^{1}H NMR (400 MHz, d_6-DMSO): 10.26 (s, 1H), 10.12 (s, 1H), 8.6 (d, 1H), 8.46 (d, 1H), 8.36 (d, 1H), 8.18 (d, 2H), 7.9 (dd, 1H), 7.77 (d, 2H), 7.54 (d, 1H), 2.46-2.32 (m, 6H), 2.1 (s, 3H), 1.0 (t, 3H). MS (EI) for $C_{24}H_{27}N_7O_2$: 446 (MH^+).

N-(4-{2-[(4-cyanophenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H MR (400 MHz, d_6-DMSO): 10.24 (d, 2H), 8.6 (d, 1H), 8.17 (d, 2H), 8.06 (d, 2H), 7.78 (d, 4H), 7.5 (d, 1H), 2.05 9s, 3H). MS (EI) for $C_{19}H_{15}N_5O$: 330 (MH^+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyridin-4-yl}phenyl)acetamide: ^{1}H MR (400 MHz, d_6-DMSO): 10.14 (s, 1H), 8.82 (s, 1H), 8.12 (d, 1H), 7.72 9d, 2H), 7.62 (d, 2H), 7.53 (d, 2H), 6.97-6.92 (m, 2H), 6.9 (d, 2H), 3.74 (t, 4H), 3.02 (t, 4H), 2.07 (s, 3H). MS (EI) for $C_{23}H_{24}N_4O_2$: 389 (MH^+).

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}-5-methylpyrimidin-4-yl)phenyl]-3-(methyloxy)propanamide: ^{1}H NMR (400 MHz, d_6-DMSO): 10.18 (s, 1H), 9.25 (s, 1H), 8.3 (s, 1H), 7.75 (d, 2H), 7.63 (d, 2H), 7.61 (d, 2H), 6.86 (d, 2H), 3.64 (t, 2H), 3.25 (s, 3H), 3.03 (t, 4H), 2.6 (t, 2H), 2.38 (br, 2H), 2.2 (s, 3H), 1.03 (t, 3H). MS (EI) for $C_{72}H_{34}N_6O_2$: 475 (MH^+).

tert-butyl 1-(4-(4-(4-acetamidophenyl)pyrimidin-2-ylamino)phenyl)piperidin-4-ylcarbamate: ^{1}H NMR (400 MHz, d_6-DMSO): 10.21 (s, 1H), 9.38 (s, br, 1H), 8.43 (s, 1H), 8.08 (m, 2H), 7.74 (m, 2H), 7.62 (m, 2H), 7.23 (m, 1H), 6.98 (m, 3H), 3.77 (m, 2H), 3.63 (m, 2H), 2.09 (s, 3H), 1.80 (m, 2H), 1.49 (m, 2H), 1.30 (s, 9H). MS (EI) for $C_{28}H_{34}N_6O_3$: 503 (MH^+).

4-(4-aminophenyl)-N-(4-(4-aminopiperidin-1-yl)phenyl)pyrimidin-2-amine: ^{1}H MR (400 MHz, d_6-DMSO): 9.19 (s, 1H), 8.3 (m, 1H), 7.87 (m, 2H), 7.63 (m, 2H), 7.14 (m, 1H), 6.92 (m, 2H), 6.62 (m, 2H), 5.74 (m, 2H), 3.57 (m, 2H), 2.67 (m, 2H), 1.81 (m, 2H), 1.38 (m, 2H). MS (EI) for $C_{21}H_{24}N_6$: 361 (MH^+).

N-(1-(4-(4-(4-acetamidophenyl)pyrimidin-2-ylamino)phenyl)piperidin-4-yl)-acetamide: ^{1}H NMR (400 MHz, d_6-DMSO): 10.26 (s, 1H), 9.34 (s, 1H), 8.43 (d, 1H), 8.1 (d, 2H), 7.85 (d, 1H), 7.75 (d, 2H), 7.64 (d, 2H), 7.27 (d, 1H), 6.94 (d, 2H), 3.67 (m, 1H), 3.55 (m, 2H), 2.72 (t, 2H), 2.09 (s, 3H), 1.88-1.76 (m, 5H), 1.48 (m, 2H). MS (EI) for $C_{25}H_{28}N_6O_2$: 445 (MH^+).

N-(4-(2-(4-(4-(cyclopropanecarbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)-phenyl)cyclopropanecarboxamide: ^{1}H NMR (400 MHz, d_6-DMSO): 10.51 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.87 (d, 2H), 7.69 (d, 2H), 7.28 (d, 1H), 6.97 (d, 2H), 3.82 (m, 2H), 3.61 (m, 2H), 3.25-2.99 (m, 4H), 2.04 (m, 1H), 1.83 (m, 1H), 0.89-0.68 (m, 8H).. MS (EI) for $C_{28}H_{30}N_6O_2$: 483 (MH^+).

N-(4-(2-(4-(4-isobutyrylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-tetrahydrofuran-2-carboxamide: ^{1}H NMR (400 MHz, d_6-DMSO): 9.94 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.87 (d, 2H), 7.68 (d, 2H), 7.31 (d, 1H), 6.96 (d, 2H), 4.42 (m, 1H), 3.99 (m, 1H), 3.85 (m, 1H), 3.62 (m, 4H), 3.08 (m, 2H), 3.02 (m, 2H), 2.92 (m, 1H) 2.21 (m, 1H), 2.01 (m, 1H), 2.73 (m, 2H), 1.03 (d, 6H). MS (EI) for $C_{29}H_{34}N_6O_3$: 515 (MH^+).

N-(4-(2-(4-(4-(cyclobutanecarbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-2-carboxamide: ^{1}H NMR (400 MHz, d_6-DMSO): 9.94 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.13 (d, 2H), 7.87 (d, 2H), 7.68 (d, 2H), 7.30 (d, 1H), 6.95 (d, 2H), 4.43 (m, 1H), 3.99 (m, 1H), 3.84 (m, 1H), 3.59 (m, 2H), 3.43 (m, 2H), 3.01 (m, 4H), 2.28-1.69 (m, 10H). MS (EI) for $C_{30}H_{34}N_6O_3$: 527 (MH^+).

N-(4-(2-(4-(4-pivaloylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-tetrahydrofuran-2-carboxamide: ^{1}H NMR (400 MHz, d_6-DMSO): 9.95 (s, 1H), 9.42 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.88 (d, 2H), 7.69 (d, 2H), 7.30 (d, 1H), 6.95 (d, 2H), 4.43 (m, 1H), 4.0 (m, 1H), 3.84 (m, 1H), 3.7 (m, 4H), 3.04 (m, 4H), 2.22 (m, 1H), 2.02 (m, 1H), 1.86 (m, 2H), 1.23 (s, 9H). MS (EI) for $C_{30}H_{36}N_6O_3$: 529 (MH^+).

N-cyclopropyl-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.51 (s, br, 1H), 8.58 (s, br, 1H), 8.52 (d, 1H), 8.21 (d,

2H), 7.96 (d, 2H), 7.67 (d, 2H), 7.39 (d, 1H), 6.93 (d, 2H), 3.76 (m, 4H), 3.05 (m, 4H), 2.89 (m, 1H), 0.71 (m, 2H), 0.60 (m, 2H). MS (EI): 416 (MH+).

N-(2-methoxyethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.51 (s, br, 1H), 8.68 (s, br, 1H), 8.52 (d, 1H), 8.23 (d, 2H), 8.00 (d, 2H), 7.67 (d, 2H), 7.40 (d, 1H), 6.94 (d, 2H), 3.75 (m, 4H), 3.47 (m, 4H), 3.28 (s, 3H), 3.05 (m, 4H). MS (EI): 434 (MH+).

2,6-dichloro-n-{3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]propyl}-benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 9.25 (br s, 1H), 8.68-8.66 (m, 2H), 8.37 (m, 2H), 7.49-7.47 (m, 3H), 7.42-7.38 (m, 1H), 7.32 (m, 1H), 7.21-7.20 (m, 1H), 3.44 (m, 2H), 3.29 (m, 2H), 1.82 (m, 2H). MS (EI): 402.0 (MH+).

2,6-dichloro-n-(3-{[4-(4-methyl-3,4-dihydro-2h-1,4-benzoxazin-7-yl)pyrimidin-2-yl]amino}propyl)benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 8.69 (t, 1H), 8.18 (d, 1H), 7.58 (dd, 1H), 7.51-7.40 (m, 4H), 7.02-6.97 (m, 2H), 6.73 (d, 1H), 4.25-4.23 (m, 2H), 3.41 (m, 2H), 3.32-3.29 (m, 4H), 2.91 (s, 3H), 1.81 (t, 2H). MS (EI): 472.3 (MH+).

2,6-dichloro-n-(3-{[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-methyl-pyrimidin-2-yl]amino}propyl)benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 8.68 (t, 1H), 7.62-7.59 (m, 2H), 7.51-7.49 (m, 2H), 7.44-7.40 (m, 1H), 7.02 (t, 1H), 6.97-6.92 (m, 2H), 4.30-4.28 (m, 4H), 3.44-3.43 (m, 2H), 3.32-3.29 (m, 2H), 2.27 (s, 3H), 1.80 (t, 2H); MS (EI): 473.3 (MH+).

N-(4-{2-[(3-{[(2,6-dichlorophenyl)carbonyl]amino}propyl)-amino]pyrimidin-4-yl}phenyl)morpholine-4-carboxamide: ^{1}H-NMR (400MHz, d6-DMSO): 8.69 (m, 2H), 8.33 (d, 1H), 8.18 (m, 1H), 7.60 (m, 2H), 7.51-7.49 (m, 2H), 7.44-7.34 (m, 2H), 7.20 (m, 1H), 7.01 (d, 1H), 3.62-3.61 (m, 4H), 3.43 (m, 6H), 3.32 (m, 2H), 1.83 (m, 2H). MS (EI): 529.1 (MH+).

2,6-dichloro-n-{3-[(4-{4-[(cyclopropylcarbonyl)amino]-phenyl}pyrimidin-2-yl)amino]propyl}benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.4 (s, 1H), 8.72 (t, 1H), 8.36-8.33 (m, 2H), 7.73 (m, 2H), 7.51-7.39 (m, 4H), 7.24 (m, 1H), 7.03 (d, 1H), 3.45 (m, 2H), 3.33 (m, 4H), 1.84-1.78 (m, 2H), 0.81-0.78 (m, 3H). MS (EI): 484.0 (MH+).

N-(4-{2-[(3-{[(2,6-dichlorophenyl)carbonyl]amino}propyl)-amino]pyrimidin-4-yl}phenyl)thiophene-2-carboxamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.4 (s, 1H), 8.72 (t, 1H), 8.44 (t, 1H), 8.37 (d, 1H), 8.05 (s, 1H), 7.90-7.81 (m, 3H), 7.50-7.39 (m, 4H),

7.25-7.23 (m, 2H), 7.07 (d, 1H), 3.47 (m, 2H), 3.34 (m, 2H), 1.85 (m, 2H). MS (EI): 526.0 (MH+).

2,6-dichloro-n-(3-{[4-(4-{[n-(2-morpholin-4-ylethyl)glycyl]-amino}phenyl)pyrimidin-2-yl]amino}propyl)benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.0 (br s, 1H), 8.72 (t, 1H), 8.35-8.32 (m, 2H), 7.82-7.75 (m, 2H), 7.51-7.40 (m, 4H), 7.22 (s, 1H), 7.05 (d, 1H), 3.56 (m, 4H), 3.45 (m, 2H), 3.30 (m, 3H), 2.64 (m, 2H), 2.41-2.35 (m, 8H), 1.84 (br s, 2H). MS (EI): 586.1 (MH+).

1-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-ethanone: ^{1}H-NMR (400MHz, d6-DMSO): 8.50 (d, 1H), 8.26-8.24 (m, 2H), 8.12-8.10 (m, 2H), 7.30 (s, 1H), 7.64-7.62 (m, 2H), 7.31 (d, 1H), 7.00-6.98 (m, 2H), 3.82-3.80 (m, 4H), 3.12-3.10 (m, 4H), 2.64 (s, 3H). MS (EI): 375.1 (MH+).

(1e)-1-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)ethanone oxime: ^{1}H-NMR (400MHz, d6-DMSO): 11.4 (s, 1H), 9.82 (br s, 1H), 8.55 (d, 1H), 8.20 (d, 2H), 7.85-7.82 (m, 4H), 7.45 (d, 1H), 7.36 (br s, 1H), 4.69 (br, 1H), 3.91 (m, 4H), 3.34 (m, 4H), 2.21 (s, 3H). MS (EI): 388.1 (MH-).

N-{4-[2-({4-[4-(cyclopropylcarbonyl)piperazin-1-yl]phenyl}-amino)pyrimidin-4-yl]phenyl}-2-phenylacetamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.4 (s, 1H), 9.43 (br s, 1H), 8.42 (d, 1H), 8.10 (d, 2H), 7.75 (d, 2H), 7.67 (d, 2H), 7.33-7.20 (m, 2H), 7.07 (s, 2H), 6.97-6.95 (m, 4H), 3.82 (m, 4H), 3.67 (s, 2H), 3.03 (m, 4H), 2.07 (m, 1H), 0.75-0.69 (m. 4H). MS (EI): 533.2 (MH+).

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2-bromobenzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.14 ppm (s, 1H), 8.42 ppm (t, 1H), 8.29 ppm (d, 1H), 8.06 ppm (d, 1H), 7.70 ppm (d,2H), 7.65 ppm (m, 1H), 7.39 ppm (m, 3H), 7.12 ppm (t, 1H), 7.07 ppm (d, 1H), 3.33 ppm (br. m, 2H), 3.31 ppm (m, 2H), 2.07 ppm (s, 3H), 1.81 ppm (m, 2H); MS (EI) $C_{22}H_{22}BrN_5O_2$: 468 (MH^+).

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2-fluorobenzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.17 ppm (s, 1H), 8.37 ppm (t, 1H), 8.30 ppm (d, 1H), 8.06 ppm (d, 2H), 7.70 ppm (d,2H), 7.61 ppm (m, 1H), 7.50 ppm (m, 1H), 7.26 ppm (m, 2H), 7.16 ppm (t, 1H), 7.08 ppm (d, 1H), 3.41 ppm (br. m, 2H), 3.33 ppm (m, 2H), 2.08 ppm (s, 3H), 1.81 ppm (br. m, 2H); MS (EI) $C_{22}H_{22}FN_5O_2$: 408 (MH^+).

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2-chlorobenzamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.14 ppm (s, 1H), 8.45 ppm (t, 1H), 8.28 ppm (d, 1H), 8.04 ppm (d, 2H), 7.68 ppm (d,2H), 7.68 ppm (d, 2H), 7.47 ppm (m, 1H), 7.41 ppm (m, 2H), 7.35 ppm (m, 1H), 7.13 ppm (t, 1H). 7.06 ppm (d, 1H), 3.42 ppm (br. m, 2H), 3.29 ppm (m, 2H), 2.05 ppm (s, 3H), 1.78 ppm (br m, 2H); MS (EI) $C_{22}H_{22}BrN_5O_2$: 468 (MH^+).

N-[4-(2-{[3-(morpholin-4-ylsulfonyl)phenyl]amino}pyrimidin-4-yl)phenyl]-acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.23 ppm (s, 1H), 10.12 ppm (s, 1H), 8.74 ppm (s, 1H), 8.58 ppm (d, 1H), 8.21 ppm (d,2H), 7.93 ppm (m, 1H), 7.76 ppm (d, 2H), 7.60 ppm (t, 1H), 7.47 ppm (d, 1H), 7.30 ppm (m, 1H), 3.64 ppm (m, 4H), 2.90 ppm (m, 4H), 2.10 ppm (s, 3H); MS (EI) $C_{22}H_{23}N_5O_4S$: 454 (MH^+).

N-{4-[2-({3-[(cyclohexylmethyl)amino]phenyl}amino)pyrimidin-4-yl]phenyl}-acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.43 ppm (s, 1H), 9.32 ppm (s, 1H), 8.46 ppm (d, 1H), 8.13 ppm (d, 2H), 7.77 ppm (d,2H), 7.30 ppm (d, 2H), 7.17 ppm (s, 1H), 6.94 ppm (m, 2H), 6.22 ppm (m, 1H), 5.56 ppm (t, 1H), 2.87 ppm (t, 2H), 2.09 ppm (s, 3H), 1.85 ppm (br d, 2H), 1.69 ppm (br m, 2H),1.64 ppm (br m, 1H), 1.19 ppm (m, 3H), 0.94 ppm (m, 2H); MS (EI) $C_{25}H_{29}N_5O$: 416 (MH^+).

N-(4-{2-[(3-{[(5-bromo-2-fluorophenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.21 ppm (s, 1H), 9.37 ppm (s, 1H), 8.45 ppm (d, 1H), 8.12 ppm (d, 2H), 7.74 ppm (d, 2H), 7.55 ppm (m, 1H), 7.47 ppm (m, 1H), 7.31 ppm (d, 1H), 7.20 ppm (m, 1H), 7.05 ppm (m, 1H), 7.00 ppm (t, 1H), 6.28 ppm (t, 1H), 6.22 ppm (m, 1H), 4.32 ppm (d, 2H), 2.09 ppm (s, 3H); MS (EI) $C_{25}H_{21}BrFN_5O$: 507 (MH^+).

N-(4-{2-[(3-{[(2,5-dimethylphenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.20 ppm (s, 1H), 9.33 ppm (s, 1H), 8.45 ppm (d, 1H), 8.13 ppm (d, 2H), 7.73 ppm (d, 2H), 7.30 ppm (d, 1H), 7.16 ppm (m, 2H), 7.06 ppm (d, 1H), 6.97 ppm (m, 3H), 6.23 ppm (m, 1H), 5.99 ppm (t, 1H), 4.17 ppm (d, 2H), 2.28 ppm (s, 3H), 2.21 ppm (s, 3H), 2.08 ppm (s, 3H); MS (EI) $C_{27}H_{27}N_5O$: 438 (MH^+).

N-(4-{2-[(3,4-dimorpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.22 ppm (s, 1H), 9.43 ppm (s, 1H), 8.46 ppm (d, 1H), 8.14 ppm (d, 2H), 7.74 ppm (d, 2H), 7.65 ppm (s, 1H), 7.34 ppm

(m, 2H), 7.29 ppm (d, 2H), 6.88 ppm (d, 1H), 3.75 ppm (m, 8H), 3.15 ppm (br s, 4H), 3.05 ppm (br s, 4H), 2.09 ppm (s, 3H); MS (EI) $C_{26}H_{30}N_6O_3$: 475 (MH^+).

N-{4-[2-({4-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}cyclopropanecarboxamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.47 ppm (s, 1H), 9.41 ppm (s, 1H), 8.67 ppm (m, 2H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.89 ppm (m, 1H), 7.76 ppm (d, 2H), 7.69 ppm (d, 2H), 7.51 ppm (m, 1H), 7.28 ppm (d, 1H), 6.97 ppm (d, 2H), 3.80 ppm (s, 2H), 3.49 ppm (s, 2H), 3.13 ppm (br d, 4H), 1.83 ppm (m, 1H), 0.84 ppm (m, 4H); MS (EI) $C_{30}H_{29}N_7O_2$: 520 (MH^+).

N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}butanamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.16 ppm (s, 1H), 9.41 ppm (s, 1H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.77 ppm (d, 2H), 7.68 ppm (d, 2H), 7.28 ppm (d, 1H), 6.96 ppm (d, 2H), 3.63 ppm (m, 4H), 3.05 ppm (m, 4H), 2.92 ppm (m, 1H), 2.33 ppm (t, 1H), 1.63 ppm (m, 2), 1.02 ppm (d, 6H), 0.93 ppm (t, 3H); MS (EI) $C_{28}H_{34}N_6O_2$: 487 (MH^+).

N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}butanamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.15 ppm (s, 1H), 9.41 ppm (s, 1H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.77 ppm (d, 2H), 7.68 ppm (d, 2H), 7.28 ppm (d, 1H), 6.95 ppm (d, 2H), 3.70 ppm (m, 4H), 3.05 ppm (m, 4H), 2.33 ppm (t, 2H), 1.63 ppm (m, 2H), 1.23 ppm (s, 9H), 0.93 ppm (t, 3H); MS (EI) $C_{29}H_{36}N_6O_2$: 501 (MH^+).

N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}butanamide: ^{1}H-NMR (400MHz, d_6-DMSO): 10.28 ppm (s, 1H), 9.41 ppm (s, 1H), 8.44 ppm (d, 1H), 8.11 ppm (d, 2H), 7.79 ppm (d, 2H), 7.68 ppm (d, 2H), 7.28 ppm (d, 1H), 6.95 ppm (d, 2H), 3.59 ppm (m, 2H), 3.46 ppm (m, 2H), 3.40 ppm (m, 1H), 3.02 ppm (m, 4H), 2.35 ppm (t, 2H), 2.14 ppm (m, 4H), 1.91 ppm (m, 1H), 1.75 ppm (m, 1H), 1.63 ppm (m 2H), 0.93 ppm (t, 3H); MS (EI) $C_{29}H_{34}N_6O_2$: 499 (MH^+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridine-2-carboxamide: 1H-NMR (400MHz, d6-DMSO): 10.91 (s, 1H), 9.41 (s, 1H), 8.78 (d, 1H), 8.47 (d, 2H), 8.17 (m, 4H), 7.69 (m, 2H), 7.33 (d, 1H), 6.95 (d, 2H), 6.80 (s, 2H), 3.75 (m, 4H), 3.06 (m, 4H). MS (EI) for $C_{26}H_{24}N_6O_2$: 453.5(MH+).

2-hydroxy-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-benzamide: 1H-NMR (400MHz, d6-DMSO): 10.39 (s, 1H), 9.51 (s, 1H), 8.47 (s, 1H),

8.16 (d, 2H), 7.91 (d, 2H), 7.17 (m, 3H), 7.53 (t, 1H), 7.34 (s, 2H) 7.20 (d, 1H), 7.07 (m, 3H), 3.91 (m, 4H), 3.12 (m, 4H). MS (EI) for $C_{27}H_{25}N_5O_3$: 468.5(MH+).

3-(methyloxy)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-benzamide: 1H-NMR (400MHz, d6-DMSO): 10.49 (s, 2H), 8.19 (m, 3H), 7.97 (m, 3H), 7.55 (m, 2H), 7.50 (m, 3H), 7.20 (dd, 3H), 3.86 (m, 8H), 3.77 (s, 3H). MS (EI) for $C_{28}H_{27}N_5O_3$: 482.6(MH+).

4-(methyloxy)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-benzamide: 1H-NMR (400MHz, d6-DMSO): 10.35 (s, 1H), 9.40 (s, 1H), 8.45 (s, 1H), 8.16 (d, 2H), 7.98 (m, 4H), 7.68 (d, 2H), 7.31 (d, 1H), 7.09 (d, 2H), 6.94(d, 2H), 3.83 (s, 3H), 3.75 (m, 4H), 3.05 (m, 4H). MS (EI) for $C_{28}H_{27}N_5O_3$: 482.6(MH+).

4-chloro-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-benzamide: 1H-NMR (400MHz, d6-DMSO):10.58 (s, 1H), 9.41 (s, 1H), 8.46 (s, 1H), 8.17 (d, 2H), 8.01 (d, 2H), 7.95 (d, 2H), 7.66 (m, 4H), 7.32 (d, 1H), 6.94 (d, 2H), 3.75 (m, 4H), 3.05 (m, 4H). MS (EI) for $C_{27}H_{24}ClN_5O_2$: 487.0(MH+).

(2R)-N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-tetrahydrofuran-2-carboxamide: 1H-NMR (400MHz, d6-DMSO):9.95 (s, 1H), 9.38 (s, 1H), 8.45 (s, 1H), 8.12 (d, 2H), 7.89 (d, 2H), 7.66 (d, 2H), 7.29 (s, 1H), 6.92 (d, 2H), 4.44 (t, 2H), 4.00 (m, 2H), 3.85 (m, 2H), 2.41 (m, 4H), 2.20 (m, 2H), 2.02 (m, 2H), 1.88 (m, 2H), 1.05 (m, 4H). MS (EI) for $C_{27}H_{32}N_6O_2$: 473.6(MH+).

(2S)-N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-tetrahydrofuran-2-carboxamide: 1H-NMR (400MHz, d6-DMSO):9.94 (s, 1H, 9.38 (s, 1H), 8.44 (s, 1H), 8.12 (d, 2H), 7.87 (d, 2H), 7.65 (d, 2H), 7.29 (s, 1H), 6.99 (d, 2H), 4.43 (m, 2H), 3.99 (m, 2H), 3.86 (m, 2H), 2.43 (m, 2H), 2.22 (m, 2H), 2.02 (m, 2H), 1.88 (m, 3H), 1.05 (m, 5H) . MS (EI) for $C_{27}H_{32}N_6O_2$: 473.6(MH+).

1-(2-hydroxyethyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}-phenyl)-L-prolinamide: 1H-NMR (400MHz, d6-DMSO): 10.31 (s, 1H), 9.39 (s, 1H), 8.44 (d, 1H), 8.14 (d, 2H), 7.81 (d, 2H), 7.67 (d, 2H), 7.29 (d, 1H), 6.95 (d, 2H), 5.05 (s, br, 1H), 3.74 (m, 4H), 3.59 (m, 1H), 3.49 (m, 1H), 3.23 (m, 2H), 3.05 (m, 4H), 2.77 (m, 1H), 2.63 (m, 1H), 2.41 (m, 1H), 2.16 (m, 1H), 1.80 (m, 3H). MS (EI) for $C_{27}H_{32}N_6O_3$: 489.6(MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)thiophene-2-carboxamide: 1H-NMR (400MHz, d6-DMSO): 10.47 (s, 1H), 9.45 (s, 1H), 8.47 (s, 1H),

8.17 (d, 2H), 8.08 (s, 1H), 7.92 (m, 3H), 7.70 (s, 2H), 7.32 (s, 1H), 7.26 (t, 1H), 6.99 (s, 2H), 3.76 (m, 4H), 3.09 (m, 4H). MS (EI) for $C_{25}H_{23}N_5O_2S$: 458.6(MH+).

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-tetrahydrofuran-3-carboxamide: 1H-NMR (400MHz, d6-DMSO): 10.31 (s, 1H), 9.37 (s, 1H), 8.44 (s, 1H), 8.14 (m, 2H), 7.79 (d, 2H), 7.65 (d, 2H), 7.27 (d, 1H), 6.92 (d, 2H), 3.96 (t, 1H), 3.76 (m, 3H), 3.19 (m, 1H), 3.09 (m, 4H), 2.55 (m, 4H), 2.42 (m, 2H), 2.10 (m, 2H), 1.05 (t, 3H). MS (EI) for $C_{27}H_{32}N_6O_2$: 473.6(MH+).

N-(4-{2-[4-(4-nicotynoylpiperazin-1-yl)phenylamino]pyrimidin-4-yl}phenyl)-2-phenylacetamide: ^{1}H NMR (400MHz, d6-DMSO): 8.8 (d, 2H), 8.40 (s, 1H), 8.05 (d, 2H), 7.80 (d,1H),7.60-7.2 (m, 10H), 7.1-6.90 (m, 5H), 3.80-3.60 (m, 4H), 3.7 (s, 2H)3.20-3.25 (m, 4H); MS (EI) for $C_{34}H_{31}N_7O_2$: 570 (MH^+).

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-(diphenylmethyl)benzamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.22 (s, 1H), 9.78 (s, 1H), 9.24 (d, 1H), 8.52 (d, 1H), 8.39 (s br, 1H), 8.16 (d, 2H), 7.95 (d, 1H), 7.75 (d, 2H), 7.53 (d t, 1H), 7.39-7.43 (m, 3H), 7.38 (d, 3H), 7.32-7.36 (m, 4H), 7.24-7.28 (m, 2H), 6.43 (d, 1H), 2.10 (s, 3H). MS (EI) for $C_{32}H_{27}N_5O_2$: 514.3 (MH+).

N-[4-(2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.24 (s, 1H), 9.35 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.65 (d, 2H), 7.26 (d, 1H), 6.93 (d, 2H), 3.07 (m, 4H), 2.45 (m, 4H), 2.22 (s, 3H), 2.09 (s, 3H). MS (EI) for $C_{23}H_{26}N_6O$: 403.4(MH+).

N-{4-[2-({4-[4-(phenylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H-NMR (400MHz,d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.45 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.73-7.79 (m, 5H), 7.28 (d, 1H), 6.98 (d, 2H), 3.78 (m, 2H), 3.48 (m, 2H), 3.15 (m, 2H), 3.07 (m, 2H), 2.09 (s, 3H). MS (EI) for $C_{29}H_{28}N_6O_2$: 493.4 (MH+).

N-{4-[2-({4-[4-(2-cyclopentylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H-NMR (400MHz,d6-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.68 (d, 2H), 7.27 (s, 1H), 6.96 (d, 2H), 3.60 (m, 4H), 3.04 (m, 4H), 2.37 (d, 2H), 2.15 (m, 1H), 2.09 (s, 3H), 1.61-1.78 (m, 2H), 1.53-1.59 (m, 2H), 1.46-1.52 (m, 2H), 1.09-1.77 (m, 2H). MS (EI) for $C_{29}H_{34}N_6O_2$: 499.3 (MH+).

N-{4-[2-({4-[4-(cyclohexylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.22 (s, 1H), 9.40 (s, 1H), 8.44

(d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.68 (d, 2H), 7.27 (d, 1H), 6.96 (d, 2H), 3.61 (m, 4H), 3.04 (m, 4H), 2.09 (s, 3H), 1.62-1.70 (m, 6H), 1.26-1.38 (m, 5H). MS (EI)for $C_{29}H_{34}N_6O$: 499.2 (MH+).

N-(4-{2-[(4-{4-[(2-chlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz,d6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.10 (d, 2H), 7.74 (d, 2H), 7.69 (d. 2H), 7.56 (d, 1H), 7.41-7.49 (m, 3H), 7.27 (d, 1H), 6.96 (d, 2H), 3.81 (m, 2H), 3.28 (m, 2H), 3.16 (m, 2H), 3.05 (m, 2H), 2.09 (s, 3H). MS (EI) for $C_{29}H_{27}ClN_6O_2$: 527.8 (MH+).

N-(4-{2-[(4-{4-[(3-fluorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.53 (m, 1H), 7.27-7.35 (m, 4H), 6.97 (d, 2H), 3.77 (m, 2H), 3.46 (m, 2H), 3.16 (m, 2H), 3.07 (m, 2H), 2.09 (s, 3H).MS(EI) for $C_{29}H_{27}FN_6O_2$: 511.5 (MH+).

N-(4-{2-[(4-{4-[(3-fluoro-4-methylphenyl)carbonyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.38 (m, 1H), 7.28 (d, 1H), 7.25 (d, 1H), 7.18 (d, 1H), 6.56 (d, 2H), 3.75 (m, 2H), 3.49 (m, 2H), 3.14 (m, 2H), 3.07 (m, 2H), 2.28 (d, 3H), 2.09 (s, 3H). MS(EI) for $C_{30}H_{29}FN_6O_2$: 525.7 (MH+).

N-(4-{2-[(4-{4-[(3,4-dichlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.45 (s, 1H), 8.11 (d, 2H), 7.75 (m, 3H), 7.69 (d, 2H), 7.45 (dd, 1H), 7.28 (d, 1H), 6.97 (d, 2H), 3.77 (m, 2H), 3.47 (m, 2H), 3.16 (m, 2H), 3.07 (m, 2H), 2.09 (s, 3H). MS (EI) for $C_{29}H_{26}Cl_2N_6O_2$: 562.3(MH+).

N-(4-{2-[(4-{4-[(3,5-dichlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.75 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.54 (d, 2H), 7.28 (d, 1H), 6.97 (d, 2H), 3.77 (m, 2H), 3.45 (m, 2H), 3.17 (m, 2H), 3.08 (m, 2H), 2.09 (s, 3H). MS (EI) for $C_{29}H_{26}Cl_2N_6O_2$: 562.6(MH+).

N-[4-(2-{[4-(4-{[3-(methyloxy)phenyl]carbonyl}piperazin-1-yl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.38 (t, 1H), 7.28 (d, 1H),

7.04 (dd, 1H), 6.95-6.99 (m, 4H), 3.79 (s, 3H), 3.77 (m, 2H), 3.47 (m, 2H), 3.15 (m, 2H), 3.06 (m, 2H), 2.09 (s, 3H). MS(EI) for $C_{30}H_{30}N_6O_3$: 523.5(MH+).

N-(4-{2-[(4-{4-[(4-chlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.53 (d, 2H), 7.49 (d, 2H), 7.27 (d, 1H), 6.97 (d, 2H), 3.77 (m, 2H), 3.47 (m, 2H), 3.15 (m, 2H), 3.06 (m, 2H), 2.09 (s, 3H). MS (EI) for $C_{29}H_{27}ClN_6O_2$: 527.8(MH+).

N-(4-{2-[(4-{4-[(4-methylphenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.44)d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.34 (d, 2H), 7.27 (m, 3H), 6.97 (d, 2H), 3.75 (m, 2H), 3.51 (m, 2H), 3.10 (m, 4H), 2.36 (s, 3H), 2.09 (s, 3H). MS (EI) for $C_{30}H_{30}N_6O_2$: 507.3 (MH+).

N-(4-{2-[(4-{4-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.21 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.27 (d, 1H), 6.98 (d, 2H), 6.92 (t, 1H), 6.37 (dd, 1H), 6.05 (dd, 1H), 3.76 (m, 4H), 3.69 (s, 3H), 3.11 (m, 4H), 2.09 (s, 3H), MS (EI) for $C_{28}H_{29}N_7O_2$: 496.4(MH+).

N-{4-[2-({4-[4-(furan-2-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H-NMR(400MHz,d6-DMSO):10.22 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.87 (d, 1H), 7.74 (d, 2H), 7.69 (d, 2H), 7.28 (d, 1H), 7.04 (d, 1H), 6.98 (d, 2H), 6.66 (dd, 1H), 3.82 (m, 4H), 3.14 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{27}H_{26}N_6O_3$: 483.3 (MH+).

N-[4-(2-{[4-(4-{2-[(4-fluorophenyl)oxy]acetyl}piperazin-1-yl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.22 (s, 1H), 9.41 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.27 (d, 1H), 7.12 (m, 2H), 6.94-6.99 (m, 4H), 4.87 (s, 2H), 3.61 (m, 4H), 3.13 (m, 2H), 3.06 (m, 2H), 2.09 (s, 3H). MS (EI) for $C_{30}H_{29}FN_6O_3$:541.4(MH+).

N-(4-{2-[(4-{4-[(3-methylphenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: MS (EI) for $C_{29}H_{30}N_6O_3S$: 543.5 (MH+).

N-{4-[2-({4-[4-(phenylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.21 (s, 1H), 9.39 (s, 1H), 8.43 (d,

1H), 8.10 (d, 2H), 7.80 (m, 1H), 7.78 (d, 1H), 7.74-7.77 (m, 2H), 7.70-7.73 (m, 2H), 7.67-7.69 (m, 1H), 7.65 (d, 2H), 7.27 (d, 1H), 6.90 (d, 2H), 3.15 (m, 4H), 3.02 (m, 4H), 2.09 (s,3H). MS (EI) for $C_{26}H_{26}N_6O_3S_2$: 529.4(MH+).

N-{4-[2-({4-[4-(2-thienylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H-NMR(400MHz,d6-DMSO):10.21 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.10 (m, 3H), 7.74 (d, 2H), 7.70 (dd, 1H), 7.66 (d, 2H), 7.33 (dd, 1H), 7.27 (d, 1H), 6.93 (d, 2H), 3.19 (m, 4H), 3.07 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{26}H_{26}N_6O_3S_2$: 535.6(MH+).

N-(4-{2-[(4-{4-[(4-fluorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR(400MHz,d6-DMSO):10.21 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.10 (d, 2H), 7.87 (m, 2H), 7.74 (d, 2H), 7.66 (d, 2H), 7.53 (m, 2H), 7.27 (d, 1H), 6.91 (d, 2H), 3.15 (m, 4H), 3.04 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{28}H_{27}FN_6O_3S$: 547.4 (MH+).

N-[4-(2-{[4-(4-{[4-(methyloxy)phenyl]sulfonyl}piperazin-1-yl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR(400MHz,d6-DMSO): MS (EI) for $C_{29}H_{30}N_6O_4S$: 559.9 (MH+).

N-(4-{2-[(4-{4-[(4-chlorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR(400MHz,d6-DMSO):10.21 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.72-7.82 (d, 6H), 7.66 (d, 2H), 7.27 (d, 1H), 6.91 (d, 2H), 3.15 (m, 4H), 3.05 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{28}H_{27}ClN_6O_3S$: 563.9 (MH+).

N-(4-{2-[(4-{4-[(3-chlorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR(400MHz,d6-DMSO):10.21 (s, 1H), 9.40 (s, 1H), 8.43 (d, 1H), 8.10 (d, 2H), 7.85 (m, 1H), 7.76-7.81 (m, 2H), 7.73 (d, 3H), 7.66 (d, 2H), 7.27 (d, 1H), 6.91 (d, 2H), 3.14 (m, 4H), 3.09 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{28}H_{27}ClN_6O_3S$: 5640 (MH+).

N-{4-[2-({4-[4-(biphenyl-4-ylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR(400MHz,d6-DMSO):10.21(s, 1H), 9.39 (s, 1H), 8.43 (d, 1H), 8.08 (d, 2H), 7.96 (d, 2H), 7.86 (d, 2H), 7.77 (d, 2H), 7.73 (d, 2H), 7.66 (d, 2H), 7.51-7.55 (m, 2H), 7.46 (m, 1H), 7.26 (d, 1H), 6.91 (d, 2H), 3.18 (m, 4H), 3.08 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{34}H_{32}N_6O_3S$: 605.8 (MH+).

N-{4-[2-({4-[4-(naphthalen-1-ylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.21 (s, 1H), 9.38 (s, 1H), 8.72 (d, 1H), 8.42 (d, 1H), 8.33 (d, 1H), 8.20 (dd, 1H), 8.14 (d, 1H), 8.09 (d, 2H), 7.74-7.79 (m, 1H), 7.73 (d, 2H), 7.62-7.70 (m, 2H), 7.64 (d, 2H), 7.26 (d, 1H), 6.88 (d, 2H), 3.21 (m, 4H), 3.09 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{32}H_{30}N_6O_3S$: 579.6 (MH+).

N-(4-{2-[(3-{4-[(2-chlorophenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.21 (s, 1H), 9.46 (s, 1H), 8.49 (d, 1H), 8.14 (d, 2H), 7.74 (d, 2H), 7.64 (s br, 1H), 7.36 (dd, 1H), 7.33 (d, 1H), 7.20-7.27 (m, 2H), 7.13 (t, 1H), 6.92-7.00 (m, 2H), 6.55 (d, 1H), 3.54 (s, 2H), 3.16 (m, 4H), 2.57 (m, 4H), 2.09 (s,3H). MS (EI) for $C_{29}H_{29}ClN_6O$: 513.8 (MH+).

N-[4-(2-{[3-(4-{[3-(methyloxy)phenyl]methyl}piperazin-1-yl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR(400MHz,d6-DMSO):10.21 (s, 1H), 9.46 (s, 1H), 8.48 (d, 1H), 8.13 (d, 2H), 7.74 (d, 2H), 7.62 (s, 1H), 7.33 (d, 1H), 7.22-7.27 (m, 2H), 7.13 (t, 1H), 6.19 (m, 2H), 6.83 (d, 1H), 6.55 (d, 1H), 3.74 (s, 3H), 3.52 (s, 2H), 3.16 (m, 4H), 2.55 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{30}H_{32}N_6O_2$: 509.8(MH+).

N-{4-[2-({3-[4-(3-methylbutyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.22 (s, 1H), 9.47 (s, 1H), 8.49 (d, 1H), 8.14 (d, 2H), 7.75 (d, 2H), 7.68 (s, 1H), 7.33 (d, 1H), 7.19 (d, 1H), 7.13 (t, 1H), 6.55 (d, 1H), 3.15 (m, 4H), 2.54 (m, 4H), 2.34 (t, 2H), 2.09 (s, 3H), 1.57-1.62 (m, 1H), 1.34-1.40 (m, 2H), 0.90 (d, 6H). MS (EI) for $C_{27}H_{34}N_6O$: 459.7 (MH+).

N-{4-[2-({3-[4-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR(400MHz,d6-DMSO): MS (EI) for $C_{31}H_{32}N_6O_3$: 537.5 (MH+).

N-{4-[2-({3-[4-(cyclopropylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.22 (s, 1H), 9.47 (s, 1H), 8.49 (d, 1H), 8.14 (d, 2H), 7.75 (d, 2H), 7.69 (s, 1H), 7.33 (d, 1H), 7.19 (d, 1H), 7.13 (t, 1H), 6.56 (d, 1H), 3.17 (m, 4H), 2.60 (m, 4H), 2.24 (d, 2H), 2.09 (s, 3H), 0.88 (m, 1H), 0.47-0.51 (m, 2H), 0.11-0.13 (m, 2H). MS (EI) for $C_{26}H_{30}N_6O$: 443.8 (MH+).

N-(4-{2-[(3-{4-[3-(methylthio)propyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR(400MHz,d6-DMSO):10.22 (s, 1H), 9.47 (s, 1H), 8.49

(d, 1H), 8.14 (d, 2H), 7.75 (d, 2H), 7.68 (s, 1H), 7.33 (d, 1H), 7.20 (d, 1H), 7.14 (t, 1H), 6.56 (d, 1H), 3.15 (m, 4H), 2.56 (m, 4H), 2.41 (t, 4H), 2.09 (s, 3H), 2.06 (s, 3H), 1.71-1.78 (m, 2H). MS (EI) for $C_{26}H_{32}N_6OS$: 477.5(MH+).

N-(4-{2-[(3-{4-[(4-{[3-(dimethylamino)propyl]oxy}phenyl)methyl]piperazin-1-yl}-phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR(400MHz,d6-DMSO):10.22 (s, 1H), 9.46 (s, 1H), 8.48 (d, 1H), 8.13 (d, 2H), 7.74 (d, 2H), 7.62 (s, 1H), 7.33 (d, 1H), 7.23 (m 3H), 7.13 (t, 1H), 6.88 (d, 2H), 6.55 (d, 1H), 3.97 (t, 2H), 3.46 (s, 2H), 3.14 (m, 4H), 2.55 (m, 4H), 2.34 (t, 2H), 2.14 (s, 6H), 2.10 (s, 3H), 1.80-1.85 (m, 2H). MS (EI) for $C_{34}H_{41}N_7O_2$: 580.5(MH+).

N-{4-[2-({3-[4-({3-[(trifluoromethyl)oxy]phenyl}methyl)piperazin-1-yl]phenyl}-amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR(400MHz,d6-DMSO):10.21 (s, 1H), 9.47 (s, 1H), 8.49 (d, 1H), 8.13 (d, 2H), 7.74 (d, 2H), 7.63 (s, 1H), 7.47 (t, 1H), 7.41 (d, 1H), 7.33 (d, 2H), 7.22-7.28 (m, 2H), 7.13 (t, 1H), 6.56 (dd, 1H), 3.62 (s, 2H), 3.16 (m ,4H), 2.56 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{30}H_{29}F_3N_6O_2$: 563.7(MH+).

4-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-N-phenylpiperazine-1-carboxamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.63 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.75 (d, 2H), 7.70 (d, 2H), 7.48 (d, 2H), 7.21-7.28 (m, 3H), 7.00 (d, 2H), 6.94 (t, 1H), 3.61 (m, 4H), 3.11 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{29}H_{29}N_7O_2$: 508.6 (MH+).

N-[4-(2-{[3-(4-propanoylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.24 (s, 1H), 9.51 (s, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.76 (d, 2H), 7.68 (s, 1H), 7.34 (d, 1H), 7.26 (d, 1H), 7.16 (t, 1H), 6.59 (dd, 1H), 3.62 (m, 4H), 3.13 (m, 4H), 2.35-2.39 (m, 2H), 2.09 (s, 3H), 1.02 (t, 3H). MS (EI) for $C_{25}H_{28}N_6O_2$: 445.4 (MH+).

N-{4-[2-({3-[4-(phenylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.21 (s, 1H), 9.48 (s, 1H), 8.47 (d, 1H), 8.11 (d, 2H), 7.72 (d, 2H), 7.63 (s, 1H), 7.41-7.47 (m, 5H), 7.31 (d, 1H), 7.26 (d, 1H), 7.14 (t, 1H), 6.56 (dd, 1H), 3.78 (m, 2H), 3.48 (m, 2H), 3.27 (m, 2H), 3.12 (m, 2H), 2.08 (s, 3H). MS (EI) for $C_{29}H_{28}N_6O_2$: 493.7 (MH+).

N-{4-[2-({3-[4-(2-phenylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.25 (s, 1H), 9.50 (s, 1H), 8.49 (d,

1H), 8.13 (d, 2H), 7.76 (d, 2H), 7.63 (s, 1H), 7.33 (d, 1H), 7.30 (d, 2H), 7.26 (m, 3H), 7.22 (m, 1H), 7.15 (t, 1H), 6.56 (dd, 1H), 3.79 (s, 2H), 3.66 (m, 4H), 3.11 (m, 2H), 3.05 (m, 2H), 2.09 (s, 3H). MS (EI) for $C_{30}H_{30}N_6O_2$: 507.7 (MH+).

N-{4-[2-({3-[4-(cyclopentylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.24 (s, 1H), 9.52 (s, 1H), 8.49 (d, 1H), 8.14 (d, 2H), 7.76 (d, 2H), 7.71 (s, 1H), 7.34 (d, 1H), 7.24 (d, 1H), 7.16 (t, 1H), 6.59 (dd, 1H), 3.66 (m, 4H), 3.13 (m, 4H), 3.00-3.07 (m, 1H), 2.09 (s, 3H), 1.80 (m, 2H), 1.51-1.71 (m, 6H). MS (EI) for $C_{28}H_{32}N_6O_2$: 485.7 (MH+).

N-{4-[2-({3-[4-(2-pyridin-3-ylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.24 (s, 1H), 9.51 (s, 1H), 8.50 (d, 1H), 8.43-8.46 (m, 2H), 8.14 (d, 2H), 7.76 (d, 2H), 7.63-7.67 (m, 2H), 7.32-7.35 (m, 2H), 7.26 (d, 1H), 7.16 (t, 1H), 6.59 (dd, 1H), 3.84 (s, 2H), 3.73 (m, 2H), 3.66 (m, 2H), 3.15 (m, 4H), 2.08 (s, 3H). MS (EI) for $C_{29}H_{29}N_7O_2$: 508.4 (MH+).

N-{4-[2-({3-[4-(2-cyclopentylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR(400MHz,d6-DMSO):10.24 (s, 1H), 9.51 (s, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.76 (d, 2H), 7.70 (s, 1H), 7.34 (d, 1H), 7.25 (d, 1H), 7.16 (t, 1H), 6.59 (dd, 1H), 3.61 (m, 4H), 3.12 (m, 4H), 2.39 (d, 2H), 2.11-2.19 (m, 1H), 2.09 (s, 3H), 1.72-7.78 (m, 2H), 1.52-1.59 (m, 2H), 1.47-1.52 (m, 2H), 1.09-1.18 (m, 2H). MS (EI) for $C_{29}H_{34}N_6O_2$: 499.4 (MH+).

N-(4-{2-[(3-{4-[(2-chlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.24 (s, 1H), 9.50 (s, 1H), 8.49 (d, 1H), 8.13 (d, 2H), 7.74 (d, 2H), 7.63 (s, 1H), 7.56 (d, 1H), 7.42-7.50 (m, 3H), 7.33 (d, 1H), 7.29 (d, 1H), 7.16 (t, 1H), 6.59 (dd, 1H), 3.79 (m, 2H), 3.50 (m, 2H), 3.24 (m, 2H), 3.15 (m, 2H), 2.09 (s, 3H). MS (EI) for $C_{29}H_{27}ClN_6O_2$: 527.9 (MH+).

N-(4-{2-[(3-{4-[(4-chlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.23 (s, 1H), 9.51 (s, 1H), 8.49 (d, 1H), 8.14 (d, 2H), 7.74 (d, 2H), 7.66 (s, 1H), 7.53 (d, 2H), 7.49 (d, 2H), 7.34 (d, 1H), 7.27 (d, 1H), 7.17 (t, 1H), 6.59 (dd, 1H), 3.79 (m, 2H), 3.50 (m, 2H), 3.24 (m, 2H), 3.15 (m, 2H), 2.09 (s, 3H). MS (EI) for $C_{29}H_{27}ClN_6O_2$: 528.1 (MH+).

N-(4-{2-[(3-{4-[(3,4-dichlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.23 (s, 1H), 9.51 (s, 1H), 8.49 (d, 1H), 8.13 (d, 2H), 7.74 (m, 4H), 7.60 (s, 1H), 7.46 (dd, 1H), 7.34 (d, 1H), 7.27 (d, 1H), 7.17 (t, 1H), 6.59 (dd, 1H), 3.79 (m, 2H), 3.50 (m, 2H), 3.24 (m, 2H), 3.15 (m, 2H), 2.09 (s, 3H). MS (EI) for $C_{29}H_{26}Cl_2N_6O_2$: 562.7 (MH+).

N-(4-{2-[(3-{4-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.23 (s, 1H), 9.51 (s, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.75 (d, 2H), 7.67 (s, 1H), 7.34 (d, 1H), 7.28 (d, 1H), 7.17 (t, 1H), 6.92 (m, 1H), 6.59 (dd, 1H), 6.37 (dd, 1H), 6.05 (m, 1H), 3.80 (m, 4H), 3.69 (s, 3H), 3.19 (m, 4H), 2.09 (s, 3H). MS (EI) for $C_{28}H_{29}N_7O_2$: 450.7 (MH+).

N^2,N^2-dimethyl-N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]glycinamide: ^{1}H-NMR(400MHz,d6-DMSO):10.0 (s, 1H), 9.48 (s, 1H), 8.48 (d, 1H), 8.15 (d, 2H), 7.84 (d, 2H), 7.65 (s, 1H), 7.29-7.33 (m, 2H), 6.86 (d, 1H), 3.81 (s, 3H), 3.72 (m, 4H), 3.11 (s, 2H), 2.92 (m, 4H), 2.29 (s, 6H). MS (EI) for$C_{25}H_{30}N_6O_3$: 463.8 (MH+).

3-(methyloxy)-N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]propanamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.21 (s, 1H), 9.46 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.74 (d, 2H), 7.64 (s, 1H), 7.26-7.30 (m, 2H), 6.84 (d, 1H), 3.79 (s, 3H), 3.70 (m, 4H), 3.61 (t, 2H), 3.23 (s, 3H), 2.89 (m, 4H), 2.57 (t, 2H). MS (EI) for $C_{25}H_{29}N_5O_4$: 464.8 (MH+).

N-(4-{2-[(4-{4-[(2-chlorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.19 (s, 1H), 9.38 (s, 1H), 8.42 (d, 1H), 8.08 (d, 2H), 8.00 (dd, 1H), 7.68-7.74 (m, 4H), 7.65 (d, 2H), 7.58 (m, 1H), 7.25 (d, 1H), 6.91 (d, 2H), 3.15 (m, 4H), 3.02 (m, 4H), 2.07 (s, 3H). MS (EI) for $C_{28}H_{27}ClN_6O_3S$: 563.9 (MH+).

N-{4-[2-({3-[4-(cyclopropylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.24 (s, 1H), 9.52 (s, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.76 (d, 2H), 7.71 (s, 1H), 7.34 (d, 1H), 7.25 (d, 1H), 7.17 (t, 1H), 6.60 (dd, 1H), 3.56 (m, 2H), 3.65 (m, 2H), 3.20 (m, 2H), 3.13 (m, 2H), 2.09 (s, 3H), 2.04 (m, 1H), 0.77-0.49 (m, 4H). MS (EI) for $C_{26}H_{28}N_6O_2$: 457.5(MH+).

N-{4-[2-({3-[4-(2-cyclopropylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.24 (s, 1H), 9.51 (s, 1H), 8.50 (d, 1H), 8.14 (d, 2H), 7.76 (d, 2H), 7.70 (s, 1H), 7.34 (d, 1H), 7.25 (d, 1H), 7.16 (t, 1H), 6.58 (dd, 1H), 3.62 (m, 4H), 3.13 (m, 4H), 2.32 (d, 2H), 2.09 (s, 3H), 0.99 (m, 1H), 0.45 (m, 2H), 0.14 (m, 2H). MS (EI) for $C_{27}H_{30}N_6O_2$: 477.5(MH+).

N-[4-(2-{[3-(4-{[3-(methyloxy)phenyl]carbonyl}piperazin-1-yl)phenyl]amino}-pyrimidin-4-yl)phenyl]acetamide: ^{1}H-NMR(400MHz,d6-DMSO): 10.22 (s, 1H), 9.48 (s, 1H), 8.47 (d, 1H), 9.11 (d, 2H), 7.72 (d, 2H), 7.62 (s, 1H), 7.35 (t, 1H), 7.31 (d, 1H), 7.26 (d, 1H), 7.14 (t, 1H), 7.01 (m, 1H), 6.97 (m, 2H), 6.56 (dd, 1H), 3.76 (s, 3H), 3.73 (m, 2H), 3.47 (m, 2H), 3.14 (m, 4H), 2.07 (s, 3H). MS (EI) for $C_{30}H_{30}N_6O_3$: 523.7 (MH+).

N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H-NMR (400MHz, d6-DMSO): 10.21 (s, 1H), 9.40 (s, 1H), 8.44 (d, 1H), 8.11 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.27 (d, 1H), 6.96 (d, 2H), 3.70 (m, 4H), 3.05 (m, 4H), 2.09 (s, 3H), 1.23 (s, 9H), MS(EI) for $C_{27}H_{32}N_6O_2$: 473.4(MH+).

2,6-dichloro-N-(3-(4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)pyrimidin-2-ylamino)propyl)benzamide: (400 MHz, CDCl3): 8.16 (br, 1H), 8.0 – 8.8 (m, 2H), 7.26 (m, 4H), 6.82 (d, 1H), 6.75 (br, 1H), 5.4 (t, 1H), 4.29 (m, 4H), 3.68 (m, 2H), 3.56 (m, 2H), 1.92 (m, 2H). MS (EI): 459 (MH+).

1-(4-(4-(4-acetamidophenyl)pyrimidin-2-ylamino)phenyl)piperidine-3-carboxylic acid: MS (EI) for $C_{24}H_{25}N_5O_3$: 432 (MH+).

tert-butyl methyl(2-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenylamino)-2-oxoethyl)carbamate: MS (EI) for $C_{28}H_{34}N_6O_4$: 519 (MH+).

tert-butyl 4-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl-carbamate: MS (EI) for $C_{27}H_{34}N_6O_2$: 475 (MH+).

2-(dimethylamino)-N-(4-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide: NMR (400 MHz, d6-DMSO): 10.0 (s, 1H), 9.37 (s, 1H), 8.41 (d, 1H), 8.11 (d, 1H), 7.85 (d, 2H), 7.63 (f, 2H), 7.46 (d, 1H), 7.25 (d, 1H), 6.83 – 6.92 (m, 2H), 3.11 (m, 4H), 2.51 (m, 4H), 2.37 (q, 2H), 2.36 (s, 6H), 2.26 (s, 2H), 1.05 (t, 3H). MS (EI): 460 (MH+).

4-(4-aminophenyl)-N-(4-(4-ethylpiperazin-1-yl)phenyl)pyrimidin-2-amine: MS (EI) for $C_{22}H_{26}N_6$: 375 (MH+).

(S)-tert-butyl 1-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenylamino)-1-oxo-3-phenylpropan-2-ylcarbamate: MS (EI) for $C_{34}H_{38}N_6O_4$: 595 (MH+).

(R)-tert-butyl 1-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenylamino)-1-oxo-3-phenylpropan-2-ylcarbamate: MS (EI) for $C_{34}H_{38}N_6O_4$: 595 (MH+).

(R)-2-amino-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-3-phenylpropanamide: NMR (400 MHz, d6-DMSO): 11.40 (s, 1H), 10.20 (s, 1H), 8.43 – 8.62 (m, 3H), 8.17 (d, 2H), 7.91 (d, 2H), 7.89 (d, 2H), 7.84 (m, 2H), 7.20 – 7.38 (m, 4H), 4.10 (m, 4H), 3.63 (m, 2H), 3.40 – 3.57 (m, 6H), 3.20 (m, 1H), MS (EI): 495 (MH+).

(S)-2-amino-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-3-phenylpropanamide: NMR (400 MHz, d6-DMSO): 11.40 (s, 1H), 10.20 (s, 1H), 8.43 – 8.62 (m, 3H), 8.17 (d, 2H), 7.91 (d, 2H), 7.89 (d, 2H), 7.84 (m, 2H), 7.20 – 7.38 (m, 4H), 4.10 (m, 4H), 3.63 (m, 2H), 3.40 – 3.57 (m, 6H), 3.20 (m, 1H), MS (EI): 495 (MH+).

(S)-2-amino-N-(4-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-methylbutanamide: MS (EI) for $C_{27}H_{35}N_7O$: 474 (MH+).

(R)-2-amino-N-(4-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-methylbutanamide: MS (EI) for $C_{27}H_{35}N_7O$: 474 (MH+).

1-ethyl-3-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)urea: NMR (400 MHz, d6-DMSO): 9.41 (s, 1H), 8.75 (s, 1H), 8.42 (d, 1H), 8.10 (d, 2H), 7.64 (s, 1H), 7.54 (d, 2H), 7.26 (m, 2H), 6.85 (d, 1H), 6.21 (br, 1H), 3.79 (s, 3H), 3.70 (m, 4H), 3.11 (q, 2H), 2.89 (m, 4H), 1.06 (t, 3H). MS (EI): 449 (MH+).

(R)-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)piperidine-2-carboxamide: NMR (400 MHz, d6-DMSO): 11.36 (s, 1H), 10.0 (s, 1H), 9.4 (d, 1H), 8.84 (m, 1H), 8.57 (d, 1H), 8.2 (d, 2H), 7.82 (m, 4H), 7.6 (br, 1H), 7.4 (d, 1H), 4.0 (m, 4H), 3.82 (m, 1H), 3.42 (m, 4H), 3.23 (m, 1H), 2.94 (m, 1H), 2.3 (m, 1H), 1.82 (m, 1H), 1.54 – 1.92 (m, 4H). MS (EI): 458 (MH+).

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}-5-methylpyrimidin-4-yl)phenyl]-acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.1 (s,1H), 9.23 (s, 1H), 8.31 (s, 1H), 7.6-7.7 (m, 6H), 6.87 (d, 2H), 3.04 (m, 4H), 2.48 (m, 4H), 3.05 (m, 4H), 2.36 (q, 2H), 2.2 (s, 3H), 2.08 (s, 3H), 1.03 (s, 3H). MS (EI): 431(MH+).

4-{4-[(4-{4-[(N,N-dimethylglycyl)amino]phenyl}pyrimidin-2-yl)amino]phenyl}-N-ethylpiperazine-1-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.0 (s,1H), 9.4 (s, 1H), 8.43 (d, 1H), 8.12 (d, 2H), 7.82 (d, 2H), 7.68 (d, 2H), 7.27 (d, 1H), 6.97 (d, 2H), 3.42 (m, 4H), 3.12 (s, 2H), 3.06 (q, 2H), 3.02 (m, 4H), 2.3 (s, 6H), 1.11 (t, 3H). MS (EI): 503 (MH+).

N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-N^2, N^2-dimethylglycinamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.0 (s,1H), 9.4 (s, 1H), 8.44 (d, 1H), 8.11(d, 2H), 7.83 (d, 2H), 7.69 (d, 2H), 7.29 (d, 1H), 6.96 (d, 2H), 3.7 (m, 4H), 3.16 (s, 2H), 3.05 (m, 4H), 2.31 (s, 6H), 1.2 (s, 9H). MS (EI): 516(MH+).

N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-N^2,N^2-dimethylglycinamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.0 (s,1H), 9.4 (s, 1H), 8.45 (d, 1H), 8.12(d, 2H), 7.84 (d, 2H), 7.67 (d, 2H), 7.30 (d, 1H), 6.95 (d, 2H), 3.56-3.62 (m, 4H), 3.1 (s, 2H), 2.99-3.05 (m, 4H), 2.31 (s, 6H), 1.8-2.25 (m, 7H). MS (EI): 514(MH+).

N^2,N^2-dimethyl-N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)-pyrimidin-4-yl]phenyl}glycinamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.0 (s,1H), 9.4 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.84 (d, 2H), 7.68 (d, 2H), 7.29 (d, 1H), 6.95 (d, 2H), 3.58-3.67 (m, 4H), 3.11 (s, 2H), 2.99-3.10 (m, 4H), 2.92 (m, 1H), 2.29 (s, 6H), 1.02 (d, 6H). MS (EI): 502(MH+).

N-{4-[2-({4-[4-(cyclopropylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-N^2,N^2-dimethylglycinamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.0 (s,1H), 9.4 (s, 1H), 8.43 (d, 1H), 8.14 (d, 2H), 7.68 (d, 2H), 7.26 (d, 1H), 6.97 (d, 2H), 3.8 (m, 2H), 3.6 (m, 2H),3.18 (m, 4H),3.07 (m, 2H), 2.28 (s, 6H), 2.02 (m, 1H), 0.78 (m, 4H). MS (EI): 501(MH+).

N-[4-(2-{[4-(4-D-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-N^2,N^2-dimethylglycinamide:^{1}H NMR (400 MHz, d6-DMSO): 10.0 (s,1H), 9.4 (s, 1H), 8.55 (d, 1H), 8.23 (d, 2H), 7.84 (d, 2H), 7.71 (d, 2H), 7.28 (d, 1H), 6.97 (d, 2H), 3.8 (m, 2H), 3.84 (q, 1H), 3.62 (m, 4H), 3.12 (s, 2H),3.05 (m, 4H), 2.31 (s, 6H), 1.12 (d, 3H). MS (EI): 504(MH+).

N-[4-(2-{[4-(4-L-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-N^2,N^2-dimethylglycinamide:^{1}H NMR (400 MHz, d6-DMSO): 10.0 (s,1H), 9.4 (s, 1H),

8.45 (d, 1H), 8.12 (d, 2H), 7.84 (d, 2H), 7.69 (d, 2H), 7.28 (d, 1H), 6.97 (d, 2H), 3.8 (m, 2H), 3.84 (q, 1H), 3.62 (m, 4H), 3.12 (s, 2H),3.05 (m, 4H), 2.31 (s, 6H), 1.12 (d, 3H). MS (EI): 504(MH+).

2,6-dichloro-N-(3-{[4-(4-fluorophenyl)pyrimidin-2-yl]amino}propyl)benzamide: ^{1}H NMR (400 MHz, DMSO): 8.705 (t, 1H), 8.354(d, 1H), 7.136 (br s, 2H), 7.515 (d, 2H), 7.5 (d, 2H), 7.425 (m, 1H), 7.34 (t, 2H), 7.26 (t, 1H), 7.14 (d, 1H), 3.456 (br s, 2H), 3.355 (m, 2H), 1.827 (t, 2H). MS (EI): 420.1 (MH^+).

N-(4-{2-[({1-[(2,6-dichlorophenyl)carbonyl]azetidin-3-yl}methyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, DMSO): 11.031 (s, 1H), 8.344 (d, 1H), 8.137 (d, 2H), 7.839 (d, 2H), 7.621 (d, 2H), 7.531 (m, 1H), 7.45 (t, 1H), 7.146 (d, 1H), 4.157 (m, 1H), 3.867 (t, 2H), 3.626-3.556 (m, 3H), 2.842 (br s, 1H), 1.725 (s, 3H). MS (EI) for $C_{23}H_{21}Cl_2N_5O_2$: 470.2 (MH^+).

N-(4-{2-[(3-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, DMSO): 10.22 (s, 1H), 9.511 (s, 1H), 8.504 (d, 1H), 8.154 (d, 2H), 7.76 (d, 3H), 7.343 (d, 1H), 7.215-7.153 (m, 2H), 6.584 (d, 1H), 3.775 (t, 4H), 3.14 (t, 4H), 2.094 (s, 3H). MS (EI) for $C_{22}H_{23}N_5O_2$: 390.1 (MH^+).

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)cyclohexyl]-2,6-dichloro-benzamide: ^{1}H NMR (400 MHz, MeOD): 8.25 (d, 1H), 8.08 (d, 2H), 7.7 (d, 2H), 7.45-7.35 (m, 3H), 7.05 (d, 1H), 4.05 (m, 2H), 2.5 (m, 1H), 2.1 (m, 3H), 2.05 (s, 3H), 1.5 (m, 1H), 1.3 (m, 3H). MS (EI) for $C_{25}H_{25}Cl_2N_5O_2$: 498.3 (MH^+).

N-{4-[2-({[4-(4-methylpiperazin-1-yl)phenyl]methyl}amino)pyrimidin-4-yl]phenyl}-acetamide: ^{1}H NMR (400 MHz, DMSO): 10.192 (s, 1H), 8.294 (d, 1H), 8.062 (d, 2H), 7.713 (d, 2H), 7.653 (t, 1H), 7.285 (br d, 2H), 7.09 (d, 1H), 6.953 (d, 2H), 4.485 (d, 2H), 3.3 (br s, 8H), 2.827 (s, 3H), 2.079 (s, 3H). MS (EI) for $C_{24}H_{28}N_6O$: 417.4 (MH^+).

N-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,6-dichloro-benzamide ^{1}H NMR (400 MHz, DMSO): 10.66 (s, 1H), 10.324 (s, 1H), 9.638 (s, 1H), 8.501 (d, 1H), 8.144 (d, 2H), 7.782 (m, 4H), 7.65 (d, 2H), 7.597 (d, 2H), 7.498 (m, 1H), 7.349 (d, 1H), 2.11 (s, 3H). MS (EI) for $C_{25}H_{19}Cl_2N_5O_2$: 492 (MH^+).

N-{4-[2-(piperidin-4-ylamino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, DMSO): 10.184 (s, 1H), 8.288 (d, 1H), 8.044 (d, 2H), 7.71 (d, 2H), 7.049 (t, 2H),

3.8 (br s, 1H), 2.962 (d, 2H), 2.077 (s, 3H), 1.838 (br d, 2H), 1.372-1.334 (m, 2H). MS (EI) for $C_{17}H_{21}N_5O$: 312.3 (MH^+).

N-{4-[2-({1-[(2,6-dichlorophenyl)carbonyl]piperidin-4-yl}amino)pyrimidin-4-yl]-phenyl}acetamide: ^{1}H NMR (400 MHz, DMSO): 10.171 (s, 1H), 8.312 (d, 1H), 8.067 (d, 2H), 7.71 9d, 2H), 7.584-7.546 (m, 2H), 7.461 (t, 1H), 7.246 (d, 1H), 7.093 (d, 1H), 4.468 (m, 1H), 4.1 (br s, 1H), 3.25-3.05 (m, 2H), 2.077 (s, 3H), 2.05 (m, 1H), 1.915 (br s, 1H0, 1.58-1.532 (m, 2H). MS (EI) for $C_{24}H_{23}Cl_2N_5O_2$: 485.3 (MH^+).

N-{4-[2-({4-[(2-hydroxyethyl)oxy]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, DMSO): 10.211 (s, 1H), 9.43 (s, 1H), 8.455 (d, 1H), 8.12 (d, 2H), 7.754-7.69 (m, 4H), 7.292 (d, 1H), 6.93 (m, 2H), 4.865 (t, 1H), 3.97 (t, 2H), 3.715 (q, 2H), 2.09 (s, 3H). MS (EI) for $C_{20}H_{20}N_4O_3$: 365.1 (MH^+).

1-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-3-phenylurea: ^{1}H NMR (400 MHz, DMSO): 9.371 (s, 1H), 8.986 (s, 1H), 8.795 9s, 1H), 8.436 (d, 1H), 8.121 (d, 2H), 7.697 (d, 2H), 7.633 (d, 2H), 7.49 (d, 2H), 7.321-7.265 (m, 3H), 7.014-6.928 (t d, 3H), 3.758 (t, 4H), 3.063 (t, 4H). MS (EI) for $C_{27}H_{26}N_6O_2$: 467.3 (MH^+).

N-[5-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-2-(4-ethylpiperazin-1-yl)phenyl]-2,6-dichlorobenzamide: ^{1}H NMR (400 MHz, DMSO): 10.224 (s, 1H), 9.623 (d, 2H), 8.6 (br s, 1H), 8.48 (d, 1H), 8.237 (d, 2H), 7.735 (d, 2H). 7.598 (d, 2H), 7.521 (m, 2H), 7.35 (d, 1H), 7.181 (d, 1H), 3.36 (br s, 4H), 2.877 (t, 4H), 2.344 (q, 2H), 2.071 (s, 3H), 1.005 (t, 3H). MS (EI) for $C_{31}H_{31}Cl_2N_7O_2$: 604.3 (MH^+).

1-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-3-(phenylmethyl)urea: ^{1}H NMR (400 MHz, MeOD): 8.082 (t, 3H), 7.53 (d, 2H), 7.422 (m, 3H), 7.236 (m, 4H), 7.159 (m, 1H), 7.037 (d, 2H), 4.32 (s, 2H), 3.971 (d, 2H), 3.608 (d, 2H), 3.195 (t, 2H), 3.126 (d, 2H), 3.045 (t, 2H), 1.3 (t, 3H). MS (EI) for $C_{30}H_{33}N_7O$: 508.4 (MH^+).

N^2,N^2-dimethyl-N-{4-[2-({4-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}glycinamide: ^{1}H NMR (400 MHz, DMSO): 9.994 (s, 1H), 9.418 (s, 1H), 8.667 (m, 2H), 8.454 (d, 1H), 8.127 (d, 2H), 7.907-7.827 (m d, 3H), 7.7 (d, 2H), 7.513 (m, 1H), 7.298 (d, 1H), 6.98 (d, 2H), 3.799 (br s, 2H), 3.489 (br s, 2H), 3.179 (br s, 2H), 3.113 (br s, 4H), 2.289 (s, 6H). MS (EI) for $C_{30}H_{32}N_8O_2$: 537.4 (MH^+).

N-(3-fluoro-4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-cyclopropanecarboxamide: ^{1}H NMR (400 MHz, DMSO): 10.671 (s, 1H), 9.452 (s, 1H), 8.47 (d, 1H), 8.045 (t, 1H), 7.758 (d, 1H), 7.656 (d, 2H), 7.46 (d, 1H), 7.12 (q, 1H), 6.932 (d, 2H), 3.749 (t, 4H), 3.052 (t, 4H), 1.813 (m, 1H), 0.847 (d, 4H). MS (EI) for $C_{24}H_{24}FN_5O_2$: 434.3(MH^+).

N-(4-{2-[(4-{4-[(1-methyl-1H-imidazol-2-yl)methyl]piperazin-1-yl}phenyl)amino]-pyrimidin-4-yl}phenyl)cyclopropanecarboxamide: ^{1}H NMR (400 MHz, DMSO): 7.851 (d, 1H), 7.67 (d, 2H), 7.452 (br d, 2H), 7.285 (d, 2H), 7.091 (d, 1H), 7.763 (d, 1H), 6.688 (d, 2H), 6.291 (br s, 1H), 3.668 (s, 3H), 3.561 (s, 2H), 2.946 (br s, 4H), 2.5 (br s, 4H), 1.413 (m, 1H), 0.541 (m, 2H), 0.3 (m, 2H). MS (EI) for $C_{29}H_{32}N_8O$: 509.4(MH^+).

N-[4-(2-{[4-(4-L-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-acetamide: ^{1}H NMR (400 MHz, DMSO): 10.212 (s, 1H), 9.407 (s, 1H), 8.449 (d, 1H), 8.121 (d, 2H), 7.732 (d, 2H), 7.698 (d, 2H), 7.282 (d, 1H), 6.978 (d, 2H), 3.804 (q, 1H), 3.621 (m, 4H), 3.037 (br m, 4H), 2.091 (s, 3H), 1.864 (br s, 2H), 1.10 (d, 3H). MS (EI) for $C_{25}H_{29}N_7O_2$: 460.4(MH^+).

N-[4-(2-{[4-(4-L-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-acetamide: ^{1}H NMR (400 MHz, DMSO): 10.234 (s, 1H), 9.409 (s, 1H), 8.449 (d, 1H), 8.121 (d, 2H), 7.757 (d, 2H), 7.699 (d, 2H), 7.282 (d, 1H), 6.979 (d, 2H), 3.849 (m, 1H), 3.619 (m, 4H), 2.992 (m, 6H), 2.625 (m, 1H), 2.092 (s, 3H), 1.986 (m, 1H), 1.685-1.536 (m, 3H). MS (EI) for $C_{27}H_{31}N_7O_2$: 486.2(MH^+).

N-[4-(2-{[4-(4-D-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl-acetamide: ^{1}H NMR (400 MHz, DMSO): 10.22 (s, 1H), 9.406 (s, 1H), 8.449 (d, 1H), 8.12 (d, 2H), 7.755 (d, 2H), 7.697 (d, 2H), 7.282 (d, 1H), 6.978 (d, 2H), 3.791 (q, 1H), 3.621 (br s, 4H), 3.081 (br d, 4H), 2.091 (s, 3H), 1.709 (br s, 2H), 1.096 (d, 3H). MS (EI) for $C_{25}H_{29}N_7O_2$: 460.4(MH^+).

N-[4-(2-{[4-(4-D-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-acetamide: ^{1}H NMR (400 MHz, DMSO): 10.211 (s, 1H), 9.407 (s, 1H), 8.449 (d, 1H), 8.121 (d, 2H), 7.754 (d, 2H), 7.698 (d, 2H), 7.282 (d, 1H), 6.979 (d, 2H), 3.872 (t, 1H), 3.621 (m, 4H), 3.082-2.979 (m, 6H), 2.656 (m, 1H), 2.091 (s, 3H), 2.013 (m, 2H), 1.676-1.522 (m, 3H). MS (EI) for $C_{27}H_{31}N_7O_2$: 486.4(MH^+).

N-{4-[2-({4-[4-(2-piperazin-1-ylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide: ^{1}H NMR (400 MHz, DMSO): 10.219 (s, 1H), 9.401 (s, 1H), 8.448 (d, 1H), 8.121 (d, 2H), 7.754 (d, 2H), 7.694 (d, 2H), 7.281 (d, 1H), 6.977 (d, 2H), 3.707 (t, 2H), 3.59 (t, 2H), 3.319 (s, 2H), 3.1 (t, 2H), 3.018 (t, 2H), 2.702 (s, 4H), 2.336 (br s, 4H), 2.090 (s, 3H). MS (EI) for $C_{28}H_{34}N_8O_2$: 515.2(MH^+).

N-[4-(2-{[4-(4-L-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-tetrahydrofuran-2-carboxamide: ^{1}H NMR (400 MHz, DMSO): 9.938 (s, 1H), 9.417 (s, 1H), 8.457 (d, 1H), 8.135 (d, 2H), 7.885 (d, 2H), 7.693 (d, 2H), 7.305 (d, 1H), 6.976 (d, 2H), 4.436 (q, 1H), 3.991 (q, 1H), 3.878-3.761 (q q, 4H), 3.622 (br s, 4H), 3.083 (br d, 4H), 2.222 (m, 1H), 2.019 (m, 1H), 1.913 (m, 2H), 1.843 (br s, 2H). MS (EI) for $C_{28}H_{33}N_7O_3$: 516.3(MH^+).

N-[4-(2-{[4-(4-L-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-tetrahydrofuran-2-carboxamide: ^{1}H NMR (400 MHz, DMSO): 9.945 (s, 1H), 9.419 (s, 1H), 8.458 (d, 1H), 8.135 (d, 2H), 7.887 (d, 2H), 7.696 (d, 2H), 7.306 (d, 1H), 6.978 (d, 2H), 4.452 (q, 1H), 4.011 (q, 1H), 3.861 (q, 2H), 3.633 (m, 4H), 3.084-2.968 (m, 6H), 2.62 (m, 1H), 2.191 (m, 1H), 2.002 (m, 2H), 1.897 (m, 2H), 1.691-1.544 (m, 3H). MS (EI) for $C_{30}H_{35}N_7O_3$: 542.3(MH^+).

N-[4-(2-{[4-(4-D-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-tetrahydrofuran-2-carboxamide: ^{1}H NMR (400 MHz, DMSO): 9.945 (s, 1H), 9.418 9s, 1H), 8.457 (d, 1H), 8.135 (d, 2H), 7.887 (d, 2H), 7.694 (d, 2H), 7.305 (d, 1H), 6.976 (d, 2H), 4.452 (q, 1H), 4.028 (q, 1H), 3.878-3.768 (m, 2H), 3.633 (m, 4H), 3.083 (br d, 4H), 2.209 (m, 1H), 2.002 (m, 1H), 1.862 (m, 3H), 1.1 (d, 3H). MS (EI) for $C_{28}H_{33}N_7O_3$: 516.3(MH^+).

N-[4-(2-{[4-(4-D-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-tetrahydrofuran-2-carboxamide: ^{1}H NMR (400 MHz, DMSO). 9.954 (s, 1H), 9.421 (s, 1H), 8.458 (d, 1H), 8.136 (d, 2H), 7.889 (d, 2H), 7.697 (d, 2H), 7.306 (d, 1H), 6.978 (d, 2H), 4.454 (q, 1H), 4.028 (q, 1H), 3.889 (m, 2H), 3.645 (m, 4H), 3.083-2.985 (m, 6H), 2.669 (m, 1H), 2.209 (m, 1H), 2.002 (m, 2H), 1.879 (m, 2H), 1.681-1.548 (m, 3H), MS (EI) for $C_{30}H_{35}N_7O_3$: 542.3(MH^+).

(2,6-dichlorophenyl)(4-(4-(4-methylthiophen-2-yl)pyrimidin-2-ylamino)piperidin-1-yl)methanone: ^{1}H-NMR (400MHz, d6-DMSO): 8.28 (d, 1H), 7.72 (m, 1H), 7.57 (m, 2H), 7.47 (m, 1H), 7.32 (s, 1H), 7.27 (m, 1H), 7.01 (m, 1H), 4.45 (m,

1H), 4.03 (m, 1H), 3.28-3.05 (m, 3H), 2.45 (s, 3H), 2.03-1.80 (m, 2H), 1.59-1.48 (m, 2H); MS (EI): 447 (MH+).

(2,6-dichlorophenyl)(4-(4-(pyridin-3-yl)pyrimidin-2-ylamino)piperidin-1-yl)-methanone: ^{1}H-NMR (400MHz, d6-DMSO): 9.28 (br. s, 1H), 8.69 (m, 1H), 8.41 (m, 2H), 7.59-7.52 (m, 2H), 7.46 (m, 2H), 7.25 (d, 1H), 4.46 (m, 1H), 4.14 (m, 1H), 3.32-3.10 (m, 3H), 2.06-1.89 (m, 2H), 1.63-1.54 (m, 3H); MS (EI): 428 (MH+).

(2,6-dichlorophenyl)(4-(4-(5-methylthiophen-2-yl)pyrimidin-2-ylamino)piperidin-1-yl)methanone: ^{1}H-NMR (400MHz, d6-DMSO): 8.24 (d, 1H), 7.70 (m, 1H), 7.57 (m, 2H), 7.47 (m, 1H), 7.24 (m, 1H), 7.00 (m, 1H), 6.88 (m, 1H), 4.45 (m, 1H), 4.02 (m, 1H), 3.28-3.05 (m, 3H), 2.47 (s, 3H), 2.03-1.80 (m, 2H), 1.57-1.50 (m, 2H); MS (EI): 447 (MH+).

1-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-1H-pyrrole-2-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 9.99 (s, 1H), 9.39 (s, 1H), 8.45 (d, 1H), 8.13 (d, 2H), 7.90 (d, 2H), 7.68 (d, 2H), 7.30 (d, 1H), 7.09-7.08 (m, 1H), 7.05 (t, 1H), 6.97 (d, 2H), 6.13-6.11 (m, 1H), 3.90 (s, 3H), 3.74 (t, 4H), 3.05 (t, 4H). MS (EI) for $C_{26}H_{26}N_6O_2$: 455 (MH+).

3-fluoro-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridine-4-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.96 (s, 1H), 9.43 (s, 1H), 8.79 (s, 1H), 8.62 (d, 1H), 8.47 (d, 1H), 8.20 (d, 2H), 7.88 (d, 2H), 7.76-7.67 (m, 2H), 7.32 (d, 1H), 6.94 (d, 2H), 6.56 (s, 1H), 3.74 (t, 4H), 3.05 (t, 4H). MS (EI) for $C_{26}H_{23}FN_6O_2$: 471 (MH+).

6-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridine-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.61 (s, 1H), 9.41 (s, 1H), 9.03 (d, 1H), 8.47 (d, 1H), 8.23 (dd, 1H), 8.19 (d, 2H), 7.95 (d, 2H), 7.68 (d, 2H), 7.45 (d, 1H), 7.31 (d, 1H), 6.94 (d, 2H), 3.74 (t, 4H), 3.05 (t, 4H), 2.57 (s, 3H). MS (EI) for $C_{27}H_{26}N_6O_2$: 467 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridazine-4-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.98 (s, 1H), 9.67 (s, 1H), 9.52 (d, 1H), 9.42 (s, 1H), 8.47 (d, 1H), 8.21 (d, 2H), 8.16-8.14 (m, 1H), 7.96 (d, 2H), 7.68 (d, 2H), 7.33 (d, 2H), 7.33 (d, 1H), 6.95 (d, 2H), 3.74 (t, 4H), 3.05 (t, 4H). MS (EI) for $C_{25}H_{23}N_7O_2$: 454 (MH+).

2-cyclopropyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.09 (s, 1H), 9.45 (s, 1H), 8.45 (d, 1H), 8.12 (d, 2H), 7.78 (d, 2H), 7.69 (d, 2H), 7.30 (d, 1H), 7.00 (s, 2H), 3.76 (s, 4H), 3.09 (s, 4H), 2.25 (d, 2H), 1.12-1.02 (m, 1H), 0.50-0.48 (m, 2H), 0.22-0.20 (m, 2H). MS (EI) for $C_{25}H_{27}N_5O_2$: 430 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)isoxazole-5-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.99 (s, 1H), 9.42 (s, 1H), 8.47 (d, 1H), 8.19 (d, 2H), 7.95 (d, 2H), 7.68 (d, 2H), 7.33-7.31 (m, 2H), 6.95 (d, 2H), 6.55 (s, 1H), 3.74 (t, 4H), 3.05 (t, 4H). MS (EI) for $C_{24}H_{22}N_6O_3$: 443 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridine-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.69 (s, 1H), 9.41 (s, 1H), 9.14 (s, 1H), 8.79 (d, 1H), 8.47 (d, 1H), 8.34-8.31 (m, 1H), 8.20 (d, 2H), 7.97 (d, 2H), 7.70 (d, 2H), 7.67-7.58 (m, 1H), 7.33 (d, 1H), 6.95 (d, 2H), 3.78 (t, 4H), 3.05 (t, 4H). MS (EI) for $C_{26}H_{24}N_6O_2$: 453 (MH+).

4-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-benzamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.42 (s, 1H), 9.53 (s, 1H), 8.47 (s, 1H), 8.17 (d, 2H), 7.98 (d, 2H), 7.91 (d, 2H), 7.72 (s, 2H), 7.37 (d, 3H), 7.05 (s, 2H), 3.78 (s, 4H), 3.14 (s, 4H), 2.40 (s, 3H). MS (EI) for $C_{28}H_{27}N_5O_2$: 466 (MH+).

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-D-prolinamide: ^{1}H NMR (400 MHz, d6-DMSO): 11.55 (s, 1H), 11.15 (s, 1H), 10.16 (s, 2H), 8.74 (s, 1H), 8.52 (s, 1H), 8.23 (d, 2H), 7.89 (d, 2H), 7.67 (d, 2H), 7.48 (s, 1H), 7.11 (d, 2H), 4.50 (s, br, 1H), 3.81 (d, 2H), 3.57 (d, 2H), 3.28-3.11 (m, 8H), 2.05-1.92 (m, 3H), 1.30 (t, 3H). MS (EI) for $C_{27}H_{33}N_7O$: 472 (MH+).

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-butanamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.25 (s, 1H), 9.37 (s, 1H), 8.43 (s, 1H), 8.12 (d, 2H), 7.77 (d, 2H), 7.68 (d, 2H), 7.29 (s, 1H), 6.93 (d, 2H), 3.08 (s, 4H), 2.42-2.30 (m, 4H), 1.68-1.58 (m, 2H), 1.05 (t, 3H), 0.93 (t, 3H). MS (EI) for $C_{26}H_{32}N_6O$: 445 (MH+).

1-ethyl-3-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]urea: ^{1}H NMR (400 MHz, d6-DMSO): 9.32 (s, 1H), 8.85 (s, 1H), 8.40 (d, 1H), 8.05 (d, 2H), 7.68 (d, 2H), 7.54 (d, 2H), 7.23 (d, 1H), 6.92 (d, 2H), 6.36 (t, 1H), 3.18-3.05

(m, 6H), 2.54 (t, 4H), 2.46-2.38 (m, 2H), 1.09-1.02 (m, 6H). MS (EI) for $C_{25}H_{31}N_7O$: 446 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)furan-3-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.17 (s, 1H), 9.46 (s, 1H), 8.47-8.43 (m, 2H), 8.18 (d, 2H), 7.91 (d, 2H), 7.83 (d, 1H), 7.70 (s, 2H), 7.32 (s, 1H), 7.03-6.95 (m, 3H), 3.76 (s, 4H), 3.09 (s, 4H). MS (EI) for $C_{25}H_{23}N_5O_3$: 442 (MH+).

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-1,3-thiazole-4-carboxamide: ^{1}H NMR (400 MHz, d6-DMSO): 10.61 (s, 1H), 9.40 (s, 1H), 9.30 (d, 1H), 8.56 (d, 1H), 8.46 (d, 1H), 8.16 (d, 2H), 8.06 (d, 2H), 7.69 (d, 2H), 7.32 (d, 1H), 6.96 (d, 2H), 6.56 (s, 1H), 3.74 (t, 4H), 3.05 (t, 4H). MS (EI) for $C_{24}H_{22}N_6O_2S$: 459 (MH+).

[00270] Based on the synthetic examples described hereinabove, the skilled artisan would be able to make the remainder of the compounds intended to be within the scope JAK-2 compounds.

ASSAYS FOR JAK-2 COMPOUNDS

Assay Example 1

Measurement of JAK-2 Kinase Activity by ATP Hydrolysis

[00271] JAK-2 kinase activity was measured by monitoring peptide substrate dependent hydrolysis of ATP via quantitation of remaining ATP with luciferase based chemiluminescence. For compound evaluation, 0.5 µl of the compound dissolved in DMSO was added to 10 µl of JAK-2 dissolved in assay buffer (20 mM HEPES pH 7.5, 10 mM $MgCl_2$, 0.03% Triton and 1mM DTT). After preincubation for 30 minutes at room temperature, the reaction was initiated by addition of 10 µl of ATP and the substrate peptide poly-Glu-Tyr in assay buffer. Final enzyme, ATP, and peptide concentrations were 3 nM, 1 µM, and 2 µM, respectively. After incubation for 60 minutes at room temperature, reaction progress was quantitated by addition of 10 µl Kinase-Glo (Promega) and measurement of chemiluminescence in a Victor reader (Perkin Elmer). A reaction in which compound was omitted was used to determine maximum reaction progress. Omission of compound and enzyme from the reaction was used to determine zero reaction progress.

Assay Example 2

Measurement of JAK-3 Kinase Activity by ATP Hydrolysis

[00272] JAK-3 was assayed similarly as JAK-2 (see Assay Example 1) except that the enzyme reaction was carried out for 180 minutes and enzyme, ATP, and peptide concentrations were 30 nM, 2 μM, and 4 μM, respectively.

Biological Activity

[00273] JAK compounds in Table 1(J) were determined to have inhibitory activity for JAK-2 of less than 10 μM. Other more preferred compounds JAK-2 compounds have inhibitory activity for JAK-2 of less than 100 nm. One of ordinary skill in the art can use the disclosures herein as well as what is known in the art to test the inhibitory activity of a particular compound.

Pharmaceutical Composition Examples

[00274] The following are representative pharmaceutical Formulations containing a compound of Formula I(J).

Tablet Formulation

[00275] The following ingredients are mixed intimately and pressed into single scored tablets.

Ingredient	Quantity per tablet, mg
compound of Formula I(J)	400
Cornstarch	50
croscarmellose sodium	25
Lactose	120
magnesium stearate	5

Capsule Formulation

[00276] The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.

Ingredient	Quantity per tablet, mg
compound of I(J)	200
lactose, spray-dried	148
magnesium stearate	2

Suspension Formulation

[00277] The following ingredients are mixed to form a suspension for oral administration.

Ingredient	Amount
compound of Formula I(J)	1.0 g
fumaric acid	0.5 g
Sodium chloride	2.0 g
methyl paraben	0.15 g
propyl paraben	0.05 g
granulated sugar	25.5 g
sorbitol (70% solution)	12.85 g
Veegum K (Vanderbilt Co.)	1.0 g
Flavoring	0.035 mL
Colorings	0.5 mg
distilled water	q.s. to 100 mL

Injectable Formulation

[00278] The following ingredients are mixed to form an injectable Formulation.

Ingredient	Amount
compound of Formula I(J)	1.2 g
Sodium acetate buffer solution	0.4 M 2.0 mL
HCl (1 N) or NaOH (1 M)	q.s. to suitable pH
water (distilled, sterile)	q.s.to 20 mL

[00279] All of the above ingredients, except water, are combined and heated to 60-70 °C. with stirring. A sufficient quantity of water at 60°C. is then added with vigorous stirring to emulsify the ingredients, and water then added q.s. to 100 g.

Suppository Formulation

[00280] A suppository of total weight 2.5 g is prepared by mixing the compound of the JAK-2 compound described herein with Witepsol® H-15 (triglycerides of saturated vegetable fatty acid; Riches-Nelson, Inc., New York), and has the following composition:

Ingredient	Quantity per tablet, mg
JAK-2 compound	500
Witepsol® H-15	Balance

General Administration

[00281] The combinations of JAK-2 compounds in combination with any of the other active agents described herein can be used to treat diseases in mammals such myeloproliferative disorder, cancer, cardiovascular disease, and/or hematopoitic abnormality wherein the mammal is in need of the treatment. In another embodiment, combinations of JAK-2 and with any of the other active agents described herein can be used to to treat cancer in mammals, such as a cancer prostate cancer, breast cancer, multiple myeloma, leukemia, lymphoma, lung cancer, colorectal cancer, renal cancer, melanoma, hepatocellular, gastric, GIST, pancreatic carcinoma, and papillary thyroid cancer. In another embodiment, combinations of JAK-2 and with any of the other active agents described herein can be used to to treat cancer in mammals, such as a cancer prostate cancer, breast cancer, multiple myeloma, leukemia, lymphoma, lung cancer, colorectal cancer, renal cancer, melanoma, hepatocellular, gastric, GIST, pancreatic carcinoma, and papillary thyroid cancer. In another embodiment, combinations of JAK-2 and with any of the other active agents described herein can be used to treat myelofibrosis, thrombocythemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia. In another embodiment, combinations of JAK-2 with any of the other active agents described herein can be used to to treat cancers selected from leukemias, lymphomas, multiple myeoloma, prostate cancers, lung cancers, breast cancers, and ovarian cancers. In another embodiment, combinations of JAK-2 and with any of the other active agents described herein can be used to to treat congestive heart failure or hypertension. In another embodiment, combinations of JAK-2 and with any of the other active agents described herein can be used to to treat a hematopoitic abnormality such as thrombocytosis.

[00282] In one aspect, the JAK-2 compounds in combination with any of the other active agents described herein can be in the form of pharmaceutical compositions comprising an inhibitor of JAK-2 according to Formula I(J), II(J), III(J), IV(J), V(J) or VI(J) as described herein in combination with any of the inhibitors of Raf, PI3K, mTor, Akt, EGFR, ErbB2, VEGFR, c-Met, c-Kit, BCR-Abl, Flt3 and Src, as described herein, each with a pharmaceutically acceptable carrier. The pharmaceutical Formulations can also include one or more excipients and/or one or more diluents. The JAK-2 compounds

and any of the other active agents described herein can be administered together in one pharmaceutical composition, or separately as two separate pharmaceutical compositions.

[00283] When the pharmaceutical compositions include both of the JAK-2 compounds with any of the other active agents described herein, the weight percentage of the JAK-2 compounds can range from about 0.01% by weight to about 0.99% by weight, or from about 0.05% by weight to about 0.95% by weight, or from about 0.1% by weight to about 0.90% by weight, or from about 0.20% by weight to about 0.80% by weight, or from about 0.30% by weight to about 0.70% by weight, or from about 0.40% by weight to about 0.60% by weight, or from about 0.1% by weight to about 0.2% by weight, or from about 0.20% by weight to about 0.30% by weight, or from about 0.30% by weight to about 0.40% by weight, or from about 0.40% by weight to about 0.50% by weight, or from about 0.50% by weight to about 0.60% by weight, or from about 0.60% by weight to about 0.70% by weight, or from about 0.70% by weight to about 0.80% by weight, or from about 0.80% by weight to about 0.90% by weight.

[00284] In another embodiment, when the pharmaceutical compositions include both of the JAK-2 compounds and any of the other active agents described herein, the weight percentage of the other active agents described herein can range from about 0.01% by weight to about 0.99% by weight, or from about 0.05% by weight to about 0.95% by weight, or from about 0.1% by weight to about 0.90% by weight, or from about 0.20% by weight to about 0.80% by weight, or from about 0.30% by weight to about 0.70% by weight, or from about 0.40% by weight to about 0.60% by weight, or from about 0.1% by weight to about 0.2% by weight, or from about 0.20% by weight to about 0.30% by weight, or from about 0.30% by weight to about 0.40% by weight, or from about 0.40% by weight to about 0.50% by weight, or from about 0.50% by weight to about 0.60% by weight, or from about 0.60% by weight to about 0.70% by weight, or from about 0.70% by weight to about 0.80% by weight, or from about 0.80% by weight to about 0.90% by weight.

[00285] In another embodiment, when the pharmaceutical compositions include both of the JAK-2 compounds and any of the other active agents described herein, and the weight ratio of "JAK-2 compounds":"other active agents" is about 0.01:100, 0.05:50, 0.1:50, 0.2:30, 0.4:25, 0.5:20, 0.6:15, 0.8:10, 1:5, 1:2, or 1:1.

[00286] In another embodiment, when the pharmaceutical compositions includes both of the JAK-2 compound and any of the other active agents described herein, the weight ratio of "other active agents":"JAK-2 compounds" is about 0.01:100, 0.05:50, 0.1:50, 0.2:30, 0.4:25, 0.5:20, 0.6:15, 0.8:10, 1:5, 1:2, or 1:1.

[00287] In certain other embodiments, administration can be by the oral route. Administration of the combination compounds of the JAK-2 compounds and any of the other active agents described herein, or their pharmaceutically acceptable salts, in pure form or in an appropriate pharmaceutical composition, can be carried out via any of the accepted modes of administration or agents for serving similar utilities. Thus, administration can be, for example, orally, nasally, parenterally (intravenous, intramuscular, or subcutaneous), topically, transdermally, intravaginally, intravesically, intracistemally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.

[00288] The compositions described herein can include a conventional pharmaceutical carrier or excipient and a JAK-2 compound or any other agent described herein as the/an active agent, and, in addition, may include carriers and adjuvants, etc.

[00289] Adjuvants include preserving, wetting, suspending, sweetening, flavoring, perfuming, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

[00290] If desired, a pharmaceutical composition described herin can also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylalted hydroxytoluene, etc.

[00291] The choice of Formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, Formulations in the form of tablets, pills or capsules are preferred) and the bioavailability of the drug substance. Recently,

pharmaceutical Formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area i.e., decreasing particle size. For example, U.S. Pat. No. 4,107,288 describes a pharmaceutical Formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a crosslinked matrix of macromolecules. U.S. Pat. No. 5,145,684 describes the production of a pharmaceutical Formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical Formulation that exhibits remarkably high bioavailability.

[00292] Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

[00293] One specific route of administration is oral, using a convenient daily dosage regimen that can be adjusted according to the degree of severity of the disease-state to be treated.

[00294] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders, as for example, cellulose derivatives, starch, alignates, gelatin, polyvinylpyrrolidone, sucrose, and gum acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, croscarmellose sodium, complex silicates, and sodium carbonate, (e) solution retarders, as for example paraffin, (f) absorption accelerators, as for example, quaternary ammonium compounds, (g) wetting agents, as for example, cetyl alcohol, and glycerol monostearate, magnesium stearate and the like (h)

adsorbents, as for example, kaolin and bentonite, and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.

[00295] Solid dosage forms as described above can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain pacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedded compositions that can be used are polymeric substances and waxes. The active JAK-2 compounds and/or any of the other active agents described herein can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.

[00296] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. Such dosage forms are prepared, for example, by dissolving, dispersing, etc., a JAK-2 compound and/or any of the other active agents described herein, or a pharmaceutically acceptable salt thereof, and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like; solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide; oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols and fatty acid esters of sorbitan; or mixtures of these substances, and the like, to thereby form a solution or suspension.

[00297] Suspensions, in addition to the active JAK-2 compounds and/or any of the other active agents described herein may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

[00298] Compositions for rectal administrations are, for example, suppositories that can be prepared by mixing the JAK-2 compounds and/or any of the other active agents described herein, with for example, suitable non-irritating excipients or carriers such as cocoa butter, polyethylene-glycol or a suppository wax, which are solid at ordinary

temperatures but liquid at body temperature and therefore, melt while in a suitable body cavity and release the active component therein.

[00299] Dosage forms for topical administration of a JAK-2 compounds and/or any of the other active agents described herein include ointments, powders, sprays, and inhalants. The active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required. Ophthalmic Formulations, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.

[00300] Compressed gases can be used to disperse the JAK-2 compounds and/or any of the other active agents described herein in aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc.

[00301] Generally, depending on the intended mode of administration, the pharmaceutically acceptable compositions will contain about 1% to about 99% by weight of a JAK-2 compound and/or any of the other active agents described herein, or a pharmaceutically acceptable salt thereof, and 99% to 1% by weight of a suitable pharmaceutical excipient. In one example, the composition will be between about 5% and about 75% by weight of a JAK-2 compound and/or any of the other active agents described herein, or a pharmaceutically acceptable salt thereof, with the rest being suitable pharmaceutical excipients.

[00302] Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing Company, Easton, Pa., 1990). The composition or compositions to be administered will, in any event, contain a therapeutically effective amount of a JAK-2 compound and/or any of the other active agents described herein, or a pharmaceutically acceptable salt thereof, for treatment of a disease-state in accordance with the teachings of this invention.

[00303] The JAK-2 compounds and/or any of the other active agents described herein, or their pharmaceutically acceptable salts or hydrates, are administered in a therapeutically effective amount which will vary depending upon a variety of factors including the activity of the specific compounds employed, the metabolic stability and length of action of the compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular disease-

states, and the host undergoing therapy. The JAK-2 compounds and/or any of the other active agents described herein can be administered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kilograms, a dosage in the range of about 0.01 to about 100 mg per kilogram of body weight per day is an example. The specific dosage used, however, can vary. For example, the dosage can depend on a number of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well known to one of ordinary skill in the art.

[00304] If formulated as a fixed dose, such combination products employ the JAK-2 compounds and any of the other active agents described herein within the dosage range described above and the other pharmaceutically active agent(s) within its approved dosage range. The JAK-2 compounds and any of the other active agents described herein may alternatively be used sequentially with known pharmaceutically acceptable agent(s) when combined with other chemotherapeutic, or otherwise active agents.

ADDITIONAL EMBODIMENTS

[00305] In another aspect of the invention, the combination of JAK-2 compounds and optionally any of the additional agents described herein, can be further combined with one or more additional treatments selected from one or more chemotherapeutic agents, one or more antibodies, radiation therapy, surgery, hormone therapy, and hypothermia therapy, wherein the chemotherapeutic agent is selected from one or more taxanes, one or more platin(s), one or more topoisomerase inhibitor(s), one or more alkylating agent(s), one or more antimetabolite(s), one or more antimicrotubule agent(s), one or more bcr-abl inhibitor(s), rapamycin, carboplatin, cisplatin, oxaliplatin, gemcitabine, dacarbazine, topotecan, irinotecan, one or more HSP90 inhibitors, and one or more IGF1R inhibitors.

[00306] In another embodiment, the one or more of the chemotherapeutic agent(s) is selected from a taxane(s), a platin(s), a topoisomerase inhibitor(s), an alkylating agent(s), an antimetabolite(s), an antimicrotubule agent(s), and a bcr-abl inhibitor(s). Non-limiting examples of chemotherapeutic agent(s) include an antimicrotubule agent(s) selected from Vincristine,Vinblastine, Vinorelbine, and Vindesine.

[00307] In another embodiment, the one or more of the chemotherapeutic agent is a taxane.

[00308] In another embodiment, the chemotherapeutic agent is a platin.

[00309] In another embodiment, the one or more of the chemotherapeutic agent(s) is selected from rapamycin, carboplatin, cisplatin, oxaliplatin, gemcitabine, dacarbazine, topotecan, and irinotecan.

[00310] In another embodiment, the one or more of the chemotherapeutic agent(s) is an EGFR inhibitor. Non-limiting examples of EGFR inhibitors include Lapatinib (Tykerb®), gefitinib (Iressa®), erlotinib (Tarceva®), Zactima (ZD6474), AEE778, HKI-272, EKB-569 and CI1033.

[00311] In another embodiment, the one or more of the chemotherapeutic agent(s) is an ErbB2 inhibitor. Non-limiting examples of ErbB2 inhibitors include lapatinib, EXB-569, HKI272, and CI1033.

[00312] In another embodiment, the one or more of the chemotherapeutic agent(s) is an HSP90 inhibitor. Non-limiting examples of the HSP90 inhibitor include 17-AAG, 17-DMAG, Geldanamycin, CNF2024, and SNX-2112.

[00313] In another embodiment, the one or more of the chemotherapeutic agent(s) is an IGF1R inhibitor.

[00314] In another embodiment, the one or more of the chemotherapeutic agent(s) is a Raf inhibitor such as, for example, sorafenib.

[00315] In another embodiment, the one or more of the chemotherapeutic agent(s) is selected from rapamycin, a rapamycin analogue, PI103, PI504, and SF1126. Non-limiting examples of the chemotherapeutic agent(s) include rapamycin, CCI-779, AP23573, RAD001, TAFA93, PI103, PI504, and SF1126. In another embodiment, the chemotherapeutic agent is rapamycin.

[00316] In another embodiment, the one or more of the treatment(s) is selected from radiation and hypothermia therapy. In another embodiment, the treatment is radiation.

[00317] In another embodiment, the one or more of the treatment(s) is one or more antibody(s). Non-limiting examples include one or more of the antibody(s) selected from an IGF1R antibody (including, for example, ∝IGF-1R A12 MoAb, 19D12, h7C10 and CP-751871), Alemtuzumab, Bevacizumab (Avastin®), Cetuximab (Erbitux®), Gemtuzumab, Gemtuzumab ozogamicin, Ibritumomab tiuxetan, Panitumumab, Rituximab, Tositumomab, and Trastuzumab (Herceptin®).

[00318] In another embodiment, the one or more of the treatment(s) is surgery.

[00319] In another embodiment, the one or more of the treatment(s) is one or more hormone therapy(s). Non-limiting examples of hormone treatments include tamoxifen and an aromatase inhibitor.

[00320] In another embodiment, the one or more of the chemotherapeutic agent(s) is gemcitabine.

[00321] In another embodiment, the one or more of the chemotherapeutic agent(s) is Imatinib (i.e. Gleevec®).

[00322] In another embodiment, the cancer is primary or relapsed CML and/or acute myelogenous leukemia (AML) and one or more of the treatment(s) is selected from one or more of the chemotherapeutic agent(s) and one or more antibody(s). Non-limiting examples of the chemotherapeutic agent(s) in this embodiment include Imatinib (i.e. Gleevec®) and PKC412. In another embodiment, the one or more of the chemotherapeutic agent(s) is Imatinib (i.e. Gleevec®). Non-limiting examples of the one or more antibody(s) in this embodiment include $^{\alpha}$IGF-1R A12 MoAb and trastuzumab.

[00323] In another embodiment, the cancer is prostate cancer and the one or more of the treatment(s) is selected from one or more antibody(s). Non-limiting examples of the one or more of the antibody(s) in this embodiment include $^{\alpha}$IGF-1R A12 MoAb.

[00324] In another embodiment, the cancer is malignant melanoma and one or more of the treatment(s) is selected from surgery and one or more chemotherapeutic agent(s). Non-limiting examples of chemotherapeutic agent(s) in this embodiment include an alkylating agent(s), a taxane(s), a platin(s), and a Raf inhibitor(s). In another embodiment, the one or more chemotherapeutic agent(s) is selected from sorafenib, Paclitaxel (Taxol®), Docetaxel (Taxotere®), dacarbazine, rapamycin, imatinib mesylate (Gleevec®), sorafenib, and carboplatin.

[00325] In another embodiment, the cancer is colon or rectal cancer and one or more of the treatment(s) is selected from surgery, radiation, one or more chemotherapeutic agent(s), and one or more antibody(s). Non-limiting examples of the chemotherapeutic agent(s) include cisplatin, oxaliplatin, carboplatin, 5-fluorouracil, Capecitabine (Xeloda), Irinotecan (Camptosar), FOLFOX (Folinic acid, 5-FU, Oxaliplatin), and leucovorin. Non-limiting examples of the one or more of the antibody(s) include bevacizumab and cetuximab.

[00326] In another embodiment, the cancer is pancreatic cancer and one or more of the treatment(s) include surgery, radiation, and one or more chemotherapeutic agent(s). Non-limiting examples of the one or more of the chemotherapeutic agent(s) include erlotinib (Tarceva®), gemcitabine, 5-fluorouracil, leucovorin, cisplatin, oxaliplatin, carboplatin, gemcitabine, irinotecan, paclitaxel, capecitabine, and streptozocin.

[00327] In another embodiment, the cancer is breast cancer and one or more of the treatment(s) is selected from surgery, radiation, one or more chemotherapeutic agent(s), one or more hormone therapy(s), and one or more antibody(s). Non-limiting examples of the chemotherapeutic agent(s) in this embodiment include lapatinib (Tykerb®), Paclitaxel (Taxol®), docetaxel, capecitabine, Cyclophosphamide (Cytoxan), methotrexate, fluorouracil, doxorubicin, epirubicin, gemcitabine, carboplatin (Paraplatin), cisplatin (Platinol), vinorelbine (Navelbine), capecitabine (Xeloda), pegylated liposomal doxorubicin (Doxil), and albumin-bound paclitaxel (Abraxane). Specifically one or more of the antibody(s) is selected from ^IGF-1R A12 MoAb, bevacizumab (Avastin), and trastuzumab. Non-limiting examples of the hormone therapy(s) in this embodiment include tamoxifen, Toremifene (Fareston), Fulvestrant (Faslodex), Megestrol acetate (Megace), ovarian ablation, and an aromatase inhibitor(s). Non-limiting examples of the aromatase inhibitor(s) include selected from etrozole (Femara), anastrozole (Arimidex), and exemestane (Aromasin).

[00328] In another embodiment, the cancer is non-small cell lung cancer and one or more of the treatment(s) is selected from surgery, radiation, one or more antibody(s), and one or more chemotherapeutic agent(s). Non-limiting examples of the chemotherapeutic agent(s) in this embodiment include cisplatin, oxaliplatin, carboplatin, Zactima (ZD6474), Paclitaxel, Docetaxel (Taxotere®), Gemcitabine (Gemzar®), Vinorelbine, Irinotecan, Etoposide, Vinblastine, Erlotinib (Tarceva®), and Pemetrexed. Non-limiting examples of the antibody(s) include Bevacizumab.

[00329] In another embodiment, the cancer is small cell lung cancer and one or more of the treatment(s) is selected from surgery, radiation, and one or more chemotherapy agent(s). Non-limiting examples of the chemotherapy agent(s) in this embodiment include cisplatin, oxaliplatin, carboplatin, etoposide, irinotecan, fosfamide, paclitaxel, docetaxel, gemcitabine, Topotecan, cyclophosphamide/doxorubicin/vincristine (CAV), methotrexate, and vinorelbine.

[00330] In another embodiment, the cancer is papillary or anaplastic thyroid cancer, and one or more of the treatment(s) is selected from surgery, radiation, radioactive iodine therapy, one or more hormone therapy(s), and one or more chemotherapeutic agent(s). Non-limiting example of the chemotherapeutic agent(s) in this embodiment include thyroid hormone pills, Doxorubucin and a platin(s).

[00331] In another embodiment, the cancer is endometrial cancer and one or more of the treatment(s) is selected from surgery, radiation, hormone therapy, and one or more chemotherapeutic agent(s). Non-limiting examples of the one or more of the chemotherapeutic agent(s) in this embodiment include paclitaxel, doxorubicin, and cisplatin. Nonlimiting examples of the one or more of the hormone therapies in this embodiment include medroxyprogesterone acetate, megestrol acetate, and Tamoxifen.

[00332] In another embodiment, the cancer is ovarian cancer and one or more of the treatment(s) is selected from surgery, radiation, and one or more chemotherapeutic agent(s). Non-limiting examples of chemotherapeutic agent(s) in this embodiment include a platin(s) compound (such as cisplatin, oxaliplatin and carboplatin), a taxane (such as paclitaxel or docetaxel), topotecan, anthracyclines (such as doxorubicin (Adriamycin) and liposomal doxorubicin (Doxil)), gemcitabine, cyclophosphamide, vinorelbine (Navelbine), hexamethylmelamine, ifosfamide, and etoposide.

[00333] In another embodiment, one or more of the treatment(s) is selected from one or more chemotherapeutic agent(s), radiation, hypothermia therapy, one or more antibody(s), and surgery.

[00334] In another embodiment one or more of the treatment(s) is selected from radiation and surgery.

[00335] In another embodiment of the invention, one or more of the treatments is selected from CCI-779, AP23573, RAD001, TAFA93, carboplatin, cisplatin, oxaliplatin, gemcitabine, dacarbazine, topotecan, irinotecan, sorafenib, paclitaxel, docetaxel, Lapatinib (Tykerb®), gefitinib (Iressa®), erlotinib (Tarceva®), Zactima (ZD6474), 5-fluorouracil, Capecitabine (Xeloda), FOLFOX (Folinic acid, 5-FU, Oxaliplatin), streptozocin, Cyclophosphamide (Cytoxan), methotrexate, doxorubicin, epirubicin, vinorelbine (Navelbine), pegylated liposomal doxorubicin (Doxil), albumin-bound paclitaxel (Abraxane), Etoposide, Vinblastine, Pemetrexed, leucovorin, fosfamide, cyclophosphamide/doxorubicin/vincristine (CAV), thyroid hormone pills,

hexamethylmelamine, ifosfamide, Imatinib (i.e. Gleevec®), $^{\alpha}$IGF-1R A12 MoAb, IGF-1R 19D12, IGF-1R h7C10, IGF-1R CP-751871, Alemtuzumab, Bevacizumab (Avastin®), Cetuximab (Erbitux®), Gemtuzumab, Gemtuzumab ozogamicin, Ibritumomab tiuxetan, Panitumumab, Rituximab, Tositumomab, Trastuzumab (Herceptin®), tamoxifen, Toremifene (Fareston), Fulvestrant (Faslodex), Megestrol acetate (Megace), ovarian ablation, medroxyprogesterone acetate, megestrol acetate, and an aromatase inhibitor.

[00336] The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. The invention has been described with reference to various specific embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. All patents, patent applications and publications cited in this application are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual patent, patent application or publication were so individually denoted.

VEGFR Compounds

[00337] In the methods of the invention, the JAK-2 compounds described hereinabove [e.g., compounds of Formula I(J), II(J), III(J), IV(J), V(J), VI(J), and VII(J)] can be combined with any VEGFR, EGFR, Flt3 c-Met, or c-Kit inhibitor known in the art. Non-limiting examples of VEGFR inhibitors (VEGFR inhibitors fall within the scope of aspect (2) of this invention) that can be combined with the JAK-2 compounds described hereinabove include bevacizumab, axitinib and any of the VEGFR compounds described below that inhibit VEGFR. The VEGFR inhibitors regulate and/or modulate the signal transduction of VEGFR. Non-limiting examples of Flt3 inhibitors (Flt3 inhibitors fall within the scope of aspect (8) of this invention) that can be combined with the JAK-2 compounds described hereinabove include sunitinib and any of the VEGFR compounds described below that inhibit Flt3. Non-limiting examples of c-Met inhibitors (c-Met inhibitors fall within the scope of aspect 5 of this invention) that can be combined with the JAK-2 compounds described hereinabove include any of the VEGFR compounds described below that inhibit c-Met. Non-limiting examples of c-Kit inhibitors (c-Kit

inhitiors fall within the scope of aspect 5 of this invention) that can be combined with the JAK-2 compounds described hereinabove include imatinib, axitinib, and any of the VEGFR compounds described below that inhibit c-Kit. Non-limiting examples of EGFR inhibitors (EGFR inhibitors fall within the scope of aspect (11) of this invention) that can be combined with the JAK-2 compounds described hereinabove include any of the VEGFR compounds described below that inhibit EGFR.

[00338] All of the VEGFR compounds described below are intended to alternatively include pharmaceutically acceptable salts of these compounds whether it is explicitely stated or not. All of the VEGFR compounds described below fall within the scope of aspect (19) of this invention.

[00339] In another embodiment the JAK-2 compounds described hereinabove [e.g., compounds of Formula I(J), II(J), III(J), IV(J), V(J), VI(J), and VII(J)] can be combined with any of the following VEGFR compounds (which can inhibit one or more of VEGFR, EGFR, Flt3 c-Met, or c-Kit) in Table I(V1), or a pharmaceutically acceptable salt thereof. :

Table I(V1)

Entry	Name
1	(3Z)-3-[[5-(methyloxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-5-{[1-(phenylmethyl)pyrrolidin-3-yl]amino}-1,3-dihydro-2H-indol-2-one
2	(3Z)-5-[(1-ethylpiperidin-3-yl)amino]-3-[[5-(methyloxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one
3	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methyloxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one
4	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(phenyl)methylidene]-1,3-dihydro-2H-indol-2-one
5	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{[5-(methyloxy)-1H-benzimidazol-2-yl][4-(methyloxy)phenyl]methylidene}-1,3-dihydro-2H-indol-2-one
6	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methyloxy)-1H-benzimidazol-2-yl](4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one
7	(3Z)-3-[1H-benzimidazol-2-yl(4-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
8	(3Z)-3-{1H-benzimidazol-2-yl[4-(methyloxy)phenyl]methylidene}-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
9	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
10	(3Z)-3-[[5-(methyloxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
11	(3Z)-3-[(4-aminophenyl)(1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one

Entry	Name
12	(3Z)-3-[1H-benzimidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
13	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one
14	(3Z)-5-[(1-ethylpiperidin-4-yl)oxy]-3-[[5-(methyloxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one
15	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1H-imidazol-2-yl[4-(methyloxy)phenyl]methylidene}-1,3-dihydro-2H-indol-2-one
16	(3Z)-3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
17	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
18	(3Z)-3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
19	(3Z)-3-[1H-benzimidazol-2-yl(3-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
20	3-((Z)-1H-benzimidazol-2-yl{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene}methyl)benzonitrile
21	(3Z)-3-[(3-aminophenyl)(1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
22	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2H-indol-2-one
23	3-((Z)-1H-benzimidazol-2-yl{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene}methyl)benzenecarboximidamide
24	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
25	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
26	(3Z)-3-{1H-benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
27	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
28	2-(2-{2-[(Z)-{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene}(phenyl)methyl]-1H-imidazol-4-yl}ethyl)-1H-isoindole-1,3(2H)-dione
29	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-(dimethylamino)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
30	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-{[1-(methylsulfonyl)piperidin-4-yl]amino}-1,3-dihydro-2H-indol-2-one
31	(3Z)-5-(8-azabicyclo[3.2.1]oct-3-ylamino)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-1,3-dihydro-2H-indol-2-one
32	(3Z)-3-{1H-benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one
33	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one
34	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-{[1-(phenylmethyl)piperidin-4-yl]oxy}-1,3-dihydro-2H-indol-2-one

Entry	Name
35	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one
36	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}oxy)-1,3-dihydro-2H-indol-2-one
37	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}oxy)-1,3-dihydro-2H-indol-2-one
38	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
39	(3Z)-3-{1H-benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
40	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
41	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
42	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
43	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)(methyl)amino]-1,3-dihydro-2H-indol-2-one
44	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one
45	(3Z)-3-[1H-benzimidazol-2-yl(4-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
46	(3Z)-3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
47	(3Z)-3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
48	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
49	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one
50	(3Z)-3-[1H-benzimidazol-2-yl(3-fluoro-4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
51	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one
52	(3Z)-3-[1H-benzimidazol-2-yl(4-fluoro-3-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
53	(3Z)-3-[(3-chloro-4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
54	(3Z)-3-[(3,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
55	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
56	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
57	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one

Entry	Name
58	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one
59	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-propylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one
60	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1H-imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene}-1,3-dihydro-2H-indol-2-one
61	(3E)-3-[(3,5-difluorophenyl)(5-fluoro-1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
62	(3Z)-3-[(3,5-difluorophenyl)(5-fluoro-1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
63	(3Z)-3-[(3-fluoro-4-methylphenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
64	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one
65	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one
66	(3Z)-3-[(4-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
67	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one
68	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1H-imidazol-2-yl[6-(trifluoromethyl)pyridin-3-yl]methylidene}-1,3-dihydro-2H-indol-2-one
69	(3Z)-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
70	(3Z)-3-[(3-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
71	(3Z)-3-{1H-imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
72	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
73	(3Z)-3-[(3,5-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
74	(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
75	(3Z)-3-[(3,5-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
76	(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
77	(3Z)-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
78	(3Z)-3-[(4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
79	(3Z)-3-[(3,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
80	(3Z)-3-[(3-chloro-4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one

Entry	Name
81	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2H-indol-2-one
82	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-{[1-(2-piperidin-1-ylethyl)piperidin-4-yl]amino}-1,3-dihydro-2H-indol-2-one
83	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-{[1-(2-morpholin-4-ylethyl)piperidin-4-yl]amino}-1,3-dihydro-2H-indol-2-one
84	(3Z)-5-({1-[2-(diethylamino)ethyl]piperidin-4-yl}amino)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one
85	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-{[1-(2-pyrrolidin-1-ylethyl)piperidin-4-yl]amino}-1,3-dihydro-2H-indol-2-one
86	(3Z)-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-methylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
87	(3Z)-3-[(3-fluorophenyl)(1H-1,2,4-triazol-5-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
88	ethyl 2-{(Z)-(3-fluorophenyl)[5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]methyl}-4-methyl-1H-imidazole-5-carboxylate
89	(3Z)-3-[1H-imidazol-2-yl(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
90	(3Z)-3-{1H-imidazol-2-yl[4-(methyloxy)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
91	(3Z)-3-[(4-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
92	(3Z)-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
93	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-{[1-(methylsulfonyl)piperidin-4-yl]amino}-1,3-dihydro-2H-indol-2-one
94	(3Z)-3-[1H-imidazol-2-yl(4-propylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
95	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-phenyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one
96	(3Z)-3-[(3-fluorophenyl)(4-phenyl-1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
97	(3Z)-3-[(3-fluoro-4-methylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
98	(3Z)-3-{1H-imidazol-2-yl[6-(trifluoromethyl)pyridin-3-yl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
99	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-1,2,4-triazol-5-yl)methylidene]-1,3-dihydro-2H-indol-2-one
100	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one
101	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{(4-methyl-1H-imidazol-2-yl)[4-(trifluoromethyl)phenyl]methylidene}-1,3-dihydro-2H-indol-2-one
102	(3Z)-3-[(4-chlorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
103	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one

Entry	Name
104	(3Z)-3-[(3,4-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
105	(3Z)-3-[(3-chloro-4-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
106	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one
107	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(2-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one
108	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one
109	(3Z)-3-[(2,3-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
110	(3Z)-3-[(2,3-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
111	(3Z)-3-[(2,4-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
112	(3Z)-3-[(2,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
113	(3Z)-3-[(2-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
114	(3Z)-3-[(3-trifluoromethylphenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
115	(3Z)-3-[(3-trifluoromethylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
116	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
117	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
118	(3Z)-3-[(4-chloro-2-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one

Synthetic Procedures for the Compounds of Table I(V1),

[00340] The compounds of Table I(V1), can be made by the synthetic schemes and examples described in publication WO 2004/050681, which is incorporated herein by reference in its entirety. The utility of the compounds in Table I(VI) is also described in WO 2004/050681.

[00341] In other embodiments of the above method of combining the compounds in Table I(V1) with the JAK-2 inhibitors of Formula I(J), one or more of any of the compounds in Table I(VI) can be combined with any one of the embodiments of the compound of Formula I(J) described hereinabove. In other embodiments of the above method of combining the compounds in Table I(V1) with the JAK-2 inhibitors of

Formula I(J), one or more of any of the compounds in Table I(VI) can be combined with one or more of any of the compounds in Table I(J).

[00342] Another aspect of the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), and a pharmaceutically acceptable carrier, in combination with a therapeutically effective amount of a compound selected from Table I(VI).

EFGR Compounds

[00343] In another embodiment of the methods described herein, the JAK-2 compounds described hereinabove [e.g., compounds of Formula I(J), II(J), III(J), IV(J), V(J), VI(J), and VII(J)] can be combined with any of the following EGFR compounds (that are inhibitors of VEFGR and/or EGFR) described hereinbelow. Non-limiting examples of EGFR inhibitors (EGFR inhibitors fall within the scope of aspect (11) of this invention) that can be combined with any of the JAK-2 compounds described hereinabove include any of the EGFR compounds described below that can inhibit EGFR. Non-limiting examples of VEGFR inhibitors (VEGFR inhibitors fall within the scope of aspect (2) of this invention) that can be combined with any of the JAK-2 compounds described hereinabove include any of the EGFR compounds described below that can inhibit VEGFR. All of the EGFR compounds described below are intended to alternatively include pharmaceutically acceptable salts of these compounds whether it is explicitely stated or not. All of the EGFR compounds described below fall within the scope of aspect (26) of this invention.

[00344] Non-limiting examples of EGFR compounds include the compounds according to Formula **I(V2):**



I(V2)

or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof, wherein,

R^1 is C_1-C_3 alkyl optionally substituted with between one and three R^{50} substituents;

R^2 is selected from halogen, trihalomethyl, -CN, $-NH_2$, $-NO_2$, $-OR^3$, $-N(R^3)R^4$, $-S(O)_{0-2}R^4$, $-SO_2N(R^3)R^4$, $-CO_2R^3$, $-C(=O)N(R^3)R^4$, $-N(R^3)SO_2R^4$, $-N(R^3)C(=O)R^3$, $-N(R^3)CO_2R^4$, $-C(=O)R^3$, optionally substituted lower alkyl, optionally substituted lower alkenyl, and optionally substituted lower alkynyl;

R^3 is -H or R^4;

R^4 is selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or

R^3 and R^4, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;

q is 0, 1, 2, 3, 4, or 5;

Z is selected from $-OCH_2-$, -O-, $-S(O)_{0-2}-$, $-N(R^5)CH_2-$, and $-NR^5-$;

R^5 is -H or optionally substituted lower alkyl;

R^{50} is -H, halo, trihalomethyl, $-OR^3$, $-N(R^3)R^4$, $-S(O)_{0-2}R^4$, $-SO_2N(R^3)R^4$, $-CO_2R^3$, $-C(=O)N(R^3)R^4$, $-C(=NR^{25})N(R^3)R^4$, $-C(=NR^{25})R^4$, $-N(R^3)SO_2R^4$, $-N(R^3)C(O)R^3$, $-NCO_2R^3$, $-C(=O)R^3$, optionally substituted alkoxy, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or

two of R^{50}, when taken together on the same carbon are oxo; or

two of R^{50}, when taken together with a common carbon to which they are attached, form a optionally substituted three- to seven-membered spirocyclyl, said optionally

substituted three- to seven-membered spirocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;

R^{25} is selected from -H, -CN, $-NO_2$, $-OR^3$, $-S(O)_{0-2}R^4$, $-CO_2R^3$, optionally substituted lower alkyl, optionally substituted lower alkenyl, and optionally substituted lower alkynyl;

M^1-M^2-M^3-M^4- together are according to Formula **II(V2)**:



II(V2)

wherein X^1, X^2, and optionally X^3, represent the atoms of a saturated bridged ring system, said saturated bridged ring system containing up to three annular heteroatoms represented by any of X^1, X^2, and X^3; wherein,

each X^1 is independently selected from $-C(R^6)R^7-$, -O-, $-S(O)_{0-2}-$, and $-NR^8-$;

each X^2 is independently a bridgehead methine optionally substituted with R^6, or a bridgehead nitrogen;

each X^3 is independently selected from $-C(R^6)R^7-$, -O-, $-S(O)_{0-2}-$, and $-NR^8-$;

provided, for X^1, X^2, and X^3, there are no nitrogen-nitrogen annular bonds nor geminal di-nitrogen substitutions;

E is selected from $-NR^9-$, -O-, and absent;

Y is either:

a C_{1-3} alkylene linker, between the oxygen at the 7-position of the quinazoline ring system of **I(V2)** and either E, or when E is absent, any ring atom of the saturated bridged ring system except X^2, when X^2 is a bridgehead nitrogen; provided there are at least two carbon atoms between the oxygen at the 7-position of the quinazoline ring system of **I(V2)** and either E, or when E is absent, any heteroatom represented by X^1, X^2 or X^3; or

Y is absent, when Y is absent, E is also absent; said saturated bridged ring system is directly attached to the oxygen at the 7-position of the

quinazoline ring system of **I(V2)** via a carbon atom of said saturated bridged ring system;

m and p are each independently from one to four;

n is from zero to two, when n is zero, then there is a direct single bond between the two bridgehead X^2's;

R^6 and R^7 are each independently selected from -H, halogen, trihalomethyl, -CN, $-NH_2$, $-NO_2$, $-OR^3$, $-N(R^3)R^4$, $-S(O)_{0-2}R^4$, $-SO_2N(R^3)R^4$, $-CO_2R^3$, $-C(O)N(R^3)R^4$, $-N(R^3)SO_2R^4$, $-N(R^3)C(O)R^3$, $-NCO_2R^3$, $-C(O)R^3$, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, optionally substituted lower heterocyclylalkyl; or

R^6 and R^7, when taken together are oxo; or

R^6 and R^7, when taken together with a common carbon to which they are attached, form a optionally substituted three- to seven-membered spirocyclyl, said optionally substituted three- to seven-membered spirocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P; and

R^8 is selected from R^3, $-SO_2N(R^3)R^4$, $-CO_2R^3$, $-C(O)N(R^3)R^4$, $-SO_2R^4$, and $-C(O)R^3$;

R^9 is -H or optionally substituted lower alkyl;

with the proviso that when Y is a C_{1-3} alkylene linker, E is absent, Z is -NH- or $-N(CH_3)-$, R^1 is a C_{1-3} alkyl, R^2 is -H or halogen, n = 0, and the atoms X^1 of one bridge of the saturated bridged ring system, when combined with both bridgehead atoms, X^2, of the saturated bridged ring system, represent:

either a pyrrolidine ring or a piperidine ring, and any atom, X^1 or X^2, of either of said pyrrolidine ring or said piperidine ring is attached to Y; then the other bridge of said saturated bridged ring system cannot be any one of $-OC(O)CH_2-$, $-CH_2OC(O)-$, $-OC(O)CH_2CH_2-$, $-CH_2OC(O)CH_2-$, $-CH_2CH_2OC(O)-$, $-OC(O)CH_2NH-$, $-OC(O)CH_2N(C_{1-4}alkyl)-$, and $-OC(O)CH_2O-$; or

either a piperazine ring or a 4-(C_{1-4} alkyl)-piperazine ring, and any atom, X^1 or X^2, of either of said piperazine ring or said 4-(C_{1-4} alkyl)-piperazine ring is attached to Y; then the other bridge of said saturated bridged ring system, only when attached

via the 2- and the 3-position of either of said piperazine ring or said 4-(C_{1-4} alkyl)-piperazine ring, cannot be one of $-CH_2OC(O)CH_2-$, $-CH_2CH_2OC(O)-$, and either of the two aforementioned bridges cannot be optionally substituted by one or two C_{1-2}alkyl groups; or a piperazine ring, and any atom, X^1 or X^2, of said piperazine ring is attached to Y; then the other bridge of said saturated bridged ring system, only when attached via the 3- and the 4-position of said piperazine ring, cannot be one of $-C(O)OCH_2CH_2-$ or $-CH_2OC(O)CH_2-$ (and only when either of $-C(O)OCH_2CH_2-$ or $-CH_2OC(O)CH_2-$ is attached to the 3-position of said piperazine ring via their left-hand end as depicted above), and either of the two aforementioned bridges cannot be optionally substituted by one or two C_{1-2} alkyl groups, and ; or a 2-oxomorpholine ring, said 2-oxomorpholine ring attached to Y via its 4-position; then the other bridge of said saturated bridged ring system, only when attached via the 5- and the 6-position of said 2-oxomorpholine ring, cannot be one of $-(CH_2)_g-$, $-CH_2WCH_2-$, $-CH_2WCH_2CH_2-$, and $-CH_2CH_2WCH_2-$, wherein W is -O-, $-S(O)_{0-2}-$, -NH-, or $-N(C_{1-4}$ alkyl)- and wherein g is 2, 3, or 4.

[00345] In another embodiment of the compound of Formula I(V2), Z is $-NR^5-$.

[00346] In another embodiment of the compound of Formula I(V2), R^2 is selected from halogen, trihalomethyl, -CN, $-NO_2$, $-OR^3$, and optionally substituted lower alkyl.

[00347] In another embodiment of the compound of Formula I(V2), R^1 is an unsubstituted C_{1-3} alkyl.

[00348] In another embodiment of the compound of Formula I(V2), the saturated bridged ring system has a geometry selected from the group consisting of [4.4.0], [4.3.0], [4.2.0], [4.1.0], [3.3.0], [3.2.0], [3.1.0], [3.3.3], [3.3.2], [3.3.1], [3.2.2], [3.2.1], [2.2.2], and [2.2.1].

[00349] In another embodiment of the compound of Formula I(V2), Y is selected from $-CH_2CH_2-$, $-CH_2-$, and absent.

[00350] In another embodiment of the compound of Formula I(V2), q is 1, 2, or 3.

[00351] In another embodiment of the compound of Formula I(V2), R^5 is -H.

[00352] In another embodiment of the compound of Formula I(V2), R^1 is methyl.

[00353] In another embodiment of the compound of Formula I(V2), the saturated bridged ring system has a geometry selected from the group consisting of [4.4.0], [4.3.0], [4.2.0], [4.1.0], [3.3.0], [3.2.0], and [3.1.0].

[00354] In another embodiment of the compound of Formula I(V2), the saturated bridged ring system contains one or two annular nitrogens, said one or two annular nitrogens are selected from $-NR^8-$, when X^1, and a bridgehead nitrogen, when X^2.

[00355] In another embodiment of the compound of Formula I(V2), E is absent.

[00356] In another embodiment of the compound of Formula I(V2), the saturated bridged ring system is according to Formula **III(V2)**;



III(V2)

wherein A is selected from -O-, $-S(O)_{0-2}-$, $-NR^8-$, and absent; and e is 0 or 1.

[00357] In another embodiment of the compound of Formula I(V2), Y is $-CH_2-$.

[00358] In another embodiment of the Formula III(V2), A is selected from $-NR^8-$, wherein R^8 is selected from -H, optionally substituted lower alkyl, $-CO_2R^3$, $-C(O)N(R^3)R^4$, $-SO_2R^4$, and $-C(O)R^3$; -O-; and absent.

[00359] In another embodiment of the compound of Formula I(V2),  of **I(V2)** is selected from:  and  , wherein R^{2a}, R^{2b}, and R^{2c} are each independently selected from F, Cl, and Br.

[00360] In another embodiment of the compound of Formula I(V2), R^{2a} is F, R^{2b} is Cl, and R^{2c} is either Cl or Br.

[00361] In another embodiment of the compound of Formula I(V2), the saturated bridged ring system is according to either Formula **V(V2)** or Formula **VI(V2)**;



V(V2)



VI(V2)

wherein R^8 is selected from -H, optionally substituted lower alkyl, $-CO_2R^3$, $-C(O)N(R^3)R^4$, $-SO_2R^4$, and $-C(O)R^3$.

[00362] In another embodiment of the compound of Formula I(V2), Y is either $-CH_2-$ or absent.

[00363] In another embodiment of the compound of Formula V(V2) or VI(V2), R^8 is methyl or ethyl.

[00364] In another embodiment of the compound of Formula I(V2), the saturated bridged ring system is according to Formula **VII(V2)**;



VII(V2)

wherein A is selected from -O-, $-S(O)_{0-2}-$, $-NR^8-$, $-CR^6R^7-$, and absent.

[00365] In another embodiment of the Formula VII(V2), R^3 is selected from -H and optionally substituted alkyl.

[00366] In another embodiment of the compound of Formula I(V2), A is either $-C(R^6)R^7-$ or absent.

[00367] In another embodiment of Formula I(V2), A is either $-CH_2-$ or absent.

[00368] In another embodiment of Formula I(V2), Y is $-CH_2-$.

[00369] In another embodiment of Formula I(V2), q is 3.

[00370] In another embodiment of Formula I(V2), the saturated bridged ring system has a geometry selected from the group consisting of [3.3.1], [3.2.1], and [2.2.1].

[00371] In another embodiment of Formula I(V2), the saturated bridged ring system contains one or two annular nitrogens, said one or two annular nitrogens are selected from -NR^8-, when X^1, and a bridgehead nitrogen, when X^2.

[00372] In another embodiment of Formula I(V2), the saturated bridged ring system is according to Formula **VIII(V2)** or Formula **IX(V2)**;



VIII(V2)



IX(V2)

wherein R^8 is selected from -H, optionally substituted lower alkyl, -CO_2R^3, -$C(O)N(R^3)R^4$, -SO_2R^4, and -$C(O)R^3$; and R^{26} is C_{1-3} alkyl.

[00373] In another embodiment of Formula I(V2), Y is -CH_2CH_2-; and E is either absent or -$N(R^9)$-.

[00374] In another embodiment of Formula I(V2), q is 3.

[00375] In another embodiment of Formula VIII(V2) or IX(V2), R^8 is methyl or ethyl.

[00376] In another embodiment of Formula I(V2), the compound is selected from one of the following compounds, or a pharmaceutically acceptable salt thereof:

N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
7-({[(3aR,5r,6aS)-2-acetyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-{[(3aR,5r,6aS)-octahydrocyclopenta[c]pyrrol-5-ylmethyl]oxy}quinazolin-4-amine;
ethyl (3aR,6aS)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate;

N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3aR,5r,6aS)-2-(methylsulfonyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3aR,5r,6aS)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,5s,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3aR,5s,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-({[(3aR,5s,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-({[(3aR,5s,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3aR,5s,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-2,3-dichlorophenyl)-7-({[(3aR,5s,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-({[(3aR,5s,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3aR,5r,6aS)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(4-bromo-2,3-dichlorophenyl)-7-{[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-{[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-{[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-{[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(3,4-dichloro-2-fluorophenyl)-7-{[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-{[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-{[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-[(hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl)oxy]-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-{[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-2,3-dichlorophenyl)-7-{[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-{[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-{[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-{[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(3R,8aR)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-{[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(3S,8aR)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(3R,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-{[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-{[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-{[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(4-bromo-2,3-dichlorophenyl)-7-{[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-{[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
(3S,9aS)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydro-2H-pyrido[1,2-a]pyrazin-1(6H)-one;
(3S,9aR)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydro-2H-pyrido[1,2-a]pyrazin-1(6H)-one;
(3S,8aS)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(3S,8aR)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(3S,8aS)-3-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(3S,8aS)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-methylhexahydropyrrolo[1,2-a]pyrazin-1(2H)-one;
N-(3,4-dichlorophenyl)-7-({2-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]ethyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(8aR)-tetrahydro-1H-[1,3]thiazolo[4,3-c][1,4]oxazin-6-ylmethyl]oxy}quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[2-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)ethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)oxy]-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-[(octahydro-2H-quinolizin-3-ylmethyl)oxy]quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;

7-({[(3aR,6aS)-2-acetyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-{[(3aR,6aS)-octahydrocyclopenta[c]pyrrol-5-ylmethyl]oxy}quinazolin-4-amine;
ethyl (3aR,5r,6aS)-5-[({4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl}oxy)methyl]hexahydrocyclopenta[c]pyrrole-2(1*H*)-carboxylate;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3aR,6aS)-2-(methylsulfonyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3aR,6aS)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-({[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;

N-(4-bromo-2,3-dichlorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-2,3-dichlorophenyl)-7-({[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-({[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3aR,6aS)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-[(2-{[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino}ethyl)oxy]-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-({2-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]ethyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-({[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]oxy}-6-(methyloxy)quinazolin-4-amine;
1,1-dimethylethyl (3aR,6aS)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyl-oxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate;
1,1-dimethylethyl (3aR,6aS)-5-({[4-[(4-bromo-5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta-[c]pyrrole-2(1H)-carboxylate;
N-(4-Bromo-5-chloro-2-fluorophenyl)-6-(methyloxy)-7-{[(3aR,5r,6aS)-octahydrocyclopenta-[c]pyrrol-5-ylmethyl]oxy}quinazolin-4-amine;
1,1-dimethylethyl (3aR,6aS)-5-({[4-[(3-chloro-2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta-[c]pyrrole-2(1H)-carboxylate;
N-(3-chloro-2,4-difluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-octahydrocyclopenta-[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
1,1-dimethylethyl (3aR,6aS)-5-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta-[c]pyrrole-2(1H)-carboxylate;
N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-{[[(3aR,5r,6aS)-octahydrocyclopenta[c]pyrrol-5-yl]methyl]oxy}quinazolin-4-amine;

1,1-dimethylethyl (3aR,6aS)-5-({[4-[(4,5-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta-[c]pyrrole-2(1H)-carboxylate;
N-(4,5-dichloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-octahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
1,1-dimethylethyl (3aR,6aS)-5-({[4-[(4-bromo-2,3-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta-[c]pyrrole-2(1H)-carboxylate;
N-(4-bromo-2,3-dichlorophenyl)-7-({[(3aR,5r,6aS)-octahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
1,1-dimethylethyl (3aR,6aS)-5-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta-[c]pyrrole-2(1H)-carboxylate;
N-(3,4-dichlorophenyl)-7-({[(3aR,5r,6aS)-octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
7-{[(3-*endo*)-8-azabicyclo[3.2.1]oct-3-ylmethyl]oxy}-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine;
1,1-dimethylethyl (3-*endo*)-3-(2-{[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}ethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate; and
7-({2-[(3-*endo*)-8-azabicyclo[3.2.1]oct-3-yl]ethyl}oxy)-*N*-(3,4-dichlorophenyl)-6-(methyloxy) quinazolin-4-amine; and

Definitions for the compounds of Formula I(V2)

[00377] The atom numbering convention for the quinazoline structure is as follows:



[00378] The symbol "-" means a single bond, "=" means a double bond, "≡" means a triple bond. The symbol "〰" refers to a group on a double-bond as occupying either position on the terminus of a double bond to which the symbol is attached; that is, the geometry, *E*- or *Z*-, of the double bond is ambiguous. When a group is depicted removed from its parent Formula, the "〜" symbol will be used at the end of the bond which was theoretically cleaved in order to separate the group from its parent structural Formula.

[00379] If a group "R" is depicted as "floating" on a ring system, as for example in the Formula:



then, unless otherwise defined, a substituent "R" may reside on any atom of the ring system, assuming replacement of a depicted, implied, or expressly defined hydrogen from one of the ring atoms, so long as a stable structure is formed.

[00380] If a group "R" is depicted as floating on a fused ring system, as for example in the Formulae:



then, unless otherwise defined, a substituent "R" may reside on any atom of the fused ring system, assuming replacement of a depicted (for example the -NH- in the Formula above), implied (for example as in the Formula above, where the hydrogens are not shown but understood to be present), or expressly defined hydrogen (for example where in the Formula above, "X" equals -CH-) from one of the ring atoms, so long as a stable structure is formed. In the example depicted, the "R" group may reside on either the 5-membered or the 6-membered ring of the fused ring system. In the Formula depicted above, when y is 2 for example, then the two "R's" may reside on any two atoms of the ring system, again assuming each replaces a depicted, implied, or expressly defined hydrogen on the ring.

[00381] When there are more than one such depicted "floating" groups, as for example in the Formulae:



where there are two groups, namely, the "R" and the bond indicating attachment to a parent structure; then, unless otherwise defined, the "floating" groups may reside on any atoms of the ring system, again assuming each replaces a depicted, implied, or expressly defined hydrogen on the ring.

[00382] When a group "R" is depicted as existing on a ring system containing saturated carbons, as for example in the Formula:



where, in this example, "y" can be more than one, assuming each replaces a currently depicted, implied, or expressly defined hydrogen on the ring; then, unless otherwise defined, where the resulting structure is stable, two "R's" may reside on the same carbon. A simple example is when R is a methyl group; there can exist a geminal dimethyl on a carbon of the depicted ring (an "annular" carbon). In another example, two R's on the same carbon, including that carbon, may form a ring, thus creating a spirocyclic ring (a "spirocyclyl" group) structure with the depicted ring as for example in the Formula:



[00383] "Alkyl" is intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof, inclusively. For example, "C_8 alkyl" may refer to an *n*-octyl, *iso*-octyl, cyclohexylethyl, and the like. Lower alkyl refers to alkyl groups of from one to six carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, *s*-butyl, *t*-butyl, isobutyl, pentyl, hexyl and the like. Higher alkyl refers to alkyl groups containing more that eight carbon atoms. Exemplary alkyl groups are those of C_{20} or below. Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of from three to thirteen carbon atoms. Examples of cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbornyl, adamantyl and the like. In this application, alkyl refers to alkanyl, alkenyl, and alkynyl residues (and combinations thereof); it is intended to include cyclohexylmethyl, vinyl, allyl, isoprenyl, and the like. Thus when an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be encompassed; thus, for example, either "butyl" or "C_4 alkyl" is meant to include *n*-butyl, *sec*-butyl, isobutyl, *t*-butyl, isobutenyl and but-2-yne radicals; and "propyl" or "C_3 alkyl" each include *n*-propyl, propenyl, and isopropyl.

[00384] "Alkylene" refers to straight or branched chain divalent radical consisting solely of carbon and hydrogen atoms, containing no unsaturation and having from one to ten carbon atoms, for example, methylene, ethylene, propylene, *n*-butylene and the like. Alkylene is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, fully saturated. Examples of alkylene include ethylene

(-CH_2CH_2-), propylene (-$CH_2CH_2CH_2$-), dimethylpropylene (-$CH_2C(CH_3)_2CH_2$-), and cyclohexylpropylene (-$CH_2CH_2CH(C_6H_{13})$).

[00385] "Alkylidene" refers to a straight or branched chain unsaturated divalent radical consisting solely of carbon and hydrogen atoms, having from two to ten carbon atoms, for example, ethylidene, propylidene, *n*-butylidene, and the like. Alkylidene is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, double bond unsaturation. The unsaturation present includes at least one double bond and a double bond can exist between the first carbon of the chain and a carbon atom of the rest of the molecule to which it is attached.

[00386] "Alkylidyne" refers to a straight or branched chain unsaturated divalent radical consisting solely of carbon and hydrogen atoms having from two to ten carbon atoms, for example, propylid-2-ynyl, *n*-butylid-1-ynyl, and the like. Alkylidyne is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, triple bond unsaturation. The unsaturation present includes at least one triple bond and a triple bond can exist between the first carbon of the chain and a carbon atom of the rest of the molecule to which it is attached.

[00387] Any of the above radicals, "alkylene," "alkylidene" and "alkylidyne," when optionally substituted, may contain alkyl substitution which itself contains unsaturation. For example, 2-(2-phenylethynyl-but-3-enyl)-naphthalene (IUPAC name) contains an *n*-butylid-3-ynyl radical with a vinyl substituent at the 2-position of said radical.

[00388] "Alkoxy" or "alkoxyl" refers to the group -O-alkyl, for example including from one to eight carbon atoms of a straight, branched, cyclic configuration, unsaturated chains, and combinations thereof attached to the parent structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to six carbons.

[00389] "Substituted alkoxy" refers to the group -O-(substituted alkyl), the substitution on the alkyl group generally containing more than only carbon (as defined by alkoxy). One exemplary substituted alkoxy group is "polyalkoxy" or -O-optionally substituted alkylene-optionally substituted alkoxy, and includes groups such as -$OCH_2CH_2OCH_3$, and glycol ethers such as polyethyleneglycol and -$O(CH_2CH_2O)_xCH_3$, where x is an integer of between about two and about twenty, in another example, between about two and about ten, and in a further example between about two and about five. Another exemplary

substituted alkoxy group is hydroxyalkoxy or $-OCH_2(CH_2)_yOH$, where y is for example an integer of between about one and about ten, in another example y is an integer of between about one and about four.

[00390] "Acyl" refers to groups of from one to ten carbon atoms of a straight, branched, cyclic configuration, saturated, unsaturated and aromatic and combinations thereof, attached to the parent structure through a carbonyl functionality. One or more carbons in the acyl residue may be replaced by nitrogen, oxygen or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples include acetyl, benzoyl, propionyl, isobutyryl, t-butoxycarbonyl, benzyloxycarbonyl and the like. Lower-acyl refers to groups containing one to six carbons.

[00391] "α-Amino Acids" refer to naturally occurring and commercially available amino acids and optical isomers thereof. Typical natural and commercially available α-amino acids are glycine, alanine, serine, homoserine, threonine, valine, norvaline, leucine, isoleucine, norleucine, aspartic acid, glutamic acid, lysine, omithine, histidine, arginine, cysteine, homocysteine, methionine, phenylalanine, homophenylalanine, phenylglycine, ortho-tyrosine, meta-tyrosine, para-tyrosine, tryptophan, glutamine, asparagine, proline and hydroxyproline. A "side chain of an α-amino acid" refers to the radical found on the α-carbon of an α-amino acid as defined above, for example, hydrogen (for glycine), methyl (for alanine), benzyl (for phenylalanine), and the like.

[00392] "Amino" refers to the group $-NH_2$. "Substituted amino," refers to the group -N(H)R or –N(R)R where each R is independently selected from the group: optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heterocyclyl, acyl, carboxy, alkoxycarbonyl, sulfanyl, sulfinyl and sulfonyl, for example, diethylamino, methylsulfonylamino, furanyl-oxy-sulfonamino.

[00393] "Aryl" refers to aromatic six- to fourteen-membered carbocyclic rings include, for example, benzene, naphthalene, indane, tetralin, fluorene and the like.

[00394] "Arylalkyl" refers to a residue in which an aryl moiety is attached to a parent structure via one of an alkylene, alkylidene, or alkylidyne radical. Examples include benzyl, phenethyl, phenylvinyl, phenylallyl and the like. The aryl, alkylene, alkylidene, or alkylidyne radical portion of an arylalkyl group may be optionally substituted. "Lower arylalkyl" refers to an arylalkyl where the "alkyl" portion of the group has one to six carbons.

[00395] "Exo-alkenyl" refers to a double bond that emanates from an annular carbon, and is not within the ring system, for example the double bond depicted in the Formula below.



[00396] "Fused-polycyclic" or "fused ring system" refers to a polycyclic ring system that contains bridged or fused rings; that is, where two rings have more than one shared atom in their ring structures. Typically, but not necessarily, fused-polycyclics share a vicinal set of atoms. Typically, a spiro ring system is not a fused-polycyclic by this definition, but fused polycyclic ring systems of the compounds described above may themselves have spiro rings attached thereto via a single ring atom of the fused-polycyclic.

[00397] "Halogen" or "halo" refers to fluorine, chlorine, bromine or iodine. Dihaloaryl, dihaloalkyl, trihaloaryl etc. refer to aryl and alkyl substituted with a plurality of halogens, but not necessarily a plurality of the same halogen; thus 4-chloro-3-fluorophenyl is within the scope of dihaloaryl.

[00398] "Heteroatom" refers to O, S, N, or P.

[00399] "Heterocyclyl" refers to a stable three- to fifteen-membered ring radical that consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, phosphorus, oxygen and sulfur. For purposes of this invention, the heterocyclyl radical may be a monocyclic, bicyclic or tricyclic ring system, which may include fused or bridged ring systems, and the nitrogen, phosphorus, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized to various oxidation states. In addition, the nitrogen atom may be optionally quaternized; and the ring radical may be partially or fully saturated or aromatic. Examples of such heterocyclyl radicals include, but are not limited to, azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofuranyl, carbazoyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrazoyl, tetrahydroisoquinolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, dihydropyridinyl, tetrahydropyridinyl, pyridinyl, pyrazinyl,

pyrimidinyl, pyridazinyl, oxazolyl, oxazolinyl, oxazolidinyl, triazolyl, indanyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl, quinolyl, isoquinolyl, decahydroisoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothieliyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, dioxaphospholanyl, and oxadiazolyl.

[00400] "Heteroalicyclic" refers specifically to a non-aromatic heterocyclyl system radical.

[00401] "Heteroaryl" refers specifically to an aromatic heterocyclyl system radical.

[00402] "Heterocyclylalkyl" refers to a residue in which a heterocyclyl is attached to a parent structure via one of an alkylene, alkylidene, or alkylidyne radical. Examples include (4-methylpiperazin-1-yl) methyl, (morpholin-4-yl) methyl, 2-(oxazolin-2-yl) ethyl, 4-(4-methylpiperazin-1-yl)-2-butenyl, and the like. The heterocyclyl, alkylene, alkylidene, or alkylidyne radical portion of an arylalkyl group may be optionally substituted. "Lower heterocyclylalkyl" refers to an arylalkyl where the "alkyl" portion of the group has one to six carbons.

[00403] "Hydrocarbyl" refers to a hydrocarbon residue, generally. The term "hydrocarbyl" can be modified to mean more specific structures, for example "a saturated or mono- or poly-unsaturated C_3-C_{14} mono- or fused-polycyclic hydrocarbyl optionally containing one, two, or three annular heteroatoms per ring" means a mono- or polycyclic (for example a bridged bicyclic) ring system, having between three and fourteen-ring atoms, that contains only carbon ring atoms, but optionally can contain up to three heteratoms per ring and/or unsaturation.

[00404] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. It will be understood by those skilled in the art with respect to any group containing one or more substituents that such groups are not intended to introduce any substitution or substitution patterns (for example, substituted alkyl includes optionally substituted cycloalkyl groups. But where a first optionally substituted group can be substituted by a second optionally substituted

group, the second substituent cannot be further substituted. Optional subsituents do not include groups that are sterically impractical and/or synthetically non-feasible.

[00405] "Optionally substituted" refers to all subsequent modifiers in a term, for example in the term "optionally substituted arylC_{1-8} alkyl," optional substitution may occur on both the "C_{1-8} alkyl" portion and the "aryl" portion of the molecule; and for example, optionally substituted alkyl includes optionally substituted cycloalkyl groups, however, optionally substituted groups cannot be further optionally substituted more than once. Examples of optional substitution include, but are not limited to alkyl, halogen, alkoxy, hydroxy, oxo, carbamyl, acylamino, sulfonamido, carboxy, alkoxycarbonyl, acyl, alkylthio, alkylsulfonyl, nitro, cyano, amino, alkylamino, cycloalkyl and the like.

[00406] Unless otherwise specified, the term "optionally substituted" applies to the chemical moiety immediately preceding it. For instance, if a variable group (such as R) is defined as aryl, optionally substituted alkyl, or cycloalkyl, then only the alkyl group is optionally substituted.

[00407] In the case where there is a point of attachment for a monovalent substituent, such as $-CH_3$, $-NH_2$, or -OH, the indication of where the point of attachment is is not necessary. That is, $-CH_3$ has the same meaning as CH_3, $-NH_2$ has the same meaning as NH_2, and -OH has the same meaning as OH.

[00408] "Saturated bridged ring system" refers to a bicyclic or polycyclic ring system that is not aromatic. Such a system may contain isolated or conjugated unsaturation, but not aromatic or heteroaromatic rings in its core structure (but may have aromatic substitution thereon). For example, 2,3,3a,4,7,7a-hexahydro-1H-indene, 7-aza-bicyclo[2.2.1]heptane and 1,2,3,4,4a,5,8,8a-octahydro-naphthalene are all included in the class "saturated bridged ring system."

[00409] "Spirocyclyl" or "spirocyclic ring" refers to a ring originating from a particular annular carbon of another ring. For example, a ring atom of the aforementioned saturated bridged ring system, but not a bridgehead atom, can be a shared atom between the saturated bridged ring system (rings B and B') and a spirocyclyl (ring A) attached thereto, as depicted below. A spirocyclyl can be either carbocyclic or heterocyclic



[00410] "Substituted" alkyl, aryl, and heterocyclyl, refer respectively to alkyl, aryl, and heterocyclyl, wherein one or more (for example up to about five, in another example, up to about three) hydrogen atoms are replaced by a substituent independently selected from the group: optionally substituted alkyl (for example, fluoroalkyl), optionally substituted alkoxy, alkylenedioxy (for example methylenedioxy), optionally substituted amino (for example, alkylamino and dialkylamino), optionally substituted amidino, optionally substituted aryl (for example, phenyl), optionally substituted arylalkyl (for example, benzyl), optionally substituted aryloxy (for example, phenoxy), optionally substituted arylalkyloxy (for example, benzyloxy), carboxy (-COOH), carboalkoxy (i.e., acyloxy or -OOCR), carboxyalkyl (i.e., esters or -COOR), carboxamido, aminocarbonyl, benzyloxycarbonylamino (CBZ-amino), cyano, carbonyl, halogen, hydroxy, optionally substituted heterocyclylalkyl, optionally substituted heterocyclyl, nitro, sulfanyl, sulfinyl, sulfonyl, and thio.

[00411] "Sulfanyl" refers to the groups: -S-(optionally substituted alkyl), -S-(optionally substituted aryl), and -S-(optionally substituted heterocyclyl).

[00412] "Sulfinyl" refers to the groups: -S(O)-H, -S(O)-(optionally substituted alkyl), -S(O)-optionally substituted aryl), and -S(O)-(optionally substituted heterocyclyl).

[00413] "Sulfonyl" refers to the groups: $-S(O_2)$-H, $-S(O_2)$-(optionally substituted alkyl), $-S(O_2)$-optionally substituted aryl), $-S(O_2)$-(optionally substituted heterocyclyl), $-S(O_2)$-(optionally substituted alkoxy), $-S(O_2)$-optionally substituted aryloxy), and $-S(O_2)$-(optionally substituted heterocyclyloxy).

Synthetic Procedures for the Compounds of Formulae I(V2)

[00414] The compounds of Formulae I(V2), can be made by the synthetic schemes and examples described in publication WO 2004/006846, which is incorporated herein by reference in its entirety. The utility of these compounds are also described in WO 2004/006846.

[00415] Aspect (30) of the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a

JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), and a pharmaceutically acceptable carrier, in combination with a therapeutically effective amount of the compound of Formula I(V2), or a pharmaceutical composition comprising a therapeutically effective amount of the compound of Formula I(V2), and a pharmaceutically acceptable carrier, wherein the mammal is in need of the treatment.

[00416] In other embodiments of aspect (2), aspect (11), aspect (26), and aspect (30) of this invention, R^2 of Formula I(J) is



(f).

[00417] In other embodiments of aspect (2), aspect (11), aspect (26), and aspect (30) of this invention, R^2 of Formula I(J) is



,

wherein R^{28a} is selected from lower alkyl, dialkylaminoalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, and hetercycloalkylalkyl.

[00418] In other embodiments of aspect (2), aspect (11), aspect (26), and aspect (30) of this invention, R^2 of Formula I(J) is



.

[00419] In other embodiments of aspect (2), aspect (11), aspect (26), and aspect (30) of this invention, L of Formula I(J) is a bond, Z is  , R^{25} is hydrogen and E and D are hydrogen.

[00420] In other embodiments of aspect (2), aspect (11), aspect (26), and aspect (30) of this invention, Z of Formula I(J) is  , R^{26a} is $-C(O)R^{32}$, R^{26} is hydrogen, and R^{32} is selected from tetrahydrofuran, pyrrolidinyl or pryimidinyl, wherein R^{32} is optionally substituted with 1, 2, 3, 4 or 5 groups selected from hydroxyl, oxo, alkyl, alkoxy, amino, hydroxyalkyl and halo.

[00421] In other embodiments of aspect (2), aspect (11), aspect (26), and aspect (30) of this invention, R^2 of Formula I(J) is  .

[00422] In other embodiments of aspect (2), aspect (11), aspect (26), and aspect (30) of this invention, R^{32} of Formula I(J) is U or $-CH_2-U$, wherein U is selected from pyrolidinyl, thiazolidinyl, morpholinyl, azetidinyl, cyclobutyl, cyclopropyl, tetrahydofuranyl, pyrazinyl, imidazolyl, piperazinyl, thienyl, thienylmethyl, furanyl, phenyl, prolinamidyl, pyridinyl, tetrahydronaphthalene, tetrazolyl, isoindolinyl, pyranyl, cyclopentyl, and octahydro-1H-indolyl.

[00423] In other embodiments of aspect (2), aspect (11), aspect (26), and aspect (30) of this invention, R^{11} of Formula I(J), when present, is halo or lower alkyl.

[00424] In other embodiments of aspect (2), aspect (11), aspect (26), and aspect (30) of this invention, R^{35} of Formula I(J) is heterocycloalkylalkyl, wherein the heterocyloalkyl is selected from piperazinyl, piperidinyl, morpholinyl and dioxanyl.

[00425] In other embodiments of aspect (2), aspect (11), aspect (26), and aspect (30) of this invention, n2 of Formula I(J) is 0.

[00426] In other embodiments of aspect (2), aspect (11), aspect (26), and aspect (30) of this invention, R^2 of Formula I(J) is  , and wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl.

[00427] In other embodiments of aspect (2), aspect (11), aspect (26), and aspect (30) of this invention, the JAK-2 compound has Formula IV(J):



wherein and R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

[00428] In other embodiments of aspect (2), aspect (11), aspect (26), and aspect (30) of this invention, the JAK-2 compound has Formula V(J):



wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

[00429] In other embodiments of aspect (2), aspect (11), aspect (26), and aspect (30) of this invention, the JAK-2 compound has Formula VI(J):



wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

C-Met Compounds

[00430] In another embodiment of the methods described herein, the JAK-2 compounds described hereinabove [e.g., compounds of Formula I(J), II(J), III(J), IV(J), V(J), VI(J), and VII(J)] can also be combined with any of the c-MET compounds (which can inhibit VEFGR, Flt3, Ret, c-Kit, and/or c-Met) described below. Non-limiting examples of c-Met inhibitors (c-Met inhibitors fall within the scope of aspect (5) of this invention) include any of the c-Met compounds described below that can inhibt c-Met. Non-limiting examples of VEGFR inhibitors (VEGFR inhibitors fall within the scope of aspect (2) of this invention) include any of the c-Met compounds below that can inhibt VEGFR. Non-limiting examples of Flt3 inhibitors (Flt3 inhibitors fall within the scope of aspect (8) of this invention) include any of the c-Met Compounds below that can inhibt Flt3. Non-limiting examples of Ret inhibitors (Ret inhibitors fall within the scope of aspect (14) of this invention) include any of the c-Met Compounds below that can inhibt Ret. Non-limiting examples of c-Kit inhibitors (c-Kit inhibitors fall within the scope of aspect (6) of this invention) include any of the c-Met Compounds below that can inhibt c-Kit. All of the c-Met compounds described herein are meant to alternatively include pharmaceutically acceptable salts of these c-Met compounds whether it is explicitely stated or not. All of the c-Met compounds described herein fall within the scope of aspect (20) of this invention.

[00431] In one non-limiting embodiment, the c-Met Compound is a compound of Formula **I(V3)**:



I(V3)

or a pharmaceutically acceptable salt thereof, wherein,

R^1 is selected from -H, halogen, $-OR^3$, $-NO_2$, $-NH_2$, $-NR^3R^4$ and optionally substituted lower alkyl;

A^1 is selected from =N- and =C(H)-;

Z is -O-;

Ar is either a group of Formula **II**, or of Formula **III**,



II



III

wherein,

R^2 is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$ and optionally substituted lower alkyl;

q is 0 to 4;

G is selected from:

		
		
		
		
		

		
		
		
		
		
		
		
		
		



each E is selected from -O-, -N(R^{13})-, -CH_2- and -$S(O)_{0-2}$-;

M is selected from -O-, -N(R^{13})-, -CH_2- and -C(=O)N(R^{13})-;

each V is independently either =N- or =C(H)-;

each methylene in any of the above Formulae is independently optionally substituted with one or two R^{25};

R^{25} is selected from halogen, trihalomethyl, -CN, -NO_2, -NH_2, -OR^3, -NR^3R^4, -$S(O)_{0-2}R^3$, -$SO_2NR^3R^3$, -CO_2R^3, -$C(O)NR^3R^3$, -$N(R^3)SO_2R^3$, -$N(R^3)C(O)R^3$, -$N(R^3)CO_2R^3$, -$C(O)R^3$, optionally substituted aryl, optionally substituted arylalkyl, heteroarylalkyl and optionally substituted lower alkyl; or two of R^{25}, together with the carbon or carbons to which they are attached, can combine to form a three- to seven-membered alicyclic or heteroalicyclic; or two of R^{25} on a single carbon can be oxo;

J is selected from -$S(O)_{0-2}$-, -O-, and -NR^{15}-;

R^3 is -H or R^4;

R^4 is selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl and optionally substituted lower heterocyclylalkyl; or

R^3 and R^4, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional annular heteroatom selected from N, O, S and P;

A^2 and A^3 are each independently selected from =N- and =C(R^2)-;

D is selected from -O-, -$S(O)_{0-2}$- and -NR^{15}-;

R^{50} is R^3;

R^{13} is selected from -H, $-C(=O)R^3$, $-C(=O)OR^3$, $-C(=O)SR^3$, $-SO_2R^4$, $-C(=O)N(R^3)R^3$ and optionally substituted lower alkyl; or, two R^{13}, together with the atom or atoms to which they are attached, can combine to form a heteroalicyclic optionally substituted with between one and four of R^{60}, said heteroalicyclic can have up to four annular heteroatoms, and said heteroalicyclic can have an aryl or heteroaryl fused thereto, in which case said aryl or heteroaryl is optionally substituted with an additional one to four of R^{60};

R^{14} is selected from -H, $-NO_2$, $-NH_2$, $-N(R^3)R^4$, -CN, $-OR^3$, optionally substituted lower alkyl, optionally substituted heteroalicyclylalkyl, optionally substituted aryl, optionally substituted arylalkyl and optionally substituted heteroalicyclic;

R^{15} is a group $-M^1-M^2$, wherein M^1 is selected from absent, $-C(=S)N(R^{13})-$, $-C(=NR^{14})N(R^{13})-$, $-SO_2N(R^{13})-$, $-SO_2-$, $-C(=O)N(R^{13})-$, $-C(=O)C(=O)N(R^{13})-$, $-C_{0-4}$alkylene-, -C(=O)- and an optionally substituted four to six-membered hetercyclyl annular containing between one and three heteratoms including at least one nitrogen; and M^2 is selected from -H, $-C_{0-6}$alkyl, alkoxy, $-C(=O)C_{0-4}$alkylQ, $-C_{0-4}$alkylQ, $-OC_{0-4}$alkylQ-, $-N(R^{13})C_{0-4}$alkylQ- and $-C(=O)N(R^{13})C_{0-4}$alkylQ;

Q is a five- to ten-membered ring system, optionally substituted with between zero and four of R^{20};

R^{20} is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$ and optionally substituted lower alkyl; and

R^{60} is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroarylalkyl and optionally substituted arylalkyl; or two of R^{60}, when attached to a non-aromatic carbon, can be oxo;

with the proviso that the conditions of:

Z is -O-;

Ar is according to Formula **II**; and

the portion of G directly attached to Ar selected from the table below:



are not met at the same time; and

with the proviso that when Ar is phenylene or substituted phenylene, then the portion of G directly attached to Ar cannot contain  , wherein R^{70} is selected from -H, C_{1-4}alkyl, and C_{1-4}alkoxyl.

[00432] In another embodiment of the compound of Formula I(V3), Ar is according to one of Formula **IIa**, **IIb** and **IIIa**:



IIa



IIb



IIIa .

[00433] In another embodiment of the compound of Formula I(V3), A^1 is =C(H)-.

[00434] In another embodiment of the compound of Formula I(V3), Ar is of Formula IIa and A^1 is =N-.

[00435] In another embodiment of the compound of Formula I(V3), D is -O- and R^1 is $-OR^3$.

[00436] In another embodiment of the compound of Formula I(V3), $-O-R^{50}$ and R^1 are interchangeably located at the 6-position and 7-position of the quinazoline or quinoline according to Formula **I**.

[00437] In another embodiment of the compound of Formula I(V3), R^1 is -OH or -OC_{1-6}alkyl.

[00438] In another embodiment of the compound of Formula I(V3), G is selected from:



and

wherein Q, R^{13}, E and R^{60} are as defined above; each methylene in any of the above Formulae, other than those in a depicted ring, is independently optionally substituted with one or two R^{25}; and R^{25} is selected from halogen, trihalomethyl, oxo, -CN, -NO_2, -NH_2, -OR^3, -NR^3R^4, -$S(O)_{0-2}R^3$, -$SO_2NR^3R^3$, -CO_2R^3, -$C(O)NR^3R^3$, -$N(R^3)SO_2R^3$, -$N(R^3)C(O)R^3$, -$N(R^3)CO_2R^3$, -$C(O)R^3$, optionally substituted aryl, optionally substituted arylalkyl, heteroarylalkyl and optionally substituted lower alkyl; or two of R^{25}, together with the carbon or carbons to which they are attached, can combine to form a three- to seven-membered alicyclic or heteroalicyclic.

[00439] In another embodiment of the compound of Formula I(V3), Q is selected from:



wherein R^{20} is defined as above, and P is a five- to seven-membered ring, including the two shared carbons of the aromatic ring to which P is fused, P optionally containing between one and three heteroatoms.

[00440] In another embodiment of the compound of Formula I(V3), Ar is according to Formula **IIb**, and G is selected from:



wherein Q, R^{13}, E, and R^{60} are as defined above, and each methylene in any of the above Formulae, other than those depicted in a ring, is independently optionally substituted with one or two R^{25}; and R^{25} is selected from halogen, trihalomethyl, oxo, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted aryl, optionally substituted arylalkyl, heteroarylalkyl and optionally substituted lower alkyl; or two of R^{25}, together with the carbon or carbons to which they are attached, can combine to form a three- to seven-membered alicyclic or heteroalicyclic.

[00441] In another embodiment of the compound of Formula I(V3), the methylene between the two carbonyls of G is di-substituted with either optionally substituted lower alkyl, or an optionally substituted spirocycle.

[00442] In another embodiment of the compound of Formula I(V3), R^{50} is a heteroalicylic or a C_{1-6}alkyl-heteroalicylic.

[00443] In another embodiment of the compound of Formula I(V3), at least one of R^2 is halogen.

[00444] In another embodiment, the compound of Formula I(V3) is selected from one or more of the following compounds, or a pharmaceutically acceptable salt thereof:

N-{[(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)(methyl)amino]carbonothioyl}-2-phenylacetamide
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl) imidazolidin-2-one
N'-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N-methyl-N-(2-phenylethyl)sulfamide
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)piperidin-2-one
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-4-phenyl-1,3-thiazol-2-amine
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-N-(phenylmethyl) Benzenesulfonamide
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-N-(2-phenylethyl) Benzenesulfonamide
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-N-(3-phenylpropyl) Benzenesulfonamide
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl (phenylmethyl)carbamate
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-N-methyl-N-(3-phenylpropyl) Benzenesulfonamide
N-[(Z)-[(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)amino](imino)methyl]-2-phenylacetamide
N,N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-bis-(3-phenylpropane-1-sulfonamide)
N2-[(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)sulfonyl]-N1-phenylglycinamide
N-{[(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)amino]carbonothioyl}-2-phenylacetamide
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-1,3-benzothiazol-2-amine
benzyl-{[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenylcarbamoyl]-methyl}-carbamic acid tert-butyl ester
N2-acetyl-N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-(phenylmethyl)glycinamide

benzyl-{[6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-ylcarbamoyl]-methyl}-carbamic acid tert-butyl ester
N2-acetyl-N1-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridine-3-yl)-N2-(phenylmethyl)glycinamide
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-4-phenylbutanamide
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-methyl-N2-(phenylmethyl)glycinamide
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-1,3-benzothiazol-2-yl)-3-phenylpropanamide
N'-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N-(2-phenylethyl)-N-(phenylmethyl)sulfamide
N-{[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenylcarbamoyl]-methyl}-benzamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N,N'-bis(phenylmethyl)sulfamide
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-(4-fluorophenyl)propanediamide
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-3-[(4-methylphenyl)sulfonyl]-4-(phenylmethyl)imidazolidin-2-one
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-2-[3-(trifluoromethyl) phenyl]acetamide
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-N-(2-piperidin-1-ylethyl)-1,3-benzothiazol-2-amine
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-N-(2-pyrrolidin-1-ylethyl)-1,3-benzothiazol-2-amine
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-N-{2-[3-(trifluoromethyl)phenyl]ethyl}-1,3-benzothiazol-2-amine
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-1,3-benzothiazol-2-yl)-2-[3-(trifluoromethyl) phenyl]acetamide
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-(2-phenylethyl)glycinamide
benzyl-{[5-chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-ylcarbamoyl]-methyl}-carbamic acid tert-butyl ester
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-1,3-benzothiazol-2-yl)-2-[3,5-bis(trifluoromethyl) phenyl]acetamide
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-methyl-N2-{[3-(trifluoromethyl) phenyl]methyl}glycinamide
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-methyl-N2-(2-phenylethyl)glycinamide
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridazin-3-yl)-N'-(4-fluorophenyl)propanediamide

N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-(3-chlorophenyl)propanediamide
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-(4-chlorophenyl)propanediamide
(2E)-N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-2-[(ethyloxy)imino] Propanamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-1-(phenylmethyl)prolinamide
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-4-(phenylmethyl) imidazolidin-2-one
6,7-bis(methyloxy)-4-({4-[4-(phenylmethyl)piperazin-1-yl]phenyl}oxy)quinoline
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N2-(phenylmethyl)alaninamide
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N2-(phenylmethyl)leucinamide
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N2-(phenylmethyl)valinamide
2-(Benzyl-methyl-amino)-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-3-methyl-butyramide (note: Alphabetic order of prefixes ignored while selecting parent chain)
2-Benzyloxyimino-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-2-phenyl-acetamide
4-(4-{3-Chloro-5-[2-(4-fluoro-phenylcarbamoyl)-acetylamino]-pyridin-2-yloxy}-6-methoxy-quinolin-7-yloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester
N-{5-Chloro-6-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-pyridin-3-yl}-N'-(4-fluoro-phenyl)-malonamide
N-[5-Chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-N'-(2,4-difluoro-phenyl)-malonamide
N-{5-Chloro-6-[6-methoxy-7-(3-piperidin-1-yl-propoxy)-quinolin-4-yloxy]-pyridin-3-yl}-N'-(4-fluoro-phenyl)-malonamide
N-{5-Chloro-6-[7-(3-diethylamino-propoxy)-6-methoxy-quinolin-4-yloxy]-pyridin-3-yl}-N'-(4-fluoro-phenyl)-malonamide
N-[5-Chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-N'-phenyl-malonamide

[00445] In another embodiment of the methods described herein, the JAK-2 compounds described hereinabove [e.g., compounds of Formula I(J), II(J), III(J), IV(J), V(J), VI(J), and VII(J)] can also be combined with any of the following c-Met compounds (that fall

within the scope of aspect 20 of this invention) of Formula A-B-C (version 3), or a pharmaceutically acceptable salt thereof, wherein A is selected from:



and -R^3;

B is selected from:



and



; and

C is selected from:





wherein:

R^2 is selected from -H, halogen, trihalomethyl, -CN, $-NH_2$, $-NO_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$ and optionally substituted lower alkyl;

q is 0 to 2;

each R^3 is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl; or, two R^3, together with the nitrogen to which they are attached, form a four- to seven-membered heteroalicyclic, said four- to seven-membered heteroalicyclic optionally containing one additional heteroatom; when one said additional heteroatom is a nitrogen, then said nitrogen is optionally substituted with a group selected from -H, trihalomethyl, $-SO_2R^5$, $-SO_2NR^5R^5$, $-CO_2R^5$, $-C(O)NR^5R^5$, $-C(O)R^5$ and optionally substituted lower alkyl;

each R^{35} is independently selected from -H, $-C(=O)R^3$, $-C(=O)OR^3$, $-C(=O)SR^3$, $-SO_2R^3$, $-C(=O)N(R^3)R^3$, and optionally substituted lower alkyl; or, two R^{35}, together with the nitrogen to which they are attached, can combine to form a heteroalicyclic optionally substituted with between one and four of R^{60}, said heteroalicyclic may have an additional annular heteroatom, and said heteroalicyclic may have an aryl fused thereto, said aryl optionally substituted with an additional one to four of R^{60};

A^1 is selected from =N- and =C(H)-;

A^2 is either =N- or =C(H)-;

R^5 is -H or optionally substituted lower alkyl;

R^8 is selected from R^3, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-SO_2R^3$ and $-C(O)R^3$, or an R^8 is absent and the alkylene linker of A is covalently bonded to the nitrogen atom in which R^8 is absent;

E^1 is selected from -O-, $-CH_2-$, $-N(R^5)-$ and $-S(O)_{0-2}-$;

Q is a five- to ten-membered ring system, optionally substituted with between zero and four of R^{20};

R^{20} is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$ and optionally substituted lower alkyl;

R^{60} is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroarylalkyl and optionally substituted arylalkyl; or, two of R^{60}, when attached to a non-aromatic carbon, can be oxo;

each methylene in any of the above Formulae is independently optionally substituted with one or two R^{25}; and

each R^{25} is independently selected from halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted aryl, optionally substituted arylalkyl, heteroarylalkyl and optionally substituted lower alkyl; or two of R^{25}, together with the carbon or carbons to which they are attached, can combine to form a three- to seven-membered alicyclic or heteroalicyclic; or two of R^{25} on a single carbon can be oxo;

with the proviso that the conditions of:

C contains 

; and

the remaining portion of C contains one of:



are not met at the same time; and

with the proviso that when C contains  directly attached to  , and R^{70} is selected from -H, C_{1-4}alkyl, and C_{1-4}alkoxyl, then A^2 is N.

[00446] In another embodiment of the compound of Formula A-B-C (version 3), Q is selected from phenyl, napthyl, 1,2,3,4-tetrahydronaphthyl, indanyl, benzodioxanyl, benzofuranyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroisoquinolyl, pyrrolyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, tetrahydropyridinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolinyl, oxazolidinyl, triazolyl, isoxazolyl, isoxazolidinyl, thiazolyl, thiazolinyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl, quinolyl, isoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, benzothieliyl and oxadiazolyl; each optionally substituted with between one and four of R^{20}; wherein each R^{20} is independently selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$ and optionally substituted lower alkyl.

[00447] In another embodiment of the compound of Formula A-B-C (version 3), B is:



wherein A^1 is =N- or =C(H)-.

[00448] In another embodiment of the compound of Formula A-B-C (version 3), R^3 is methyl.

[00449] In another embodiment of the compound of Formula A-B-C (version 3), C is selected from:














,


,


,



and



.

[00450] In another embodiment of the compound of Formula A-B-C (version 3), R^2 is selected from halogen, trihalomethyl, -CN, $-NO_2$, $-OR^3$, $-NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$ and optionally substituted lower alkyl.

[00451] In another embodiment of the compound of Formula A-B-C (version 3), R^2 is halogen.

[00452] In another embodiment of the compound of Formula A-B-C (version 3), R^2 is fluorine or chlorine.

[00453] In another embodiment of the compound of Formula A-B-C (version 3), the compound is according to Formula **XI(V3)**,



XI(V3)

or a pharmaceutically acceptable salt thereof, wherein:

each R^1 is independently selected from halogen, $-OR^3$, $-NO_2$, $-NH_2$, $-NR^3R^4$, -D-R^{50} and optionally substituted C_{1-6}alkyl;

Q is selected from =N- or =C(H)-;

Z is -O-;

Ar is either a five- or six-membered arylene or a five- or six-membered heteroarylene containing between one and three heteroatoms;

G is either an optionally substituted cycloalkyl or an optionally substituted heteroalicyclic;

each R^2 is independently selected from halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$ and optionally substituted C_{1-6}alkyl;

each R^3 is independently -H or R^4;

each R^4 is independently selected from optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl and optionally substituted heterocyclyl C_{1-6}alkyl; or

R^3 and R^4, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional annular heteroatom selected from N, O, S and P;

R^5 is -H or optionally substituted C_{1-6}alkyl;

each D is independently selected from $-O-$, $-S(O)_{0-2}-$ and $-NR^5-$;

each R^{30} is independently selected from halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$ and optionally substituted C_{1-6}alkyl;

each R^{50} is R^3; and

R^{70} is selected from -H, halogen, $-OR^3$, $-S(O)_{0-2}R^3$, $-NO_2$, $-NH_2$, $-NR^3R^4$ and optionally substituted C_{1-6}alkyl.

[00454] In another embodiment of the compound of Formula **XI(V3)**, R^{70} is hydrogen.

[00455] In another embodiment of the compound of Formula **XI(V3)**, at least one of R^1 is $-D-R^{50}$.

[00456] In another embodiment of the compound of Formula **XI(V3)**, D is -O- and at least one other R^1 is $-OR^3$.

[00457] In another embodiment of the compound of Formula A-B-C (version 3), the compound is according to Formula **XIIIa(V3)** or **XIIIb(V3)**:



XIIIa(V3)



XIIIb(V3)

wherein Q^1 is either =N- or =C(H)-, R^{3a} is C_{1-6}alkyl, and -N(R^{3b})R^4 is selected from the following:



wherein:

J is a five- to ten-membered ring, optionally substituted with between zero and five of R^{20}, wherein each R^{20} is independently selected from -H, halogen, trihalomethyl, -CN, -NO_2, -NH_2, -OR^3, -NR^3R^4, -$S(O)_{0-2}R^3$, -$SO_2NR^3R^3$, -CO_2R^3, -$C(O)NR^3R^3$, -$N(R^3)SO_2R^3$, -$N(R^3)C(O)R^3$, -$N(R^3)CO_2R^3$, -$C(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl and optionally substituted heterocyclyl C_{1-6}alkyl, or two of R^{20}, together with the atom or atoms to which they are

attached, combine to form an optionally substituted three- to seven-membered heteroalicyclic, said optionally substituted three- to seven-membered heteroalicyclic either spiro- to J or fused to J;

E is selected from -O-, -N(R^5)-, -CH_2- and -$S(O)_{0-2}$-;

each R^{60} is independently selected from halogen, trihalomethyl, -CN, -NO_2, -NH_2, -OR^3, -NR^3R^4, -$S(O)_{0-2}R^3$, -$SO_2NR^3R^3$, -CO_2R^3, -$C(O)NR^3R^3$, -$N(R^3)SO_2R^3$, -$N(R^3)C(O)R^3$, -$N(R^3)CO_2R^3$, -$C(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted heteroaryl C_{1-6}alkyl and optionally substituted aryl C_{1-6}alkyl;

each methylene in any of the above Formulae, other than those in a depicted ring, is independently optionally substituted with one or two R^{25}, wherein R^{25} is selected from halogen, trihalomethyl, oxo, -CN, -NO_2, -NH_2, -OR^3, -NR^3R^4, -$S(O)_{0-2}R^3$, -$SO_2NR^3R^3$, -CO_2R^3, -$C(O)NR^3R^3$, -$N(R^3)SO_2R^3$, -$N(R^3)C(O)R^3$, -$N(R^3)CO_2R^3$, -$C(O)R^3$, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, heteroaryl C_{1-6}alkyl and optionally substituted C_{1-6}alkyl; or two of R^{25}, together with the carbon or carbons to which they are attached, can combine to form a three- to seven-membered alicyclic or heteroalicyclic; and

R^{3b} has the same meaning as R^3.

[00458] In another embodiment of the compound of Formula **XIIIa(V3)** or **XIIIb(V3)**, R^{50} is selected from C_{1-6}alkyl optionally substituted with at least one of optionally substituted amino, optionallysubstituted C_{1-6}alkyl amino, optionally substituted C_{1-6}dialkyl amino, optionally substituted heteroalicylic and a group of Formula **XII**.

[00459] In another embodiment of the compound of Formula A-B-C (version 3), the compound is according to Formula **XIIIa(V3)** or **XIIIb(V3)**, G is selected from cyclopropyl, aziradine, cyclobutyl and azetidine, each optionally substituted with between zero and four of R^{30}.

[00460] In another embodiment of the compound of Formula A-B-C (version 3), the compound is according to Formula **XIIIa(V3)** or **XIIIb(V3)**, wherein R^2 is selected from -H, halogen, C_{1-6} alkyl and perfluoro C_{1-6} alkyl.

[00461] In another embodiment of the compound of Formula A-B-C (version 3), the compound is according to Formula **XIIIa(V3)** or **XIIIb(V3)**, wherein $(R^{30})_{0-4}$ is $(R^{30})_0$ or methyl.

[00462] In another embodiment of the compound of Formula A-B-C (version 3), the compound is according to Formula **XIVa(V3)** or **XIVb(V3)**:



XIVa(V3)



XIVb(V3)

or a pharmaceutically acceptable salt thereof, wherein R^{50} is C_{1-6}alkyl substituted with a group selected from optionally substituted amino, optionally substituted alkylamino, optionally substituted dialkylamino and optionally substituted heteroalicylic.

[00463] In another embodiment of the compound of Formula **XIVa(V3)** or **XIVb(V3)**, Q is -CH=.

[00464] In another embodiment of the compound of Formula **XIVa(V3)** or **XIVb(V3)**, the heteroalicyclic portion of R^{50} is selected from piperidine, piperazine, morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, 2-oxo-morpholine, pyrrolidine and azepine.

[00465] In another embodiment of the compound of Formula **XIVa(V3)** or **XIVb(V3)**, $(R^{30})_{0-4}$ is $(R^{30})_0$ or methyl.

[00466] In another embodiment of the compound of Formula **XIVa(V3)** or **XIVb(V3)**, R^2 is selected from C_{1-6} alkyl, perfluoro C_{1-6} alkyl, hydrogen and halogen.

[00467] In another embodiment of the compound of Formula **XIVa(V3)** or **XIVb(V3)**, R^2 is halogen.

[00468] In another embodiment of the compound of Formula **XIVa(V3)** or **XIVb(V3)**, R^2 is hydrogen.

[00469] In another embodiment of the compound of Formula **XIVa(V3)** or **XIVb(V3)**, R^{20} is selected from halogen, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, optionally substituted heterocyclyl and optionally substituted heterocyclyl C_{1-6}alkyl, and (two of R^{20}) together with the atom or atoms to which they are attached, form an optionally substituted three- to six-membered heteroalicyclic, said optionally substituted three- to six-membered heteroalicyclic fused to the phenyl as in **XIVa**(V3) or **XIVb(V3)**.

[00470] In another embodiment of the compound of Formula **XIVa(V3)** or **XIVb(V3)**, R^{20} is selected from halogen, $-NR^3R^4$, optionally substituted heterocyclyl and optionally substituted heterocyclyl C_{1-6}alkyl, and (two of R^{20}) together with the atom or atoms to which they are attached, form an optionally substituted five- to six-membered heteroalicyclic, said optionally substituted five- to six-membered heteroalicyclic fused to the phenyl as in **XIVa(V3)** or **XIVb(V3)**.

[00471] In another embodiment of the compound of Formula **XIVa(V3)** or **XIVb(V3)**, R^2 is selected from C_{1-6} alkyl, perfluoro C_{1-6} alkyl and halogen.

[00472] In another embodiment of the compound of Formula **XIVa(V3)** or **XIVb(V3)**, R^2 is selected from perfluoro C_{1-3} alkyl and halogen.

[00473] In another embodiment, the compounds of Formula A-B-C (version 3) is selected from one or more of the following compounds, or a pharceutically acceptable salt thereof:

1,1-dimethylethyl 4-(3-{[4-[(2-fluoro-4-{[(1-{[(4-fluorophenyl)amino]-carbonyl}cyclopropyl)carbonyl]amino}phenyl)oxy]-6-(methyloxy)quinolin-7-yl]oxy}propyl)piperazine-1-carboxylate
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-(4-{[7-{[3-(4-acetylpiperazin-1-yl)propyl]oxy}-6-(methyloxy-)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-(3-fluoro-4-{[7-({3-[4-(1-methylethyl)piperazin-1-yl]propyl}oxy)-6-(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinazolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1-dicarboxamide
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1-dicarboxamide
N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1-dicarboxamide
(1R,2R,3S)-N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1-dicarboxamide
N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,2-dimethyl-cyclopropane-1,1-dicarboxamide
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1-dicarboxamide

N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide
N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinazolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperazin-1-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide
N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-{5-chloro-6-[(6-(methyloxy)-7-{[(1-methylpiperidin-4-yl)methyl]oxy}quinolin-4-yl)oxy]pyridin-3-yl}-N'-(4 fluorophenyl)cyclopropane-1,1-dicarboxamide
N-[5-chloro-6-({6-(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-yl}oxy)pyridin-3-yl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

N-[5-chloro-6-({6-(methyloxy)-7-[(phenylmethyl)oxy]quinolin-4-yl}oxy)pyridin-3-yl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide
N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1-methylpiperidin-4-yl)methyl]oxy}quinazolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-(4-fluorophenyl)-N'-[2-methyl-6-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)pyridin-3-yl]cyclopropane-1,1-dicarboxamide
N-[3-fluoro-4-({7-(methyloxy)-6-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-[3-fluoro-4-({7-(methyloxy)-6-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-{3-fluoro-4-[(7-(methyloxy)-6-{[(1-methylpiperidin-4-yl)methyl]oxy}quinazolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-[5-fluoro-2-methyl-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-(4-fluorophenyl)-N'-[2-methyl-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]cyclopropane-1,1-dicarboxamide
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperazin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1-methylpiperidin-4-yl)methyl]oxy}quinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-(4-fluorophenyl)-N'-[4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]cyclopropane-1,1-dicarboxamide
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-(4-{[6-{[3-(diethylamino)propyl]oxy}-7-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-(4-{[6-{[2-(diethylamino)ethyl]oxy}-7-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
(1S,2R)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide
(1R,2R)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide
(1R,2R)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide
(1R,2R)-N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide
1,1-dimethylethyl 4-(3-{[4-[(2-fluoro-4-{[((1R,2R)-1-{[(4-fluorophenyl)amino]carbonyl}-2-methylcyclopropyl)carbonyl]amino}phenyl)oxy]-6-(methyloxy)quinolin-7-yl]oxy}propyl)piperazine-1-carboxylate
(1R,2S)-N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide
(1R,2R)-N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide
(1R,2R)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperazin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide
(1R,2R)-N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide
(1R,2R)-N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide
(1R,2S)-N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide
(1R,2S)-N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide

(1R,2S)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperazin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide
(1R,2R,3S)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide
(1R,2R,3S)-N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide
(1R,2R,3S)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide
(1R,2R,3S)-N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinazolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide
(2R,3R)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide
(2R,3R)-N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide
(1R,2R,3S)-N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide
(2R,3R)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide
(1R,2R)-N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide
(1R,2R)-N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinazolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide
(2R,3R)-N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide
(2R,3R)-N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide
(1R,2R)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperazin-1-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide
(2R,3R)-N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide

[00474] In another embodiment of the methods described herein, the JAK-2 compounds described hereinabove [e.g., compounds of Formula I(J), II(J), III(J), IV(J), V(J), VI(J), and VII(J)] can also be combined with c-Met compounds (that are VEFGR, Flt3, Ret, and/or c-Met inhibitors) of Formula **I(V4):**



I(V4)

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from -H, halogen, $-OR^3$, $-NO_2$, $-NH_2$, $-NR^3R^4$, and optionally substituted lower alkyl;

A^1 is selected from =N- and =C(H)-;

Z is -O- or $-NR^5$-;

Ar is either a group of Formula **II**, or of Formula **III**,



II



III

wherein,

R^2 is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, and optionally substituted lower alkyl;

q is 0 to 4;

G is selected from:

		
		
		
		
		
		
		
		



each E is selected from -O-, -N(R^{13})-, -CH_2-, and -S(O)$_{0-2}$-;

M is selected from -O-, -N(R^{13})-, -CH_2-, and -C(=O)N(R^{13})-;

each V is independently either =N- or =C(H)-;

each methylene in any of the above Formulae is independently optionally substituted with one or two R^{25};

R^{25} is selected from halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted aryl, optionally substituted arylalkyl, heteroarylalkyl, and optionally substituted lower alkyl; or two of R^{25}, together with the carbon or carbons to which they are attached, can combine to form a three- to seven-membered alicyclic or heteroalicyclic; or two of R^{25} on a single carbon can be oxo;

J is selected from $-S(O)_{0-2}-$, -O-, and $-NR^{15}-$;

R^3 is -H or R^4;

R^4 is selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or

R^3 and R^4, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional annular heteroatom selected from N, O, S, and P;

A^2 and A^3 are each independently selected from =N- and $=C(R^2)-$;

R^5 is -H or optionally substituted lower alkyl;

D is selected from -O-, $-S(O)_{0-2}-$, and $-NR^{15}-$;

R^{50} is R^3;

R^{13} is selected from -H, $-C(=O)R^3$, $-C(=O)OR^3$, $-C(=O)SR^3$, $-SO_2R^4$, $-C(=O)N(R^3)R^3$, and optionally substituted lower alkyl; or, two R^{13}, together with the atom or atoms to which they are attached, can combine to form a heteroalicyclic optionally substituted with between one and four of R^{60}, said heteroalicyclic can have up to four annular heteroatoms, and said heteroalicyclic can have an aryl or heteroaryl fused thereto, in which case said aryl or heteroaryl is optionally substituted with an additional one to four of R^{60};

R^{14} is selected from -H, $-NO_2$, $-NH_2$, $-N(R^3)R^4$, -CN, $-OR^3$, optionally substituted lower alkyl, optionally substituted heteroalicyclylalkyl, optionally substituted aryl, optionally substituted arylalkyl and optionally substituted heteroalicyclic;

R^{15} is a group $-M^1-M^2$, wherein M^1 is selected from absent, $-C(=S)N(R^{13})-$, $-C(=NR^{14})N(R^{13})-$, $-SO_2N(R^{13})-$, $-SO_2-$, $-C(=O)N(R^{13})-$, $-C(=O)C(=O)N(R^{13})-$;

$-C_{0-4}$alkylene-, -C(=O)-, and an optionally substituted four to six-membered hetercyclyl annular containing between one and three heteratoms including at least one nitrogen; and M^2 is selected from -H, $-C_{0-6}$alkyl, alkoxy, $-C(=O)C_{0-4}$alkylQ, $-C_{0-4}$alkylQ, $-OC_{0-4}$alkylQ-, $-N(R^{13})C_{0-4}$alkylQ-, and $-C(=O)N(R^{13})C_{0-4}$alkylQ; and

Q is a five- to ten-membered ring system, optionally substituted with between zero and four of R^{20};

R^{20} is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, and optionally substituted lower alkyl; and

R^{60} is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroarylalkyl, and optionally substituted arylalkyl; or, two of R^{60}, when attached to a non-aromatic carbon, can be oxo;

with the proviso that the conditions of:

Z is-O-; and

Ar is according to Formula **II**; and

the portion of G directly attached to Ar selected from the table below:

		
		



are not met at the same time; and

with the proviso that when Ar is phenylene or substituted phenylene and Z is -O-, then the portion of G directly attached to Ar cannot contain  , wherein R^{70} is selected from -H, C_{1-4}alkyl, and C_{1-4}alkoxyl.

[00475] In another embodiment of the compound of Formula I(V4), Ar is according to one of Formula **IIa**, **IIb**, and **IIIa**:



IIa



IIb



IIIa .

[00476] In another embodiment of the compound of Formula I(V4), A^1 is =C(H)-.

[00477] In another embodiment of the compound of Formula I(V4), Ar is of Formula IIa and A^1 is =N-.

[00478] In another embodiment of the compound of Formula I(V4), D is -O- and R^1 is $-OR^3$.

[00479] In another embodiment of the compound of Formula I(V4), $-O-R^{50}$ and R^1 are interchangeably located at the 6-position and 7-position of the quinazoline or quinoline according to Formula **I**.

[00480] In another embodiment of the compound of Formula I(V4), R^1 is -OH or $-OC_{1-6}$alkyl.

[00481] In another embodiment of the compound of Formula I(V4), G is selected from:


,

,

,

,

,

,

5


,

,

,

and

,

wherein Q, R^{13}, E, and R^{60} are as defined above; each methylene in any of the above Formulae, other than those in a depicted ring, is independently optionally substituted with one or two R^{25}; and R^{25} is selected from halogen, trihalomethyl, oxo, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted aryl, optionally substituted arylalkyl, heteroarylalkyl, and optionally substituted lower alkyl; or two of R^{25}, together with the carbon or carbons to which they are attached, can combine to form a three- to seven-membered alicyclic or heteroalicyclic.

[00482] In another embodiment of the compound of Formula I(V4), Q is selected from:



wherein R^{20} is defined as above, and P is a five- to seven-membered ring, including the two shared carbons of the aromatic ring to which P is fused, P optionally containing between one and three heteroatoms.

[00483] In another embodiment of the compound of Formula I(V4), Ar is according to Formula **IIb**, and G is selected from:



wherein Q, R^{13}, E, and R^{60} are as defined above, and each methylene in any of the above Formulae, other than those depicted in a ring, is independently optionally substituted with

one or two R^{25}; and R^{25} is selected from halogen, trihalomethyl, oxo, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted aryl, optionally substituted arylalkyl, heteroarylalkyl, and optionally substituted lower alkyl; or two of R^{25}, together with the carbon or carbons to which they are attached, can combine to form a three- to seven-membered alicyclic or heteroalicyclic..

[00484] In another embodiment of the compound of Formula I(V4), the methylene between the two carbonyls of G is di-substituted with either optionally substituted lower alkyl, or an optionally substituted spirocycle.

[00485] In another embodiment of the compound of Formula I(V4), R^{50} is a heteroalicylic or a C_{1-6}alkyl-heteroalicylic.

[00486] In another embodiment of the compound of Formula I(V4), at least one of R^2 is halogen.

[00487] In another embodiment, the compound of Formula I(V4) is selected from one or more of the following compounds, or a pharmaceutically acceptable salt thereof:

Name
1-(4-{[6,7-bis (methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-3-(phenylmethyl)imidazolidin-2-one
1-(4-{[6,7-bis (methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl) 3-(phenylacetyl) imidazolidin-2-one
N-{[(4-{[6,7-bis(methyloxy) quinazolin-4-yl]amino}-3-fluorophenyl)amino] carbonothioyl}-2-phenylacetamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-1-phenylmethanesulfonamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-2-phenylethanesulfonamide
4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}-3-fluoro-N-methyl-N-(phenylmethyl) benzenesulfonamide
4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}-3-fluoro-N-methyl-N-(2-phenylethyl) benzenesulfonamide

Name
1-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}-3-fluorophenyl)pyrrolidin-2-one
4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl (2-phenylethyl)carbamate
4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}-3-fluoro-N-[2-(phenyloxy)ethyl] benzenesulfonamide
N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}-3-fluorophenyl)-3-phenylpropane-1-sulfonamide
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-2-phenylacetamide
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-1,3-benzothiazol-2-amine
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-1,3-benzothiazol-2-yl)-2-phenylacetamide
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-(phenylmethyl)glycinamide
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-1,3-benzothiazol-2-yl)-2-phenylacetamide
N1-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-N2-(phenylmethyl)glycinamide
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-3-phenylpropanamide
N1-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-N2-methyl-N2-(phenylmethyl)glycinamide
4-[(2-amino-1,3-benzothiazol-6-yl)oxy]-6,7-bis(methyloxy)-1-(2-oxo-2-phenylethyl) Quinolinium
N-{[(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)amino]carbonothioyl}-2-phenylacetamide
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-(trifluoroacetyl)glycinamide
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-N'-(4-fluorophenyl)propanediamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N,N'-bis(2-phenylethyl)sulfamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-[2-hydroxy-1-(phenylmethyl)ethyl]urea
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-3-oxo-4-phenylbutanamide
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-N-[2-(phenyloxy)ethyl]-1,3-benzothiazol-2-amine

Name
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-N-methyl-N-(2-phenylethyl)-1,3-benzothiazol-2-amine
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-N-{[3-(trifluoromethyl)phenyl] methyl}-1,3-benzothiazol-2-amine
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-[3-(trifluoromethyl) phenyl]propanediamide
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-{[3-(trifluoromethyl) phenyl]methyl}glycinamide
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-{2-[3-(trifluoromethyl) phenyl]ethyl}glycinamide
N1-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N2-(phenylmethyl) Glycinamide
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-1,3-benzothiazol-2-yl)-2-[2-chloro-5-(trifluoromethyl) phenyl]acetamide
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-methyl-N2-{2-[3-(trifluoromethyl) phenyl]ethyl}glycinamide
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-4-(phenylmethyl)imidazolidin-2-one
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-(2-chlorophenyl) Propanediamide
N1-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N2-methyl-N2-(phenylmethyl)glycinamide
(2E)-N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-2-[(methyloxy)imino] Propanamide
(2E)-N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-2-{[(phenylmethyl)oxy]imino} Propanamide
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-3-[(4-methylphenyl)sulfonyl]-4-(phenylmethyl)imidazolidin-2-one
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-4-(phenylmethyl)-4,5-dihydro-1,3-oxazol-2-amine

Name
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-4-(phenylmethyl)piperazin-2-one
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N2-methyl-N2-(phenylmethyl) Alaninamide
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N2-methyl-N2-(phenylmethyl) Leucinamide
4-benzyl-1-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-tetrahydro-pyrimidin-2-one
N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-2-phenoxyimino-propionamide
4-[4-(4-Benzyl-piperidin-1-yl)-phenoxy]-6,7-dimethoxy-quinoline
N-{5-Chloro-6-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-pyridin-3-yl}-N'-(4-fluoro-phenyl)-malonamide
N-[5-Chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-2,2-difluoro-N'-(4-fluoro-phenyl)-malonamide
N-[5-Chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-N'-(4-fluoro-phenyl)-N'-methyl-malonamide
N-{5-Chloro-6-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-pyridin-3-yl}-N'-(4-fluoro-phenyl)-malonamide
N-[5-Chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-N'-(3-fluoro-phenyl)-malonamide
N-[5-Chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-N'-(4-fluoro-phenyl)-2,2-dimethyl-malonamide

[00488] In another embodiment of the methods described herein, the JAK-2 compounds described hereinabove [e.g., compounds of Formula I(J), II(J), III(J), IV(J), V(J), VI(J), and VII(J)] can also be combined with c-MET compounds (that are VEFGR, Flt3, Ret, and/or c-Met inhibitors) of Formula A-B-C (version 4), or a pharmaceutically acceptable salt thereof, wherein:

A is selected from:



B is selected from:



C is selected from:





wherein:

R^2 is selected from -H, halogen, trihalomethyl, -CN, $-NH_2$, $-NO_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, and optionally substituted lower alkyl;

q is 0 to 2;

each R^3 is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted arylalkyl, and optionally substituted heteroarylalkyl; or, two R^3, together with the nitrogen to which they are attached, form a four- to seven-membered heteroalicyclic, said four- to seven-membered heteroalicyclic optionally containing one additional heteroatom; when one said additional heteroatom is a nitrogen, then said nitrogen is optionally substituted with a group selected from -H, trihalomethyl, $-SO_2R^5$, $-SO_2NR^5R^5$, $-CO_2R^5$, $-C(O)NR^5R^5$, $-C(O)R^5$, and optionally substituted lower alkyl;

each R^{35} is independently selected from -H, $-C(=O)R^3$, $-C(=O)OR^3$, $-C(=O)SR^3$, $-SO_2R^3$, $-C(=O)N(R^3)R^3$, and optionally substituted lower alkyl; or, two R^{35}, together with the nitrogen to which they are attached, can combine to form a heteroalicyclic optionally substituted with between one and four of R^{60}, said heteroalicyclic may have an additional annular heteroatom, and said heteroalicyclic may have an aryl fused thereto, said aryl optionally substituted with an additional one to four of R^{60};

A^1 is selected from =N- and =C(H)-;

A^2 is either =N- or =C(H)-;

R^5 is -H or optionally substituted lower alkyl;

R^8 is selected from R^3, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-SO_2R^3$, and $-C(O)R^3$, or an R^8 is absent and the alkylene linker of A is covalently bonded to the nitrogen atom in which R^8 is absent;

E^1 is selected from -O-, $-CH_2-$, $-N(R^5)-$, and $-S(O)_{0-2}-$;

Q is a five- to ten-membered ring system, optionally substituted with between zero and four of R^{20};

R^{20} is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, and optionally substituted lower alkyl;

R^{60} is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroarylalkyl, and optionally substituted arylalkyl; or, two of R^{60}, when attached to a non-aromatic carbon, can be oxo;

each methylene in any of the above Formulae is independently optionally substituted with one or two R^{25}; and

each R^{25} is independently selected from halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted aryl, optionally substituted arylalkyl, heteroarylalkyl, and optionally substituted lower alkyl; or two of R^{25}, together with the carbon or carbons to which they are attached, can combine to form a three- to seven-membered alicyclic or heteroalicyclic; or two of R^{25} on a single carbon can be oxo;

with the proviso that the conditions of:

C contains 

; and

the remaining portion of C contains one of:



are not met at the same time; and

with the proviso that when C contains  directly attached to  and R^{70} is selected from -H, C_{1-4}alkyl, and C_{1-4}alkoxyl, then A^2 is N.

[00489] In another embodiment of the compound of Formula A-B-C (version 4), Q is selected from phenyl, napthyl, 1,2,3,4-tetrahydronaphthyl, indanyl, benzodioxanyl, benzofuranyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroisoquinolyl, pyrrolyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, tetrahydropyridinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolinyl, oxazolidinyl, triazolyl, isoxazolyl, isoxazolidinyl, thiazolyl, thiazolinyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl, quinolyl, isoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, benzothieliyl, and oxadiazolyl; each optionally substituted with between one and four of R^{20}; wherein each R^{20} is independently selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$,

$-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, and optionally substituted lower alkyl.

[00490] In another embodiment of the compound of Formula A-B-C (version 4), B is:



or



wherein A^1 is either =N- or =C(H)-.

[00491] In another embodiment of the compound of Formula A-B-C (version 4), B is



.

[00492] In another embodiment of the compound of Formula A-B-C (version 4), C is selected from:



,



,



,



,



,



,


,

,

,


and


.

[00493] In another embodiment of the compound of Formula A-B-C (version 4), R^2 is selected from halogen, trihalomethyl, -CN, $-NO_2$, $-OR^3$, $-NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, and optionally substituted lower alkyl.

[00494] In another embodiment of the compound of Formula A-B-C (version 4), R^2 is halogen.

[00495] In another embodiment of the compound of Formula A-B-C (version 4), R^2 is fluorine or chlorine.

[00496] In another embodiment of the compound of Formula A-B-C (version 4), the compound is according to Formula **XI(V4)**,



XI

or a pharmaceutically acceptable salt thereof, wherein:

each R^1 is independently selected from halogen, $-OR^3$, $-NO_2$, $-NH_2$, $-NR^3R^4$, -D-R^{50} and optionally substituted C_{1-6}alkyl;

Q is =N-, or =C(H)-;

Z is -O- or $-NR^5$-;

Ar is either a five- or six-membered arylene or a five- or six-membered heteroarylene containing between one and three heteroatoms;

G is either an optionally substituted cycloalkyl or an optionally substituted heteroalicyclic;

each R^2 is independently selected from halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, and optionally substituted C_{1-6}alkyl;

each R^3 is independently -H or R^4;

each R^4 is independently selected from optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl; or

R^3 and R^4, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional annular heteroatom selected from N, O, S, and P;

R^5 is -H or optionally substituted C_{1-6}alkyl;

each D is independently selected from $-O-$, $-S(O)_{0-2}-$, and $-NR^5-$;

each R^{30} is independently selected from halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, and optionally substituted C_{1-6}alkyl;

each R^{50} is R^3; and

R^{70} is selected from -H, halogen, $-OR^3$, $-S(O)_{0-2}R^3$, $-NO_2$, $-NH_2$, $-NR^3R^4$, and optionally substituted C_{1-6}alkyl.

[00497] In another embodiment of the compound of Formula **XI(V4)**, R^{70} = H.

[00498] In another embodiment of the compound of Formula **XI(V4)**, at least one of R^1 is $-D-R^{50}$.

[00499] In another embodiment of the compound of Formula **XI(V4)**, D is -O- and at least one other R^1 is $-OR^3$.

[00500] In another embodiment of the compound of Formula A-B-C (version 4), the compound is according to Formula **XIIIa(V4)** or **XIIIb(V4)**:



XIIIa(V4)



XIIIb(V4)

or a pharmaceutically acceptable salt thereof, wherein Q^1 is either =N- or =C(H)-, R^{3a} is C_{1-6}alkyl, and -N(R^{3b})R^4 is selected from the following:



wherein:

J is a five- to ten-membered ring, optionally substituted with between zero and five of R^{20}, wherein each R^{20} is independently selected from -H, halogen, trihalomethyl, -CN, -NO_2, -NH_2, -OR^3, -NR^3R^4, -$S(O)_{0-2}R^3$, -$SO_2NR^3R^3$, -CO_2R^3, -$C(O)NR^3R^3$, -$N(R^3)SO_2R^3$, -$N(R^3)C(O)R^3$, -$N(R^3)CO_2R^3$, -$C(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl; or two of R^{20}, together with the atom or atoms to which they are attached, combine to form an optionally substituted three- to seven-membered heteroalicyclic, said optionally substituted three- to seven-membered heteroalicyclic either spiro- to J or fused to J;

E is selected from -O-, -N(R^5)-, -CH_2-, and -$S(O)_{0-2}$-;

each R^{60} is independently selected from halogen, trihalomethyl, -CN, -NO_2, -NH_2, -OR^3, -NR^3R^4, -$S(O)_{0-2}R^3$, -$SO_2NR^3R^3$, -CO_2R^3, -$C(O)NR^3R^3$, -$N(R^3)SO_2R^3$, -$N(R^3)C(O)R^3$, -$N(R^3)CO_2R^3$, -$C(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted heteroaryl C_{1-6}alkyl, and optionally substituted aryl C_{1-6}alkyl;

each methylene in any of the above Formulae, other than those in a depicted ring, is independently optionally substituted with one or two R^{25};

R^{25} is selected from halogen, trihalomethyl, oxo, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, heteroaryl C_{1-6}alkyl, and optionally substituted C_{1-6}alkyl; or two of R^{25}, together with the carbon or carbons to which they are attached, can combine to form a three- to seven-membered alicyclic or heteroalicyclic; and

R^{3b} has the same meaning as R^3.

[00501] In another embodiment of the compound of Formula **XIIIa(V3)** or **XIIIb(V3)**, R^{50} is selected from C_{1-6}alkyl optionally substituted with at least one of optionally substituted amino, optionally substituted C_{1-6}alkyl amino, optionally substituted C_{1-6}dialkyl amino, optionally substituted heteroalicylic, and a group of Formula **XII**.

[00502] In another embodiment of the compound of Formula **XIIIa(V3)** or **XIIIb(V3)**, G is selected from cyclopropyl, aziradine, cyclobutyl, and azetidine, each optionally substituted with between zero and four of R^{30}.

[00503] In another embodiment of the compound of Formula **XIIIa(V3)** or **XIIIb(V3)**, R^2 is selected from -H, halogen, C_{1-6} alkyl and perfluoro C_{1-6} alkyl.

[00504] In another embodiment of the compound of Formula **XIIIa(V3)** or **XIIIb(V3)**, $(R^{30})_{0-4}$ is $(R^{30})_0$ or methyl.

[00505] In another embodiment of the compound of Formula A-B-C (version 4), the compound is according to Formula **XIVa(V4)** or **XIVb(V4)**:



XIVa(V4)



XIVb(V4)

or a pharmaceutically acceptable salt thereof, wherein R^{50} is unsubstituted C_{1-6}alkyl.

[00506] In another embodiment of the compound of Formula **XIVa(V4)** or **XIVb(V4)**, Q is -CH=.

[00507] In another embodiment of the compound of Formula **XIVa(V4)** or **XIVb(V4)**, $(R^{30})_{0-4} = (R^{30})_0$ or methyl.

[00508] In another embodiment of the compound of Formula **XIVa(V4)** or **XIVb(V4)**, R^2 is selected from C_{1-6} alkyl, perfluoro C_{1-6} alkyl, hydrogen, and halogen.

[00509] In another embodiment of the compound of Formula **XIVa(V4)** or **XIVb(V4)**, R^2 is hydrogen.

[00510] In another embodiment of the compound of Formula **XIVa(V4)** or **XIVb(V4)**, R^2 is halogen.

[00511] In another embodiment of the compound of Formula **XIVa(V4)** or **XIVb(V4)**, R^{20} is selected from halogen, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl, and (two of R^{20}) together with the atom or atoms to which they are attached, an optionally substituted three- to six-membered heteroalicyclic, said optionally substituted three- to six-membered heteroalicyclic fused to the phenyl as in **XIVa(V4)** or **XIVb(V4)**.

[00512] In another embodiment of the compound of Formula **XIVa(V4)** or **XIVb(V4)**, R^{20} is selected from halogen, $-NR^3R^4$, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl, and (two of R^{20}) together with the atom or atoms to which they are attached, an optionally substituted five- to six-membered heteroalicyclic, said optionally substituted five- to six-membered heteroalicyclic fused to the phenyl as in **XIVa(V4)** or **XIVb(V4)**.

[00513] In another embodiment of the compound of Formula **XIVa(V4)** or **XIVb(V4)**, R^2 is selected from C_{1-6} alkyl, perfluoro C_{1-6} alkyl, and halogen.

[00514] In another embodiment of the compound of Formula **XIVa(V4)** or **XIVb(V4)**, R^2 is selected from perfluoro C_{1-3} alkyl and halogen.

[00515] In another embodiment, the compounds of Formula A-B-C (version 4) is selected from one or more of the following compounds, or a pharmaceutically acceptable salt thereof:

N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-(4-fluorophenyl) Cyclopropane-1,1-dicarboxamide
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-(4-fluorophenyl) cyclobutane-1,1-dicarboxamide
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-(phenylmethyl) cyclopropane-1,1-dicarboxamide
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-phenylcyclopropane-1,1-dicarboxamide
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-(2-phenylethyl) cyclopropane-1,1-dicarboxamide
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2-methylpyridin-3-yl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
N-{4-[(7-chloroquinolin-4-yl)oxy]-3-fluorophenyl} -N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
N-{4-[(7-chloroquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinazolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy) quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2-methylphenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloro-2-methylpyridin-3-yl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide

N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3,5-difluorophenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2,5-difluorophenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2,3,5-trifluorophenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-2-methylphenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2-chloro-5-methylphenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
N-(3-fluoro-4-{[6-hydroxy-7-(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2-chloro-5-fluorophenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy)-2-(methylthio)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
N-(4-fluorophenyl)-N'-(4-{[2-methyl-6,7-bis(methyloxy)quinazolin-4-yl]oxy}phenyl) cyclopropane-1,1-dicarboxamide
N-(4-{[2-amino-6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
N-(3-fluoro-4-{[2-(methylamino)-6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)-1-(phenylmethyl)azetidine-3,3-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)azetidine-3,3-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[(4-fluorophenyl)methyl] cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(2-morpholin-4-ylethyl)cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[2-(piperidin-1-ylmethyl)phenyl] cyclopropane-1,1-dicarboxamide

N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[2-(pyrrolidin-1-ylmethyl) phenyl]cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[3-(morpholin-4-ylmethyl) phenyl]cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[2-(morpholin-4-ylmethyl) phenyl]cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-phenylcyclopropane-1,1-dicarboxamide
N-[3-(aminomethyl) phenyl]-N'-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl) cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[3-(piperidin-1-ylmethyl)phenyl] cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[3-(pyrrolidin-1-ylmethyl)phenyl] cyclopropane-1,1-dicarboxamide

[00516] In another embodiment of the methods described herein, the JAK-2 compounds described hereinabove [e.g., compounds of Formula I(J), II(J), III(J), IV(J), V(J), VI(J), and VII(J)] can also be combined with c-Met compounds (that are VEFGR, Flt3, c-Kit, and/or c-Met inhibitors) of Formula **I(V5):**

:



I(V5)

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from -H, halogen, $-OR^3$, $-NO_2$, $-NH_2$, $-NR^3R^4$, and optionally substituted lower alkyl;

A^1 is selected from =N- and =C(H)-;

Z is -O-;

Ar is either a group of Formula **II**, or of Formula **III**,



II



III

wherein:

R^2 is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, and optionally substituted lower alkyl;

q is 0 to 4;

G is selected from one of the following:



,



,



,



,

and



;

each E is selected from -O-, $-N(R^{13})-$, $-CH_2-$, and $-S(O)_{0-2}-$;

each methylene in any of the above Formulae is independently optionally substituted with one or two R^{25};

R^{25} is selected from halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted aryl, optionally substituted arylalkyl,

heteroarylalkyl, and optionally substituted lower alkyl; two of R^{25}, together with the carbon or carbons to which they are attached, can combine to form a three- to seven-membered alicyclic or heteroalicyclic, or, two of R^{25} on a single carbon can be oxo;

J is selected from $-S(O)_{0-2}-$, -O-, and $-NR^{15}-$;

R^3 is -H or R^4;

R^4 is selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or, R^3 and R^4, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional annular heteroatom selected from N, O, S, and P;

A^2 and A^3 are each independently selected from =N- and $=C(R^2)-$;

D is selected from -O-, $-S(O)_{0-2}-$, and $-NR^{15}-$;

R^{50} is R^3;

R^{13} is selected from -H, $-C(=O)R^3$, $-C(=O)OR^3$, $-C(=O)SR^3$, $-SO_2R^4$, $-C(=O)N(R^3)R^3$, and optionally substituted lower alkyl, or two R^{13}, together with the atom or atoms to which they are attached, can combine to form a heteroalicyclic optionally substituted with between one and four of R^{60}, said heteroalicyclic can have up to four annular heteroatoms, and said heteroalicyclic can have an aryl or heteroaryl fused thereto, in which case said aryl or heteroaryl is optionally substituted with an additional one to four of R^{60};

R^{14} is selected from -H, $-NO_2$, $-NH_2$, $-N(R^3)R^4$, -CN, $-OR^3$, optionally substituted lower alkyl, optionally substituted heteroalicyclylalkyl, optionally substituted aryl, optionally substituted arylalkyl and optionally substituted heteroalicyclic;

R^{15} is a group $-M^1-M^2$, wherein M^1 is selected from absent, $-C(=S)N(R^{13})-$, $-C(=NR^{14})N(R^{13})-$, $-SO_2N(R^{13})-$, $-SO_2-$, $-C(=O)N(R^{13})-$, $-C(=O)C(=O)N(R^{13})-$, $-C_{0-4}$alkylene-, -C(=O)-, and an optionally substituted four to six-membered hetercyclyl annular containing between one and three heteratoms including at least one nitrogen; and

M^2 is selected from -H, -C_{0-6}alkyl, alkoxy, -C(=O)C_{0-4}alkylQ, -C_{0-4}alkylQ, -OC_{0-4}alkylQ-, -N(R^{13})C_{0-4}alkylQ-, and -C(=O)N(R^{13})C_{0-4}alkylQ;

Q is a five- to ten-membered ring system, optionally substituted with between zero and four of R^{20};

R^{20} is selected from -H, halogen, trihalomethyl, -CN, -NO_2, -NH_2, -OR^3, -NR^3R^4, -$S(O)_{0-2}R^3$, -$SO_2NR^3R^3$, -CO_2R^3, -C(O)NR^3R^3, -N(R^3)SO_2R^3, -N(R^3)C(O)R^3, -N(R^3)CO_2R^3, -C(O)R^3, and optionally substituted lower alkyl; and

R^{60} is selected from -H, halogen, trihalomethyl, -CN, -NO_2, -NH_2, -OR^3, -NR^3R^4, -$S(O)_{0-2}R^3$, -$SO_2NR^3R^3$, -CO_2R^3, -C(O)NR^3R^3, -N(R^3)SO_2R^3, -N(R^3)C(O)R^3, -N(R^3)CO_2R^3, -C(O)R^3, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroarylalkyl, and optionally substituted arylalkyl; or, two of R^{60}, when attached to a non-aromatic carbon, can be oxo.

[00517] In another embodiment of the compound of Formula I(V5), Ar is according to one of Formula **IIa**, **IIb**, and **IIIa:**



IIa



IIb



IIIa

[00518] In another embodiment of the compound of Formula I(V5), A^1 is =C(H)-.

[00519] In another embodiment of the compound of Formula I(V5), Ar is of Formula IIa and A^1 is =N-.

[00520] In another embodiment of the compound of Formula I(V5), D is -O- and R^1 is -OR^3.

[00521] In another embodiment of the compound of Formula I(V5), -O-R^{50} and R^1 are interchangeably located at the 6-position and 7-position of the quinazoline or quinoline according to Formula **I**.

[00522] In another embodiment of the compound of Formula I(V5), R^1 is -OH or -OC_{1-6}alkyl.

[00523] In another embodiment of the compound of Formula I(V5), G is selected from:



wherein Q, R^{20}, R^{13}, E, and R^{60} are as defined above; each methylene in any of the above Formulae, other than those in a depicted ring, is independently optionally substituted with R^{25}; and R^{25} is selected from halogen, trihalomethyl, oxo, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted aryl, optionally substituted arylalkyl, heteroarylalkyl, and optionally substituted lower alkyl; two of R^{25}, together with the carbon or carbons to which they are attached, can combine to form a three- to seven-membered alicyclic or heteroalicyclic.

[00524] In another embodiment of the compound of Formula I(V5), Q is selected from:



wherein R^{20} is defined as above, and P is a five- to seven-membered ring, including the two shared carbons of the aromatic ring to which P is fused, P optionally containing between one and three heteroatoms.

[00525] In another embodiment of the compound of Formula I(V5), Ar is according to Formula **IIa**, and G is selected from:



wherein Q, R^{20}, R^{13}, E, and R^{60} are as defined above, and each methylene in any of the above Formulae, other than those in a depicted ring, is independently optionally substituted with R^{25}; and R^{25} is selected from halogen, trihalomethyl, oxo, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^4$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted aryl, optionally substituted arylalkyl, heteroarylalkyl, and optionally substituted lower alkyl; two of R^{25}, together with the carbon or carbons to which they are attached, can combine to form a three- to seven-membered alicyclic or heteroalicyclic.

[00526] In another embodiment of the compound of Formula I(V5), R^{50} is a heteroalicyclic or a C_{1-6}alkyl-heteroalicylic.

[00527] In another embodiment of the compound of Formula I(V5), at least one of R^2 is halogen.

[00528] In another embodiment, the compound of Formula I(V5) is selected from one or more of the following compounds, or a pharmaceutically acceptable salt thereof:

ethyl [(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl) amino](oxo)acetate
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(phenylmethyl)ethanediamide

N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(2-phenylethyl)ethanediamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-phenylethanediamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(2-morpholin-4-ylethyl)ethanediamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-{2-[4-(methyloxy) phenyl]ethyl}ethanediamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(2,3-dihydro-1H-inden-1-yl)ethanediamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(2,3-dihydro-1H-inden-2-yl)ethanediamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(1,2,3,4-tetrahydronaphthalen-1-yl)ethanediamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-[(2S)-1,2,3,4-tetrahydronaphthalen-2-yl]ethanediamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-[2-(4-methylphenyl) ethyl]ethanediamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(2-phenylpropyl) Ethanediamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-[2-(4-chlorophenyl) ethyl]ethanediamide
ethyl [(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)amino](oxo)acetate
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-(2-phenylethyl) Ethanediamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(1,2,3,4-tetrahydronaphthalen-2-yl)ethanediamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-[2-(1-methylpyrrolidin-2-yl)ethyl]ethanediamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-[2-(phenyloxy) ethyl]ethanediamide
N'-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N-methyl-N-(2-phenylethyl) Ethanediamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-{[3-(trifluoromethyl) phenyl]methyl}ethanediamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-{2-[3-(trifluoromethyl) phenyl]ethyl}ethanediamide

N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1-methylpiperidin-4-yl)methyl]oxy}quinolin-4-yl)oxy]phenyl}-N'-(2-phenylethyl)ethanediamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(1,2,3,4-tetrahydroisoquinolin-1-ylmethyl)ethanediamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-[(2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]ethanediamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-phenethyl-oxalamide
N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-N'-(2-isopropyl-1,2,3,4-tetrahydro-isoquinolin-1-ylmethyl)-oxalamide
N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-N'-(2-ethyl-1,2,3,4-tetrahydro-isoquinolin-1-ylmethyl)-oxalamide
N-{4-[7-(3-Diethylamino-propoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-N'-phenethyl-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-N'-phenethyl-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)-quinolin-4-yloxy]-phenyl}-N'-phenethyl-oxalamide
N-{4-[7-(2-Diethylamino-ethoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-N'-phenethyl-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-methyl-N'-phenethyl-oxalamide
2-(3,4-Dihydro-1H-isoquinolin-2-yl)-N-{3-fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-2-oxo-acetamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-2-oxo-2-(3-phenyl-pyrrolidin-1-yl)-acetamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-2-oxo-2-(2-phenyl-morpholin-4-yl)-acetamide
N-(2-Dimethylamino-2-phenyl-ethyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-oxo-2-phenyl-ethyl)-oxalamide
N-Benzyl-N'-{3-fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(2-fluoro-phenyl)-ethyl]-oxalamide
N-[2-(3-Chloro-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(2-methoxy-phenyl)-ethyl]-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-pyridin-3-yl-ethyl)-oxalamide
N-Benzyl-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide

N-[2-(2,5-Dimethoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(2-trifluoromethyl-phenyl)-ethyl]-oxalamide
N-[2-(2-Ethoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[2-(2,4-Dimethyl-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1*S*-phenyl-2-p-tolyl-ethyl)-oxalamide
N-[2-(4-Chloro-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamic acid
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(3-fluoro-phenyl)-ethyl]-oxalamide
N-[2-(2-Chloro-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(3-methoxy-phenyl)-ethyl]-oxalamide
N-(1,2-Diphenyl-ethyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[2-(2,4-Dichloro-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[2-(3,4-Dimethoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[2-(4-Ethyl-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[2-(4-Ethoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[2-(4-Ethoxy-3-methoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(4-phenoxy-phenyl)-ethyl]-oxalamide
N-[2-(3-Ethoxy-4-methoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-pyridin-2-yl-ethyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-pyridin-4-yl-ethyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(4-fluoro-phenyl)-ethyl]-oxalamide
N-[2-(2-Bromo-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide

N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2*R*-phenyl-propyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-indan-1-yl-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-isobutyl-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(3-methyl-butyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2*R*-phenyl-propyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-phenyl-propyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-indan-2-yl-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1*R*-phenyl-ethyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1*S*-phenyl-ethyl)-oxalamide
N-[2-(3-Bromo-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[2-(2,6-Dichloro-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[2-(2,4-Dichloro-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-(2-Benzo[1,3]dioxol-5-yl-ethyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[2-(3-Bromo-4-methoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[2-(3,5-Dimethoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-o-tolyl-ethyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-m-tolyl-ethyl)-oxalamide
N-[2-(3-Ethoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[2-(3,4-Dimethyl-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[2-(2,5-Dimethyl-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[2-(3-Chloro-4-propoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[2-(4-Butoxy-3-chloro-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[2-(4-tert-Butyl-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide

N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(4-sulfamoyl-phenyl)-ethyl]-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(4-hydroxy-3-methoxy-phenyl)-ethyl]-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(3-hydroxy-4-methoxy-phenyl)-ethyl]-oxalamide
N-(2,4-Dichloro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(4-fluoro-2-trifluoromethyl-benzyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1-p-tolyl-ethyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(3-fluoro-4-trifluoromethyl-benzyl)-oxalamide
N-(3-Chloro-4-fluoro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[1-(3-methoxy-phenyl)-ethyl]-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1-naphthalen-2-yl-ethyl)-oxalamide
N-(4-Chloro-3-trifluoromethyl-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1-p-tolyl-ethyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(6-trifluoromethyl-pyridin-3-ylmethyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-methyl-benzyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(3-methyl-benzyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(4-fluoro-3-trifluoromethyl-benzyl)-oxalamide
N-(3,5-Dichloro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1R,2,3,4-tetrahydro-naphthalen-1-yl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1S,2,3,4-tetrahydro-naphthalen-1-yl)-oxalamide
N-Cyclopentyl-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[1-(4-Bromo-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-(2-Fluoro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[2-(3,4-Dichloro-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide

N-(4-Fluoro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-(2,3-Difluoro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-phenoxy-ethyl)-oxalamide
N-(2,2-Diphenyl-ethyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(4-methoxy-phenyl)-ethyl]-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-phenyl-propyl)-oxalamide
N-[2-(4-Bromo-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{4-[7-(1-Ethyl-piperidin-4-ylmethoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-2-oxo-2-(2-phenyl-morpholin-4-yl)-acetamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(3-fluoro-5-trifluoromethyl-benzyl)-oxalamide
N-(3,5-Difluoro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-(2-Chloro-5-trifluoromethyl-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-N'-(2-dimethylamino-2-phenyl-ethyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(4-methoxy-benzyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(4-trifluoromethyl-benzyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(3-methoxy-benzyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(3-trifluoromethyl-benzyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(3-trifluoromethoxy-benzyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-methoxy-benzyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-trifluoromethyl-benzyl)-oxalamide
N-(3-Chloro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-trifluoromethoxy-benzyl)-oxalamide
N-(2-Chloro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(4-trifluoromethoxy-benzyl)-oxalamide

N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(4-methoxy-benzyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(4-trifluoromethyl-benzyl)-oxalamide
N-{4-[7-(Azetidin-3-ylmethoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-N'-phenethyl-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-azetidin-3-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-phenethyl-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-hydroxy-2-phenyl-ethyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1R-phenyl-propyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1R-phenyl-propyl)-oxalamide
N-(3,4-Difluoro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-(2,6-Difluoro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(4-fluoro-phenyl)-ethyl]-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-phenyl-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(3-fluoro-phenyl)-oxalamide
N-(4-Chloro-3-fluoro-phenyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-(3,4-Dimethoxy-phenyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(3-methyl-butyl)-oxalamide
N-(3,3-Dimethyl-butyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-(4-Chloro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-(3,5-Dimethoxy-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-(4-Butyl-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-p-tolyl-ethyl)-oxalamide
N-(3,5-Bis-trifluoromethyl-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-pyrazin-2-ylmethyl-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-pyridin-2-ylmethyl-oxalamide

N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yloxy]-phenyl}-N'-phenethyl-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yloxy]-phenyl}-N'-phenethyl-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-fluoro-3-trifluoromethyl-benzyl)-oxalamide
N-[2-(2-Bromo-6-methoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[2-(3,4-Dimethoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N-methyl-oxalamide
N-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-fluoro-5-trifluoromethyl-benzyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[1-(4-fluoro-phenyl)-ethyl]-oxalamide
N-(1S-Benzyl-2-oxo-2-pyrrolidin-1-yl-ethyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-[2-(4-Amino-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
2-(4-Benzyl-piperidin-1-yl)-N-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-2-oxo-acetamide
N-Ethyl-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-isopropyl-oxalamide
N-Butyl-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-methoxy-ethyl)-oxalamide
N-Cyclopropylmethyl-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-morpholin-4-yl-ethyl)-oxalamide
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-2-oxo-2-pyrrolidin-1-yl-acetamide
N-Ethyl-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N-methyl-oxalamide

[00529] In another embodiment of the methods described herein, the JAK-2 compounds described hereinabove [e.g., compounds of Formula I(J), II(J), III(J), IV(J), V(J), VI(J), and VII(J)] can also be combined with c-Met compounds (that are VEFGR, Flt3 and/or c-

Met inhibitors) of Formula A-B-C (version 5), or a pharmaceutically acceptable salt thereof, wherein:

A is selected from:



and -R^3;

B is selected from:



; and

C is selected from:



;



,

wherein:

R^2 is selected from -H, halogen, trihalomethyl, -CN, -NH_2, -NO_2, -OR^3, -NR^3R^3, -$S(O)_{0-2}R^3$, -$SO_2NR^3R^3$, -CO_2R^3, -$C(O)NR^3R^3$, -$N(R^3)SO_2R^3$, -$N(R^3)C(O)R^3$, -$N(R^3)CO_2R^3$, -$C(O)R^3$, and optionally substituted lower alkyl;

q is 0 to 2;

each R^3 is independently selected from –H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted arylalkyl, and optionally substituted heteroarylalkyl; or, two R^3, together with the nitrogen to which they are attached, form a four- to seven-membered heteroalicyclic, said four- to seven-membered heteroalicyclic optionally containing one additional heteroatom; when one said additional heteroatom is a nitrogen, then said nitrogen is optionally substituted with a group selected from -H, trihalomethyl, $-SO_2R^5$, $-SO_2NR^5R^5$, $-CO_2R^5$, $-C(O)NR^5R^5$, $-C(O)R^5$, and optionally substituted lower alkyl;

each R^{35} is independently selected from -H, $-C(=O)R^3$, $-C(=O)OR^3$, $-C(=O)SR^3$, $-SO_2R^3$, $-C(=O)N(R^3)R^3$, and optionally substituted lower alkyl; or, two R^{35}, together with the nitrogen to which they are attached, can combine to form a heteroalicyclic optionally substituted with between one and four of R^{60}, said heteroalicyclic may have an additional annular heteroatom, and said heteroalicyclic may have an aryl fused thereto, said aryl optionally substituted with an additional one to four of R^{60};

A^1 is selected from =N- and =C(H)-;

A^2 is either =N- or =C(H)-;

R^5 is -H or optionally substituted lower alkyl;

R^8 is selected from R^3, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-SO_2R^3$, and $-C(O)R^3$, or wherein the A group contains at least one R^8, R^8 is absent and the alkylene linker is bonded to the corresponding nitrogen atom;

E^1 is selected from -O-, $-CH_2-$, $-N(R^5)-$, and $-S(O)_{0-2}-$;

Q is a five- to ten-membered ring system, optionally substituted with between zero and four of R^{20};

R^{20} is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, and optionally substituted lower alkyl;

R^{60} is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted lower alkyl, optionally substituted aryl,

optionally substituted heteroarylalkyl, and optionally substituted arylalkyl, or two of R^{60}, when attached to a non-aromatic carbon, can be oxo;

each methylene in any of the above Formulae is independently optionally substituted with one or two R^{25}; and

each R^{25} is independently selected from halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted aryl, optionally substituted arylalkyl, heteroarylalkyl, and optionally substituted lower alkyl; two of R^{25}, together with the carbon or carbons to which they are attached, can combine to form a three- to seven-membered alicyclic or heteroalicyclic; or, two of R^{25} on a single carbon can be oxo.

[00530] In another embodiment of the compound of Formula A-B-C (version 5), Q is selected from phenyl, napthyl, 1,2,3,4-tetrahydronaphthyl, indanyl, benzodioxanyl, benzofuranyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroisoquinolyl, pyrrolyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, tetrahydropyridinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolinyl, oxazolidinyl, triazolyl, isoxazolyl, isoxazolidinyl, thiazolyl, thiazolinyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl, quinolyl, isoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, benzothieliyl, and oxadiazolyl; each optionally substituted with between one and four of R^{20}; wherein each R^{20} is independently selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, and optionally substituted lower alkyl.

[00531] In another embodiment of the compound of Formula A-B-C (version 5), B is:



wherein A^1 is =N- or =C(H)-.

[00532] In another embodiment of the compound of Formula A-B-C (version 5), B is



[00533] In another embodiment of the compound of Formula A-B-C (version 5), C is selected from:


,

,

,

,

,

and

,

wherein E, R^2, R^3, R^5, R^{20} and R^{60} are as defined above.

[00534] In another embodiment of the compound of Formula A-B-C (version 5), C is



[00535] In another embodiment of the compound of Formula A-B-C (version 5), R^2 is selected from halogen, trihalomethyl, -CN, $-NO_2$, $-OR^3$, $-NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, and optionally substituted lower alkyl.

[00536] In another embodiment of the compound of Formula A-B-C (version 5), R^2 is halogen.

[00537] In another embodiment of the compound of Formula A-B-C (version 5), R^2 is either fluorine or chlorine.

[00538] In another embodiment of the compound of Formula A-B-C (version 5), R^2 is hydrogen.

Definitions for Compounds of Formulae I(V3), I(V4), I(V5), A-B-C (version 3), A-B-C (version 4) and A-B-C (version 5)

[00539] The following abbreviations and terms apply to compounds of Formulae I(V3), I(V4), I(V5), A-B-C (version 3), A-B-C (version 4) and A-B-C (version 5) described above only. These definitions are not to be considered when determining the scope and meaning of the JAK-2 compounds. To the same extent, the JAK-2 definitions are not to be considered when determining the scope and meaning of the compounds of Formulae I(V3), I(V4), I(V5), A-B-C (version 3), A-B-C (version 4) and A-B-C (version 5).

[00540] Some ring structures are depicted generically and will be described textually. For example, in the schematic below, if in the structure on the left, ring A is used to describe a "spirocyclyl," then if ring A is cyclopropyl, there are at most four hydrogens on ring A (when "R" can also be -H). In another example, as depicted on the right side of the schematic below, if ring B is used to describe a "phenylene" then there can be at most four hydrogens on ring B (assuming depicted cleaved bonds are not C-H bonds).

[00541] If a group "R" is depicted as "floating" on a ring system, as for example in the Formula:



then, unless otherwise defined, a substituent "R" may reside on any atom of the ring system, assuming replacement of a depicted, implied, or expressly defined hydrogen from one of the ring atoms, so long as a stable structure is formed.

[00542] If a group "R" is depicted as floating on a fused ring system, as for example in the Formulae:



then, unless otherwise defined, a substituent "R" may reside on any atom of the fused ring system, assuming replacement of a depicted (for example the -NH- in the Formula above), implied (for example as in the Formula above, where the hydrogens are not shown but understood to be present), or expressly defined hydrogen (for example where in the Formula above, "X" equals =CH-) from one of the ring atoms, so long as a stable structure is formed. In the example depicted, the "R" group may reside on either the 5-membered or the 6-membered ring of the fused ring system. In the Formula depicted above, when y is 2 for example, then the two "R's" may reside on any two atoms of the ring system, again assuming each replaces a depicted, implied, or expressly defined hydrogen on the ring.

[00543] When there are more than one such depicted "floating" groups, as for example in the Formulae:



where there are two groups, namely, the "R" and the bond indicating attachment to a parent structure; then, unless otherwise defined, the "floating" groups may reside on any atoms of the ring system, again assuming each replaces a depicted, implied, or expressly defined hydrogen on the ring.

[00544] When a group "R" is depicted as existing on a ring system containing saturated carbons, as for example in the Formula:



where, in this example, "y" can be more than one, assuming each replaces a currently depicted, implied, or expressly defined hydrogen on the ring; then, unless otherwise defined, where the resulting structure is stable, two "R's" may reside on the same carbon. A simple example is when R is a methyl group; there can exist a geminal dimethyl on a carbon of the depicted ring (an "annular" carbon). In another example, two R's on the same carbon, including that carbon, may form a ring, thus creating a spirocyclic ring (a "spirocyclyl" group) structure with the depicted ring as for example in the Formula:



[00545] "Alkyl" is intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof, inclusively. For example, "C_8 alkyl" may refer to an *n*-octyl, *iso*-octyl, cyclohexylethyl, and the like. Lower alkyl refers to alkyl groups of from one to six carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, *s*-butyl, *t*-butyl, isobutyl, pentyl, hexyl and the like. Higher alkyl refers to alkyl groups containing more that eight carbon atoms. Exemplary alkyl groups are those of C_{20} or below. Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of from three to thirteen carbon atoms. Examples of cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbornyl, adamantyl and the like. In this application, alkyl refers to alkanyl, alkenyl, and alkynyl residues (and combinations thereof); it is intended to include cyclohexylmethyl, vinyl, allyl, isoprenyl, and the like. Thus when an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be encompassed; thus, for example, either "butyl" or "C_4 alkyl" is meant to include *n*-butyl, *sec*-butyl, isobutyl, *t*-butyl, isobutenyl and but-2-

yne radicals; and for example, "propyl" or "C_3 alkyl" each include *n*-propyl, propenyl, and isopropyl.

[00546] "Alkylene" refers to straight or branched chain divalent radical consisting solely of carbon and hydrogen atoms, containing no unsaturation and having from one to ten carbon atoms, for example, methylene, ethylene, propylene, *n*-butylene and the like. Alkylene is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, fully saturated. Examples of alkylene include ethylene ($-CH_2CH_2-$), propylene ($-CH_2CH_2CH_2-$), dimethylpropylene ($-CH_2C(CH_3)_2CH_2-$), and cyclohexylpropylene ($-CH_2CH_2CH(C_6H_{13})$).

[00547] "Alkylidene" refers to a straight or branched chain unsaturated divalent radical consisting solely of carbon and hydrogen atoms, having from two to ten carbon atoms, for example, ethylidene, propylidene, *n*-butylidene, and the like. Alkylidene is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, double bond unsaturation. The unsaturation present includes at least one double bond.

[00548] "Alkylidyne" refers to a straight or branched chain unsaturated divalent radical consisting solely of carbon and hydrogen atoms having from two to ten carbon atoms, for example, propylid-2-ynyl, *n*-butylid-1-ynyl, and the like. Alkylidyne is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, triple bond unsaturation. The unsaturation present includes at least one triple bond.

[00549] Any of the above radicals, "alkylene," "alkylidene" and "alkylidyne," when optionally substituted, may contain alkyl substitution which itself contains unsaturation. For example, 2-(2-phenylethynyl-but-3-enyl)-naphthalene (IUPAC name) contains an *n*-butylid-3-ynyl radical with a vinyl substituent at the 2-position of said radical.

[00550] "Alkoxy" or "alkoxyl" refers to the group -O-alkyl, for example including from one to eight carbon atoms of a straight, branched, cyclic configuration, unsaturated chains, and combinations thereof attached to the parent structure through an oxygen atom. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to six carbons.

[00551] "Substituted alkoxy" refers to the group -O-(substituted alkyl), the substitution on the alkyl group generally containing more than only carbon (as defined by alkoxy). One exemplary substituted alkoxy group is "polyalkoxy" or -O-optionally substituted alkylene-optionally substituted alkoxy, and includes groups such as $-OCH_2CH_2OCH_3$, and glycol ethers such as polyethyleneglycol and $-O(CH_2CH_2O)_xCH_3$, where x is an integer of between about two and about twenty, in another example, between about two and about ten, and in a further example between about two and about five. Another exemplary substituted alkoxy group is hydroxyalkoxy or $-OCH_2(CH_2)_yOH$, where y is for example an integer of between about one and about ten, in another example y is an integer of between about one and about four.

[00552] "Acyl" refers to groups of from one to ten carbon atoms of a straight, branched, cyclic configuration, saturated, unsaturated and aromatic and combinations thereof, attached to the parent structure through a carbonyl functionality. One or more carbons in the acyl residue may be replaced by nitrogen, oxygen or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples include acetyl, benzoyl, propionyl, isobutyryl, *t*-butoxycarbonyl, benzyloxycarbonyl and the like. Lower-acyl refers to groups containing one to six carbons.

[00553] "α-Amino Acids" refer to naturally occurring and commercially available amino acids and optical isomers thereof. Typical natural and commercially available α-amino acids are glycine, alanine, serine, homoserine, threonine, valine, norvaline, leucine, isoleucine, norleucine, aspartic acid, glutamic acid, lysine, omithine, histidine, arginine, cysteine, homocysteine, methionine, phenylalanine, homophenylalanine, phenylglycine, ortho-tyrosine, meta-tyrosine, para-tyrosine, tryptophan, glutamine, asparagine, proline and hydroxyproline. A "side chain of an α-amino acid" refers to the radical found on the α-carbon of an α-amino acid as defined above, for example, hydrogen (for glycine), methyl (for alanine), benzyl (for phenylalanine), and the like.

[00554] "Amino" refers to the group $-NH_2$. "Substituted amino," refers to the group -N(H)R or –N(R)R where each R is independently selected from the group: optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heterocyclyl, acyl, carboxy, alkoxycarbonyl, sulfanyl, sulfinyl and sulfonyl, for example, diethylamino, methylsulfonylamino, furanyl-oxy-sulfonamino.

[00555] "Aryl" refers to aromatic six- to fourteen-membered carbocyclic ring, for example, benzene, naphthalene, indane, tetralin, fluorene and the like, univalent radicals. As univalent radicals, the aforementioned ring examples are named, phenyl, naphthyl, indanyl, tetralinyl, and fluorenyl.

[00556] "Arylene" generically refers to any aryl that has at least two groups attached thereto. For a more specific example, "phenylene" refers to a divalent phenyl ring radical. A phenylene, thus may have more than two groups attached, but is defined by a minimum of two non-hydrogen groups attached thereto.

[00557] "Arylalkyl" refers to a residue in which an aryl moiety is attached to a parent structure via one of an alkylene, alkylidene, or alkylidyne radical. Examples include benzyl, phenethyl, phenylvinyl, phenylallyl and the like. Both the aryl, and the corresponding alkylene, alkylidene, or alkylidyne radical portion of an arylalkyl group may be optionally substituted. "Lower arylalkyl" refers to an arylalkyl where the "alkyl" portion of the group has one to six carbons; this can also be refered to as C_{1-6} arylalkyl.

[00558] "Exo-alkenyl" refers to a double bond that emanates from an annular carbon, and is not within the ring system, for example the double bond depicted in the Formula below.



[00559] In some examples, as appreciated by one of ordinary skill in the art, two adjacent groups on an aromatic system may be fused together to form a ring structure. The fused ring structure may contain heteroatoms and may be optionally substituted with one or more groups. It should additionally be noted that saturated carbons of such fused groups (i.e. saturated ring structures) can contain two substitution groups.

[00560] "Fused-polycyclic" or "fused ring system" refers to a polycyclic ring system that contains bridged or fused rings; that is, where two rings have more than one shared atom in their ring structures. In this application, fused-polycyclics and fused ring systems are not necessarily all aromatic ring systems. Typically, but not necessarily, fused-polycyclics share a vicinal set of atoms, for example naphthalene or 1,2,3,4-tetrahydro-naphthalene. A spiro ring system is not a fused-polycyclic by this definition, but fused

polycyclic ring systems of the the compounds described above may themselves have spiro rings attached thereto via a single ring atom of the fused-polycyclic.

[00561] "Halogen" or "halo" refers to fluorine, chlorine, bromine or iodine. "Haloalkyl" and "haloaryl" refer generically to alkyl and aryl radicals that are substituted with one or more halogens, respectively. Thus, "dihaloaryl," "dihaloalkyl," "trihaloaryl" etc. refer to aryl and alkyl substituted with a plurality of halogens, but not necessarily a plurality of the same halogen; thus 4-chloro-3-fluorophenyl is within the scope of dihaloaryl.

[00562] "Heteroarylene" generically refers to any heteroaryl that has at least two groups attached thereto. For a more specific example, "pyridylene" refers to a divalent pyridyl ring radical. A pyridylene, thus may have more than two groups attached, but is defined by a minimum of two non-hydrogen groups attached thereto.

[00563] "Heteroatom" refers to O, S, N, or P.

[00564] "Heterocyclyl" refers to a stable three- to fifteen-membered ring radical that consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, phosphorus, oxygen and sulfur. For purposes of this invention, the heterocyclyl radical may be a monocyclic, bicyclic or tricyclic ring system, which may include fused or bridged ring systems as well as spirocyclic systems; and the nitrogen, phosphorus, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized to various oxidation states. In a specific example, the group $-S(O)_{0-2}-$, refers to -S- (sulfide), -S(O)- (sulfoxide), and $-SO_2-$ (sulfone). For convenience, nitrogens, particularly but not exclusively, those defined as annular aromatic nitrogens, are meant to include their corresponding *N*-oxide form, although not explicitly defined as such in a particular example. Thus, for a compound described above having, for example, a pyridyl ring; the corresponding pyridyl-*N*-oxide is meant to be included. In addition, annular nitrogen atoms may be optionally quaternized; and the ring radical may be partially or fully saturated or aromatic. Examples of heterocyclyl radicals include, but are not limited to, azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofuranyl, carbazoyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrazoyl, tetrahydroisoquinolyl, piperidinyl, piperazinyl,

2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, dihydropyridinyl, tetrahydropyridinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolinyl, oxazolidinyl, triazolyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl, quinolyl, isoquinolyl, decahydroisoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothieliyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, dioxaphospholanyl, and oxadiazolyl.

[00565] "Heteroalicyclic" refers specifically to a non-aromatic heterocyclyl radical. A heteroalicyclic may contain unsaturation, but is not aromatic.

[00566] "Heteroaryl" refers specifically to an aromatic heterocyclyl radical.

[00567] "Heterocyclylalkyl" refers to a residue in which a heterocyclyl is attached to a parent structure via one of an alkylene, alkylidene, or alkylidyne radical. Examples include (4-methylpiperazin-1-yl) methyl, (morpholin-4-yl) methyl, (pyridine-4-yl) methyl, 2-(oxazolin-2-yl) ethyl, 4-(4-methylpiperazin-1-yl)-2-butenyl, and the like. Both the heterocyclyl, and the corresponding alkylene, alkylidene, or alkylidyne radical portion of a heterocyclylalkyl group may be optionally substituted. "Lower heterocyclylalkyl" refers to a heterocyclylalkyl where the "alkyl" portion of the group has one to six carbons. "Heteroalicyclylalkyl" refers specifically to a heterocyclylalkyl where the heterocyclyl portion of the group is non-aromatic; and "heteroarylalkyl" refers specifically to a heterocyclylalkyl where the heterocyclyl portion of the group is aromatic Such terms may be described in more than one way, for example, "lower heterocyclylalkyl" and "heterocyclyl C_{1-6}alkyl" are equivalent terms.

[00568] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. One of ordinary skill in the art would understand that, with respect to any molecule described as containing one or more optional substituents, that only sterically practical and/or synthetically feasible compounds are meant to be included. "Optionally substituted" refers to all subsequent

modifiers in a term, for example in the term "optionally substituted arylC_{1-8} alkyl," optional substitution may occur on both the "C_{1-8} alkyl" portion and the "aryl" portion of the molecule; and for example, optionally substituted alkyl includes optionally substituted cycloalkyl groups, however. But where a first optionally substituted group can be substituted by a second optionally substituted group, the second substituent cannot be further substituted. Optional subsituents do not include groups that are sterically impractical and/or synthetically non-feasible. A list of exemplary optional substitution are listed below in the definition of "substituted."

[00569] Unless otherwise specified, the term "optionally substituted" applies to the chemical moiety immediately preceding it. For instance, if a variable group (such as R) is defined as aryl, optionally substituted alkyl, or cycloalkyl, then only the alkyl group is optionally substituted.

[00570] In the case where there is a point of attachment for a monovalent substituent, such as $-CH_3$, $-NH_2$, or -OH, the indication of where the point of attachment is is not necessary. That is, $-CH_3$ has the same meaning as CH_3, $-NH_2$ has the same meaning as NH_2, and -OH has the same meaning as OH.

[00571] "Saturated bridged ring system" refers to a bicyclic or polycyclic ring system that is not aromatic. Such a system may contain isolated or conjugated unsaturation, but not aromatic or heteroaromatic rings in its core structure (but may have aromatic substitution thereon). For example, hexahydro-furo[3,2-b]furan, 2,3,3a,4,7,7a-hexahydro-1H-indene, 7-aza-bicyclo[2.2.1]heptane, and 1,2,3,4,4a,5,8,8a-octahydro-naphthalene are all included in the class "saturated bridged ring system."

[00572] "Spirocyclyl" or "spirocyclic ring" refers to a ring originating from a particular annular carbon of another ring. For example, as depicted below, a ring atom of a saturated bridged ring system (rings B and B'), but not a bridgehead atom, can be a shared atom between the saturated bridged ring system and a spirocyclyl (ring A) attached thereto. A spirocyclyl can be carbocyclic or heteroalicyclic.



[00573] "Substituted" alkyl, aryl, and heterocyclyl, refer respectively to alkyl, aryl, and heterocyclyl, wherein one or more (for example up to about five, in another example, up to about three) hydrogen atoms are replaced by a substituent independently selected from: optionally substituted alkyl (for example, fluoromethyl), optionally substituted aryl (for example, 4-hydroxyphenyl), optionally substituted arylalkyl (for example, 1-phenyl-ethyl), optionally substituted heterocyclylalkyl (for example, 1-pyridin-3-yl-ethyl), optionally substituted heterocyclyl (for example, 5-chloro-pyridin-3-yl or 1-methyl-piperidin-4-yl), optionally substituted alkoxy, alkylenedioxy (for example methylenedioxy), optionally substituted amino (for example, alkylamino and dialkylamino), optionally substituted amidino, optionally substituted aryloxy (for example, phenoxy), optionally substituted arylalkyloxy (for example, benzyloxy), carboxy (-CO_2H), carboalkoxy (that is, acyloxy or -OC(=O)R), carboxyalkyl (that is, esters or -CO_2R), carboxamido, benzyloxycarbonylamino (CBZ-amino), cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, thiol, halogen, hydroxy, oxo, carbamyl, acylamino, and sulfonamido.

[00574] "Suitable leaving group" is defined as the term would be understood by one of ordinary skill in the art; that is, a carbon with such a group attached, upon reaction wherein a new bond is to be formed, loses such a group upon formation of the new bond. The compounds described above pertains particularly with respect convergent synthesis, to reactions where such a leaving group is bonded to a reaction partner that is aromatic, undergoes a bond-forming reaction and remains aromatic. A typical example of such a reaction is a nucleophilic aromatic substitution reaction, as would be understood by one of ordinary skill in the art. However, the compounds described above are not limited to such mechanistic restrictions; for example, reactions where there is, for example, an insertion reaction (for example by a transition metal) into the bond between the aromatic reaction partner and its leaving group followed by reductive coupling can also be used within the scope of the compounds described above. Examples of suitable leaving groups include halogens, optionally substituted aryl or alkyl sulfonates, phosphonates, azides, $RS(O)_{0-2}$- where R is, for example optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl.

[00575] "Sulfanyl" refers to the groups: -S-(optionally substituted alkyl), -S-(optionally substituted aryl), and -S-(optionally substituted heterocyclyl).

[00576] "Sulfinyl" refers to the groups: -S(O)-H, -S(O)-(optionally substituted alkyl), -S(O)-optionally substituted aryl), and -S(O)-(optionally substituted heterocyclyl).

[00577] "Sulfonyl" refers to the groups: $-S(O_2)$-H, $-S(O_2)$-(optionally substituted alkyl), $-S(O_2)$-optionally substituted aryl), $-S(O_2)$-(optionally substituted heterocyclyl), $-S(O_2)$-(optionally substituted alkoxy), $-S(O_2)$-optionally substituted aryloxy), and $-S(O_2)$-(optionally substituted heterocyclyloxy).

Synthetic Procedures for the Compounds of Formulae I(V3), I(V4), I(V5), A-B-C (version 3), A-B-C (version 4) and A-B-C (version 5)

[00578] The Compounds of the Compounds of Formulae I(V3), I(V4), I(V5), A-B-C (version 3), A-B-C (version 4) and A-B-C (version 5) can be made by the synthetic schemes and examples described in publication WO 2005/030140, which is incorporated herein by reference in its entirety. The utility of these compounds are also described in WO 2005/030140.

[00579] Aspect (31) of the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), and a pharmaceutically acceptable carrier, in combination with a therapeutically effective amount of a compound of Formulae I(V3), I(V4), I(V5), A-B-C (version 3), A-B-C (version 4) or A-B-C (version 5), or a pharmaceutical composition comprising a therapeutically effective amount of the compound of Formulas I(V3), I(V4), I(V5), A-B-C (version 3), A-B-C (version 4) or A-B-C (version 5), and a pharmaceutically acceptable carrier, wherein the mammal is in need of the treatment.

[00580] In other embodiments of aspect (2), aspect (5), aspect (6), aspect (8), aspect (14), aspect (20), and aspect (31) of this invention, R^2 of Formula I(J) is



(f).

[00581] In other embodiments of aspect (2), aspect (5), aspect (6), aspect (8), aspect (14), aspect (20), and aspect (31) of this invention, R^2 of Formula I(J) is



wherein R^{28a} is selected from lower alkyl, dialkylaminoalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, and hetercycloalkylalkyl.

[00582] In other embodiments of aspect (2), aspect (5), aspect (6), aspect (8), aspect (14), aspect (20), and aspect (31) of this invention, R^2 of Formula I(J) is



[00583] In other embodiments of aspect (2), aspect (5), aspect (6), aspect (8), aspect (14), aspect (20), and aspect (31) of this invention, L of Formula I(J) is a bond, Z is  , R^{25} is hydrogen and E and D are hydrogen.

In other embodiments of aspect (2), aspect (5), aspect (6), aspect (8), aspect (14), aspect (20), and aspect (31) of this invention, Z of Formula I(J) is  , R^{26a} is $-C(O)R^{32}$, R^{26} is hydrogen, and R^{32} is selected from tetrahydrofuran, pyrrolidinyl or pryimidinyl, wherein R^{32} is optionally substituted with 1, 2, 3, 4 or 5 groups selected from hydroxyl, oxo, alkyl, alkoxy, amino, hydroxyalkyl and halo.

[00584] In other embodiments of aspect (2), aspect (5), aspect (6), aspect (8), aspect (14), aspect (20), and aspect (31) of this invention, R^2 of Formula I(J) is  .

[00585] In other embodiments of aspect (2), aspect (5), aspect (6), aspect (8), aspect (14), aspect (20), and aspect (31) of this invention, R^{32} of Formula I(J) is U or -CH_2-U, wherein U is selected from pyrolidinyl, thiazolidinyl, morpholinyl, azetidinyl, cyclobutyl, cyclopropyl, tetrahydofuranyl, pyrazinyl, imidazolyl, piperazinyl, thienyl, thienylmethyl, furanyl, phenyl, prolinamidyl, pyridinyl, tetrahydronaphthalene, tetrazolyl, isoindolinyl, pyranyl, cyclopentyl, and octahydro-1H-indolyl.

[00586] In other embodiments of aspect (2), aspect (5), aspect (6), aspect (8), aspect (14), aspect (20), and aspect (31) of this invention, R^{11} of Formula I(J), when present, is halo or lower alkyl.

[00587] In other embodiments of aspect (2), aspect (5), aspect (6), aspect (8), aspect (14), aspect (20), and aspect (31) of this invention, R^{35} of Formula I(J) is heterocycloalkylalkyl, wherein the heterocyloalkyl is selected from piperazinyl, piperidinyl, morpholinyl and dioxanyl.

[00588] In other embodiments of aspect (2), aspect (5), aspect (6), aspect (8), aspect (14), aspect (20), and aspect (31) of this invention, n2 of Formula I(J) is 0.

[00589] In other embodiments of aspect (2), aspect (5), aspect (6), aspect (8), aspect (14), aspect (20), and aspect (31) of this invention, R^2 of Formula I(J) is



, and wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl.

[00590] In other embodiments of aspect (2), aspect (5), aspect (6), aspect (8), aspect (14), aspect (20), and aspect (31) of this invention, the JAK-2 compound has Formula IV(J):



IV(J)

wherein and R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

[00591] In other embodiments of aspect (2), aspect (5), aspect (6), aspect (8), aspect (14), aspect (20), and aspect (31) of this invention, the JAK-2 compound has Formula V(J):



V(J)

wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

[00592] In other embodiments of aspect (2), aspect (5), aspect (6), aspect (8), aspect (14), aspect (20), and aspect (31) of this invention, the JAK-2 compound has Formula VI(J):



VI(J)

wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.



wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

PI3K COMPOUNDS OF FORMULA I(P)

[00593] The PI3K compounds regulate and/or modulate the signal transduction of phosphatidylinositol 3-kinase (PI3K or PIK3CA), a protein kinase. In another embodiment of the methods described herein, the JAK-2 compounds described hereinabove [e.g., compounds of Formula I(J), II(J), III(J), IV(J), V(J), VI(J), and VII(J)] can be combined with any of the PI3K inhibitors known in the art, including the pharmaceutically acceptable salts thereof. The PI3K compounds described below are non-limiting examples of PI3K inhibitors that fall within the scope of aspect (1) of this invention. All of the substituents for the PI3K compounds described below are defined separately from all of the other compounds described herein that are not PI3K compounds so that every substituent in the PI3K compounds that also appears in any of the other compounds described herein has a separate and distinct meaning for each of these two compounds. For instance, R^1 for the JAK-2 compounds has a separate and distinct meaning from R^1 for the PI3K compounds of Formula I(P). All of the PI3K compounds disclosed herein include either their free base form or their pharmaceutically acceptable salts whether it is stated in the specification that these compounds can exist as their pharmaceutically acceptable salts or not. All of the PI3K compounds disclosed herein fall within the scope of aspect (16) of this invention.

[00594] In another embodiment of the methods described herein, the JAK-2 compounds described hereinabove [e.g., compounds of Formula I(J), II(J), III(J), IV(J), V(J), VI(J), and VII(J)] can be combined with compounds that are PI3K compound according to Formula I(P):



I(P)

or a pharmaceutically acceptable salt thereof, where

W^1, W^2, W^3, and W^4 are $-C(R^1)=$; or one or two of W^1, W^2, W^3, and W^4 are independently $-N=$ and the remaining are $-C(R^1)=$; and where each R^1 is independently hydrogen, alkyl, haloalkyl, nitro, alkoxy, haloalkoxy, halo, hydroxy, cyano, amino, alkylamino, or dialkylamino;

R^{51} is hydrogen or alkyl;

R^{52} is hydrogen or halo;

R^{50}, R^{53}, and R^{54} are independently hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, $-N(R^{55})C(O)-C_1-C_6$-alkylene-$N(R^{55a})R^{55b}$, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, $-S(O)_2NR^{55}R^{55a}$, or alkylcarbonylamino and where R^{55} and R^{55b} are indepedently hydrogen, alkyl, or alkenyl and R^{55a} is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; or R^{53} and R^{54} together with the carbons to which they are attached form a 5- or 6-membered heteroaryl or 5- or 6-membered heterocycloalkyl;

B is phenyl substituted with R^{3a} and optionally further substituted with one, two, or three R^3; or

B is heteroaryl optionally substituted with one, two, or three R^3;

R^{3a} is cyano; hydroxyamino; carboxy; alkoxycarbonyl; alkylamino; dialkylamino; r alkylcarbonyl; haloalkoxy; alkylsulfonyl; aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; or

a) $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$ where R^7 is hydrogen, alkyl, or alkenyl and R^{7a} and R^{7b} are independently hydrogen, alkyl, alkenyl, hydroxyalkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, arylalkyl, or arylalkyloxy and where the aryl, cycloalkyl,

heterocycloalkyl and heteroaryl rings in R^{7a} and R^{7b} (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, amino, alkylamino, dialkylamino, hydroxy, halo, alkoxy, alkylthio, and oxo);

b) $-C(O)NR^8R^{8a}$ where R^8 is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and R^{8a} is hydrogen, alkyl, alkenyl, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, alkylthioalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl and where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in R^{8a} (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxycarbonyl, and -C(O)H;

c) $-NR^9C(O)R^{9a}$ where R^9 is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and R^{9a} is hydrogen, C_{2-6}-alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl; where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in R^{9a} (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, halo, haloalkyl, haloalkoxy, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, alkoxycarbonyl, -C(O)H, aryl (optionally substituted with one or two halo), arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cyloalkyl, cyloalkylalkyl, and cycloalkylcarbonyl;

d) $-C(O)N(R^{10})$-C_1-C_6-alkylene-$N(R^{10a})R^{10b}$ where R^{10a} is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, or hydroxyalkyl and R^{10} and R^{10b} are independently hydrogen, alkyl, alkenyl, haloalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, or hydroxyalkyl;

e) $-NR^{11}C(O)NR^{11a}R^{11b}$ where R^{11a} is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy and R^{11} and R^{11b} are independently hydrogen, alkyl, alkenyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

f) $-C(O)R^{12}$ where R^{12} is heterocycloalkyl optionally substituted with 1, 2, or 3 groups selected from alkyl, oxo, amino, alkylamino, and heterocycloalkylalkyl;

g) $-NR^{13}C(O)OR^{13a}$ where R^{13} is hydrogen, alkyl, or alkenyl and R^{13a} is aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aryl, or arylalkyl;

h) $-C(O)N(R^{14})N(R^{14a})(R^{14b})$ where R^{14}, R^{14a}, and R^{14b} are independently hydrogen, alkyl, or alkenyl;

i) $-S(O)_2N(R^{15})$-C_1-C_6-alkylene-$N(R^{15a})R^{15b}$ where R^{15}, R^{15a}, and R^{15b} are independently hydrogen, alkyl, or alkenyl;

j) $-C(O)N(R^{16})$-C_1-C_6-alkylene-$C(O)OR^{16a}$ where R^{16} is hydrogen, alkyl, or alkenyl and R^{16a} is alkyl or alkenyl;

k) heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

l) $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$ where R^{17}, R^{17a}, R^{17b}, R^{17c}, and R^{17d} are independently hydrogen, alkyl, or alkenyl;

m) $-N(R^{18})C(O)$-C_1-C_6-alkylene-$N(R^{18b})C(O)R^{18a}$ where R^{18a} is hydrogen, alkyl, alkenyl, or alkoxy and R^{18} and R^{18b} are independently hydrogen, alkyl, or alkenyl;

n) $-C(O)N(R^{19})$-C_1-C_6-alkylene-$C(O)R^{19a}$ where R^{19} is hydrogen, alkyl, or alkenyl and R^{19a} is amino, alkylamino, dialkylamino, or heterocycloalkyl;

o) $-N(R^{20})C(O)$-C_1-C_6-alkylene-$C(O)R^{20a}$ where R^{20} is hydrogen, alkyl, or alkenyl and R^{20a} is cycloalkyl or heterocycloalkyl;

p) $-NR^{21}S(O)_2R$-C_1-C_6-alkylene-$N(R^{21b})R^{21a}$ where R^{21} is hydrogen, alkyl, or alkenyl and R^{21a} and R^{21b} are independently hydrogen, alkyl, or alkenyl;

q) $-N(R^{22})C(O)$-C_1-C_6-alkylene-$N(R^{22b})$-$N(R^{22c})(R^{22a})$ where R^{22}, R^{22a} and R^{22b} are independently hydrogen, alkyl, or alkenyl;

r) $-C_0$-C_6-alkylene-$N(R^{23})$-C_1-C_6-alkylene-$N(R^{23b})R^{23a}$ where R^{23}, R^{23a} and R^{23b} are independently hydrogen, alkyl, or alkenyl; or

s) $-NR^{24}C(O)$-C_1-C_6-alkylene-OR^{24a} where R^{24} is hydrogen, alkyl, or alkenyl and R^{24a} is alkoxyalkyl or aryl optionally substituted with one or two halo or alkyl; and

where each of the alkylene in R^{3a} is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; and

each R^3 (when R^3 is present) is independently alkyl; alkenyl; alkynyl; halo; hydroxy; oxo; alkoxy; cyano; hydroxyamino; carboxy; alkoxycarbonyl; amino; alkylamino; dialkylamino; alkylcarbonyl; haloalkoxy; alkylsulfonyl; aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; or

a) $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$ where R^7 is hydrogen, alkyl, or alkenyl and R^{7a} and R^{7b} are independently hydrogen, alkyl, alkenyl, hydroxyalkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, arylalkyl, or arylalkyloxy and where the aryl, cycloalkyl, heterocycloalkyl and heteroaryl rings in R^{7a} and R^{7b} (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, amino, alkylamino, dialkylamino, hydroxy, halo, alkoxy, alkylthio, and oxo);

b) $-C(O)NR^8R^{8a}$ where R^8 is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and R^{8a} is hydrogen, alkyl, alkenyl, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, alkylthioalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl and where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in R^{8a} (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxycarbonyl, and -C(O)H;

c) $-NR^9C(O)R^{9a}$ where R^9 is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and R^{9a} is hydrogen, C_{2-6}-alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl; where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in R^{9a} (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently

optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, halo, haloalkyl, haloalkoxy, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, alkoxycarbonyl, -C(O)H, aryl (optionally substituted with one or two halo), arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cyloalkyl, cyloalkylalkyl, and cycloalkylcarbonyl;

d) $-C(O)N(R^{10})-C_1-C_6$-alkylene-$N(R^{10a})R^{10b}$ where R^{10a} is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or hydroxyalkyl and R^{10} and R^{10b} are independently hydrogen, alkyl, alkenyl, haloalkyl, or hydroxyalkyl;

e) $-NR^{11}C(O)NR^{11a}R^{11b}$ where R^{11a} is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy and R^{11} and R^{11b} are independently hydrogen, alkyl, alkenyl, aminoalkyl, alkylaminooalkyl, dialkylaminoalkyl;

f) $-C(O)R^{12}$ where R^{12} is heterocycloalkyl optionally substituted with 1, 2, or 3 groups selected from alkyl, oxo, amino, alkylamino, and heterocycloalkylalkyl;

g) $-NR^{13}C(O)OR^{13a}$ where R^{13} is hydrogen, alkyl, or alkenyl and R^{13a} is aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aryl, or arylalkyl);

h) $-C(O)N(R^{14})N(R^{14a})(R^{14b})$ where R^{14}, R^{14a}, and R^{14b} are independently hydrogen, alkyl, or alkenyl;

i) $-S(O)_2N(R^{15})-C_1$-C_6-alkylene-$N(R^{15a})R^{15b}$ where R^{15}, R^{15a}, and R^{15b} are independently hydrogen, alkyl, or alkenyl;

j) $-C(O)N(R^{16})-C_1$-C_6-alkylene-$C(O)OR^{16a}$ where R^{16} is hydrogen, alkyl, or alkenyl and R^{16a} is alkyl or alkenyl;

k) heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

l) $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$ where R^{17}, R^{17a}, R^{17b}, R^{17c}, and R^{17d} are independently hydrogen, alkyl, or alkenyl;

m) $-N(R^{18})C(O)-C_1-C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$ where R^{18a} is hydrogen, alkyl, alkenyl, or alkoxy and R^{18} and R^{18b} are independently hydrogen, alkyl, or alkenyl;

n) $-C(O)N(R^{19})-C_1-C_6$-alkylene-$C(O)R^{19a}$ where R^{19} is hydrogen, alkyl, or alkenyl and R^{19a} is amino, alkylamino, dialkylamino, or heterocycloalkyl;

o) $-N(R^{20})C(O)-C_1-C_6$-alkylene-$C(O)R^{20a}$ where R^{20} is hydrogen, alkyl, or alkenyl and R^{20a} is cycloalkyl or heterocycloalkyl;

p) $-NR^{21}S(O)_2R-C_1$-C_6-alkylene-$N(R^{21b})R^{21a}$ where R^{21} is hydrogen, alkyl, or alkenyl and R^{21a} and R^{21b} are independently hydrogen, alkyl, or alkenyl;

q) $-N(R^{22})C(O)-C_1$-C_6-alkylene-$N(R^{22b})$-$N(R^{22c})(R^{22a})$, where R^{22}, R^{22a} and R^{22b} are independently hydrogen, alkyl, or alkenyl;

r) $-C_0$-C_6-alkylene-$N(R^{23})-C_1$-C_6-alkylene-$N(R^{23b})R^{23a}$ where R^{23}, R^{23a} and R^{23b} are independently hydrogen, alkyl, or alkenyl; or

s) $-NR^{24}C(O)-C_1$-C_6-alkylene-OR^{24a} where R^{24} is hydrogen, alkyl, or alkenyl and R^{24a} is alkoxyalkyl or aryl optionally substituted with one or two halo or alkyl;

wherein each of the alkylene in R^3 is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; and

provided that when R^{50} and R^{52} are hydrogen, R^{51} is hydrogen or methyl, R^{53} is hydrogen or methoxy, and R^{54} is hydrogen or methoxy, then B is not 2,3-dihydro-1,4-benzodioxinyl, thien-2-yl, or thien-2-yl substituted with one R^3 where R^3 is halo.

[00595] Another aspect of the PI3K compound is a compound of Formula II(P):



II(P)

or a pharmaceutically acceptable salt or solvate thereof, wherein

W^1, W^2, W^3, and W^4 are $-C(R^{1a})=$; or one or two of W^1, W^2, W^3, and W^4 are independently $-N=$ and the remaining are $-C(R^{1a})=$;

X^1 is $-N(R^{5a})-$;

A is aryl, $-S(O)_2$-aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkoxy, alkyl, alkoxy, or $-alkyl-N(R^7)R^{7a}$, where each of the aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkyl and alkoxy groups, each either alone or as part of another group within A, are independently optionally substituted with one, two, three, or four R^{2a}; or

B^1 is aryl, arylalkyl, alkyl, heteroaryl, or heteroaryalkyl, wherein each of the aryl, heteroaryl and alkyl groups are independently optionally substituted with one, two, three, or four R^{3d};

each R^{1a} is independently selected from hydrogen, alkoxy, alkyl, nitro, halo, cyano, and -C_0-C_6-alkyl-$N(R^7)R^{7a}$, wherein each of the alkyl and alkoxy groups is optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, $-N(R^8)R^{8a}$, and $-C(O)OR^6$;

each R^{2a} (when R^{2a} is present) is independently selected from alkyl, alkenyl, -alkenyl-$C(O)OR^6$, $-OR^6$, $-N(R^7)C(O)R^6$, $-N(R^7)C(O)$-C_0-C_6 alkyl-$N(R^{7b})R^{7a}$, $-OC(O)$-C_0-C_6 alkyl-$N(R^7)R^{7a}$, $-N(R^7)C(O)$-C_1-C_6 alkyl$C(O)OR^6$, C_0-C_6-alkyl-$C(O)R^6$, oxo, dioxo, $-S(O)_2$-$N(R^7)R^{7a}$, $-C(O)OR^6$, $-CH(R^6)_2$-$C(O)OR^6$, $-S(O)_2R^6$, cycloalkyl, heterocycloalkyl, heteroaryl, $-C(O)N(R^7)$-alkyl-OR^6, -C_0-C_6 alkyl-$C(O)N(R^7)$-C_0-C_6-alkyl-$C(O)OR^6$, -C_0-C_6-alkyl-$C(O)N(R^7)R^{7a}$, aryl, arylalkyl, -S-(C_1-C_6 alkyl), halo, oxo, nitro, -SCN, cyano, and -C_0-C_6 alkyl-$N(R^7)R^{7a}$, wherein each of the alkyl (including, for example the alkyl within alkoxy), aryl, cycloalkyl, heterocycloalkyl, and heteroaryl groups, either alone or as part of another group within R^2, is independently optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, oxo, nitro, cyano, hydroxy, $-N(R^8)R^{8a}$, alkoxy, and $-C(O)OR^9$;

each R^{3d} (when R^{3d} is present) is independently oxo, nitro, halo, cyano, alkyl, alkenyl, alkynyl, alkoxy, C_3-C_6-cycloalkyl, -C_0-C_6-alkyl-heterocycloalkyl, -C_0-C_6 alkyl-$N(R^7)C(O)$-C_0-C_6-alkyl-$N(R^{7b})R^{7a}$, -C_0-C_6 alkyl-$N(R^7)C(O)$-C_0-C_6-alkyl-$N(R^{7b})C(O)R^{7a}$, -C_0-C_6 alkyl-$C(O)$-C_0-C_6-alkyl-$N(R^7)R^{7a}$, -C_0-C_6-alkyl-$C(O)N(R^7)$-C_0-C_6-alkyl-$N(R^{7b})R^{7a}$, -C_0-C_6-alkyl-$C(O)N(R^7)$-C_1-C_6alkyl$C(O)OR^{7a}$, -C_0-C_6 alkyl-$N(R^7)C(O)$-C_0-C_6-alkyl-(R^{7a}), -C_0-C_6 alkyl-$N(R^7)$-C_0-C_6-alkyl-$N(R^{7b})R^{7a}$, -C_0-C_6 alkyl-$N(R^7)C(O)$-C_0-C_6-alkyl-$N(R^{7b})$-$N(R^{7c})R^{7a}$, -C_0-C_6 alkyl-$N(R^7)C(O)O$-C_0-C_6-alkyl-aryl, -C_0-C_6 alkyl-$C(O)N(R^7)$-C_0-C_6-alkyl-$N(R^{7b})R^{7a}$, -C_0-C_6 alkyl-$N(R^7)$-C_0-C_6 alkyl-$C(=N(R^{7b})(R^{7a}))(NR^{7c}R^{7d})$, -$C_0$-$C_6$-alkyl-aryl, -$C_0$-$C_6$-alkyl-heteroaryl, -$C_0$-$C_6$ alkyl-heterocycloalkyl, -O-C_0-C_6 alkyl-$N(R^7)R^{7a}$, -C_0-C_6 alkyl-OR_6, -C_0-C_6 alkyl-$C(O)OR_6$, C_0-C_6-alkyl-$N(R^7)R^{7a}$, -C_0-C_6 alkyl-$C(O)NR_7R^{7a}$, -C_0-C_6 alkyl-$C(O)R^7$, $-SR_7$, $-S(O)_2R_7$, $-S(O)_3R_7$, $-S(O)R^7$, $-SO_2N(R^7)R^{7a}$, $-SO_2N(R^7)$-C_0-C_6 alkyl-$N(R^{7b})R^{7a}$, -C_0-C_6-alkyl-$N(R^7)$-aryl, -C_0-C_6-alkyl-$N(R^7)$-heteroaryl, -C_0-C_6-alkyl-$N(R^7)$-heterocycloalkyl, -C_0-C_6-alkyl-$C(O)N(R^7)$-C_0-C_6-alkyl-cycloalkyl, C_0-C_6-alkyl-$C(O)N(R^7)$-C_0-C_6-alkyl-aryl, C_0-C_6 alkyl-$C(O)N(R^7)$-C_0-C_6 alkyl-heteroaryl, C_0-C_6 alkyl-$C(O)N(R^7)$-C_0-C_6-alkyl-heterocycloalkyl, -C_0-C_6-alkyl-$N(R^7)C(O)$-C_0-C_6-alkyl-cycloalkyl, -C_0-C_6-alkyl-$N(R^7)C(O)$-C_0-C_6-alkyl-aryl, C_0-C_6-alkyl-

$N(R^7)C(O)$-C_0-C_6-alkyl-heteroaryl, -C_0-C_6-alkyl-$N(R^7)C(O)$-C_0-C_6-alkyl-heterocycloalkyl, C_0-C_6-alkyl-$N(R^7)C(O)$-C_0-C_6-alkyl-heterocycloalkyl-aryl, $-N(R^7)C(O)OR^6$, or -NHC(O)H, wherein each of the alkyl, alkenyl, cycloalkyl, aryl, (including, for example the alkyl within alkoxy), heterocycloalkyl, and heteroaryl groups, either alone or as part of another group within R^{3d}, is independently optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, alkenyl, -C_0-C_6-alkyl-OR^9, cycloalkyl, halo, haloalkyl, haloalkoxy, $-C(O)R^9$, nitro, cyano, oxo, -C_0-C_6-alkyl-$N(R^8)R^{8a}$, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, $-C(O)OR^9$, alkylthio, and hydroxyalkyl;

R^4 is hydrogen, aryl, -C_0-C_6-alkyl-$N(R^7)R^{7a}$, alkoxy, or C_1-C_6 alkyl, wherein each of the alkyl and aryl groups, either alone or as part of another group in R^4, is independently optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, $-N(R^8)R^{8a}$, alkoxy, and $-C(O)OR^6$; or

R^4 and X^1 together with the atoms to which they are attached form a heterocycloalkyl or heteroaryl group, wherein R^{5a} is absent when X is $-N(R^{5a})-$, wherein each of the heterocycloalkyl or heteroaryl is optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, $-N(R^7)R^{7a}$, alkoxy, and $-C(O)OR^6$;

R^{5a} is hydrogen, -C_1-C_6 alkyl-$N(R^7)R^{7a}$, alkoxy, alkyl, or aryl, wherein each of the alkyl and aryl is optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, $-N(R^8)R^{8a}$, C_1-C_6 alkoxy, or $-C(O)OR^6$; or

R^{5a} and R^4 together with the atoms to which they are attached form a heterocycloalkyl or heteroaryl group, wherein the heterocycloalkyl and heteroaryl is optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, $-N(R^7)R^{7a}$, C_1-C_6 alkoxy, and $-C(O)OR^6$;

R^6 and R^9 are independently hydrogen, hydroxy, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, or aryl, each alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl, either alone or as part of another group within R^6 and R^9, is independently optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from amino, hydroxy, alkoxy, alkyl, and halo; and

R^7, R^{7a} R^{7b}, R^{7c}, R^{7d}, R^8, and R^{8a} are independently hydrogen, alkyl, alkenyl, hydroxy, alkyloxy, alkenyloxy, -O-C_0-C_6 alkyl-aryl, -C_0-C_6 alkyl-C(O)OR^6, -C_0-C_6 alkyl-C(O)R^6, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, or heterocycloalkylalkyl, wherein each of the alkyl, aryl, heteroaryl, and heterocycloalkyl, either alone or part of another group within R^7, R^{7a} R^{7b}, R^{7c}, R^{7d}, R^8, and R^{8a} is independently optionally substituted with 1, 2, 3, 4, or 5 groups selected from amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, -S-C_1-C_6 alkyl, cyano, nitro, hydroxy, C_1-C_6 alkoxy, C_1-C_6 alkyl, halo, aryl, heterocycloalkylalkyl, and heteroaryl optionally substituted with one or two C_1-C_6 alkyl.

[00596] One embodiment (P-A) of the PI3K compound is directed to a compound of Formula I(P) where W^1, W^2, W^3, and W^4 are -C(R^1)=; or one or two of W^1, W^2, W^3, and W^4 are independently –N= and the remaining are -C(R^1)=; where each R^1 is independently hydrogen, alkyl, haloalkyl, nitro, alkoxy, haloalkoxy, halo, hydroxy, cyano, amino, alkylamino, or dialkylamino; and all other groups are as defined in the Summary of the Invention. Specifically, W^1, W^2, W^3, and W^4 are -C(R^1)= and each R^1 is independently hydrogen or alkyl; or one of W^1 and W^4 is –N= and the other is -C(H)=. More specifically, W^1, W^2, W^3, and W^4 are -C(R^1)= where each R^1 is independently hydrogen or alkyl. Even more specifically, R^1 is hydrogen.

[00597] Another embodiment (P-B) is a Compound of Formula I(P) where R^{50} is hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, -N(R^{55})C(O)-C_1-C_6-alkylene-N(R^{55a})R^{55b}, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, -S(O)$_2$N$R^{55}R^{55a}$, or alkylcarbonylamino; where R^{55} and R^{55b} are indepedently hydrogen, alkyl, or alkenyl and R^{55a} is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; and all other groups are as defined in the Summary of the Invention. Specifically, R^{50} is hydrogen.

[00598] Another embodiment (P-C) is a Compound of Formula I(P) where R^{51} is hydrogen or alkyl; and all other groups are as defined in the Summary of the Invention. Specifically, R^{51} is alkyl. More specifically, R^{51} is methyl.

[00599] Another embodiment (P-D) of the invention is a Compound of Formula I(P) where R^{52} is hydrogen or halo; and all other groups are as defined in the Summary of the Invention. Specifically R^{52} is hydrogen or fluoro. More specifically, R^{52} is hydrogen.

[00600] Another embodiment (P-E) is a Compound of Formula I(P) where R^{53} is hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, -$N(R^{55})C(O)$-C_1-C_6-alkylene-$N(R^{55a})R^{55b}$, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, -$S(O)_2NR^{55}R^{55a}$, or alkylcarbonylamino; where R^{55} and R^{55b} are indepedently hydrogen, alkyl, or alkenyl and R^{55a} is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; and all other groups are as defined in the Summary of the Invention. Specifically, R^{53} is hydrogen, alkoxy, nitro, amino, or -$N(R^{55})C(O)$-C_1-C_6-alkylene-$N(R^{55a})R^{55b}$. More specifically, R^{53} is hydrogen, methoxy, nitro, amino, or -$NHC(O)CH_2N(CH_3)_2$. Even more specifically, R^{53} is hydrogen or methoxy.

[00601] Another embodiment (P-F) is a Compound of Formula I(P) where R^{54} is hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, -$N(R^{55})C(O)$-C_1-C_6-alkylene-$N(R^{55a})R^{55b}$, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, -$S(O)_2NR^{55}R^{55a}$, or alkylcarbonylamino; where R^{55} and R^{55b} are indepedently hydrogen, alkyl, or alkenyl and R^{55a} is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; and all other groups are as defined in the Summary of the Invention. Specifically, R^{54} is hydrogen, alkyl, alkoxy, or halo. More specifically, R^{54} is hydrogen, methyl, methoxy, bromo, or chloro. Even more specifically, R^{54} is hydrogen, methoxy, or chloro.

[00602] Another embodiment (P-G) is directed to a compound of Formula I(P) where R^{50}, R^{52}, and R^{53} are hydrogen and R^{54} is halo or alkoxy; R^{50}, R^{52}, and R^{54} are hydrogen and R^{53} is alkoxy; or R^{50} and R^{52} are hydrogen and R^{53} and R^{54} together with the carbons to which they are attached form a 6-membered heteroaryl; and all other groups are as defined in the Summary of the Invention. More specifically, R^{50}, R^{52}, and R^{53} are hydrogen and R^{54} is chloro or methoxy; R^{50}, R^{52}, and R^{54} are hydrogen and R^{53} is methoxy; or R^{50} and R^{52} are hydrogen and R^{53} and R^{54} together with the carbons to which they are attached form pyridinyl. Even more speicfically, R^{50}, R^{52}, and R^{53} are hydrogen and R^{54} is chloro or methoxy; or R^{50}, R^{52}, and R^{54} are hydrogen and R^{53} is methoxy.

[00603] In a more specific embodiment (P-G1) of embodiment G is a compound of Formula I(P) where R^{51} is methyl.

[00604] Another embodiment (P-H) of the invention is a compound of Formula I(P) where B is phenyl substituted with R^{3a} and optionally further substituted with one, two,

or three R^3; and all other groups are as defined in the Summary of the Invention. Specifically, B is phenyl substituted with R^{3a}. More specifically the Compound is of Formula I(P)a:



I(P)a

[00603] Even more specifically, B is phenyl substituted with R^{3a} as depicted in I(P)a and is not further substituted with R^3.

[00604] Another embodiment (P-J) is directed to a compound of Formula I(P) where B is heteroaryl optionally substituted with one, two, or three R^3. Specifically, B is thien-3-yl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, oxazolyl, isoxazolyl, pyrrolyl, imidazolyl, pyrazolyl, or thiazolyl, each of which is optionally substituted with one or two R^3. More specifically, B is thien-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, imidazol-2-yl, pyrrol-2-yl, pyrrol-3-yl, imidazol-4-yl, imidazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, or pyrazol-5-yl, each of which is optionally substituted with one or two R^3. Even more specifically, B is thien-3-yl, pyridin-3-yl, pyridin-4-yl, isoxazol-4-yl, or pyrazol-4-yl, each of which is optionally substituted with one or two R^3. Yet even more specifically, B is pyridin-3-yl, 2-hydroxy-pyridin-5-yl, isoxazol-4-yl, or pyrazol-4-yl, each of which is optionally substituted with one or two R^3.

[00605] Another embodiment (P-K) provides a compound of Formula I(P) or I(P)a where R^{3a} is cyano; hydroxyamino; carboxy; alkylsulfonyl, aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$; $-C(O)NR^8R^{8a}$; $-NR^9C(O)R^{9a}$; $-C(O)N(R^{10})-C_1-C_6$-alkylene-$N(R^{10a})R^{10b}$; $-NR^{11}C(O)NR^{11a}R^{11b}$ where R^{11a}; $-C(O)R^{12}$; $-NR^{13}C(O)OR^{13a}$; $-C(O)N(R^{14})N(R^{14a})(R^{14b})$; $-S(O)_2N(R^{15})-C_1.C_6$-alkylene-$N(R^{15a})R^{15b}$; $-C(O)N(R^{16})-C_1.C_6$-alkylene-$C(O)OR^{16a}$; heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; $-N(R^{17})-$

$C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$; $-N(R^{18})C(O)-C_1-C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$; $-C(O)N(R^{19})-C_1-C_6$-alkylene-$C(O)R^{19a}$; $-N(R^{22})C(O)-C_1.C_6$-alkylene-$N(R^{22b})$-$N(R^{22c})(R^{22a})$; $-C_0.C_6$-alkylene-$N(R^{23})-C_1.C_6$-alkylene-$N(R^{23b})R^{23a}$; or $-NR^{24}C(O)-C_1.C_6$-alkylene-OR^{24a}; where each of the alkylene in R^{3a} is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; and all other groups are as defined in the Summary of the Invention.

[00606] Specifically, R^{3a} is $-NHC(O)CH_2NH(CH_3)$, $-NHC(O)CH_2NH(CH_2CH_3)$, $-NHC(O)CH(CH_3)NH_2$, $-NHC(O)C(CH_3)_2NH_2$, $-NHC(O)CH_2N(CH_3)_2$, $-NHC(O)CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, $-NHC(O)CH(NH_2)CH_2CH_3$, $-NHC(O)CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, $-NHC(O)CH(CH_3)NH(CH_3)$, $-NHC(O)CH_2NH_2$, -NHC(O)H, $-NHC(O)CH_2$(azetidin-1-yl), -NHC(O)(pyrrolidin-2-yl), $-NHC(O)CH(NH_2)CH_2OH$, -NHC(O)(azetidin-4-yl), $-NHC(O)C(CH_3)_2NH(CH_3)$, $-NH_2$, $-NHC(O)CH_2NH(CH_2CH_2CH_3)$, $-NHC(O)CH_2CH_2NH_2$, -NHOH, -NHC(O)(piperidin-3-yl), $-NHC(O)CH_2$(4-methyl-1,4-diazepan-1-yl), $-NHC(O)CH(NH_2)(CH_2CH_3)$, $-NHC(O)CH_2NH(CH_2CH(OH)(CH_3))$, $-NHC(O)CH_2NHCH_2CH_2F$, $-NHC(O)CH_2NH(OCH_2CH(CH_3)_2)$, -NHC(O)(1-aminocycloprop-1-yl), $-NHC(O)CH_2NH(CH_2$cyclopropyl), $-NHC(O)CH_2$(3-(dimethylamino)-azetidin-1-yl), -NHC(O)(piperidin-2-yl), -NHC(O)(morpholin-4-yl), $-NHC(O)CH_2$(pyrrolidin-1-yl), $-NHC(O)CH(NH_2)CH_2CH_2CH_2CH_2N(CH_3)_2$, $-NHC(O)CH_2N(CH_3)(CH_2CH_3)$, $-NHC(O)CH_2$(imidazol-5-yl), -NHC(O)(1-aminocyclopent-1-yl), $-NHC(O)CH_2NH(CH_2CH(CH_3)_2)$, $-NHC(O)CH_2N(CH_3)(CH_2CH_3)$, -NHC(O)(*N*-(imidazol-4-ylmethyl)-azetidin-3-yl), -NHC(O)(*N*-ethyl-azetidin-3-yl), $-NHCH_2N(CH_3)CH_2CH_2N(CH_3)_2$, $-NHC(O)CH_2N(CH_3)$(*N*-methyl-pyrrolidin-3-yl), $-NHC(O)CH_2N(CH_3)(CH_2CH_2N(CH_3)_2)$, $-NHC(O)CH_2$(3-hydroxy-pyrrolidin-1-yl), -NHC(O)(1-amino-cyclobut-1-yl), $-NHC(O)CH_2NH(CH_2)_3CH_3$, $-NHC(O)CH_2$(3-piperidin-1-ylazetidin-1yl), $-NHC(O)NH_2$, -NHC(O)(1-hydroxycyclopropyl), $-NHC(O)CH_2NHN(CH_3)_2$, $-NHC(O)NH(CH_2)_2N(CH_3)_2$, $-NHC(O)CH_2OH$, -NHC(O)(pyridazin-4-yl), -NHC(O)(N-methyl-piperidin-4-yl), $-NHC(O)CH_2NHCH(CH_3)_3$, $-NHC(O)CH_2$(3-dimethylamino-pyrrolidin-1yl), $-NHC(O)CH_2NH(CH_2)_2N(CH_3)_2$, -NHC(O)(1-cyclopropylmethyl-azetidin-3-yl), $-NHC(O)CH_2NH(CH_3)_3$, -NHC(O)(imidazol-2-yl), -NHC(O)(imidazol-4-yl), -NHC(O)(1,2-oxazol-5-yl), $-NHC(O)CH_2NHCH_2CF_3$, $-NHC(O)CH_2CH_2$(piperidin-1-yl), -NHC(O)(3-oxo-cyclopent-1-yl), -NHC(O)(2-hydroxy-pyridin-6-yl),

-NHC(O)CH_2NH(3-fluoro-4-hydroxyphenyl), -NHC(O)$(CH_2)_3N(CH_3)_2$, -NHC(O)(1-(furan-2-ylmethyl)-azetidin-3-yl), -NHC(O)(pyrimidin-5-yl), -NHC(O)(pyrrol-2-yl), -NHC(O)$CH_2N(CH_3)CH(CH_3)_2$, -NHC(O)$CH_2N(CH_2CH_3)_2$, -NHC(O)CH_2(3-methyl-1,2-oxazol-5-yl), -NHC(O)CH_2NHCH_2(3-hydroxyphenyl), -NHC(O)(*N*-methyl-pyrrol-2-yl), -NHC(O)(2-amino-tetrahydropyran-2-yl), -NHC(O)CH_2(4-methylamino-piperidin-1-yl), -NHC(O)(piperidin-1-yl), -NHC(O)(*N*-methyl-pyrrolidin-2yl), -NHC(O)(thien-3yl), -NHC(O)(*N*-(cyclopropylcarbonyl)azetidin-3-yl), -NHC(O)CH_2(4-methylpiperazin-1-yl), -NHC(O)(*N*-benzylazetidin-3-yl), -NHC(O)(2-chloro-pyridin-3-yl), -NHC(O)CH_2(pyridin-4-yl), -NHC(O)$CH_2N(CH_3)(CH_2CH{=}CH_2)$, -NHC(O)$CH_2$NH(benzyl), -NHC(O)$CH_2OCH_3$, -NHC(O)[1-(C(O)$CH_2CH_3$)-azetidin-3-yl], -NHC(O)(pyridin-3-yl), -NHC(O)$CH_2NHCH_2CH_2OCH_3$, -NHC(O)(1-[C(O)CH_3]piperidin-4-yl), -NHC(O)CH_2(2-methyl-pyrrolidin-1-yl), -NHC(O)(furan-3-yl), -NHC(O)$CH_2N(CH_3)_2$, -NHC(O)(2-chloro-pyridin-5-yl), -NHC(O)(2-chlorophenyl), -NHC(O)CH_2(pyridin-2-yl), -NHC(O)CH_2(3-dimethylamino-azetidin-1-yl), -NHC(O)CH_2(pyridin-3-yl), -NHC(O)CH_2(2-chlorophenyl), -NHC(O)$CH_2N(CH_3)CH_2CH_2CH_2N(CH_3)_2$, -NHC(O)$CH_2N(CH_2CH_3)CH_2CH_2OH$, -NHC(O)$CH_2$(2-benzyl-pyrrolidin-1-yl), -NHC(O)(furan-2-yl, -NHC(O)(2-chloro-pyridin-4-yl), -NHC(O)$CH_2NHC(O)CH_3$, -NHC(O)$CH_2CH_2CH_3$, -NHC(O)(4-chlorophenyl), -NHC(O)(4-methyl-phenyl), -NHC(O)$CH_2NHC(O)O(CH_3)_3$, -NHC(O)(benzo[d][1,3]dioxol-5-yl), -NHC(O)CH_2NHOCH_2(2-methoxyphenyl), -NHC(O)(pyridin-4-yl), -NHC(O)CH_2[4-(3,4-dichlorophenyl)-piperazin-1-yl], -NHC(O)CH_2CH_2(pyridin-3-yl), -NHC(O)(tetrahydrofuran-3-yl), -NHC(O)CH_2NHCH_2(2-methylphenyl), -NHC(O)$CH(CH_3)CH_2CH_3$, -NHC(O)CH_2(3-fluorophenyl), -NHC(O)$CH_2C(CH_3)_2$phenyl, -NHC(O)(2-methyl-cycloprop-1-yl), -NHC(O)(2-methyl-4-methoxyphenyl), -NHC(O)(2-methylpyridin-3-yl), -NHC(O)(4-methoxyphenyl), -NHC(O)CH_2(4-ethylpiperazin-1-yl), -NHC(O)(thien-2-yl), -NHC(O)(3-fluoro-2-methylphenyl), -NHC(O)(2-bromo-thien-3-yl), -NHC(O)(4-fluorophenyl), -NHC(O)CH_2(3-methylpiperidin-1-yl), -NHC(O)$CH(CH_3)_2$, -NHC(O)$(CH_2)_3CH_3$, -NHC(O)$CH_2OCH_2CH_3$, -NHC(O)CH_2NH(2-fluorophenyl), -NHC(O)(3-dimethylaminophenyl), -NHC(O)CH_2(4-methylpiperidin-1-yl), -NHC(O)CH_2NH(2-*n*-propylphenyl), -NHC(O)phenyl, -NHC(O)(pyrazin2-yl), -NHC(O)(3-fluoro-4-methoxyphenyl), -NHC(O)$C(CH_3)_2CH_2CH_3$, -NHC(O)CH_2O(4-fluorophenyl), -NHC(O)(1-methylcarbonyl-azetidin-3-yl),

-NHC(O)CH_2NH(4-methylphenyl), -NHC(O)CH_2NH(phenyl), -NHC(O)CH_2(4-allyl-piperazin-1-yl), -NHC(O)(2-methylphenyl), -NHC(O)$CH_2CH_2OCH_3$, -NHC(O)(3-methyl-furan-2-yl), -NHC(O)$C(CH_3)_3$, -NHC(O)CH_2NHObenzyl, -NHC(O)CH_2NH(3-chlorophenyl), -NHC(O)cyclobutyl, -NHC(O)CH_2(3-methoxyphenyl), -NHC(O)(1-methylcycloprop-1-yl), -NHC(O)(3-flurophenyl), -NHC(O)(4-dimethylaminophenyl), -NHC(O)(3,4-dichlorophenyl), -NHC(O)CH_2NHCH_2(2-methylthiophenyl), -NHC(O)CH_2(2-fluorophenyl), -NHC(O)$CH_2N(CH_2CH_3)CH(CH_3)_2$, -NHC(O)(thiazol-4-yl), -NHC(O)$CH_2N(CH_3)$benzyl, -NHC(O)CH_2NHCH_2(thien-2-yl), -NHC(O)CH_2NHCH_2(pyridin-2-yl), -NHC(O)(3-methoxyphenyl), -NHC(O)CH_2NHCH_2(3-chloro-4-methylphenyl), -NHC(O)$CH(CH_3)CH_2CH_2CH_3$, -NHC(O)CH_2(4-chlorophenyl), -NHC(O)(3-fluoro-4-methylphenyl), -NHC(O)CH_2O(2-methylphenyl), -NHC(O)CH_2(cyclohexyl), -NHC(O)(2-phenyl-cycloprop-1-yl), -NHC(O)(3-chlorophenyl), -NHC(O)CH_2(2-methoxyphenyl), -NHC(O)CH_2CH_2(3-methoxyphenyl), -NHC(O)CH_2NH(2-fluoro-4-methyl-phenyl), -NHC(O)CH_2NHCH_2(3-fluoro-phenyl), -NHC(O)CH_2(4-methoxy-phenyl), -NHC(O)benzyl, -NHC(O)(2,4-dichlorophenyl), -NHC(O)(3-oxo-cyclohex-1-yl), -NHC(O)CH_2NH(3-fluorophenyl), -NHC(O)CH_2(3-chlorophenyl), -NHC(O)CH_2NH$CH_2CH(CH_3)$phenyl, -NHC(O)CH_2NHCH_2(2,4-dimethylphenyl), -NHC(O)CH_2(2-methyl-piperidin-1-yl), -NHC(O)CH_2NH(2-methoxyphenyl), -NHC(O)CH_2(1,2,3,4-tetrahydroisoquinolin-2-yl), -NHC(O)$CH_2CH_2CH=CH_2$, -NHC(O)CH_2NH(2-methylphenyl), -NHC(O)CH_2(4-oxo-piperidin-1-yl), -NHC(O)(2-fluorophenyl), -NHC(O)CH_2NH$CH(CH_3)$phenyl, -NHC(O)(2-fluoro-6-methoxyphenyl), -NHC(O)CH_2NH(2-isopropylphenyl), -NHC(O)CH_2CH_2(2-methoxyphenyl), -NHC(O)$CH_2CH_2CH(CH_3)_2$, -NHC(O)CH_2(2-phenyl-morpholin-4-yl), -NHC(O)CH_2CH_2(4-methoxyphenyl), -NHC(O)CH_2N(allyl)cyclopentyl, -NHC(O)$CH_2N(CH_3)CH_2CH_2OCH_3$, -NHC(O)CH_2CH_2C(O)cyclopropyl, -NHC(O)CH_2NH(3-*tert*-butylphenyl), -NHC(O)CH_2N(*n*-propyl)(cyclopropylmethyl), -NHC(O)CH_2(2-oxo-cyclopentyl), -NHC(O)CH_2NH(4-chlorophenyl), -NHC(O)CH_2(4-piperidin-1-ylpiperidin-1-yl), -NHC(O)CH_2(4-cyclopentylpiperazin-1-yl), -NHC(O)CH_2(2-methylphenyl), -NHC(O)CH_2NHCH_2(3-fluoro-6-methylphenyl), -NHC(O)$CH_2C(CH_3)_3$, -NHC(O)CH_2NH(2-chlorophenyl), -NHC(O)(3-fluoro-6-methylphenyl), -NHC(O)(4-fluoro-3-methylphenyl), -NHC(O)(2,3-dichlorophenyl), -NHC(O)CH_2Ophenyl,

-NHC(O)CH_2NH(2,3-dimethylphenyl), -NHC(O)(2-fluoro-5-methylphenyl), -NHC(O)CH_2NHOCH_2(4-methylphenyl), -NHC(O)CH_2(4-isopropylpiperazin-1-yl), -NHC(O)CH_2(4-fluorophenyl), -NHC(O)$CH_2CH(CH_3)_2$, -NHC(O)(2-methoxy-4-methylphenyl), -NHC(O)CH_2(4-*n*-propylpiperidin-1-yl), -NHC(O)CH_2O(3-methylphenyl), -NHC(O)(tetrahydrofuran-2-yl), -NHC(O)CH_2(3-hydroxymethylpiperidin-1-yl), -NHC(O)(1-*tert*-butoxycarbonylpiperidin-2-yl), -NHC(O)$CH_2N(CH_3)CH_2$(pyridin-3-yl), -NHC(O)$CH_2N(CH_2CH_3)$phenyl, -NHC(O)$CH_2OCH_2CH_2OCH_3$, -NHC(O)CH_2CH_2(cyclopentyl), -NHC(O)(2,5-dichlorophenyl), -NHC(O)CH_2(4-methylcarbonylpiperazin-1-yl), -NHC(O)(5-fluoro-2-methoxyphenyl), -NHC(O)$CH_2N(CH_2CH_3)$cyclohexyl, -NHC(O)(5-methyl-1,2-oxazol-3-yl), -NHC(O)(3-methylpyridin-3-yl), -NHC(O)(2-methoxypyridin-3-yl), -NHC(O)(3,5-dichlorophenyl), -NHC(O)CH_2(thiazolidin3-yl), -NHC(O)CH_2(4-[C(O)H]-piperazin-1-yl), -NHC(O)CH_2(2-pyridin-4-ylpiperidin-1-yl), -NHC(O)(2-methoxyphenyl), -NHC(O)$CH_2N(CH_3)CH_2CH(CH_3)_2$, -NHC(O)$CH_2$(4-[C(O)H]-homopiperazin-1-yl), -NHC(O)(1-phenylcycloprop-1-yl), -NHC(O)CH_2(2,6-dimethylmorpholin-4-yl), NHC(O)CH_2(2-phenylpyrrolidin-1-yl), -NHC(O)CH_2(morpholin-4-yl), -C(O)NHCH$(CH_3)CH_2N(CH_3)_2$, -C(O)NHC$H_2CH_2N(CH_3)_2$, -C(O)NH(pyrrolidin-3-yl), -C(O)NHCH_2CH_2(pyrrolidin-1-yl), -C(O)NHC$H_2CH_2NH_2$, -C(O)N$(CH_3)CH_2CH_2N(CH_3)_2$, -C(O)NHCH_2(piperidin-2-yl), -C(O)NH(1-methylazetidin-3-yl), -C(O)NHCH_2CH_2(piperidin-1-yl), -C(O)NHC$H_2CH_2N(CH_2CH_3)_2$, -C(O)NH(1-methylpiperidin-3-yl), -C(O)NH(piperidin-3-yl), -C(O)NHCH_2(1-methylpiperidin-3-yl), -C(O)NHC$H_2CH_2N(CH_2CH_2OH)_2$, -C(O)NH(1-ethylpiperidin-3-yl), -C(O)NH_2, -C(O)(3-aminopyrrolidin-1-yl), -C(O)(3-methylaminopyrrolidin-1-yl), -C(O)OH, -C(O)NHCH_2CH_2(morpholin-4-yl), -C(O)NHCH_2(1-ethylpyrrolidin-2-yl), -C(O)(4-amino-3-oxo-pyrazolidin-1-yl), -C(O)$NHCH_3$, -C(O)(3-aminocyclobut-1-yl), -C(O)NHCH_2(pyridin-3-yl), -C(O)NHCH_2CH_2OH, -C(O)NH(3-oxo-pyrazolidin-4-yl), -NHCH_2CH_2(imidazol-4-yl), -C(O)(3-dimethylaminopyrrolidin-1-yl), -C(O)NHCH_2(pyridin-4-yl), -C(O)N(CH_3)(1-methyl-pyrrolidin-3-yl), -C(O)(3-diethylaminopyrrolidin-1-yl), -C(O)NH(pyrrol-1-yl), -C(O)NHC$H_2CH_2CH_2$(pyrrolidin-1-yl), -C(O)N$(CH_3)CH_2CH_2CN$, -C(O)NHC$H_2CH_2OCH_3$, -C(O)N$(CH_2CH_3)CH_2CH_2CN$, -C(O)(3-aminopiperidin-1-yl), -C(O)NHC$H_2CH_2CH_2N(CH_3)_2$, -C(O)NH(morpholin-4-yl), -C(O)N$HN(CH_3)_2$, -C(O)NHC$H_2CH_2CH_2$(imidazol-1-yl), -C(O)NHC$H_2CH_2CH_2N(CH_2CH_3)_2$, -C(O)NHCH_2CH_2CN,

-C(O)NHCH$_2$CH$_2$C(O)OCH$_3$, -C(O)NHCH$_2$CH$_2$SCH$_3$, -C(O)NHCH$_2$CH$_2$SCH$_2$CH$_3$, -C(O)N(CH$_2$CH$_3$)CH$_2$CH$_2$N(CH$_3$)$_2$, -C(O)NHCH$_2$CH$_2$CH$_2$(2-oxo-pyrrolidin-1-yl), -C(O)NHCH$_2$CH$_2$(pyridin-4-yl), -C(O)NHCH$_2$CH$_2$CH$_2$OCH$_2$CH$_3$, -C(O)NHCH$_2$CH$_2$CH$_2$(morpholin-4-yl), -C(O)NHCH$_2$CH$_2$CH$_2$OCH$_3$, -C(O)N(CH$_3$)CH$_2$CH$_2$CH$_2$N(CH$_3$)$_2$, -C(O)NHCH$_2$CH$_2$CH$_2$OCH$_2$CH$_2$CH$_3$, -C(O)NHCH$_2$CH$_2$C(O)OCH$_2$CH$_3$, -C(O)NHCH$_2$CH$_2$CH$_2$OCH(CH$_3$)$_2$, -C(O)NHC(CH$_3$)$_2$CH$_2$(piperidin-1-yl), -C(O)N(CH$_3$)CH$_2$CH$_2$CH$_3$, -C(O)NH(piperidin-1-yl), -C(O)NHCH(CH$_3$)CH$_2$OCH$_3$, -C(O)NHC(CH$_3$)$_2$CH$_2$(morpholin-4-yl), -C(O)(2-dimethylaminomethylpiperidin-1-yl), -C(O)NH(CH$_2$)$_3$O(CH$_2$)$_3$CH$_3$, -C(O)NHCH(CH$_3$)(CH$_2$)$_3$N(CH$_2$CH$_3$)$_2$, -C(O)NHC(CH$_3$)$_2$C(O)(piperidin-1-yl), -C(O)(4-methylpiperazin-1-yl), -C(O)(2-piperidin-1-ylmethyl-piperidin-1-yl), cyano, -NHCH$_3$, -CH(CH$_3$)NHCH$_2$CH$_2$N(CH$_3$)$_2$, -C(O)CH$_3$, -S(O)$_2$NHCH$_2$CH$_2$N(CH$_3$)$_2$, -S(O)$_2$NH(CH$_2$)$_3$N(CH$_3$)$_2$, 5-(*N,N*-dimethylaminomethyl)-1,3,4-oxadiazol-2-yl, -NHCH$_2$CH$_2$N(CH$_3$)$_2$, -N(CH$_3$)$_2$, -OCH$_2$CH$_2$N(CH$_3$)$_2$, -NHC[N(CH$_3$)$_2$][=N(CH$_3$)$_2$], -OCHF$_2$, -S(O)$_2$CH$_3$, -OCF$_3$, or -NHC(O)CH$_2$(4-dimethylaminopiperidin-1-yl).

[00607] In a more specific embodiment (P-L), the compound of Formula I(P) or I(P)a is that where R^{3a} is hydroxyamino, -N(R^7)C(O)-C_1-C_6-alkylene-N(R^{7a})(R^{7b}), -C(O)NR^8R^{8a}, -NR^9C(O)R^{9a}, -C(O)N(R^{10})-C_1-C_6-alkylene-N(R^{10a})R^{10b}, -NR^{11}C(O)N$R^{11a}R^{11b}$, -N(R^{22})C(O)-C_1-C_6-alkylene-N(R^{22b})-N(R^{22c})(R^{22a}), -NR^{13}C(O)OR^{13a}, -N(R^{18})C(O)-C_1-C_6-alkylene-N(R^{18b})C(O)R^{18a}, -NR^{24}C(O)-C_1-C_6-alkylene-OR^{24a}, or -N(R^{20})C(O)-C_1-C_6-alkylene-C(O)R^{20a}; where each of the alkylene in R^{3a} is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; and all other groups are as defined in the Summary of the Invention. Specifically, R^{3a} is -NHC(O)CH$_2$NH(CH$_3$), -NHC(O)CH(CH$_3$)NH$_2$, -NHC(O)C(CH$_3$)$_2$NH$_2$, -NHC(O)CH$_2$N(CH$_3$)$_2$, -NHC(O)CH$_2$N(CH$_3$)CH$_2$CH$_2$N(CH$_3$)$_2$, -NHC(O)CH(NH$_2$)CH$_2$CH$_3$, -NHC(O)CH$_2$N(CH$_3$)CH$_2$CH$_2$N(CH$_3$)$_2$, -NHC(O)CH(CH$_3$)NH(CH$_3$), -NHC(O)H, -NHC(O)CH$_2$(azetidin-1-yl), -NHC(O)(pyrrolidin-2-yl), -NHC(O)CH(NH$_2$)CH$_2$OH, -NHC(O)(azetidin-4-yl), -NHC(O)C(CH$_3$)$_2$NH(CH$_3$), -NH$_2$, -NHC(O)CH$_2$NH(CH$_2$CH$_2$CH$_3$), -NHC(O)CH$_2$CH$_2$NH$_2$, -NHOH, or -NHC(O)(piperidin-3-yl).

[00608] In a more specific embodiment (P-M) the compound is of Formula I(P) or I(P)a and R^{3a} -N(R^7)C(O)-C_1-C_6-alkylene-N(R^{7a})(R^{7b}); and R^7 is hydrogen or alkyl and R^{7a} and R^{7b} are independently hydrogen, alkyl, aminoalkyl, alkylaminoalkyl, or

dialkylaminoalkyl; and all other groups are as defined in the Summary of the Invention. More specifically, R^{3a} is -NHC(O)$CH_2NH(CH_3)$, -NHC(O)$CH(CH_3)NH_2$, -NHC(O)$C(CH_3)_2NH_2$, -NHC(O)$CH_2N(CH_3)_2$, -NHC(O)$CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, -NHC(O)$CH(NH_2)CH_2CH_3$, -NHC(O)$CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, or -NHC(O)$CH(CH_3)NH(CH_3)$.

[00609] Embodiment (P-N) provides a compound of Formula I(P) where each R^3 is independently halo; cyano; alkyl; alkenyl; alkoxy; hydroxyamino; carboxy; alkylsulfonyl, aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; -$N(R^7)C(O)$-C_1-C_6-alkylene-$N(R^{7a})(R^{7b})$; -$C(O)NR^8R^{8a}$; -$NR^9C(O)R^{9a}$; -$C(O)N(R^{10})$-C_1-C_6-alkylene-$N(R^{10a})R^{10b}$; -$NR^{11}C(O)NR^{11a}R^{11b}$ where R^{11a}; -$C(O)R^{12}$; -$NR^{13}C(O)OR^{13a}$; -$C(O)N(R^{14})N(R^{14a})(R^{14b})$; -$S(O)_2N(R^{15})$-$C_1$.$C_6$-alkylene-$N(R^{15a})R^{15b}$; -$C(O)N(R^{16})$-$C_1$.$C_6$-alkylene-$C(O)OR^{16a}$; heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; -$N(R^{17})$-$C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$; -$N(R^{18})C(O)$-$C_1$-$C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$; -$C(O)N(R^{19})$-$C_1$-$C_6$-alkylene-$C(O)R^{19a}$; -$N(R^{22})C(O)$-$C_1$.$C_6$-alkylene-$N(R^{22b})$-$N(R^{22c})(R^{22a})$; -$C_0$.$C_6$-alkylene-$N(R^{23})$-$C_1$.$C_6$-alkylene-$N(R^{23b})R^{23a}$; or -$NR^{24}C(O)$-$C_1$.$C_6$-alkylene-$OR^{24a}$; where each of the alkylene in R^3 is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; and all other groups are as defined in the Summary of the Invention.

[00610] Specifically, each R^3 is independently methyl, bromo, chloro, fluoro, NHC(O)$CH_2NH(CH_3)$, -NHC(O)$CH_2NH(CH_2CH_3)$, -NHC(O)$CH(CH_3)NH_2$, -NHC(O)$C(CH_3)_2NH_2$, -NHC(O)$CH_2N(CH_3)_2$, -NHC(O)$CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, -NHC(O)$CH(NH_2)CH_2CH_3$, -NHC(O)$CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, -NHC(O)$CH(CH_3)NH(CH_3)$, -NHC(O)$CH_2NH_2$, -NHC(O)H, -NHC(O)$CH_2$(azetidin-1-yl), -NHC(O)(pyrrolidin-2-yl), -NHC(O)$CH(NH_2)CH_2OH$, -NHC(O)(azetidin-4-yl), -NHC(O)$C(CH_3)_2NH(CH_3)$, -NH_2, -NHC(O)$CH_2NH(CH_2CH_2CH_3)$, -NHC(O)$CH_2CH_2NH_2$, -NHOH, -NHC(O)(piperidin-3-yl), -NHC(O)CH_2(4-methyl-1,4-diazepan-1-yl), -NHC(O)$CH(NH_2)(CH_2CH_3)$, -NHC(O)$CH_2NH(CH_2CH(OH)(CH_3))$, -NHC(O)$CH_2NHCH_2CH_2F$, -NHC(O)$CH_2NH(OCH_2CH(CH_3)_2)$, -NHC(O)(1-aminocycloprop-1-yl), -NHC(O)$CH_2NH(CH_2$cyclopropyl), -NHC(O)CH_2(3-(dimethylamino)-azetidin-1-yl), -NHC(O)(piperidin-2-yl), -NHC(O)(morpholin-4-yl), -NHC(O)CH_2(pyrrolidin-1-yl), -NHC(O)$CH(NH_2)CH_2CH_2CH_2CH_2N(CH_3)_2$, -NHC(O)$CH_2N(CH_3)(CH_2CH_3)$, -NHC(O)$CH_2$(imidazol-5-yl), -NHC(O)(1-

aminocyclopent-1-yl), -NHC(O)CH_2NH(CH_2CH(CH_3)$_2$), -NHC(O)CH_2N(CH_3)(CH_2CH_3), -NHC(O)(*N*-(imidazol-4-ylmethyl)-azetidin-3-yl), -NHC(O)(*N*-ethyl-azetidin-3-yl), -NHCH_2N(CH_3)CH_2CH_2N(CH_3)$_2$, -NHC(O)CH_2N(CH_3)(*N*-methyl-pyrrolidin-3-yl), -NHC(O)CH_2N(CH_3)(CH_2CH_2N(CH_3)$_2$), -NHC(O)CH_2(3-hydroxy-pyrrolidin-1-yl), -NHC(O)(1-amino-cyclobut-1-yl), -NHC(O)CH_2NH(CH_2)$_3CH_3$, -NHC(O)CH_2(3-piperidin-1-ylazetidin-1yl), -NHC(O)NH_2, -NHC(O)(1-hydroxycyclopropyl), -NHC(O)CH_2NHN(CH_3)$_2$, -NHC(O)NH(CH_2)$_2$N(CH_3)$_2$, -NHC(O)CH_2OH, -NHC(O)(pyridazin-4-yl), -NHC(O)(N-methyl-piperidin-4-yl), -NHC(O)CH_2NHCH(CH_3)$_3$, -NHC(O)CH_2(3-dimethylamino-pyrrolidin-1yl), -NHC(O)CH_2NH(CH_2)$_2$N(CH_3)$_2$, -NHC(O)(1-cyclopropylmethyl-azetidin-3-yl), -NHC(O)CH_2NH(CH_3)$_3$, -NHC(O)(imidazol-2-yl), -NHC(O)(imidazol-4-yl), -NHC(O)(1,2-oxazol-5-yl), -NHC(O)CH_2NHCH_2CF_3, -NHC(O)CH_2CH_2(piperidin-1-yl), -NHC(O)(3-oxo-cyclopent-1-yl), -NHC(O)(2-hydroxy-pyridin-6-yl), -NHC(O)CH_2NH(3-fluoro-4-hydroxyphenyl), -NHC(O)(CH_2)$_3$N(CH_3)$_2$, -NHC(O)(1-(furan-2-ylmethyl)-azetidin-3-yl), -NHC(O)(pyrimidin-5-yl), -NHC(O)(pyrrol-2-yl), -NHC(O)CH_2N(CH_3)CH(CH_3)$_2$, -NHC(O)CH_2N(CH_2CH_3)$_2$, -NHC(O)CH_2(3-methyl-1,2-oxazol-5-yl), -NHC(O)CH_2NHCH_2(3-hydroxyphenyl), -NHC(O)(*N*-methyl-pyrrol-2-yl), -NHC(O)(2-amino-tetrahydropyran-2-yl), -NHC(O)CH_2(4-methylamino-piperidin-1-yl), -NHC(O)(piperidin-1-yl), -NHC(O)(*N*-methyl-pyrrolidin-2yl), -NHC(O)(thien-3yl), -NHC(O)(*N*-(cyclopropylcarbonyl)azetidin-3-yl), -NHC(O)CH_2(4-methylpiperazin-1-yl), -NHC(O)(*N*-benzylazetidin-3-yl), -NHC(O)(2-chloro-pyridin-3-yl), -NHC(O)CH_2(pyridin-4-yl), -NHC(O)CH_2N(CH_3)(CH_2CH=CH_2), -NHC(O)CH_2NH(benzyl), -NHC(O)CH_2OCH_3, -NHC(O)[1-(C(O)CH_2CH_3)-azetidin-3-yl], -NHC(O)(pyridin-3-yl), -NHC(O)CH_2NHC$H_2CH_2OCH_3$, -NHC(O)(1-[C(O)CH_3]piperidin-4-yl), -NHC(O)CH_2(2-methyl-pyrrolidin-1-yl), -NHC(O)(furan-3-yl), -NHC(O)CH_2N(CH_3)$_2$, -NHC(O)(2-chloro-pyridin-5-yl), -NHC(O)(2-chlorophenyl), -NHC(O)CH_2(pyridin-2-yl), -NHC(O)CH_2(3-dimethylamino-azetidin-1-yl), -NHC(O)CH_2(pyridin-3-yl), -NHC(O)CH_2(2-chlorophenyl), -NHC(O)CH_2N(CH_3)$CH_2CH_2CH_2$N(CH_3)$_2$, -NHC(O)CH_2N(CH_2CH_3)CH_2CH_2OH, -NHC(O)CH_2(2-benzyl-pyrrolidin-1-yl), -NHC(O)(furan-2-yl, -NHC(O)(2-chloro-pyridin-4-yl), -NHC(O)CH_2NHC(O)CH_3, -NHC(O)$CH_2CH_2CH_3$, -NHC(O)(4-chlorophenyl), -NHC(O)(4-methyl-phenyl), -NHC(O)CH_2NHC(O)O(CH_3)$_3$,

-NHC(O)(benzo[d][1,3]dioxol-5-yl), -NHC(O)CH_2NHOCH_2(2-methoxyphenyl), -NHC(O)(pyridin-4-yl), -NHC(O)CH_2[4-(3,4-dichlorophenyl)-piperazin-1-yl], -NHC(O)CH_2CH_2(pyridin-3-yl), -NHC(O)(tetrahydrofuran-3-yl), -NHC(O)CH_2NHCH_2(2-methylphenyl), -NHC(O)CH(CH_3)CH_2CH_3, -NHC(O)CH_2(3-fluorophenyl), -NHC(O)$CH_2C(CH_3)_2$phenyl, -NHC(O)(2-methyl-cycloprop-1-yl), -NHC(O)(2-methyl-4-methoxyphenyl), -NHC(O)(2-methylpyridin-3-yl), -NHC(O)(4-methoxyphenyl), -NHC(O)CH_2(4-ethylpiperazin-1-yl), -NHC(O)(thien-2-yl), -NHC(O)(3-fluoro-2-methylphenyl), -NHC(O)(2-bromo-thien-3-yl), -NHC(O)(4-fluorophenyl), -NHC(O)CH_2(3-methylpiperidin-1-yl), -NHC(O)CH(CH_3)$_2$, -NHC(O)$(CH_2)_3CH_3$, -NHC(O)$CH_2OCH_2CH_3$, -NHC(O)CH_2NH(2-fluorophenyl), -NHC(O)(3-dimethylaminophenyl), -NHC(O)CH_2(4-methylpiperidin-1-yl), -NHC(O)CH_2NH(2-*n*-propylphenyl), -NHC(O)phenyl, -NHC(O)(pyrazin2-yl), -NHC(O)(3-fluoro-4-methoxyphenyl), -NHC(O)$C(CH_3)_2CH_2CH_3$, -NHC(O)CH_2O(4-fluorophenyl), -NHC(O)(1-methylcarbonyl-azetidin-3-yl), -NHC(O)CH_2NH(4-methylphenyl), -NHC(O)CH_2NH(phenyl), -NHC(O)CH_2(4-allyl-piperazin-1-yl), -NHC(O)(2-methylphenyl), -NHC(O)$CH_2CH_2OCH_3$, -NHC(O)(3-methyl-furan-2-yl), -NHC(O)$C(CH_3)_3$, -NHC(O)CH_2NHObenzyl, -NHC(O)CH_2NH(3-chlorophenyl), -NHC(O)cyclobutyl, -NHC(O)CH_2(3-methoxyphenyl), -NHC(O)(1-methylcycloprop-1-yl), -NHC(O)(3-flurophenyl), -NHC(O)(4-dimethylaminophenyl), -NHC(O)(3,4-dichlorophenyl), -NHC(O)CH_2NHCH_2(2-methylthiophenyl), -NHC(O)CH_2(2-fluorophenyl), -NHC(O)$CH_2N(CH_2CH_3)CH(CH_3)_2$, -NHC(O)(thiazol-4-yl), -NHC(O)$CH_2N(CH_3)$benzyl, -NHC(O)CH_2NHCH_2(thien-2-yl), -NHC(O)CH_2NHCH_2(pyridin-2-yl), -NHC(O)(3-methoxyphenyl), -NHC(O)CH_2NHCH_2(3-chloro-4-methylphenyl), -NHC(O)CH(CH_3)$CH_2CH_2CH_3$, -NHC(O)CH_2(4-chlorophenyl), -NHC(O)(3-fluoro-4-methylphenyl), -NHC(O)CH_2O(2-methylphenyl), -NHC(O)CH_2(cyclohexyl), -NHC(O)(2-phenyl-cycloprop-1-yl), -NHC(O)(3-chlorophenyl), -NHC(O)CH_2(2-methoxyphenyl), -NHC(O)CH_2CH_2(3-methoxyphenyl), -NHC(O)CH_2NH(2-fluoro-4-methyl-phenyl), -NHC(O)CH_2NHCH_2(3-fluoro-phenyl), -NHC(O)CH_2(4-methoxy-phenyl), -NHC(O)benzyl, -NHC(O)(2,4-dichlorophenyl), -NHC(O)(3-oxo-cyclohex-1-yl), -NHC(O)CH_2NH(3-fluorophenyl), -NHC(O)CH_2(3-chlorophenyl), -NHC(O)CH_2NHCH_2CH(CH_3)phenyl, -NHC(O)CH_2NHCH_2(2,4-dimethylphenyl), -NHC(O)CH_2(2-methyl-piperidin-1-yl),

-NHC(O)CH_2NH(2-methoxyphenyl), -NHC(O)CH_2(1,2,3,4-tetrahydroisoquinolin-2-yl), -NHC(O)$CH_2CH_2CH{=}CH_2$, -NHC(O)CH_2NH(2-methylphenyl), -NHC(O)CH_2(4-oxo-piperidin-1-yl), -NHC(O)(2-fluorophenyl), -NHC(O)$CH_2NHCH(CH_3)$phenyl, -NHC(O)(2-fluoro-6-methoxyphenyl), -NHC(O)CH_2NH(2-isopropylphenyl), -NHC(O)CH_2CH_2(2-methoxyphenyl), -NHC(O)$CH_2CH_2CH(CH_3)_2$, -NHC(O)CH_2(2-phenyl-morpholin-4-yl), -NHC(O)CH_2CH_2(4-methoxyphenyl), -NHC(O)CH_2N(allyl)cyclopentyl, -NHC(O)$CH_2N(CH_3)CH_2CH_2OCH_3$, -NHC(O)CH_2CH_2C(O)cyclopropyl, -NHC(O)CH_2NH(3-*tert*-butylphenyl), -NHC(O)CH_2N(*n*-propyl)(cyclopropylmethyl), -NHC(O)CH_2(2-oxo-cyclopentyl), -NHC(O)CH_2NH(4-chlorophenyl), -NHC(O)CH_2(4-piperidin-1-ylpiperidin-1-yl), -NHC(O)CH_2(4-cyclopentylpiperazin-1-yl), -NHC(O)CH_2(2-methylphenyl), -NHC(O)CH_2NHCH_2(3-fluoro-6-methylphenyl), -NHC(O)$CH_2C(CH_3)_3$, -NHC(O)CH_2NH(2-chlorophenyl), -NHC(O)(3-fluoro-6-methylphenyl), -NHC(O)(4-fluoro-3-methylphenyl), -NHC(O)(2,3-dichlorophenyl), -NHC(O)CH_2Ophenyl, -NHC(O)CH_2NH(2,3-dimethylphenyl), -NHC(O)(2-fluoro-5-methylphenyl), -NHC(O)CH_2NHOCH_2(4-methylphenyl), -NHC(O)CH_2(4-isopropylpiperazin-1-yl), -NHC(O)CH_2(4-fluorophenyl), -NHC(O)$CH_2CH(CH_3)_2$, -NHC(O)(2-methoxy-4-methylphenyl), -NHC(O)CH_2(4-*n*-propylpiperidin-1-yl), -NHC(O)CH_2O(3-methylphenyl), -NHC(O)(tetrahydrofuran-2-yl), -NHC(O)CH_2(3-hydroxymethylpiperidin-1-yl), -NHC(O)(1-*tert*-butoxycarbonylpiperidin-2-yl), -NHC(O)$CH_2N(CH_3)CH_2$(pyridin-3-yl), -NHC(O)$CH_2N(CH_2CH_3)$phenyl, -NHC(O)$CH_2OCH_2CH_2OCH_3$, -NHC(O)CH_2CH_2(cyclopentyl), -NHC(O)(2,5-dichlorophenyl), -NHC(O)CH_2(4-methylcarbonylpiperazin-1-yl), -NHC(O)(5-fluoro-2-methoxyphenyl), -NHC(O)$CH_2N(CH_2CH_3)$cyclohexyl, -NHC(O)(5-methyl-1,2-oxazol-3-yl), -NHC(O)(3-methylpyridin-3-yl), -NHC(O)(2-methoxypyridin-3-yl), -NHC(O)(3,5-dichlorophenyl), -NHC(O)CH_2(thiazolidin3-yl), -NHC(O)CH_2(4-[C(O)H]-piperazin-1-yl), -NHC(O)CH_2(2-pyridin-4-ylpiperidin-1-yl), -NHC(O)(2-methoxyphenyl), -NHC(O)$CH_2N(CH_3)CH_2CH(CH_3)_2$, -NHC(O)$CH_2$(4-[C(O)H]-homopiperazin-1-yl), -NHC(O)(1-phenylcycloprop-1-yl), -NHC(O)CH_2(2,6-dimethylmorpholin-4-yl), NHC(O)CH_2(2-phenylpyrrolidin-1-yl), -NHC(O)CH_2(morpholin-4-yl), -C(O)NHCH$(CH_3)CH_2N(CH_3)_2$, -C(O)$NHCH_2CH_2N(CH_3)_2$, -C(O)NH(pyrrolidin-3-yl), -C(O)$NHCH_2CH_2$(pyrrolidin-1-yl), -C(O)$NHCH_2CH_2NH_2$, -C(O)$N(CH_3)CH_2CH_2N(CH_3)_2$, -C(O)$NHCH_2$(piperidin-2-yl), -C(O)NH(1-

methylazetidin-3-yl), -C(O)NHCH$_2$CH$_2$(piperidin-1-yl), -C(O)NHCH$_2$CH$_2$N(CH$_2$CH$_3$)$_2$, -C(O)NH(1-methylpiperidin-3-yl), -C(O)NH(piperidin-3-yl), -C(O)NHCH$_2$(1-methylpiperidin-3-yl), -C(O)NHCH$_2$CH$_2$N(CH$_2$CH$_2$OH)$_2$, -C(O)NH(1-ethylpiperidin-3-yl), -C(O)NH$_2$, -C(O)(3-aminopyrrolidin-1-yl), -C(O)(3-methylaminopyrrolidin-1-yl), -C(O)OH, -C(O)NHCH$_2$CH$_2$(morpholin-4-yl), -C(O)NHCH$_2$(1-ethylpyrrolidin-2-yl), -C(O)(4-amino-3-oxo-pyrazolidin-1-yl), -C(O)NHCH$_3$, -C(O)(3-aminocyclobut-1-yl), -C(O)NHCH$_2$(pyridin-3-yl), -C(O)NHCH$_2$CH$_2$OH, -C(O)NH(3-oxo-pyrazolidin-4-yl), -NHCH$_2$CH$_2$(imidazol-4-yl), -C(O)(3-dimethylaminopyrrolidin-1-yl), -C(O)NHCH$_2$(pyridin-4-yl), -C(O)N(CH$_3$)(1-methyl-pyrrolidin-3-yl), -C(O)(3-diethylaminopyrrolidin-1-yl), -C(O)NH(pyrrol-1-yl), -C(O)NHCH$_2$CH$_2$CH$_2$(pyrrolidin-1-yl), -C(O)N(CH$_3$)CH$_2$CH$_2$CN, -C(O)NHCH$_2$CH$_2$OCH$_3$, -C(O)N(CH$_2$CH$_3$)CH$_2$CH$_2$CN, -C(O)(3-aminopiperidin-1-yl), -C(O)NHCH$_2$CH$_2$CH$_2$N(CH$_3$)$_2$, -C(O)NH(morpholin-4-yl), -C(O)NHN(CH$_3$)$_2$, -C(O)NHCH$_2$CH$_2$CH$_2$(imidazol-1-yl), -C(O)NHCH$_2$CH$_2$CH$_2$N(CH$_2$CH$_3$)$_2$, -C(O)NHCH$_2$CH$_2$CN, -C(O)NHCH$_2$CH$_2$C(O)OCH$_3$, -C(O)NHCH$_2$CH$_2$SCH$_3$, -C(O)NHCH$_2$CH$_2$SCH$_2$CH$_3$, -C(O)N(CH$_2$CH$_3$)CH$_2$CH$_2$N(CH$_3$)$_2$, -C(O)NHCH$_2$CH$_2$CH$_2$(2-oxo-pyrrolidin-1-yl), -C(O)NHCH$_2$CH$_2$(pyridin-4-yl), -C(O)NHCH$_2$CH$_2$CH$_2$OCH$_2$CH$_3$, -C(O)NHCH$_2$CH$_2$CH$_2$(morpholin-4-yl), -C(O)NHCH$_2$CH$_2$CH$_2$OCH$_3$, -C(O)N(CH$_3$)CH$_2$CH$_2$CH$_2$N(CH$_3$)$_2$, -C(O)NHCH$_2$CH$_2$CH$_2$OCH$_2$CH$_2$CH$_3$, -C(O)NHCH$_2$CH$_2$C(O)OCH$_2$CH$_3$, -C(O)NHCH$_2$CH$_2$CH$_2$OCH(CH$_3$)$_2$, -C(O)NHC(CH$_3$)$_2$CH$_2$(piperidin-1-yl), -C(O)N(CH$_3$)CH$_2$CH$_2$CH$_3$, -C(O)NH(piperidin-1-yl), -C(O)NHCH(CH$_3$)CH$_2$OCH$_3$, -C(O)NHC(CH$_3$)$_2$CH$_2$(morpholin-4-yl), -C(O)(2-dimethylaminomethylpiperidin-1-yl), -C(O)NH(CH$_2$)$_3$O(CH$_2$)$_3$CH$_3$, -C(O)NHCH(CH$_3$)(CH$_2$)$_3$N(CH$_2$CH$_3$)$_2$, -C(O)NHC(CH$_3$)$_2$C(O)(piperidin-1-yl), -C(O)(4-methylpiperazin-1-yl), -C(O)(2-piperidin-1-ylmethyl-piperidin-1-yl), cyano, -NHCH$_3$, -CH(CH$_3$)NHCH$_2$CH$_2$N(CH$_3$)$_2$, -C(O)CH$_3$, -S(O)$_2$NHCH$_2$CH$_2$N(CH$_3$)$_2$, -S(O)$_2$NH(CH$_2$)$_3$N(CH$_3$)$_2$, 5-(*N,N*-dimethylaminomethyl)-1,3,4-oxadiazol-2-yl, -NHCH$_2$CH$_2$N(CH$_3$)$_2$, -N(CH$_3$)$_2$, -OCH$_2$CH$_2$N(CH$_3$)$_2$, -NHC[N(CH$_3$)$_2$][=N(CH$_3$)$_2$], -OCHF$_2$, -CF$_3$, -S(O)$_2$CH$_3$, -OCF$_3$, -NHC(O)CH$_2$(4-dimethylaminopiperidin-1-yl), or methoxy.

[00611] In a more specific embodiment (P-P), the Compound of Formula I(P) is that where each R^3 is independently halo, alkyl, hydroxyamino, -N(R^7)C(O)-C$_1$-C$_6$-alkylene-N(R^{7a})(R^{7b}), -C(O)NR^{8}R^{8a} , -NR^{9}C(O)R^{9a}, -C(O)N(R^{10})-C$_1$-C$_6$-alkylene-

$N(R^{10a})R^{10b}$-$NR^{11}C(O)NR^{11a}R^{11b}$, -$N(R^{22})C(O)$-$C_1$-$C_6$-alkylene-$N(R^{22b})$-$N(R^{22c})(R^{22a})$, -$NR^{13}C(O)OR^{13a}$, -$N(R^{18})C(O)$-$C_1$-$C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$, -$NR^{24}C(O)$-$C_1$-$C_6$-alkylene-$OR^{24a}$, or -$N(R^{20})C(O)$-$C_1$-$C_6$-alkylene-$C(O)R^{20a}$; where each of the alkylene in R^3 is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; and all other groups are as defined in the Summary of the Invention. Specifically, each R^3 is independently methyl, chloro, -$NHC(O)CH_2NH(CH_3)$, -$NHC(O)CH(CH_3)NH_2$, -$NHC(O)C(CH_3)_2NH_2$, -$NHC(O)CH_2N(CH_3)_2$, -$NHC(O)CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, -$NHC(O)CH(NH_2)CH_2CH_3$, -$NHC(O)CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, -$NHC(O)CH(CH_3)NH(CH_3)$, -NHC(O)H, -$NHC(O)CH_2$(azetidin-1-yl), -NHC(O)(pyrrolidin-2-yl), -$NHC(O)CH(NH_2)CH_2OH$, -NHC(O)(azetidin-4-yl), -$NHC(O)C(CH_3)_2NH(CH_3)$, -NH_2, -$NHC(O)CH_2NH(CH_2CH_2CH_3)$, -$NHC(O)CH_2CH_2NH_2$, -NHOH, or -NHC(O)(piperidin-3-yl).

[00612] In a more specific embodiment (P-Q), the Compound of Formula I(P) is that where R^3 is alkyl or -$N(R^7)C(O)$-C_1-C_6-alkylene-$N(R^{7a})(R^{7b})$; and R^7 is hydrogen or alkyl and R^{7a} and R^{7b} are independently hydrogen, alkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; and all other groups are as defined in herein. More specifically, each R^3 is independently methyl, -$NHC(O)CH_2NH(CH_3)$, -$NHC(O)CH(CH_3)NH_2$, -$NHC(O)C(CH_3)_2NH_2$, -$NHC(O)CH_2N(CH_3)_2$, -$NHC(O)CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, -$NHC(O)CH(NH_2)CH_2CH_3$, -$NHC(O)CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, or -$NHC(O)CH(CH_3)NH(CH_3)$.

[00613] In another specific embodiment (P-R), the Compound of Formula I(P) is that where B is phenyl, R^3 is not present or R^3 is halo, alkyl, or alkoxy; R^{3a} is -$C(O)NR^8R^{8a}$, -$NR^9C(O)R^{9a}$, -$N(R^7)C(O)$-C_1-C_6-alkylene-$N(R^{7a})(R^{7b})$, or -$C(O)N(R^{10})$-C_1-C_6-alkylene-$N(R^{10a})R^{10b}$ where each of the alkylene in R^{3a} is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; and all other groups are as defined herein.

[00614] In a more specific embodiment (P-R1) of embodiment (P-R), the compound is that where R^{50}, R^{52}, and R^{53} are hydrogen and R^{54} is halo or alkoxy; R^{50}, R^{52}, and R^{54} are hydrogen and R^{53} is alkoxy; or R^{50} and R^{52} are hydrogen and R^{53} and R^{54} together with the carbons to which they are attached form a 6-membered heteroaryl; and all other groups are as defined in the Summary of the Invention. Specifically, R^{50}, R^{52}, and R^{53}

are hydrogen and R^{54} is halo or alkoxy; or R^{50}, R^{52}, and R^{54} are hydrogen and R^{53} is alkoxy.

[00615] In a more specific embodiment of (P-R2) of embodiment (P-R), the compound is that where R^{51} is methyl.

[00616] In a more specific embodiment (P-S), the compound of Formula I(P)a:



I(P)a

is that where R^3 is not present or R^3 is alkyl and R^{3a} is $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$, $-C(O)NR^8R^{8a}$, $-NR^9C(O)R^{9a}$, or $-C(O)N(R^{10})-C_1-C_6$-alkylene-$N(R^{10a})R^{10b}$; where each of the alkylene in R^{3a} is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; and all other groups are as defined in the Summary of the Invention. Specifically, R^3 is is not present or is methyl. More specifically, R^3 is is not present.

[00617] In a more specific embodiment (P-S1) of embodiment (P-S) is that where R^7 is hydrogen or alkyl and R^{7a}, and R^{7b} are independently hydrogen, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; R^8 is hydrogen or alkyl and R^{8a} is heterocycloalkyl or heterocycloalkylalkyl; R^9 is hydrogen or alkyl and R^{9a} is hydrogen, heterocycloalkyl, or heterocycloalkylalkyl; and R^{10}, R^{10a}, and R^{10b} are independently hydrogen, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl.

[00618] In a more specific embodiment (P-S2) of embodiment (P-S) is that where R^{50}, R^{52}, and R^{53} are hydrogen and R^{54} is halo or alkoxy; or R^{50}, R^{52}, and R^{54} are hydrogen and R^{53} is alkoxy; or R^{50} and R^{52} are hydrogen and R^{53} and R^{54} together with the carbons to which they are attached form a 6-membered heteroaryl. Specifically, R^{50}, R^{52}, and R^{53} are hydrogen and R^{54} is halo or alkoxy; or R^{50}, R^{52}, and R^{54} are hydrogen and R^{53} is alkoxy.

[00619] In a more specific embodiment of (P-S3) of embodiment (P-S), the compound is that where R^{51} is methyl.

[00620] In another specific embodiment (P-T), the Compound of Formula I(P) is that where B is heteroaryl, one R^3 is halo, alkyl, or alkoxy and a second R^3 is $-C(O)NR^8R^{8a}$, $-NR^9C(O)R^{9a}$, $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$, or $-C(O)N(R^{10})-C_1-C_6$-alkylene-$N(R^{10a})R^{10b}$ where each of the alkylene in R^3 is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; and all other groups are as defined herein.

[00621] In another specific embodiment (P-T1) of embodiment (P-T), the compound is that where R^7 is hydrogen or alkyl and R^{7a}, and R^{7b} are independently hydrogen, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; R^8 is hydrogen or alkyl and R^{8a} is heterocycloalkyl or heterocycloalkylalkyl; R^9 is hydrogen or alkyl and R^{9a} is hydrogen, heterocycloalkyl, or heterocycloalkylalkyl; R^{10}, R^{10a}, and R^{10b} are independently hydrogen, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl.

[00622] In another specific embodiment (P-U), the compound of Formula I(P) is that where B is



; each R^3 (when R^3 is present) is independently halo, alkyl, alkoxy, aminoalkyloxy, alkylaminoalkyloxy, dialkylaminoalkyloxy, alkylamino, dialkylamino, $-C(O)NR^8R^{8a}$, $-NR^9C(O)R^{9a}$, $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$, or $-C(O)N(R^{10})-C_1-C_6$-alkylene-$N(R^{10a})R^{10b}$; and all other groups are as defined herein.

[00623] In a more specific embodiment (P-U1) of embodiment (P-U), the compound of Formula I(P) is that where R^{50}, R^{52}, and R^{53} are hydrogen and R^{54} is halo or alkoxy; R^{50}, R^{52}, and R^{54} are hydrogen and R^{53} is alkoxy; or R^{50} and R^{52} are hydrogen and R^{53} and R^{54} together with the carbons to which they are attached form a 6-membered heteroaryl; and all other groups are as defined in the Summary of the Invention. Specifically, R^{50}, R^{52}, and R^{53} are hydrogen and R^{54} is halo or alkoxy; or R^{50}, R^{52}, and R^{54} are hydrogen and R^{53} is alkoxy.

[00624] In a more specific embodiment (P-U2) of embodiment (P-U1), the compound of Formula I(P) is that where R^{51} is methyl.

[00625] In another specific embodiment (P-U3) of embodiment (P-U), the compound of Formula I(P) is that where R^7 is hydrogen or alkyl and R^{7a}, and R^{7b} are independently hydrogen, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; R^8 is hydrogen or alkyl and R^{8a} is heterocycloalkyl or heterocycloalkylalkyl; R^9 is hydrogen or alkyl and R^{9a} is hydrogen, heterocycloalkyl, or heterocycloalkylalkyl; R^{10}, R^{10a}, and R^{10b} are independently hydrogen, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl

[00626] In another embodiment of the Invention (P-V) the Compound of Formula I(P) is that where:

W^1, W^2, W^3, and W^4 are -C(H)=; or W^2 and W^3 are -C(H)= and one of W^1 and W^4 is -N= and the other is -C(H)=;

R^{50} is hydrogen;

R^{51} is hydrogen or alkyl;

R^{52} is hydrogen;

R^{53} is hydrogen, alkoxy, nitro, amino, or $-N(R^{55})C(O)-C_1-C_6$-alkylene-$N(R^{55a})R^{55b}$; and R^{54} is hydrogen, alkyl, alkoxy, or halo; or R^{53} and R^{54} together with the carbons to which they are attached form a 6-membered heteroaryl;

B is phenyl substituted with R^{3a} and optionally further substituted with one R^3; or

B is heteroaryl optionally substituted with one or two R^3;

R^{3a} is cyano; hydroxyamino; carboxy; alkylsulfonyl, aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$; $-C(O)NR^8R^{8a}$; $-NR^9C(O)R^{9a}$; $-C(O)N(R^{10})-C_1-C_6$-alkylene-$N(R^{10a})R^{10b}$; $-NR^{11}C(O)NR^{11a}R^{11b}$ where R^{11a}; $-C(O)R^{12}$; $-NR^{13}C(O)OR^{13a}$; $-C(O)N(R^{14})N(R^{14a})(R^{14b})$; $-S(O)_2N(R^{15})-C_1.C_6$-alkylene-$N(R^{15a})R^{15b}$; $-C(O)N(R^{16})-C_1.C_6$-alkylene-$C(O)OR^{16a}$; heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$; $-N(R^{18})C(O)-C_1-C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$; $-C(O)N(R^{19})-C_1-C_6$-alkylene-$C(O)R^{19a}$; $-N(R^{22})C(O)-C_1.C_6$-alkylene-$N(R^{22b})-N(R^{22c})(R^{22a})$; $-C_0.C_6$-alkylene-$N(R^{23})-C_1.C_6$-alkylene-$N(R^{23b})R^{23a}$; or $-NR^{24}C(O)-C_1.C_6$-alkylene-OR^{24a}; where each of the alkylene in R^{3a} is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino;

each R^3 (when R^3 is present) is independently halo; cyano; alkyl; alkenyl; alkoxy; hydroxyamino; carboxy; alkylsulfonyl, aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; -N(R^7)C(O)-C_1-C_6-alkylene-N(R^{7a})(R^{7b}); -C(O)NR^8R^{8a}; -NR^9C(O)R^{9a}; -C(O)N(R^{10})-C_1-C_6-alkylene-N(R^{10a})R^{10b}; -NR^{11}C(O)N$R^{11a}R^{11b}$ where R^{11a}; -C(O)R^{12}; -NR^{13}C(O)OR^{13a}; -C(O)N(R^{14})N(R^{14a})(R^{14b}); -S(O)$_2$N(R^{15})-C_1-C_6-alkylene-N(R^{15a})R^{15b}; -C(O)N(R^{16})-C_1-C_6-alkylene-C(O)OR^{16a}; heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; -N(R^{17})-C(=N(R^{17b})(R^{17a}))(N$R^{17c}R^{17d}$); -N(R^{18})C(O)-C_1-C_6-alkylene-N(R^{18b})C(O)R^{18a}; -C(O)N(R^{19})-C_1-C_6-alkylene-C(O)R^{19a}; -N(R^{22})C(O)-C_1-C_6-alkylene-N(R^{22b})-N(R^{22c})(R^{22a}); -C_0-C_6-alkylene-N(R^{23})-C_1-C_6-alkylene-N(R^{23b})R^{23a}; or -NR^{24}C(O)-C_1-C_6-alkylene-OR^{24a}; where each of the alkylene in R^3 is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino;

provided that when R^{50} and R^{52} are hydrogen, R^{51} is hydrogen or methyl, R^{53} is hydrogen or methoxy, and R^{54} is hydrogen or methoxy, then B is not 2,3-dihydro-1,4-benzodioxinyl, thien-2-yl, or thien-2-yl substituted with one R^3 where R^3 is halo.

[00627] Another embodiment (P-W) of the invention is a Compound of Formula I(P) where R^{50}, R^{53}, and R^{54} are independently hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, -N(R^{55})C(O)-C_1-C_6-alkylene-N(R^{55a})R^{55b}, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, -S(O)$_2$N$R^{55}R^{55a}$, or alkylcarbonylamino and where R^{55} and R^{55b} are indepedently hydrogen, alkyl, or alkenyl and R^{55a} is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; or R^{53} and R^{54} together with the carbons to which they are attached form a 5- or 6-membered heteroaryl or 5- or 6-membered heterocycloalkyl.

[00628] Another embodiment (P-X) of the invention is a Compound of Formula I(P) where R^{53} and R^{54} together with the carbons to which they are attached form a 5- or 6-membered heteroaryl or 5- or 6-membered heterocycloalkyl.

Representative Compounds

[00629] Representative PI3K compounds of Formula I(P) and/or II(P), or pharmaceutically acceptable salts thereof, are depicted below in Table P. These compounds in Table P, and pharmaceutically acceptable salts thereof, are merely

illustrative and do not limit the scope of the PI3K compounds or PI3K modulators in any way.

Table P

Cpd. No.	Name
1	*N*-(4-{[(3-{[4-(methoxy)phenyl]amino}quinoxalin-2-yl) ami no]sulfonyl}phenyl) acetamide
2	4-bromo-*N*-[3-(phenylamino)quinoxalin-2-yl] benzene sulfonamide
3	4-bromo-*N*-{3-[(2-methylphenyl)amino]quinoxalin-2-yl}benzene sulfonamide
4	4-bromo-*N*-(3-{[4-(methoxy)phenyl]amino}quinoxalin-2-yl) benzene sulfonamide
5	4-chloro-*N*-{3-[(4-chlorophenyl)amino]-6-(methoxy)quinoxalin-2-yl}benzenesulfonamide
6	*N*-(4-{[3-{[(4-chlorophenyl)sulfonyl]amino}-7-(methoxy)quinoxalin-2-yl]amino} phenyl) acetamide
7	4-chloro-*N*-{6-(methoxy)-3-[(2-oxo-2,3-dihydro-1*H*-benzimidazol-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide
8	*N*-{4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl) amino]phenyl}acetamide
9	*N*-(3-{[4-(ethyloxy) phenyl]amino}quinoxalin-2-yl)-4-methylbenzene sulfonamide
10	*N*-{3-[(3,4-dimethylphenyl)amino]-6-methylquinoxalin-2-yl}-4-methylbenzene sulfonamide
11	*N*-(3-{[3-(dimethylamino)phenyl]amino}quinoxalin-2-yl)-4-methylbenzene sulfonamide
12	4-methyl-*N*-{6-methyl-3-[(4-methylphenyl)amino]quinoxalin-2-yl} benzene sulfonamide
13	*N*-{3-[(4-hydroxyphenyl)amino]-6-methylquinoxalin-2-yl}-4-methylbenzene sulfonamide
14	*N*-{3-[(2,5-dimethylphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide
15	4-chloro-*N*-[3-(naphthalen-2-ylamino)quinoxalin-2-yl]benzenesulfonamide
16	*N*-{3-[(3-aminophenyl)amino]quinoxalin-2-yl}-4-chlorobenzenesulfonamide
17	*N*-(3-{[4-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide
18	4-chloro-*N*-{3-[(4-chlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide
19	4-chloro-*N*-{3-[(4-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
20	4-chloro-*N*-{3-[(2-methylphenyl)amino]quinoxalin-2-yl} benzenesulfonamide

Cpd. No.	Name
21	methyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino} quinoxalin-2-yl) amino]benzoate
22	methyl 2-chloro-5-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl) amino]benzoate
23	*N*-{4-[(7-methyl-3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl) amino]phenyl}acetamide
24	4-methyl-*N*-(6-methyl-3-{[2-(methoxy)phenyl]amino} quinoxalin-2-yl)benzenesulfonamide
25	*N*-{3-[(phenylmethyl)amino]quinoxalin-2-yl}benzenesulfonamide
26	4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzoic acid
27	3-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzenesulfonamide
28	*N*-{3-[(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1*H*-pyrazol-4-yl)amino]quinoxalin-2-yl}benzenesulfonamide
29	*N*-{3-[(4-hydroxyphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
30	*N*-{3-[(4-hydroxyphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide
31	*N*-(3-{[4-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-4-methylbenzenesulfonamide
32	3-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid
33	*N*-[4-({[3-(phenylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide
34	*N*-(4-{[(3-{[4-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide
35	*N*-[4-({[3-(naphthalen-1-ylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide
36	*N*-{4-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}acetamide
37	*N*-(3-{[3-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-4-bromobenzenesulfonamide
38	*N*-{3-[(3-hydroxyphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide
39	4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-2-hydroxybenzoic acid
40	*N*-(3-{[4-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide
41	3-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid
42	*N*-(3-{[4-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-4-chlorobenzenesulfonamide

Cpd. No.	Name
43	*N*-(3-{[3-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-4-chlorobenzenesulfonamide
44	*N*-[3-(naphthalen-2-ylamino)quinoxalin-2-yl]-4-nitrobenzenesulfonamide
45	*N*-(3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
46	*N*-{3-[(4-bromophenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide
47	3-[(3-{[(4-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid
48	4-nitro-*N*-[3-(phenylamino)quinoxalin-2-yl]benzenesulfonamide
49	4-chloro-*N*-[3-(phenylamino)quinoxalin-2-yl]benzenesulfonamide
50	3-nitro-*N*-[3-(phenylamino)quinoxalin-2-yl]benzenesulfonamide
51	4-[(3-{[(4-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid
52	*N*-[3-(naphthalen-2-ylamino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide
53	4-methyl-*N*-(3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
54	*N*-(3-{[3-chloro-4-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
55	*N*-{3-[(3-chloro-4-fluorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide
56	methyl 2-chloro-5-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzoate
57	4-chloro-*N*-{3-[(3-hydroxyphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
58	4-methyl-*N*-[6-methyl-3-(phenylamino)quinoxalin-2-yl]benzenesulfonamide
59	*N*-{4-[({3-[(4-methylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide
60	1-methylethyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}-7-methylquinoxalin-2-yl)amino]benzoate
61	*N*-{3-[(4-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
62	*N*-{3-[(3-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
63	*N*-{3-[(4-bromophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide

Cpd. No.	Name
64	4-methyl-*N*-{3-[(3-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
65	4-methyl-*N*-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]benzenesulfonamide
66	*N*-{4-[({3-[(4-chlorophenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide
67	*N*-(4-{[(3-{[3-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide
68	4-methyl-*N*-{3-[(phenylmethyl)amino]quinoxalin-2-yl}benzenesulfonamide
69	4-[(3-{[(4-bromophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-2-hydroxybenzoic acid
70	4-bromo-*N*-{3-[(4-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
71	4-bromo-*N*-{3-[(3-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
72	*N*-{4-[({3-[(2-hydroxyethyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide
73	4-bromo-*N*-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]benzenesulfonamide
74	4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid
75	3-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid
76	*N*-{3-[(2-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
77	4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzenesulfonamide
78	*N*-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide
79	*N*-(3-{[3-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide
80	*N*-{3-[(4-bromophenyl)amino]quinoxalin-2-yl}-4-nitrobenzenesulfonamide
81	4-chloro-*N*-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]benzenesulfonamide
82	*N*-{4-[({3-[(phenylmethyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide
83	*N*-[4-({[3-(butylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide
84	*N*-[3-(butylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide
85	*N*-[3-(cyclohexylamino)quinoxalin-2-yl]benzenesulfonamide

Cpd. No.	Name
86	1-(phenylsulfonyl)-3-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxaline
87	1-(phenylsulfonyl)-3-[4-(piperidin-1-ylsulfonyl)phenyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxaline
88	2,5-dichloro-*N*-[3-(3,4-dihydroquinolin-1(2*H*)-yl)quinoxalin-2-yl]benzenesulfonamide
89	ethyl 2-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
90	2,5-dichloro-*N*-{3-[(2-morpholin-4-ylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
91	*N*-{4-[({3-[(3-methylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide
92	4-chloro-*N*-{3-[(3-chloro-4-piperidin-1-ylphenyl)amino]-6-methylquinoxalin-2-yl}benzenesulfonamide
93	3-nitro-*N*-[3-(quinolin-6-ylamino)quinoxalin-2-yl]benzenesulfonamide
94	butyl *N*-{[4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)phenyl]carbonyl}glycinate
95	4-nitro-*N*-(3-{[3-(trifluoromethyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
96	*N*-[4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)phenyl]acetamide
97	*N*-{3-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}acetamide
98	ethyl 3,3,3-trifluoro-2-hydroxy-2-{4-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}propanoate
99	*N*-{3-[(4-{[(2,6-dimethylpyrimidin-4-yl)amino]sulfonyl}phenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide
100	4-chloro-*N*-{3-[(3,4-dimethylphenyl)amino]-6-methylquinoxalin-2-yl}benzenesulfonamide
101	4-chloro-*N*-(6-methyl-3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
102	butyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}-7-methylquinoxalin-2-yl)amino]benzoate
103	4-chloro-*N*-{3-[(3-chloro-4-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
104	1-methylethyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoate
105	*N*-{3-[(2,5-dimethylphenyl)amino]-6-nitroquinoxalin-2-yl}-4-methylbenzenesulfonamide
106	*N*-[3-(cyclohexylamino)-6-nitroquinoxalin-2-yl]-4-methylbenzenesulfonamide
107	*N*-{3-[(2,4-dimethylphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide

Cpd. No.	Name
108	*N*-(3-{[4-(ethyloxy)phenyl]amino}-6-methylquinoxalin-2-yl)-4-methylbenzenesulfonamide
109	3-({3-[({4-[hydroxy(oxido)amino]phenyl}sulfonyl)amino]quinoxalin-2-yl}amino)benzoic acid
110	*N*-{[4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)phenyl]carbonyl}glycine
111	*N*-{3-[(3-{[(4-chlorophenyl)sulfonyl]amino}-7-methylquinoxalin-2-yl)amino]phenyl}acetamide
112	4-chloro-*N*-{3-[(3,5-dimethyl-1*H*-pyrazol-4-yl)amino]-6-methylquinoxalin-2-yl}benzenesulfonamide
113	4-bromo-*N*-{3-[(4'-nitrobiphenyl-3-yl)amino]quinoxalin-2-yl}benzenesulfonamide
114	4-bromo-*N*-{3-[(2-chlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide
115	*N*-{3-[(4-butylphenyl)amino]-6-methylquinoxalin-2-yl}-4-chlorobenzenesulfonamide
116	*N*-{4-[(3-{[(4-chlorophenyl)sulfonyl]amino}-7-methylquinoxalin-2-yl)amino]phenyl}acetamide
117	4-chloro-*N*-{6-methyl-3-[(2-oxo-2,3-dihydro-1*H*-benzimidazol-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide
118	propyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}-7-methylquinoxalin-2-yl)amino]benzoate
119	4-chloro-*N*-{3-[(4-fluorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide
120	*N*-[4-({[3-(naphthalen-2-ylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide
121	4-bromo-*N*-(3-{[4-(phenylamino)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
122	2-hydroxy-4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzoic acid
123	*N*-(3-{[3-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-4-methylbenzenesulfonamide
124	4-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid
125	*N*-(3-{[3-(butyloxy)phenyl]amino}quinoxalin-2-yl)-4-methylbenzenesulfonamide
126	*N*-{3-[(4-fluorophenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide
127	4-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-2-hydroxybenzoic acid
128	*N*-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]-4-nitrobenzenesulfonamide
129	4-[(3-{[(4-bromophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid

Cpd. No.	Name
130	*N*-{4-[({3-[(3-hydroxyphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide
131	3-[(3-{[(4-bromophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid
132	4-bromo-*N*-(3-{[3-(butyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
133	4-bromo-*N*-(3-{[3-(trifluoromethyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
134	4-methyl-*N*-{3-[(4'-nitrobiphenyl-3-yl)amino]quinoxalin-2-yl}benzenesulfonamide
135	4-chloro-*N*-{3-[(3-fluorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide
136	*N*-{3-[(2-chlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide
137	4-bromo-*N*-[3-(quinolin-5-ylamino)quinoxalin-2-yl]benzenesulfonamide
138	*N*-{3-[(3-fluorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide
139	*N*-{3-[(4-fluorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide
140	3-nitro-*N*-(3-{[3-(trifluoromethyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
141	2-hydroxy-4-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid
142	*N*-{3-[(3-chlorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide
143	*N*-[3-(1,3-benzodioxol-5-ylamino)quinoxalin-2-yl]-4-bromobenzenesulfonamide
144	*N*-{3-[(3-acetylphenyl)amino]quinoxalin-2-yl}-4-chlorobenzenesulfonamide
145	3-nitro-*N*-(3-{[4-(9*H*-xanthen-9-yl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
146	4-chloro-*N*-{3-[(4'-nitrobiphenyl-3-yl)amino]quinoxalin-2-yl}benzenesulfonamide
147	*N*-[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]-4-tolylsulfonamide
148	*N*-{3-[(2-methyl-1,3-dioxo-2,3-dihydro-1*H*-isoindol-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide
149	4-methyl-*N*-[3-(quinolin-5-ylamino)quinoxalin-2-yl]benzenesulfonamide
150	4-methyl-*N*-{3-[(1-oxo-1,3-dihydro-2-benzofuran-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide
151	4-chloro-*N*-{3-[(2-chlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide

Cpd. No.	Name
152	2-hydroxy-5-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid
153	*N*-(3-{[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]amino}quinoxalin-2-yl)benzenesulfonamide
154	*N*-[3-({2-[(trifluoromethyl)thio]phenyl}amino)quinoxalin-2-yl]benzenesulfonamide
155	*N*-{4-[({3-[(4-hydroxyphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide
156	*N*-[3-(1,3-benzodioxol-5-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide
157	*N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
158	*N*-{3-[(2,4-dichlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide
159	*N*-[4-({[3-(2,3-dihydro-1,4-benzodioxin-6-ylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide
160	4-chloro-*N*-{3-[(3,4-dimethylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
161	*N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide
162	4-bromo-*N*-{3-[(3,4-dimethylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
163	5-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-2-hydroxybenzoic acid
164	*N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-chlorobenzenesulfonamide
165	*N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-methylbenzenesulfonamide
166	*N*-{3-[(2,4-dichlorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide
167	4-bromo-*N*-{3-[(3-fluorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide
168	4-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}benzoic acid
169	*N*-{3-[(2-fluorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide
170	*N*-[3-(2,3-dihydro-1,4-benzodioxin-6-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide
171	*N*-{3-[(3,4-dimethylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
172	4-methyl-*N*-(3-{[3-(trifluoromethyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
173	5-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-2-hydroxybenzoic acid

Cpd. No.	Name
174	3-nitro-*N*-{3-[(1-oxo-1,3-dihydro-2-benzofuran-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide
175	*N*-{4-[({3-[(2-bromo-4-methylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide
176	*N*-{3-[(2-fluorophenyl)amino]quinoxalin-2-yl}-4-nitrobenzenesulfonamide
177	*N*-{3-[(2-methyl-1,3-dioxo-2,3-dihydro-1*H*-isoindol-5-yl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide
178	4-chloro-*N*-{3-[(1-oxo-1,3-dihydro-2-benzofuran-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide
179	*N*-{3-[(1-oxo-1,3-dihydro-2-benzofuran-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide
180	*N*-{3-[(2-fluorophenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide
181	*N*-[2-(butyloxy)-2-hydroxyethyl]-4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzamide
182	3-nitro-*N*-(3-{[4-(phenylamino)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
183	4-bromo-*N*-{3-[(4-fluorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide
184	4-methyl-*N*-[3-({2-[(trifluoromethyl)thio]phenyl}amino)quinoxalin-2-yl]benzenesulfonamide
185	*N*-[4-({3-[2-(methoxy)phenyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxalin-1-yl}sulfonyl)phenyl]acetamide
186	4-(3-{[4-(acetylamino)phenyl]sulfonyl}-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxalin-1-yl)benzoic acid
187	1-naphthalen-2-yl-3-[(3-nitrophenyl)sulfonyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxaline
188	*N*-[4-({3-[4-(methoxy)phenyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxalin-1-yl}sulfonyl)phenyl]acetamide
189	1-(3-methylphenyl)-3-[(4-methylphenyl)sulfonyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxaline
190	*N*-(4-{[3-(4-methylphenyl)-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxalin-1-yl]sulfonyl}phenyl)acetamide
191	*N*-{4-[(3-phenyl-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxalin-1-yl)sulfonyl]phenyl}acetamide
192	*N*-(4-{[3-(3-methylphenyl)-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxalin-1-yl]sulfonyl}phenyl)acetamide
193	1-[4-(methoxy)phenyl]-3-[(4-methylphenyl)sulfonyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxaline
194	*N*-(4-{[3-(2-methylphenyl)-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxalin-1-yl]sulfonyl}phenyl)acetamide
195	1-(3-methylphenyl)-3-[(3-nitrophenyl)sulfonyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxaline

Cpd. No.	Name
196	1-(4-methylphenyl)-3-[(3-nitrophenyl)sulfonyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxaline
197	*N*-{3-[(4-methylphenyl)amino]quinoxalin-2-yl}-3-(1*H*-tetrazol-1-yl)benzenesulfonamide
198	*N*-(3-{[2-(ethyloxy)phenyl]amino}quinoxalin-2-yl)-4-methylbenzenesulfonamide
199	*N*-{4-[({3-[(4-ethylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide
200	4-bromo-*N*-(3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
201	*N*-(4-{[(3-{[4-(ethyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide
202	*N*-{4-[({3-[(2-ethylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide
203	*N*-(4-{[(3-{[2-(ethyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide
204	*N*-{3-[(4-nitrophenyl)amino]quinoxalin-2-yl}benzenesulfonamide
205	4-(ethyloxy)-*N*-(3-{[4-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
206	methyl *N*-acetyl-*N*-[4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)phenyl]-beta-alaninate
207	methyl *N*-acetyl-*N*-{4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}-beta-alaninate
208	*N*-{3-[(3-chloro-5-methylphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide
209	*N*-{3-[(3-acetylphenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide
210	4-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-*N*-[4-(methoxy)phenyl]benzamide
211	2-hydroxy-5-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzoic acid
212	*N*-[3-(2,3-dihydro-1,4-benzodioxin-6-ylamino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide
213	*N*-[4-(methoxy)phenyl]-4-[(3-{[(4-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzamide
214	4-chloro-*N*-{3-[(2-oxo-2,3-dihydro-1*H*-benzimidazol-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide
215	4-methyl-*N*-{3-[methyl(phenylmethyl)amino]quinoxalin-2-yl}benzenesulfonamide
216	*N*-[3-(3,4-dihydroisoquinolin-2(1*H*)-yl)quinoxalin-2-yl]-2-methylbenzenesulfonamide
217	*N*-[4-({[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamida

Cpd. No.	Name
218	4-bromo-*N*-{3-[(4-phenylquinolin-8-yl)amino]quinoxalin-2-yl}benzenesulfonamide
219	4-methyl-*N*-{3-[(4-phenylquinolin-8-yl)amino]quinoxalin-2-yl}benzenesulfonamide
220	1-[(4-chlorophenyl)sulfonyl]-3-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxaline
221	1-(4-morpholin-4-ylphenyl)-3-(phenylsulfonyl)-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxaline
222	methyl 4,5-dimethyl-2-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)thiophene-3-carboxylate
223	ethyl 6-methyl-2-[(3-{[(2-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
224	ethyl 2-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-6-phenyl-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
225	ethyl 6-methyl-2-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
226	propyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoate
227	*N*-{3-[(4-butylphenyl)amino]quinoxalin-2-yl}-4-chlorobenzenesulfonamide
228	*N*-{3-[(2-chlorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide
229	*N*-{3-[(2,3-dimethylphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide
230	*N*-{3-[(3,4-dimethylphenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide
231	*N*-{4-[({3-[(2,3-dimethylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide
232	4-chloro-*N*-{3-[(2,3-dimethylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
233	3-nitro-*N*-(3-{[3,4,5-tris(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
234	4-chloro-*N*-{3-[(2,4-dichlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide
235	*N*-{3-[(2,3-dimethylphenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide
236	*N*-{4-[({3-[(3,4-dimethylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide
237	ethyl 2-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-5,6-dihydro-4*H*-cyclopenta[b]thiophene-3-carboxylate
238	4-chloro-*N*-(3-{[4-chloro-3-(morpholin-4-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
239	ethyl 2-[(3-{[(2-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate

Cpd. No.	Name
240	4-bromo-*N*-{3-[(2,4-dichlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide
241	ethyl 5-ethyl-2-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]thiophene-3-carboxylate
242	*N*-(3-{[3-(morpholin-4-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
243	ethyl 2-[(3-{[(4-bromophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
244	4-methyl-*N*-(3-{[3-(piperidin-1-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
245	4-chloro-*N*-(3-{[4-(morpholin-4-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
246	4-chloro-*N*-(3-{[3-(morpholin-4-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
247	4-methyl-*N*-[3-(quinolin-6-ylamino)quinoxalin-2-yl]benzenesulfonamide
248	*N*-(3-{[3-(piperidin-1-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
249	*N*-(3-{[4-(phenylamino)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
250	*N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-bromobenzenesulfonamide
251	ethyl 2-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-5,6-dihydro-4*H*-cyclopenta[b]thiophene-3-carboxylate
252	*N*-{3-[(4'-nitrobiphenyl-4-yl)amino]quinoxalin-2-yl}benzenesulfonamide
253	ethyl 2-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
254	*N*-(3-{[4-chloro-3-(morpholin-4-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
255	ethyl 5-ethyl-2-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)thiophene-3-carboxylate
256	*N*-[4-({[3-(quinolin-6-ylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide
257	ethyl 2-[(3-{[(2-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-5,6-dihydro-4*H*-cyclopenta[b]thiophene-3-carboxylate
258	3,4-dichloro-*N*-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]benzenesulfonamide
259	ethyl 2-{[3-({[4-(acetylamino)-3,5-dibromophenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
260	ethyl 2-[(3-{[(2-chloro-5-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
261	*N*-{3-[(3-fluorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide

Cpd. No.	Name
262	*N*-(3-{[4-(morpholin-4-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
263	ethyl 2-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
264	ethyl 2-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-5-ethylthiophene-3-carboxylate
265	*N*,*N*-diethyl-4-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzenesulfonamide
266	ethyl 2-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-5-ethylthiophene-3-carboxylate
267	ethyl 2-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
268	ethyl 2-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
269	*N*-[4-(methoxy)phenyl]-4-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzamide
270	*N*-[3-({4-[(4-aminophenyl)oxy]phenyl}amino)quinoxalin-2-yl]-4-chlorobenzenesulfonamide
271	*N*-[4-({[3-({4-[(4-aminophenyl)oxy]phenyl}amino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide
272	(2E)-3-{3-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}prop-2-enoic acid
273	*N*-{3-[(9-ethyl-9*H*-carbazol-3-yl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide
274	*N*-[3-({4-[(4-aminophenyl)oxy]phenyl}amino)quinoxalin-2-yl]benzenesulfonamide
275	4-bromo-*N*-{3-[(9-ethyl-9*H*-carbazol-3-yl)amino]quinoxalin-2-yl}benzenesulfonamide
276	*N*-{3-[(9-ethyl-9*H*-carbazol-3-yl)amino]quinoxalin-2-yl}benzenesulfonamide
277	*N*-{3-[(2-iodophenyl)amino]quinoxalin-2-yl}benzenesulfonamide
278	*N*-{3-[(1-phenylethyl)amino]quinoxalin-2-yl}benzenesulfonamide
279	4-bromo-*N*-{3-[(4-bromophenyl)amino]quinoxalin-2-yl}benzenesulfonamide
280	4-bromo-*N*-{3-[(4-chlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide
281	4-bromo-*N*-[3-(naphthalen-2-ylamino)quinoxalin-2-yl]benzenesulfonamide
282	*N*-{3-[(2,3-dimethylphenyl)amino]-6-methylquinoxalin-2-yl}-4-methylbenzenesulfonamide
283	4-chloro-*N*-{3-[(2-iodophenyl)amino]quinoxalin-2-yl}benzenesulfonamide

Cpd. No.	Name
284	*N*-(3-{[4-(octyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
285	*N*-[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide
286	*N*-{3-[(2-bromo-4-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
287	*N*-[3-({4-[(3-aminophenyl)sulfonyl]phenyl}amino)quinoxalin-2-yl]-4-chlorobenzenesulfonamide
288	*N*-[3-({2-[(difluoromethyl)oxy]phenyl}amino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide
289	8-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]quinoline-2-carboxylic acid
290	ethyl 3,3,3-trifluoro-2-hydroxy-2-{4-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}propanoate
291	*N*-[3-(quinolin-6-ylamino)quinoxalin-2-yl]benzenesulfonamide
292	4-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}phenyl thiocyanate
293	1-[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]-4-methylpyridinium
294	*N*-{3-[(2-chlorophenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide
295	4-methyl-*N*-[3-(phenylamino)quinoxalin-2-yl]benzenesulfonamide
296	4-methyl-*N*-{3-[(2-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
297	4-methyl-*N*-{3-[(4-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
298	*N*-{3-[(4-chlorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide
299	4-methyl-*N*-[3-(naphthalen-2-ylamino)quinoxalin-2-yl]benzenesulfonamide
300	*N*-{4-[({3-[(4-bromophenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide
301	*N*-{4-[({3-[(2-methylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]-phenyl}acetamide
302	*N*-{3-[bis(phenylmethyl)amino]quinoxalin-2-yl}benzenesulfonamide
303	4-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid
304	2-hydroxy-4-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid
305	4-bromo-*N*-(3-{[2-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
306	*N*-{3-[(3-hydroxyphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
307	*N*-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]benzenesulfonamide
308	3-methyl-1-(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)pyridinium

Cpd. No.	Name
309	*N*-(3-{[3-{[(4-chlorophenyl)sulfonyl]amino}-7-(methoxy)quinoxalin-2-yl]amino}phenyl)acetamide
310	*N*-{3-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}acetamide
311	*N*-{3-[(4-bromophenyl)amino]quinoxalin-2-yl}-4-chlorobenzenesulfonamide
312	*N*-{3-[(2,4-dimethylphenyl)amino]-6-methylquinoxalin-2-yl}-4-methylbenzenesulfonamide
313	*N*-{3-[(3,4-dimethylphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide
314	*N*-{3-[(2,5-dimethylphenyl)amino]-6-methylquinoxalin-2-yl}-4-methylbenzenesulfonamide
315	ethyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoate
316	4-chloro-*N*-{3-[(4-ethylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
317	4-chloro-*N*-(6-methyl-3-{[4-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
318	4-chloro-*N*-{3-[(4-chlorophenyl)amino]-6-methylquinoxalin-2-yl}benzenesulfonamide
319	*N*-(3-{[4-chloro-2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
320	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
321	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-methylbenzenesulfonamide
322	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide
323	*N*-(3-{[2-methyl-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
324	*N*-[3-(2-Chloro-5-methoxy-phenylamino)-quinoxalin-2-yl]-benzensulfonamide
325	3-amino-*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
326	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-chlorobenzenesulfonamide
327	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide
328	*N*-(3-{[4-chloro-3-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
329	*N*-(3-{[4-fluoro-3-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
330	3-amino-*N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
331	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-bromobenzenesulfonamide
332	*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide
333	3-amino-*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide

Cpd. No.	Name
334	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-,*N*-2-dimethylglycinamide
335	*N*-(3-{[2,5-bis(methoxy)phenyl]amino}-7-methylquinoxalin-2-yl)benzenesulfonamide
336	*N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-(methoxy)benzenesulfonamide
337	*N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-bromobenzenesulfonamide
338	*N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-fluorobenzenesulfonamide
339	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2-fluorobenzenesulfonamide
340	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-(methoxy)benzenesulfonamide
341	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-bromobenzenesulfonamide
342	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methylpiperidine-4-carboxamide
343	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-piperidin-1-ylpropanamide
344	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-(dimethylamino)butanamide
345	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(hydroxyamino)benzenesulfonamide
346	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-morpholin-4-ylacetamide
347	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-*N*-2-methylglycinamide
348	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-L-alaninamide
349	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-2-methylalaninamide
350	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-*N*-2-,*N*-2-dimethylglycinamide
351	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-alaninamide
352	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methylglycinamide
353	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-D-alaninamide
354	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methylglycinamide
355	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-alaninamide
356	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-alaninamide
357	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylalaninamide
358	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylalaninamide
359	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-*N*-2-,*N*-2-dimethylglycinamide

Cpd. No.	Name
360	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[2-(dimethylamino)ethyl]-*N*-2-methylglycinamide
361	(2S)-2-amino-*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)butanamide
362	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[2-(dimethylamino)ethyl]-*N*-2-methylglycinamide
363	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-,*N*-2-dimethylglycinamide
364	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-L-alaninamide
365	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide
366	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide
367	*N*-(2-chloro-5-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methylglycinamide
368	2-(dimethylamino)-*N*-(3-(*N*-(3-(3-(2-(dimethylamino)acetamido)-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide
369	*N*-(3-{[(3-{[2-acetyl-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-,*N*-2-dimethylglycinamide
370	*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(formylamino)benzenesulfonamide
371	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-ethylglycinamide
372	*N*-(5-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-2-methylphenyl)glycinamide
373	2-azetidin-1-yl-*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide
374	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-prolinamide
375	*N*-(3-{[(3-{[2-bromo-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methylglycinamide
376	*N*-2-,*N*-2-dimethyl-*N*-(3-{[(3-{[6-(methoxy)quinolin-8-yl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide
377	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-alaninamide
378	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-D-alaninamide
379	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-prolinamide
380	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-serinamide
381	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)azetidine-3-carboxamide
382	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-,2-dimethylalaninamide
383	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-D-alaninamide
384	*N*-(3-{[(3-{[2-bromo-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-,*N*-2-dimethylglycinamide
385	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-propylglycinamide
386	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-L-alaninamide
387	*N*-(5-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-2-methylphenyl)-beta-alaninamide

Cpd. No.	Name
388	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)piperidine-3-carboxamide
389	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-methyl-1,4-diazepan-1-yl)acetamide
390	(2S)-2-amino-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)butanamide
391	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2-hydroxypropyl)glycinamide
392	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2-fluoroethyl)glycinamide
393	3-amino-*N*-(2-{[3,5-bis(methoxy)phenyl]amino}pyrido[2,3-b]pyrazin-3-yl)benzenesulfonamide
394	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[(2-methylpropyl)oxy]glycinamide
395	1-amino-*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopropanecarboxamide
396	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(formylamino)benzenesulfonamide
397	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(cyclopropylmethyl)glycinamide
398	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-prolinamide
399	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(dimethylamino)azetidin-1-yl]acetamide
400	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-prolinamide
401	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)piperidine-2-carboxamide
402	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)morpholine-4-carboxamide
403	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyrrolidin-1-ylacetamide
404	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-6-,*N*-6-dimethyl-L-lysinamide
405	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-ethyl-*N*-2-methylglycinamide
406	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(1*H*-imidazol-4-yl)acetamide
407	1-amino-*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopentanecarboxamide
408	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2-methylpropyl)glycinamide
409	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-ethyl-*N*-2-methylglycinamide
410	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(1*H*-imidazol-4-ylmethyl)azetidine-3-carboxamide
411	*N*-(5-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-2-methylphenyl)-*N*-2-,*N*-2-dimethylglycinamide
412	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-ethylazetidine-3-carboxamide
413	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-*N*-2-(1-methylpyrrolidin-3-yl)glycinamide
414	*N*-(3-{[(2-{[3,5-bis(methoxy)phenyl]amino}pyrido[2,3-b]pyrazin-3-yl)amino]sulfonyl}phenyl)-*N*-2-[2-(dimethylamino)ethyl]-*N*-2-methylglycinamide
415	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(3S)-3-hydroxypyrrolidin-1-yl]acetamide

Cpd. No.	Name
416	1-amino-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclobutanecarboxamide
417	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-butylglycinamide
418	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-piperidin-1-ylazetidin-1-yl)acetamide
419	3-[(aminocarbonyl)amino]-*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
420	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-hydroxycyclopropanecarboxamide
421	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2,2-dimethylhydrazino)acetamide
422	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-[({[2-(dimethylamino)ethyl]amino}carbonyl)amino]benzenesulfonamide
423	*N*-(3-{[(3-{[3-fluoro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methylglycinamide
424	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-hydroxyacetamide
425	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyridazine-4-carboxamide
426	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(1-methylethyl)glycinamide
427	1-amino-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopentanecarboxamide
428	1-amino-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopropanecarboxamide
429	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(dimethylamino)pyrrolidin-1-yl]acetamide
430	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[2-(dimethylamino)ethyl]glycinamide
431	2-(dimethylamino)ethyl(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)carbamate
432	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(cyclopropylmethyl)azetidine-3-carboxamide
433	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(1,1-dimethylethyl)glycinamide
434	*N*-2-methyl-*N*-(3-{[(3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide
435	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1*H*-imidazole-2-carboxamide
436	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)isoxazole-5-carboxamide
437	*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2,2,2-trifluoroethyl)glycinamide
438	3-amino-*N*-(3-{[2-methyl-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
439	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-oxocyclopentanecarboxamide
440	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-6-hydroxypyridine-2-carboxamide
441	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(3-fluoro-4-hydroxyphenyl)glycinamide
442	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(furan-2-ylmethyl)azetidine-3-carboxamide
443	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyrimidine-5-carboxamide

Cpd. No.	Name
444	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1*H*-pyrrole-2-carboxamide
445	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-*N*-2-(1-methylethyl)glycinamide
446	*N*-(3-{[(3-{[3-fluoro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-,*N*-2-dimethylglycinamide
447	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1*H*-imidazole-4-carboxamide
448	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-,*N*-2-diethylglycinamide
449	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-methylisoxazol-5-yl)acetamide
450	*N*-2-,*N*-2-dimethyl-*N*-(3-{[(3-{[2-methyl-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide
451	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[(3-hydroxyphenyl)methyl]glycinamide
452	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methyl-1*H*-pyrrole-2-carboxamide
453	4-amino-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)tetrahydro-2*H*-pyran-4-carboxamide
454	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(methylamino)piperidin-1-yl]acetamide
455	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-piperidin-1-ylacetamide
456	*N*-(4-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-,*N*-2-dimethylglycinamide
457	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methyl-L-prolinamide
458	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)thiophene-3-carboxamide
459	3-amino-*N*-{3-[(2-chloro-5-hydroxyphenyl)amino]quinoxalin-2-yl}benzenesulfonamide
460	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(cyclopropylcarbonyl)azetidine-3-carboxamide
461	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-methylpiperazin-1-yl)acetamide
462	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(phenylmethyl)azetidine-3-carboxamide
463	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-chloropyridine-3-carboxamide
464	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyridin-4-ylacetamide
465	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-*N*-2-prop-2-en-1-ylglycinamide
466	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(phenylmethyl)glycinamide
467	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(methoxy)acetamide
468	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-propanoylazetidine-3-carboxamide
469	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyridine-3-carboxamide
470	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[2-(methoxy)ethyl]glycinamide
471	1-acetyl-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)piperidine-4-carboxamide

Cpd. No.	Name
472	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-methylpyrrolidin-1-yl)acetamide
473	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)furan-3-carboxamide
474	*N*-2-,*N*-2-dimethyl-*N*-(3-{[(3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide
475	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-6-chloropyridine-3-carboxamide
476	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-chlorobenzamide
477	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyridin-2-ylacetamide
478	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(dimethylamino)azetidin-1-yl]acetamide
479	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyridin-3-ylacetamide
480	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-chlorophenyl)acetamide
481	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[3-(dimethylamino)propyl]-*N*-2-methylglycinamide
482	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-ethyl-*N*-2-(2-hydroxyethyl)glycinamide
483	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[2-(phenylmethyl)pyrrolidin-1-yl]acetamide
484	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)propanamide
485	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)furan-2-carboxamide
486	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-chloropyridine-4-carboxamide
487	*N*-2-acetyl-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide
488	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)butanamide
489	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-chlorobenzamide
490	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methylbenzamide
491	1,1-dimethylethyl{2-[(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)amino]-2-oxoethyl}carbamate
492	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1,3-benzodioxole-5-carboxamide
493	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-({[2-(methoxy)phenyl]methyl}oxy)glycinamide
494	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyridine-4-carboxamide
495	*N*-(3-{[(3-{[4-fluoro-3-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-,*N*-2-dimethylglycinamide
496	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(3,4-dichlorophenyl)piperazin-1-yl]acetamide
497	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-pyridin-3-ylpropanamide
498	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)tetrahydrofuran-3-carboxamide
499	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[(2-methylphenyl)methyl]glycinamide

Cpd. No.	Name
500	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylbutanamide
501	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-fluorophenyl)acetamide
502	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(1-methyl-1-phenylethyl)glycinamide
503	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylcyclopropanecarboxamide
504	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methyl-4-(methoxy)benzamide
505	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylpyridine-3-carboxamide
506	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-(methoxy)benzamide
507	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-ethylpiperazin-1-yl)acetamide
508	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)thiophene-2-carboxamide
509	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluoro-2-methylbenzamide
510	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-bromothiophene-3-carboxamide
511	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-fluorobenzamide
512	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-methylpiperidin-1-yl)acetamide
513	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylpropanamide
514	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pentanamide
515	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(ethyloxy)acetamide
516	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2-fluorophenyl)glycinamide
517	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-(dimethylamino)benzamide
518	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-methylpiperidin-1-yl)acetamide
519	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2-propylphenyl)glycinamide
520	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)benzamide
521	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyrazine-2-carboxamide
522	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluoro-4-(methoxy)benzamide
523	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,2-dimethylbutanamide
524	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(4-fluorophenyl)oxy]acetamide
525	1-acetyl-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)azetidine-3-carboxamide
526	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(4-methylphenyl)glycinamide
527	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-phenylglycinamide

Cpd. No.	Name
528	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-prop-2-en-1-ylpiperazin-1-yl)acetamide
529	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylbenzamide
530	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-(methoxy)propanamide
531	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-methylfuran-2-carboxamide
532	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide
533	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[(phenylmethyl)oxy]glycinamide
534	*N*-{3-[({3-[(2-chloro-5-hydroxyphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}-*N*-2-,*N*-2-dimethylglycinamide
535	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(3-chlorophenyl)glycinamide
536	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclobutanecarboxamide
537	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(methoxy)phenyl]acetamide
538	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methylcyclopropanecarboxamide
539	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluorobenzamide
540	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-(dimethylamino)benzamide
541	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3,4-dichlorobenzamide
542	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-{[2-(methylthio)phenyl]methyl}glycinamide
543	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-fluorophenyl)acetamide
544	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-ethyl-*N*-2-(1-methylethyl)glycinamide
545	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1,3-thiazole-4-carboxamide
546	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-*N*-2-(phenylmethyl)glycinamide
547	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2-thienylmethyl)glycinamide
548	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(pyridin-2-ylmethyl)glycinamide
549	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-(methoxy)benzamide
550	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[(3-chloro-4-methylphenyl)methyl]glycinamide
551	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylpentanamide
552	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-chlorophenyl)acetamide
553	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluoro-4-methylbenzamide
554	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(2-methylphenyl)oxy]acetamide
555	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-cyclohexylacetamide

Cpd. No.	Name
556	(1R,2R)-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-phenylcyclopropanecarboxamide
557	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-chlorobenzamide
558	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[2-(methoxy)phenyl]acetamide
559	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-[3-(methoxy)phenyl]propanamide
560	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2-fluoro-4-methylphenyl)glycinamide
561	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[(3-fluorophenyl)methyl]glycinamide
562	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(methoxy)phenyl]acetamide
563	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-phenylacetamide
564	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,4-dichlorobenzamide
565	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-oxocyclohexanecarboxamide
566	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(3-fluorophenyl)glycinamide
567	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-chlorophenyl)acetamide
568	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2-phenylpropyl)glycinamide
569	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[(2,4-dimethylphenyl)methyl]glycinamide
570	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-methylpiperidin-1-yl)acetamide
571	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[2-(methoxy)phenyl]glycinamide
572	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3,4-dihydroisoquinolin-2(1*H*)-yl)acetamide
573	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pent-4-enamide
574	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2-methylphenyl)glycinamide
575	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-oxopiperidin-1-yl)acetamide
576	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-fluorobenzamide
577	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(1-phenylethyl)glycinamide
578	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-fluoro-6-(methoxy)benzamide
579	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[2-(1-methylethyl)phenyl]glycinamide
580	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-[2-(methoxy)phenyl]propanamide
581	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methylpentanamide
582	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-phenylmorpholin-4-yl)acetamide
583	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-[4-(methoxy)phenyl]propanamide

Cpd. No.	Name
584	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-cyclopentyl-*N*-2-prop-2-en-1-ylglycinamide
585	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-*N*-2-[2-(methoxy)ethyl]glycinamide
586	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-cyclopropyl-4-oxobutanamide
587	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[3-(1,1-dimethylethyl)phenyl]glycinamide
588	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(cyclopropylmethyl)-*N*-2-propylglycinamide
589	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-oxocyclopentyl)acetamide
590	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(4-chlorophenyl)glycinamide
591	2-(1,4'-bipiperidin-1'-yl)-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide
592	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-cyclopentylpiperazin-1-yl)acetamide
593	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-methylphenyl)acetamide
594	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[(5-fluoro-2-methylphenyl)methyl]glycinamide
595	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3,3-dimethylbutanamide
596	*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N^2-(2-chlorophenyl)glycinamide
597	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-5-fluoro-2-methylbenzamide
598	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-fluoro-3-methylbenzamide
599	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,3-dichlorobenzamide
600	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(phenyloxy)acetamide
601	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2,3-dimethylphenyl)glycinamide
602	3-amino-*N*-(3-{[3,5-bis(methoxy)phenyl]amino}pyrido[2,3-b]pyrazin-2-yl)benzenesulfonamide
603	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-fluoro-5-methylbenzamide
604	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-{[(4-methylphenyl)methyl]oxy}glycinamide
605	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(1-methylethyl)piperazin-1-yl]acetamide
606	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-fluorophenyl)acetamide
607	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-methylbutanamide
608	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methyl-2-(methoxy)benzamide
609	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-propylpiperidin-1-yl)acetamide
610	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(3-methylphenyl)oxy]acetamide
611	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)tetrahydrofuran-2-carboxamide

Cpd. No.	Name
612	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(hydroxymethyl)piperidin-1-yl]acetamide
613	1,1-dimethylethyl2-{[(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)amino]carbonyl}piperidine-1-carboxylate
614	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-*N*-2-(pyridin-3-ylmethyl)glycinamide
615	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-ethyl-*N*-2-phenylglycinamide
616	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-{[2-(methoxy)ethyl]oxy}acetamide
617	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-cyclopentylpropanamide
618	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,5-dichlorobenzamide
619	2-(4-acetylpiperazin-1-yl)-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide
620	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-5-fluoro-2-(methoxy)benzamide
621	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-cyclohexyl-*N*-2-ethylglycinamide
622	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-5-methylisoxazole-3-carboxamide
623	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-methylpyridine-2-carboxamide
624	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(methoxy)pyridine-3-carboxamide
625	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3,5-dichlorobenzamide
626	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(1,3-thiazolidin-3-yl)acetamide
627	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-formylpiperazin-1-yl)acetamide
628	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-pyridin-4-ylpiperidin-1-yl)acetamide
629	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(methoxy)benzamide
630	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-*N*-2-(2-methylpropyl)glycinamide
631	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-formyl-1,4-diazepan-1-yl)acetamide
632	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-phenylcyclopropanecarboxamide
633	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2,6-dimethylmorpholin-4-yl)acetamide
634	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-phenylpyrrolidin-1-yl)acetamide
635	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)-1-methylethyl]benzamide
636	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]benzamide
637	5-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-2-fluorobenzamide
638	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-pyrrolidin-3-ylbenzamide
639	3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]benzamide

Cpd. No.	Name
640	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-pyrrolidin-1-ylethyl)benzamide
641	*N*-(2-aminoethyl)-3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide
642	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-*N*-methylbenzamide
643	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(piperidin-2-ylmethyl)benzamide
644	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1-methylazetidin-3-yl)benzamide
645	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-piperidin-1-ylethyl)benzamide
646	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(diethylamino)ethyl]benzamide
647	3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-*N*-methylbenzamide
648	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1-methylpiperidin-3-yl)benzamide
649	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-piperidin-3-ylbenzamide
650	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[(1-methylpiperidin-2-yl)methyl]benzamide
651	*N*-{2-[bis(2-hydroxyethyl)amino]ethyl}-3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide
652	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1-ethylpiperidin-3-yl)benzamide
653	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide
654	3-[(3-aminopyrrolidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
655	5-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-2-(methoxy)benzamide
656	*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}benzenesulfonamide
657	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzoicacid
658	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-morpholin-4-ylethyl)benzamide
659	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[(1-ethylpyrrolidin-2-yl)methyl]benzamide
660	3-[(4-amino-3-oxopyrazolidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
661	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-methylbenzamide
662	3-[(3-aminoazetidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
663	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(pyridin-3-ylmethyl)benzamide
664	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(pyridin-2-ylmethyl)benzamide
665	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-hydroxyethyl)benzamide
666	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(3-oxopyrazolidin-4-yl)benzamide
667	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(1*H*-imidazol-4-yl)ethyl]benzamide

Cpd. No.	Name
668	*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-{[3-(dimethylamino)pyrrolidin-1-yl]carbonyl}benzenesulfonamide
669	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(pyridin-4-ylmethyl)benzamide
670	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-methyl-*N*-(1-methylpyrrolidin-3-yl)benzamide
671	*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-{[3-(diethylamino)pyrrolidin-1-yl]carbonyl}benzenesulfonamide
672	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-1*H*-pyrrol-1-ylbenzamide
673	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(3-pyrrolidin-1-ylpropyl)benzamide
674	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-cyanoethyl)-*N*-methylbenzamide
675	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(methoxy)ethyl]benzamide
676	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-cyanoethyl)-*N*-ethylbenzamide
677	3-[(3-aminopiperidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
678	3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzoicacid
679	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(dimethylamino)propyl]benzamide
680	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-morpholin-4-ylbenzamide
681	*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-[(2,2-dimethylhydrazino)carbonyl]benzenesulfonamide
682	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(1*H*-imidazol-1-yl)propyl]benzamide
683	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(diethylamino)propyl]benzamide
684	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-cyanoethyl)benzamide
685	methyl*N*-[(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)carbonyl]-beta-alaninate
686	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(methylthio)ethyl]benzamide
687	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(ethylthio)ethyl]benzamide
688	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-*N*-ethylbenzamide
689	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]benzamide
690	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-pyridin-4-ylethyl)benzamide
691	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(ethyloxy)propyl]benzamide
692	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(3-morpholin-4-ylpropyl)benzamide
693	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(methoxy)propyl]benzamide
694	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(dimethylamino)propyl]-*N*-methylbenzamide
695	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(propyloxy)propyl]benzamide

Cpd. No.	Name
696	ethyl*N*-[(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)carbonyl]-beta-alaninate
697	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-{3-[(1-methylethyl)oxy]propyl}benzamide
698	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1,1-dimethyl-2-piperidin-1-ylethyl)benzamide
699	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-methyl-*N*-propylbenzamide
700	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-piperidin-1-ylbenzamide
701	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[1-methyl-2-(methoxy)ethyl]benzamide
702	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1,1-dimethyl-2-morpholin-4-ylethyl)benzamide
703	*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-({2-[(dimethylamino)methyl]piperidin-1-yl}carbonyl)benzenesulfonamide
704	*N*-[3-(butyloxy)propyl]-3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide
705	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[4-(diethylamino)-1-methylbutyl]benzamide
706	3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1,1-dimethyl-2-oxo-2-piperidin-1-ylethyl)benzamide
707	*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-[(4-methylpiperazin-1-yl)carbonyl]benzenesulfonamide
708	*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-{[2-(piperidin-1-ylmethyl)piperidin-1-yl]carbonyl}benzenesulfonamide
709	*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-6-oxo-1,6-dihydropyridine-3-sulfonamide
710	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-6-oxo-1,6-dihydropyridine-3-sulfonamide
711	3-amino-*N*-(3-{[6-(methoxy)quinolin-8-yl]amino}quinoxalin-2-yl)benzenesulfonamide
712	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)thiophene-2-sulfonamide
713	*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-cyanobenzenesulfonamide
714	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(methylamino)benzenesulfonamide
715	*N*-(2-{[3,5-bis(methoxy)phenyl]amino}pyrido[2,3-b]pyrazin-3-yl)-3-nitrobenzenesulfonamide
716	*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(1-{[2-(dimethylamino)ethyl]amino}ethyl)benzenesulfonamide
717	3-amino-*N*-(3-{[3-(methoxy)-5-nitrophenyl]amino}quinoxalin-2-yl)benzenesulfonamide
718	3-acetyl-*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
719	3-amino-*N*-(3-{[3-fluoro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
720	*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-*N'*-[2-(dimethylamino)ethyl]benzene-1,3-disulfonamide
721	*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-*N'*-[3-(dimethylamino)propyl]benzene-1,3-disulfonamide
722	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-6-chloropyridine-3-sulfonamide
723	*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-{5-[(dimethylamino)methyl]-1,3,4-oxadiazol-2-yl}benzenesulfonamide
724	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-6-{[2-(dimethylamino)ethyl]amino}pyridine-3-sulfonamide

Cpd. No.	Name
725	3-amino-*N*-(3-{[3-amino-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
726	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(dimethylamino)benzenesulfonamide
727	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-6-{[2-(dimethylamino)ethyl]oxy}pyridine-3-sulfonamide
728	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-6-(dimethylamino)pyridine-3-sulfonamide
729	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-cyanobenzenesulfonamide
730	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-fluorobenzenesulfonamide
731	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-fluoro-2-methylbenzenesulfonamide
732	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2-methylbenzenesulfonamide
733	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-cyanobenzenesulfonamide
734	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3,5-difluorobenzenesulfonamide
735	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2-chlorobenzenesulfonamide
736	*N*-(4-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide
737	*N*-(3-{[6-(methoxy)quinolin-8-yl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide
738	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(2*H*-tetrazol-5-yl)benzenesulfonamide
739	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)naphthalene-1-sulfonamide
740	*N*-{[(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)amino](dimethylamino)methylidene}-*N*-methylmethanaminium
741	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-fluorobenzenesulfonamide
742	*N*-(3-{[2-bromo-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide
743	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-[(difluoromethyl)oxy]benzenesulfonamide
744	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2-(trifluoromethyl)benzenesulfonamide
745	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-chloro-4-fluorobenzenesulfonamide
746	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-(trifluoromethyl)benzenesulfonamide
747	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(methylsulfonyl)benzenesulfonamide
748	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2,5-dichlorothiophene-3-sulfonamide
749	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3,5-dichlorobenzenesulfonamide
750	*N*-(3-{[2-methyl-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide
751	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-[(trifluoromethyl)oxy]benzenesulfonamide
752	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(dimethylamino)piperidin-1-yl]acetamide

Cpd. No.	Name
753	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-5-chloro-2-(methoxy)benzenesulfonamide
754	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(trifluoromethyl)benzenesulfonamide
755	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2,5-bis(methoxy)benzenesulfonamide
756	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3,5-dimethylisoxazole-4-sulfonamide
757	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-5-bromo-2-(methoxy)benzenesulfonamide
758	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-fluoro-3-(trifluoromethyl)benzenesulfonamide
759	*N*-(3-{[3-fluoro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide
760	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-fluoro-4-methylbenzenesulfonamide
761	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-chloro-4-methylbenzenesulfonamide
762	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2,5-dimethylthiophene-3-sulfonamide
763	*N*-(3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide
764	*N*-{3-[(2-chloro-5-hydroxyphenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide
765	*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methyl-3-(methoxy)benzamide
766	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-1-phenylmethanesulfonamide
767	*N*-(3-{[3-(methoxy)-5-nitrophenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide
768	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-1-(3-chlorophenyl)methanesulfonamide
769	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4,5-dichlorothiophene-2-sulfonamide
770	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-5-chloro-1,3-dimethyl-1*H*-pyrazole-4-sulfonamide
771	*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3,5-bis(trifluoromethyl)benzenesulfonamide

Definitions for PI3K Compounds

[00630] The following terms apply to PI3K compounds described above only. These definitions are not to be considered when determining the scope and meaning of any of the other compounds described herein that are not PI3K compounds. To the same extent, the definitions for all of the other compounds described herein that are not PI3K compounds are not to be considered when determining the scope and meaning of the PI3K compounds.

[00631] "Alkenyl" or "lower alkenyl" means a straight or branched hydrocarbon radical having from 2 to 6 carbon atoms and at least one double bond and includes ethenyl, propenyl, 1-but-3-enyl, 1-pent-3-enyl, 1-hex-5-enyl and the like.

[00632] "Alkenylcarbonyl" means a C(O)R group where R is alkenyl, as defined herein.

[00633] "Alkenyloxy" or "lower alkenyloxy" means an –OR group where R is alkenyl, as defined herein. Representative examples include methoxy, ethoxy, 1-methoxyprop-1-en-3-yl, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like.

[00634] "Alkoxy" or "lower alkoxy" means an –OR group where R is alkyl, as defined herein. Representative examples include methoxy, ethoxy, 1-methoxyprop-1-en-3-yl, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like.

[00635] "Alkoxyalkyl" means an alkyl group, as defined herein, substituted with one, two, or three alkoxy groups, as defined herein.

[00636] "Akoxycarbonyl" means a -C(O)OR group where R is alkyl as defined herein.

[00637] "Alkoxyycarbonylalkyl" means an alkyl group, as defined herein, substituted with one, two, or three alkoxycarbonyl groups, as defined herein.

[00638] "Alkyl" or "lower alkyl" means a linear or branched hydrocarbon group having one to six carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, *s*-butyl, *t*-butyl, isobutyl, pentyl, hexyl and the like. A "C_0" alkyl (as in "C_0-C_6-alkyl") is a covalent bond. "C_6 alkyl" refers to, for example, *n*-hexyl, *iso*-hexyl, and the like.

[00639] "Alkylamino" means a -NHR radical where R is alkyl as defined herein, or an N-oxide derivative thereof, e.g., methylamino, ethylamino, *n*-, *iso*-propylamino, *n*-, *iso*-, *tert*-butylamino, or methylamino-N-oxide, and the like.

[00640] "Alkylaminoalkyl" means an alkyl group substituted with one or two alkylamino groups, as defined herein.

[00641] "Alkylaminoalkyloxy" means an -OR group where R is alkylaminoalkyl, as defined herein.

[00642] "Alkylcarbonyl" means a C(O)R group where R is alkyl, as defined herein.

[00643] "Alkylcarbonylamino" means a -NRC(O)R' group where R is hydrogen or alkyl, as defiend herein, and R' is alkyl, as defiend herein.

[00644] "Alkylene" refers to straight or branched divalent hydrocarbon, containing no unsaturation and having from two to eight carbon atoms. Examples of alkylene include

ethdiyl ($-CH_2CH_2-$), prop-1,3-diyl ($-CH_2CH_2CH_2-$), 2,2-dimethylprop-1,3-diyl ($-CH_2C(CH_3)_2CH_2-$), and the like.

[00645] "Alkylsulfonyl" means a $-S(O)_2R$ group where R is lakyl, as defined herien.

[00646] "Alkylthio" means a -SR group where R is alkyl, as defined herein. Examples of alkylthio include methylthio and ethylthio, and the like.

[00647] "Alkylthioalkyl" means an alkyl group substituted with one or two alkylthio groups, as defined herein, e.g. 2-(methylthio)-ethyl and 2-(ethylthio)-ethyl.

[00648] "Alkynyl" or "lower alkynyl" means a straight or branched hydrocarbon radical having from 2 to 6 carbon atoms and at least one triple bond and includes ethynyl, propynyl, butynyl, pentyn-2-yl and the like.

[00649] "Amino" means a $-NH_2$.

[00650] "Aminoalkyl" means an alkyl group subsitutted with at least one, specifically one, two, or three, amino groups.

[00651] "Aminoalkyloxy" means an -OR group where R is aminoalkyl, as defined herein.

[00652] "Aryl" means a monovalent six- to fourteen-membered, mono- or bi-carbocyclic ring, wherein the monocyclic ring is aromatic and at least one of the rings in the bicyclic ring is aromatic. Representative examples include phenyl, naphthyl, and indanyl, and the like.

[00653] "Arylalkyl" means an alkyl group, as defined herein, subsituted with one or two aryl groups, as defined herein. Examples include benzyl, phenethyl, phenylvinyl, phenylallyl and the like.

[00654] "Aryloxy"means a -OR group where R is aryl as defined herein.

[00655] "Arylalkyloxy" means a -OR group where R is arylalkyl as defined herein.

[00656] "Arylsulfonyl" means a $-SO_2R$ group where R is aryl as defined herein.

[00657] "Carboxyalkyl" means an alkyl group, as defined herein, substituted with one, two, or three -C(O)OH groups.

[00658] "Carboxy ester" means a -C(O)OR group where R is lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl or arylalkyl, each of which is defined herein. Representative examples include methoxycarbonyl, ethoxycarbonyl, and benzyloxycarbonyl, and the like.

[00659] "Cyanoalkyl" means an alkyl, alkenyl, or alkynyl radical, as defined herein, substituted with at least one, specifically one, two, or three, cyano groups.

[00660] "Cycloalkyl" means a monocyclic or polycyclic hydrocarbon radical having three to thirteen carbon atoms. The cycloalkyl can be saturated or partially unsaturated, but cannot contain an aromatic ring. Cycloalkyl includes fused, bridged, and spiro ring systems. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

[00661] "Cycloalkylalkyl" means alkyl group substituted with one or two cycloalkyl group(s), as defined herein. Representative examples include cyclopropylmethyl and 2-cyclobutyl-ethyl, and the like.

[00662] "Cycloalkylcarbonyl" means a -C(O)R group where R is cycloalkyl as defined herein.

[00663] "Dialkylamino" means a -NRR' radical where R and R' are independently alkyl as defined herein, or an N-oxide derivative, or a protected derivative thereof, e.g., dimethylamino, diethylamino, *N,N*-methylpropylamino or *N,N*-methylethylamino, and the like.

[00664] "Dialkylaminoalkyl" means an alkyl group substituted with one or dialkylamino group(s), as defined herein.

[00665] "Dialkylaminoalkyloxy" means an -OR group where R is dialkylaminoalkyl, as defined herein.

[00666] "Fused ring system" and "fused ring" refer to a polycyclic ring system that contains bridged or fused rings; that is, where two rings have more than one shared atom in their ring structures. In this application, fused-polycyclics and fused ring systems are not necessarily all aromatic ring systems. Typically, but not necessarily, fused-polycyclics share a vicinal set of atoms, for example naphthalene or 1,2,3,4-tetrahydro-naphthalene. A spiro ring system is not a fused-polycyclic by this definition, but fused polycyclic ring systems of the invention may themselves have spiro rings attached thereto via a single ring atom of the fused-polycyclic. In some examples, as appreciated by one of ordinary skill in the art, two adjacent groups on an aromatic system may be fused together to form a ring structure. The fused ring structure may contain heteroatoms and may be optionally substituted with one or more groups. It should additionally be noted that saturated carbons of such fused groups (*i.e.* saturated ring structures) can contain two substitution groups.

[00667] "Haloaloxy" means an -OR' group where R' is haloalkyl as defined herein, e.g., trifluoromethoxy or 2,2,2-trifluoroethoxy, and the like.

[00668] "Haloalkoxyalkyl" means an alkyl group, as defined herein, substituted with one, two, or three haloalkoxy, as defined herein.

[00669] "Halogen" or "halo" means fluoro, chloro, bromo and iodo.

[00670] "Haloalkenyl means an alkenyl group, as defined herein, substituted with one or more halogens, specifically one to five halo atoms.

[00671] "Haloalkyl" means an alkyl group, as defined herein, substituted with one or more halogens, specifically one to five halo atoms. Representative examples includes 2,2-difluoroethyl, trifluoromethyl, and 2-chloro-1-fluoroethyl, and the like.

[00672] "Heteroaryl" means a monocyclic, fused bicyclic, or fused tricyclic, monovalent radical of 5 to 14 ring atoms containing one or more, specifically one, two, three, or four ring heteroatoms independently selected from -O-, -S(O)$_n$- (n is 0, 1, or 2), -N-, -N(R^x)-, and the remaining ring atoms being carbon, wherein the ring comprising a monocyclic radical is aromatic and wherein at least one of the fused rings comprising a bicyclic or tricyclic radical is aromatic. One or two ring carbon atoms of any nonaromatic rings comprising a bicyclic or tricyclic radical may be replaced by a -C(O)-, -C(S)-, or -C(=NH)- group. R^x is hydrogen, alkyl, hydroxy, alkoxy, acyl, or alkylsulfonyl. Fused bicyclic radical includes bridged ring systems. Unless stated otherwise, the valency may be located on any atom of any ring of the heteroaryl group, valency rules permitting. In particular, when the point of valency is located on the nitrogen, R^x is absent. More specifically, the term heteroaryl includes, but is not limited to, 1,2,4-triazolyl, 1,3,5-triazolyl, phthalimidyl, pyridinyl, pyrrolyl, imidazolyl, thienyl, furanyl, indolyl, 2,3-dihydro-1*H*-indolyl (including, for example, 2,3-dihydro-1*H*-indol-2-yl or 2,3-dihydro-1*H*-indol-5-yl, and the like), isoindolyl, indolinyl, isoindolinyl, benzimidazolyl, benzodioxol-4-yl, benzofuranyl, cinnolinyl, indolizinyl, naphthyridin-3-yl, phthalazin-3-yl, phthalazin-4-yl, pteridinyl, purinyl, quinazolinyl, quinoxalinyl, tetrazoyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isooxazolyl, oxadiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl (including, for example, tetrahydroisoquinolin-4-yl or tetrahydroisoquinolin-6-yl, and the like), pyrrolo[3,2-c]pyridinyl (including, for example, pyrrolo[3,2-c]pyridin-2-yl or pyrrolo[3,2-c]pyridin-7-yl, and the like), benzopyranyl, thiazolyl, isothiazolyl, thiadiazolyl, benzothiazolyl, benzothienyl, and the derivatives thereof, or N-oxide or a protected derivative thereof.

[00673] "Hetereoarylalkyl" means an alkyl group substituted with one or two heteroaryl group(s) as defined herein.

[00674] "Heterocycloalkyl" means a saturated or partially unsaturated monovalent monocyclic group of 3 to 8 ring atoms or a saturated or partially unsaturated monovalent fused bicyclic group of 5 to 12 ring atoms in which one or more, specifically one, two, three, or four ring heteroatoms independently selected from -O-, -S(O)$_n$- (n is 0, 1, or 2), -N=, -N(R^y)- (where R^y is hydrogen, alkyl, hydroxy, alkoxy, acyl, or alkylsulfonyl), the remaining ring atoms being carbon. One or two ring carbon atoms may be replaced by a -C(O)-, -C(S)-, or -C(=NH)- group. Fused bicyclic radical includes bridged ring systems. Unless otherwise stated, the valency of the group may be located on any atom of any ring within the radical, valency rules permitting. In particular, when the point of valency is located on a nitrogen atom, R^y is absent. More specifically the term heterocycloalkyl includes, but is not limited to, azetidinyl, pyrrolidinyl, 2-oxopyrrolidinyl, 2,5-dihydro-1*H*-pyrrolyl, piperidinyl, 4-piperidonyl, morpholinyl, piperazinyl, 2-oxopiperazinyl, tetrahydropyranyl, 2-oxopiperidinyl, thiomorpholinyl, thiamorpholinyl, perhydroazepinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, dihydropyridinyl, tetrahydropyridinyl, oxazolinyl, oxazolidinyl, isoxazolidinyl, thiazolinyl, thiazolidinyl, quinuclidinyl, isothiazolidinyl, octahydroindolyl, octahydroisoindolyl, decahydroisoquinolyl, tetrahydrofuryl, and tetrahydropyranyl, and the derivatives thereof and N-oxide or a protected derivative thereof.

[00675] "Heterocycloalkylalkyl" means an alkyl group, as defined herein, substituted with one or two heterocycloalkyl group(s), as defined herein.

[00676] "Hydroxyalkyl" means an alkyl radical, as defined herein, substituted with at least one, specifically one, two, or three, hydroxy group(s), provided that if two hydroxy groups are present they are not both on the same carbon atom. Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 1-(hydroxymethyl)-2-hydroxyethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxypropyl, specifically 2-hydroxyethyl, 2,3-dihydroxypropyl, or 1-(hydroxymethyl)-2-hydroxyethyl, and the like.

[00677] "Hydroxyamino" means a -NH(OH) group.

[00678] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. One of ordinary skill in the art would understand that with respect to any molecule described as containing one or more optional substituents, only sterically practical and/or synthetically feasible compounds are meant to be included. "Optionally substituted " refers to all subsequent modifiers in a term. So, for example, in the term "optionally substituted arylC_{1-8} alkyl," both the "C_{1-8} alkyl" portion and the "aryl" portion of the molecule may or may not be substituted. A list of exemplary optional substitutions is presented below in the definition of "substituted." But where a first optionally substituted group can be substituted by a second optionally substituted group, the second substituent cannot be further substituted.

[00679] "Optionally substituted alkyl" means an alkyl radical, as defined herein, optionally substituted with one or more group(s), specifically one, two, three, four, or five groups, independently selected from alkylcarbonyl, alkenylcarbonyl, cycloalkylcarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, amino, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cyano, cyanoalkylaminocarbonyl, alkoxy, alkenyloxy, hydroxy, hydroxyalkoxy, carboxy, alkylcarbonylamino, alkylcarbonyloxy, alkyl-$S(O)_{0-2}$-, alkenyl-$S(O)_{0-2}$-, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonyl-NR^c- (where R^c is hydrogen, alkyl, optionally substituted alkenyl, optionally substituted alkynyl, hydroxy, alkoxy, alkenyloxy, or cyanoalkyl), alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkylaminoalkyloxy, dialkylaminoalkyloxy, alkoxycarbonyl, alkenyloxycarbonyl, alkoxycarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, alkoxyalkyloxy, and -$C(O)NR^aR^b$ (where R^a and R^b are independently hydrogen, alkyl, optionally substituted alkenyl, optionally substituted alkynyl, hydroxy, alkoxy, alkenyloxy, or cyanoalkyl).

[00680] "Optionally substituted alkenyl" means an alkenyl radical, as defined herein, optionally substituted with one or more group(s), specifically one, two, or three groups, independently selected from alkylcarbonyl, alkenylcarbonyl, cycloalkylcarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, amino, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cyano, cyanoalkylaminocarbonyl, alkoxy, alkenyloxy, hydroxy, hydroxyalkoxy, carboxy,

alkylcarbonylamino, alkylcarbonyloxy, alkyl-$S(O)_{0-2}$-, alkenyl-$S(O)_{0-2}$-, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonyl-NR^c- (where R^c is hydrogen, optionally substituted alkyl, optionally substituted alkynyl, hydroxy, alkoxy, or alkenyloxy), alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkylaminoalkyloxy, dialkylaminoalkyloxy, alkoxycarbonyl, alkenyloxycarbonyl, alkoxycarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, alkoxyalkyloxy, and -$C(O)NR^aR^b$ (where R^a and R^b are independently hydrogen, optionally substituted alkyl, alkenyl, optionally substituted alkynyl, hydroxy, alkoxy, or alkenyloxy).

[00681] "Optionally substituted aryl" means an aryl group, as defined herein, which is optionally substituted with one, two, three, four, of five groups selected from halo, haloalkyl, haloalkoxy, hydroxy, lower alkyl, lower alkenyl, lower alkynyl, alkoxy, carboxy, carboxy ester, amino, alkylamino, dialkylamino, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, -C(O)NR'R" (where R' is hydrogen or alkyl and R" is hydrogen, alkyl, aryl, heteroaryl, or heterocycloalkyl), -NR'C(O)R" (where R' is hydrogen or alkyl and R" is alkyl, aryl, heteroaryl, or heterocycloalkyl), and -$NHS(O)_2$R' (where R' is alkyl, aryl, or heteroaryl).

[00682] "Optionally substituted heteroaryl" means a heteroaryl group, as defined herein, optionally substituted with one, two, three, four, or five groups selected from halo, haloalkyl, haloalkoxy, lower alkyl, lower alkenyl, lower alkynyl, alkoxy, hydroxy, oxo (valency rules permitting), carboxy, carboxy ester, amino, alkylamino, dialkylamino, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, heteroaryl, optionally substituted aryl, -C(O)NR'R" (where R' is hydrogen or alkyl and R" is hydrogen, alkyl, aryl, heteroaryl, or heterocycloalkyl), -NR'C(O)R" (where R' is hydrogen or alkyl and R" is alkyl, aryl, heteroaryl, or heterocycloalkyl), and -$NHS(O)_2$R' (where R' is alkyl, aryl, or heteroaryl).

[00683] "Optionally substituted heterocycloalkyl" means a heterocycloalkyl, as defined herein, optionally substituted with one, two, three, four, or five groups selected from halo, haloalkyl, haloalkoxy, hydroxy, oxo, lower alkyl, lower alkenyl, lower alkynyl, alkoxy, optionally substituted cycloalkyl, heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, alkylaminoalkyl, dialkylaminoalkyl, carboxy, carboxy ester, -C(O)NR'R" (where R' is hydrogen or alkyl and R" is hydrogen, alkyl, aryl, heteroaryl, or heterocycloalkyl), -NR'C(O)R" (where R' is hydrogen or alkyl

and R" is alkyl, aryl, heteroaryl, or heterocycloalkyl), amino, alkylamino, dialkylamino, and -$NHS(O)_2R$' (where R' is alkyl, aryl, or heteroaryl).

[00684] "Saturated bridged ring system" refers to a bicyclic or polycyclic ring system that is not aromatic. Such a system may contain isolated or conjugated unsaturation, but not aromatic or heteroaromatic rings in its core structure (but may have aromatic substitution thereon). For example, hexahydro-furo[3,2-b]furan, 2,3,3a,4,7,7a-hexahydro-1H-indene, 7-aza-bicyclo[2.2.1]heptane, and 1,2,3,4,4a,5,8,8a-octahydro-naphthalene are all included in the class "saturated bridged ring system."

Synthetic Procedures for PI3K Compounds

[00685] Compounds of Formula I(P) and/or II(P) can be made by the synthetic schemes and examples described in publication WO 2007/044729, which is incorporated herein by reference in its entirety. The utility of these compounds are also described in WO 2007/044729.

[00686] The PI3K compounds of Formula I(P) and II(P), or their pharmaceutically acceptable salts, may have asymmetric carbon atoms or quaternized nitrogen atoms in their structure. Compounds of Formula I(P) may exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. The compounds may also exist as geometric isomers. All such single stereoisomers, racemates and mixtures thereof, and geometric isomers are intended to be within the scope of this invention. Some of the compounds may exist as tautomers. For example, where a ketone or aldehyde is present, the molecule may exist in the enol form; where an amide is present, the molecule may exist as the imidic acid; and where an enamine is present, the molecule may exist as an imine. All such tautomers are within the scope of the invention.

[00687] In particular, B can be 2-hydroxy-pyridinyl, also described as its structure:



14.

Both 2-hydroxy-pyridinyl and the above structure **14** include, and are equivalent to, pyridin-2(1*H*)-one and its structure **15**:



15.

Regardless of which structure or which terminology is used, each tautomer is included within the scope of the compounds of Formula I(P) and II(P).

[00688] Compounds of Formula I(P) and II(P) also includes N-oxide derivatives and protected derivatives of compounds of Formula I(P). For example, when compounds of Formula I(P) and II(P) contain an oxidizable nitrogen atom, the nitrogen atom can be converted to an N-oxide by methods well known in the art. When compounds of Formula I(P) and II(P) contain groups such as hydroxy, carboxy, thiol or any group containing a nitrogen atom(s), these groups can be protected with a suitable "protecting group" or "protective group". A comprehensive list of suitable protective groups can be found in T.W. Greene, *Protective Groups in Organic Synthesis*, John Wiley & Sons, Inc. 1991, the disclosure of which is incorporated herein by reference in its entirety. The protected derivatives of compounds of Formula I(P) and II(P) can be prepared by methods well known in the art.

[00689] Methods for the preparation and/or separation and isolation of single stereoisomers from racemic mixtures or non-racemic mixtures of stereoisomers are well known in the art. For example, optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. Enantiomers (R- and S-isomers) may be resolved by methods known to one of ordinary skill in the art, for example by: formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallization; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallization, selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where a desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step may be required to liberate the desired enantiomeric form. Alternatively, specific enantiomer may be

synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents or by converting on enantiomer to the other by asymmetric transformation. For a mixture of enantiomers, enriched in a particular enantiomer, the major component enantiomer may be further enriched (with concomitant loss in yield) by recrystallization.

[00690] In addition, the compounds of Formula I(P) and II(P) can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the present invention.

[00691] In compounds of Formula I(P) and II(P)



the hydrogen on the $-NHS(O)_2-$ group is highly acidic. Thus, intermediates leading to compounds of Formula I(P) and II(P), as well as compounds of Formula I(P) and II(P) themselves, can be recovered as uncharged or zwitterionic molecules, or cationic salts such a sodium or potassium, depending on the substitutions on the B ring and on reaction conditions. In the representative compounds provided herein, unless otherwise specified, the final form of the compound was assumed to be the uncharged molecule in the absence of analytical techniques that would have determined otherwise.

[00692] The PI3K compounds of Formula I(P) and II(P), or their pharmaceutically acceptable salts, can have asymmetric carbon atoms, oxidized sulfur atoms or quaternized nitrogen atoms in their structure.

[00693] The PI3K compounds of of Formula I(P) and II(P) and their pharmaceutically acceptable salts can exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. The compounds can also exist as geometric isomers. All such single stereoisomers, racemates and mixtures thereof, and geometric isomers are intended to be within the scope of this invention.

[00694] It is assumed that when considering generic descriptions of PI3K compounds of Formula I(P) and II(P) for the purpose of constructing a compound, such construction results in the creation of a stable structure. That is, one of ordinary skill in the art would recognize that theoretically some constructs which would not normally be considered as stable compounds (that is, sterically practical and/or synthetically feasible, *supra*).

[00695] In addition, it is intended that the PI3K compounds of Formula I(P) and II(P) are made either using standard organic synthetic techniques, including combinatorial chemistry or by biological methods, such as bacterial digestion, metabolism, enzymatic conversion, and the like.

Pharmaceutical Composition Examples

[00696] The following are representative pharmaceutical Formulations containing a PI3K compound of Formula I(P) or II(P).

Tablet Formulation

[00697] The following ingredients are mixed intimately and pressed into single scored tablets.

Ingredient	Quantity per tablet, mg
PI3K compound	400
Cornstarch	50
croscarmellose sodium	25
Lactose	120
Magnesium stearate	5

Capsule Formulation

[00698] The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.

Ingredient	Quantity per tablet, mg
PI3K compound	200
lactose, spray-dried	148
Magnesium stearate	2

Suspension Formulation

[00699] The following ingredients are mixed to form a suspension for oral administration.

Ingredient	Amount
PI3K compound	1.0 g
fumaric acid	0.5 g
sodium chloride	2.0 g
methyl paraben	0.15 g
propyl paraben	0.05 g
granulated sugar	25.5 g
sorbitol (70% solution)	12.85 g
Veegum K (Vanderbilt Co.)	1.0 g
Flavoring	0.035 mL
Colorings	0.5 mg
distilled water	q.s. to 100 mL

Injectable Formulation

[00700] The following ingredients are mixed to form an injectable Formulation.

Ingredient	Amount
PI3K compound	1.2 g
sodium acetate buffer solution	0.4 M 2.0 mL
HCl (1 N) or NaOH (1 M)	q.s. to suitable pH
water (distilled, sterile)	q.s.to 20 mL

[00701] All of the above ingredients, except water, are combined and heated to 60-70° C with stirring. A sufficient quantity of water at 60 ° C is then added with vigorous stirring to emulsify the ingredients, and water then added q.s. to 100 g.

Suppository Formulation

[00702] A suppository of total weight 2.5 g is prepared by mixing the compound of the invention with Witepsol® H-15 (triglycerides of saturated vegetable fatty acid; Riches-Nelson, Inc., New York), and has the following composition:

Ingredient	Quantity per tablet, mg
PI3K compound	500
Witepsol®H-15	Balance

[00703] Aspect (32) of the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J) (including pharmaceutically acceptable salts thereof), or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), and a pharmaceutically acceptable carrier, in combination with a therapeutically effective amount of a PI3K compound of Formula I(P), II(P), I(P)a, (P-A), (P-B), (P-C), (P-D), (P-E), (P-F), (P-G), (P-G1), (P-H), (P-J), (P-K), (P-L), (P-M), (P-N), (P-P), (P-Q), (P-R), (P-R1), (P-R2), (P-S), (P-S1), (P-S2), (P-S3), (P-T), (P-T1), (P-U), (P-U1), (P-U2), (P-U3), (P-V), or (P-X), or a pharmaceutical composition comprising a therapeutically effective amount of the PI3K compound of Formula I(P), II(P), I(P)a, (P-A), (P-B), (P-C), (P-D), (P-E), (P-F), (P-G), (P-G1), (P-H), (P-J), (P-K), (P-L), (P-M), (P-N), (P-P), (P-Q), (P-R), (P-R1), (P-R2), (P-S), (P-S1), (P-S2), (P-S3), (P-T), (P-T1), (P-U), (P-U1), (P-U2), (P-U3), (P-V), or (P-X), and a pharmaceutically acceptable carrier, wherein the mammal is in need of the treatment.

[00704] In another embodiments of aspect (1), aspect (16) and aspect (32) of this invention, R^2 of Formula I(J) is



(f).

[00705] In another embodiments of aspect (1), aspect (16) and aspect (32) of this invention, R^2 of Formula I(J) is



,

wherein R^{28a} is selected from lower alkyl, dialkylaminoalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, and hetercycloalkylalkyl.

[00706] In another embodiments of aspect (1), aspect (16) and aspect (32) of this invention, R^2 of Formula I(J) is



[00707] In another embodiments of aspect (1), aspect (16) and aspect (32) of this invention, L of Formula I(J) is a bond, Z is  , R^{25} is hydrogen and E and D are hydrogen.

[00708] In another embodiments of aspect (1), aspect (16) and aspect (32) of this invention, Z of Formula I(J) is  , R^{26a} is $-C(O)R^{32}$, R^{26} is hydrogen, and R^{32} is selected from tetrahydrofuran, pyrrolidinyl or pryimidinyl, wherein R^{32} is optionally substituted with 1, 2, 3, 4 or 5 groups selected from hydroxyl, oxo, alkyl, alkoxy, amino, hydroxyalkyl and halo.

[00709] In another embodiments of aspect (1), aspect (16) and aspect (32) of this invention, R^2 of Formula I(J) is  .

[00710] In another embodiments of aspect (1), aspect (16) and aspect (32) of this invention, R^{32} of Formula I(J) is U or $-CH_2-U$, wherein U is selected from pyrolidinyl, thiazolidinyl, morpholinyl, azetidinyl, cyclobutyl, cyclopropyl, tetrahydofuranyl, pyrazinyl, imidazolyl, piperazinyl, thienyl, thienylmethyl, furanyl, phenyl, prolinamidyl, pyridinyl, tetrahydronaphthalene, tetrazolyl, isoindolinyl, pyranyl, cyclopentyl, and octahydro-1H-indolyl.

[00711] In another embodiments of aspect (1), aspect (16) and aspect (32) of this invention, R^{11} of Formula I(J), when present, is halo or lower alkyl.

[00712] In another embodiments of aspect (1), aspect (16) and aspect (32) of this invention, R^{35} of Formula I(J) is heterocycloalkylalkyl, wherein the heterocyloalkyl is selected from piperazinyl, piperidinyl, morpholinyl and dioxanyl.

[00713] In another embodiments of aspect (1), aspect (16) and aspect (32) of this invention, n2 of Formula I(J) is 0.

[00714] In another embodiments of aspect (1), aspect (16) and aspect (32) of this invention, R^2 of Formula I(J) is  , and wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl.

[00715] In another embodiments of aspect (1), aspect (16) and aspect (32) of this invention, the JAK-2 compound has Formula IV(J):



wherein and R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

[00716] In another embodiments of aspect (1), aspect (16) and aspect (32) of this invention, the JAK-2 compound has Formula V(J):



wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

[00717] In another embodiments of aspect (1), aspect (16) and aspect (32) of this invention, the JAK-2 compound has Formula VI(J):



wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

[00718] In other embodiments of the method of combining the PI3K inhibitors with the JAK-2 inhibitors of Formula I(J), any of the embodiments described above for the PI3K compounds can be combined with any one of the embodiments of the compound of Formula I(J) described hereinabove. In other embodiments of the method of combining the PI3K inhibitors with the JAK-2 inhibitors of Formula I(J), one or more of any of the PI3K compounds in Table P can be combined with any one of the embodiments of the compound of Formula I(J) described hereinabove. In other embodiments of the above method of combining the PI3K compounds with the JAK-2 inhibitors of Formula I(J), one or more of any of the PI3K compounds in Table P can be combined with one or more of any of the compounds in Table I(J).

PI3Kα INHIBITORS

[00719] The PI3Kα compounds inhibit, regulate and/or modulate the signal transduction of PI3Kα, and are expected to be useful in the treatment of hyperproliferative diseases, such as cancer, in humans. In another embodiment of the methods described herein, the JAK-2 compounds described hereinabove [e.g., compounds of Formula I(J), II(J), III(J), IV(J), V(J), VI(J), and VII(J)] can be combined with any of the PI3Kα inhibitors known in the art. The PI3Kα compounds described below are non-limiting examples of "PI3Kα inhibitors" that fall within the scope of aspect (2) of this invention. All of the substituents for the PI3Kα compounds described below are defined separately from all of the other compounds described herein that are not PI3Kα compounds so that every substituent in the PI3Kα compounds that also appears in any of the other compounds described herein has a separate and distinct

meaning for each of these two compounds. For instance, R^1 for the JAK-2 compounds has a separate and distinct meaning from R^1 for the PI3Kα compounds.

[00720] All of the PI3Kα compounds disclosed herein include either their free base form or their pharmaceutically acceptable salts whether it is stated in the specification that these compounds can exist as their pharmaceutically acceptable salts or not. All of the PI3Kα compounds disclosed herein fall within the scope of aspect (17) of this invention.

[00721] In another embodiment of the methods described herein, the JAK-2 compounds described hereinabove [e.g., compounds of Formula I(J), II(J), III(J), IV(J), V(J), VI(J), and VII(J)] can be combined with PI3Kα compounds of Formula I(K):



I(K)

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;

R^2 is hydrogen or alkyl where the alkyl is optionally substituted with 1, 2, 3, 4, or 5 R^8 groups;

X is $-NR^3-$;

R^3 hydrogen;

R^4 is optionally substituted alkyl;

R^5 is hydrogen; and

R^6 is phenyl, acyl, or heteroaryl wherein the phenyl and heteroaryl are optionally substituted with 1, 2, 3, 4, or 5 R^9 groups;

each R^8, when present, is independently hydroxy, halo, alkoxy, haloalkoxy, amino, alkylamino, dialkylaminoalkyl, or alkoxyalkylamino; and

each R^9, when present, is independently halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cyano, amino, alkylamino, dialkylamino, alkoxyalkyl, carboxyalkyl, alkoxycarbonyl, aminoalkyl, cycloalkyl, aryl, arylalkyl, aryloxy, heterocycloalkyl, or heteroaryl and where the cycloalkyl, aryl, heterocycloalkyl, and heteroaryl, each either alone or as part of another group within R^9, are independently optionally substituted with 1, 2, 3, or 4 groups selected from halo, alkyl, haloalkyl, hydroxy, alkoxy, haloalkxy, amino, alkylamino, and dialkylamino.

[00722] In another embodiment, the PI3Kα compound is a compound of Formula II(K):



II(K)

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is hydrogen, optionally substituted alkyl, optionally substituted C_3-C_7 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;

X is S, SO_2, or -NR^3-;

R^2 is hydrogen, haloalkyl, optionally substituted alkyl, optionally substituted C_3-C_7 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkyl-aryl- or optionally substituted heteroaryl; R^2 is optionally further substituted with one or more R^8 groups;

R^3, R^{3a}, and R^{3b} are independently hydrogen, optionally substituted alkyl, optionally substituted C_3-C_7 cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl or optionally substituted heteroaryl;

R^4 is hydrogen, halo, haloalkyl, haloalkoxy, -NR^{3a}-, optionally substituted alkyl, optionally substituted C_1-C_6 alkoxy, optionally substituted C_1-C_6 alkoxyalkyl, optionally substituted aminoalkyl, optionally substituted C_3-C_7 cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;

R^5 is hydrogen, halo, haloalkyl, haloalkoxy, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 alkoxy, optionally substituted C_1-C_6 alkoxyalkyl, optionally substituted aminoalkyl, optionally substituted C_3-C_7 cycloalkyl, optionally substituted aryl, optionally substituted aryl C_1-C_6 alkyl or optionally substituted heteroaryl; and

R^6 is hydrogen, halo, haloalkyl, haloalkoxy, -NR^{3b}-, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 alkoxy, optionally substituted C_1-C_6 alkoxyalkyl, optionally substituted acyl, optionally substituted aminoalkyl, optionally substituted C_3-C_7 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl; substitutable R^6 groups are optionally further substituted with 1, 2, 3, 4, or 5 R^9 groups;

each R^8, when present, is independently hydroxy, halo, haloalkyl, haloalkoxy, optionally substituted alkyl, optionally substituted C_1-C_6 alkoxy, optionally substituted C_1-C_6 alkoxyalkyl, optionally substituted C_1-C_6 alkoxyalkylaminoalkyl, C_1-C_6 alkylcarboxyheterocycloalkyl, oxy C_1-C_6alkylheterocycloalkyl, optionally substituted aminoalkyl, optionally substituted C_3-C_7 cycloalkyl, optionally substituted aryl, optionally substituted aryl C_1-C_6 alkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;

each R^9, when present, is independently halo, haloalkyl, haloalkoxy, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 alkoxy, optionally substituted C_1-C_6 alkoxyalkyl, optionally substituted C_1-C_6 carboxyalkyl, optionally substituted alkoxycarbonyl, optionally substituted aminoalkyl, optionally substituted C_3-C_7 cycloalkyl, optionally substituted aryl, optionally substituted aryl C_1-C_6 alkyl, optionally substituted aryloxy, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl.

In a specific embodiment (K-A) of the PI3Kα compound of Formula I(K) is a compound of Formula I(K) where R^1 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl. Specifically, R^1 is hydrogen, optionally substituted alkyl,

optionally substituted cycloalkyl, optionally substituted arylalkyl, or optionally substituted heterocycloalkylalkyl. More specifically, R^1 is hydrogen, alkyl, alkyl substituted with one or two hydroxy, alkyl substituted with alkoxy, cycloalkyl, arylalkyl, or heterocycloalkylalkyl. Even more specifically, R^1 is hydrogen, methyl, ethyl, propyl, isopropyl, 2-hydroxypropyl, 3-hydroxypropyl, 2-ethoxyethyl, 3-methoxypropyl, 3-ethoxypropyl, 3-isopropoxypropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, benzyl, or 2-piperidin-1-ylethyl. Yet even more specifically, R^1 is ethyl, isopropyl, cyclopentyl, or cyclohexyl. Yet even more specifically, R^1 is ethyl.

[00723] Another embodiment (K-B) of the compound of Formula I(K) is a Compound of Formula I(K) where R^2 is hydrogen or alkyl where the alkyl is optionally substituted with 1, 2, 3, 4, or 5 R^8 groups. Specifically, R^2 is hydrogen or alkyl where the alkyl is optionally substituted with one, two, or three R^8 groups. More specifically, R^2 is hydrogen or alkyl where the alkyl is optionally substitued with one, two, or three R^8 groups; and each R^8, when present, is independently selected from amino, alkylamino, dialkylamino, and halo. Even more specifically, R^2 is hydrogen, methyl, ethyl, propyl, isopropyl, *tert*-butyl, 3-aminopropyl, 3-(*N*-methylamino)-propyl, 3-(*N,N*-dimethylamino)-propyl, 2-fluoroethyl, or 2,2,2-trifluoroethyl. Yet even more specifically, R^2 is hydrogen or ethyl. Yet even more preferably, R^2 is hydrogen.

[00724] In another embodiment, R^2 is hydrogen.

[00725] In another embodiment, R^2 is alkyl optionally substituted with 1, 2, 3, 4, or 5, R^8 groups. Specifically, R^2 is alkyl where the alkyl is optionally substituted with one, two, or three R^8 groups; and each R^8, when present, is independently selected from amino, alkylamino, dialkylamino, and halo. Even more specifically, R^2 is methyl, ethyl, propyl, isopropyl, *tert*-butyl, 3-aminopropyl, 3-(*N*-methylamino)-propyl, 3-(*N,N*-dimethylamino)-propyl, 2-fluoroethyl, or 2,2,2-trifluoroethyl. Yet even more specifically, R^2 is ethyl.

[00726] Another embodiment (K-C) of the PI3Kα compound of Formula I(K) is a Compound of Formula I(K) where R^4 is optionally substituted alkyl. Specifically, R^4 is methyl or ethyl. More specifically, R^4 is methyl.

[00727] Another embodiment (K-D) of the PI3Kα compound of Formula I(K) is directed to a Compound of Formula I(K) where R^6 is acyl. More specifically, R^6 is alkylcarbonyl. Even more specifically, R^6 is acetyl.

[00728] Another embodiment (K-E) of the PI3Kα compound of Formula I(K) is directed to a Compound of Formula I(K) where R^6 is phenyl optionally substituted with 1, 2, 3, 4, or 5 R^9 groups. Specifically, R^6 is phenyl optionally substituted with one or two R^9 groups; and each R^9, when present, is independently selected from aryl, halo, alkoxy, aryloxy, and haloalkyl. More specifically, R^6 is phenyl optionally substituted with one or two R^9 groups; and each R^9, when present, is independently selected from phenyl, fluoro, chloro, methoxy, phenyloxy, and trifluoromethyl. Even more specifically, R^6 is phenyl, phenyl substituted with phenyl, fluorophenyl, difluorophenyl, chlorophenyl, dichlorophenyl, phenyl substituted with chloro and fluoro, methoxyphenyl, dimethoxyphenyl, phenyloxyphenyl, or trifluoromethylphenyl. Yet even more specifically, R^6 is phenyl, 2-phenyl-phenyl, 3-phenyl-phenyl, 4-phenyl-phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 3-chloro-4-fluoro-phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 2,4-dimethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 4-phenyloxyphenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, or 4-trifluoromethylphenyl.

[00729] Another embodiment (K-F) of the compound of Formula I(K) is directed to a Compound of Formula I(K) where R^6 is phenyl subtituted with 1, 2, 3, 4, or 5 R^9 groups.

[00730] Another embodiment (K-G) of the compound of Formula I(K) is directed to a Compound of Formula I(K) where R^6 is heteroaryl optionally substituted with 1, 2, 3, 4, or 5 R^9 groups.

[00731] A more specific embodiment (K-G1) of embodiment (K-G) is a Compound of Formula I(K) where R^6 is a 6-membered heteroaryl optionally substituted with one or two R^9. More specifically, R^6 is pyridinyl, pyrazinyl, pyrimidinyl, or pyridazinyl each of which is optionally substituted with one R^9 where R^9, when present, is halo. Even more specifically, R^6 is pyridi*N*-2-yl, pyridi*N*-3-yl, pyridi*N*-4-yl, 3-fluoropyridi*N*-4-yl, pyrazin-2-yl, pyrazin-3-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-3-yl, or pyridazin-4-yl, each of which is optionally substituted with one or two R^9.

[00732] In an even more specific embodiment (K-G2) of embodiment (K-G) is a Compound of Formula I(K) where R^6 is pyrazinyl, pyrimidinyl, or pyridazinyl each of

which is optionally substituted with one R^9 where R^9, when present, is halo. Even more specifically, R^6 is pyrazin-2-yl, pyrazin-3-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-3-yl, or pyridazin-4-yl.

[00733] A more specific embodiment (K-G3) of embodiment (K-G) is a Compound of Formula I(K) where R^6 is 5-membered heteroaryl optionally substituted with one or two R^9. Specifically R^6 is pyrazolyl, imidazolyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, furanyl, pyrrolyl, triazolyl, or tetrazolyl, each of which is optionally substituted with one R^9 where R^9, when present, is alkyl, arylalkyl, cyano, aryl, alkoxycarbonyl, or halo. More specifically, R^6 is pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-1-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, thien-2-yl, thien-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, 1,2,3-oxadiazol-4-yl, 1,2,3-oxadiazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, furan-2-yl, furan-3-yl, pyrrol-1-yl, pyrrol-2-yl, pyrrol-3-yl, triazol-1-yl, triazol-4-yl, triazol-5-yl, tetrazol-1-yl, or tetrazol-5-yl; each of which is optionally substituted with one R^9 where R^9, when present, is methyl, benzyl, cyano, phenyl, *N-tert*-butoxycarbonyl, or chloro. Even more specifically, R^6 is pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, thien-2-yl, thien-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, 1,2,3-oxadiazol-4-yl, 1,2,3-oxadiazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, furan-2-yl, furan-3-yl, pyrrol-2-yl, pyrrol-3-yl, triazol-4-yl, triazol-5-yl, or tetrazol-5-yl; each of which is optionally substituted with one R^9 where R^9, when present, is methyl, benzyl, cyano, phenyl, *N-tert*-butoxycarbonyl, or chloro.

[00734] A more specific embodiment (K-G4) of embodiment (K-G) is a Compound of Formula I(K) where R^6 is thienyl, pyrrolyl, furanyl, pyrazolyl, thiazolyl, isoxazolyl, imidazolyl, triazolyl, or tetrazolyl, each of which is optionally substituted with one R^9 where R^9, when present, is methyl, benzyl, cyano, phenyl, *N-tert*-butoxycarbonyl, or chloro. Specifically, R^6 is thien-2-yl, thien-3-yl, pyrrol-2-yl, furan-2-yl, furan-3-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, thiazol-2-yl, thiazol-5-yl, isoxazol-4-yl, imidazol-5-yl, triazol-5-yl, tetrazol-5-yl, each of which is optionally substituted with one R^9 where R^9, when present, is methyl, benzyl, cyano, phenyl, *N-tert*-butoxycarbonyl, or chloro. More specifically, R^6 is thien-2-yl, thien-3-yl, 5-cyano-thien-2-yl, 4-methyl-thien-2-yl, 4-methyl-thien-3-yl, 5-chloro-thien-5-yl, 5-phenyl-thien-2-yl, pyrrol-2-yl,

N-tert-butoxycarbonyl-pyrrol-2-yl, *N*-methyl-pyrrol-2-yl, furan-2-yl, furan-3-yl, pyrazol-3-yl, pyrazol-4-yl, *N*-benzyl-pyrazol-4-yl, pyrazol-5-yl, thiazol-2-yl, thiazol-5-yl, isoxazol-4-yl, imidazol-5-yl, triazol-5-yl, tetrazol-5-yl,

[00735] A more specific embodiment (K-G5) of embodiment (K-G) is a Compound of Formula I(K) where R^6 is thien-2-yl, thien-3-yl, pyrrol-2-yl, furan-2-yl, furan-3-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, thiazol-2-yl, thiazol-5-yl, isoxazol-4-yl, imidazol-5-yl, triazol-5-yl, or tetrazol-5-yl, each of which is optionally substituted with one R^9 where R^9, when present, is methyl, benzyl, cyano, phenyl, *N-tert*-butoxycarbonyl, or chloro.

[00736] A more specific embodiment (K-G6) of embodiment (K-G) is a Compound of Formula I(K) where R^6 is indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, or benzoisoxazolyl each of which is optionally substituted with 1, 2, 3, 4, or 5 R^9 groups. Specifically, R^6 is indol-2-yl, indol-3-yl, indol-4-yl, indol-5-yl, indol-6-yl, indol-7-yl, benzimidazol-2-yl, benzimidazol-4-yl, benzimidazol-5-yl, benzimidazol-6-yl, benzimidazol-7-yl, benzofuran-2-yl, benzofuran-3-yl, benzofuran-4-yl, benzofuran-5-yl, benzofuran-6-yl, benzofuran-7-yl, benzoxazol-2-yl, benzoxazol-4-yl, benzoxazol-5-yl, benzoxazol-6-yl, benzoxazol-7-yl, benzoisoxazol-3-yl, benzoisoxazol-4-yl, benzoisoxazol-5-yl, benzoisoxazol-6-yl, or benzoisoxazol-7-yl; each of which is optionally substituted with 1, 2, 3, 4, or 5 R^9 groups. More specifically, R^6 is indol-6-yl.

[00737] Another embodiment (K-H) of the compound of Formula I(K) is a Compound of Formula I(K) where R^1 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkylalkyl, or optionally substituted arylalkyl; X is -NH-; R^2 is hydrogen or alkyl where the alkyl is optionally substituted with one or two R^8 groups; R^4 is alkyl; R^5 is hydrogen; R^6 is phenyl or heteroaryl wherein the phenyl and heteroaryl are optionally substituted with one, two, or three R^9 groups; each R^8, when present, is independently amino, alkylamino, dialkylamino, or halo; and each R^9, when present, is independently alkyl, arylalkyl, cyano, aryl, alkoxycarbonyl, or halo.

[00738] Another embodiment (K-J) is a Compound of Formula I(K) where R^6 is pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, thien-2-yl, thien-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, 1,2,3-oxadiazol-4-yl, 1,2,3-oxadiazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, furan-2-

yl, furan-3-yl, pyrrol-2-yl, pyrrol-3-yl, triazol-4-yl, triazol-5-yl, or tetrazol-5-yl; each of which is optionally substituted with 1, 2, 3, 4, or 5 R^9 groups.

[00739] Another embodiment (K-K) is a Compound of Formula I(K) where R^1 is alkyl or cycloalkyl; R^4 is methyl; and R^6 is heteroaryl optionally substituted with one or two R^9 groups. Specifically, each R^9, when present, is independently alkyl, arylalkyl, cyano, aryl, alkoxycarbonyl, or halo. Specifically, R^6 is pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, thien-2-yl, thien-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, 1,2,3-oxadiazol-4-yl, 1,2,3-oxadiazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, furan-2-yl, furan-3-yl, pyrrol-2-yl, pyrrol-3-yl, triazol-4-yl, triazol-5-yl, or tetrazol-5-yl; each of which is optionally substituted with one R^9 where R^9, when present, is methyl, benzyl, cyano, phenyl, or *N-tert*-butoxycarbonyl.

[00740] A more specific embodiment (K-K1) of embodiment (K-K) is a Compound of Formula I(K) where R^2 is hydrogen.

[00741] A more specific embodiment (K-K2) of embodiment (K-K) is a Compound of Formula I(K) where R^2 is methyl or ethyl.

[00742] Another embodiment (K-L) of a Compound of Formula I(K) is a Compound of Formula I(K) where R^1 is alkyl or cycloalkyl; R^4 is methyl; and R^6 is phenyl optionally substituted with one or two R^9 groups. Specifically each R^9, when present, is independently halo, alkoxy, or haloalkyl.

[00743] Another embodiment (K-M) is a Compound of Formula I(K) where R^1 is alkyl or cycloalkyl; R^4 is methyl; and R^2 is hydrogen.

[00744] Another embodiment (K-N) is a Compound of Formula I(K) where R^1 is alkyl or cycloalkyl; R^4 is methyl; and R^2 is optionally subtituted alkyl.

Representative Compounds

[00745] Representative PI3Kα compounds, including pharmaceutically acceptael salts thereof, are depicted below in Table K. These PI3Kα compounds are merely illustrative and do not limit the scope of the PI3Kα compounds or PI3Kα inhibitors in any way. Compounds of the invention are named according to systematic application of the nomenclature rules agreed upon by the International Union of Pure and Applied Chemistry (IUPAC), International Union of Biochemistry and Molecular Biology

(IUBMB), and the Chemical Abstracts Service (CAS). Names were generated using ACD/Labs naming software 8.00 release, product version 8.08.

TABLE K

No.	Name
1	8-ethyl-2-(ethylamino)-4-methyl-6-phenylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
2	6-bromo-8-ethyl-4-methyl-2-[(1-methylethyl)amino]pyrido[2,3-d]pyrimidin-7(8*H*)-one;
3	6-bromo-2-[(1,1-dimethylethyl)amino]-8-ethyl-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
4	6-biphenyl-4-yl-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
5	6-(2,4-difluorophenyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
6	6-(3-chloro-4-fluorophenyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
7	8-ethyl-2-(ethylamino)-4-methyl-6-[4-(methyloxy)phenyl]pyrido[2,3-d]pyrimidin-7(8*H*)-one;
8	6-(2,4-dichlorophenyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
9	6-(3,4-difluorophenyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
10	8-ethyl-2-(ethylamino)-4-methyl-6-[2-(methyloxy)phenyl]pyrido[2,3-d]pyrimidin-7(8*H*)-one;
11	6-bromo-2-{[3-(dimethylamino)propyl]amino}-8-ethyl-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
12	8-ethyl-2-(ethylamino)-4-methyl-6-[4-(phenyloxy)phenyl]pyrido[2,3-d]pyrimidin-7(8*H*)-one;
13	6-[2,4-bis(methyloxy)phenyl]-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
14	8-ethyl-2-(ethylamino)-6-(3-fluorophenyl)-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
15	8-ethyl-2-(ethylamino)-6-(2-fluorophenyl)-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
16	8-ethyl-2-(ethylamino)-4-methyl-6-[3-(trifluoromethyl)phenyl]pyrido[2,3-d]pyrimidin-7(8*H*)-one;
17	8-ethyl-2-(ethylamino)-6-(4-fluorophenyl)-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
18	8-ethyl-2-(ethylamino)-4-methyl-6-(2-thienyl)pyrido[2,3-d]pyrimidin-7(8*H*)-one;
19	8-ethyl-2-(ethylamino)-4-methyl-6-[3-(methyloxy)phenyl]pyrido[2,3-d]pyrimidin-7(8*H*)-one;
20	6-(3-chlorophenyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
21	6-(4-chlorophenyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;

No.	Name
22	8-ethyl-2-(ethylamino)-4-methyl-6-(3-thienyl)pyrido[2,3-d]pyrimidin-7(8*H*)-one;
23	8-ethyl-2-(ethylamino)-4-methyl-6-(4-methyl-2-thienyl)pyrido[2,3-d]pyrimidin-7(8*H*)-one;
24	8-ethyl-2-(ethylamino)-4-methyl-6-(4-methyl-3-thienyl)pyrido[2,3-d]pyrimidin-7(8*H*)-one;
25	1,1-dimethylethyl 2-[8-ethyl-2-(ethylamino)-4-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl]-1*H*-pyrrole-1-carboxylate
26	8-ethyl-2-(ethylamino)-4-methyl-6-(1*H*-pyrrol-2-yl)pyrido[2,3-d]pyrimidin-7(8*H*)-one;
27	6-(5-chloro-2-thienyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
28	8-ethyl-2-(ethylamino)-4-methyl-6-pyrimidin-5-ylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
29	8-ethyl-2-(ethylamino)-6-(3-fluoropyridi*N*-4-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
30	8-ethyl-2-(ethylamino)-6-furan-3-yl-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
31	8-ethyl-2-(ethylamino)-4-methyl-6-[1-(phenylmethyl)-1*H*-pyrazol-4-yl]pyrido[2,3-d]pyrimidin-7(8*H*)-one;
32	6-bromo-2-(ethylamino)-4-methyl-8-(1-methylethyl)pyrido[2,3-d]pyrimidin-7(8*H*)-one;
33	2-(ethylamino)-4-methyl-8-(1-methylethyl)-6-(2-thienyl)pyrido[2,3-d]pyrimidin-7(8*H*)-one;
34	8-ethyl-2-(ethylamino)-6-(1*H*-indol-6-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
35	8-ethyl-2-(ethylamino)-4-methyl-6-(5-phenyl-2-thienyl)pyrido[2,3-d]pyrimidin-7(8*H*)-one;
36	2-(ethylamino)-6-furan-3-yl-4-methyl-8-(1-methylethyl)pyrido[2,3-d]pyrimidin-7(8*H*)-one;
37	8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
38	8-ethyl-2-(ethylamino)-4-methyl-6-(1*H*-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7(8*H*)-one;
39	8-cyclohexyl-2-(ethylamino)-4-methyl-6-(2-thienyl)pyrido[2,3-d]pyrimidin-7(8*H*)-one;
40	6-bromo-2-(ethylamino)-4-methyl-8-[3-(methyloxy)propyl]pyrido[2,3-d]pyrimidin-7(8*H*)-one;
41	6-bromo-2-(ethylamino)-8-[2-(ethyloxy)ethyl]-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
42	6-bromo-2-(ethylamino)-4-methyl-8-(2-piperidin-1-ylethyl)pyrido[2,3-d]pyrimidin-7(8*H*)-one;
43	6-bromo-2-(ethylamino)-8-[3-(ethyloxy)propyl]-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
44	6-bromo-2-(ethylamino)-4-methyl-8-{3-[(1-methylethyl)oxy]propyl}pyrido[2,3-d]pyrimidin-7(8*H*)-one;
45	6-bromo-2-(ethylamino)-8-(3-hydroxypropyl)-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;

No.	Name
46	6-bromo-2-(ethylamino)-8-(2-hydroxyethyl)-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
47	6-bromo-8-cyclopropyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
48	8-ethyl-2-(ethylamino)-4-methyl-6-(1,3-thiazol-2-yl)pyrido[2,3-d]pyrimidin-7(8*H*)-one;
49	6-bromo-8-cyclopentyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8*H*)-one;
50	8-cyclopentyl-2-(ethylamino)-4-methyl-6-(1*H*-pyrazol-3-yl)pyrido[2,3-d]pyrimidin-7(8*H*)-one;
51	2-(ethylamino)-4-methyl-8-(1-methylethyl)-6-(1*H*-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7(8*H*)-one;
52	8-ethyl-2-(ethylamino)-4-methyl-6-(1*H*-pyrazol-1-yl)pyrido[2,3-d]pyrimidin-7(8*H*)-one;
53	2-(ethylamino)-4-methyl-8-(1-methylethyl)-6-(1*H*-pyrazol-1-yl)pyrido[2,3-d]pyrimidin-7(8*H*)-one;
54	8-cyclopentyl-2-(ethylamino)-4-methyl-6-(1*H*-pyrazol-1-yl)pyrido[2,3-d]pyrimidin-7(8*H*)-one;
55	8-ethyl-4-methyl-6-(1*H*-pyrazol-5-yl)-2-[(2,2,2-trifluoroethyl)amino]pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
56	2-amino-8-ethyl-4-methyl-6-(1*H*-pyrazol-5-yl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
57	2-(ethylamino)-4-methyl-6-(1*H*-pyrazol-3-yl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
58	8-ethyl-4-methyl-2-(methylamino)-6-(1*H*-pyrazol-5-yl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
59	2-amino-8-cyclopentyl-4-methyl-6-(1*H*-pyrazol-3-yl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
60	8-ethyl-2-[(2-fluoroethyl)amino]-4-methyl-6-(1*H*-pyrazol-5-yl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
61	2-amino-4-methyl-8-(1-methylethyl)-6-(1*H*-pyrazol-3-yl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
62	2-amino-8-ethyl-4-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
63	2-amino-4-methyl-8-(phenylmethyl)-6-(1*H*-pyrazol-3-yl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
64	2-amino-8-ethyl-4-methyl-6-(4-methyl-3-thienyl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
65	2-amino-8-ethyl-4-methyl-6-(2-thienyl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
66	2-amino-8-ethyl-6-(4-fluorophenyl)-4-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
67	2-amino-8-ethyl-6-(3-fluorophenyl)-4-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
68	2-amino-8-ethyl-6-(2-fluorophenyl)-4-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
69	2-amino-8-ethyl-4-methyl-6-(3-thienyl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
70	2-amino-8-ethyl-6-furan-3-yl-4-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;

No.	Name
71	2-amino-8-ethyl-4-methyl-6-phenylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
72	2-amino-8-ethyl-4-methyl-6-[4-(methyloxy)phenyl]pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
73	2-amino-6-(4-chlorophenyl)-8-ethyl-4-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
74	2-amino-6-(3-chlorophenyl)-8-ethyl-4-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
75	2-amino-8-ethyl-6-isoxazol-4-yl-4-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
76	2-amino-8-ethyl-6-furan-2-yl-4-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
77	2-amino-6-(2,4-dichlorophenyl)-8-ethyl-4-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
78	5-(2-amino-8-ethyl-4-methyl-7-oxo-7,8-dihydropyrido[2,3-*d*]pyrimidin-6-yl)thiophene-2-carbonitrile
79	2-amino-8-ethyl-4-methyl-6-pyrimidin-5-ylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
80	2-amino-8-ethyl-6-(1*H*-imidazol-5-yl)-4-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
81	2-amino-8-ethyl-4-methyl-6-(1*H*-1,2,3-triazol-5-yl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
82	2-amino-8-ethyl-4-methyl-6-(1*H*-pyrazol-4-yl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
83	2-amino-8-ethyl-4-methyl-6-(1,3-thiazol-2-yl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
84	2-amino-8-ethyl-4-methyl-6-(1*H*-tetrazol-5-yl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
85	2-amino-8-ethyl-4-methyl-6-(1-methyl-1*H*-pyrrol-2-yl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
86	2-amino-6-bromo-8-cyclopentyl-4-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;
87	2-amino-4,8-diethyl-6-(1*H*-pyrazol-5-yl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one; and
88	2-amino-8-cyclopentyl-4-methyl-6-(1,3-thiazol-5-yl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one

Definitions for PI3Kα Compounds

[00746] The following abbreviations and terms apply to PI3Kα compounds described above only. These definitions are not to be considered when determining the scope and meaning of any of the other compounds described herein that are not PI3Kα compounds. To the same extent, any of the other compounds described herein are not to be considered when determining the scope and meaning of the PI3Kα compounds.

[00747] "Acyl" means a -C(O)R radical where R is optionally substituted alkyl, optionally substituted alkenyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, or heterocycloalkylalkyl, as defined herein, e.g., acetyl, trifluoromethylcarbonyl, or 2-methoxyethylcarbonyl, and the like.

[00748] "Acylamino" means a -NRR' radical where R is hydrogen, hydroxy, alkyl, or alkoxy and R' is acyl, as defined herein.

[00749] "Acyloxy" means an -OR radical where R is acyl, as defined herein, e.g. cyanomethylcarbonyloxy, and the like.

[00750] "Alkenyl" means a means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to 6 carbon atoms which radical contains at least one double bond, e.g., ethenyl, propenyl, 1-but-3-enyl, and 1-pent-3-enyl, and the like.

[00751] "Alkoxy" means an -OR group where R is alkyl group as defined herein. Examples include methoxy, ethoxy, propoxy, isopropoxy, and the like.

[00752] "Alkoxyalkyl" means an alkyl group, as defined herein, substituted with at least one, preferably one, two, or three, alkoxy groups as defined herein. Representative examples include methoxymethyl and the like.

[00753] "Alkoxyalkylamino" means an –NRR' group where R is hydrogen, alkyl, or alkoxyalkyl and R' is alkoxyalkyl, as defined herein.

[00754] "Alkoxyalkylaminoalkyl" means an alkyl group substituted with at least one, specifcially one or two, alkoxyalkylamino group(s), as defined herein.

[00755] "Alkoxycarbonyl" means a -C(O)R group where R is alkoxy, as defined herein.

[00756] "Alkyl" means a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to 6 carbon atoms, e.g., methyl, ethyl, propyl, 2-propyl, butyl (including all isomeric forms), or pentyl (including all isomeric forms), and the like.

[00757] "Alkylamino" means an -NHR group where R is alkyl, as defined herein.

[00758] "Alkylaminoalkyl" means an alkyl group substituted with one or two alkylamino groups, as defined herein.

[00759] "Alkylaminoalkyloxy" means an -OR group where R is alkylaminoalkyl, as defined herein.

[00760] "Alkylcarbonyl" means a -C(O)R group where R is alkyl, as defined herein.

[00761] "Alkynyl" means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to 6 carbon atoms which radical contains at least one triple bond, e.g., ethynyl, propynyl, butynyl, penty*N*-2-yl and the like.

[00762] "Amino" means $-NH_2$.

[00763] "Aminoalkyl" means an alkyl group substiuted with at least one, specifically one, two or three, amino groups.

[00764] "Aminoalkyloxy" means an -OR group where R is aminoalkyl, as defined herein.

[00765] "Aryl" means a monovalent six- to fourteen-membered, mono- or bi-carbocyclic ring, wherein the monocyclic ring is aromatic and at least one of the rings in the bicyclic ring is aromatic. Unless stated otherwise, the valency of the group may be located on any atom of any ring within the radical, valency rules permitting. Representative examples include phenyl, naphthyl, and indanyl, and the like.

[00766] "Arylalkyl" means an alkyl radical, as defined herein, substituted with one or two aryl groups, as defined herein, e.g., benzyl and phenethyl, and the like.

[00767] "Aryloxy" means an -OR gorup where R is aryl, as defined herein.

[00768] "Carboxyalkyl" means an alkyl group, as defined herein, substituted with at least one, specifically one or two, -C(O)OH group(s).

[00769] "Cycloalkyl" means a monocyclic or fused bicyclic, saturated or partially unsaturated (but not aromatic), monovalent hydrocarbon radical of three to ten carbon ring atoms. Fused bicyclic hydrocarbon radical includes bridged ring systems. Unless stated otherwise, the valency of the group may be located on any atom of any ring within the radical, valency rules permitting. One or two ring carbon atoms may be replaced by a -C(O)-, -C(S)-, or -C(=NH)- group. More specifically, the term cycloalkyl includes, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexyl, or cyclohex-3-enyl, and the like.

[00770] "Cycloalkylalkyl" means an alkyl group substituted with at least one, specificallyone or two, cycloalkyl group(s) as defined herein.

[00771] "Dialkylamino" means a -NRR' radical where R and R' are alkyl as defined herein, or an N-oxide derivative, or a protected derivative thereof, e.g., dimethylamino, diethylamino, *N,N*-methylpropylamino or *N,N*-methylethylamino, and the like.

[00772] "Dialkylaminoalkyl" means an alkyl group substituted with one or two dialkylamino groups, as defined herein.

[00773] "Dialkylaminoalkyloxy" means an -OR group where R is dialkylaminoalkyl, as defined herein. Representative examples include 2-(*N,N*-diethylamino)-ethyloxy, and the like.

[00774] "Fused-polycyclic" or "fused ring system" means a polycyclic ring system that contains bridged or fused rings; that is, where two rings have more than one shared atom in their ring structures. In this application, fused-polycyclics and fused ring systems are not necessarily all aromatic ring systems. Typically, but not necessarily, fused-polycyclics share a vicinal set of atoms, for example naphthalene or 1,2,3,4-tetrahydro-naphthalene. A spiro ring system is not a fused-polycyclic by this definition, but fused polycyclic ring systems of the invention may themselves have spiro rings attached thereto via a single ring atom of the fused-polycyclic. In some examples, as appreciated by one of ordinary skill in the art, two adjacent groups on an aromatic system may be fused together to form a ring structure. The fused ring structure may contain heteroatoms and may be optionally substituted with one or more groups. It should additionally be noted that saturated carbons of such fused groups (*i.e.* saturated ring structures) can contain two substitution groups.

[00775] "Halogen" or "halo" refers to fluorine, chlorine, bromine or iodine.

[00776] "Haloalkoxy" means an -OR' group where R' is haloalkyl as defined herein, e.g., trifluoromethoxy or 2,2,2-trifluoroethoxy, and the like.

[00777] "Haloalkyl" mean an alkyl group substituted with one or more halogens, specifically one to five halo atoms, e.g., trifluoromethyl, 2-chloroethyl, and 2,2-difluoroethyl, and the like.

[00778] "Heteroaryl" means a monocyclic, fused bicyclic, or fused tricyclic, monovalent radical of 5 to 14 ring atoms containing one or more, specifically one, two, three, or four ring heteroatoms independently selected from -O-, -S(O)$_N$- (n is 0, 1, or 2), -*N*-, -N(R^x)-, and the remaining ring atoms being carbon, wherein the ring comprising a monocyclic radical is aromatic and wherein at least one of the fused rings comprising a bicyclic or tricyclic radical is aromatic. One or two ring carbon atoms of any nonaromatic rings comprising a bicyclic or tricyclic radical may be replaced by a -C(O)-, -C(S)-, or -C(=NH)- group. R^x is hydrogen, alkyl, hydroxy, alkoxy, acyl, or alkylsulfonyl. Fused bicyclic radical includes bridged ring systems. Unless stated

otherwise, the valency may be located on any atom of any ring of the heteroaryl group, valency rules permitting. When the point of valency is located on the nitrogen, R^x is absent. More specifically, the term heteroaryl includes, but is not limited to, 1,2,4-triazolyl, 1,3,5-triazolyl, phthalimidyl, pyridinyl, pyrrolyl, imidazolyl, thienyl, furanyl, indolyl, 2,3-dihydro-1*H*-indolyl (including, for example, 2,3-dihydro-1*H*-indol-2-yl or 2,3-dihydro-1*H*-indol-5-yl, and the like), isoindolyl, indolinyl, isoindolinyl, benzimidazolyl, benzodioxol-4-yl, benzofuranyl, cinnolinyl, indolizinyl, naphthyridi*N*-3-yl, phthalazi*N*-3-yl, phthalazi*N*-4-yl, pteridinyl, purinyl, quinazolinyl, quinoxalinyl, tetrazoyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isooxazolyl, oxadiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl (including, for example, tetrahydroisoquinoli*N*-4-yl or tetrahydroisoquinoli*N*-6-yl, and the like), pyrrolo[3,2-c]pyridinyl (including, for example, pyrrolo[3,2-c]pyridi*N*-2-yl or pyrrolo[3,2-c]pyridi*N*-7-yl, and the like), benzopyranyl, thiazolyl, isothiazolyl, thiadiazolyl, benzothiazolyl, benzothienyl, and the derivatives thereof, or N-oxide or a protected derivative thereof.

[00779] "Heteroarylalkyl" means an alkyl group, as defined herein, substituted with at least one, specifically one or two heteroaryl group(s), as defined herein.

[00780] "Heteroatom" refers to O, S, N, or P.

[00781] "Heterocycloalkyl" means a saturated or partially unsaturated (but not aromatic) monovalent monocyclic group of 3 to 8 ring atoms or a saturated or partially unsaturated (but not aromatic) monovalent fused bicyclic group of 5 to 12 ring atoms in which one or more, specifically one, two, three, or four ring heteroatoms independently selected from O, $S(O)_n$ (n is 0, 1, or 2), N, $N(R^y)$ (where R^y is hydrogen, alkyl, hydroxy, alkoxy, acyl, or alkylsulfonyl), the remaining ring atoms being carbon. One or two ring carbon atoms may be replaced by a -C(O)-, -C(S)-, or -C(=NH)- group. Fused bicyclic radical includes bridged ring systems. Unless otherwise stated, the valency of the group may be located on any atom of any ring within the radical, valency rules permitting. When the point of valency is located on a nitrogen atom, R^y is absent. More specifically the term heterocycloalkyl includes, but is not limited to, azetidinyl, pyrrolidinyl, 2-oxopyrrolidinyl, 2,5-dihydro-1*H*-pyrrolyl, piperidinyl, 4-piperidonyl, morpholinyl, piperazinyl, 2-oxopiperazinyl, tetrahydropyranyl, 2-oxopiperidinyl, thiomorpholinyl, thiamorpholinyl, perhydroazepinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, dihydropyridinyl, tetrahydropyridinyl, oxazolinyl, oxazolidinyl, isoxazolidinyl,

thiazolinyl, thiazolidinyl, quinuclidinyl, isothiazolidinyl, octahydroindolyl, octahydroisoindolyl, decahydroisoquinolyl, tetrahydrofuryl, and tetrahydropyranyl, and the derivatives thereof and N-oxide or a protected derivative thereof.

[00782] "Heterocycloalkylalkyl" means an alkyl radical, as defined herein, substituted with one or two heterocycloalkyl groups, as defined herein, e.g., morpholinylmethyl, *N*-pyrrolidinylethyl, and 3-(*N*-azetidinyl)propyl, and the like.

[00783] "Heterocycloalkylalkyloxy means an -OR group where R is heterocycloalkylalkyl, as defined herein.

[00784] "Saturated bridged ring system" refers to a bicyclic or polycyclic ring system that is not aromatic. Such a system may contain isolated or conjugated unsaturation, but not aromatic or heteroaromatic rings in its core structure (but may have aromatic substitution thereon). For example, hexahydro-furo[3,2-b]furan, 2,3,3a,4,7,7a-hexahydro-1*H*-indene, 7-aza-bicyclo[2.2.1]heptane, and 1,2,3,4,4a,5,8,8a-octahydro-naphthalene are all included in the class "saturated bridged ring system.

[00785] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. One of ordinary skill in the art would understand that with respect to any molecule described as containing one or more optional substituents, only sterically practical and/or synthetically feasible compounds are meant to be included. "Optionally substituted" refers to all subsequent modifiers in a term. So, for example, in the term "optionally substituted arylC_{1-8} alkyl," optional substitution may occur on both the "C_{1-8} alkyl" portion and the "aryl" portion of the molecule may or may not be substituted. But where a first optionally substituted group can be substituted by a second optionally substituted group, the second substituent cannot be further substituted. A list of exemplary optional substitutions is presented below in the definition of "substituted."

[00786] "Optionally substituted alkoxy" means an -OR group where R is optionally substituted alkyl, as defined herein.

[00787] "Optionally substituted alkyl" means an alkyl radical, as defined herein, optionally substituted with one or more group(s), specifically one, two, three, four, or five groups, independently selected from alkylcarbonyl, alkenylcarbonyl, cycloalkylcarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, amino, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cyano,

cyanoalkylaminocarbonyl, alkoxy, alkenyloxy, hydroxy, hydroxyalkoxy, halo, carboxy, alkylcarbonylamino, alkylcarbonyloxy, alkyl-$S(O)_{0-2}$-, alkenyl-$S(O)_{0-2}$-, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonyl-NR^c- (where R^c is hydrogen, alkyl, optionally substituted alkenyl, hydroxy, alkoxy, alkenyloxy, or cyanoalkyl), alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkylaminoalkyloxy, dialkylaminoalkyloxy, alkoxycarbonyl, alkenyloxycarbonyl, alkoxycarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, alkoxyalkyloxy, and -$C(O)NR^aR^b$ (where R^a and R^b are independently hydrogen, alkyl, optionally substituted alkenyl, hydroxy, alkoxy, alkenyloxy, or cyanoalkyl).

[00788] "Optionally substituted alkenyl" means an alkyl radical, as defined herein, optionally substituted with one or more group(s), specifically one, two, three, four, or five groups, independently selected from alkylcarbonyl, alkenylcarbonyl, cycloalkylcarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, amino, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cyano, cyanoalkylaminocarbonyl, alkoxy, alkenyloxy, hydroxy, hydroxyalkoxy, halo, carboxy, alkylcarbonylamino, alkylcarbonyloxy, alkyl-$S(O)_{0-2}$-, alkenyl-$S(O)_{0-2}$-, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonyl-NR^c- (where R^c is hydrogen, alkyl, optionally substituted alkenyl, hydroxy, alkoxy, alkenyloxy, or cyanoalkyl), alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkylaminoalkyloxy, dialkylaminoalkyloxy, alkoxycarbonyl, alkenyloxycarbonyl, alkoxycarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, alkoxyalkyloxy, and -$C(O)NR^aR^b$ (where R^a and R^b are independently hydrogen, alkyl, optionally substituted alkenyl, hydroxy, alkoxy, alkenyloxy, or cyanoalkyl).

[00789] "Optionally substituted amino" refers to the group -N(H)R or –N(R)R where each R is independently selected from the group: optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, acyl, carboxy, alkoxycarbonyl, -$S(O)_2$-(optionally substituted alkyl), -$S(O)_2$-optionally substituted aryl), -$S(O)_2$-(optionally substituted heterocycloalkyl), -$S(O)_2$-(optionally substitutted heteroaryl), and -$S(O)_2$-(optionally substituted heteroaryl). For example, "optionally substituted amino" includes diethylamino, methylsulfonylamino, and furanyl-oxy-sulfonamino.

[00790] "Optionally substituted aminoalkyl" means an alkyl group, as defined herein, substituted with at least one, specifically one or two, optionally substituted amino group(s), as defined herein.

[00791] "Optionally substituted aryl" means an aryl group, as defined herein, optionally substituted with one, two, or three substituents independently selected from acyl, acylamino, acyloxy, optionally substituted alkyl, optionally substituted alkenyl, alkoxy, alkenyloxy, halo, hydroxy, alkoxycarbonyl, alkenyloxycarbonyl, amino, alkylamino, dialkylamino, nitro, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, carboxy, cyano, alkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, aminoalkoxy, or aryl is pentafluorophenyl. Within the optional substituents on "aryl", the alkyl and alkenyl, either alone or as part of another group (including, for example, the alkyl in alkoxycarbonyl), are independently optionally substituted with one, two, three, four, or five halo.

[00792] "Optionally substituted arylalkyl" means an alkyl group, as defined herein, substituted with optionally substituted aryl, as defined herein.

[00793] "Optionally substituted cycloalkyl" means a cycloalkyl group, as defined herein, substituted with one, two, or three groups independently selected from acyl, acyloxy, acylamino, optionally substituted alkyl, optionally substituted alkenyl, alkoxy, alkenyloxy, alkoxycarbonyl, alkenyloxycarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, halo, hydroxy, amino, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, nitro, alkoxyalkyloxy, aminoalkoxy, alkylaminoalkoxy, dialkylaminoalkoxy, carboxy, and cyano. Within the above optional substitutents on "cycloalkyl", the alkyl and alkenyl,, either alone or as part of another substituent on the cycloalkyl ring, are independently optionally substituted with one, two, three, four, or five halo, e.g. haloalkyl, haloalkoxy, haloalkenyloxy, or haloalkylsulfonyl.

[00794] "Optionally substituted cycloalkylalkyl" means an alkyl group substituted with at least one, specifically one or two, optionally substituted cycloalkyl groups, as defined herein.

[00795] "Optionally substituted heteroaryl" means a heteroaryl group optionally substituted with one, two, or three substituents independently selected from acyl, acylamino, acyloxy, optionally substituted alkyl, optionally substituted alkenyl, alkoxy,

alkenyloxy, halo, hydroxy, alkoxycarbonyl, alkenyloxycarbonyl, amino, alkylamino, dialkylamino, nitro, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, carboxy, cyano, alkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, aminoalkoxy, alkylaminoalkoxy, and dialkylaminoalkoxy. Within the optional substituents on "heteroaryl", the alkyl and alkenyl, either alone or as part of another group (including, for example, the alkyl in alkoxycarbonyl), are independently optionally substituted with one, two, three, four, or five halo.

[00796] "Optionally substituted heteroarylalkyl" means an alkyl group, as defined herein, substituted with at least one, specifically one or two, optionally substituted heteroaryl group(s), as defined herein.

[00797] "Optionally substituted heterocycloalkyl" means a heterocycloalkyl group, as defined herein, optionally substituted with one, two, or three substituents independently selected from acyl, acylamino, acyloxy, optionally substituted alkyl, optionally substituted alkenyl, alkoxy, alkenyloxy, halo, hydroxy, alkoxycarbonyl, alkenyloxycarbonyl, amino, alkylamino, dialkylamino, nitro, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, carboxy, cyano, alkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, aminoalkoxy, or aryl is pentafluorophenyl. Within the optional substituents on "heterocycloalkyl", the alkyl and alkenyl, either alone or as part of another group (including, for example, the alkyl in alkoxycarbonyl), are independently optionally substituted with one, two, three, four, or five halo.

[00798] "Optionally substituted heterocycloalkylalkyl" means an alkyl group, as defined herein, substituted with at least one, specifically one or two, optionally substituted heterocycloalkyl group(s) as defined herein.

Synthetic Procedures for PI3Kα Compounds

[00799] Compounds of Formula I(K) and II(K) can be made by the synthetic schemes and examples described in publication WO 2007/044813, which is incorporated herein by reference in its entirety. The utility of these compounds are also described in WO 2007/044813.

[00800] The PI3Kα compounds of the invention, or their pharmaceutically acceptable salts, may have asymmetric carbon atoms or quaternized nitrogen atoms in their

structure. Compounds of Formula I(K) and II(K) that may be prepared through the syntheses described herein may exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. The compounds may also exist as geometric isomers. All such single stereoisomers, racemates and mixtures thereof, and geometric isomers are intended to be within the scope of this invention. Some of the compounds of the invention may exist as tautomers. For example, where a ketone or aldehyde is present, the molecule may exist in the enol form; where an amide is present, the molecule may exist as the imidic acid; and where an enamine is present, the molecule may exist as an imine. All such tautomers are within the scope of the invention. In particular, imidazol-5-yl and pyrazol-5-yl each can also exist in their respective tautomeric forms imidazol-4-yl and pyrazol-3-yl. Regardless of which structure or which terminology is used, each tautomer is included within the scope of the Invention.

[00801] Compounds of Formula I(K) and II(K) also includes N-oxide derivatives and protected derivatives of compounds of Formula I(K) and II(K). For example, when compounds of Formula I(K) and II(K) contain an oxidizable nitrogen atom, the nitrogen atom can be converted to an N-oxide by methods well known in the art. When compounds of Formula I(K) and II(K) contain groups such as hydroxy, carboxy, thiol or any group containing a nitrogen atom(s), these groups can be protected with a suitable "protecting group" or "protective group". A comprehensive list of suitable protective groups can be found in T.W. Greene, *Protective Groups in Organic Synthesis*, John Wiley & Sons, Inc. 1991, the disclosure of which is incorporated herein by reference in its entirety. The protected derivatives of compounds of Formula I(K) and II(K) can be prepared by methods well known in the art.

[00802] Methods for the preparation and/or separation and isolation of single stereoisomers from racemic mixtures or non-racemic mixtures of stereoisomers are well known in the art. For example, optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. Enantiomers (R- and S-isomers) may be resolved by methods known to one of ordinary skill in the art, for example by: formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallization; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallization, selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or

reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where a desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step may be required to liberate the desired enantiomeric form. Alternatively, specific enantiomer may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents or by converting on enantiomer to the other by asymmetric transformation. For a mixture of enantiomers, enriched in a particular enantiomer, the major component enantiomer may be further enriched (with concomitant loss in yield) by recrystallization.

[00803] In addition, the compounds of Formula I(K) and II(K) can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the present invention.

[00804] In addition, it is intended that the PI3Kα compounds are made either using standard organic synthetic techniques, including combinatorial chemistry or by biological methods, such as bacterial digestion, metabolism, enzymatic conversion, and the like.

Pharmaceutical Composition Examples

[00805] The following are representative pharmaceutical Formulations containing a PI3Kα compound of Formula I(K) or II(K).

Tablet Formulation

[00806] The following ingredients are mixed intimately and pressed into single scored tablets.

Ingredient	Quantity per tablet, mg
PI3Kα compound	400
Cornstarch	50
croscarmellose sodium	25
Lactose	120
magnesium stearate	5

Capsule Formulation

[00807] The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.

Ingredient	Quantity per tablet, mg
PI3Kα compound	200
lactose, spray-dried	148
magnesium stearate	2

Suspension Formulation

[00808] The following ingredients are mixed to form a suspension for oral administration.

Ingredient	Amount
PI3Kα compound	1.0 g
fumaric acid	0.5 g
sodium chloride	2.0 g
methyl paraben	0.15 g
propyl paraben	0.05 g
granulated sugar	25.5 g
sorbitol (70% solution)	12.85 g
Veegum K (Vanderbilt Co.)	1.0 g
Flavoring	0.035 mL
Colorings	0.5 mg
distilled water	q.s. to 100 mL

Injectable Formulation

[00809] The following ingredients are mixed to form an injectable Formulation.

Ingredient	Amount
PI3Kα compound	1.2 g
sodium acetate buffer solution	0.4 M 2.0 mL
HCl (1 N) or NaOH (1 M)	q.s. to suitable pH
water (distilled, sterile)	q.s.to 20 mL

[00810] All of the above ingredients, except water, are combined and heated to 60-70° C with stirring. A sufficient quantity of water at 60° C is then added with vigorous stirring to emulsify the ingredients, and water then added q.s. to 100 g.

Suppository Formulation

[00811] A suppository of total weight 2.5 g is prepared by mixing the compound of the invention with Witepsol®. H-15 (triglycerides of saturated vegetable fatty acid; Riches-Nelson, Inc., New York), and has the following composition:

Ingredient	Quantity per tablet, mg
PI3Kα compound	500
Witepsol® H-15	Balance

[00812] Aspect (33) of this ivention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), and a pharmaceutically acceptable carrier, in combination with a therapeutically effective amount of a PI3Kα compound of Formula I(K), II(K), (K-A), (K-B), (K-C), (K-D), (K-E), (K-F), (K-G), (K-G1), (K-G2), (K-G3), (K-G4), (K-G5), (K-G6), (K-H), (K-J), (K-K), (K-K1), (K-K2), (K-L), (K-M), or (K-N), or a pharmaceutical composition comprising a therapeutically effective amount of the PI3Kα compound of Formula I(K), II(K), (K-A), (K-B), (K-C), (K-D), (K-E), (K-F), (K-G), (K-G1), (K-G2), (K-G3), (K-G4), (K-G5), (K-G6), (K-H), (K-J), (K-K), (K-K1), (K-K2), (K-L), (K-M), or (K-N), and a pharmaceutically acceptable carrier, wherein the mammal is in need of the treatment.

[00813] In other embodiments of aspect (2), aspect (17), and aspect (33) of this invention, R^2 of Formula I(J) is



(f).

[00814] In other embodiments of aspect (2), aspect (17), and aspect (33) of this invention, R^2 of Formula I(J) is



,

wherein R^{28a} is selected from lower alkyl, dialkylaminoalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, and hetercycloalkylalkyl.

[00815] In other embodiments of aspect (2), aspect (17), and aspect (33) of this invention, R^2 of Formula I(J) is



[00816] In another embodiment of the above method of combining the PI3Kα inhibitors of Formula I(K), II(K), (K-A), (K-B), (K-C), (K-D), (K-E), (K-F), (K-G), (K-G1), (K-G2), (K-G3), (K-G4), (K-G5), (K-G6), (K-H), (K-J), (K-K), (K-K1), (K-K2), (K-L), (K-M), or (K-N), with the JAK-2 inhibitors of Formula I(J), L of Formula I(J) is a bond, Z is  , R^{25} is hydrogen and E and D are hydrogen.

In other embodiments of aspect (2), aspect (17), and aspect (33) of this invention, Z of Formula I(J) is  , R^{26a} is $-C(O)R^{32}$, R^{26} is hydrogen, and R^{32} is selected from tetrahydrofuran, pyrrolidinyl or pryimidinyl, wherein R^{32} is optionally substituted with 1, 2, 3, 4 or 5 groups selected from hydroxyl, oxo, alkyl, alkoxy, amino, hydroxyalkyl and halo.

[00817] In other embodiments of aspect (2), aspect (17), and aspect (33) of this invention, R^2 of Formula I(J) is  .

[00818] In other embodiments of aspect (2), aspect (17), and aspect (33) of this invention, R^{32} of Formula I(J) is U or $-CH_2$-U, wherein U is selected from pyrolidinyl, thiazolidinyl, morpholinyl, azetidinyl, cyclobutyl, cyclopropyl, tetrahydofuranyl, pyrazinyl, imidazolyl, piperazinyl, thienyl, thienylmethyl, furanyl, phenyl, prolinamidyl, pyridinyl, tetrahydronaphthalene, tetrazolyl, isoindolinyl, pyranyl, cyclopentyl, and octahydro-1H-indolyl.

[00819] In other embodiments of aspect (2), aspect (17), and aspect (33) of this invention, R^{11} of Formula I(J), when present, is halo or lower alkyl.

[00820] In other embodiments of aspect (2), aspect (17), and aspect (33) of this invention, R^{35} of Formula I(J) is heterocycloalkylalkyl, wherein the heterocyloalkyl is selected from piperazinyl, piperidinyl, morpholinyl and dioxanyl.

[00821] In other embodiments of aspect (2), aspect (17), and aspect (33) of this invention, n2 of Formula I(J) is 0.

[00822] In other embodiments of aspect (2), aspect (17), and aspect (33) of this invention, R^2 of Formula I(J) is  , and wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl.

[00823] In other embodiments of aspect (2), aspect (17), and aspect (33) of this invention, the JAK-2 compound has Formula IV(J):



IV(J)

wherein and R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

[00824] In other embodiments of aspect (2), aspect (17), and aspect (33) of this invention, the JAK-2 compound has Formula V(J):



V(J)

wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

[00825] In other embodiments of aspect (2), aspect (17), and aspect (33) of this invention, the JAK-2 compound has Formula VI(J):



wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

[00826] In other embodiments of the method of combining the PI3Kα inhibitors with the JAK-2 inhibitors of Formula I(J), any of the embodiments described above for the PI3Kα compounds can be combined with any one of the embodiments of the compound of Formula I(J) described hereinabove. In other embodiments of the method of combining the PI3Kα inhibitors with the JAK-2 inhibitors of Formula I(J), one or more of any of the PI3Kα compounds in Table K can be combined with any one of the embodiments of the compound of Formula I(J) described hereinabove. In other embodiments of the above method of combining the PI3Kα compounds with the JAK-2 inhibitors of Formula I(J), one or more of any of the PI3Kα compounds in Table K can be combined with one or more of any of the compounds in Table I(J).

Src and BCR-Abl COMPOUNDS

[00827] The Src and/or BCR-Abl compounds (inhibitors of Src and/or BCR-Abl) described herein regulate and/or modulate Src and/or BCR-Abl and/or IGF1R protein kinase enzymatic activity. In another embodiment of the methods described herein, the JAK-2 compounds described hereinabove [e.g., compounds of Formula I(J), II(J), III(J), IV(J), V(J), VI(J), and VII(J)] can be combined with any of the Src and/or BCR-Abl inhibitors known in the art. Non-limiting examples of Src inhibitors that fall within the scope of aspect (7) of this invention are the Src and/or BCR-Abl compounds described below that inhibit Src. Non-limiting examples of BCR-Abl inhibitors that fall within the scope of aspect (9) of this invention are the Src and/or BCR-Abl compounds described

below that inhibit BCR-Abl. Non-limiting examples of IGF1R inhibitors that fall within the scope of aspect (15) of this invention are the Src and/or BCR-Abl compounds described below that inhibit IGF1R. All of the substituents for the Src and/or BCR-Abl compounds described below are defined separately from all of the other compounds described herein that are not Src and/or BCR-Abl compounds so that every substituent that appear in all of the other compounds described herein that also appears in the Src and/or BCR-Abl compounds has a separate and distinct meaning for each of these two compounds. For instance, R^1 for the JAK-2 compounds has a separate and distinct meaning from R^1 for the Src and/or BCR-Abl compounds.

[00828] All of the compounds disclosed herein include either their free base form or their pharmaceutically acceptable salts whether it is stated in the specification that these compounds can exist as their pharmaceutically acceptable salts or not. All of the BCR-Abl compounds disclosed herein fall within the scope of aspect (24) of this invention.

[00829] In another embodiment of the methods described herein, the JAK-2 compounds described hereinabove [e.g., compounds of Formula I(J), II(J), III(J), IV(J), V(J), VI(J), and VII(J)] can be combined with Src and/or BCR-Abl compounds represented by Formula I(S):



I(S)

or a pharmaceutically acceptable salt thereof, wherein:

V is NR_1R_{1a}, or O-R_1, wherein

R_1 is H, CN, halo, -$NR_{13}R_{14}$, C(O)$NR_{13}R_{14}$, C_1-C_6 alkyl, -C(O)-C_1-C_6 alkyl, -C_0-C_6 alkyl-R_{20}, wherein R_{20} is aryl, heteroaryl, heterocyclyl, or a 5-12 membered fused bicyclical or tricyclic saturated, partially saturated, or unsaturated ring system containing 0-4 ring atoms selected from N, O, and S, wherein aryl, heteroaryl, C_3-C_7 heterocyclyl, or the 5-12 membered ring system are optionally substituted with one, two, or three groups independently selected from C_1-C_6 alkyl, and -C_0-C_6 alkyl-R_{21};

R_{1a} is H or C_1-C_6 alkyl; or

when V is NR_1R_{1a}, R_1 and R_{1a} together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group containing, in addition to the nitrogen, up to two additional heteroatoms independently selected from O, N, and S, and wherein each heterocyclyl or heteroaryl group is optionally substituted with one or two of C_1-C_6 alkyl, -$NR_{13}R_{14}$ or C_3-C_7 cycloalkyl;

X is H, halo, C_1-C_6 alkyl, NO_2, mono-, di-, or tri-halo substituted methyl, $NR_{13}R_{14}$, C(O)O-C_1-C_6 alkyl, or N(R_{13})-C(O)-C_1-C_6 alkyl;

Y is H, halo, OH, C_1-C_6 alkyl, C_0-C_6 alkyl-$NR_{15}R_{16}$, C_1-C_6 alkoxy, -N(R_{13})-$(CH_2)_n$-$NR_{15}R_{16}$, -C(O)O-C_1-C_6 alkyl, -O-$(CH_2)_n$-$NR_{15}R_{16}$, -C(O)-C_1-C_6 alkyl, -C_0-C_6-alkyl-R_{21}, -O-R_{21}, -C(O)-R_{21}, -O-$(CH_2)_n$-R_{21}, -C(O)-$NR_{13}R_{14}$, -C(O)-N(R_{13})-aryl, -C(O)-N(R_{13})-$(CH_2)_n$-$NR_{15}R_{16}$, -C(O)-N(R_{13})-$(CH_2)_n$-aryl, -C(O)-N(R_{13})-$(CH_2)_n$-heterocyclyl;

or X and Y together with the atoms to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group containing one or two heteroatoms independently selected from O, N, and S, wherein the heterocyclyl or heteroaryl group is optionally substituted with one or two moieties independently selected from halo, C_1-C_6 alkyl, aryl-C_1-C_6 alkyl-, aryl-$(CH_2)_n$-O-$(CH_2)_n$-aryl-, arylOH, C_3-C_7 cycloalkyl, heterocyclyl, -aryl-N(R_{13})C(O)-C_3-C_7 cycloalkyl-C(O)-N(R_{14})-aryl, or a group of the Formula -L-M-Q, wherein

L is a bond or C_3-C_7 cycloalkyl,

M is C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl,

Q is $NR_{13}R_{14}$, N(R_{13})C(O)-C_1-C_6 alkyl, heterocyclyl, or a saturated fused bicyclic ring containing one or two heteroatoms independently selected from O, N, and S,

wherein each aryl, heteroaryl, or heterocyclyl substituent on the group formed by X and Y is optionally further substituted with one or two moieties independently selected from halo, C(O)O-$(CH_2)_n$-phenyl, and C(O)-C_1-C_6 alkyl;

Z is H, NR_2R_3, -S-R_{2a}, or -O-R_{2a}, wherein

R_2 is -C_1-C_6 alkyl, -C_1-C_6 alkyl-$NR_{13}R_{14}$, -C(O)-aryl, -C_0-C_6-alkyl-aryl, -C_0-C_6-alkyl-heteroaryl, -C_0-C_6-alkyl-(C_3-C_7-cycloalkyl), -C_0-C_6-alkyl-heterocyclyl, or -C_0-C_6 alkyl-5-12 membered fused bicyclic or tricyclic saturated, partially saturated, or unsaturated ring system containing 0-4 ring atoms selected from N, O, and S, wherein each alkyl is optionally substituted with phenyl, and each aryl, heteroaryl,

C_3-C_7 cycloalkyl, heterocyclyl, or 5-12 membered ring system is optionally substituted with one, two, or three groups independently selected from halo, mono-, di-, or tri-halo substituted methyl or methoxy, CN, NO_2, $NR_{13}R_{14}$, C(O)O-C_1-C_6 alkyl, $N(R_{13})C(O)$-C_1-C_6 alkyl, $-SO_2NR_{13}R_{14}$, -O-C(O)-$NR_{13}R_{14}$, -C_0-C_6 alkyl-$C(O)NR_{15}R_{16}$, C_1-C_6 alkoxy, C_1-C_6 thioalkoxy, -O-$(CH_2)_n$-$NR_{15}R_{16}$, -C_1-C_6 alkyl-$NR_{13}R_{14}$, -$N(R_{13})$-C(O)-C_1-C_6 alkyl, -$N(R_{13})$-C(O)-aryl, -C_0-C_6 alkyl-C(O)-$N(R_{13})$-$(CH_2)_n$-$NR_{15}R_{16}$, -C_0-C_6 alkyl-C(O)-$N(R_{13})$-$(CH_2)_n$-aryl, -O-$(CH_2)_n$-C(O)-$N(R_{13})$-$(CH_2)_n$-$NR_{15}R_{16}$, -O-$(CH_2)_n$-C(O)-$NR_{15}R_{16}$, -C_0-C_6 alkyl-C(O)-$N(R_{13})$-$(CH_2)_n$-O-C_1-C_6 alkyl, -C_0-C_6 alkyl-$N(R_{13})$-C(O)O-C_1-C_6 alkyl, -C_0-C_6alkyl-C(O)-heterocyclyl, -C_0-C_6alkyl-C(O)-heteroaryl, -C_0-C_6alkyl-C(O)-aryl, -C_0-C_6-alkyl-R_{21}, aryloxy, -O-$(CH_2)_n$-R_{21}, -SO_2-heterocyclyl, $N(R_{13})$-C(O)-C_3-C_7-cycloalkyl, -C_0-C_6alkyl C(O)O-R_{21} ,C_3-C_7-cycloalkyl, -C_0-C_6alkylR_{21}, -SC_1-C_6alkyl or C_1-C_6 alkyl optionally substituted with halo or cyano, wherein each aryl, heteroaryl, cycloalkyl, or heterocyclyl substituent is further optionally substituted with 1-3 groups independently selected from halo, CF_3, C_1-C_6 alkyl, C_1-C_6 haloalkoxy, $NR_{13}R_{14}$ and C_1-C_6 alkoxy;

R_3 is H or C_1-C_6 alkyl;

or R_2 and R_3 together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group containing up to three heteroatoms independently selected from O, N, and S, and wherein the heterocyclyl or heteroaryl group is optionally substituted with one or two of halo or C_1-C_6 alkyl;

R_{2a} is aryl or C_0-C_6 alkyl-heteroaryl, wherein the aryl and heteroaryl are optionally substituted with aryl, $-N(R_{13})$-C(O)-C_3-C_7 cycloalkyl or $-C(O)NR_{13}R_{14}$;

R_{13} and R_{14} are independently H or C_1-C_6 alkyl;

R_{15} and R_{16} are independently H, C_1-C_6 alkyl, heteroaryl, or heterocyclyl, or R_{15} and R_{16} together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group wherein one or two ring carbons are each optionally replaced with a heteroatom independently selected from O, N, and S, and wherein each heterocyclyl or heteroaryl group is optionally substituted with one or two moieties independently selected from halo, C_1-C_6 alkyl, or -C(O)O-C_1-C_6 alkyl;

R_{21} is heterocyclyl, aryl, heteroaryl, or C_3-C_7 cycloalkyl, and wherein alkyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, and heterocyclyl are optionally substituted with one

or two moieties independently selected from halo, $-S(O)_2-C_0-C_1$ alkyl, $-C(O)-C_0-C_1$ alkyl, -C(O)-H, $-C_0-C_1$ alkyl-aryl, C_1-C_6 alkyl, $NR_{13}R_{14}$, and heterocyclyl;

n is 0-6;

provided that when V is NH_2, X, Y and Z are not simultaneously H.

[00830] In a specific embodiment of the protein kinase modulator compound of Formula I(S), is a compound of Formula I(S) wherein V is NHR_1.

[00831] In another specific embodiment of the protein kinase modulator compound of Formula I(S), is a compound of Formula I(S) wherein Z is NR_2R_3.

[00832] In another specific embodiment of the protein kinase modulator compound of Formula I(S), is a compound of Formula I(S) wherein V is NHR_1 and Z is NR_2R_3.

[00833] Another specific embodiment of the Src and/or BCR-Abl compounds is a compound having Formula II(S):



II(S)

or a pharmaceutically acceptable salt thereof, wherein:

R_1 is H, CN, halo, $-NR_{13}R_{14}$, $C(O)NR_{13}R_{14}$, C_1-C_6 alkyl, $-C(O)-C_1-C_6$ alkyl, $-C_0-C_6$ alkyl-R_{20}, wherein R_{20} is aryl, heteroaryl, heterocyclyl, or a 5-12 membered fused bicyclical or tricyclic saturated, partially saturated, or unsaturated ring system containing 0-4 ring atoms selected from N, O, and S, wherein aryl, heteroaryl, C_3-C_7 heterocyclyl, or the 5-12 membered ring system are optionally substituted with one, two, or three groups independently selected from C_1-C_6 alkyl, and $-C_0-C_6$ alkyl-R_{21};

X is H, halo, C_1-C_6 alkyl, NO_2, mono-, di-, or tri-halo substituted methyl, $NR_{13}R_{14}$, $C(O)O-C_1-C_6$ alkyl, or $N(R_{13})-C(O)-C_1-C_6$ alkyl;

Y is H, halo, OH, C_1-C_6 alkyl, $NR_{15}R_{16}$, C_1-C_6 alkoxy, $-N(R_{13})-(CH_2)_n-NR_{15}R_{16}$, $-C(O)O-C_1-C_6$ alkyl, $-O-(CH_2)_n-NR_{15}R_{16}$, $-C(O)-C_1-C_6$ alkyl, $-C_0-C_6$-alkyl-R_{21}, $-O-R_{21}$, $-C(O)-R_{21}$, $-O-(CH_2)_n-R_{21}$, $-C(O)-NR_{13}R_{14}$, $-C(O)-N(R_{13})$-aryl, $-C(O)-N(R_{13})-(CH_2)_n-NR_{15}R_{16}$, $-C(O)-N(R_{13})-(CH_2)_n$-aryl, $-C(O)-N(R_{13})-(CH_2)_n$-heterocyclyl, wherein R_{21} is heterocyclyl, aryl, heteroaryl, or C_3-C_7 cycloalkyl, and wherein alkyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, and heterocyclyl are

optionally substituted with one or two moieties independently selected from halo, C_1-C_6 alkyl, $NR_{13}R_{14}$, and heterocyclyl;

or X and Y together with the atoms to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group containing one or two heteroatoms independently selected from O, N, and S, wherein the heterocyclyl or heteroaryl group is optionally substituted with one or two moieties independently selected from halo, C_1-C_6 alkyl, aryl-C_1-C_6 alkyl-, aryl-$(CH_2)_n$-O-$(CH_2)_n$-aryl-, arylOH, C_3-C_7 cycloalkyl, heterocyclyl, -aryl-$N(R_{13})C(O)$-C_3-C_7 cycloalkyl-$C(O)$-$N(R_{14})$-aryl, and a group of the Formula -L-M-Q, wherein

L is a bond or C_3-C_7 cycloalkyl,

M is C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl,

Q is $NR_{13}R_{14}$, $N(R_{13})C(O)$-C_1-C_6 alkyl, heterocyclyl, or a saturated fused bicyclic ring containing one or two heteroatoms independently selected from O, N, and S,

wherein each aryl, heteroaryl, or heterocyclyl substituent on the group formed by X and Y is optionally further substituted with one or two moieties independently selected from halo, $C(O)O$-$(CH_2)_n$-phenyl, and $C(O)$-C_1-C_6 alkyl;

R_2 is -C_1-C_6 alkyl, -C_1-C_6 alkyl-$NR_{13}R_{14}$, -$C(O)$-aryl, -C_0-C_6-alkyl-aryl, -C_0-C_6-alkyl-heteroaryl, -C_0-C_6-alkyl-(C_3-C_7-cycloalkyl), -C_0-C_6-alkyl-heterocyclyl, or -C_0-C_6 alkyl-5-12 membered fused bicyclic or tricyclic saturated, partially saturated, or unsaturated ring system containing 0-4 ring atoms selected from N, O, and S, wherein each alkyl is optionally substituted with phenyl, and

each aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocyclyl, or 5-12 membered ring system is optionally substituted with one, two, or three groups independently selected from halo, mono-, di-, or tri-halo substituted methyl or methoxy, CN, NO_2, $NR_{13}R_{14}$, $C(O)O$-C_1-C_6 alkyl, $N(R_{13})C(O)$-C_1-C_6 alkyl, -$SO_2NR_{13}R_{14}$, -O-$C(O)$-$NR_{13}R_{14}$, -C_0-C_6 alkyl-$C(O)NR_{15}R_{16}$, C_1-C_6 alkoxy, C_1-C_6 thioalkoxy, -O-$(CH_2)_n$-$NR_{15}R_{16}$, -C_1-C_6 alkyl-$NR_{13}R_{14}$, -$N(R_{13})$-$C(O)$-C_1-C_6 alkyl, -$N(R_{13})$-$C(O)$-aryl, -C_0-C_6 alkyl-$C(O)$-$N(R_{13})$-$(CH_2)_n$-$NR_{15}R_{16}$, -C_0-C_6 alkyl-$C(O)$-$N(R_{13})$-$(CH_2)_n$-aryl, -O-$(CH_2)_n$-$C(O)$-$N(R_{13})$-$(CH_2)_n$-$NR_{15}R_{16}$, -O-$(CH_2)_n$-$C(O)$-$NR_{15}R_{16}$, -C_0-C_6 alkyl-$C(O)$-$N(R_{13})$-$(CH_2)_n$-O-C_1-C_6 alkyl, -C_0-C_6 alkyl-$N(R_{13})$-$C(O)O$-C_1-C_6 alkyl,

$-C_0-C_6$alkyl-C(O)-heterocyclyl, $-C_0-C_6$alkyl-C(O)-heteroaryl, $-C_0-C_6$alkyl-C(O)-aryl, $-C_0-C_6$-alkyl-R_{21}, aryloxy, $-O-(CH_2)_n-R_{21}$, $-SO_2$-heterocyclyl, $N(R_{13})$-C(O)-C_3-C_7-cycloalkyl, $-C_0-C_6$alkyl C(O)O-R_{21} ,C_3-C_7-cycloalkyl, $-C_0-C_6$alkylR_{21}, $-SC_1-C_6$alkyl or C_1-C_6 alkyl optionally substituted with halo or cyano,

wherein each aryl, heteroaryl, cycloalkyl, or heterocyclyl substituent is further optionally substituted with 1-3 groups independently selected from halo, mono-, di-, or tri-halo substituted methyl, C_1-C_6 alkyl, C_1-C_6 haloalkoxy, $NR_{13}R_{14}$ and C_1-C_6 alkoxy;

R_{13} and R_{14} are independently H or C_1-C_6 alkyl, or R_{13} and R_{14} together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group wherein one or two ring carbons are each optionally replaced with a heteroatom independently selected from O, N, and S, and wherein each heterocyclyl or heteroaryl group is optionally substituted with one or two of halo, C_1-C_6 alkyl, or C_1-C_6 alkoxy;

R_{15} and R_{16} are independently H, C_1-C_6 alkyl, heteroaryl, or heterocyclyl, or R_{15} and R_{16} together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group wherein one or two ring carbons are each optionally replaced with a heteroatom independently selected from O, N, and S, and wherein each heterocyclyl or heteroaryl group is optionally substituted with one or two of halo, C_1-C_6 alkyl, or -C(O)O-C_1-C_6 alkyl; and

n is 1-6.

[00834] In a specific embodiment of the compound according to Formula II(S), X is H, C_1-C_6 alkyl, or halo.

[00835] In another specific embodiment of the compound according to Formula II(S), X is H or halo.

[00836] In another specific embodiment of the compound according to Formula II(S), X is halo. For example, the halo is Cl or Br; or Br.

[00837] In another specific embodiment of the compound according to Formula II(S), Y is H, halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, $NR_{15}R_{16}$, -C(O)O-C_1-C_6 alkyl, $-O-(CH_2)_n-NR_{15}R_{16}$, $-N(R_{13})-(CH_2)_n-NR_{15}R_{16}$, $-O-R_{21}$, $-O-(CH_2)_n-R_{21}$, or aryl.

[00838] In another specific embodiment of the compound according to Formula I(S), Y is H.

[00839] In another specific embodiment of the compound according to Formula II(S), Y is halo, for example, bromo or chloro; or bromo.

[00840] In another specific embodiment of the compound according to Formula II(S), Y is C_1.C_6 alkyl, for example, C_1-C_3 alkyl; or methyl.

[00841] In another specific embodiment of the compound according to Formula II(S), R_1 is aryl or heteroaryl optionally substituted with one, two, or three groups independently selected from C_1-C_6 alkyl, C_3-C_7 cycloalkyl, aryl, and heteroaryl.

[00842] In another specific embodiment of the compound according to Formula II(S), R_1 is heteroaryl, optionally substituted with one, two, or three groups independently selected from C_1-C_6 alkyl, C_3-C_7 cycloalkyl, aryl, and heteroaryl.

[00843] In another specific embodiment of the compound according to Formula II(S), R_1 is pyrazolyl or isoxazolyl, optionally substituted with one, two, or three groups independently selected from C_1-C_6 alkyl, C_3-C_7 cycloalkyl, aryl, and heteroaryl.

[00844] In another specific embodiment of the compound according to Formula II(S), R_2 is aryl or -C_1-C_6-alkyl-heteroaryl, wherein aryl or heteroaryl are optionally substituted as defined above for compounds of Formula II.

[00845] In another specific embodiment of the compound according to Formula II(S), R_2 is C_1-C_6-alkyl-heteroaryl, optionally substituted as defined above for compounds of Formula II. In a further specific embodiment, R_2 is C_1-C_2-isoxazolyl, optionally substituted with aryl, heterocyclyl, or C_1-C_6 alkyl.

[00846] In another specific embodiment of the compound according to Formula II(S), R_2 is aryl, optionally substituted as defined above for compounds of Formula II. In a further specific embodiment, R_2 is phenyl, optionally substituted with -O-$(CH_2)_n$-$NR_{15}R_{16}$, $NR_{13}R_{14}$, -C_0-C_6 alkyl-$C(O)NR_{15}R_{16}$, -C_0-C_6 alkyl-$C(O)$-$N(R_{13})$-$(CH_2)_n$-$NR_{15}R_{16}$, $N(R_{13})C(O)$-C_1-C_6 alkyl, halo, -C_1-C_6 alkyl-$NR_{13}R_{14}$, C_1-C_6 alkoxy, or heterocyclyl.

[00847] Another specific embodiment of the Src and/or BCR-Abl compounds is a compound according to Formula III(S):



III(S)

or a pharmaceutically acceptable salt thereof, wherein:

m is 1 or 2;

R_5 at each occurrence is independently H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, aryl, or heteroaryl;

X is H, halo, C_1-C_6 alkyl, NO_2, mono-, di-, or tri-halo substituted methyl, $NR_{13}R_{14}$, C(O)O-C_1-C_6 alkyl, or N(R_{13})-C(O)-C_1-C_6 alkyl;

Y is H, halo, OH, C_1-C_6 alkyl, $NR_{15}R_{16}$, C_1-C_6 alkoxy, -N(R_{13})-$(CH_2)_n$-$NR_{15}R_{16}$, -C(O)O-C_1-C_6 alkyl, -O-$(CH_2)_n$-$NR_{15}R_{16}$, -C(O)-C_1-C_6 alkyl, -C_0-C_6-alkyl-R_{21}, -O-R_{21}, -C(O)-R_{21}, -O-$(CH_2)_n$-R_{21}, -C(O)-$NR_{13}R_{14}$, -C(O)-N(R_{13})-aryl, -C(O)-N(R_{13})-$(CH_2)_n$-$NR_{15}R_{16}$, -C(O)-N(R_{13})-$(CH_2)_n$-aryl, -C(O)-N(R_{13})-$(CH_2)_n$-heterocyclyl, wherein R_{21} is heterocyclyl, aryl, heteroaryl, or C_3-C_7 cycloalkyl, and wherein alkyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, and heterocyclyl are optionally substituted with one or two moieties independently selected from halo, C_1-C_6 alkyl, $NR_{13}R_{14}$, and heterocyclyl;

or X and Y together with the atoms to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group containing one or two heteroatoms independently selected from O, N, and S, wherein the heterocyclyl or heteroaryl group is optionally substituted with one or two moieties independently selected from halo, C_1-C_6 alkyl, aryl-C_1-C_6 alkyl-, aryl-$(CH_2)_n$-O-aryl-, C_3-C_7 cycloalkyl, heterocyclyl, -aryl-N(R_{13})C(O)-C_3-C_7 cycloalkyl-C(O)-N(R_{14})-aryl, and a group of the Formula -L-M-Q, wherein

L is a bond or C_3-C_7 cycloalkyl,

M is C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl,

Q is $NR_{13}R_{14}$, N(R_{13})C(O)-C_1-C_6 alkyl, heterocyclyl, or a saturated fused bicyclic ring containing one or two heteroatoms independently selected from O, N, and S,

wherein each aryl, heteroaryl, or heterocyclyl substituent on the group formed by X and Y is optionally further substituted with one or two moieties independently selected from halo, C(O)O-$(CH_2)_n$-phenyl, and C(O)-C_1-C_6 alkyl;

R_2 is -C_1-C_6 alkyl, -C_1-C_6 alkyl-$NR_{13}R_{14}$, -C(O)-aryl, -C_0-C_6-alkyl-aryl, -C_0-C_6-alkyl-heteroaryl, -C_0-C_6-alkyl-(C_3-C_7-cycloalkyl), -C_0-C_6-alkyl-heterocyclyl, or -C_0-C_6 alkyl-5-12 membered fused bicyclic or tricyclic saturated, partially saturated, or

unsaturated ring system containing 0-4 ring atoms selected from N, O, and S, wherein each alkyl is optionally substituted with phenyl, and each aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocyclyl, or 5-12 membered ring system is optionally substituted with one, two, or three groups independently selected from halo, mono-, di-, or tri-halo substituted methyl or methoxy, CN, NO_2, $NR_{13}R_{14}$, $C(O)O$-C_1-C_6 alkyl, $N(R_{13})C(O)$-C_1-C_6 alkyl, $-SO_2NR_{13}R_{14}$, $-OC(O)-NR_{13}R_{14}$, $-C_0$-C_6 alkyl-$C(O)NR_{15}R_{16}$, C_1-C_6 alkoxy, C_1-C_6 thioalkoxy, $-O-(CH_2)_n-NR_{15}R_{16}$, $-C_1$-C_6 alkyl-$NR_{13}R_{14}$, $-N(R_{13})-C(O)-C_1$-C_6 alkyl, $-N(R_{13})-C(O)$-aryl, $-C_0$-C_6 alkyl-$C(O)-N(R_{13})-(CH_2)_n-NR_{15}R_{16}$, $-C_0$-C_6 alkyl-$C(O)-N(R_{13})-(CH_2)_n$-aryl, $-O-(CH_2)_n-C(O)-N(R_{13})-(CH_2)_n-NR_{15}R_{16}$, $-O-(CH_2)_n-C(O)-NR_{15}R_{16}$, $-C_0$-C_6 alkyl-$C(O)-N(R_{13})-(CH_2)_n-O-C_1$-$C_6$ alkyl, $-C_0$-C_6 alkyl-$N(R_{13})-C(O)O-C_1$-C_6 alkyl, $-C_0$-C_6alkyl-C(O)-heterocyclyl, $-C_0$-C_6alkyl-C(O)-heteroaryl, $-C_0$-C_6alkyl-C(O)-aryl, $-C_0$-C_6-alkyl-R_{21}, aryloxy, $-O-(CH_2)_n-R_{21}$, $-SO_2$-heterocyclyl, $N(R_{13})-C(O)-C_3$-C_7-cycloalkyl, or C_1-C_6 alkyl optionally substituted with halo or cyano,wherein each aryl, heteroaryl, cycloalkyl, or heterocyclyl substituent is further optionally substituted with 1-3 groups independently selected from halo, mono-, di-, or tri-halo substituted methyl, C_1-C_6 alkyl, and C_1-C_6 alkoxy;

R_{13} and R_{14} are independently H or C_1-C_6 alkyl, or R_{13} and R_{14} together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group wherein one or two ring carbons are each optionally replaced with a heteroatom independently selected from O, N, and S, and wherein each heterocyclyl or heteroaryl group is optionally substituted with one or two of halo, C_1-C_6 alkyl, or C_1-C_6 alkoxy;

R_{15} and R_{16} are independently H, C_1-C_6 alkyl, heteroaryl, or heterocyclyl, or R_{15} and R_{16} together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group wherein one or two ring carbons are each optionally replaced with a heteroatom independently selected from O, N, and S, and wherein each heterocyclyl or heteroaryl group is optionally substituted with one or two moieties independently selected from halo, C_1-C_6 alkyl, and $-C(O)O-C_1$-C_6 alkyl; and

n is 1-6.

[00848] In one specific embodiment of the compound according to Formula III(S), X is H, C_1-C_6 alkyl, or halo.

[00849] In another specific embodiment of the compound is according to Formula III(S), X is H or halo.

[00850] In another specific embodiment of the compound according to Formula III(S), X is halo, such as Cl or Br,or Br.

[00851] In another specific embodiment of the compound according to Formula III(S), Y is H, halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, $NR_{15}R_{16}$, -C(O)O-C_1-C_6 alkyl, -O-$(CH_2)_n$-$NR_{15}R_{16}$, -N(R_{13})-$(CH_2)_n$-$NR_{15}R_{16}$, -O-$(CH_2)_n$-R_{21}, -O-R_{21}, or aryl.

[00852] In another specific embodiment of the compound according to Formula III(S), Y is H.

[00853] In another specific embodiment of the compound according to Formula III(S), Y is halo;such as bromo or chloro; or bromo.

[00854] In another specific embodiment of the compound according to Formula III(S), Y is C_1-C_6 alkyl; such as C_1-C_3 alkyl; or methyl.

[00855] In another specific embodiment of the compound according to Formula III(S), R_2 is aryl or -C_1-C_6-alkyl-heteroaryl, wherein aryl or heteroaryl are optionally substituted as defined above for compounds of Formula III(S).

[00856] In another specific embodiment of the compound according to Formula III(S), R_2 is C_1-C_6-alkyl-heteroaryl, optionally substituted as defined above for compounds of Formula III(S). For example, R_2 is C_1-C_2-isoxazolyl, optionally substituted with 1 or 2 of aryl, heterocyclyl, or C_1-C_6 alkyl.

[00857] In another specific embodiment of the compound according to Formula III(S), R_2 is aryl, optionally substituted as defined above for compounds of Formula III(S). For example, R_2 is phenyl, optionally substituted with 1 or 2 of -O-$(CH_2)_n$-$NR_{15}R_{16}$, $NR_{13}R_{14}$, -C_0-C_6 alkyl-C(O)$NR_{15}R_{16}$, -C_0-C_6 alkyl-C(O)-N(R_{13})-$(CH_2)_n$-$NR_{15}R_{16}$, N(R_{13})C(O)-C_1-C_6 alkyl, halo, -C_1-C_6 alkyl-$NR_{13}R_{14}$, C_1-C_6 alkoxy, or heterocyclyl.

[00858] Another specific embodiment of the Src and/or BCR-Abl compounds, is a compound according to Formula IV(S):



IV(S)

or a pharmaceutically acceptable salt thereof, wherein:

R_1 is H, CN, halo, $-NR_{13}R_{14}$, $C(O)NR_{13}R_{14}$, C_1-C_6 alkyl, $-C(O)$-C_1-C_6 alkyl, $-C_0$-C_6 alkyl-R_{20}, wherein R_{20} is aryl, heteroaryl, heterocyclyl, or a 5-12 membered fused bicyclical or tricyclic saturated, partially saturated, or unsaturated ring system containing 0-4 ring atoms selected from N, O, and S, wherein aryl, heteroaryl, C_3-C_7 heterocyclyl, or the 5-12 membered ring system are optionally substituted with one, two, or three groups independently selected from C_1-C_6 alkyl, and $-C_0$-C_6 alkyl-R_{21};

X is H, halo, C_1-C_6 alkyl, NO_2, mono-, di-, or tri-halo substituted methyl, $NR_{13}R_{14}$, $C(O)O$-C_1-C_6 alkyl, or $N(R_{13})$-$C(O)$-C_1-C_6 alkyl;

Y is H, halo, OH, C_1-C_6 alkyl, $NR_{15}R_{16}$, C_1-C_6 alkoxy, $-N(R_{13})$-$(CH_2)_n$-$NR_{15}R_{16}$, $-C(O)O$-C_1-C_6 alkyl, $-O$-$(CH_2)_n$-$NR_{15}R_{16}$, $-C(O)$-C_1-C_6 alkyl, $-C_0$-C_6-alkyl-R_{21}, $-O$-R_{21}, $-C(O)$-R_{21}, $-O$-$(CH_2)_n$-R_{21}, $-C(O)$-$NR_{13}R_{14}$, $-C(O)$-$N(R_{13})$-aryl, $-C(O)$-$N(R_{13})$-$(CH_2)_n$-$NR_{15}R_{16}$, $-C(O)$-$N(R_{13})$-$(CH_2)_n$-aryl, $-C(O)$-$N(R_{13})$-$(CH_2)_n$-heterocyclyl, wherein R_{21} is heterocyclyl, aryl, heteroaryl, or C_3-C_7 cycloalkyl, and wherein alkyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, and heterocyclyl are optionally substituted with one or two moieties independently selected from halo, C_1-C_6 alkyl, $NR_{13}R_{14}$, and heterocyclyl;

or X and Y together with the atoms to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group containing one or two heteroatoms independently selected from O, N, and S, wherein the heterocyclyl and heteroaryl group is optionally substituted with one or two moieties selected from halo, C_1-C_6 alkyl, aryl-C_1-C_6 alkyl-, aryl-$(CH_2)_n$-O-aryl-, C_3-C_7 cycloalkyl, heterocyclyl, -aryl-$N(R_{13})C(O)$-C_3-C_7 cycloalkyl-$C(O)$-$N(R_{14})$-aryl, and a group of the Formula -L-M-Q, wherein

L is a bond or C_3-C_7 cycloalkyl,

M is C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl,

Q is $NR_{13}R_{14}$, $N(R_{13})C(O)$-C_1-C_6 alkyl, heterocyclyl, or a saturated fused bicyclic ring containing one or two heteroatoms independently selected from O, N, and S, wherein each aryl, heteroaryl, and heterocyclyl substituent on the group formed by X and Y is optionally further substituted with one or two moieties selected from halo, $C(O)O$-$(CH_2)_n$-phenyl, and $C(O)$-C_1-C_6 alkyl;

R_6 at each occurrence is independently H, halo, mono-, di-, or tri-halo substituted methyl or methoxy, CN, NO_2, $NR_{13}R_{14}$, $C(O)O$-C_1-C_6 alkyl, $N(R_{13})C(O)$-C_1-C_6 alkyl, $-SO_2NR_{13}R_{14}$, $-O$-$C(O)$-$NR_{13}R_{14}$, $-C_0$-C_6 alkyl-$C(O)NR_{15}R_{16}$, C_1-C_6 alkoxy, C_1-C_6 thioalkoxy, $-O$-$(CH_2)_n$-$NR_{15}R_{16}$, $-C_1$-C_6 alkyl-$NR_{13}R_{14}$, $-N(R_{13})$-$C(O)$-C_1-C_6 alkyl, $-N(R_{13})$-$C(O)$-aryl, $-C_0$-C_6 alkyl-$C(O)$-$N(R_{13})$-$(CH_2)_n$-$NR_{15}R_{16}$, $-C_0$-C_6 alkyl-$C(O)$-$N(R_{13})$-$(CH_2)_n$-aryl, $-O$-$(CH_2)_n$-$C(O)$-$N(R_{13})$-$(CH_2)_n$-$NR_{15}R_{16}$, $-O$-$(CH_2)_n$-$C(O)$-$NR_{15}R_{16}$, $-C_0$-C_6 alkyl-$C(O)$-$N(R_{13})$-$(CH_2)_n$-O-C_1-C_6 alkyl, $-C_0$-C_6 alkyl-$N(R_{13})$-$C(O)O$-C_1-C_6 alkyl, $-C_0$-C_6alkyl-$C(O)$-heterocyclyl, $-C_0$-C_6alkyl-$C(O)$-heteroaryl, $-C_0$-C_6alkyl-$C(O)$-aryl, $-C_0$-C_6-alkyl-R_{21}, aryloxy, $-O$-$(CH_2)_n$-R_{21}, $-SO_2$-heterocyclyl, $N(R_{13})$-$C(O)$-C_3-C_7-cycloalkyl, or C_1-C_6 alkyl optionally substituted with halo or cyano, wherein each aryl, heteroaryl, cycloalkyl, or heterocyclyl substituent is further optionally substituted with 1-3 groups independently selected from halo, mono-, di-, or tri-halo substituted methyl, C_1-C_6 alkyl, and C_1-C_6 alkoxy;

R_{13} and R_{14} are independently H or C_1-C_6 alkyl, or R_{13} and R_{14} together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group wherein one or two ring carbons are each optionally replaced with a heteroatom independently selected from O, N, and S, and wherein each heterocyclyl or heteroaryl group is optionally substituted with one or two of halo, C_1-C_6 alkyl, or C_1-C_6 alkoxy;

R_{15} and R_{16} are independently H, C_1-C_6 alkyl, heteroaryl, or heterocyclyl, or R_{15} and R_{16} together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group wherein one or two ring carbons are each optionally replaced with a heteroatom independently selected from O, N, and S, and wherein each heterocyclyl or heteroaryl group is optionally substituted with one or two moieties selected from halo, C_1-C_6 alkyl, or $-C(O)O$-C_1-C_6 alkyl; and

m is 1 or 2; and n is 1-6.

In one specific embodiment of the compound according to Formula IV(S), X is H, C_1-C_6 alkyl, or halo.

[00859] In another specific embodiment of the compound according to Formula IV(S), X is H or halo.

[00860] In another specific embodiment of the compound according to Formula IV(S), X is halo. For example, the halo is Cl or Br, or Br.

[00861] In another specific embodiment of the compound according to Formula IV(S), Y is H, halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, $NR_{15}R_{16}$, -C(O)O-C_1-C_6 alkyl, -O-$(CH_2)_n$-$NR_{15}R_{16}$, -N(R_{13})-$(CH_2)_n$-$NR_{15}R_{16}$, -O-$(CH_2)_n$-R_{21}, -O-R_{21}, or aryl.

[00862] In another specific embodiment of the compound according to Formula IV(S), Y is H.

[00863] In another specific embodiment of the compound according to Formula I(S), Y is halo; bromo or chloro; or bromo.

[00864] In another specific embodiment of the compound according to Formula IV(S), Y is C_1-C_6 alkyl, such as C_1-C_3 alkyl; or methyl.

[00865] In another specific embodiment of the compound according to Formula IV(S), R_1 is aryl or heteroaryl optionally substituted with one, two, or three groups independently selected from C_1-C_6 alkyl, C_3-C_7 cycloalkyl, aryl, or heteroaryl.

[00866] In another specific embodiment of the compound according to Formula IV(S), R_1 is heteroaryl, optionally substituted with one, two, or three groups independently selected from C_1-C_6 alkyl, C_3-C_7 cycloalkyl, aryl, or heteroaryl.

[00867] In another specific embodiment of the compound according to Formula IV(S), R_1 is pyrazolyl or isoxazolyl, optionally substituted with one, two, or three groups independently selected from C_1-C_6 alkyl, C_3-C_7 cycloalkyl, aryl, or heteroaryl.

[00868] In another specific embodiment of the compound according to Formula IV(S), m is 1 and R_6 is aryl, heterocyclyl, or C_1-C_6 alkyl.

[00869] Another embodiment of the Src and/or BCR-Abl compounds is a compound according to Formula V(S):



V(S)

or a pharmaceutically acceptable salt thereof, wherein:

m is independently 1 or 2;

R_5 at each occurrence is independently H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, aryl, or heteroaryl; X is H, halo, C_1-C_6 alkyl, NO_2, mono-, di-, or tri-halo substituted methyl, $NR_{13}R_{14}$, C(O)O-C_1-C_6 alkyl, or N(R_{13})-C(O)-C_1-C_6 alkyl;

Y is H, halo, OH, C_1-C_6 alkyl, $NR_{15}R_{16}$, C_1-C_6 alkoxy, -N(R_{13})-$(CH_2)_n$-$NR_{15}R_{16}$, -C(O)O-C_1-C_6 alkyl, -O-$(CH_2)_n$-$NR_{15}R_{16}$, -C(O)-C_1-C_6 alkyl, -C_0-C_6-alkyl-R_{21}, -O-R_{21}, -C(O)-R_{21}, -O-$(CH_2)_n$-R_{21}, -C(O)-$NR_{13}R_{14}$, -C(O)-N(R_{13})-aryl, -C(O)-N(R_{13})-$(CH_2)_n$-$NR_{15}R_{16}$, -C(O)-N(R_{13})-$(CH_2)_n$-aryl, -C(O)-N(R_{13})-$(CH_2)_n$-heterocyclyl, wherein R_{21} is heterocyclyl, aryl, heteroaryl, or C_3-C_7 cycloalkyl, and wherein alkyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, and heterocyclyl are optionally substituted with one or two moieties independently selected from halo, C_1-C_6 alkyl, $NR_{13}R_{14}$, and heterocyclyl;

or X and Y together with the atoms to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group containing one or two heteroatoms independently selected from O, N, and S, wherein the heterocyclyl and heteroaryl group is optionally substituted with one or two moieties selected from halo, C_1-C_6 alkyl, aryl-C_1-C_6 alkyl-, aryl-$(CH_2)_n$-O-aryl-, C_3-C_7 cycloalkyl, heterocyclyl, -aryl-N(R_{13})C(O)-C_3-C_7 cycloalkyl-C(O)-N(R_{14})-aryl, and a group of the Formula -L-M-Q, wherein

L is a bond or C_3-C_7 cycloalkyl,

M is C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl,

Q is $NR_{13}R_{14}$, N(R_{13})C(O)-C_1-C_6 alkyl, heterocyclyl, or a saturated fused bicyclic ring containing one or two heteroatoms independently selected from O, N, and S,

wherein each aryl, heteroaryl, or heterocyclyl substituent on the group formed by X and Y is optionally further substituted with one or two moieties selected from halo, C(O)O-$(CH_2)_n$-phenyl, and C(O)-C_1-C_6 alkyl;

R_6 at each occurrence is independently H, halo, mono-, di-, or tri-halo substituted methyl or methoxy, CN, NO_2, $NR_{13}R_{14}$, C(O)O-C_1-C_6 alkyl, N(R_{13})C(O)-C_1-C_6 alkyl, -$SO_2NR_{13}R_{14}$, -O-C(O)-$NR_{13}R_{14}$, -C_0-C_6 alkyl-C(O)$NR_{15}R_{16}$, C_1-C_6 alkoxy, C_1-C_6 thioalkoxy, -O-$(CH_2)_n$-$NR_{15}R_{16}$, -C_1-C_6 alkyl-$NR_{13}R_{14}$, -N(R_{13})-C(O)-C_1-C_6 alkyl, -N(R_{13})-C(O)-aryl, -C_0-C_6 alkyl-C(O)-N(R_{13})-$(CH_2)_n$-$NR_{15}R_{16}$, -C_0-C_6 alkyl-C(O)-N(R_{13})-$(CH_2)_n$-aryl, -O-$(CH_2)_n$-C(O)-N(R_{13})-$(CH_2)_n$-$NR_{15}R_{16}$, -O-$(CH_2)_n$-C(O)-$NR_{15}R_{16}$, -C_0-C_6 alkyl-C(O)-N(R_{13})-$(CH_2)_n$-O-C_1-C_6 alkyl, -C_0-C_6 alkyl-N(R_{13})-C(O)O-C_1-C_6 alkyl, -C_0-C_6alkyl-C(O)-heterocyclyl, -C_0-C_6alkyl-C(O)-heteroaryl, -C_0-C_6alkyl-C(O)-aryl, -C_0-C_6-alkyl-R_{21}, aryloxy, -O-$(CH_2)_n$-R_{21}, -SO_2-heterocyclyl, N(R_{13})-C(O)-C_3-C_7-cycloalkyl, or C_1-C_6 alkyl optionally substituted with halo or cyano,

wherein each aryl, heteroaryl, cycloalkyl, or heterocyclyl is optionally substituted with 1-3 groups independently selected from halo, mono-, di-, or tri-halo substituted methyl, C_1-C_6 alkyl, and C_1-C_6 alkoxy;

R_{13} and R_{14} are independently H or C_1-C_6 alkyl, or R_{13} and R_{14} together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group wherein one or two ring carbons are each optionally replaced with a heteroatom independently selected from O, N, and S, and wherein each heterocyclyl or heteroaryl group is optionally substituted with one or two of halo, C_1-C_6 alkyl, or C_1-C_6 alkoxy;

R_{15} and R_{16} are independently H, C_1-C_6 alkyl, heteroaryl, or heterocyclyl, or R_{15} and R_{16} together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group wherein one or two ring carbons are each optionally replaced with a heteroatom independently selected from O, N, and S, and wherein each heterocyclyl and heteroaryl group is optionally substituted with one or two moieties selected from halo, C_1-C_6 alkyl, and -C(O)O-C_1-C_6 alkyl; and

n is 1-6.

[00870] In one specific embodiment of the compound according to Formula V(S), X is H, C_1-C_6 alkyl, or halo.

[00871] In another specific embodiment of the compound according to Formula V(S), X is H or halo.

[00872] In another specific embodiment of the compound according to Formula V(S), X is halo. For example, X is Cl or Br; or Br.

[00873] In another specific embodiment of the compound according to Formula V(S), Y is H, halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, $NR_{15}R_{16}$, -C(O)O-C_1-C_6 alkyl, -O-$(CH_2)_n$-$NR_{15}R_{16}$, -N(R_{13})-$(CH_2)_n$-$NR_{15}R_{16}$, -O-$(CH_2)_n$-R_{21}, -O-R_{21}, or aryl.

[00874] In another specific embodiment of the compound according to Formula V(S), Y is H.

[00875] In another specific embodiment of the compound according to Formula V(S), Y is halo. For example, Y is bromo or chloro; or bromo.

[00876] In another specific embodiment of the compound according to Formula V(S), Y is C_1-C_6 alkyl, such as C_1-C_3 alkyl, or methyl.

[00877] In another specific embodiment of the compound according to Formula V(S), m is 1 and R_6 is aryl, heterocyclyl, or C_1-C_6 alkyl.

[00878] Another specific embodiment of a compound for modulating protein kinase enzymatic activity, is a compound according to Formula I(S)1, wherein,

V is NR_1R_{1a},

R_1 is -C_0-C_6 alkyl-R_{20}, wherein R_{20} heteroaryl, wherein the heteroaryl is optionally substituted with one, two, or three groups independently selected from C_1-C_6 alkyl, and -C_0-C_6 alkyl-R_{21};

R_{1a} is H;

X is H, or halo;

Y is H, C_1-C_6 alkyl, $NR_{15}R_{16}$, C_0-C_6 alkyl-$NR_{15}R_{16}$, -N(R_{13})-$(CH_2)_n$-$NR_{15}R_{16}$, -O-$(CH_2)_n$-$NR_{15}R_{16}$, -C_0-C_6-alkyl-R_{21}, -O-R_{21} or -O-$(CH_2)_n$-R_{21};

Z is NR_2R_3, or -O-R_{2a}, wherein

R_2 is -C_0-C_6-alkyl-heteroaryl, wherein the heteroaryl is optionally substituted with one, two, or three groups independently selected from -C_0-C_6-alkyl-R_{21} or C_1-C_6 alkyl;

R_3 is H;

R_{2a} is C_0-C_6 alkyl-heteroaryl, wherein the heteroaryl is optionally substituted with aryl;

R_{13} is H;

R_{15} and R_{16} are independently H, C_1-C_6 alkyl or heterocyclyl optionally substituted with C_1-C_6 alkyl;

R_{21} is heterocyclyl, aryl, heteroaryl, or C_3-C_7 cycloalkyl, and wherein alkyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, and heterocyclyl are optionally substituted with one or two moieties independently selected from halo, -$S(O)_2$-C_0-C_1 alkyl, -C(O)-C_0-C_1 alkyl, -C(O)-H, -C_0-C_1 alkyl-aryl, C_1-C_6 alkyl or $NR_{13}R_{14}$; and

n is 1-4.

[00879] In another specific embodiment of the compound according to Formula I(S)1, Z is NR_2R_3, wherein R_2 is -C_1-C_3-alkyl-heteroaryl, wherein the heteroaryl is optionally substituted with R_{21} or C_1-C_4 alkyl. For example, the C_1-C_4 alkyl is methyl, propyl or isopropyl. Also specific are compounds wherein the R_{21} is heteroaryl or aryl wherein the heteroaryl and aryl are optionally substituted with halo or NH_2; for example, fluoro.

[00880] In another specific embodiment of the compound according to Formula I(S)1, Z is -O-R_{2a}, wherein R_{2a} is C_1-C_2 alkyl-heteroaryl, wherein the heteroaryl is optionally substituted with phenyl.

[00881] In another specific embodiment of the compound according to Formula I(S)1, R_1 is heteroaryl optionally substituted with C_1-C_4 alkyl or R_{21}. For example, the C_1-C_4 alkyl is methyl, propyl, isopropyl. Also specific are compounds wherein R_{21} is C_3-C_4 cycloalkyl. For example, R_{21} is cyclopropyl.

[00882] In another specific embodiment of the compound according to Formula I(S)1, X is chloro.

[00883] In another specific embodiment of the compound according to Formula I(S)1, Y is C_1-C_4 alkyl, $NR_{15}R_{16}$, C_1-C_4 alkyl-$NR_{15}R_{16}$, -N(H)-$(CH_2)_{2\text{-}3}$-$NR_{15}R_{16}$, -O-$(CH_2)_2$-$NR_{15}R_{16}$, -R_{21}, -O-R_{21} or -O-$(CH_2)_2$-R_{21}. For example, R_{15} and R_{16} are independently H, C_1-C_4 alkyl or heterocyclyl optionally substituted with C_1-C_3 alkyl; such as, for example, R_{15} and R_{16} are independently methyl, ethyl, propyl, or heterocyclyl optionally substituted with methyl, ethyl or propyl. Also specific are compounds wherein R_{21} is heterocyclyl optionally substituted with one or two moieties independently selected from -$S(O)_2$-C_1-C_3 alkyl, -C(O)-C_1-C_3 alkyl, -C(O)-H, C_1-C_2 alkyl-aryl, or C_1-C_4 alkyl. For example, R_{21} is optionally substituted with one or two

moieties independently selected from $-S(O)_2-CH_3$, $-C(O)-CH_3$, $-CH_2$-phenyl, methyl, ethyl or propyl.

[00884] Another embodiment of a Src and/or BCR-Abl compound is a compound according to Formula VI(S):



VI(S)

or a pharmaceutically acceptable salt thereof, wherein:

m is 1 or 2 or 3;

R_5 is C_1-C_6 alkyl, and $-C_0$-C_6 alkyl-R_{21};

X is H, or halo;

Y is $-C_0$-C_6-alkyl-R_{21};

R_6 is $-C_0$-C_6-alkyl-R_{21} or C_1-C_6 alkyl;

R_{21} is heterocyclyl, aryl, heteroaryl, or C_3-C_7 cycloalkyl, and wherein alkyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, and heterocyclyl are optionally substituted with one or two moieties independently selected from halo, $-S(O)_2-C_0-C_1$ alkyl, $-C(O)-C_0-C_1$ alkyl, -C(O)-H, $-C_0-C_1$ alkyl-aryl, C_1-C_6 alkyl or $NR_{13}R_{14}$.

[00885] In another specific embodiment of the compound according to Formula VI(S), Y is heterocyclyl optionally substituted with C_1-C_3 alkyl, X is H or halo, R_5 is C_3-C_4 cycloalkyl and R_6 is C_1-C_4 alkyl. For example, Y is heterocyclyl optionally substituted with methyl, ethyl, propyl or isopropyl, X is H, R_5 is cyclopropyl and R_6 is methyl, ethyl, propyl or isopropyl.

[00886] Representative Src and BCR-Abl compounds of Formula I(S), and pharmaceutically acceptable salts thereof, are depicted below in Table S. The compounds in Table S are merely illustrative and do not limit the scope of BCR-Abl compounds of Formula I(S).

Table S

NAME
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methyl-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;

NAME
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~6~-methyl-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine;
6-methyl-N~4~-[3-(1-methylethyl)-1H-pyrazol-5-yl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-(methyloxy)-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-5-methyl-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-phenyl-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]-6-(propyloxy)pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~2~-[3,5-bis(methyloxy)phenyl]-5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine;
5-bromo-N~4~-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(4-morpholin-4-ylphenyl)pyrimidine-2,4-diamine;
N~4~-(3-cyclopentyl-1H-pyrazol-5-yl)-6-methyl-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-methyl-1H-pyrazol-5-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~2~-[4-(aminomethyl)phenyl]-5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine;
N~2~-(2-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methylpyrimidine-2,4-diamine;
N-[3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-4-chlorophenyl]acetamide;
5-bromo-N~4~-(5-methylisoxazol-3-yl)-N~2~-(4-morpholin-4-ylphenyl)pyrimidine-2,4-diamine;
3-[4-({5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-[2-(diethylamino)ethyl]propanamide;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-(2,3-dihydro-1H-inden-1-yl)pyrimidine-2,4-diamine;
5-bromo-N~2~-(4-morpholin-4-ylphenyl)-N~4~-phenylpyrimidine-2,4-diamine;
3-[4-({5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-(1-methylethyl)propanamide;
4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-(1-methylpiperidin-4-yl)benzamide;
N~2~-(3-aminophenyl)-5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
3-[3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-[2-(diethylamino)ethyl]propanamide;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{[2-(methyloxy)phenyl]methyl}pyrimidine-2,4-diamine;
2-[4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-[2-(diethylamino)ethyl]acetamide;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrimidine-2,4-diamine;

NAME
3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl dimethylcarbamate;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-(1-phenylethyl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]phenyl}pyrimidine-2,4-diamine;
3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-[2-(diethylamino)ethyl]benzamide;
4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-[2-(diethylamino)ethyl]benzamide;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-methylpyrimidin-2-yl}amino)phenyl]-N-(2-pyrrolidin-1-ylethyl)propanamide;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~6~-[3-(diethylamino)propyl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-(4-methylpiperazin-1-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-(2-piperidin-1-ylethyl)propanamide;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~6~-[2-(diethylamino)ethyl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-morpholin-4-yl-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-(2-pyrrolidin-1-ylethyl)propanamide;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-methylpyrimidin-2-yl}amino)phenyl]-N-(3-pyrrolidin-1-ylpropyl)propanamide;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-methylpyrimidin-2-yl}amino)phenyl]-N-(3-piperidin-1-ylpropyl)propanamide;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-methylpyrimidin-2-yl}amino)phenyl]-N-[2-(diethylamino)ethyl]propanamide;
N~2~-[3,5-bis(methyloxy)phenyl]-5-bromo-N~4~-(5-methylisoxazol-3-yl)pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-{[2-(dimethylamino)ethyl]oxy}-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-(3-piperidin-1-ylpropyl)propanamide;
N-[3-({5-bromo-4-[(5-methylisoxazol-3-yl)amino]pyrimidin-2-yl}amino)-4-chlorophenyl]acetamide;
3-[4-({5-bromo-4-[(5-methylisoxazol-3-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-[2-(diethylamino)ethyl]propanamide;
5-bromo-N~4~-(3-methylisoxazol-5-yl)-N~2~-(4-morpholin-4-ylphenyl)pyrimidine-2,4-diamine;
3-[4-({5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-methylpropanamide;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[4-(dimethylamino)phenyl]pyrimidine-2,4-diamine;
4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-[(3R)-pyrrolidin-3-yl]benzamide;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
5-chloro-N~2~-(2-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~6~-[3-(diethylamino)propyl]pyrimidine-2,4,6-triamine;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-methylpyrimidin-2-yl}amino)phenyl]-N-(2-morpholin-4-ylethyl)propanamide;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-(3-pyrrolidin-1-ylpropyl)propanamide;

NAME
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-[2-(diethylamino)ethyl]propanamide;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{4-[(3-morpholin-4-ylpropyl)oxy]phenyl}pyrimidine-2,4-diamine;
5-bromo-N~2~-[4-(dimethylamino)phenyl]-N~4~-phenylpyrimidine-2,4-diamine;
5-bromo-N~2~-[(3-bromoisoxazol-5-yl)methyl]-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)benzamide;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-methylpyrimidin-2-yl}amino)phenyl]-N-[3-(1H-imidazol-1-yl)propyl]propanamide;
4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-[3-(diethylamino)propyl]benzamide;
3-[4-({5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-[3-(diethylamino)propyl]propanamide;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
2-[4-({5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-[3-(diethylamino)propyl]acetamide;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(6-morpholin-4-ylpyridin-3-yl)pyrimidine-2,4-diamine;
N~2~-[(3-cyclohexylisoxazol-5-yl)methyl]-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methylpyrimidine-2,4-diamine;
5-bromo-N~2~-(2-bromophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{2-[(trifluoromethyl)oxy]phenyl}pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{4-[3-(4-methylpiperazin-1-yl)-3-oxopropyl]phenyl}pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-(2-methylphenyl)pyrimidine-2,4-diamine;
N~2~-(4-aminophenyl)-5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[4-(methyloxy)phenyl]pyrimidine-2,4-diamine;
3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-[(3S)-pyrrolidin-3-yl]benzamide;
5-bromo-N~4~-(3-methyl-1H-pyrazol-5-yl)-N~2~-phenylpyrimidine-2,4-diamine;
4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamide;
1,1-dimethylethyl {[4-({5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)phenyl]methyl}carbamate;
3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-4-chlorobenzamide;
5-bromo-N~2~-(2-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
5-bromo-N~2~-[2-chloro-5-(methyloxy)phenyl]-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
3-[3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-(1-methylethyl)propanamide;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{3-[3-(4-methylpiperazin-1-yl)-3-oxopropyl]phenyl}pyrimidine-2,4-diamine;
5-chloro-N~2~-(2-chlorophenyl)-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine;

NAME
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[2-(methyloxy)phenyl]pyrimidine-2,4-diamine;
2-[4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-methylacetamide;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(2,3-dihydro-1,4-benzodioxin-6-yl)pyrimidine-2,4-diamine;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-(2-morpholin-4-ylethyl)propanamide;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-[3-(1H-imidazol-1-yl)propyl]propanamide;
3-[3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-[3-(diethylamino)propyl]propanamide;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(1S)-1-phenylethyl]pyrimidine-2,4-diamine;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-methylpyrimidin-2-yl}amino)phenyl]-N-(3-morpholin-4-ylpropyl)propanamide;
N~6~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~4~,N~4~-dimethyl-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-methylpyrimidin-2-yl}amino)phenyl]-N,N-dimethylpropanamide;
5-bromo-N~4~-(2-chlorophenyl)-N~2~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
2-[4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-(1-methylethyl)acetamide;
5-bromo-N~4~-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N~2~-phenylpyrimidine-2,4-diamine;
4-({5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)benzonitrile;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-(2-methylpropyl)pyrimidine-2,4-diamine;
N~2~-[2,5-bis(methyloxy)phenyl]-5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
5-bromo-N,N'-diphenylpyrimidine-2,4-diamine;
5-bromo-N~2~-(2-bromo-4-fluorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-phenylpyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[3-(methyloxy)phenyl]pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}pyrimidine-2,4-diamine;
3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-[3-(diethylamino)propyl]benzamide;
3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)benzamide;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{3-[(4-methylpiperazin-1-yl)carbonyl]phenyl}pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-naphthalen-1-ylpyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[2-(methylthio)phenyl]pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-1H-indol-5-ylpyrimidine-2,4-diamine;
5-bromo-N,N'-bis(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;

NAME
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(2-methyl-1,3-thiazol-5-yl)methyl]pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(2,3-dichlorophenyl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(furan-2-ylmethyl)pyrimidine-2,4-diamine;
N~2~-(2-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-5-methylpyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[4-(morpholin-4-ylsulfonyl)phenyl]pyrimidine-2,4-diamine;
1,1-dimethylethyl (3S)-3-({[3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]carbonyl}amino)pyrrolidine-1-carboxylate;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(5-methylfuran-2-yl)methyl]pyrimidine-2,4-diamine;
5-bromo-N~2~-(4-bromo-2-chlorophenyl)-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[2-(1H-pyrrol-1-yl)phenyl]pyrimidine-2,4-diamine;
1,1-dimethylethyl (3R)-3-({[4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]carbonyl}amino)pyrrolidine-1-carboxylate;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-(3-morpholin-4-ylpropyl)propanamide;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[5-methyl-2-(methyloxy)phenyl]pyrimidine-2,4-diamine;
ethyl 2-[(2-chlorophenyl)amino]-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-nitropyrimidine-4-carboxylate;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{[3-(methyloxy)phenyl]methyl}pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(1S)-1-phenylpropyl]pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(2-phenylethyl)pyrimidine-2,4-diamine;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-methylpyrimidin-2-yl}amino)phenyl]-N-[3-(4-methylpiperazin-1-yl)propyl]propanamide;
5-bromo-N~2~-[(4-chlorophenyl)methyl]-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
N~2~-(2-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-5-(trifluoromethyl)pyrimidine-2,4-diamine;
4-[(3-amino-1H-pyrazol-5-yl)oxy]-5-bromo-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;
4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-methylpyrimidin-2-yl}amino)-N-(1-methylpiperidin-4-yl)benzamide;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-(1-methylethyl)pyrimidine-2,4-diamine;
5-chloro-N~4~-(2-chlorophenyl)-N~6~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[3-(diethylamino)propyl]pyrimidine-2,4,6-triamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-(pyridin-3-ylmethyl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(2,4-dibromophenyl)pyrimidine-2,4-diamine;
4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-(1-methylpiperidin-4-yl)benzamide;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[2-methyl-5-(1-methylethyl)phenyl]pyrimidine-2,4-diamine;
4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)benzonitrile;

NAME
4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-methylpyrimidin-2-yl}amino)-N-[2-(diethylamino)ethyl]benzamide;
N~2~-(2-chlorophenyl)-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-5-fluoropyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[2-(2-thienyl)ethyl]pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(2,5-dibromophenyl)pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[4-(dimethylamino)phenyl]-5-methylpyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[4-(methyloxy)phenyl]methyl}pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-(2,3-dihydro-1H-inden-5-yl)pyrimidine-2,4-diamine;
4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-methylpyrimidin-2-yl}amino)-N-[3-(diethylamino)propyl]benzamide;
N~2~-(2-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~6~-[3-(diethylamino)propyl]pyrimidine-2,4,6-triamine;
4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-[2-(diethylamino)ethyl]benzamide;
5-bromo-N~2~-[(2-chlorophenyl)methyl]-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{[4-(4-methylpiperazin-1-yl)phenyl]methyl}pyrimidine-2,4-diamine;
N~2~-{[3,5-bis(methyloxy)phenyl]methyl}-5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(phenylmethyl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-(3-phenylpropyl)pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-5-methyl-N~2~-(4-morpholin-4-ylphenyl)pyrimidine-2,4-diamine;
5-bromo-N~2~-(2-chlorophenyl)-N~4~-1H-pyrazol-3-ylpyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{[4-(dimethylamino)phenyl]methyl}pyrimidine-2,4-diamine;
4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-[3-(diethylamino)propyl]benzamide;
3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)benzonitrile;
5-bromo-N~2~-(4-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(piperidin-4-ylmethyl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(1R)-1-phenylethyl]pyrimidine-2,4-diamine;
N~2~-{[2,5-bis(methyloxy)phenyl]methyl}-5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N~2~-{[2-(methyloxy)phenyl]methyl}pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(2,4-dichlorophenyl)pyrimidine-2,4-diamine;
N~2~-(2-chlorophenyl)-N~6~-(3-cyclopropyl-1H-pyrazol-5-yl)-9H-purine-2,6-diamine;
N~2~-(2-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;

NAME
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[2-(2-thienyl)-1,3-thiazol-4-l]methyl}pyrimidine-2,4-diamine;
N~2~-(2-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4,5-triamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-methyl-N~2~-phenylpyrimidine-2,4-diamine;
2-[(2-chlorophenyl)amino]-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-N-(2-morpholin-4-ylethyl)-5-nitropyrimidine-4-carboxamide;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[2-(1-methylethyl)phenyl]pyrimidine-2,4-diamine;
5-bromo-N~2~-(3-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]-7-(phenylmethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N~2~-({3-[4-(methyloxy)phenyl]isoxazol-5-yl}methyl)pyrimidine-2,4-diamine;
2-[(2-chlorophenyl)amino]-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-N-(1-methylethyl)-5-nitropyrimidine-4-carboxamide;
N~2~-[3,5-bis(methyloxy)phenyl]-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methylpyrimidine-2,4-diamine;
N-[4-({4-(4-methylpiperazin-1-yl)-6-[(3-methyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}thio)phenyl]cyclopropanecarboxamide;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methyl-N~2~-[3-(methyloxy)-5-nitrophenyl]pyrimidine-2,4-diamine;
N-{[3-(4-amino-5-{3-[(phenylmethyl)oxy]phenyl}-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclobutyl]methyl}acetamide;
N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-morpholin-4-yl-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-methylpiperazin-1-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N~2~-[(3-pyridin-2-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(2-morpholin-4-ylethyl)oxy]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-({[(2S)-1-methylpyrrolidin-2-yl]methyl}oxy)-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(3S)-3-methylpiperazin-1-yl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(1-methylpiperidin-4-yl)oxy]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-morpholin-4-ylpyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]-6-[(2-piperidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;
N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~6~-[2-(4-methylpiperazin-1-yl)ethyl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]-N~6~-(2-pyrrolidin-1-ylethyl)pyrimidine-2,4,6-triamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(3R)-3-methylpiperazin-1-yl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]-6-[(2-pyrrolidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(1-methylpyrrolidin-3-yl)oxy]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine

NAME
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(1-methylpiperidin-3-yl)oxy]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
6-{[2-(dimethylamino)ethyl]oxy}-N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-morpholin-4-ylpyrimidine-2,4-diamine;
6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-{[(3-phenylisoxazol-5-yl)methyl]amino}-N-(2-pyrrolidin-1-ylethyl)pyrimidine-4-carboxamide;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methyl-N~2~-[(5-phenylisoxazol-3-yl)methyl]pyrimidine-2,4-diamine;
5-bromo-N~2~-(4-morpholin-4-ylphenyl)-N~4~-[4-(2-pyrrolidin-1-ylethyl)phenyl]pyrimidine-2,4-diamine;
6-methyl-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]pyrimidine-2,4-diamine;
5-bromo-N~2~-(4-morpholin-4-ylphenyl)-N~4~-[4-(2-piperidin-1-ylethyl)phenyl]pyrimidine-2,4-diamine;
6-chloro-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]pyrimidine-2,4-diamine;
N~2~-(2-amino-2,3-dihydro-1H-inden-5-yl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methylpyrimidine-2,4-diamine;
N~2~-[4-(2-aminoethyl)phenyl]-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methylpyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methyl-N~2~-[4-(2-pyrrolidin-1-ylethyl)phenyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methyl-N~2~-(4-piperidin-4-ylphenyl)pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(3R)-3-methylpiperazin-1-yl]pyrimidine-2,4-diamine;
N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N~6~-[2-(4-methylpiperazin-1-yl)ethyl]pyrimidine-2,4,6-triamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~6~-[2-(4-methylpiperazin-1-yl)ethyl]pyrimidine-2,4,6-triamine;
N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N~6~-[2-(4-methylpiperazin-1-yl)ethyl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~6~-[2-(diethylamino)ethyl]-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4,6-triamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-{[2-(dimethylamino)ethyl]oxy}-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
N~4~-[3-(1-methylethyl)-1H-pyrazol-5-yl]-6-[(1-methylpyrrolidin-3-yl)oxy]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(1-methylpyrrolidin-3-yl)oxy]pyrimidine-2,4-diamine;
N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[3-(1-methylethyl)-1H-pyrazol-5-yl]-6-[(1-methylpyrrolidin-3-yl)oxy]pyrimidine-2,4-diamine;
N~4~-[2-(diethylamino)ethyl]-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~6~-[5-(1-methylethyl)-1H-pyrazol-3-yl]pyrimidine-2,4,6-triamine;
N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine;
6-{[2-(dimethylamino)ethyl]oxy}-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]pyrimidine-2,4-diamine;
N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(2-morpholin-4-ylethyl)oxy]pyrimidine-2,4-diamine;
N~4~-[3-(1-methylethyl)-1H-pyrazol-5-yl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]-6-[(2-piperidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;

NAME
N~4~-[3-(diethylamino)propyl]-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~6~-[5-(1-methylethyl)-1H-pyrazol-3-yl]pyrimidine-2,4,6-triamine;
N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(3S)-3-methylpiperazin-1-yl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-4-yl)oxy]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(2-morpholin-4-ylethyl)oxy]pyrimidine-2,4-diamine;
N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[3-(1-methylethyl)-1H-pyrazol-5-yl]-6-[(2-piperidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-[3-(diethylamino)propyl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(2-piperidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;
N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[3-(1-methylethyl)-1H-pyrazol-5-yl]-6-[(1-methylpiperidin-4-yl)oxy]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methyl-N~2~-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(3-methylisoxazol-5-yl)methyl]-6-morpholin-4-ylpyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(3-methylisoxazol-5-yl)methyl]-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(1-methylpiperidin-4-yl)oxy]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{[3-(4-fluorophenyl)isoxazol-5-yl]methyl}-6-morpholin-4-ylpyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-N~2~-[(3-pyridin-2-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-morpholin-4-yl-N~2~-[(3-pyridin-2-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-piperazin-1-ylpyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[4-(methylsulfonyl)piperazin-1-yl]pyrimidine-2,4-diamine;
4-{6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-({[3-(1-methylethyl)isoxazol-5-yl]methyl}amino)pyrimidin-4-yl}piperazine-1-carbaldehyde;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N~2~-[(3-pyrazin-2-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~2~-[(3-methylisoxazol-5-yl)methyl]-6-(4-methylpiperazin-1-yl)-N~4~-(3-methyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
N~2~-[(3-methylisoxazol-5-yl)methyl]-N~4~-(3-methyl-1H-pyrazol-5-yl)-6-morpholin-4-ylpyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-N~2~-[(3-pyrimidin-4-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(3-furan-3-ylisoxazol-5-yl)methyl]-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~6~-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-N~2~-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)-N~2~-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
N~4~-bicyclo[2.2.1]hept-2-yl-N~6~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4,6-triamine;
N~4~-bicyclo[2.2.1]hept-2-yl-N~6~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine;

NAME
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(3-methylisoxazol-5-yl)methyl]-6-[(1R,4R)-5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(1R,4R)-5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-morpholin-4-yl-N~2~-[(3-pyrimidin-4-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-{[2-(dimethylamino)ethyl]oxy}-N~2~-[(3-pyrimidin-4-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-N~2~-{[3-(2-thienyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-{[2-(diethylamino)ethyl]oxy}-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(2-pyrrolidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-{[2-(diethylamino)ethyl]oxy}-N~2~-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(3-methylisoxazol-5-yl)methyl]-6-[(2-pyrrolidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-N~2~-{[3-(1,3-thiazol-2-yl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-{[2-(dimethylamino)ethyl]oxy}-N~2~-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(3-ethylisoxazol-5-yl)methyl]-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(3-ethylisoxazol-5-yl)methyl]-6-morpholin-4-ylpyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-{[2-(dimethylamino)ethyl]oxy}-N~2~-[(3-ethylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-{[2-(diethylamino)ethyl]oxy}-N~2~-[(3-ethylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine; and
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(3-ethylisoxazol-5-yl)methyl]-6-[(2-pyrrolidin-1-ylethyl)oxy]pyrimidine-2,4-diamine.

[00887] For purposes of this application, in the above table (Table S), any compound that has "N~4~" and/or "N~2~" mean the same thing as "N^4" and "N^2", respectively. For example, N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-{[2-(dimethylamino)ethyl]oxy}-N~2~-[(3-ethylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine is exactly the same compound as N^4-(3-cyclopropyl-1H-pyrazol-5-yl)-6-{[2-(dimethylamino)ethyl]oxy}-N^2-[(3-ethylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine.

Definitions for Compounds of Formula I(S), I(S)1, II(S), III(S), IV(S), V(S), and VI(S)

[00888] The following definitions apply to the compounds of Formula I(S), I(S)1, II(S), III(S), IV(S), V(S), and VI(S) described hereinabove only. These definitions are not to be considered when determining the scope and meaning of any of the other

compounds described herein. To the same extent, all of the other compounds described herein that are not compounds of Formula I(S), I(S)1, II(S), III(S), IV(S), V(S), and VI(S) are not to be considered when determining the scope of the compounds of Formula I(S), I(S)1, II(S), III(S), IV(S), V(S), and VI(S).

[00889] "Alkyl" is intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof, inclusively. For example, "C_8 alkyl" may mean an *n*-octyl, *iso*-octyl, cyclohexylethyl, and the like. "Lower alkyl" means an alkyl groups of from one to six carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, *s*-butyl, *t*-butyl, isobutyl, pentyl, hexyl and the like. "Higher alkyl" means alkyl groups containing more that eight carbon atoms. A "C_0" alkyl (as in "C_0-C_6-alkyl") is a covalent bond. Exemplary alkyl groups are those of C_{20} or below. Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of from three to thirteen carbon atoms. Examples of cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbornyl, adamantyl and the like. In this application, "alkyl" means an alkanyl, alkenyl, and alkynyl residues (and combinations thereof). "Alkyl" includes cyclohexylmethyl, vinyl, allyl, isoprenyl, and the like. Thus when an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be encompassed; thus, for example, either "butyl" or "C_4 alkyl" is meant to include *n*-butyl, *sec*-butyl, isobutyl, *t*-butyl, isobutenyl and but-2-ynyl groups; and for example, "propyl" or "C_3 alkyl" each include *n*-propyl, propenyl, and isopropyl.

[00890] "Alkylene" means a straight or branched chain divalent group consisting solely of carbon and hydrogen atoms, containing no unsaturation and having from one to ten carbon atoms, for example, methylene, ethylene, propylene, *n*-butylene and the like. Alkylene is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, fully saturated. Examples of alkylene include ethylene ($-CH_2CH_2-$), propylene ($-CH_2CH_2CH_2-$), dimethylpropylene ($-CH_2C(CH_3)_2CH_2-$), and cyclohexylpropylene ($-CH_2CH_2CH(C_6H_{13})$).

[00891] "Alkylidene" means a straight or branched chain unsaturated divalent group consisting solely of carbon and hydrogen atoms, having from two to ten carbon atoms, for example, ethylidene, propylidene, *n*-butylidene, and the like. Alkylidene is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, double bond unsaturation. The unsaturation present includes at least one double bond.

[00892] "Alkylidyne" means a straight or branched chain unsaturated divalent group consisting solely of carbon and hydrogen atoms having from two to ten carbon atoms, for example, propylid-2-ynyl, *n*-butylid-1-ynyl, and the like. Alkylidyne is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, triple bond unsaturation. The unsaturation present includes at least one triple bond.

[00893] Any of the above groups, "alkylene," "alkylidene" and "alkylidyne," when optionally substituted, may contain alkyl substitution which itself contains unsaturation. For example, 2-(2-phenylethynyl-but-3-enyl)-naphthalene (IUPAC name) contains an *n*-butylid-3-ynyl group with a vinyl substituent at the 2-position of said group.

[00894] "Alkoxy" or "alkoxyl" means the group -O-alkyl, for example including from one to eight carbon atoms of a straight, branched, cyclic configuration, unsaturated chains, and combinations thereof attached to the parent structure through an oxygen atom. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to six carbons.

[00895] "Substituted alkoxy" means the group -O-(substituted alkyl), the substitution on the alkyl group generally containing more than only carbon (as defined by alkoxy). One exemplary substituted alkoxy group is "polyalkoxy" or -O-optionally substituted alkylene-optionally substituted alkoxy, and includes groups such as $-OCH_2CH_2OCH_3$, and glycol ethers such as polyethyleneglycol and $-O(CH_2CH_2O)_xCH_3$, where x is an integer of between about two and about twenty, in another example, between about two and about ten, and in a further example between about two and about five. Another exemplary substituted alkoxy group is hydroxyalkoxy or $-OCH_2(CH_2)_yOH$, where y is for example an integer of between about one and about ten, in another example y is an integer of between about one and about four.

[00896] "Acyl" means groups of from one to ten carbon atoms of a straight, branched, cyclic configuration, saturated, unsaturated and aromatic and combinations thereof, attached to the parent structure through a carbonyl functionality. One or more carbons in the acyl residue may be replaced by nitrogen, oxygen or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples include acetyl, benzoyl, propionyl, isobutyryl, *t*-butoxycarbonyl, benzyloxycarbonyl and the like. Lower-acyl refers to groups containing one to six carbons.

[00897] "α-Amino Acids" means naturally occurring and commercially available amino acids and optical isomers thereof. Typical natural and commercially available α-amino acids are glycine, alanine, serine, homoserine, threonine, valine, norvaline, leucine, isoleucine, norleucine, aspartic acid, glutamic acid, lysine, ornithine, histidine, arginine, cysteine, homocysteine, methionine, phenylalanine, homophenylalanine, phenylglycine, ortho-tyrosine, meta-tyrosine, para-tyrosine, tryptophan, glutamine, asparagine, proline and hydroxyproline. A "side chain of an α-amino acid" refers to the group found on the α-carbon of an α-amino acid as defined above, for example, hydrogen (for glycine), methyl (for alanine), benzyl (for phenylalanine), and the like.

[00898] "Amino" means the group $-NH_2$. "Substituted amino," means the group -N(H)R or -N(R)R where each R is independently selected from the group: optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heterocyclyl, acyl, carboxy, alkoxycarbonyl, sulfanyl, sulfinyl and sulfonyl, for example, diethylamino, methylsulfonylamino, and furanyl-oxy-sulfonamino.

[00899] "Aryl" means an aromatic six- to fourteen-membered carbocyclic ring, for example, benzene, naphthalene, indane, tetralin, fluorene and the like, univalent substituents. As univalent substituents, the aforementioned ring examples are named, phenyl, naphthyl, indanyl, tetralinyl, and fluorenyl.

[00900] "Arylene" means any aryl that has at least two groups attached thereto. For a more specific example, "phenylene" refers to a divalent phenyl ring group. A phenylene, thus may have more than two groups attached, but is defined by a minimum of two non-hydrogen groups attached thereto.

[00901] "Arylalkyl" means a residue in which an aryl moiety is attached to a parent structure via one of an alkylene, alkylidene, or alkylidyne group. Examples include benzyl, phenethyl, phenylvinyl, phenylallyl and the like. Both the aryl and the corresponding alkylene, alkylidene, or alkylidyne group portion of an arylalkyl group may be optionally substituted. "Lower arylalkyl"means an arylalkyl where the "alkyl" portion of the group has one to six carbons; this can also be referred to as C_{1-6} arylalkyl.

[00902] "Exo-alkenyl" means a double bond that emanates from an annular carbon, and is not within the ring system, for example the double bond depicted in the Formula below.



[00903] In some examples, as appreciated by one of ordinary skill in the art, two adjacent groups on an aromatic system may be fused together to form a ring structure. The fused ring structure may contain heteroatoms and may be optionally substituted with one or more groups. It should additionally be noted that saturated carbons of such fused groups (*i.e.* saturated ring structures) can contain two substitution groups.

[00904] "Fused-polycyclic" or "fused ring system" means a polycyclic ring system that contains bridged or fused rings; that is, where two rings have more than one shared atom in their ring structures. In this application, fused-polycyclics and fused ring systems are not necessarily all aromatic ring systems. Typically, but not necessarily, fused-polycyclics share a vicinal set of atoms, for example naphthalene or 1,2,3,4-tetrahydro-naphthalene. A spiro ring system is not a fused-polycyclic by this definition, but fused polycyclic ring systems of the invention may themselves have spiro rings attached thereto via a single ring atom of the fused-polycyclic.

[00905] "Halogen" or "halo" means fluorine, chlorine, bromine or iodine. "Haloalkyl" and "haloaryl" refer generically to alkyl and aryl groups that are substituted with one or more halogens, respectively. Thus, "dihaloaryl," "dihaloalkyl," "trihaloaryl" etc. mean an aryl and alkyl substituted with a plurality of halogens, but not necessarily a plurality of the same halogen; thus 4-chloro-3-fluorophenyl is within the scope of dihaloaryl.

[00906] "Heteroarylene" means any heteroaryl that has at least two groups attached thereto. For a more specific example, "pyridylene" means a divalent pyridyl ring group. A pyridylene, thus may have more than two groups attached, but is defined by a minimum of two non-hydrogen groups attached thereto.

[00907] "Heteroatom" means O, S, N, or P.

[00908] "Heterocyclyl" means a stable three- to fifteen-membered ring substituent that consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, phosphorus, oxygen and sulfur. For purposes of this invention, the heterocyclyl substituent may be a monocyclic, bicyclic or tricyclic ring system, which may include fused or bridged ring systems as well as spirocyclic systems; and the nitrogen, phosphorus, carbon or sulfur atoms in the heterocyclyl group may be optionally

oxidized to various oxidation states. In a specific example, the group -$S(O)_{0-2}$-, refers to -S- (sulfide), -S(O)- (sulfoxide), and -SO_2- (sulfone). For convenience, nitrogens, particularly but not exclusively, those defined as annular aromatic nitrogens, are meant to include their corresponding *N*-oxide form, although not explicitly defined as such in a particular example. Thus, for a compound of the invention having, for example, a pyridyl ring; the corresponding pyridyl-*N*-oxide is meant to be included as another compound of the invention. In addition, annular nitrogen atoms may be optionally quaternized; and the ring substituent may be partially or fully saturated or aromatic. Examples of heterocyclyl groups include, but are not limited to, azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofuranyl, carbazoyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrazoyl, tetrahydroisoquinolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, dihydropyridinyl, tetrahydropyridinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolinyl, oxazolidinyl, triazolyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl, quinolyl, isoquinolyl, decahydroisoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, dioxaphospholanyl, and oxadiazolyl.

[00909] "Heteroalicyclic" means specifically a non-aromatic heterocyclyl group. A heteroalicyclic may contain unsaturation, but is not aromatic.

[00910] "Heteroaryl" means specifically an aromatic heterocyclyl group.

[00911] "Heterocyclylalkyl" means a residue in which a heterocyclyl is attached to a parent structure via one of an alkylene, alkylidene, or alkylidyne group. Examples include (4-methylpiperazin-1-yl) methyl, (morpholin-4-yl) methyl, (pyridine-4-yl) methyl, 2-(oxazolin-2-yl) ethyl, 4-(4-methylpiperazin-1-yl)-2-butenyl, and the like. Both the heterocyclyl and the corresponding alkylene, alkylidene, or alkylidyne portion of a heterocyclylalkyl group may be optionally substituted. "Lower heterocyclylalkyl" refers to a heterocyclylalkyl where the "alkyl" portion of the group has one to six carbons.

"Heteroalicyclylalkyl" means specifically a heterocyclylalkyl where the heterocyclyl portion of the group is non-aromatic; and "heteroarylalkyl" means specifically a heterocyclylalkyl where the heterocyclyl portion of the group is aromatic Such terms may be described in more than one way, for example, "lower heterocyclylalkyl" and "heterocyclyl C_{1-6}alkyl" are equivalent terms. Additionally, for simplicity, the number of annular atoms (including heteroatoms) in a heterocycle may be denoted as "C_x-C_y" (as in "C_x-C_y-heterocyclyl" and "C_x-C_y-heteroaryl" (and the like)), where x and y are integers. So, for example, C_5-C_{14}-heterocyclyl refers to a 5 to 14 membered ring system having at least one heteroatom and not a ring system containing 5 to 14 annular carbon atoms.

[00912] Preferred heterocyclyls and heteroaryls include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, pyridotriazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,3,4-triazolyl, and xanthenyl.

[00913] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. One of ordinary skill in the art would understand that with respect to any molecule described as

containing one or more optional substituents, only sterically practical and/or synthetically feasible compounds are meant to be included. "Optionally substituted" refers to all subsequent modifiers in a term, for example in the term "optionally substituted arylC_{1-8} alkyl," optional substitution may occur on both the "C_{1-8} alkyl" portion and the "aryl" portion of the molecule; and for example, optionally substituted alkyl includes optionally substituted cycloalkyl groups. But where a first optionally substituted group can be substituted by a second optionally substituted group, the second substituent cannot be further substituted. A list of exemplary optional substitutions is presented below in the definition of "substituted."

[00914] Unless otherwise specified, the term "optionally substituted" applies to the chemical moiety immediately preceding it. For instance, if a variable group (such as R) is defined as aryl, optionally substituted alkyl, or cycloalkyl, then only the alkyl group is optionally substituted.

[00915] In the case where there is a point of attachment for a monovalent substituent, such as $-CH_3$, $-NH_2$, or -OH, the indication of where the point of attachment is is not necessary. That is, $-CH_3$ has the same meaning as CH_3, $-NH_2$ has the same meaning as NH_2, and -OH has the same meaning as OH.

[00916] In Table S, where there appears to be an empty valence for oxygen or nitrogen for any of the compounds listed in this table, where the name of the structure requires that the empty valence is filled with hydrogen, it is assumed that the missing valence is filled with hydrogen for each of these cases.

[00917] "Saturated bridged ring system" means a bicyclic or polycyclic ring system that is not aromatic. Such a system may contain isolated or conjugated unsaturation, but not aromatic or heteroaromatic rings in its core structure (but may have aromatic substitution thereon). For example, hexahydro-furo[3,2-b]furan, 2,3,3a,4,7,7a-hexahydro-1H-indene, 7-aza-bicyclo-[2.2.1]heptane, and 1,2,3,4,4a,5,8,8a-octahydro-naphthalene are all included in the class "saturated bridged ring system.

Synthetic Procedures of Formula I(S)1, II(S), III(S), IV(S), V(S), and VI(S)

[00918] Compounds of Formula I(S), I(S)1, II(S), III(S), IV(S), V(S), and VI(S) can be made by the synthetic schemes and examples described in publication WO

2005/074057, which is incorporated herein by reference in its entirety. The utility of these compounds are also described in WO 2005/074057.

[00919] Compounds of Formula I(S), I(S)1, II(S), III(S), IV(S), V(S), and VI(S) and their pharmaceutically acceptable salts can exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. The compounds may also exist as geometric isomers. All such single stereoisomers, racemates and mixtures thereof, and geometric isomers are intended to be within the scope of this invention.

[00920] Methods for the preparation and/or separation and isolation of single stereoisomers from racemic mixtures or non-racemic mixtures of stereoisomers are well known in the art. For example, optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. Enantiomers (R- and S-isomers) may be resolved by methods known to one of ordinary skill in the art, for example by: formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallization; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallization, selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where a desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step may be required to liberate the desired enantiomeric form. Alternatively, specific enantiomer may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents or by converting on enantiomer to the other by asymmetric transformation. For a mixture of enantiomers, enriched in a particular enantiomer, the major component enantiomer may be further enriched (with concomitant loss in yield) by recrystallization.

[00921] In addition, the compounds of Formula I(S), I(S)1, II(S), III(S), IV(S), V(S), and VI(S) can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the present invention.

[00922] In addition, it is intended that the protein kinase modulator compounds are made either using standard organic synthetic techniques, including combinatorial chemistry or by biological methods, such as bacterial digestion, metabolism, enzymatic conversion, and the like.

Pharmaceutical Composition Examples

[00923] The following are representative pharmaceutical Formulations containing a compound of Formula I(S), I(S)1, II(S), III(S), IV(S), V(S), or VI(S).

Tablet Formulation

[00924] The following ingredients are mixed intimately and pressed into single scored tablets.

Ingredient	Quantity per tablet, mg
Compound of Formula I(S), I(S)1, II(S), III(S), IV(S), V(S), or VI(S)	400
Cornstarch	50
croscarmellose sodium	25
Lactose	120
Magnesium stearate	5

Capsule Formulation

[00925] The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.

Ingredient	Quantity per tablet, mg
Compound of Formula I(S), I(S)1, II(S), III(S), IV(S), V(S), or VI(S)	200
lactose, spray-dried	148
Magnesium stearate	2

Suspension Formulation

[00926] The following ingredients are mixed to form a suspension for oral administration.

Ingredient	Amount
Compound of Formula I(S), I(S)1, II(S), III(S), IV(S), V(S), or VI(S)	1.0 g
fumaric acid	0.5 g
sodium chloride	2.0 g
methyl paraben	0.15 g
propyl paraben	0.05 g

Ingredient	Amount
granulated sugar	25.5 g
sorbitol (70% solution)	12.85 g
Veegum K (Vanderbilt Co.)	1.0 g
Flavoring	0.035 mL
Colorings	0.5 mg
Distilled water	q.s. to 100 mL

Injectable Formulation

[00927] The following ingredients are mixed to form an injectable Formulation.

Ingredient	Amount
Compound of Formula I(S), I(S)1, II(S), III(S), IV(S), V(S), or VI(S)	1.2 g
sodium acetate buffer solution	0.4 M 2.0 mL
HCl (1 N) or NaOH (1 M)	q.s. to suitable pH
water (distilled, sterile)	q.s.to 20 mL

[00928] All of the above ingredients, except water, are combined and heated to 60-70° C with stirring. A sufficient quantity of water at 60° C is then added with vigorous stirring to emulsify the ingredients, and water then added q.s. to 100 g.

Suppository Formulation

[00929] A suppository of total weight 2.5 g is prepared by mixing the compound of the invention with Witepsol®. H-15 (triglycerides of saturated vegetable fatty acid; Riches-Nelson, Inc., New York), and has the following composition:

Ingredient	Quantity per tablet, mg
Compound of Formula I(S), I(S)1, II(S), III(S), IV(S), V(S), or VI(S)	500
Witepsol® H-15	Balance

[00930] Aspect (34) of the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), and a pharmaceutically

acceptable carrier, in combination with a therapeutically effective amount of a protein kinase modulator compounds of Formula I(S), I(S)1, II(S), III(S), IV(S), V(S), or VI(S) or a pharmaceutical composition comprising a therapeutically effective amount of the protein kinase modulator compounds of Formula I(S), I(S)1, II(S), III(S), IV(S), V(S), or VI(S), and a pharmaceutically acceptable carrier, wherein the mammal is in need of the treatment.

[00931] In another embodiments of aspect (7), aspect (9), aspect (15), aspect (24), and aspect (34) of this invention, R^2 of Formula I(J) is



(f)

[00932] In another embodiments of aspect (7), aspect (9), aspect (15), aspect (24), and aspect (34) of this invention, R^2 of Formula I(J) is



(a) or



(b),

wherein R^{28a} is selected from lower alkyl, dialkylaminoalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, and hetercycloalkylalkyl.

[00933] In another embodiments of aspect (7), aspect (9), aspect (15), aspect (24), and aspect (34) of this invention, R^2 of Formula I(J) is



(g) or



(e).

[00934] In another embodiments of aspect (7), aspect (9), aspect (15), aspect (24), and aspect (34) of this invention, L of Formula I(J) is a bond, Z is 

, R^{25} is hydrogen and E and D are hydrogen.

[00935] In another embodiments of aspect (7), aspect (9), aspect (15), aspect (24), and aspect (34) of this invention, Z of Formula I(J) is  , R^{26a} is $-C(O)R^{32}$, R^{26} is hydrogen, and R^{32} is selected from tetrahydrofuran, pyrrolidinyl or pryimidinyl, wherein R^{32} is optionally substituted with 1, 2, 3, 4 or 5 groups selected from hydroxyl, oxo, alkyl, alkoxy, amino, hydroxyalkyl and halo.

[00936] In another embodiments of aspect (7), aspect (9), aspect (15), aspect (24), and aspect (34) of this invention, R^2 of Formula I(J) is  .

[00937] In another embodiments of aspect (7), aspect (9), aspect (15), aspect (24), and aspect (34) of this invention, R^{32} of Formula I(J) is U or $-CH_2$-U, wherein U is selected from pyrolidinyl, thiazolidinyl, morpholinyl, azetidinyl, cyclobutyl, cyclopropyl, tetrahydofuranyl, pyrazinyl, imidazolyl, piperazinyl, thienyl, thienylmethyl, furanyl, phenyl, prolinamidyl, pyridinyl, tetrahydronaphthalene, tetrazolyl, isoindolinyl, pyranyl, cyclopentyl, and octahydro-1H-indolyl.

[00938] In another embodiments of aspect (7), aspect (9), aspect (15), aspect (24), and aspect (34) of this invention, R^{11} of Formula I(J), when present, is halo or lower alkyl.

[00939] In another embodiments of aspect (7), aspect (9), aspect (15), aspect (24), and aspect (34) of this invention, R^{35} of Formula I(J) is heterocycloalkylalkyl, wherein the heterocyloalkyl is selected from piperazinyl, piperidinyl, morpholinyl and dioxanyl.

[00940] In another embodiments of aspect (7), aspect (9), aspect (15), aspect (24), and aspect (34) of this invention, n2 of Formula I(J) is 0.

[00941] In another embodiments of aspect (7), aspect (9), aspect (15), aspect (24), and aspect (34) of this invention, R^2 of Formula I(J) is  , and wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl.

[00942] In another embodiments of aspect (7), aspect (9), aspect (15), aspect (24), and aspect (34) of this invention, the JAK-2 compound has Formula IV(J):



wherein and R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

[00943] In another embodiments of aspect (7), aspect (9), aspect (15), aspect (24), and aspect (34) of this invention, the JAK-2 compound has Formula V(J):



wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

[00944] In another embodiments of aspect (7), aspect (9), aspect (15), aspect (24), and aspect (34) of this invention, the JAK-2 compound has Formula VI(J):



wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

[00945] In other embodiments of the methods of combining compounds of Formula I(S), I(S)1, II(S), III(S), IV(S), V(S), or VI(S) with the JAK-2 inhibitors of Formula I(J), any of the embodiments described above for the compounds of Formula I(S), I(S)1, II(S), III(S), IV(S), V(S), or VI(S) can be combined with any one of the embodiments of the compound of Formula I(J) described hereinabove. In other embodiments of the methods of combining compounds of Formula I(S), I(S)1, II(S), III(S), IV(S), V(S), or VI(S) with the JAK-2 inhibitors of Formula I(J), one or more of any of the compounds Table S can be combined with any one of the embodiments of the compound of Formula I(J) described hereinabove. In other embodiments of the methods of combining compounds of Formula I(S), I(S)1, II(S), III(S), IV(S), V(S), or VI(S) with the JAK-2 inhibitors of Formula I(J), one or more of any of the compounds in Table S can be combined with one or more of any of the compounds in Table I(J).

Raf COMPOUNDS

[00946] The Raf compounds inhibit, regulate and/or modulate the signal transduction of protein kinases, particularly Raf, and are expected to be useful in the treatment of hyperproliferative diseases, such as cancer, in humans. In another embodiment of the methods described herein, the JAK-2 compounds described hereinabove [e.g., compounds of Formula I(J), II(J), III(J), IV(J), V(J), VI(J), and VII(J)] can be combined with any of the Raf inhibitors known in the art. The Raf compounds described below are non-limiting examples of "Raf inhibitors" that are within the scope of aspect (12) of this invention. All of the substituents for the Raf compounds described below are defined separately from all of the other compounds described herein that are not Raf compound so that every substituent in the Raf compounds that also appears in any of the other compounds described herein has a separate and distinct meaning for each of these two compounds. For instance, R^1 for the JAK-2 compounds has a separate and distinct meaning from R^1 for the Raf compounds.

[00947] All of the Raf compounds disclosed herein include either their free base form or their pharmaceutically acceptable salts whether it is stated in the specification that these compounds can exist as their pharmaceutically acceptable salts or not.

[00948] All of the Raf compounds disclosed herein fall within the scope of aspect (27) of this invention.

[00949] The Raf compound is a compound for modulating kinase activity, particularly Raf, of Formula I(R),



I(R)

or a tautomer thereof, or a pharmaceutically acceptable salt the compound of Formula I(R) or tautomere thereof, wherein:

A is a three- to seven-membered alicyclic, a five- to six-membered ortho-arylene or a five- to six-membered ortho-heteroarylene containing between one and three heteroatoms, either of the aforementioned optionally substituted with up to four R;

each R is independently selected from -H, halogen, -CN, $-NO_2$, $-OR^3$, $-N(R^3)R^3$, $-S(O)_{0-2}R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, $-OC(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl;

optionally two of R, together with the atoms to which they are attached, form a first ring system fused with A, said first ring system substituted with zero to three of R^1;

X_1, X_2 and X_3 are independently selected from $-CR^1=$ or $-N=$;

each R^1 is independently selected from -H, halogen, -CN, $-NO_2$, $-OR^3$, $-N(R^3)R^3$, $-S(O)_{0-2}R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, $-OC(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl;

Z and X are each independently selected from $-C(R^2)=$, $-N=$, $-N(R^2)-$, $-S(O)_{0-2}-$, and -O-;

E and Y are each independently selected from absent, -C(R^2)(R^2)-, -C(=O)-, -C(R^2)= and -N=, but E and Y are not both absent, and E and Y are not both –N= when both Z and X are –N=;

each R^2 is independently selected from R^3, -N(R^3)(R^3), -C(O)N(R^3)R^3, -N(R^3)CO_2R^3, -N(R^3)C(O)N(R^3)R^3, and -N(R^3)C(O)R^3;

each R^3 is independently selected from -H, optionally substituted C_{1-6}alkyl, optionally substituted C_{3-7}alicyclic, optionally substituted aryl, optionally substituted aryl C_{1-3}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-3}alkyl;

optionally two of R^3, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P; and

G is selected from –CO_2R^3, -C(O)R^3, -C(O)N(R^3)R^3, -C(O)(NR^3), -C(O)NR^3[C(R^3)$_2$]$_{0-1}R^3$, -C(O)NR^3O[C(R^3)$_2$]$_{0-1}R^3$, -N(R^3)CO_2R^3, -N(R^3)C(O)N(R^3)R^3, -N(R^3)C(O)R^3, -N(R^3)R^3, -S(O)$_{0-2}R^3$, -SO_2N(R^3)R^3, optionally substituted aryl C_{0-3}alkyl, and optionally substituted heterocyclyl C_{0-3}alkyl;

with the proviso, however, that the compound is not CAS Registry No. 439096-29-4, 439107-32-1 or 439107-34-3.

[00950] In one embodiment(IR-A), the Raf compound is a compound of Formula I(R) wherein A is a six-membered ortho-arylene.

[00951] In another embodiment (IR-B), the Raf compound of (IR-A) is a compound of Formula I(R) wherein A is ortho-phenylene.

[00952] In another embodiment (IR-C), the Raf compound is according to embodiment (IR-B), wherein G is -C(O)R^3, -C(O)N(R^3)R^3, -C(O)(NR^3), -C(O)NR^3[C(R^3)$_2$]$_{0-1}R^3$, -C(O)NR^3O[C(R^3)$_2$]$_{0-1}R^3$.

[00953] In another embodiment (IR-D), the Raf compound is according to embodiment (IR-C), wherein G is -C(O)N(R^3)R^3.

[00954] In another embodiment (IR-E), the Raf compound is according to embodiment (IR-D), wherein G is -C(O)NHR^3.

[00955] In another embodiment (IR-F), the Raf compound is according to embodiment (IR-E), wherein R^3 is optionally substituted C_{1-6}alkyl.

[00956] In another embodiment (IR-G), the Raf compound is according to embodiment (IR-E), wherein R^3 is optionally substituted aryl.

[00957] In another embodiment (IR-H), the Raf compound is according to embodiment (IR-E), wherein R^3 is optionally substituted aryl C_{1-3}alkyl.

[00958] In another embodiment (IR-J), the Raf compound is according to embodiment (IR-E), wherein R^3 is optionally substituted heterocyclyl.

[00959] In another embodiment (IR-K), the Raf compound is according to embodiment (IR-E), wherein R^3 is optionally substituted heterocyclyl C_{1-3}alkyl.

[00960] In another embodiment (IR-L), the Raf compound is according to embodiment (IR-E), wherein X_1, X_2 and X_3 are $-CR^1=$.

[00961] In another embodiment (IR-M), the Raf compound is according to embodiment (IR-L), wherein E is absent.

[00962] In another embodiment (IR-N), the Raf compound is according to embodiment (IR-M), wherein Z is -N=; Y is $-C(R^2)=$; and X is selected from $-N(R^2)-$, -S-, and -O-.

[00963] In another embodiment (IR-O), the Raf compound is according to embodiment (IR-E), wherein it is recognized that the Raf compound includes tautomeric interconversions of each compound.

[00964] In another embodiment (IR-P), the Raf compound is a compound according to Formula I(R), wherein it is recognized that the Raf compound includes tautomeric interconversions of each compound according to the following Formula I(R)a, wherein R^3, A, X_1, X_2, X_3, Z, E, Y and X are as defined above according to Formula I(R), or embodiment (IR-A), (IR-B), (IR-C), (IR-D), (IR-E), (IR-F), (IR-G), (IR-H), (IR-J), (IR-K), (IR-L), (IR-M), (IR-N), or (IR-O),



I(R)a

[00965] In another embodiment (IR-Q), the Raf compound is according to Formula I(R), wherein the compound is a pharmaceutically acceptable salt.

[00966] In another embodiment (IR-S), the Raf compound is according to Formula I(R), wherein the compound is a prodrug.

[00967] In another embodiment, the Raf compounds are according to of Formula II(R),



II(R)

or a pharmaceutically acceptable salt thereof, wherein:

A is either a five- to six-membered ortho-arylene or a five- to six-membered ortho-heteroarylene containing between one and three heteroatoms, either of the aforementioned optionally substituted with up to four R;

each R is independently selected from -H, halogen, -CN, $-NO_2$, $-OR^3$, $-N(R^3)R^3$, $-S(O)_{0-2}R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, $-OC(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl;

optionally two of R, together with the atoms to which they are attached, form a first ring system fused with A, said first ring system substituted with zero to three of R^1;

n is zero to three;

each R^1 is independently selected from -H, halogen, -CN, $-NO_2$, $-OR^3$, $-N(R^3)R^3$, $-S(O)_{0-2}R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, $-OC(O)R^3$, optionally substituted C_{1-6}alkyl, optionally

substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl;

Z and X are each independently selected from $-C(R^2)=$, $-N=$, $-N(R^2)-$, $-S(O)_{0-2}-$, and $-O-$;

E and Y are each independently selected from absent, $-C(R^2)(R^2)-$, $-C(=O)-$, $-C(R^2)=$ and $-N=$, but E and Y are not both absent, and E and Y are not both $-N=$ when both Z and X are $-N=$;

each R^2 is independently selected from R^3, $-C(O)N(R^3)R^3$, $-N(R^3)CO_2R^3$, $-N(R^3)C(O)N(R^3)R^3$, and $-N(R^3)C(O)R^3$;

each R^3 is independently selected from -H, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-3}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-3}alkyl;

optionally two of R^3, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P; and

G is selected from $-C(O)R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)CO_2R^3$, $-N(R^3)C(O)N(R^3)R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)R^3$, $-S(O)_{0-2}R^3$, $-SO_2N(R^3)R^3$, optionally substituted aryl C_{1-3}alkyl, and optionally substituted heterocyclyl C_{1-3}alkyl;

with the proviso, however, that the compound is not CAS Registry No. 439096-29-4, 439107-32-1 or 439107-34-3.

[00968] In another embodiment (IIR-A), the Raf compound is according to Formula II(R), wherein E is absent.

[00969] In another embodiment (IIR-B), the Raf compound is according to embodiment (IR-A), wherein A is ortho-phenylene.

[00970] In an example of embodiment (IIR-B), the Raf compound is of Formula III(R):



III(R)

or a pharmaceutically acceptable salt thereof, wherein Z, Y, and X are as defined in any of the Raf compound embodiments described above; G is selected from $-C(O)R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)CO_2R^3$, $-N(R^3)C(O)N(R^3)R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)R^3$, $-SO_2N(R^3)R^3$, optionally substituted aryl C_{1-3}alkyl, and optionally substituted heterocyclyl C_{1-3}alkyl; R is selected from -H, halogen, -CN, $-NO_2$, $-OR^3$, $-N(R^3)R^3$, $-SR^3$, $-CO_2R^3$, and optionally substituted C_{1-6}alkyl; and R^1 is selected from -H, halogen, -CN, $-NO_2$, $-OR^3$, $-N(R^3)R^3$, $-S(O)_{0-2}R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, $-OC(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl.

[00971] In another embodiment (IIIR-A), the Raf compound is according to Formula III(R), wherein Z is -N=; Y is $-C(R^2)=$; and X is selected from $-N(R^2)-$, -S-, and -O-.

[00972] In another embodiment (IIIR-B), the Raf compound is according to embodiment (IIIR-A), wherein R and R^1 are -H.

[00973] In another example of embodiment (IIIR-B), the Raf compound is a Raf compound of Formula IV(R)a or IV(R)b:



IV(R)a **IV(R)b**

or a pharmaceutically acceptable salt thereof, wherein G is selected from $-C(O)R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)CO_2R^3$, $-N(R^3)C(O)N(R^3)R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)R^3$, $-SO_2N(R^3)R^3$, optionally substituted aryl C_{1-3}alkyl, and optionally substituted heterocyclyl C_{1-3}alkyl; wherein R^3 is as defined above; R^2 is either -H or optionally substituted C_{1-6}alkyl, it being understood that when R^2 is -H and all other groups are the same, IVa and IVb represent tautomers of a single molecule; R^{3a} is either -H or optionally substituted C_{1-6}alkyl; R^{3b} is selected from optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-3}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-3}alkyl.

[00974] In another embodiment (IVR-A), the Raf compound is a compound of Formula IV(R)a or IV(R)b wherein R^{3a} is -H.

[00975] In another embodiment (IVR-B), the Raf compound is according to embodiment (IIR-A), wherein R^2 is –H.

[00976] In another embodiment (IVR-C), the Raf compound is according to embodiment (IIR-B), wherein G is selected from $-C(O)R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)CO_2R^3$, $-N(R^3)C(O)N(R^3)R^3$, and $-N(R^3)C(O)R^3$.

[00977] In another example of embodiment (IVR-C), the Raf compound is according to to Formula V(R):



V(R)

or a pharmaceutically acceptable salt thereof, wherein W is R^3 or $-N(R^3)R^3$; and R^{3b} is selected from optionally substituted C_{1-6}alkyl, optionally substituted aryl, and optionally substituted aryl C_{1-3}alkyl.

[00978] In another embodiment (VR-A), the Raf compound is a compound of Formula V(R), wherein W is $-N(H)R^3$.

[00979] In another embodiment (VR-B), the Raf compound is according to embodiment (VR-A), wherein R^3 is optionally substituted aryl.

[00980] In another embodiment (VR-C), the Raf compound is according to embodiment (VR-B), wherein R^{3b} is optionally substituted C_{1-6}alkyl.

[00981] In another embodiment (VR-D), the Raf compound is according to embodiment (VR-C), wherein R^{3b} is C_{1-6}alkyl.

[00982] In another embodiment (IIR-C), the Raf compound is a Raf compound of Formula II(R), wherein the compound is a pharmaceutically acceptable salt.

[00983] In another embodiment (IIR-D), the Raf compound is a Raf compound of Formula II(R), wherein the compound is a prodrug.

[00984] In another embodiment, the Raf compound is a compound of Formula VI(R),



VI(R)

or a pharmaceutically acceptable salt thereof, wherein:

each R^5 and R^6 is independently selected from -H, halogen, -CN, $-NO_2$, $-OR^3$, $-N(R^3)R^3$, $-S(O)_{0-2}R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, $-OC(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl;

m is 1 or 2 dependent upon the presence or absence of saturation of the carbon bond between R^5 and R^6;

X_1, X_2 and X_3 are independently selected from $-CR^1=$ or $-N=$;

each R^1 is independently selected from -H, halogen, -CN, $-NO_2$, $-OR^3$, $-N(R^3)R^3$, $-S(O)_{0-2}R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, $-OC(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl;

Z and X are each independently selected from -C(R^2)=, -N=, -N(R^2)-, -S(O)$_{0-2}$-, and -O-;

E and Y are each independently selected from absent, -C(R^2)(R^2)-, -C(=O)-, -C(R^2)= and -N=, but E and Y are not both absent, and E and Y are not both –N= when both Z and X are –N=;

each R^2 is independently selected from R^3, -N(R^3)(R^3), -C(O)N(R^3)R^3, -N(R^3)CO_2R^3, -N(R^3)C(O)N(R^3)R^3, and -N(R^3)C(O)R^3;

each R^3 is independently selected from -H, optionally substituted C_{1-6}alkyl, optionally substituted C_{3-7}alicyclic, optionally substituted aryl, optionally substituted aryl C_{1-3}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-3}alkyl;

optionally two of R^3, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P; and

G is selected from –CO_2R^3, -C(O)R^3, -C(O)N(R^3)R^3, -C(O)(NR^3), -C(O)NR^3[C(R^3)$_2$]$_{0-1}R^3$, -C(O)NR^3O[C(R^3)$_2$]$_{0-1}R^3$, -N(R^3)CO_2R^3, -N(R^3)C(O)N(R^3)R^3, -N(R^3)C(O)R^3, -N(R^3)R^3, -S(O)$_{0-2}R^3$, -SO_2N(R^3)R^3, optionally substituted aryl C_{0-3}alkyl, and optionally substituted heterocyclyl C_{0-3}alkyl.

[00985] In one embodiment (VIR-A), the Raf compound is a compound according to Formula VI(R), wherein R^4 is -OH.

[00986] In another embodiment (VIR-B), the Raf compound is according to embodiment (VIR-A), wherein G is -C(O)R^3, -C(O)N(R^3)R^3, -C(O)(NR^3), -C(O)NR^3[C(R^3)$_2$]$_{0-1}R^3$, -C(O)NR^3O[C(R^3)$_2$]$_{0-1}R^3$.

[00987] In another embodiment (VIR-C), the Raf compound is according to embodiment (VIR-B), wherein G is -C(O)N(R^3)R^3.

[00988] In another embodiment (VIR-D), the Raf compound is according to embodiment (VIR-C), wherein G is -C(O)NHR^3.

[00989] In another embodiment (VIR-E), the Raf compound is a compound of Formula VI(R), wherein R^3 is optionally substituted C_{1-6}alkyl.

[00990] In another embodiment (VIR-F), the Raf compound is a compound of Formula VI(R), wherein R^3 is optionally substituted aryl.

[00991] In another embodiment (VIR-G), the Raf compound is a compound of Formula VI(R), wherein R^3 is optionally substituted aryl C_{1-3}alkyl.

[00992] In another embodiment (VIR-H), the Raf compound is a compound of Formula VI(R), wherein R^3 is optionally substituted heterocyclyl.

[00993] In another embodiment (VIR-J), the Raf compound is a compound of Formula VI(R), wherein R^3 is optionally substituted heterocyclyl C_{1-3}alkyl.

[00994] In another embodiment (VIR-K), the Raf compound is a compound of Formula VI(R), wherein X_1, X_2 and X_3 are $-CR^1=$.

[00995] In another embodiment (VIR-L), the Raf compound is according to embodiment (VIR-K), wherein E is absent.

[00996] In another embodiment (VIR-M), the Raf compound is according to embodiment (VIR-L), wherein Z is -N=; Y is $-C(R^2)=$; and X is selected from $-N(R^2)-$, -S-, and -O-.

[00997] In another embodiment (VIR-N), the Raf compound is according to embodiment (VIR-M), wherein R^5 and R^6 are optionally substituted C_{1-6}alkyl.

[00998] In another embodiment (VIR-O), the Raf compound is according to embodiment (VIR-N), wherein m is 1.

[00999] In another embodiment (VIR-P), the Raf compound is a compound of Formula VI(R), wherein the compound is a pharmaceutically acceptable salt.

[001000] In another embodiment (VIR-Q), the Raf compound is a compound of Formula VI(R),, wherein the compound is a prodrug.

[001001] In another embodiment, the Raf compound is a compound of Formula VII(R),



VII(R)

or a pharmaceutically acceptable salt thereof, wherein:

A is a three- to seven-membered alicyclic, a five- to six-membered ortho-arylene or a five- to six-membered ortho-heteroarylene containing between one and three heteroatoms, either of the aforementioned optionally substituted with up to four R;

each R is independently selected from -H, halogen, -CN, $-NO_2$, $-OR^3$, $-N(R^3)R^3$, $-S(O)_{0-2}R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, $-OC(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl;

optionally two of R, together with the atoms to which they are attached, form a first ring system fused with A, said first ring system substituted with zero to three of R^1;

X_1, X_2 and X_3 are independently selected from $-CR^1=$ or $-N=$;

each R^1 is independently selected from -H, halogen, -CN, $-NO_2$, $-OR^3$, $-N(R^3)R^3$, $-S(O)_{0-2}R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, $-OC(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl;

Z and X are each independently selected from $-C(R^2)=$, $-N=$, $-N(R^2)-$, $-S(O)_{0-2}-$, and -O-;

E and Y are each independently selected from absent, $-C(R^2)(R^2)-$, -C(=O)-, $-C(R^2)=$ and $-N=$, but E and Y are not both absent, and E and Y are not both $-N=$ when both Z and X are $-N=$;

each R^2 is independently selected from R^3, $-N(R^3)(R^3)$, $-C(O)N(R^3)R^3$, $-N(R^3)CO_2R^3$, $-N(R^3)C(O)N(R^3)R^3$, and $-N(R^3)C(O)R^3$;

each R^3 is independently selected from -H, optionally substituted C_{1-6}alkyl, optionally substituted C_{3-7}alicyclic, optionally substituted aryl, optionally substituted aryl C_{1-3}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-3}alkyl;

optionally two of R^3, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P; and

R^4 is selected from –H, -OH, optionally substituted C_{1-6} alkyl and optionally substituted C_{1-6} alkoxy;

with the proviso, however, that the compound is not CAS Registry No. 439096-29-4, 439107-32-1 or 439107-34-3.

[001002] In one embodiment (VIIR-A), the Raf compound is a compound of Formula VII(R), wherein A is a six-membered ortho-arylene.

[001003] In another embodiment (VIIR-B), the Raf compound is according to embodiment (VIIR-A), , wherein A is ortho-phenylene.

[001004] In another embodiment (VIIR-C), the Raf compound is according to embodiment (VIIR-B), wherein R^4 is -OH.

[001005] In another embodiment (VIIR-D), the Raf compound is a compound of Formula VII(R), wherein R^3 is optionally substituted C_{1-6}alkyl.

[001006] In another embodiment (VIIR-E), the Raf compound is a compound of Formula VII(R), wherein R^3 is optionally substituted aryl.

[001007] In another embodiment (VIIR-F), the Raf compound is a compound of Formula VII(R), wherein R^3 is optionally substituted aryl C_{1-3}alkyl.

[001008] In another embodiment (VIIR-G), the Raf compound is a compound of Formula VII(R), wherein R^3 is optionally substituted heterocyclyl.

[001009] In another embodiment (VIIR-H), the Raf compound is a compound of Formula VII(R), wherein R^3 is optionally substituted heterocyclyl C_{1-3}alkyl.

[001010] In another embodiment (VIIR-J), the Raf compound is according to embodiment (VIIR-H), wherein X_1, X_2 and X_3 are $–CR^1=$.

[001011] In another embodiment (VIIR-K), the Raf compound is according to embodiment (VIIR-J), wherein E is absent.

[001012] In another embodiment (VIIR-L), the Raf compound is according to embodiment (VIIR-K), wherein Z is -N=; Y is $-C(R^2)=$; and X is selected from $-N(R^2)-$, -S-, and -O-.

[001013] In another embodiment (VIIR-M), the Raf compound is a compound of Formula VII(R), wherein the compound is a pharmaceutically acceptable salt.

[001014] In another embodiment (VIIR-N), the Raf compound is a compound of Formula VII(R), wherein the compound is a prodrug.

[001015] In another embodiment, the Raf compound is a compound of Formula VIII(R):



VIII(R)

or a pharmaceutically acceptable salt thereof, wherein:

A is either a five- to six-membered ortho-arylene or a five- to six-membered ortho-heteroarylene containing between one and three heteroatoms, either of the aforementioned optionally substituted with up to four R;

each R is independently selected from -H, halogen, -CN, $-NO_2$, $-OR^3$, $-N(R^3)R^3$, $-S(O)_{0-2}R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, $-OC(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl;

optionally two of R, together with the atoms to which they are attached, form a first ring system fused with A, said first ring system substituted with zero to three of R^1;

n is zero to three;

each R^1 is independently selected from -H, halogen, -CN, $-NO_2$, $-OR^3$, $-N(R^3)R^3$, $-S(O)_{0-2}R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, $-OC(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl;

Z and X are each independently selected from $-C(R^2)=$, -N=, $-N(R^2)-$, $-S(O)_{0-2}-$, and -O-;

E and Y are each independently selected from absent, -C(R^2)(R^2)-, -C(=O)-, -C(R^2)= and -N=, but E and Y are not both absent, and E and Y are not both –N= when both Z and X are –N=;

each R^2 is independently selected from R^3, -C(O)N(R^3)R^3, -N(R^3)CO_2R^3, -N(R^3)C(O)N(R^3)R^3, and -N(R^3)C(O)R^3;

each R^3 is independently selected from -H, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-3}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-3}alkyl;

optionally two of R^3, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P; and

R^4 is selected from –H, -OH, optionally substituted C_{1-6} alkyl and optionally substituted C_{1-6} alkoxy;

with the proviso, however, that the compound is not CAS Registry No. 439096-29-4, 439107-32-1 or 439107-34-3.

[001016] In another embodiment (VIIIR-A), the Raf compound is a compound of Formula VIII(R), wherein E is absent.

[001017] In another embodiment (VIIIR-B), the Raf compound is according to embodiment (VIIIR-A), wherein A is ortho-phenylene.

[001018] In another example of embodiment (VIII-B), the Raf compound is a compound of Formula IX(R):



IX(R)

or a pharmaceutically acceptable salt thereof, wherein A, n, R, R^1, R^2, R^3, R^4, Z, Y, and X are as defined in any of the embodiments of the Raf compounds above.

[001019] In another embodiment (IXR-A), the Raf compound is a compound of Formula IX(R), wherein Z is -N=; Y is -C(R^2)=; and X is selected from -N(R^2)-, -S-, and -O-.

[001020] In another embodiment (IXR-B), the Raf compound is according to embodiment (IXR-A), wherein R and R^1 are -H.

[001021] In another example of embodiment (IXR-B), the Raf compound is a compound of Formula X(R)a or X(R)b:



X(R)a **X(R)b**

or a pharmaceutically acceptable salt thereof, wherein:

A, R^3 and R^4 are as defined in any of the embodiments of the Raf compounds above; R^2 is either -H or optionally substituted C_{1-6}alkyl (it being understood that when R^2 is -H and all other groups are the same, Xa and Xb represent tautomers of a single molecule); R^{3a} is either -H or optionally substituted C_{1-6}alkyl; R^{3b} is selected from optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-3}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-3}alkyl.

[001022] In another embodiment (XR-A), the Raf compound is a compound of Formula X(R)a or X(R)b, wherein R^{3a} is –H.

[001023] In another embodiment (XR-B), the Raf compound is according to embodiment (XR-A), wherein R^2 is -H.

[001024] In another embodiment (XR-C), the Raf compound is according to embodiment (XR-B), wherein R^3 is optionally substituted aryl.

[001025] In another example of embodiment (XR-C), the Raf compound is a compound of Formula XI(R):



XI(R)

or a pharmaceutically acceptable salt thereof, wherein:

R^3 is as defined in any of the embodimets of the Raf compounds described above; and R^{3b} is selected from optionally substituted C_{1-6}alkyl, optionally substituted aryl, and optionally substituted aryl C_{1-3}alkyl.

[001026] In another embodiment (XIR-A), the Raf compound is a compound of Formula XI(R), wherein R^3 is disubstituted aryl.

[001027] In another embodiment (XIR-B), the Raf compound is according to embodiment (XIR-A), wherein R^3 is aryl disubstituted with alkyl and halogen.

[001028] In another embodiment (VIIIR-C), the Raf compound is a compound of Formula VIII(R), wherein the compound is a pharmaceutically acceptable salt.

[001029] In another embodiment (VIIIR-D), the Raf compound is a compound of Formula VIII(R), wherein the compound is a prodrug.

[001030] In another embodiment, the Raf compound is a compound of Formula XII(R):



XII(R)

or a pharmaceutically acceptable salt thereof, wherein:

each R^5 and R^6 is independently selected from -H, halogen, -CN, $-NO_2$, $-OR^3$, $-N(R^3)R^3$, $-S(O)_{0-2}R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, $-OC(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl;

m is 1 or 2 dependent upon the presence or absence of saturation of the carbon bond between R^5 and R^6;

X_1, X_2 and X_3 are independently selected from $-CR^1=$ or $-N=$;

each R^1 is independently selected from -H, halogen, -CN, -NO_2, -OR^3, -$N(R^3)R^3$, -$S(O)_{0-2}R^3$, -$SO_2N(R^3)R^3$, -CO_2R^3, -$C(O)N(R^3)R^3$, -$N(R^3)SO_2R^3$, -$N(R^3)C(O)R^3$, -$N(R^3)CO_2R^3$, -$C(O)R^3$, -$OC(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl;

Z and X are each independently selected from -$C(R^2)$=, -N=, -$N(R^2)$-, -$S(O)_{0-2}$-, and -O-;

E and Y are each independently selected from absent, -$C(R^2)(R^2)$-, -C(=O)-, -$C(R^2)$= and -N=, but E and Y are not both absent, and E and Y are not both –N= when both Z and X are –N=;

each R^2 is independently selected from R^3, -$N(R^3)(R^3)$, -$C(O)N(R^3)R^3$, -$N(R^3)CO_2R^3$, -$N(R^3)C(O)N(R^3)R^3$, and -$N(R^3)C(O)R^3$;

each R^3 is independently selected from -H, optionally substituted C_{1-6}alkyl, optionally substituted C_{3-7}alicyclic, optionally substituted aryl, optionally substituted aryl C_{1-3}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-3}alkyl;

optionally two of R^3, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P; and

R^4 is selected from –H, -OH, optionally substituted C_{1-6} alkyl and optionally substituted C_{1-6} alkoxy.

[001031] In another embodiment (XIIR-A), the Raf compound is a compound of Formula XII(R), wherein R^4 is -OH.

[001032] In another embodiment (XIIR-B), the Raf compound is according to embodiment (XIIR-A), wherein G is -$C(O)R^3$, -$C(O)N(R^3)R^3$, -$C(O)(NR^3)$, -$C(O)NR^3[C(R^3)_2]_{0-1}R^3$, -$C(O)NR^3O[C(R^3)_2]_{0-1}R^3$.

[001033] In another embodiment (XIIR-C), the Raf compound is according to embodiment (XIIR-B), wherein G is -$C(O)N(R^3)R^3$.

[001034] In another embodiment (XIIR-D), the Raf compound is according to embodiment (XIIR-C), wherein G is -$C(O)NHR^3$.

[001035] In another embodiment (XIIR-E), the Raf compound is a compound of Formula XII(R), wherein R^3 is optionally substituted C_{1-6}alkyl.

[001036] In another embodiment (XIIR-F), the Raf compound is a compound of Formula XII(R), wherein R^3 is optionally substituted aryl.

[001037] In another embodiment (XIIR-G), the Raf compound is a compound of Formula XII(R), wherein R^3 is optionally substituted aryl C_{1-3}alkyl.

[001038] In another embodiment (XIIR-H), the Raf compound is a compound of Formula XII(R), wherein R^3 is optionally substituted heterocyclyl.

[001039] In another embodiment (XIIR-J), the Raf compound is a compound of Formula XII(R), wherein R^3 is optionally substituted heterocyclyl C_{1-3}alkyl.

[001040] In another embodiment (XIIR-K), the Raf compound is a compound of Formula XII(R), wherein X_1, X_2 and X_3 are $-CR^1=$.

[001041] In another embodiment (XIIR-L), the Raf compound is according to embodiment (XIIR-K) [00111], wherein E is absent.

[001042] In another embodiment (XIIR-M), the Raf compound is according to embodiment (XIIR-L), wherein Z is -N=; Y is $-C(R^2)=$; and X is selected from $-N(R^2)-$, -S-, and -O-.

[001043] In another embodiment (XIIR-N), the Raf compound is according to embodiment (XIIR-M) wherein R^5 and R^6 are optionally substituted C_{1-6}alkyl.

[001044] In another embodiment (XIIR-O), the Raf compound is according to embodiment (XIIR-N) wherein m is 1.

[001045] In another embodiment (XIIR-P), the Raf compound is a compound of Formula XII(R), wherein the compound is a pharmaceutically acceptable salt.

[001046] In another embodiment (XIIR-Q), the Raf compound is a compound of Formula XII(R), wherein the compound is a prodrug.

[001047] In another embodiment, the Raf compound is a compound of Formula XIII(R):



XIII(R)

or a pharmaceutically acceptable salt thereof, wherein:

A is either a five- to six-membered ortho-arylene or a five- to six-membered ortho-heteroarylene containing between one and three heteroatoms, either of the aforementioned optionally substituted with up to four R;

each R is independently selected from -H, halogen, -CN, $-NO_2$, $-OR^3$, $-N(R^3)R^3$, $-S(O)_{0-2}R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, $-OC(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl;

optionally two of R, together with the atoms to which they are attached, form a first ring system fused with A, said first ring system substituted with zero to three of R^1;

each R^1 is independently selected from -H, halogen, -CN, $-NO_2$, $-OR^3$, $-N(R^3)R^3$, $-S(O)_{0-2}R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, $-OC(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl;

each R^3 is independently selected from -H, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-3}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-3}alkyl;

optionally two of R^3, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P; and

R^4 is selected from –H, -OH, optionally substituted C_{1-6} alkyl and optionally substituted C_{1-6} alkoxy;

with the proviso, however, that the compound is not CAS Registry No. 439096-29-4, 439107-32-1 or 439107-34-3.

[001048] In another embodiment (XIIIR-A), the Raf compound is a compound of Formula XIII(R), wherein A is ortho-phenylene.

[001049] In another embodiment (XIIIR-B), the Raf compound is according to embodiment (XIIIR-A), wherein R^4 is –OH.

[001050] In another embodiment (XIIIR-C), the Raf compound is according to embodiment (XIIIR-B), wherein R^3 is optionally substituted aryl.

[001051] In another embodiment (XIIIR-D), the Raf compound is according to embodiment (XIIIR-C), wherein R^3 is mono- or di-substituted phenyl.

[001052] In another embodiment (XIIIR-E), the Raf compound is according to embodiment (XIIIR-B), wherein R^3 is optionally substituted aryl C_{1-3}alkyl.

[001053] In another embodiment (XIIIR-F), the Raf compound is according to embodiment (XIIIR-B), wherein R^3 is optionally substituted heterocyclyl.

[001054] In another embodiment (XIIIR-G), the Raf compound is according to embodiment (XIIIR-B), wherein R^3 is optionally substituted heterocyclyl C_{1-3}alkyl.

[001055] In another embodiment (XIIIR-H), the Raf compound is a compound of Formula XIII(R), wherein the compound is a pharmaceutically acceptable salt.

[001056] In another embodiment (XIIIR-J), the Raf compound is a compound of Formula XIII(R), wherein the compound is a prodrug.

[001057] Representative Raf compounds of Formula I(R), II(R), III(R), IV(R)a, IV(R)b, V(R), VI(R), VII(R), VIII(R), IX(R), X(R)a, X(R)b, XI(R), XII(R), or XIII(R), or pharmaceutically acceptable salts thereof, are depicted below in Table R. These compound in Table R are merely illustrative and do not limit the scope of the Raf compounds or Raf inhibitors in any way.

Table R

No.	Name
1	6-(2-butyl-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one

No.	Name
2	6-[1-hydroxy-3-oxo-2-(2-phenylethyl)-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
3	6-(1-hydroxy-2-{[4-(methyloxy)phenyl]methyl}-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one
4	6-(1-hydroxy-2-{[3-(methyloxy)phenyl]methyl}-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one
5	6-{2-[(4-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
6	6-(1-hydroxy-3-oxo-2-phenyl-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one
7	6-{2-[(3-bromophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
8	6-{2-[(4-bromophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
9	6-[1-hydroxy-3-oxo-2-(3-phenylpropyl)-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
10	6-{2-[(3,4-dichlorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
11	6-{1-hydroxy-2-[(4-methylphenyl)methyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
12	6-{2-[(4-chlorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
13	6-[1-hydroxy-2-(1-methylethyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
14	methyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
15	6-{2-[(3,4-dimethylphenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
16	6-(2-{[4-chloro-3-(trifluoromethyl)phenyl]methyl}-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one
17	6-(2-{[4-(dimethylamino)phenyl]methyl}-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one
18	6-[2-(3-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
19	6-[2-(4-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
20	6-[2-(3,4-dichlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
21	6-[1-hydroxy-2-(4-methylphenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
22	3-(2-{[3,5-bis(methyloxy)phenyl]amino}-1H-benzimidazol-5-yl)-3-(methyloxy)-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one
23	3-(2-{[3,5-bis(methyloxy)phenyl]amino}-1H-benzimidazol-5-yl)-2-(1-methylethyl)-3-(methyloxy)-2,3-dihydro-1H-isoindol-1-one

No.	Name
24	3-(2-{[3,5-bis(methyloxy)phenyl]amino}-1H-benzimidazol-5-yl)-3-hydroxy-2-phenyl-2,3-dihydro-1H-isoindol-1-one
25	3-(2-{[3,5-bis(methyloxy)phenyl]amino}-1H-benzimidazol-5-yl)-3-hydroxy-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one
26	methyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1-methyl-1H-benzimidazol-2-yl}carbamate
27	3-(1H-benzimidazol-5-yl)-3-hydroxy-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one
28	5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-N-methyl-1H-benzimidazole-2-carboxamide
29	3-hydroxy-3-(2-methyl-1H-benzimidazol-5-yl)-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one
30	7-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-3,4-dihydroquinoxalin-2(1H)-one
31	7-[2-(3-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-3,4-dihydroquinoxalin-2(1H)-one
32	1,1-dimethylethyl 4-{[1-hydroxy-3-oxo-1-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-1,3-dihydro-2H-isoindol-2-yl]methyl}piperidine-1-carboxylate
33	6-(1-hydroxy-2-{[2-(methyloxy)phenyl]methyl}-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one
34	6-{2-[(3-chlorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
35	6-{2-[(2-chlorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
36	6-{2-[(3-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
37	6-{2-[(2-bromophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
38	6-{2-[(2-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
39	6-[2-(3-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
40	6-[1-hydroxy-2-(3-iodophenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
41	6-[2-(3-bromophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
42	6-[1-hydroxy-2-(3-nitrophenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
43	6-{1-hydroxy-2-[3-(methyloxy)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
44	6-[1-hydroxy-2-(3-methylphenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
45	3-hydroxy-3-(1H-indol-5-yl)-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one

No.	Name
46	methyl [6-(1-hydroxy-3-oxo-2-phenyl-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate
47	6-[2-(2-aminophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
48	6-{[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]carbonyl}-2H-1,4-benzoxazin-3(4H)-one
49	6-{[2-(1H-benzimidazol-2-yl)phenyl]carbonyl}-2H-1,4-benzoxazin-3(4H)-one
50	6-(1-hydroxy-3-oxo-2-{[2-(trifluoromethyl)phenyl]methyl}-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one
51	6-{2-[(5-bromo-2-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
52	6-{1-hydroxy-2-[(3-nitrophenyl)methyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
53	6-(1-hydroxy-3-oxo-2-{[3-(trifluoromethyl)phenyl]methyl}-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one
54	6-(2-{[2,3-bis(methyloxy)phenyl]methyl}-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one
55	6-{1-hydroxy-2-[(3-iodophenyl)methyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
56	6-[1-hydroxy-3-oxo-2-({3-[(trifluoromethyl)oxy]phenyl}-methyl)-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
57	6-(1-hydroxy-2-{[2-(methylthio)phenyl]methyl}-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one
58	6-[2-(3,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
59	6-{1-hydroxy-2-[3-(1-methylethyl)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
60	6-(1-hydroxy-3-oxo-2-{3-[(trifluoromethyl)oxy]phenyl}-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one
61	6-{1-hydroxy-3-oxo-2-[3-(trifluoromethyl)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
62	3-[1-hydroxy-3-oxo-1-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-1,3-dihydro-2H-isoindol-2-yl]benzene-sulfonamide
63	6-{2-[5-chloro-2-(methyloxy)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
64	6-{2-[4-fluoro-3-(trifluoromethyl)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
65	3-hydroxy-3-(1H-indol-6-yl)-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one
66	6-[2-(3-fluoro-5-iodophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one

No.	Name
67	6-[2-(3-aminophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
68	6-[2-(3,5-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
69	6-{1-hydroxy-2-[3-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
70	ethyl 3-[1-hydroxy-3-oxo-1-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-1,3-dihydro-2H-isoindol-2-yl]benzoate
71	3-[1-hydroxy-3-oxo-1-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-1,3-dihydro-2H-isoindol-2-yl]benzonitrile
72	6-[2-(2-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
73	6-[2-(3-amino-5-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
74	6-[2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
75	6-[2-(3-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
76	6-[2-(3-ethylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
77	6-[2-(3-ethynylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
78	6-[1-hydroxy-2-(3-hydroxyphenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
79	6-{1-hydroxy-3-oxo-2-[3-(phenyloxy)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
80	6-(1-hydroxy-3-oxo-2-{3-[(phenylmethyl)oxy]phenyl}-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one
81	3-[1-hydroxy-3-oxo-1-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-1,3-dihydro-2H-isoindol-2-yl]benzamide
82	6-{1-hydroxy-2-[3-(hydroxymethyl)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one
83	6-[2-(2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
84	3-hydroxy-3-[2-(methylamino)-1H-benzimidazol-5-yl]-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one
85	6-(2-biphenyl-3-yl-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one
86	6-(2-{3-[(dimethylamino)methyl]phenyl}-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one
87	6-[2-(3,5-dichlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
88	6-(1-hydroxy-3-oxo-2-piperidin-4-yl-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one
89	6-[2-(3-{[2-(dimethylamino)ethyl]oxy}phenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one

No.	Name
90	6-[1-hydroxy-2-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one
91	N-methyl-2-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)carbonyl]-N-phenylbenzamide
92	methyl {5-[1-(ethyloxy)-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
93	Phenylmethyl 2-[(2-{[(methyloxy)carbonyl]-amino}-1H-benzimidazol-5-yl)carbonyl]-benzoate
94	3-hydroxy-3-(1H-indazol-5-yl)-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one
95	3-hydroxy-3-(1H-indazol-6-yl)-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one
96	ethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
97	2-methylpropyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
98	methyl {5-[1-hydroxy-3-oxo-2-(2-thienylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
99	methyl {5-[1-hydroxy-3-oxo-2-(2-phenylethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
100	3-[2-amino-1-(1,1-dimethylethyl)-1H-benzimidazol-5-yl]-3-hydroxy-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one
101	3-(2-amino-1H-benzimidazol-5-yl)-3-hydroxy-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one
102	methyl [5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate
103	3-(methyloxy)butyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
104	methyl (5-{1-hydroxy-3-oxo-2-[(1R)-1-phenylethyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
105	methyl (5-{1-hydroxy-3-oxo-2-[(1S)-1-phenylethyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
106	2-(methyloxy)ethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
107	methyl {6-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1-methyl-1H-benzimidazol-2-yl}carbamate
108	prop-2-yn-1-yl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
109	but-2-yn-1-yl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
110	1-methylethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate

No.	Name
111	methyl {5-[2-(2,3-dihydro-1H-inden-2-yl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
112	methyl {5-[1-hydroxy-3-oxo-2-(pyridin-4-ylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
113	methyl {5-[1-hydroxy-3-oxo-2-(pyridin-3-ylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
114	methyl (6-{2-[(3-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
115	methyl {5-[1-hydroxy-2-(3-methylphenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
116	methyl [5-(1-hydroxy-2-{[2-(methyloxy)phenyl]methyl}-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate
117	methyl [5-(1-hydroxy-2-{[3-(methyloxy)phenyl]methyl}-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate
118	methyl [5-(1-hydroxy-2-{[4-(methyloxy)phenyl]methyl}-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate
119	methyl (6-{2-[(4-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
120	methyl (6-{2-[(3-bromophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
121	methyl (5-{1-hydroxy-2-[(3-iodophenyl)methyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
122	methyl (5-{2-[(3-chlorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
123	methyl (5-{2-[(2-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
124	methyl {5-[1-hydroxy-3-oxo-2-(pyridin-2-ylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
125	phenylmethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
126	2-fluoroethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
127	propyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
128	methyl (5-{1-hydroxy-2-[4-(methyloxy)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate

No.	Name
129	methyl (5-{2-[(2-chlorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
130	methyl (5-{2-[(2-bromophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
131	methyl (5-{1-hydroxy-2-[(3-methylphenyl)methyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
132	methyl (5-{1-hydroxy-2-[(4-methylphenyl)methyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
133	methyl (5-{1-hydroxy-2-[(2-methylphenyl)methyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
134	methyl {5-[2-(3-bromophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
135	methyl {5-[2-(3-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
136	methyl {5-[2-(3-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
137	methyl (5-{1-hydroxy-2-[3-(methyloxy)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
138	methyl {5-[2-(4-bromophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
139	methyl {5-[2-(4-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
140	methyl {5-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
141	methyl {5-[2-(3,5-dimethylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
142	methyl {5-[2-(2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
143	methyl {5-[2-(2-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
144	methyl {5-[1-hydroxy-2-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
145	methyl (5-{1-hydroxy-2-[2-(methyloxy)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
146	methyl {5-[1-hydroxy-2-(4-methylphenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
147	methyl (5-{1-hydroxy-3-oxo-2-[3-(trifluoromethyl)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
148	but-2-yn-1-yl (5-{1-hydroxy-3-oxo-2-[(1R)-1-phenylethyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate

No.	Name
149	N-ethyl-N'-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}urea
150	phenylmethyl (5-{1-hydroxy-3-oxo-2-[(1R)-1-phenylethyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
151	methyl {6-[2-(3-amino-5-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
152	piperidin-4-ylmethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
153	methyl {5-[2-(cyclopropylmethyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
154	methyl {5-[2-(2,2-dimethylpropyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
155	methyl {5-[2-(3,5-dichlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
156	methyl {5-[2-(3,5-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
157	N-ethyl-N'-(5-{1-hydroxy-3-oxo-2-[(1R)-1-phenylethyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)urea
158	N'-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-N,N-dimethylurea
159	methyl {5-[2-(3-{[2-(dimethylamino)ethyl]oxy}phenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
160	3-(4-methylpiperazin-1-yl)propyl {6-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
161	methyl {5-[2-(cyclohexylmethyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
162	methyl {5-[1-hydroxy-2-(2-methylpropyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
163	methyl {5-[1-hydroxy-3-oxo-2-(1,3-thiazol-2-ylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
164	methyl {5-[2-(3,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
165	methyl (5-{2-[1-(3,5-difluorophenyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
166	methyl (5-{2-[1-(3-fluorophenyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
167	methyl [5-(2-cyclohexyl-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate
168	methyl {5-[2-(2,5-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate

No.	Name
169	N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-N'-(phenylmethyl)urea
170	piperidin-4-yl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
171	N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-N'-methylurea
172	methyl (5-{2-[1-(2-fluorophenyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
173	methyl (5-{1-hydroxy-3-oxo-2-[1-(2-thienyl)ethyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
174	methyl (5-{2-[1-(3-chlorophenyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
175	methyl (5-{1-hydroxy-2-[3-methyl-5-(trifluoromethyl)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
176	N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}propanamide
177	methyl {5-[2-(3,4-dichlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
178	methyl {5-[2-(3-ethylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
179	methyl {5-[2-(3-ethynylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
180	methyl {5-[2-(4-chloro-3-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
181	methyl [5-(1-hydroxy-3-oxo-2-{1-[3-(trifluoromethyl)phenyl]ethyl}-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate
182	methyl (5-{1-hydroxy-3-oxo-2-[(1R)-1-phenylpropyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
183	methyl [5-(1-hydroxy-3-oxo-2-{2-[(trifluoromethyl)oxy]phenyl}-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate
184	methyl {5-[2-(2,3-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
185	cyclohexyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
186	tetrahydrofuran-2-ylmethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
187	cyclopropylmethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate

No.	Name
188	N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}morpholine-4-carboxamide
189	methyl {5-[2-(cyclopentylmethyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
190	methyl {5-[2-(2,3-dimethylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
191	methyl {5-[2-(2,3-dihydro-1H-inden-1-yl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
192	methyl (2S)-cyclohexyl[1-hydroxy-1-(2-{[(methyloxy)carbonyl]amino}-1H-benzimidazol-5-yl)-3-oxo-1,3-dihydro-2H-isoindol-2-yl]ethanoate
193	methyl {5-[2-(2,6-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
194	methyl {5-[2-(3-chloro-4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
195	but-3-en-1-yl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
196	2,2,2-trifluoroethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
197	methyl {5-[2-(5-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
198	methyl (5-{2-[1-(5-chloro-2-methylphenyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
199	methyl (5-{1-hydroxy-3-oxo-2-[(1S)-1-phenylpropyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
200	methyl (5-{2-[1-(3-chloro-2-methylphenyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
201	methyl (5-{1-hydroxy-2-[1-(5-methyl-2-thienyl)ethyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
202	methyl (5-{2-[1-(5-chloro-2-thienyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
203	methyl {5-[1-hydroxy-2-(3-iodophenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
204	methyl (5-{1-hydroxy-2-[3-(1-methylethyl)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
205	methyl {5-[2-(furan-2-ylmethyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate

No.	Name
206	methyl {5-[1-hydroxy-3-oxo-2-(3-thienylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
207	methyl {5-[2-(cyclobutylmethyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
208	3,3,3-trifluoro-2-hydroxy-N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-2-(trifluoromethyl)propanamide
209	methyl (5-{1-hydroxy-2-[1-(4-methyl-2-thienyl)ethyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
210	methyl (5-{2-[1-(4-bromo-2-thienyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
211	methyl {5-[1-hydroxy-2-(3-{[2-(methyloxy)ethyl]oxy}phenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
212	tetrahydrofuran-3-ylmethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
213	N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}piperidine-1-carboxamide
214	methyl {5-[2-(3-bromo-4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
215	2,3-dihydroxypropyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
216	methyl {5-[1-hydroxy-3-oxo-2-(tetrahydrofuran-2-ylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
217	methyl (5-{2-[3-(aminocarbonyl)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
218	4,4,4-trifluoro-3-hydroxy-N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-3-(trifluoromethyl)butanamide
219	methyl (5-{1-hydroxy-2-[3-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
220	methyl (5-{1-hydroxy-3-oxo-2-[3-(phenyloxy)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
221	methyl [5-(1-hydroxy-3-oxo-2-{3-[(phenylmethyl)oxy]phenyl}-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate
222	methyl [5-(2-biphenyl-3-yl-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate

No.	Name
223	2,2-dimethyl-3-[(phenylmethyl)oxy]propyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
224	methyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
225	methyl {5-[2-(3-cyanophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
226	methyl {5-[2-(3-ethynyl-4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
227	methyl {5-[2-(4-fluoro-3-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
228	methyl {6-[2-(3,4-dichloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
229	[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
230	methyl {5-[2-(5-bromo-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
231	methyl (5-{2-[3-(acetylamino)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
232	methyl (5-{1-hydroxy-3-oxo-2-[3-(phenylmethyl)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
233	methyl (5-{2-[1-(4-chloro-2-thienyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
234	methyl (5-{1-hydroxy-3-oxo-2-[3-(phenylcarbonyl)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
235	methyl [5-(2-{3-[(dimethylamino)methyl]phenyl}-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate
236	methyl (5-{2-[3-(aminosulfonyl)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
237	methyl {5-[2-(3-acetylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
238	methyl {5-[2-(3-ethyl-4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
239	methyl {5-[2-(3-chloro-5-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate

No.	Name
240	N-{6-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-2-methylpropanamide
241	methyl (5-{2-[1-(3-chloro-2-thienyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
242	methyl [5-(1-hydroxy-3-oxo-2-pyridin-3-yl-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate
243	methyl (5-{1-hydroxy-3-oxo-2-[3-(phenylamino)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
244	methyl {5-[2-(5-bromo-2,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
245	methyl {5-[2-(5-chloro-2,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
246	methyl {5-[2-(3,5-dichloro-4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
247	2,2-dimethyl-3-(methyloxy)propyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
248	3-hydroxy-2,2-dimethylpropyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
249	methyl (5-{2-[1-(5-bromo-2-thienyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
250	methyl {5-[2-(4,5-dichloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
251	methyl {5-[2-(3-bromo-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
252	methyl {5-[2-(3-chloro-2,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
253	N-{6-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}pent-4-ynamide
254	methyl (6-{1-methyl-3-oxo-2-[3-(trifluoromethyl)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
255	methyl [5-(1-hydroxy-3-oxo-2-{3-[(1,1,2,2-tetrafluoroethyl)oxy]phenyl}-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate
256	methyl {5-[1-hydroxy-3-oxo-2-(3-piperidin-4-ylphenyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate

No.	Name
257	methyl {5-[2-(3-ethenylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
258	methyl (5-{2-[3-(dimethylamino)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
259	2,2-difluoro-N-{6-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}cyclopropanecarboxamide
260	N-ethyl-N'-{6-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}urea
261	methyl {5-[2-(3-aminophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
262	N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-4-[(phenylmethyl)oxy]butanamide
263	N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-4-piperidin-1-ylbutanamide
264	N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-4-(4-methylpiperazin-1-yl)butanamide
265	N-{6-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}butanamide
266	methyl {6-[2-(3-bromophenyl)-5,6-dichloro-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
267	methyl [5-(1-hydroxy-2-{3-[methyl(phenyl)amino]phenyl}-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate
268	methyl {5-[1-hydroxy-3-oxo-2-(phenylsulfonyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
269	methyl {5-[(2-{[(phenylamino)carbonyl]amino}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
270	methyl (5-{[2-({[(phenylmethyl)oxy]carbonyl}amino)phenyl]carbonyl}-1H-benzimidazol-2-yl)carbamate
271	methyl [5-({2-[(2-phenylhydrazino)carbonyl]phenyl}carbonyl)-1H-benzimidazol-2-yl]carbamate
272	methyl {5-[(2-{[(phenyloxy)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
273	but-2-yn-1-yl {5-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate

No.	Name
274	N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-3-piperidin-1-ylpropanamide
275	N-{6-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}propanamide
276	N-(4-fluorophenyl)-2-{[2-(pent-4-ynoylamino)-1H-benzimidazol-6-yl]carbonyl}benzamide
277	4-(diethylamino)-N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}butanamide
278	N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-4-pyrrolidin-1-ylbutanamide
279	3-piperidin-1-ylpropyl {6-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
280	3-(4-methylpiperazin-1-yl)propyl {6-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
281	methyl {5-[2-(3-bromophenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
282	methyl {5-[2-(3-ethynyl-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
283	2-piperidin-1-ylethyl {5-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
284	methyl {5-[2-(3-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
285	methyl {5-[2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
286	N-{6-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-2,2-dimethyl-3-piperidin-1-ylpropanamide
287	N-{5-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-4-piperidin-1-ylbutanamide
288	N-{5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-4-piperidin-1-ylbutanamide
289	methyl [6-({2-[(phenylcarbonyl)amino]phenyl}carbonyl)-1H-benzimidazol-2-yl]carbamate
290	methyl {5-[1-hydroxy-2-(3-morpholin-4-ylphenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate

No.	Name
291	2-(dimethylamino)ethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
292	2-(diethylamino)ethyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
293	2-piperidin-1-ylethyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
294	3-piperidin-1-ylpropyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
295	2-piperidin-1-ylethyl {6-[2-(3-bromophenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
296	methyl {6-[2-(3-bromophenyl)-4,7-difluoro-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
297	2-[methyl(phenylmethyl)amino]ethyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
298	methyl {5-[1-hydroxy-3-oxo-2-(3-pyrrolidin-1-ylphenyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
299	methyl {5-[2-(5-chloro-2,3-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
300	methyl {5-[1-hydroxy-3-oxo-2-(pyrrolidin-2-ylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
301	methyl {5-[1-hydroxy-3-oxo-2-(pyrrolidin-3-ylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
302	(1-methylpiperidin-2-yl)methyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
303	[(2S)-1-methylpyrrolidin-2-yl]methyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
304	octahydro-2H-quinolizin-1-ylmethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
305	methyl {5-[2-(5-bromo-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
306	5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1,3-dihydro-2H-benzimidazol-2-one

No.	Name
307	methyl {5-[2-(3-bromo-2,5-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
308	2-morpholin-4-ylethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
309	(1-methylpiperidin-3-yl)methyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
310	methyl (5-{2-[5-chloro-2-(methyloxy)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
311	methyl [5-(2-{3-[cyclohexyl(methyl)amino]phenyl}-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate
312	8-azabicyclo[3.2.1]oct-3-ylmethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
313	methyl {6-[1-(3-bromophenyl)-5-oxopyrrolidin-2-yl]-1H-benzimidazol-2-yl}carbamate
314	(1-methylpiperidin-4-yl)methyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
315	1,1-dimethylethyl 4-({[({5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}amino)carbonyl]oxy}methyl)piperidine-1-carboxylate
316	(1-methylpiperidin-4-yl)methyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
317	2-(1-methylpiperidin-4-yl)ethyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
318	methyl ({6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}amino)(oxo)acetate
319	N-(5-{1-hydroxy-3-oxo-2-[3-(phenyloxy)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)-4-piperidin-1-ylbutanamide
320	methyl {6-[2-(3-bromophenyl)-1-methyl-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
321	4-(diethylamino)but-2-yn-1-yl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
322	methyl {5-[2-(3-chloro-2,6-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate

No.	Name
323	2-(2-oxopyrrolidin-1-yl)ethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
324	2-(2,5-dioxopyrrolidin-1-yl)ethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
325	2,2,3,3-tetrafluorocyclobutyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
326	1-acetyl-N-{5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}piperidine-4-carboxamide
327	N-{5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}cyclobutanecarboxamide
328	methyl [5-(2-{3-[ethyl(phenyl)amino]phenyl}-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate
329	N-{6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-2,2-difluorocyclopropanecarboxamide
330	cyclobutyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
331	2,2-difluoroethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
332	2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-[2-(pyridin-2-ylamino)-1H-benzimidazol-5-yl]-2,3-dihydro-1H-isoindol-1-one
333	1-methylethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
334	cyclopropylmethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
335	N-{5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}cyclopropanecarboxamide
336	2-(methyloxy)ethyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
337	tetrahydrofuran-2-ylmethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate

No.	Name
338	N-{5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-2-(2-thienyl)acetamide
339	methyl {6-[2-(3-chloro-2-fluorophenyl)-4,7-difluoro-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
340	ethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
341	2-fluoroethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
342	methyl (5-{1-hydroxy-3-oxo-2-[2-(phenyloxy)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
343	N'-{5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-N,N-diethylpentanediamide
344	cyclobutylmethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
345	2,2,2-trifluoroethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
346	methyl (5-{2-[3-(1,1-dimethylethyl)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
347	methyl {6-[2-(3-chloro-2-fluorophenyl)-7-fluoro-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
348	2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-[2-(phenylamino)-1H-benzimidazol-5-yl]-2,3-dihydro-1H-isoindol-1-one
349	methyl {6-[4,7-dichloro-2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
350	phenylmethyl 2-[(2-{[(ethyloxy)carbonyl]amino}-1,3-benzoxazol-5-yl)carbonyl]benzoate
351	methyl {5-[2-(5-chloro-3-ethynyl-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
352	methyl {5-[2-(5-ethynyl-2,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
353	methyl {5-[2-(3-ethynyl-2,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
354	2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-[2-(pyrimidin-2-ylamino)-1H-benzimidazol-5-yl]-2,3-dihydro-1H-isoindol-1-one

No.	Name
355	methyl {5-[2-(3-ethynyl-2-fluorophenyl)-4,7-difluoro-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
356	2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-[2-(1,3-thiazol-2-ylamino)-1H-benzimidazol-5-yl]-2,3-dihydro-1H-isoindol-1-one
357	ethyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1,3-benzoxazol-2-yl}carbamate
358	methyl {5-[2-(5-chloro-3-iodo-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
359	methyl {5-[2-(3-ethyl-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
360	methyl {5-[2-(5-ethynyl-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
361	2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-[2-(pyrazin-2-ylamino)-1H-benzimidazol-5-yl]-2,3-dihydro-1H-isoindol-1-one
362	methyl {5-[2-(2-fluoro-3-iodophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
363	methyl {6-[2-(5-ethynyl-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
364	2-(3-ethynyl-2-fluorophenyl)-3-hydroxy-3-[2-(pyrimidin-2-ylamino)-1H-benzimidazol-5-yl]-2,3-dihydro-1H-isoindol-1-one
365	methyl {5-[2-(2,5-dimethylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
366	methyl {5-[2-(3-ethenyl-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
367	methyl (6-{2-[2-fluoro-3-(methyloxy)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
368	methyl (5-{1-hydroxy-2-[2-methyl-5-(methyloxy)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
369	methyl {5-[2-(3-ethynyl-2-fluorophenyl)-7-fluoro-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
370	methyl {5-[2-(2-fluoro-3-prop-1-yn-1-ylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
371	methyl {5-[2-(5-chloro-2-methylphenyl)-7-fluoro-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate

No.	Name
372	methyl {5-[2-(3-ethynyl-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
373	3-hydroxy-2-[3-(methyloxy)phenyl]-3-[2-(pyrimidin-2-ylamino)-1H-benzimidazol-6-yl]-2,3-dihydro-1H-isoindol-1-one
374	3-hydroxy-2-(3-methylphenyl)-3-[2-(pyrimidin-2-ylamino)-1H-benzimidazol-6-yl]-2,3-dihydro-1H-isoindol-1-one
375	2-(5-chloro-2-methylphenyl)-3-hydroxy-3-[2-(pyrimidin-2-ylamino)-1H-benzimidazol-6-yl]-2,3-dihydro-1H-isoindol-1-one
376	methyl {6-[2-(5-chloro-2-methylphenyl)-4,7-difluoro-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
377	methyl {5-[2-(3-ethynyl-2-fluorophenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
378	2-(3-chloro-2-fluorophenyl)-3-{2-[(6-chloropyridazin-3-yl)amino]-1H-benzimidazol-5-yl}-3-hydroxy-2,3-dihydro-1H-isoindol-1-one
379	2-(3-chloro-2-fluorophenyl)-4,7-difluoro-3-hydroxy-3-[2-(pyrimidin-2-ylamino)-1H-benzimidazol-5-yl]-2,3-dihydro-1H-isoindol-1-one
380	methyl {5-[2-(2-fluoro-5-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
381	methyl (5-{2-[2-fluoro-5-(methyloxy)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
382	methyl (5-{1-hydroxy-2-[5-methyl-2-(methyloxy)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate
383	methyl {5-[2-(3-ethynyl-5-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
384	2-(3-chloro-2-fluorophenyl)-3-{2-[(5-chloropyrimidin-2-yl)amino]-1H-benzimidazol-5-yl}-3-hydroxy-2,3-dihydro-1H-isoindol-1-one
385	2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-{2-[(4-methylpyrimidin-2-yl)amino]-1H-benzimidazol-5-yl}-2,3-dihydro-1H-isoindol-1-one
386	3-(2-{[4,6-bis(methyloxy)pyrimidin-2-yl]amino}-1H-benzimidazol-5-yl)-2-(3-chloro-2-fluorophenyl)-3-hydroxy-2,3-dihydro-1H-isoindol-1-one
387	2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-(2-{[4-methyl-6-(methyloxy)pyrimidin-2-yl]amino}-1H-benzimidazol-5-yl)-2,3-dihydro-1H-isoindol-1-one

No.	Name
388	3-hydroxy-2-(3-methylphenyl)-3-[2-(pyrazin-2-ylamino)-1H-benzimidazol-6-yl]-2,3-dihydro-1H-isoindol-1-one
389	2-(5-chloro-2-methylphenyl)-3-hydroxy-3-[2-(pyrazin-2-ylamino)-1H-benzimidazol-6-yl]-2,3-dihydro-1H-isoindol-1-one
390	methyl {6-[2-(2-fluoro-3-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate
391	3-hydroxy-2-[3-(methyloxy)phenyl]-3-[2-(pyrazin-2-ylamino)-1H-benzimidazol-5-yl]-2,3-dihydro-1H-isoindol-1-one
392	methyl {6-[(2-{[(2-thienylmethyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
393	methyl {6-[(2-{[(3-methylphenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
394	methyl {6-[(2-{[(3-bromophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
395	methyl {6-[(2-{[(3-chlorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
396	methyl {6-[(2-{[(3-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
397	methyl (6-{[2-({[3-(methyloxy)phenyl]amino}carbonyl)phenyl]carbonyl}-1H-benzimidazol-2-yl)carbamate
398	methyl (6-{[2-({[3-(trifluoromethyl)phenyl]amino}carbonyl)phenyl]carbonyl}-1H-benzimidazol-2-yl)carbamate
399	methyl {6-[(2-{[(3-ethylphenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
400	methyl {6-[(2-{[(3-ethynylphenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
401	methyl {6-[(2-{[(3-chloro-4-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
402	methyl {6-[(2-{[(5-chloro-2-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
403	methyl {6-[(2-{[(3-iodophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate

No.	Name
404	methyl (6-{[2-({[3-(1-methylethyl)phenyl]amino}carbonyl)phenyl]carbonyl}-1H-benzimidazol-2-yl)carbamate
405	methyl {6-[(2-{[(3-thienylmethyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
406	methyl {6-[(2-{[(3-bromo-4-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
407	methyl {6-[(2-{[(3-chloro-2-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
408	methyl {6-[(2-{[(4-fluoro-3-methylphenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
409	methyl {6-[(2-{[(5-bromo-2-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
410	methyl {6-[(2-{[(5-bromo-2,4-difluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
411	methyl {6-[(2-{[(5-chloro-2,4-difluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
412	methyl {6-[(2-{[(3-bromo-2-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
413	methyl {6-[(2-{[(3-ethenylphenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
414	methyl {6-[(2-{[(3-ethynyl-2-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
415	methyl {6-[(2-{[(5-chloro-2-methylphenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
416	methyl {6-[(2-{[(5-bromo-2-methylphenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
417	methyl {6-[(2-{[(2-fluoro-3-iodophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate
418	methyl {6-[(2-{[(3-ethenyl-2-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate

No.	Name
419	methyl {6-[(2-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate

Raf Compound Definitions

[001058] The following definitions apply to the Raf compounds described above only. These definitions are not to be considered when determining the scope and meaning of the JAK-2 compounds. To the same extent, the JAK-2 definitions are not to be considered when determining the scope and meaning of the Raf compounds.

[001059] Chemical Formulae use descriptors such as "R^1" accompanied by a list of Formulae or verbage describing the scope of what is meant by the descriptor. A subsequent descriptor such as "R^{1a}" is used to describe some subset of the scope of R^1, and "R^{1b}" is used to describe another subset of the scope of R^1, and so on. In such subsequent cases, all other Formulae containing simply "R^1" are meant to include the entire scope of the descriptor.

[001060] "Alkyl" is intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof, inclusively. For example, "C_8 alkyl" may refer to an *n*-octyl, *iso*-octyl, cyclohexylethyl, and the like. Lower alkyl refers to alkyl groups of from one to six carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, *s*-butyl, *t*-butyl, isobutyl, pentyl, hexyl and the like. Higher alkyl refers to alkyl groups containing more that eight carbon atoms. Exemplary alkyl groups are those of C_{20} or below. Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of from three to thirteen carbon atoms. Examples of cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbornyl, adamantyl and the like. In this application, alkyl refers to alkanyl, alkenyl, and alkynyl residues (and combinations thereof); it is intended to include cyclohexylmethyl, vinyl, allyl, isoprenyl, and the like. Thus, when an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of *carbons* are intended to be encompassed; thus, for example, either "butyl" or "C_4alkyl" is meant to include *n*-butyl, *sec*-butyl, isobutyl, *t*-butyl, isobutenyl and but-2-yne radicals; and for example, "propyl" or "C_3alkyl" each include *n*-propyl, propenyl, and isopropyl. Otherwise, if alkenyl and/or alkynyl descriptors *are used* in a particular definition of a group, for example "C_4alkyl" along "C_4alkenyl," then C_4alkenyl geometric isomers are not meant to be included in

"C_4alkyl," but other 4-carbon isomers are, for example C_4alkynyl. For example, a more general description, may describe a particular group as "C_{1-8}alkyl" while a preferred species may describe the same group as including, "C_{1-8}alkyl," "C_{1-6}alkenyl" and "C_{1-5}alkynyl."

[001061] "Alkylene" refers to straight or branched chain divalent radical consisting solely of carbon and hydrogen atoms, containing no unsaturation and having from one to ten carbon atoms, for example, methylene, ethylene, propylene, *n*-butylene and the like. Alkylene is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, fully saturated. Examples of alkylene include ethylene ($-CH_2CH_2-$), propylene ($-CH_2CH_2CH_2-$), dimethylpropylene ($-CH_2C(CH_3)_2CH_2-$), and cyclohexylpropylene ($-CH_2CH_2CH(C_6H_{13})$).

[001062] "Alkylidene" refers to a straight or branched chain unsaturated divalent radical consisting solely of carbon and hydrogen atoms, having from two to ten carbon atoms, for example, ethylidene, propylidene, *n*-butylidene, and the like. Alkylidene is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, double bond unsaturation. The unsaturation present includes at least one double bond.

[001063] "Alkylidyne" refers to a straight or branched chain unsaturated divalent radical consisting solely of carbon and hydrogen atoms having from two to ten carbon atoms, for example, propylid-2-ynyl, *n*-butylid-1-ynyl, and the like. Alkylidyne is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, triple bond unsaturation. The unsaturation present includes at least one triple bond.

[001064] Any of the above radicals, "alkylene," "alkylidene" and "alkylidyne," when optionally substituted, may contain alkyl substitution which itself contains unsaturation. For example, 2-(2-phenylethynyl-but-3-enyl)-naphthalene (IUPAC name) contains an *n*-butylid-3-ynyl radical with a vinyl substituent at the 2-position of said radical.

[001065] "Alkoxy" or "alkoxyl" refers to the group -O-alkyl, for example including from one to eight carbon atoms of a straight, branched, cyclic configuration, unsaturated chains, and combinations thereof attached to the parent structure through an oxygen atom. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to six carbons.

[001066] "Substituted alkoxy" refers to the group -O-(substituted alkyl), the substitution on the alkyl group generally containing more than only carbon (as defined by alkoxy). One exemplary substituted alkoxy group is "polyalkoxy" or -O-optionally substituted alkylene-optionally substituted alkoxy, and includes groups such as $-OCH_2CH_2OCH_3$, and glycol ethers such as polyethyleneglycol and $-O(CH_2CH_2O)_xCH_3$, where x is an integer of between about two and about twenty, in another example, between about two and about ten, and in a further example between about two and about five. Another exemplary substituted alkoxy group is hydroxyalkoxy or $-OCH_2(CH_2)_yOH$, where y is for example an integer of between about one and about ten, in another example y is an integer of between about one and about four.

[001067] "Acyl" refers to groups of from one to ten carbon atoms of a straight, branched, cyclic configuration, saturated, unsaturated and aromatic and combinations thereof, attached to the parent structure through a carbonyl functionality. One or more carbons in the acyl residue may be replaced by nitrogen, oxygen or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples include acetyl, benzoyl, propionyl, isobutyryl, *t*-butoxycarbonyl, benzyloxycarbonyl and the like. Lower-acyl refers to groups containing one to six carbons.

[001068] "α-Amino Acids" refer to naturally occurring and commercially available amino acids and optical isomers thereof. Typical natural and commercially available α-amino acids are glycine, alanine, serine, homoserine, threonine, valine, norvaline, leucine, isoleucine, norleucine, aspartic acid, glutamic acid, lysine, omithine, histidine, arginine, cysteine, homocysteine, methionine, phenylalanine, homophenylalanine, phenylglycine, ortho-tyrosine, meta-tyrosine, para-tyrosine, tryptophan, glutamine, asparagine, proline and hydroxyproline. A "side chain of an α-amino acid" refers to the radical found on the α-carbon of an α-amino acid as defined above, for example, hydrogen (for glycine), methyl (for alanine), benzyl (for phenylalanine), and the like.

[001069] "Amino" refers to the group $-NH_2$. "Substituted amino," refers to the group -N(H)R or –N(R)R where each R is independently selected from the group: optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heterocyclyl, acyl, carboxy, alkoxycarbonyl, sulfanyl, sulfinyl and sulfonyl, for example, diethylamino, methylsulfonylamino, and furanyl-oxy-sulfonamino.

[001070] "Aryl" refers to aromatic six- to fourteen-membered carbocyclic ring, for example, benzene, naphthalene, indane, tetralin, fluorene and the like, univalent radicals.

As univalent radicals, the aforementioned ring examples are named, phenyl, naphthyl, indanyl, tetralinyl, and fluorenyl.

[001071] "Arylene" generically refers to any aryl that has at least two non-hydrogen groups attached thereto. For a more specific example, "phenylene" refers to a divalent phenyl ring radical. A phenylene, thus may have more than two groups attached, but is defined by a minimum of two non-hydrogen groups attached thereto. The terms "ortho-arylene," "meta-arylene" or "para-arylene" refer to geometrical isomers of a particular arylene wherein, two groups attached to an aryl as depicted in a Formula are situated in an ortho, meta or para geometrical relationship about the aryl, respectively.

[001072] Arylalkyl" refers to a residue in which an aryl moiety is attached to a parent structure via one of an alkylene, alkylidene, or alkylidyne radical. Examples include benzyl, phenethyl, phenylvinyl, phenylallyl and the like. Both the aryl, and the corresponding alkylene, alkylidene, or alkylidyne radical portion of an arylalkyl group may be optionally substituted. "Lower arylalkyl" refers to an arylalkyl where the "alkyl" portion of the group has one to six carbons; this can also be refered to as aryl C_{1-6}alkyl.

[001073] "Exo-alkenyl" refers to a double bond that emanates from an annular carbon, and is not within the ring system, for example the double bond depicted in the Formula below.



[001074] In some examples, as appreciated by one of ordinary skill in the art, two adjacent groups on an aromatic system may be fused together to form a ring structure. The fused ring structure may contain heteroatoms and may be optionally substituted with one or more groups. It should additionally be noted that saturated carbons of such fused groups (i.e. saturated ring structures) can contain two substitution groups.

[001075] "Fused-polycyclic" or "fused ring system" refers to a polycyclic ring system that contains bridged or fused rings; that is, where two rings have more than one shared atom in their ring structures. In this application, fused-polycyclics and fused ring systems are not necessarily all aromatic ring systems. Typically, but not necessarily, fused-polycyclics share a vicinal set of atoms, for example naphthalene or 1,2,3,4-tetrahydro-naphthalene. A spiro ring system is not a fused-polycyclic by this definition,

but fused polycyclic ring systems may themselves have spiro rings attached thereto via a single ring atom of the fused-polycyclic.

[001076] "Halogen" or "halo" refers to fluorine, chlorine, bromine or iodine. "Haloalkyl" and "haloaryl" refer generically to alkyl and aryl radicals that are substituted with one or more halogens, respectively. Thus, "dihaloaryl," "dihaloalkyl," "trihaloaryl" etc. refer to aryl and alkyl substituted with a plurality of halogens, but not necessarily a plurality of the same halogen; thus 4-chloro-3-fluorophenyl is within the scope of dihaloaryl.

[001077] "Heteroarylene" generically refers to any heteroaryl that has at least two groups attached thereto. For a more specific example, "pyridylene" refers to a divalent pyridyl ring radical. A pyridylene, thus may have more than two groups attached, but is defined by a minimum of two non-hydrogen groups attached thereto. For the purposes of this application, the term "ortho-heteroarylene" refers to a geometrical isomer of a particular heteroarylene wherein two groups attached to a heteroaryl as depicted in a Formula are situated on contiguous atoms of the heteroaryl.

[001078] "Heteroatom" refers to O, S, N, or P.

[001079] "Heterocyclyl" refers to a stable three- to fifteen-membered ring radical that consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, phosphorus, oxygen and sulfur. The heterocyclyl radical may be a monocyclic, bicyclic or tricyclic ring system, which may include fused or bridged ring systems as well as spirocyclic systems; and the nitrogen, phosphorus, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized to various oxidation states. In a specific example, the group $-S(O)_{0-2}-$, refers to -S- (sulfide), -S(O)- (sulfoxide), and $-SO_2-$ (sulfone). For convenience, nitrogens, particularly but not exclusively, those defined as annular aromatic nitrogens, are meant to include their corresponding *N*-oxide form, although not explicitly defined as such in a particular example. Thus, for a Raf compound having, for example, a pyridyl ring; the corresponding pyridyl-*N*-oxide is meant to be included as another Raf compound of the invention. In addition, annular nitrogen atoms may be optionally quaternized; and the ring radical may be partially or fully saturated or aromatic. Examples of heterocyclyl radicals include, but are not limited to, azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofuranyl, carbazoyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, quinazolinyl,

quinoxalinyl, quinolinyl, isoquinolinyl, tetrazoyl, tetrahydroisoquinolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, dihydropyridinyl, tetrahydropyridinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolinyl, oxazolidinyl, triazolyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl, quinolyl, isoquinolyl, decahydroisoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothieliyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, dioxaphospholanyl, and oxadiazolyl.

[001080] "Heteroalicyclic" refers specifically to a non-aromatic heterocyclyl radical. A heteroalicyclic may contain unsaturation, but is not aromatic.

[001081] "Heteroaryl" refers specifically to an aromatic heterocyclyl radical.

[001082] "Heterocyclylalkyl" refers to a residue in which a heterocyclyl is attached to a parent structure via one of an alkylene, alkylidene, or alkylidyne radical. Examples include (4-methylpiperazin-1-yl) methyl, (morpholin-4-yl) methyl, (pyridine-4-yl) methyl, 2-(oxazolin-2-yl) ethyl, 4-(4-methylpiperazin-1-yl)-2-butenyl, and the like. Both the heterocyclyl, and the corresponding alkylene, alkylidene, or alkylidyne radical portion of a heterocyclylalkyl group may be optionally substituted. "Lower heterocyclylalkyl" refers to a heterocyclylalkyl where the "alkyl" portion of the group has one to six carbons. "Heteroalicyclylalkyl" refers specifically to a heterocyclylalkyl where the heterocyclyl portion of the group is non-aromatic; and "heteroarylalkyl" refers specifically to a heterocyclylalkyl where the heterocyclyl portion of the group is aromatic Such terms may be described in more than one way, for example, "lower heterocyclylalkyl" and "heterocyclyl C_{1-6}alkyl" are equivalent terms.

[001083] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. One of ordinary skill in the art would understand that, with respect to any molecule described as containing one or more optional substituents, that only sterically practical and/or synthetically feasible compounds are meant to be included. "Optionally substituted" refers to all subsequent modifiers in a term, for example in the term "optionally

substituted aryl C_{1-8}alkyl," optional substitution may occur on both the "C_{1-8}alkyl" portion and the "aryl" portion of the molecule; and for example, optionally substituted alkyl includes optionally substituted cycloalkyl groups. But where a first optionally substituted group can be substituted by a second optionally substituted group, the second substituent cannot be further substituted. A list of exemplary optional substitutions is included below in the definition of "substituted."

[001084] Unlesss otherwise specified, the term "optionally substituted" applies to the chemical moiety immediately preceding it. For instance, if a variable group (such as R) is defined as aryl, optionally substituted alkyl, or cycloalkyl, then only the alkyl group is optionally substituted.

[001085] "Saturated bridged ring system" refers to a bicyclic or polycyclic ring system that is not aromatic. Such a system may contain isolated or conjugated unsaturation, but not aromatic or heteroaromatic rings in its core structure (but may have aromatic substitution thereon). For example, hexahydro-furo[3,2-b]furan, 2,3,3a,4,7,7a-hexahydro-1H-indene, 7-aza-bicyclo[2.2.1]heptane, and 1,2,3,4,4a,5,8,8a-octahydro-naphthalene are all included in the class "saturated bridged ring system.

[001086] "Substituted" alkyl, aryl, and heterocyclyl, refer respectively to alkyl, aryl, and heterocyclyl, wherein one or more (for example up to about five, in another example, up to about three) hydrogen atoms are replaced by a substituent independently selected from: optionally substituted alkyl (for example, fluoromethyl, hydroxypropyl, nitromethyl, aminoethyl and the like.), optionally substituted aryl (for example, 4-hydroxyphenyl, 2,3-difluorophenyl, and the like), optionally substituted arylalkyl (for example, 1-phenyl-ethyl, *para*-methoxyphenylethyl and the like), optionally substituted heterocyclylalkyl (for example, 1-pyridin-3-yl-ethyl, N-ethylmorphonlino and the like), optionally substituted heterocyclyl (for example, 5-chloro-pyridin-3-yl, 1-methyl-piperidin-4-yl and the like), optionally substituted alkoxy (for example methoxyethoxy, hydroxypropyloxy, methylenedioxy and the like), optionally substituted amino (for example, methylamino, diethylamino, trifluoroacetylamino and the like), optionally substituted amidino, optionally substituted aryloxy (for example, phenoxy, *para*-chlorophenoxy, *meta*-aminophenoxy, *para*-phenoxyphenoxy and the like), optionally substituted arylalkyloxy (for example, benzyloxy, 3-chlorobenzyloxy, *meta*-phenoxybenzyloxy and the like), carboxy (-CO_2H), optionally substituted carboalkoxy (that is, acyloxy or -OC(=O)R), optionally substituted carboxyalkyl (that is, esters or

-CO_2R), optionally substituted carboxamido, optionally substituted benzyloxycarbonylamino (CBZ-amino), cyano, optionally substituted acyl, halogen, hydroxy, nitro, optionally substituted alkylsulfanyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, thiol, oxo, carbamyl, optionally substituted acylamino, optionally substituted hydrazino, optionally substituted hydroxylamino, and optionally substituted sulfonamido.

[001087] "Sulfanyl" refers to the groups: -S-(optionally substituted alkyl), -S-(optionally substituted aryl), and -S-(optionally substituted heterocyclyl).

[001088] "Sulfinyl" refers to the groups: -S(O)-H, -S(O)-(optionally substituted alkyl), -S(O)-optionally substituted aryl), and -S(O)-(optionally substituted heterocyclyl).

[001089] "Sulfonyl" refers to the groups: -$S(O_2)$-H, -$S(O_2)$-(optionally substituted alkyl), -$S(O_2)$-optionally substituted aryl), -$S(O_2)$-(optionally substituted heterocyclyl), -$S(O_2)$-(optionally substituted alkoxy), -$S(O_2)$-optionally substituted aryloxy), and -$S(O_2)$-(optionally substituted heterocyclyloxy).

[001090] Some of the Raf compounds described herein may have imino, amino, oxo or hydroxy substituents off aromatic heterocyclyl systems. For purposes of this disclosure, it is understood that such imino, amino, oxo or hydroxy substituents may exist in their corresponding tautomeric form, i.e., amino, imino, hydroxy or oxo, respectively.

Synthetic Procedures for Raf Compounds

[001091] Raf compounds of Formula I(R), II(R), III(R), IV(R)a, IV(R)b, V(R), VI(R), VII(R), VIII(R), IX(R), X(R)a, X(R)b, XI(R), XII(R), and XIII(R) can be made by the synthetic schemes and examples described in publication WO 2005/112932, which is incorporated herein by reference in its entirety. The utility of these compounds are also described in WO 2005/112932.

[001092] The Raf compounds described herein and their pharmaceutically acceptable salts can exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. The compounds can also exist as geometric isomers. All such single stereoisomers, racemates and mixtures thereof, and geometric isomers are intended to be within the scope of the Raf compounds described herein.

[001093] It is assumed that when considering generic descriptions of Raf compounds for the purpose of constructing a compound, such construction results in the creation of a

stable structure. That is, one of ordinary skill in the art would recognize that theoretically some constructs which would not normally be considered as stable compounds (that is, sterically practical and/or synthetically feasible, *supra*).

[001094] Methods for the preparation and/or separation and isolation of single stereoisomers from racemic mixtures or non-racemic mixtures of stereoisomers are well known in the art. For example, optically active (R)- and (S)- isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. Enantiomers (R- and S-isomers) can be resolved by methods known to one of ordinary skill in the art, for example by: formation of diastereoisomeric salts or complexes which can be separated, for example, by crystallization; via formation of diastereoisomeric derivatives which can be separated, for example, by crystallization, selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where a desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step can be required to liberate the desired enantiomeric form. Alternatively, specific enantiomer can be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents or by converting on enantiomer to the other by asymmetric transformation. For a mixture of enantiomers, enriched in a particular enantiomer, the major component enantiomer can be further enriched (with concomitant loss in yield) by recrystallization.

[001095] In addition, the Raf compounds can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the Raf compounds described herein.

[001096] In addition, it is intended that the Raf compounds are made either using standard organic synthetic techniques, including combinatorial chemistry or by biological methods, such as bacterial digestion, metabolism, enzymatic conversion, and the like.

Pharmaceutical Composition Examples

[001097] The following are representative pharmaceutical Formulations containing a Raf compound, such as, for example, a Raf compound of Formula I(R), II(R), III(R), IV(R)a, IV(R)b, V(R), VI(R), VII(R), VIII(R), IX(R), X(R)a, X(R)b, XI(R), XII(R), or XIII(R).

Tablet Formulation

[001098] The following ingredients are mixed intimately and pressed into single scored tablets.

Ingredient	Quantity per tablet, mg
Raf compound	400
Cornstarch	50
croscarmellose sodium	25
Lactose	120
magnesium stearate	5

Capsule Formulation

[001099] The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.

Ingredient	Quantity per tablet, mg
Raf compound	200
lactose, spray-dried	148
magnesium stearate	2

Suspension Formulation

[001100] The following ingredients are mixed to form a suspension for oral administration.

Ingredient	Amount
Raf compound	1.0 g
fumaric acid	0.5 g
sodium chloride	2.0 g
methyl paraben	0.15 g
propyl paraben	0.05 g
granulated sugar	25.5 g
sorbitol (70% solution)	12.85 g
Veegum K (Vanderbilt Co.)	1.0 g
Flavoring	0.035 mL
Colorings	0.5 mg
distilled water	q.s. to 100 mL

Injectable Formulation

[001101] The following ingredients are mixed to form an injectable Formulation.

Ingredient	Amount
Raf compound	1.2 g
sodium acetate buffer solution	0.4 M 2.0 mL
HCl (1 N) or NaOH (1 M)	q.s. to suitable pH
water (distilled, sterile)	q.s.to 20 mL

[001102] All of the above ingredients, except water, are combined and heated to 60-70° C with stirring. A sufficient quantity of water at 60° C is then added with vigorous stirring to emulsify the ingredients, and water then added q.s. to 100 g.

Suppository Formulation

[001103] A suppository of total weight 2.5 g is prepared by mixing the compound of the invention with Witepsol®. H-15 (triglycerides of saturated vegetable fatty acid; Riches-Nelson, Inc., New York), and has the following composition:

Ingredient	Quantity per tablet, mg
Raf compound	500
Witepsol® H-15	Balance

[001104] Aspect (35) relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), and a pharmaceutically acceptable carrier, in combination with a therapeutically effective amount of a Raf compound of Formula I(R), II(R), III(R), IV(R)a, IV(R)b, V(R), VI(R), VII(R), VIII(R), IX(R), X(R)a, X(R)b, XI(R), XII(R), or XIII(R) or a pharmaceutical composition comprising a therapeutically effective amount of the Raf compound of Formula I(R), II(R), III(R), IV(R)a, IV(R)b, V(R), VI(R), VII(R), VIII(R), IX(R), X(R)a, X(R)b, XI(R), XII(R), or XIII(R), and a pharmaceutically acceptable carrier, wherein the mammal is in need of the treatment.

[001105] In other embodiments of aspect (12), aspect (27), and aspect (35) of this invention, R^2 of Formula I(J) is



(f)

[001106] In other embodiments of aspect (12), aspect (27), and aspect (35) of this invention, R^2 of Formula I(J) is



(a) (b)

wherein R^{28a} is selected from lower alkyl, dialkylaminoalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, and hetercycloalkylalkyl.

[001107] In other embodiments of aspect (12), aspect (27), and aspect (35) of this invention, R^2 of Formula I(J) is



(g) (e)

[001108] In other embodiments of aspect (12), aspect (27), and aspect (35) of this invention, L of Formula I(J) is a bond, Z is  , R^{25} is hydrogen and E and D are hydrogen.

[001109] In other embodiments of aspect (12), aspect (27), and aspect (35) of this invention, Z of Formula I(J) is  , R^{26a} is $-C(O)R^{32}$, R^{26} is hydrogen, and R^{32} is selected from tetrahydrofuran, pyrrolidinyl or pryimidinyl, wherein R^{32} is optionally substituted with 1, 2, 3, 4 or 5 groups selected from hydroxyl, oxo, alkyl, alkoxy, amino, hydroxyalkyl and halo.

[001110] In other embodiments of aspect (12), aspect (27), and aspect (35) of this invention, R^2 of Formula I(J) is  .

[001111] In other embodiments of aspect (12), aspect (27), and aspect (35) of this invention, R^{32} of Formula I(J) is U or $-CH_2$-U, wherein U is selected from pyrolidinyl, thiazolidinyl, morpholinyl, azetidinyl, cyclobutyl, cyclopropyl, tetrahydofuranyl, pyrazinyl, imidazolyl, piperazinyl, thienyl, thienylmethyl, furanyl, phenyl, prolinamidyl, pyridinyl, tetrahydronaphthalene, tetrazolyl, isoindolinyl, pyranyl, cyclopentyl, and octahydro-1H-indolyl.

[001112] In other embodiments of aspect (12), aspect (27), and aspect (35) of this invention, R^{11} of Formula I(J), when present, is halo or lower alkyl.

[001113] In other embodiments of aspect (12), aspect (27), and aspect (35) of this invention, R^{35} of Formula I(J) is heterocycloalkylalkyl, wherein the heterocyloalkyl is selected from piperazinyl, piperidinyl, morpholinyl and dioxanyl.

[001114] In other embodiments of aspect (12), aspect (27), and aspect (35) of this invention, n2 of Formula I(J) is 0.

[001115] In other embodiments of aspect (12), aspect (27), and aspect (35) of this invention, R^2 of Formula I(J) is  , and wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl.

[001116] In other embodiments of aspect (12), aspect (27), and aspect (35) of this invention, the JAK-2 compound has Formula IV(J):



wherein and R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

[001117] In other embodiments of aspect (12), aspect (27), and aspect (35) of this invention, the JAK-2 compound has Formula V(J):



V(J)

wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

[001118] In other embodiments of aspect (12), aspect (27), and aspect (35) of this invention, the JAK-2 compound has Formula VI(J):



VI(J)

wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

Akt Compounds

[001119] The Akt compounds described below regulate and/or modulate the signal transduction of protein kinases, such as Akt kinase and the enzyme p70S6K (a serine-theoronine kinase that is a component of the phosphatidylinositol 3 kinase (PI3K)/Akt kinase (AktK) pathway). In another embodiment of the methods described herein, the JAK-2 compounds described hereinabove [e.g., compounds of Formula I(J), II(J), III(J), IV(J), V(J), VI(J), and VII(J)] can be combined with any of the Akt inhibitors known in the art. The Akt compounds described below are non-limiting examples of "Akt" or "p70S6K" inhibitors" that fall within the scope of aspect (3) of this invention.

[001120] Representative Akt compounds, or pharmaceutically acceptable salts thereof, are depicted below in Table A2. The Akt compounds below fall within the scope of aspect (18) of this invention. These Akt compounds are merely illustrative and do not limit the scope of the Akt compounds or Akt/p70S6 inhibitors in any way

5

Table A2

No.	**Name**
1	3-(azetidin-3-ylidenemethyl)-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
2	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-fluoropyridin-4-yl)-1H-pyrazolo[3,4-d]pyrimidine
3	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-chloropyridin-4-yl)-1H-pyrazolo[3,4-d]pyrimidine
4	2-({5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}oxy)-N,N-dimethylethanamine
5	2-({5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}oxy)-N,N-diethylethanamine
6	4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
7	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-piperazin-1-yl-1H-pyrazolo[3,4-d]pyrimidine
8	N-(3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-yn-1-yl)acetamide
9	N,N-diethyl-2-({3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}oxy)ethanamine
10	3-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}-N,N-diethylpropan-1-amine
11	3-bromo-4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
12	3-bromo-4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
13	2-({3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}oxy)-N,N-diethylethanamine
14	4-[4-(5-chloro-2-methyl-3-{[2-(1-methylpiperidin-4-yl)ethyl]oxy}phenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
15	5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
16	4-(4-{5-chloro-2-methyl-3-[(2-morpholin-4-ylethyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
17	4-(4-{5-chloro-2-methyl-3-[(2-piperidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
18	3-bromo-4-{4-[5-chloro-2-methyl-3-(3-morpholin-4-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
19	3-bromo-4-(4-{5-chloro-2-methyl-3-[3-(4-methylpiperazin-1-yl)propyl]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
20	3-bromo-4-(4-{5-chloro-2-methyl-3-[(2-piperidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine

No.	**Name**
21	3-bromo-4-(4-{5-chloro-2-methyl-3-[(2-morpholin-4-ylethyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
22	4-{4-[5-chloro-2-methyl-3-(3-morpholin-4-ylpropyl)phenyl]piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
23	N'-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N,N-diethylethane-1,2-diamine
24	4-{4-[5-chloro-2-methyl-3-(3-piperidin-1-ylpropyl)phenyl]piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
25	4-[4-(5-chloro-3-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-2-methylphenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
26	4-(4-{5-chloro-2-methyl-3-[(3-morpholin-4-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
27	3-bromo-4-{4-[5-chloro-2-methyl-3-(3-piperidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
28	N'-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}-N,N-diethylethane-1,2-diamine
29	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
30	4-[4-(5-chloro-2-methyl-3-{[2-(4-methylpiperazin-1-yl)ethyl]oxy}phenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
31	4-[4-(5-chloro-2-methyl-3-{[(1-methylpiperidin-4-yl)methyl]oxy}phenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
32	N,N-diethyl-2-({3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}oxy)ethanamine
33	2-[(5-chloro-3-{4-[1-(1,1-dimethylethyl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}-2-methylphenyl)oxy]-N,N-diethylethanamine
34	2-[(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)oxy]-N,N-diethylethanamine
35	4-(4-{5-chloro-2-methyl-3-[(3-pyrrolidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
36	4-[4-(5-chloro-2-methyl-3-{[3-(4-methylpiperazin-1-yl)propyl]oxy}phenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
37	3-bromo-4-(4-{5-chloro-2-methyl-3-[(3-piperidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
38	3-bromo-4-(4-{5-chloro-2-methyl-3-[(3-morpholin-4-ylpropyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
39	4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine
40	4-(4-{5-chloro-2-methyl-3-[(3-morpholin-4-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine
41	4-(4-{5-chloro-2-methyl-3-[(2-morpholin-4-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine
42	4-(4-{5-chloro-2-methyl-3-[(3-piperidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
43	4-[4-(5-chloro-3-{[3-(4-ethylpiperazin-1-yl)propyl]oxy}-2-methylphenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
44	5-chloro-2-methyl-3-[4-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-(2-pyrrolidin-1-ylethyl)aniline
45	5-chloro-2-methyl-3-[4-(3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-(2-pyrrolidin-1-ylethyl)aniline

No.	Name
46	N'-(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)-N,N-dimethylethane-1,2-diamine
47	3-({5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}oxy)-N,N-diethylpropan-1-amine
48	N'-(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)-N,N-diethylethane-1,2-diamine
49	5-chloro-2-methyl-N-(2-pyrrolidin-1-ylethyl)-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}aniline
50	3-bromo-4-(4-{4-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
51	4-(4-{4-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
52	3-methyl-4-(4-{4-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
53	4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
54	4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-methyl-1H-pyrazolo[3,4-d]pyrimidine
55	4-(4-{5-chloro-2-methyl-3-[(2-piperidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine
56	3-[(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)oxy]-N,N-diethylpropan-1-amine
57	5-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
58	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-fluoro-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
59	4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
60	3-bromo-4-{4-[5-fluoro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
61	4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine
62	4-(4-{5-chloro-2-methyl-3-[3-(4-methylpiperazin-1-yl)propyl]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
63	3-bromo-4-(4-pyridin-2-ylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
64	3-bromo-4-[4-(2,4-dimethylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
65	3-bromo-4-{4-[3-(methyloxy)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
66	3-bromo-4-{4-[2-(methyloxy)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
67	3-bromo-4-{4-[4-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
68	4-(4-{5-chloro-2-methyl-3-[(3-pyrrolidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine
69	4-(4-{5-chloro-2-methyl-3-[(3-piperidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine
70	4-[4-(5-chloro-2-methyl-3-{[3-(4-methylpiperazin-1-yl)propyl]oxy}phenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine
71	4-[4-(5-chloro-3-{[3-(4-ethylpiperazin-1-yl)propyl]oxy}-2-methylphenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine
72	3-bromo-4-[4-(5-chloro-2-methyl-3-{[2-(4-methylpiperazin-1-yl)ethyl]oxy}phenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine

No.	**Name**
73	4-[4-(5-chloro-2-methyl-3-{[2-(4-methylpiperazin-1-yl)ethyl]oxy}phenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine
74	3-bromo-4-[4-(5-chloro-3-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
75	3-bromo-4-[4-(3,4-dichlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
76	3-bromo-4-[4-(3,4-difluorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
77	3-bromo-4-[4-(2,4-dichlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
78	3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-fluoro-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
79	5-fluoro-2-methyl-N-(2-pyrrolidin-1-ylethyl)-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}aniline
80	4-{4-[3,5-bis(methyloxy)phenyl]piperazin-1-yl}-3-bromo-1H-pyrazolo[3,4-d]pyrimidine
81	4-[4-(5-chloro-3-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-2-methylphenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine
82	N-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N,N',N'-trimethylethane-1,2-diamine
83	3-({3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}oxy)-N,N-diethylpropan-1-amine
84	3-bromo-4-(4-{5-chloro-2-methyl-3-[(3-pyrrolidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
85	3-bromo-4-[4-(5-chloro-2-methyl-3-{[3-(4-methylpiperazin-1-yl)propyl]oxy}phenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
86	3-bromo-4-[4-(5-chloro-3-{[3-(4-ethylpiperazin-1-yl)propyl]oxy}-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
87	3-(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)-N,N-diethylpropan-1-amine
88	3-bromo-4-[4-(5-chloro-2-methyl-3-{[(1-methylpiperidin-4-yl)methyl]oxy}phenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
89	3-bromo-4-[4-(5-chloro-2-methyl-3-{[2-(1-methylpiperidin-4-yl)ethyl]oxy}phenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
90	4-[4-(5-chloro-2-methyl-3-{[(1-methylpiperidin-4-yl)methyl]oxy}phenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine
91	4-[4-(5-chloro-2-methyl-3-{[2-(1-methylpiperidin-4-yl)ethyl]oxy}phenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine
92	4-(4-{5-chloro-2-methyl-3-[3-(4-methylpiperazin-1-yl)propyl]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine
93	3-bromo-4-[4-(3-chloro-4-fluorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
94	1-{4-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}ethanone
95	3-bromo-4-[4-(2,5-dichlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
96	3-bromo-4-[4-(3,4-dimethylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
97	3-bromo-4-[4-(4-nitrophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
98	3-ethyl-4-(4-phenylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
99	3-ethyl-4-{4-[3-(methyloxy)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
100	4-{4-[5-chloro-2-methyl-3-(3-piperidin-1-ylpropyl)phenyl]piperazin-1-yl}-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine
101	4-[4-(3,6-dimethylpyrazin-2-yl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
102	1-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]isoquinoline

No.	Name
103	3-bromo-4-[4-(2,6-dimethylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
104	3-bromo-4-{4-[4-(ethyloxy)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
105	3-bromo-4-[4-(2-ethylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
106	4-{4-[2,4-bis(methyloxy)phenyl]piperazin-1-yl}-3-bromo-1H-pyrazolo[3,4-d]pyrimidine
107	3-bromo-4-(4-pyrazin-2-ylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
108	3-bromo-4-(4-pyrimidin-2-ylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
109	4-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(trifluoromethyl)quinoline
110	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyrazine-2-carbonitrile
111	4-[4-(4,6-dimethylpyrimidin-2-yl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
112	ethyl 4-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(trifluoromethyl)pyrimidine-5-carboxylate
113	4-{4-[3-chloro-5-(methyloxy)phenyl]piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
114	4-[4-(3-bromo-2-chloro-5-fluorophenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
115	2-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyridine-3-carboxamide
116	3-ethyl-4-{4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
117	3-bromo-4-{4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
118	3-bromo-4-{4-[4-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
119	2-({3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyrazin-2-yl}oxy)-N,N-dimethylethanamine
120	4-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylquinoline
121	3-bromo-4-[4-(2-nitrophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
122	2-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]benzonitrile
123	4-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]benzonitrile
124	3-bromo-4-{4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
125	3-bromo-4-(4-{4-[(phenylmethyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
126	4-{4-[5-chloro-2-methyl-3-(methyloxy)phenyl]piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
127	2-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyridine-3-carbonitrile
128	3-bromo-4-[4-(3,5-dichlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
129	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-chloro-5-fluoro-N-(2-pyrrolidin-1-ylethyl)aniline
130	2-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-fluoro-N-(2-pyrrolidin-1-ylethyl)aniline
131	3-bromo-4-[4-(2,5-difluorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
132	4-[4-(2,5-difluorophenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
133	3-bromo-4-{4-[3-(methyloxy)pyrazin-2-yl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
134	3-bromo-4-[4-(3-chlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine

No.	Name
135	3-bromo-4-{4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
136	3-bromo-4-{4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
137	4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidine
138	5-chloro-2-methyl-3-{4-[3-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}-N-(2-pyrrolidin-1-ylethyl)aniline
139	2-({3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}oxy)-N-ethylacetamide
140	2-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,N-diethylpyrimidin-4-amine
141	3-bromo-4-[4-(3-{[(3-methylphenyl)methyl]oxy}phenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
142	3-bromo-4-(4-{3-[(2-piperidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
143	3-bromo-4-[4-(4-furan-2-ylpyrimidin-2-yl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
144	6-{2-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyrimidin-4-yl}-2H-1,4-benzoxazin-3(4H)-one
145	3-ethyl-4-{4-[2-methyl-3-(methyloxy)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
146	N'-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N-methyl-N-(1-methylethyl)ethane-1,2-diamine
147	N'-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N-ethyl-N-methylethane-1,2-diamine
148	N'-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}-N,N-dimethylethane-1,2-diamine
149	3-({6-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-chloro-5-methylpyrimidin-4-yl}oxy)-N,N-diethylpropan-1-amine
150	3-bromo-4-[4-(2,3-dichlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
151	3-bromo-4-{4-[2-(trifluoromethyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
152	3-bromo-4-(4-phenylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
153	3-bromo-4-[4-(4-fluorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
154	3-bromo-4-[4-(4-chlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
155	3-bromo-4-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
156	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-6-amine
157	3-bromo-4-[4-(4-bromophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
158	3-bromo-4-[3-methyl-4-(3-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
159	4-[4-(3-bromo-5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-6-amine
160	4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-cyclopropyl-1H-pyrazolo[3,4-d]pyrimidine
161	5-chloro-3-[4-(3-cyclopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
162	5-chloro-2-methyl-3-{4-[3-(2-methylpropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}-N-(2-pyrrolidin-1-ylethyl)aniline

No.	Name
163	4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(2-methylpropyl)-1H-pyrazolo[3,4-d]pyrimidine
164	3-bromo-4-[(3S)-4-(5-chloro-2-methylphenyl)-3-methylpiperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
165	5-bromo-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylaniline
166	2-({3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}oxy)-N-cyclopropylacetamide
167	3-bromo-4-(4-{3-[(2-piperidin-1-ylethyl)oxy]pyrazin-2-yl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
168	4-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-6,7-bis(methyloxy)quinazoline
169	2-({3-chloro-5-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}oxy)-N,N-diethylethanamine
170	4-{4-[2-chloro-5-(trifluoromethyl)phenyl]piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
171	3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(2-methylpropyl)oxy]-N-(2-pyrrolidin-1-ylethyl)aniline
172	3-({4-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-6-chloro-5-methylpyrimidin-2-yl}oxy)-N,N-diethylpropan-1-amine
173	3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(phenylmethyl)oxy]-N-(2-pyrrolidin-1-ylethyl)aniline
174	3-bromo-4-[(3R)-4-(5-chloro-2-methylphenyl)-3-methylpiperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
175	3-[(2S)-4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-methylpiperazin-1-yl]-4-methyl-N-phenylbenzamide
176	3-[(2S)-4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-methylpiperazin-1-yl]-4-methyl-N-(phenylmethyl)benzamide
177	methyl 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylbenzoate
178	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylbenzoic acid
179	(2E)-3-(4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidin-3-yl)prop-2-enoic acid
180	3-(4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidin-3-yl)prop-2-yn-1-ol
181	4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-(5-chloro-2-methylphenyl)piperazin-2-one
182	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(2-methylpropyl)oxy]-N-(2-pyrrolidin-1-ylethyl)aniline
183	N'-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(2-methylpropyl)oxy]phenyl}-N,N-diethylethane-1,2-diamine
184	methyl 3-bromo-5-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylbenzoate
185	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-phenylbenzamide
186	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,4-dimethylbenzamide
187	2-({3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}oxy)-N,N-diethylethanamine

No.	Name
188	methyl 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzoate
189	3-bromo-5-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-phenylbenzamide
190	3-bromo-5-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-phenylbenzamide
191	N'-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}-N-methyl-N-(1-methylethyl)ethane-1,2-diamine
192	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-phenyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide
193	N'-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(2-methylpropyl)oxy]phenyl}-N,N-dimethylethane-1,2-diamine
194	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,N,4-trimethylbenzamide
195	3-[4-(3-chloro-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-(2-methylpropyl)benzamide
196	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,N,4-trimethyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide
197	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-oxopiperazin-1-yl]-4-methyl-N-phenylbenzamide
198	3-[(2R)-4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-(hydroxymethyl)piperazin-1-yl]-4-methyl-N-phenylbenzamide
199	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(pyrrolidin-1-ylcarbonyl)-N-(2-pyrrolidin-1-ylethyl)aniline
200	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,4-dimethyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide
201	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-(4-chlorophenyl)-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide
202	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-(2-chlorophenyl)-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide
203	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(cyclopropylmethyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
204	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(3-methylbutyl)oxy]-N-(2-pyrrolidin-1-ylethyl)aniline
205	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2-ethylbutyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
206	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(butyloxy)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
207	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-(1-methylethyl)-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide
208	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,4-dimethyl-N-(1-methylethyl)-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide
209	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(cyclobutylmethyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
210	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(ethyloxy)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
211	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-[2-(dimethylamino)ethyl]-4-methylbenzamide
212	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-(1,1-dimethylethyl)-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide

No.	Name
213	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-pyridin-3-yl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide
214	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2-fluoro-2-methylpropyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
215	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(cyclohexylmethyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
216	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(cyclopentylmethyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
217	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-ethyl-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide
218	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(1-methylethyl)oxy]-N-(2-pyrrolidin-1-ylethyl)aniline
219	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2,2-dimethylpropyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
220	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[(tetrahydrofuran-2-ylmethyl)oxy]aniline
221	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-{[2-(methyloxy)ethyl]oxy}-N-(2-pyrrolidin-1-ylethyl)aniline
222	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(propyloxy)-N-(2-pyrrolidin-1-ylethyl)aniline
223	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-{[2-(dimethylamino)ethyl]amino}-4-methyl-N-phenylbenzamide
224	N'-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2-fluoro-2-methylpropyl)oxy]-2-methylphenyl}-N,N-dimethylethane-1,2-diamine
225	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-{[2-(dimethylamino)ethyl]amino}-4-methyl-N-(1-methylethyl)benzamide
226	1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}pentan-1-one
227	N'-(3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methylphenyl)-N,N-dimethylethane-1,2-diamine
228	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
229	5-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-(2-pyrrolidin-1-ylethyl)biphenyl-3-amine
230	1-(3-{5-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylbiphenyl-3-yl}propyl)pyridinium
231	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-(1,3-thiazol-2-yl)aniline
232	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzoic acid
233	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(phenylethynyl)-N-(2-pyrrolidin-1-ylethyl)aniline
234	{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}(phenyl)methanone
235	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-ethynyl-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
236	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(3,3-dimethylbut-1-yn-1-yl)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
237	3-bromo-4-{4-[5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine

No.	**Name**
238	3-bromo-4-{4-[2-methyl-5-[(2-methylpropyl)oxy]-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
239	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(3-phenyl-1,2,4-oxadiazol-5-yl)-N-(2-pyrrolidin-1-ylethyl)aniline
240	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-N-(2-pyrrolidin-1-ylethyl)aniline
241	1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}propan-1-one
242	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(3,3-dimethylbutyl)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
243	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-ethyl-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
244	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[2-(trimethylsilyl)ethyl]aniline
245	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(2-phenylethyl)-N-(2-pyrrolidin-1-ylethyl)aniline
246	1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-one
247	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,4-dimethyl-N-(methyloxy)-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide
248	3-bromo-4-[4-(3-bromo-5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
249	4-[4-(3-bromo-5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methylphenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
250	1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}ethanone
251	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(difluoromethyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
252	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-{[(difluoromethyl)oxy]methyl}-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
253	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(methyloxy)-N-(2-pyrrolidin-1-ylethyl)aniline
254	5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
255	2-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-3,5,6-trifluoro-N-(3-methylbutyl)pyridin-4-amine
256	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-[(cyclopropylmethyl)oxy]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide
257	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(5-methyl-1,2,4-oxadiazol-3-yl)-N-(2-pyrrolidin-1-ylethyl)aniline
258	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(ethylsulfonyl)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
259	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(methylsulfonyl)-N-(2-pyrrolidin-1-ylethyl)aniline
260	1-{3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}pentan-1-one
261	3-bromo-4-[4-(5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
262	6-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-3,5-difluoro-N~4~-(3-methylbutyl)-N~2~-(2-pyrrolidin-1-ylethyl)pyridine-2,4-diamine

No.	Name
263	3-bromo-5-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-(2-pyrrolidin-1-ylethyl)aniline
264	3-bromo-4-[4-(3',4',6-trifluoro-4-methylbiphenyl-3-yl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
265	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-N-(2-pyrrolidin-1-ylethyl)aniline
266	{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}methanol
267	3-bromo-4-(4-{4-methyl-2'-[(2-pyrrolidin-1-ylethyl)oxy]biphenyl-3-yl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
268	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-{[(2,2-difluorocyclopropyl)methyl]oxy}-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
269	5-bromo-3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
270	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(ethyloxy)methyl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
271	3-[4-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-1-methyl-6-(trifluoromethyl)-1H-benzimidazol-2-yl]propan-1-ol
272	1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}-4,4,4-trifluorobutan-1-one
273	{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}(cyclopropyl)methanone
274	3-({3'-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4'-methylbiphenyl-2-yl}oxy)-N,N-dimethylpropan-1-amine
275	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(1,1-difluorobutyl)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
276	3-bromo-4-(4-{4-methyl-2'-[(3-morpholin-4-ylpropyl)oxy]biphenyl-3-yl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
277	3-bromo-4-(4-{4-methyl-2'-[(2-morpholin-4-ylethyl)oxy]biphenyl-3-yl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
278	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-{[(2,2,2-trifluoroethyl)oxy]methyl}aniline
279	1-[2-({3'-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4'-methylbiphenyl-2-yl}oxy)ethyl]pyrrolidine-2,5-dione
280	3-bromo-4-(4-{3'-fluoro-4-methyl-2'-[(2-pyrrolidin-1-ylethyl)oxy]biphenyl-3-yl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
281	1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-one
282	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[(3,3,3-trifluoropropyl)oxy]aniline
283	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[(2,2,2-trifluoroethyl)oxy]aniline
284	1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-ol
285	3-bromo-4-(4-{4-chloro-2'-[(2-pyrrolidin-1-ylethyl)oxy]biphenyl-3-yl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
286	3-[4-(4-{5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-yn-1-ol
287	3-bromo-4-(4-{4-chloro-4'-fluoro-2'-[(2-pyrrolidin-1-ylethyl)oxy]biphenyl-3-yl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine

No.	Name
288	3-bromo-4-(4-{4-methyl-3'-[(2-pyrrolidin-1-ylethyl)oxy]biphenyl-3-yl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
289	(2E)-3-[4-(4-{5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-enoic acid
290	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[4,4,4-trifluoro-1,1-bis(methyloxy)butyl]aniline
291	6-(4-phenylpiperazin-1-yl)-9H-purine
292	6-[4-(3-chlorophenyl)piperazin-1-yl]-9H-purine
293	4-(4-phenylpiperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine
294	4-[4-(3-chlorophenyl)piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine
295	4-(4-phenylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
296	4-[4-(3-chlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
297	6-[4-(2-chlorophenyl)piperazin-1-yl]-9H-purine
298	6-[4-(2-fluorophenyl)piperazin-1-yl]-9H-purine
299	4-[4-(2-methylphenyl)piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine
300	4-{4-[2-(methyloxy)phenyl]piperazin-1-yl}-7H-pyrrolo[2,3-d]pyrimidine
301	4-{4-[3-(methyloxy)phenyl]piperazin-1-yl}-7H-pyrrolo[2,3-d]pyrimidine
302	4-{4-[4-(methyloxy)phenyl]piperazin-1-yl}-7H-pyrrolo[2,3-d]pyrimidine
303	4-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}-7H-pyrrolo[2,3-d]pyrimidine
304	6-{4-[4-(methyloxy)phenyl]piperazin-1-yl}-9H-purine
305	6-{4-[2-(methyloxy)phenyl]piperazin-1-yl}-9H-purine
306	6-[4-(4-chlorophenyl)piperazin-1-yl]-9H-purine
307	6-[4-(4-fluorophenyl)piperazin-1-yl]-9H-purine
308	4-[4-(4-chlorophenyl)piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine
309	4-[4-(2-chlorophenyl)piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine
310	4-[4-(4-fluorophenyl)piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine
311	4-[4-(2-fluorophenyl)piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine
312	6-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}-9H-purine
313	6-[4-(2-methylphenyl)piperazin-1-yl]-9H-purine
314	4-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine
315	4-[4-(2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
316	4-[4-(3-chlorophenyl)piperazin-1-yl]-3-methyl-1H-pyrazolo[3,4-d]pyrimidine
317	3-methyl-4-[4-(2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
318	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
319	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-methyl-1H-pyrazolo[3,4-d]pyrimidine
320	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-methyl-6-phenyl-1H-pyrazolo[3,4-d]pyrimidine
321	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
322	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-6-methyl-1H-pyrazolo[3,4-d]pyrimidine
323	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-6-ethyl-1H-pyrazolo[3,4-d]pyrimidine
324	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-6-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidine

No.	Name
325	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine
326	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-({[2-(methyloxy)ethyl]oxy}methyl)-1H-pyrazolo[3,4-d]pyrimidine
327	3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
328	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-propyl-1H-pyrazolo[3,4-d]pyrimidine
329	4-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}phenol
330	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-N-phenyl-1H-pyrazolo[3,4-d]pyrimidin-3-amine
331	4-[4-(3-chlorophenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
332	4-{4-[5-chloro-2-(methyloxy)phenyl]piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
333	3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}phenol
334	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-{3-[(phenylmethyl)oxy]phenyl}-1H-pyrazolo[3,4-d]pyrimidine
335	3-(1,3-benzodioxol-5-yl)-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
336	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(2-thienyl)-1H-pyrazolo[3,4-d]pyrimidine
337	3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}aniline
338	3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}benzoic acid
339	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidine
340	N-(4-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}phenyl)acetamide
341	4-[4-(3-chlorophenyl)-1,4-diazepan-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
342	4-[5-(3-chlorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
343	4-(4-{3-chloro-4-[(2-morpholin-4-ylethyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
344	methyl 1-(3-chlorophenyl)-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazine-2-carboxylate
345	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-methylbut-2-en-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
346	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine
347	methyl 4-(3-chlorophenyl)-1-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazine-2-carboxylate
348	4-(4-{3-chloro-4-[(2-piperidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
349	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidine
350	1-(3-chlorophenyl)-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazine-2-carboxylic acid
351	1-(3-chlorophenyl)-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-N-methylpiperazine-2-carboxamide

No.	**Name**
352	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidine
353	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(2-methylpropyl)-1H-pyrazolo[3,4-d]pyrimidine
354	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[4-(methyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidine
355	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidine
356	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[4-(phenyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidine
357	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-{4-[(piperidin-4-ylmethyl)oxy]phenyl}-1H-pyrazolo[3,4-d]pyrimidine
358	1-(3-chlorophenyl)-N-[2-(dimethylamino)ethyl]-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazine-2-carboxamide
359	4-[4-(5-chloro-2-methyl-3-morpholin-4-ylphenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
360	4-(3-chlorophenyl)-1-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-N-methylpiperazine-2-carboxamide
361	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[2-(methyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidine
362	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-pyridin-4-yl-1H-pyrazolo[3,4-d]pyrimidine
363	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[3-(methyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidine
364	4-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}benzonitrile
365	[5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)phenyl]methanol
366	methyl 5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)benzoate
367	(2E)-3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-enoic acid
368	3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}propanoic acid
369	3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}propan-1-ol
370	methyl (2E)-3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-enoate
371	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-{4-[(2-morpholin-4-ylethyl)oxy]phenyl}-1H-pyrazolo[3,4-d]pyrimidine
372	5-chloro-N-[2-(dimethylamino)ethyl]-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)benzamide
373	4-(4-{5-chloro-2-(methyloxy)-3-[(4-methylpiperazin-1-yl)carbonyl]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
374	2-(dimethylamino)ethyl 5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)benzoate
375	1-[5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)phenyl]-N,N-dimethylmethanamine
376	N'-{[5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)phenyl]methyl}-N,N-dimethylethane-1,2-diamine

No.	**Name**
377	[1-(3-chlorophenyl)-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-2-yl]methanol
378	3-[(4-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}phenyl)oxy]-N,N-dimethylpropan-1-amine
379	2-chloro-4-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-methylphenol
380	1-(3-chlorophenyl)-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-N-(1-methylpiperidin-4-yl)piperazine-2-carboxamide
381	1-(3-chlorophenyl)-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-N-(2-morpholin-4-ylethyl)piperazine-2-carboxamide
382	2-{[5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)phenyl]oxy}-N,N-dimethylethanamine
383	3-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N,N-dimethylprop-2-yn-1-amine
384	N'-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N,N-dimethylethane-1,2-diamine
385	1,1-dimethylethyl (2E)-3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-enoate
386	3-({2-chloro-4-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-methylphenyl}oxy)-N,N-dimethylpropan-1-amine
387	2-({2-chloro-4-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-methylphenyl}oxy)-N,N-dimethylethanamine
388	4-{4-[5-chloro-2-methyl-4-(methyloxy)phenyl]piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine
389	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-methylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
390	3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-N,N-diethylprop-2-yn-1-amine
391	3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-yn-1-ol
392	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(piperidin-4-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidine
393	phenylmethyl (3aR,6aS)-5-({4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}methylidene)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate
394	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[(E)-(3aR,6aS)-hexahydrocyclopenta[c]pyrrol-5(1H)-ylidenemethyl]-1H-pyrazolo[3,4-d]pyrimidine
395	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-pyrrolidin-1-ylprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
396	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[3-(4-methylpiperazin-1-yl)prop-1-yn-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
397	3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-N,N-diethylpropan-1-amine
398	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-pyrrolidin-1-ylpropyl)-1H-pyrazolo[3,4-d]pyrimidine
399	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-d]pyrimidine
400	3-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N,N-diethylpropan-1-amine

No.	Name
401	4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine

Synthetic Procedures for Akt Compounds

[001121] The Akt compounds listed above can be made by the synthetic schemes and examples described in publication WO 2005/117909, which is incorporated herein by reference in its entirety. The utility of these compounds are also described in WO 2005/117909.

[001122] Another aspect of the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), and a pharmaceutically acceptable carrier, in combination with a therapeutically effective amount of a Akt compound.

[001123] Another aspect of the invention relates to a method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J), II(J), III(J), IV(J), V(J), or VI(J), and a pharmaceutically acceptable carrier, in combination with a therapeutically effective amount of an Akt compound.

[001124] In other embodiments of the above method of combining the Akt compounds with the JAK-2 inhibitors of Formula I(J), one or more of any of the Akt compounds in Table A2 can be combined with any one of the embodiments of the compound of Formula I(J) described hereinabove. In other embodiments of the above method of combining the Akt compounds with the JAK-2 inhibitors of Formula I(J), one or more of any of the Akt compounds in Table A2 can be combined with one or more of any of the compounds in Table I(J).

[001125] The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. The invention has

been described with reference to various specific embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. All patents, patent applications and publications cited in this application are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual patent, patent application or publication were so individually denoted.

What is claimed is:

1. A method of treating a disease in a mammal, wherein the mammal is in need of the treatment, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J), or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J) and a pharmaceutically acceptable carrier, in combination with an active agent selected from of a Raf inhibitor, an EGFR inhibitor, a VEGFR inhibitor, a ErbB2 inhibitor, a BCR-Abl, inhibitor, a Flt3 inhibitor, a Src inhibitor, a c-Kit inhibitor, an Akt inhibitor, a Ret inhibitor, an IFG1R inhibitor, an m-Tor inhibitor, a PI3K inhibitior, a PI3Kα inhibitor, and a taxane, wherein the JAK-2 compound of Formula I(J) is defined as follows:



I(J)

or a pharmaceutically acceptable salt thereof, wherein:

D is hydrogen, halo, $-CF_3$, heterocycloalkyl or alkyl;

E is hydrogen, halo, $-CF_3$, heterocycloalkyl or alkyl; or

D and E, together with the carbon atoms to which they are attached, form a 5-7 membered heteroaryl or a 5-7 membered heterocycloalkyl, wherein the 5-7 membered heteroaryl or 5-7 membered heterocycloalkyl are each fused to the pyrimidinyl moiety to which D and E are attached;

L is a bond, -O- or -N(H)-;

Z is selected from alkoxy, cycloalkyl, heteroaryl optionally substituted with alkyl, halo,

$-C(O)OR^{26}$, -C(=N-OH)alkyl, $-C(O)R^{8}$, $-C(O)NR^{30}R^{30a}$, $-CH_2R^{2}$, $-(CH_2)_{n5}NR^{26}R^{26a}$, $-CF_3$, -CN, $-SO_2R^{12}$, $-S-R^{12a}$, $-OR^{32a}$, $-NHC(O)R^{32}$, aryl, and heterocycloalkyl optionally substituted with 1 or 2 oxo, or

Z and R^{25}, together with the carbon atoms to which they are attached, join to form a 5 or 6 membered heterocycloalkyl, a 5 or 6 membered heteroaryl, or a 5 or 6 membered cycloalkyl ring, wherein the 5 or 6 membered heterocycloalkyl, 5 or 6 membered heteroaryl, or 5 or 6 membered cycloalkyl ring are fused to the phenyl moiety to which Z and R^{25} are attached, and wherein the 5 or 6 membered heterocycloalkyl, 5 or 6 membered heteroaryl, or 5 or 6 membered cycloalkyl ring are each optionally substituted with 1, 2, or 3 groups independently selected from oxo, alkyl, alkoxy and halo;

n1 is 0, 1, 2, 3, or 4, and each n1 is independently selected when more than one n1 is present;

n2 is 0, 1, 2, 3, or 4, and each n2 is independently selected when more than one n2 is present;

n3 is 0, 1, 2, or 3, and each n3 is independently selected when more than one n3 is present;

n4 is 0, 1, 2, 3 or 4, and each n4 is independently selected when more than one n4 is present;

n5 is 0, 1, 2, 3 or 4, and each n5 is independently selected when more than one n5 is present;

p is 0-3;

r is 1-3;

R^1 is hydrogen;

R^2 is selected from one of the following groups:



5



;

or R^2 is selected from one of the following groups:


(s) ,

(t) ,

(u) ,


(v) ,

(w) , or

(x) ;

ring X in Formula (d) of R^2 is a 5 or 6 membered unsaturated heterocyclic ring fused to the two carbon atoms of the phenyl moiety to which ring X is attached, wherein ring X contains 1 or 2 nitrogen atoms;

R^7, $R^{7'}$, R^9, R^{10}, R^{12} and R^{15} are each independently hydrogen, alkyl, alkoxy, or alkoxyalkyl;

R^8 is selected from hydrogen, hydroxy, alkyl, alkenyl, lower alkynyl, hydroxyamino, hydroxyalkyl, alkoxyalkyl, dihydroxyalkyl, alkylamino, dialkylamino, aminoalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, alkylaminoalkyl, dialkylaminoalkyl, $-(CH_2)_r-C(O)OR^7$, $-(CH_2)_r-C(O)NR^7R^{7'}$, aryl, heteroaryl, cycloalkyl, arylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, heteroaryl, cycloalkyl, arylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently optionally substituted at the ring position with one, two, three, four or five groups independently selected from alkyl, alkenyl, lower alkynyl, halo, hydroxy, haloalkyl, haloalkoxy, lower alkoxy, amino, aryl, alkylamino, dialkylamino, heterocyclylalkoxy, oxo and haloalkyl;

each R^{11}, when R^{11} is present, is independently selected from alkyl, alkenyl, lower alkynyl,

$-CF_3$, alkoxy, halo, haloalkoxy, haloalkyl, aminoalkyl, aminoalkoxy, alkylaminoalkyl, alkylaminoalkoxy, dialkylaminoalkyl, dialkylaminoalkoxy, oxo, thioalkyl, alkylthioalkyl, $-(CH_2)_p-OR^{17}$, -CN, $-O-CH_2-C(O)-R^{17}$, $-C(O)R^{16}$, $-(CH_2)_p-C(O)OR^{17}$, $-S(O)_2R^{17}$, $-S(O)_2NR^{15}R^{17}$, aryl, heteroaryl,

cycloalkyl, arylalkyl, arylalkoxy, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, heteroaryl, cycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently optionally substituted at any ring position with 1, 2, 3 or 4 R^{21};

R^{12} is hydrogen or alkyl;

R^{12a} is hydrogen or alkyl;

R^{13} is selected from hydrogen, hydroxy, alkyl, alkenyl, lower alkynyl, hydroxyamino, haloalkyl, alkyl substituted with halo and hydroxy, hydroxyalkyl, alkoxyalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, $-(CH_2)_r-C(O)OR^7$, $-(CH_2)_r-C(O)NR^7R^{7'}$, aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently optionally substituted at the ring position with 1, 2, 3, 4 or 5 groups independently selected from alkyl, alkenyl, lower alkynyl, halo, hydroxy, hydroxyalkyl, alkoxycarbonyl, alkylcarbonyl, haloalkyl, haloalkoxy, lower alkoxy, amino, aryl, alkylamino, dialkylamino, heterocyclylalkoxy, oxo and haloalkyl; and wherein the alkyl of cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl are independently optionally substituted with 1, 2, 3, 4, or 5 groups selected from halo and hydroxy;

R^{14} is a bond, heterocycloalkyl or cycloalkyl;

R^{16} is selected from hydrogen, hydroxy, alkyl, alkenyl, lower alkynyl, hydroxyamino, haloalkyl, alkyl substituted with halo and hydroxy, hydroxyalkyl, alkoxyalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, dialkylaminoalkyl,
$-(CH_2)_r-C(O)OR^7$, aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently optionally substituted at the ring position with one, two, three, four or five groups independently selected from alkyl, alkenyl, lower alkynyl, halo, hydroxy, hydroxyalkyl, alkoxycarbonyl,

alkylcarbonyl, haloalkyl, haloalkoxy, lower alkoxy, amino, aryl, alkylamino, dialkylamino, heterocyclylalkoxy, oxo and haloalkyl; and wherein the alkyl of cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl is optionally substituted with 1, 2, 3, 4, or 5 groups selected from halo and hydroxy;

R^{17} is selected from hydrogen, hydroxy, alkyl, alkenyl, lower alkynyl, hydroxyamino, haloalkyl, alkyl substituted with halo and hydroxy, hydroxyalkyl, alkoxyalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, dialkylaminoalkyl, $-(CH_2)_r-C(O)OR^7$, $-(CH_2)_r-C(O)NR^7R^{7'}$, aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, heteroaryl, cycloalkyl, arylalkyl, diarylalkyl, aryloxyalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently optionally substituted at the ring position with one, two, three, four or five groups independently selected from alkyl, alkenyl, lower alkynyl, halo, hydroxy, hydroxyalkyl, alkoxycarbonyl, alkylcarbonyl, haloalkyl, haloalkoxy, lower alkoxy, amino, aryl, alkylamino, dialkylamino, heterocyclylalkoxy, oxo and haloalkyl; and wherein the alkyl of cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl is optionally substituted with 1, 2, 3, 4, or 5 groups selected from halo and hydroxy;

each R^{21}, when R^{21} is present, is independently selected from alkyl, alkenyl, lower alkynyl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, amino, alkylamino, dialkylamino, dialkylaminoalkyl, dialkylaminoalkyloxy, haloalkyl, oxo, $-OR^{13}$, $-NHS(O)_2R^{17}$, $-S(O)_2R^{17}$, $-C(O)R^{17}$, $-C(O)OR^{17}$, $-C(O)NR^{15}R^{17}$, $-NR^{15}C(O)R^{17}$, aryl, arylalkyl, heteroarylalkyl, aryloxy, and heteroaryl; wherein each of the aryl, arylalkyl, heteroarylalkyl, aryloxy, and heteroaryl within R^{21} are optionally substituted at any ring position with 1, 2, or 3 groups selected from alkyl, lower alkoxy halo, phenyl, heteroaryl and alkylheteroalkyl;

R^{25} is selected from alkyl, alkenyl, lower alkyl, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, $-OR^{12}$, cyano, $-CH_2NHC(O)OR^7$, $-CH_2NHC(O)R^7$, $-SR^7$, $-S(O)_2R^7$, $-S(O)_2NR^7R^8$, $-C(O)OR^8$, $-C(O)NR^7R^8$, cycloalkyl, heterocycloalkyl, aryl and heteroaryl;

wherein the cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optionally substituted with one, two or three groups independently selected from alkyl, alkenyl, halo, haloalkoxy, haloalkyl, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, $-OR^8$, $-NHS(O)_2R^8$, cyano, $-C(O)R^8$, $-CH_2NHC(O)OR^7$, $-CH_2NHC(O)R^7$, $-SR^7$, $-S(O)_2R^7$, $-S(O)_2NR^7R^8$, $-C(O)OR^8$, $-C(O)NR^7R^8$, $-NR^{7'}C(O)-CHR^3-OR^8$, $-NR^{7'}C(O)-CHR^3-NR^7-R^8$, and $-NR^7C(O)R^8$;

R^{26} is hydrogen, -C(O)-phenyl or alkyl, wherein the -C(O)-phenyl is optionally substituted at any ring position with 1, 2 or 3 halo;

R^{26a} is hydrogen, alkyl, heteroaryl, $-C(O)R^{32}$, $-C(O)NHR^{32a}$, $-S(O)_2R^9$, $-SR^9$, $-C(O)OR^{32}$, or $-C(O)NR^{32a}R^{32}$;

R^{27} and R^{28} are each independently selected from alkyl, alkenyl, hydroxy, alkoxy, and alkoxyalkyl;

R^{27a} and R^{28a} are independently selected from hydrogen, alkyl, alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, dialkylaminoalkyl, arylcarbonylalkyl, aryloxyalkyl, dialkylaminoalkyl, alkyl-O-C(O)heterocylcoalkyl, $-(CH_2)_{n4}$heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, $-(CH_2)_{n4}-C(O)R^{29}$, $-(CH_2)_{n4}NR^{28}R^{28a}$, $-(CH_2)_{n4}NHR^{28a}$, $-CH(phenyl)_2$, $-S(O)_2R^{29}$, $-C(O)R^{29}$, $-C(O)OR^{29}$, and $-C(O)NR^{29a}R^{29}$, wherein the aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl groups within R^{27a} and R^{28a} are each independently optionally substituted at any ring position with 1, 2, 3, 4, or 5 groups selected from halo, alkyl, alkoxy, alkylcarbonyl, phenyl, phenoxy, arylcarbonyl, $-CF_3$, oxo, $-OCF_3$, alkoxyphenyl, and heteroaryl optionally substituted with alkyl or halo;

or R^{27} and R^{27a}, together with the nitrogen to which they are attached, form heterocycloalkylamino, heterocycloalkyl or heteroaryl, wherein the heterocycloalkylamino and heteroaryl are each independently optionally substituted with 1, 2, 3, 4, or 5 R^{31};

or R^{28} and R^{28a} together with the nitrogen to which they are attached form heterocycloalkyl or heteroaryl, wherein the heterocycloalkyl and heteroaryl are each optionally substituted with 1, 2, 3, 4, or 5 R^{31};

R^{29a} is hydrogen or alkyl;

R^{29} is selected from alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl groups within R^{29} are each optionally substituted at any ring position with 1, 2, 3, 4, or 5 groups selected from halo, alkyl, alkoxy, alkylcarbonyl, phenyl, phenoxy, arylcarbonyl, $-CF_3$, oxo, $-OCF_3$, alkoxyphenyl, and heteroaryl optionally substituted with alkyl or halo;

R^{30a} is hydrogen or alkyl;

R^{30} is selected from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkoxycarbonylalkyl, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aryl, arylalkyl, phenoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, arylheteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl; wherein the aryl, arylalkyl, phenoxyalkyl, cycloalkyl, arylheteroarylalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl groups within R^{30} are each independently optionally substituted at any ring position with 1, 2, 3, 4, or 5 groups selected from halo, alkyl, alkoxy, alkoxyalkyl, $-C(O)OCH_3$, $-CF_3$, $-OCF_3$, alkylcarbonyl, phenyl, phenoxy, alkylphenoxy, dialkylaminoalkoxy and heteroaryl;

R^{31} is selected from alkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, alkylthioalkyl, $-C(O)R^{30}$, $-C(O)NR^{30}R^{30a}$, $-C(O)OR^{30}$, $-S(O)_2R^{30}$, amino, dihydroxyalkyl, arylcarbonyl, alkylcarbonylamino, alkoxyphenyl, phenylalkoxyalkyl, arylheteroarylalkyl, alkylamino,-O-dialkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, dialkylaminoalkoxy, oxo, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, spirocyclic cycloalkyl, spirocyclic heterocycloalkyl, and heterocycloalkylalkyl, wherein the aryl, arylalkyl, cycloalkyl, arylheteroarylalkyl, arylalkoxyalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl groups within R^{31} are each independently optionally substituted at any ring position with 1, 2, 3, 4, or 5 groups selected from halo, alkyl, $-CF_3$, $-OCF_3$, cyano, alkoxy, alkoxyalkyl, $-C(O)OCH_3$, alkylcarbonyl, phenyl optionally substituted at any ring position with halo, phenoxy, alkylphenoxy, arylalkoxyalkyl, dialkylaminoalkoxy and heteroaryl;

R^{32a} is hydrogen, $-OCF_3$, $-CF_3$, or alkyl;

R^{32} is selected from aryl, arylalkyl, arylalkoxy, arylcycloalkyl, alkoxycarbonylalkoxy, cycloalkyl, cycloalkylalkyl, cycloalkylhydroxyalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl, wherein the aryl, arylalkyl, cycloalkyl, arylcycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl are each independently optionally substituted at any ring position with 1, 2, 3, 4, or 5 groups selected from hydroxy, oxo, alkyl, alkoxy, amino, hydroxyalkyl, alkylcarbonyl, alkoxycarbonyl, halo, $-CF_3$, $-OCF_3$, aminoalkyl, alkylaminoalkyl, aryl and dialkylaminoalkyl, and wherein the alkyl portion of the heteroarylalkyl can be substituted with amino;

or R^{32} is alkyl optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from hydroxy, alkoxycarbonyl, alkoxy, $-CF_3$, halo, aminocarbonyl, alkylaminocarbonyl, alkoxycarbonylalkylamino, dialkylaminocarbonyl, $-NR^{34}R^{34a}$ and phenyl optionally substituted with 1, 2, or 3 halo;

or R^{32} is alkylamino or arylalkylamino;

R^{34} is hydrogen or alkyl;

R^{34a} is selected from hydrogen, alkyl, heteroaryl, aryl, aminoalkyl, aminocarbonylalkyl, heteroarylalkyl, arylalkoxy and arylalkyloxycarbonylalkyl; wherein the heteroaryl, aryl, heteroarylalkyl, arylalkoxy or arylalkyloxycarbonylalkyl are each independently optionally substituted at any ring position with 1, 2, 3, 4, or 5 groups selected from hydroxy, oxo, alkyl, amino, hydroxyalkyl, alkylcarbonyl, alkoxycarbonyl, halo, aminoalkyl, alkylaminoalkyl, and dialkylaminoalkyl; and

R^{35} is selected from halo, $-(CH_2)_pC(O)OR_{17}$, cycloalkyl, heterocycloalkyl, and heterocycloalklylalkyl; wherein the heterocycloalkyl and heterocycloalklylalkyl are each optionally substituted with 1, 2, 3, 4, or 5 groups each independently selected from alkyl, alkoxy, and halo,

wherein the mammal is in need of the treatment.

2. The method according to Claim 1, wherein the Raf inhibitor is sorafenib, the PI3K inhibitor is BEZ, the Akt inhibitor is GSK, the BCR-Abl inhibitor is imatinib, rituximab, axitinib, nilotinib, or dasatinib, the Flt3 inhibitor is sunitinib, the Src

inhibitor is dasatinib or AZ, the mTor/Raptor inhibitor is rapamycin, the VEGFR inhibitor is bevacizumab or axitinib, and the c-Kit inhibitor is imatinib or axitinib.

3. The method according to claim 1, wherein the active agent is a compound of Formula **I(V2):**



I(V2)

or a pharmaceutically acceptable salt thereof, wherein,

R^1 is C_1-C_3 alkyl optionally substituted with between one and three R^{50} substituents;

R^2 is selected from halogen, trihalomethyl, -CN, $-NH_2$, $-NO_2$, $-OR^3$, $-N(R^3)R^4$, $-S(O)_{0-2}R^4$, $-SO_2N(R^3)R^4$, $-CO_2R^3$, $-C(=O)N(R^3)R^4$, $-N(R^3)SO_2R^4$, $-N(R^3)C(=O)R^3$, $-N(R^3)CO_2R^4$, $-C(=O)R^3$, optionally substituted lower alkyl, optionally substituted lower alkenyl, and optionally substituted lower alkynyl;

R^3 is -H or R^4;

R^4 is selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or

R^3 and R^4, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;

q is 0, 1, 2, 3, 4, or 5;

Z is selected from $-OCH_2-$, -O-, $-S(O)_{0-2}-$, $-N(R^5)CH_2-$, and $-NR^5-$;

R^5 is -H or optionally substituted lower alkyl;

R^{50} is -H, halo, trihalomethyl, $-OR^3$, $-N(R^3)R^4$, $-S(O)_{0-2}R^4$, $-SO_2N(R^3)R^4$, $-CO_2R^3$, $-C(=O)N(R^3)R^4$, $-C(=NR^{25})N(R^3)R^4$, $-C(=NR^{25})R^4$, $-N(R^3)SO_2R^4$, $-N(R^3)C(O)R^3$, $-NCO_2R^3$, $-C(=O)R^3$, optionally substituted alkoxy, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or

two of R^{50}, when taken together on the same carbon are oxo; or

two of R^{50}, when taken together with a common carbon to which they are attached, form a optionally substituted three- to seven-membered spirocyclyl, said optionally substituted three- to seven-membered spirocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;

R^{25} is selected from -H, -CN, $-NO_2$, $-OR^3$, $-S(O)_{0-2}R^4$, $-CO_2R^3$, optionally substituted lower alkyl, optionally substituted lower alkenyl, and optionally substituted lower alkynyl;

M^1-M^2-M^3-M^4- together are according to Formula **II(V2)**:



II(V2)

wherein X^1, X^2, and optionally X^3, represent the atoms of a saturated bridged ring system, said saturated bridged ring system containing up to three annular heteroatoms represented by any of X^1, X^2, and X^3; wherein,

each X^1 is independently selected from $-C(R^6)R^7-$, -O-, $-S(O)_{0-2}-$, and $-NR^8-$;

each X^2 is independently a bridgehead methine optionally substituted with R^6, or a bridgehead nitrogen;

each X^3 is independently selected from $-C(R^6)R^7-$, -O-, $-S(O)_{0-2}-$, and $-NR^8-$;

provided, for X^1, X^2, and X^3, there are no nitrogen-nitrogen annular bonds nor geminal di-nitrogen substitutions;

E is selected from $-NR^9-$, -O-, and absent;

Y is either:

a C_{1-3} alkylene linker, between the oxygen at the 7-position of the quinazoline ring system of **I(V2)** and either E, or when E is absent, any ring atom of the saturated bridged ring system except X^2, when X^2 is a bridgehead nitrogen; provided there are at least two carbon atoms between the oxygen at the 7-position of the quinazoline ring system of **I(V2)** and either E, or when E is absent, any heteroatom represented by X^1, X^2 or X^3; or

Y is absent, when Y is absent, E is also absent; said saturated bridged ring system is directly attached to the oxygen at the 7-position of the quinazoline ring system of **I(V2)** via a carbon atom of said saturated bridged ring system;

m and p are each independently from one to four;

n is from zero to two, when n is zero, then there is a direct single bond between the two bridgehead X^2's;

R^6 and R^7 are each independently selected from -H, halogen, trihalomethyl, -CN, $-NH_2$, $-NO_2$, $-OR^3$, $-N(R^3)R^4$, $-S(O)_{0-2}R^4$, $-SO_2N(R^3)R^4$, $-CO_2R^3$, $-C(O)N(R^3)R^4$, $-N(R^3)SO_2R^4$, $-N(R^3)C(O)R^3$, $-NCO_2R^3$, $-C(O)R^3$, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, optionally substituted lower heterocyclylalkyl; or

R^6 and R^7, when taken together are oxo; or

R^6 and R^7, when taken together with a common carbon to which they are attached, form a optionally substituted three- to seven-membered spirocyclyl, said optionally substituted three- to seven-membered spirocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P; and

R^8 is selected from R^3, $-SO_2N(R^3)R^4$, $-CO_2R^3$, $-C(O)N(R^3)R^4$, $-SO_2R^4$, and $-C(O)R^3$;

R^9 is -H or optionally substituted lower alkyl;

with the proviso that when Y is a C_{1-3} alkylene linker, E is absent, Z is -NH- or $-N(CH_3)$-, R^1 is a C_{1-3} alkyl, R^2 is -H or halogen, n = 0, and the atoms X^1 of one bridge of the saturated bridged ring system, when combined with both bridgehead atoms, X^2, of the saturated bridged ring system, represent: either a pyrrolidine ring or a piperidine ring, and any atom, X^1 or X^2, of either of said pyrrolidine ring or said piperidine ring is attached to Y; then the other bridge of said saturated bridged ring system cannot be any one of $-OC(O)CH_2$-, $-CH_2OC(O)$-, $-OC(O)CH_2CH_2$-, $-CH_2OC(O)CH_2$-, $-CH_2CH_2OC(O)$-, $-OC(O)CH_2NH$-, $-OC(O)CH_2N(C_{1-4}$alkyl)-, and $-OC(O)CH_2O$-; or either a piperazine ring or a 4-(C_{1-4} alkyl)-piperazine ring, and any atom, X^1 or X^2, of either of said piperazine ring or said 4-(C_{1-4} alkyl)-piperazine ring is attached to Y; then the other bridge of said saturated

bridged ring system, only when attached via the 2- and the 3-position of either of said piperazine ring or said 4-(C_{1-4} alkyl)-piperazine ring, cannot be one of $-CH_2OC(O)CH_2-$, $-CH_2CH_2OC(O)-$, and either of the two aforementioned bridges cannot be optionally substituted by one or two C_{1-2}alkyl groups; or a piperazine ring, and any atom, X^1 or X^2, of said piperazine ring is attached to Y; then the other bridge of said saturated bridged ring system, only when attached via the 3- and the 4-position of said piperazine ring, cannot be one of $-C(O)OCH_2CH_2-$ or $-CH_2OC(O)CH_2-$ (and only when either of $-C(O)OCH_2CH_2-$ or $-CH_2OC(O)CH_2-$ is attached to the 3-position of said piperazine ring via their left-hand end as depicted above), and either of the two aforementioned bridges cannot be optionally substituted by one or two C_{1-2} alkyl groups, and ; or a 2-oxomorpholine ring, said 2-oxomorpholine ring attached to Y via its 4-position; then the other bridge of said saturated bridged ring system, only when attached via the 5- and the 6-position of said 2-oxomorpholine ring, cannot be one of $-(CH_2)_g-$, $-CH_2WCH_2-$, $-CH_2WCH_2CH_2-$, and $-CH_2CH_2WCH_2-$, wherein W is -O-, $-S(O)_{0-2}-$, -NH-, or $-N(C_{1-4}$ alkyl)- and wherein g is 2, 3, or 4.

4. The method according to claim 1, wherein the active agent is according to Formula A-B-C (version 3), or a pharmaceutically acceptable salt thereof, wherein:

A is selected from:





and $-R^3$;

B is selected from:



and



; and

C is selected from:



wherein:

R^2 is selected from -H, halogen, trihalomethyl, -CN, $-NH_2$, $-NO_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$ and optionally substituted lower alkyl;

q is 0 to 2;

each R^3 is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl; or, two R^3, together with the nitrogen to which they are attached, form a four- to seven-membered heteroalicyclic, said four- to seven-membered heteroalicyclic optionally containing one additional heteroatom; when one said additional heteroatom is a nitrogen, then said nitrogen is optionally substituted with a group selected from -H, trihalomethyl, $-SO_2R^5$, $-SO_2NR^5R^5$, $-CO_2R^5$, $-C(O)NR^5R^5$, $-C(O)R^5$ and optionally substituted lower alkyl;

each R^{35} is independently selected from -H, $-C(=O)R^3$, $-C(=O)OR^3$, $-C(=O)SR^3$, $-SO_2R^3$, $-C(=O)N(R^3)R^3$, and optionally substituted lower alkyl; or, two R^{35}, together with the nitrogen to which they are attached, can combine to form a heteroalicyclic optionally substituted with between one and four of R^{60}, said heteroalicyclic may have an additional annular heteroatom, and said heteroalicyclic may have an aryl fused thereto, said aryl optionally substituted with an additional one to four of R^{60};

A^1 is selected from =N- and =C(H)-;

A^2 is either =N- or =C(H)-;

R^5 is -H or optionally substituted lower alkyl;

R^8 is selected from R^3, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-SO_2R^3$ and $-C(O)R^3$, or an R^8 is absent and the alkylene linker of A is covalently bonded to the nitrogen atom in which R^8 is absent;

E^1 is selected from -O-, $-CH_2-$, $-N(R^5)-$ and $-S(O)_{0-2}-$;

Q is a five- to ten-membered ring system, optionally substituted with between zero and four of R^{20};

R^{20} is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$ and optionally substituted lower alkyl;

R^{60} is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted lower alkyl, optionally substituted aryl,

optionally substituted heteroarylalkyl and optionally substituted arylalkyl; or, two of R^{60}, when attached to a non-aromatic carbon, can be oxo;

each methylene in any of the above Formulae is independently optionally substituted with one or two R^{25}; and

each R^{25} is independently selected from halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted aryl, optionally substituted arylalkyl, heteroarylalkyl and optionally substituted lower alkyl; or two of R^{25}, together with the carbon or carbons to which they are attached, can combine to form a three- to seven-membered alicyclic or heteroalicyclic; or two of R^{25} on a single carbon can be oxo;

with the proviso that the conditions of:

C contains 

; and

the remaining portion of C contains one of:



are not met at the same time; and

with the proviso that when C contains 

directly attached to



, and R^{70} is selected from -H, C_{1-4}alkyl, and C_{1-4}alkoxyl, then A^2 is N.

5. The method according to claim 1, wherein the active agent is a compound according to A-B-C (version 4) or a pharmaceutically acceptable salt thereof, wherein:

A is selected from:





and -R^3;

B is selected from:



and



; and

C is selected from:





wherein:

R^2 is selected from -H, halogen, trihalomethyl, -CN, $-NH_2$, $-NO_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, and optionally substituted lower alkyl;

q is 0 to 2;

each R^3 is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted arylalkyl, and optionally substituted heteroarylalkyl; or, two R^3, together with the nitrogen to which they are attached, form a four- to seven-membered heteroalicyclic, said four- to seven-membered heteroalicyclic optionally containing one additional heteroatom; when one said additional heteroatom is a nitrogen, then said nitrogen is optionally substituted with a group selected from -H, trihalomethyl, $-SO_2R^5$, $-SO_2NR^5R^5$, $-CO_2R^5$, $-C(O)NR^5R^5$, $-C(O)R^5$, and optionally substituted lower alkyl;

each R^{35} is independently selected from -H, $-C(=O)R^3$, $-C(=O)OR^3$, $-C(=O)SR^3$, $-SO_2R^3$, $-C(=O)N(R^3)R^3$, and optionally substituted lower alkyl; or, two R^{35}, together with the nitrogen to which they are attached, can combine to form a

heteroalicyclic optionally substituted with between one and four of R^{60}, said heteroalicyclic may have an additional annular heteroatom, and said heteroalicyclic may have an aryl fused thereto, said aryl optionally substituted with an additional one to four of R^{60};

A^1 is selected from =N- and =C(H)-;

A^2 is either =N- or =C(H)-;

R^5 is -H or optionally substituted lower alkyl;

R^8 is selected from R^3, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-SO_2R^3$, and $-C(O)R^3$, or an R^8 is absent and the alkylene linker of A is covalently bonded to the nitrogen atom in which R^8 is absent;

E^1 is selected from -O-, $-CH_2-$, $-N(R^5)-$, and $-S(O)_{0-2}-$;

Q is a five- to ten-membered ring system, optionally substituted with between zero and four of R^{20};

R^{20} is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, and optionally substituted lower alkyl;

R^{60} is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroarylalkyl, and optionally substituted arylalkyl; or, two of R^{60}, when attached to a non-aromatic carbon, can be oxo;

each methylene in any of the above Formulae is independently optionally substituted with one or two R^{25}; and

each R^{25} is independently selected from halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted aryl, optionally substituted arylalkyl, heteroarylalkyl, and optionally substituted lower alkyl; or two of R^{25}, together with the carbon or carbons to which they are attached, can combine to form a three- to seven-membered alicyclic or heteroalicyclic; or two of R^{25} on a single carbon can be oxo;

with the proviso that the conditions of:

C contains  ; and

the remaining portion of C contains one of:

		
		
		
		

are not met at the same time; and

with the proviso that when C contains  directly attached to  and R^{70} is selected from -H, C_{1-4}alkyl, and C_{1-4}alkoxyl, then A^2 is N.

6. The method according to claim 1, wherein the active agent is according to Formula A-B-C (version 5), or a pharmaceutically acceptable salt thereof, wherein:

A is selected from:

 ,  ,  ,  and -R^3;

B is selected from:


and

; and

C is selected from:


;

;


and

,

wherein:

R^2 is selected from -H, halogen, trihalomethyl, -CN, $-NH_2$, $-NO_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, and optionally substituted lower alkyl;

q is 0 to 2;

each R^3 is independently selected from –H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted arylalkyl, and optionally substituted heteroarylalkyl; or, two R^3, together with the nitrogen to which they are attached, form a four- to seven-membered heteroalicyclic, said four- to seven-membered heteroalicyclic optionally containing one additional heteroatom; when one said additional heteroatom is a nitrogen, then said nitrogen is optionally substituted with a group selected from -H, trihalomethyl, $-SO_2R^5$, $-SO_2NR^5R^5$, $-CO_2R^5$, $-C(O)NR^5R^5$, $-C(O)R^5$, and optionally substituted lower alkyl;

each R^{35} is independently selected from -H, $-C(=O)R^3$, $-C(=O)OR^3$, $-C(=O)SR^3$, $-SO_2R^3$, $-C(=O)N(R^3)R^3$, and optionally substituted lower alkyl; or, two

R^{35}, together with the nitrogen to which they are attached, can combine to form a heteroalicyclic optionally substituted with between one and four of R^{60}, said heteroalicyclic may have an additional annular heteroatom, and said heteroalicyclic may have an aryl fused thereto, said aryl optionally substituted with an additional one to four of R^{60};

A^1 is selected from =N- and =C(H)-;

A^2 is either =N- or =C(H)-;

R^5 is -H or optionally substituted lower alkyl;

R^8 is selected from R^3, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-SO_2R^3$, and $-C(O)R^3$, or wherein the A group contains at least one R^8, R^8 is absent and the alkylene linker is bonded to the corresponding nitrogen atom;

E^1 is selected from -O-, $-CH_2-$, $-N(R^5)-$, and $-S(O)_{0-2}-$;

Q is a five- to ten-membered ring system, optionally substituted with between zero and four of R^{20};

R^{20} is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, and optionally substituted lower alkyl;

R^{60} is selected from -H, halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroarylalkyl, and optionally substituted arylalkyl, or two of R^{60}, when attached to a non-aromatic carbon, can be oxo;

each methylene in any of the above Formulae is independently optionally substituted with one or two R^{25}; and

each R^{25} is independently selected from halogen, trihalomethyl, -CN, $-NO_2$, $-NH_2$, $-OR^3$, $-NR^3R^3$, $-S(O)_{0-2}R^3$, $-SO_2NR^3R^3$, $-CO_2R^3$, $-C(O)NR^3R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, optionally substituted aryl, optionally substituted arylalkyl, heteroarylalkyl, and optionally substituted lower alkyl; two of R^{25}, together with the carbon or carbons to which they are attached, can combine to form a three- to seven-membered alicyclic or heteroalicyclic; or, two of R^{25} on a single carbon can be oxo.

7. The method according to claim 1, wherein the active agent is a compound according to Formula I(P):



I(P)

or a pharmaceutically acceptable salt thereof, where

W^1, W^2, W^3, and W^4 are $-C(R^1)=$; or one or two of W^1, W^2, W^3, and W^4 are independently $-N=$ and the remaining are $-C(R^1)=$; and where each R^1 is independently hydrogen, alkyl, haloalkyl, nitro, alkoxy, haloalkoxy, halo, hydroxy, cyano, amino, alkylamino, or dialkylamino;

R^{51} is hydrogen or alkyl;

R^{52} is hydrogen or halo;

R^{50}, R^{53}, and R^{54} are independently hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, $-N(R^{55})C(O)-C_1-C_6$-alkylene-$N(R^{55a})R^{55b}$, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, $-S(O)_2NR^{55}R^{55a}$, or alkylcarbonylamino and where R^{55} and R^{55b} are indepedently hydrogen, alkyl, or alkenyl and R^{55a} is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; or R^{53} and R^{54} together with the carbons to which they are attached form a 5- or 6-membered heteroaryl or 5- or 6-membered heterocycloalkyl;

B is phenyl substituted with R^{3a} and optionally further substituted with one, two, or three R^3; or

B is heteroaryl optionally substituted with one, two, or three R^3;

R^{3a} is cyano; hydroxyamino; carboxy; alkoxycarbonyl; alkylamino; dialkylamino; alkylcarbonyl; haloalkoxy; alkylsulfonyl; aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; or

a) $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$ where R^7 is hydrogen, alkyl, or alkenyl and R^{7a} and R^{7b} are independently hydrogen, alkyl, alkenyl, hydroxyalkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkylaminoalkyl,

dialkylaminoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, arylalkyl, or arylalkyloxy and where the aryl, cycloalkyl, heterocycloalkyl and heteroaryl rings in R^{7a} and R^{7b} (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, amino, alkylamino, dialkylamino, hydroxy, halo, alkoxy, alkylthio, and oxo);

b) $-C(O)NR^8R^{8a}$ where R^8 is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and R^{8a} is hydrogen, alkyl, alkenyl, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, alkylthioalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl and where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in R^{8a} (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxycarbonyl, and -C(O)H;

c) $-NR^9C(O)R^{9a}$ where R^9 is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and R^{9a} is hydrogen, C_{2-6}-alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl; where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in R^{9a} (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, halo, haloalkyl, haloalkoxy, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, alkoxycarbonyl, -C(O)H, aryl (optionally substituted with one or two halo), arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cyloalkyl, cyloalkylalkyl, and cycloalkylcarbonyl;

d) $-C(O)N(R^{10})$-C_1-C_6-alkylene-$N(R^{10a})R^{10b}$ where R^{10a} is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, or hydroxyalkyl and R^{10} and R^{10b} are independently

hydrogen, alkyl, alkenyl, haloalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, or hydroxyalkyl;

e) $-NR^{11}C(O)NR^{11a}R^{11b}$ where R^{11a} is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy and R^{11} and R^{11b} are independently hydrogen, alkyl, alkenyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

f) $-C(O)R^{12}$ where R^{12} is heterocycloalkyl optionally substituted with 1, 2, or 3 groups selected from alkyl, oxo, amino, alkylamino, and heterocycloalkylalkyl;

g) $-NR^{13}C(O)OR^{13a}$ where R^{13} is hydrogen, alkyl, or alkenyl and R^{13a} is aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aryl, or arylalkyl;

h) $-C(O)N(R^{14})N(R^{14a})(R^{14b})$ where R^{14}, R^{14a}, and R^{14b} are independently hydrogen, alkyl, or alkenyl;

i) $-S(O)_2N(R^{15})$-C_1-C_6-alkylene-$N(R^{15a})R^{15b}$ where R^{15}, R^{15a}, and R^{15b} are independently hydrogen, alkyl, or alkenyl;

j) $-C(O)N(R^{16})$-C_1-C_6-alkylene-$C(O)OR^{16a}$ where R^{16} is hydrogen, alkyl, or alkenyl and R^{16a} is alkyl or alkenyl;

k) heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

l) $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$ where R^{17}, R^{17a}, R^{17b}, R^{17c}, and R^{17d} are independently hydrogen, alkyl, or alkenyl;

m) $-N(R^{18})C(O)$-C_1-C_6-alkylene-$N(R^{18b})C(O)R^{18a}$ where R^{18a} is hydrogen, alkyl, alkenyl, or alkoxy and R^{18} and R^{18b} are independently hydrogen, alkyl, or alkenyl;

n) $-C(O)N(R^{19})$-C_1-C_6-alkylene-$C(O)R^{19a}$ where R^{19} is hydrogen, alkyl, or alkenyl and R^{19a} is amino, alkylamino, dialkylamino, or heterocycloalkyl;

o) $-N(R^{20})C(O)$-C_1-C_6-alkylene-$C(O)R^{20a}$ where R^{20} is hydrogen, alkyl, or alkenyl and R^{20a} is cycloalkyl or heterocycloalkyl;

p) $-NR^{21}S(O)_2R$-C_1-C_6-alkylene-$N(R^{21b})R^{21a}$ where R^{21} is hydrogen, alkyl, or alkenyl and R^{21a} and R^{21b} are independently hydrogen, alkyl, or alkenyl;

q) $-N(R^{22})C(O)$-C_1-C_6-alkylene-$N(R^{22b})$-$N(R^{22c})(R^{22a})$ where R^{22}, R^{22a} and R^{22b} are independently hydrogen, alkyl, or alkenyl;

r) $-C_0$-C_6-alkylene-$N(R^{23})$-C_1-C_6-alkylene-$N(R^{23b})R^{23a}$ where R^{23}, R^{23a} and R^{23b} are independently hydrogen, alkyl, or alkenyl; or

s) $-NR^{24}C(O)-C_1-C_6$-alkylene-OR^{24a} where R^{24} is hydrogen, alkyl, or alkenyl and R^{24a} is alkoxyalkyl or aryl optionally substituted with one or two halo or alkyl; and

where each of the alkylene in R^{3a} is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; and

each R^3 (when R^3 is present) is independently alkyl; alkenyl; alkynyl; halo; hydroxy; oxo; alkoxy; cyano; hydroxyamino; carboxy; alkoxycarbonyl; amino; alkylamino; dialkylamino; alkylcarbonyl; haloalkoxy; alkylsulfonyl; aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; or

a) $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$ where R^7 is hydrogen, alkyl, or alkenyl and R^{7a} and R^{7b} are independently hydrogen, alkyl, alkenyl, hydroxyalkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, arylalkyl, or arylalkyloxy and where the aryl, cycloalkyl, heterocycloalkyl and heteroaryl rings in R^{7a} and R^{7b} (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, amino, alkylamino, dialkylamino, hydroxy, halo, alkoxy, alkylthio, and oxo);

b) $-C(O)NR^8R^{8a}$ where R^8 is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and R^{8a} is hydrogen, alkyl, alkenyl, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, alkylthioalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl and where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in R^{8a} (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxycarbonyl, and -C(O)H;

c) $-NR^9C(O)R^{9a}$ where R^9 is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and R^{9a} is hydrogen, C_{2-6}-alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl,

heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl; where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in R^{9a} (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, halo, haloalkyl, haloalkoxy, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, alkoxycarbonyl, -C(O)H, aryl (optionally substituted with one or two halo), arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cyloalkyl, cyloalkylalkyl, and cycloalkylcarbonyl;

d) $-C(O)N(R^{10})-C_1-C_6$-alkylene-$N(R^{10a})R^{10b}$ where R^{10a} is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or hydroxyalkyl and R^{10} and R^{10b} are independently hydrogen, alkyl, alkenyl, haloalkyl, or hydroxyalkyl;

e) $-NR^{11}C(O)NR^{11a}R^{11b}$ where R^{11a} is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy and R^{11} and R^{11b} are independently hydrogen, alkyl, alkenyl, aminoalkyl, alkylaminooalkyl, dialkylaminoalkyl;

f) $-C(O)R^{12}$ where R^{12} is heterocycloalkyl optionally substituted with 1, 2, or 3 groups selected from alkyl, oxo, amino, alkylamino, and heterocycloalkylalkyl;

g) $-NR^{13}C(O)OR^{13a}$ where R^{13} is hydrogen, alkyl, or alkenyl and R^{13a} is aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aryl, or arylalkyl);

h) $-C(O)N(R^{14})N(R^{14a})(R^{14b})$ where R^{14}, R^{14a}, and R^{14b} are independently hydrogen, alkyl, or alkenyl;

i) $-S(O)_2N(R^{15})-C_1$-C_6-alkylene-$N(R^{15a})R^{15b}$ where R^{15}, R^{15a}, and R^{15b} are independently hydrogen, alkyl, or alkenyl;

j) $-C(O)N(R^{16})-C_1$-C_6-alkylene-$C(O)OR^{16a}$ where R^{16} is hydrogen, alkyl, or alkenyl and R^{16a} is alkyl or alkenyl;

k) heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

l) $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$ where R^{17}, R^{17a}, R^{17b}, R^{17c}, and R^{17d} are independently hydrogen, alkyl, or alkenyl;

m) $-N(R^{18})C(O)-C_1-C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$ where R^{18a} is hydrogen, alkyl, alkenyl, or alkoxy and R^{18} and R^{18b} are independently hydrogen, alkyl, or alkenyl;

n) $-C(O)N(R^{19})-C_1-C_6$-alkylene-$C(O)R^{19a}$ where R^{19} is hydrogen, alkyl, or alkenyl and R^{19a} is amino, alkylamino, dialkylamino, or heterocycloalkyl;

o) $-N(R^{20})C(O)-C_1-C_6$-alkylene-$C(O)R^{20a}$ where R^{20} is hydrogen, alkyl, or alkenyl and R^{20a} is cycloalkyl or heterocycloalkyl;

p) $-NR^{21}S(O)_2R-C_1.C_6$-alkylene-$N(R^{21b})R^{21a}$ where R^{21} is hydrogen, alkyl, or alkenyl and R^{21a} and R^{21b} are independently hydrogen, alkyl, or alkenyl;

q) $-N(R^{22})C(O)-C_1.C_6$-alkylene-$N(R^{22b})-N(R^{22c})(R^{22a})$, where R^{22}, R^{22a} and R^{22b} are independently hydrogen, alkyl, or alkenyl;

r) $-C_0.C_6$-alkylene-$N(R^{23})-C_1.C_6$-alkylene-$N(R^{23b})R^{23a}$ where R^{23}, R^{23a} and R^{23b} are independently hydrogen, alkyl, or alkenyl; or

s) $-NR^{24}C(O)-C_1.C_6$-alkylene-OR^{24a} where R^{24} is hydrogen, alkyl, or alkenyl and R^{24a} is alkoxyalkyl or aryl optionally substituted with one or two halo or alkyl;

wherein each of the alkylene in R^3 is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; and

provided that when R^{50} and R^{52} are hydrogen, R^{51} is hydrogen or methyl, R^{53} is hydrogen or methoxy, and R^{54} is hydrogen or methoxy, then B is not 2,3-dihydro-1,4-benzodioxinyl, thien-2-yl, or thien-2-yl substituted with one R^3 where R^3 is halo.

8. The method according to claim 1, wherein the active agent is according to Formula II(P):



II(P)

or a pharmaceutically acceptable salt thereof, wherein:

W^1, W^2, W^3, and W^4 are $-C(R^{1a})=$; or one or two of W^1, W^2, W^3, and W^4 are independently $-N=$ and the remaining are $-C(R^{1a})=$;

X^1 is $-N(R^{5a})-$;

A is aryl, $-S(O)_2$-aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkoxy, alkyl, alkoxy, or -alkyl-$N(R^7)R^{7a}$, where each of the aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkyl and alkoxy groups, each either alone or as part

of another group within A, are independently optionally substituted with one, two, three, or four R^{2a}; or

B^1 is aryl, arylalkyl, alkyl, heteroaryl, or heteroaryalkyl, wherein each of the aryl, heteroaryl and alkyl groups are independently optionally substituted with one, two, three, or four R^{3d};

each R^{1a} is independently selected from hydrogen, alkoxy, alkyl, nitro, halo, cyano, and -C_0-C_6-alkyl-$N(R^7)R^{7a}$, wherein each of the alkyl and alkoxy groups is optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, $-N(R^8)R^{8a}$, and $-C(O)OR^6$;

each R^{2a} (when R^{2a} is present) is independently selected from alkyl, alkenyl, -alkenyl-$C(O)OR^6$, $-OR^6$, $-N(R^7)C(O)R^6$, $-N(R^7)C(O)$-C_0-C_6 alkyl-$N(R^{7b})R^{7a}$, $-OC(O)$-C_0-C_6 alkyl-$N(R^7)R^{7a}$, $-N(R^7)C(O)$-C_1-C_6 alkyl$C(O)OR^6$, C_0-C_6-alkyl-$C(O)R^6$, oxo, dioxo, $-S(O)_2-N(R^7)R^{7a}$, $-C(O)OR^6$, $-CH(R^6)_2-C(O)OR^6$, $-S(O)_2R^6$, cycloalkyl, heterocycloalkyl, heteroaryl, $-C(O)N(R^7)$-alkyl-OR^6, $-C_0$-C_6 alkyl-$C(O)N(R^7)$-C_0-C_6-alkyl-$C(O)OR^6$, $-C_0$-C_6-alkyl-$C(O)N(R^7)R^{7a}$, aryl, arylalkyl, -S-(C_1-C_6 alkyl), halo, oxo, nitro, -SCN, cyano, and -C_0-C_6 alkyl-$N(R^7)R^{7a}$, wherein each of the alkyl (including, for example the alkyl within alkoxy), aryl, cycloalkyl, heterocycloalkyl, and heteroaryl groups, either alone or as part of another group within R^2, is independently optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, oxo, nitro, cyano, hydroxy, $-N(R^8)R^{8a}$, alkoxy, and $-C(O)OR^9$;

each R^{3d} (when R^{3d} is present) is independently oxo, nitro, halo, cyano, alkyl, alkenyl, alkynyl, alkoxy, C_3-C_6-cycloalkyl, -C_0-C_6-alkyl-heterocycloalkyl, -C_0-C_6 alkyl-$N(R^7)C(O)$-C_0-C_6-alkyl-$N(R^{7b})R^{7a}$, -C_0-C_6 alkyl-$N(R^7)C(O)$-C_0-C_6-alkyl-$N(R^{7b})C(O)R^{7a}$, -C_0-C_6 alkyl-$C(O)$-C_0-C_6-alkyl-$N(R^7)R^{7a}$, -C_0-C_6-alkyl-$C(O)N(R^7)$-C_0-C_6-alkyl-$N(R^{7b})R^{7a}$, -C_0-C_6-alkyl-$C(O)N(R^7)$-C_1-C_6alkyl$C(O)OR^{7a}$, -C_0-C_6 alkyl-$N(R^7)C(O)$-C_0-C_6-alkyl-(R^{7a}), -C_0-C_6 alkyl-$N(R^7)$-C_0-C_6-alkyl-$N(R^{7b})R^{7a}$, -C_0-C_6 alkyl-$N(R^7)C(O)$-C_0-C_6-alkyl-$N(R^{7b})$-$N(R^{7c})R^{7a}$, -C_0-C_6 alkyl-$N(R^7)C(O)O$-C_0-C_6-alkyl-aryl, -C_0-C_6 alkyl-$C(O)N(R^7)$-C_0-C_6-alkyl-$N(R^{7b})R^{7a}$, -C_0-C_6 alkyl-$N(R^7)$-C_0-C_6 alkyl-$C(=N(R^{7b})(R^{7a}))(NR^{7c}R^{7d})$, -$C_0$-$C_6$-alkyl-aryl, -$C_0$-$C_6$-alkyl-heteroaryl, -$C_0$-$C_6$ alkyl-heterocycloalkyl, -O-C_0-C_6 alkyl-$N(R^7)R^{7a}$, -C_0-C_6 alkyl-OR_6, -C_0-C_6 alkyl-$C(O)OR_6$, C_0-C_6-alkyl-$N(R^7)R^{7a}$, -C_0-C_6 alkyl-$C(O)NR_7R^{7a}$, -C_0-C_6 alkyl-$C(O)R^7$, $-SR_7$, $-S(O)_2R_7$, $-S(O)_3R_7$, $-S(O)R^7$, $-SO_2N(R^7)R^{7a}$, $-SO_2N(R^7)$-C_0-C_6 alkyl-

$N(R^{7b})R^{7a}$, $-C_0$-C_6-alkyl-$N(R^7)$-aryl, $-C_0$-C_6-alkyl-$N(R^7)$-heteroaryl, $-C_0$-C_6-alkyl-$N(R^7)$-heterocycloalkyl, $-C_0$-C_6-alkyl-$C(O)N(R^7)$-C_0-C_6-alkyl-cycloalkyl, C_0-C_6-alkyl-$C(O)N(R^7)$-C_0-C_6-alkyl-aryl, C_0-C_6 alkyl-$C(O)N(R^7)$-C_0-C_6 alkyl-heteroaryl, C_0-C_6 alkyl-$C(O)N(R^7)$-C_0-C_6-alkyl-heterocycloalkyl, $-C_0$-C_6-alkyl-$N(R^7)C(O)$-C_0-C_6-alkyl-cycloalkyl, $-C_0$-C_6-alkyl-$N(R^7)C(O)$-C_0-C_6-alkyl-aryl, C_0-C_6-alkyl-$N(R^7)C(O)$-C_0-C_6-alkyl-heteroaryl, $-C_0$-C_6-alkyl-$N(R^7)C(O)$-C_0-C_6-alkyl-heterocycloalkyl, C_0-C_6-alkyl-$N(R^7)C(O)$-C_0-C_6-alkyl-heterocycloalkyl-aryl, $-N(R^7)C(O)OR^6$, or -NHC(O)H, wherein each of the alkyl, alkenyl, cycloalkyl, aryl, (including, for example the alkyl within alkoxy), heterocycloalkyl, and heteroaryl groups, either alone or as part of another group within R^{3d}, is independently optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, alkenyl, $-C_0$-C_6-alkyl-OR^9, cycloalkyl, halo, haloalkyl, haloalkoxy, $-C(O)R^9$, nitro, cyano, oxo, $-C_0$-C_6-alkyl-$N(R^8)R^{8a}$, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, $-C(O)OR^9$, alkylthio, and hydroxyalkyl;

R^4 is hydrogen, aryl, $-C_0$-C_6-alkyl-$N(R^7)R^{7a}$, alkoxy, or C_1-C_6 alkyl, wherein each of the alkyl and aryl groups, either alone or as part of another group in R^4, is independently optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, $-N(R^8)R^{8a}$, alkoxy, and $-C(O)OR^6$; or

R^4 and X^1 together with the atoms to which they are attached form a heterocycloalkyl or heteroaryl group, wherein R^{5a} is absent when X is $-N(R^{5a})-$, wherein each of the heterocycloalkyl or heteroaryl is optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, $-N(R^7)R^{7a}$, alkoxy, and $-C(O)OR^6$;

R^{5a} is hydrogen, $-C_1$-C_6 alkyl-$N(R^7)R^{7a}$, alkoxy, alkyl, or aryl, wherein each of the alkyl and aryl is optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, $-N(R^8)R^{8a}$, C_1-C_6 alkoxy, or $-C(O)OR^6$; or

R^{5a} and R^4 together with the atoms to which they are attached form a heterocycloalkyl or heteroaryl group, wherein the heterocycloalkyl and heteroaryl is optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, $-N(R^7)R^{7a}$, C_1-C_6 alkoxy, and $-C(O)OR^6$;

R^6 and R^9 are independently hydrogen, hydroxy, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, or aryl, each alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl, either alone or as part of another group within R^6 and R^9, is independently optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from amino, hydroxy, alkoxy, alkyl, and halo; and

R^7, R^{7a} R^{7b}, R^{7c}, R^{7d}, R^8, and R^{8a} are independently hydrogen, alkyl, alkenyl, hydroxy, alkyloxy, alkenyloxy, -O-C_0-C_6 alkyl-aryl, -C_0-C_6 alkyl-C(O)OR^6, -C_0-C_6 alkyl-C(O)R^6, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, or heterocycloalkylalkyl, wherein each of the alkyl, aryl, heteroaryl, and heterocycloalkyl, either alone or part of another group within R^7, R^{7a} R^{7b}, R^{7c}, R^{7d}, R^8, and R^{8a} is independently optionally substituted with 1, 2, 3, 4, or 5 groups selected from amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, -S-C_1-C_6 alkyl, cyano, nitro, hydroxy, C_1-C_6 alkoxy, C_1-C_6 alkyl, halo, aryl, heterocycloalkylalkyl, and heteroaryl optionally substituted with one or two C_1-C_6 alkyl.

9. The method according to claim 1, wherein the active agent is a compound according to Formula I(K):



I(K)

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;

R^2 is hydrogen or alkyl where the alkyl is optionally substituted with 1, 2, 3, 4, or 5 R^8 groups;

X is -NR^3-;

R^3 hydrogen;

R^4 is optionally substituted alkyl;

R^5 is hydrogen; and

R^6 is phenyl, acyl, or heteroaryl wherein the phenyl and heteroaryl are optionally substituted with 1, 2, 3, 4, or 5 R^9 groups;

each R^8, when present, is independently hydroxy, halo, alkoxy, haloalkoxy, amino, alkylamino, dialkylaminoalkyl, or alkoxyalkylamino; and

each R^9, when present, is independently halo, alkyl, haloalkyl, alkoxy, haloalkoxy, cyano, amino, alkylamino, dialkylamino, alkoxyalkyl, carboxyalkyl, alkoxycarbonyl, aminoalkyl, cycloalkyl, aryl, arylalkyl, aryloxy, heterocycloalkyl, or heteroaryl and where the cycloalkyl, aryl, heterocycloalkyl, and heteroaryl, each either alone or as part of another group within R^9, are independently optionally substituted with 1, 2, 3, or 4 groups selected from halo, alkyl, haloalkyl, hydroxy, alkoxy, haloalkxy, amino, alkylamino, and dialkylamino; or

the PI3Kα inhibitor is a compound of Formula II(K):



II(K)

or a pharmaceutically acceptable salt thereof, wherein

R^1 is hydrogen, optionally substituted alkyl, optionally substituted C_3-C_7 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;

X is S, SO_2, or $-NR^3-$;

R^2 is hydrogen, haloalkyl, optionally substituted alkyl, optionally substituted C_3-C_7 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heterocycloalkyl-aryl- or optionally substituted heteroaryl; R^2 is optionally further substituted with one or more R^8 groups;

R^3, R^{3a}, and R^{3b} are independently hydrogen, optionally substituted alkyl, optionally substituted C_3-C_7 cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl or optionally substituted heteroaryl;

R^4 is hydrogen, halo, haloalkyl, haloalkoxy, -NR^{3a}-, optionally substituted alkyl, optionally substituted C_1-C_6 alkoxy, optionally substituted C_1-C_6 alkoxyalkyl, optionally substituted aminoalkyl, optionally substituted C_3-C_7 cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;

R^5 is hydrogen, halo, haloalkyl, haloalkoxy, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 alkoxy, optionally substituted C_1-C_6 alkoxyalkyl, optionally substituted aminoalkyl, optionally substituted C_3-C_7 cycloalkyl, optionally substituted aryl, optionally substituted aryl C_1-C_6 alkyl or optionally substituted heteroaryl; and

R^6 is hydrogen, halo, haloalkyl, haloalkoxy, -NR^{3b}-, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 alkoxy, optionally substituted C_1-C_6 alkoxyalkyl, optionally substituted acyl, optionally substituted aminoalkyl, optionally substituted C_3-C_7 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl; substitutable R^6 groups are optionally further substituted with 1, 2, 3, 4, or 5 R^9 groups;

each R^8, when present, is independently hydroxy, halo, haloalkyl, haloalkoxy, optionally substituted alkyl, optionally substituted C_1-C_6 alkoxy, optionally substituted C_1-C_6 alkoxyalkyl, optionally substituted C_1-C_6 alkoxyalkylaminoalkyl, C_1-C_6 alkylcarboxyheterocycloalkyl, oxy C_1-C_6alkylheterocycloalkyl, optionally substituted aminoalkyl, optionally substituted C_3-C_7 cycloalkyl, optionally substituted aryl, optionally substituted aryl C_1-C_6 alkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;

each R^9, when present, is independently halo, haloalkyl, haloalkoxy, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 alkoxy, optionally substituted C_1-C_6 alkoxyalkyl, optionally substituted C_1-C_6 carboxyalkyl, optionally substituted alkoxycarbonyl, optionally substituted aminoalkyl, optionally substituted C_3-C_7 cycloalkyl, optionally substituted aryl, optionally

substituted aryl C_1-C_6 alkyl, optionally substituted aryloxy, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl.

10. The method according to claim 1, wherein the active agent is a compound according to Formula I(S):



I(S)

or a pharmaceutically acceptable salt thereof, wherein:

V is NR_1R_{1a}, or O-R_1, wherein

R_1 is H, CN, halo, -$NR_{13}R_{14}$, C(O)$NR_{13}R_{14}$, C_1-C_6 alkyl, -C(O)-C_1-C_6 alkyl, -C_0-C_6 alkyl-R_{20}, wherein R_{20} is aryl, heteroaryl, heterocyclyl, or a 5-12 membered fused bicyclical or tricyclic saturated, partially saturated, or unsaturated ring system containing 0-4 ring atoms selected from N, O, and S, wherein aryl, heteroaryl, C_3-C_7 heterocyclyl, or the 5-12 membered ring system are optionally substituted with one, two, or three groups independently selected from C_1-C_6 alkyl, and -C_0-C_6 alkyl-R_{21};

R_{1a} is H or C_1-C_6 alkyl; or when V is NR_1R_{1a}, R_1 and R_{1a} together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group containing, in addition to the nitrogen, up to two additional heteroatoms independently selected from O, N, and S, and wherein each heterocyclyl or heteroaryl group is optionally substituted with one or two of C_1-C_6 alkyl, -$NR_{13}R_{14}$ or C_3-C_7 cycloalkyl;

X is H, halo, C_1-C_6 alkyl, NO_2, mono-, di-, or tri-halo substituted methyl, $NR_{13}R_{14}$, C(O)O-C_1-C_6 alkyl, or N(R_{13})-C(O)-C_1-C_6 alkyl;

Y is H, halo, OH, C_1-C_6 alkyl, C_0-C_6 alkyl-$NR_{15}R_{16}$, C_1-C_6 alkoxy, -N(R_{13})-$(CH_2)_n$-$NR_{15}R_{16}$, -C(O)O-C_1-C_6 alkyl, -O-$(CH_2)_n$-$NR_{15}R_{16}$, -C(O)-C_1-C_6 alkyl, -C_0-C_6-alkyl-R_{21}, -O-R_{21}, -C(O)-R_{21}, -O-$(CH_2)_n$-R_{21}, -C(O)-$NR_{13}R_{14}$, -C(O)-N(R_{13})-aryl, -C(O)-N(R_{13})-$(CH_2)_n$-$NR_{15}R_{16}$, -C(O)-N(R_{13})-$(CH_2)_n$-aryl, -C(O)-N(R_{13})-$(CH_2)_n$-heterocyclyl;

or X and Y together with the atoms to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group containing one or two heteroatoms independently selected from O, N, and S, wherein the heterocyclyl or heteroaryl group is optionally substituted with one or two moieties

independently selected from halo, C_1-C_6 alkyl, aryl-C_1-C_6 alkyl-, aryl-$(CH_2)_n$-O-$(CH_2)_n$-aryl-, arylOH, C_3-C_7 cycloalkyl, heterocyclyl, -aryl-$N(R_{13})C(O)$-C_3-C_7 cycloalkyl-$C(O)$-$N(R_{14})$-aryl, or a group of the Formula -L-M-Q, wherein

L is a bond or C_3-C_7 cycloalkyl,

M is C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl,

Q is $NR_{13}R_{14}$, $N(R_{13})C(O)$-C_1-C_6 alkyl, heterocyclyl, or a saturated fused bicyclic ring containing one or two heteroatoms independently selected from O, N, and S, wherein each aryl, heteroaryl, or heterocyclyl substituent on the group formed by X and Y is optionally further substituted with one or two moieties independently selected from halo, $C(O)O$-$(CH_2)_n$-phenyl, and $C(O)$-C_1-C_6 alkyl;

Z is H, NR_2R_3, -S-R_{2a}, or -Q-R_{2a}, wherein

R_2 is -C_1-C_6 alkyl, -C_1-C_6 alkyl-$NR_{13}R_{14}$, -C(O)-aryl, -C_0-C_6-alkyl-aryl, -C_0-C_6-alkyl-heteroaryl, -C_0-C_6-alkyl-(C_3-C_7-cycloalkyl), -C_0-C_6-alkyl-heterocyclyl, or -C_0-C_6 alkyl-5-12 membered fused bicyclic or tricyclic saturated, partially saturated, or unsaturated ring system containing 0-4 ring atoms selected from N, O, and S, wherein each alkyl is optionally substituted with phenyl, and each aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocyclyl, or 5-12 membered ring system is optionally substituted with one, two, or three groups independently selected from halo, mono-, di-, or tri-halo substituted methyl or methoxy, CN, NO_2, $NR_{13}R_{14}$, $C(O)O$-C_1-C_6 alkyl, $N(R_{13})C(O)$-C_1-C_6 alkyl, -$SO_2NR_{13}R_{14}$, -O-$C(O)$-$NR_{13}R_{14}$, -C_0-C_6 alkyl-$C(O)NR_{15}R_{16}$, C_1-C_6 alkoxy, C_1-C_6 thioalkoxy, -O-$(CH_2)_n$-$NR_{15}R_{16}$, -C_1-C_6 alkyl-$NR_{13}R_{14}$, -$N(R_{13})$-$C(O)$-C_1-C_6 alkyl, -$N(R_{13})$-C(O)-aryl, -C_0-C_6 alkyl-$C(O)$-$N(R_{13})$-$(CH_2)_n$-$NR_{15}R_{16}$, -C_0-C_6 alkyl-$C(O)$-$N(R_{13})$-$(CH_2)_n$-aryl, -O-$(CH_2)_n$-$C(O)$-$N(R_{13})$-$(CH_2)_n$-$NR_{15}R_{16}$, -O-$(CH_2)_n$-$C(O)$-$NR_{15}R_{16}$, -C_0-C_6 alkyl-$C(O)$-$N(R_{13})$-$(CH_2)_n$-O-C_1-C_6 alkyl, -C_0-C_6 alkyl-$N(R_{13})$-$C(O)O$-C_1-C_6 alkyl, -C_0-C_6alkyl-C(O)-heterocyclyl, -C_0-C_6alkyl-C(O)-heteroaryl, -C_0-C_6alkyl-C(O)-aryl, -C_0-C_6-alkyl-R_{21}, aryloxy, -O-$(CH_2)_n$-R_{21}, -SO_2-heterocyclyl, $N(R_{13})$-$C(O)$-C_3-C_7-cycloalkyl, -C_0-C_6alkyl $C(O)O$-R_{21} ,C_3-C_7-cycloalkyl, -C_0-C_6alkylR_{21}, -SC_1-C_6alkyl or C_1-C_6 alkyl optionally substituted with halo or cyano,

wherein each aryl, heteroaryl, cycloalkyl, or heterocyclyl substituent is further optionally substituted with 1-3 groups independently selected from halo, CF_3, C_1-C_6 alkyl, C_1-C_6 haloalkoxy, $NR_{13}R_{14}$ and C_1-C_6 alkoxy;

R_3 is H or C_1-C_6 alkyl;

or R_2 and R_3 together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group containing up to three heteroatoms independently selected from O, N, and S, and wherein the heterocyclyl or heteroaryl group is optionally substituted with one or two of halo or C_1-C_6 alkyl;

R_{2a} is aryl or C_0-C_6 alkyl-heteroaryl, wherein the aryl and heteroaryl are optionally substituted with aryl, -N(R_{13})-C(O)-C_3-C_7 cycloalkyl or -C(O)N$R_{13}R_{14}$;

R_{13} and R_{14} are independently H or C_1-C_6 alkyl;

R_{15} and R_{16} are independently H, C_1-C_6 alkyl, heteroaryl, or heterocyclyl, or R_{15} and R_{16} together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl or heteroaryl group wherein one or two ring carbons are each optionally replaced with a heteroatom independently selected from O, N, and S, and wherein each heterocyclyl or heteroaryl group is optionally substituted with one or two moieties independently selected from halo, C_1-C_6 alkyl, or -C(O)O-C_1-C_6 alkyl;

R_{21} is heterocyclyl, aryl, heteroaryl, or C_3-C_7 cycloalkyl, and wherein alkyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, and heterocyclyl are optionally substituted with one or two moieties independently selected from halo, -S(O)$_2$-C_0-C_1 alkyl, -C(O)-C_0-C_1 alkyl, -C(O)-H, -C_0-C_1 alkyl-aryl, C_1-C_6 alkyl, N$R_{13}R_{14}$, and heterocyclyl;

n is 0-6;

provided that when V is NH_2, X, Y and Z are not simultaneously H.

11. The method according to claim 1, wherein the active agent is a compound according to Formula I(R):



I(R)

or a pharmaceutically acceptable salt thereof, wherein:

A is a three- to seven-membered alicyclic, a five- to six-membered ortho-arylene or a five- to six-membered ortho-heteroarylene containing between one and three heteroatoms, either of the aforementioned optionally substituted with up to four R;

each R is independently selected from -H, halogen, -CN, $-NO_2$, $-OR^3$, $-N(R^3)R^3$, $-S(O)_{0-2}R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, $-OC(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl;

optionally two of R, together with the atoms to which they are attached, form a first ring system fused with A, said first ring system substituted with zero to three of R^1;

X_1, X_2 and X_3 are independently selected from $-CR^1=$ or $-N=$;

each R^1 is independently selected from -H, halogen, -CN, $-NO_2$, $-OR^3$, $-N(R^3)R^3$, $-S(O)_{0-2}R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, $-N(R^3)SO_2R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)CO_2R^3$, $-C(O)R^3$, $-OC(O)R^3$, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6}alkyl;

Z and X are each independently selected from $-C(R^2)=$, $-N=$, $-N(R^2)-$, $-S(O)_{0-2}-$, and -O-;

E and Y are each independently selected from absent, $-C(R^2)(R^2)-$, -C(=O)-, $-C(R^2)=$ and $-N=$, but E and Y are not both absent, and E and Y are not both $-N=$ when both Z and X are $-N=$;

each R^2 is independently selected from R^3, $-N(R^3)(R^3)$, $-C(O)N(R^3)R^3$, $-N(R^3)CO_2R^3$, $-N(R^3)C(O)N(R^3)R^3$, and $-N(R^3)C(O)R^3$;

each R^3 is independently selected from -H, optionally substituted C_{1-6}alkyl, optionally substituted C_{3-7}alicyclic, optionally substituted aryl, optionally substituted aryl C_{1-3}alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-3}alkyl;

optionally two of R^3, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said

optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P; and

G is selected from $-CO_2R^3$, $-C(O)R^3$, $-C(O)N(R^3)R^3$, $-C(O)(NR^3)$, $-C(O)NR^3[C(R^3)_2]_{0-1}R^3$, $-C(O)NR^3O[C(R^3)_2]_{0-1}R^3$, $-N(R^3)CO_2R^3$, $-N(R^3)C(O)N(R^3)R^3$, $-N(R^3)C(O)R^3$, $-N(R^3)R^3$, $-S(O)_{0-2}R^3$, $-SO_2N(R^3)R^3$, optionally substituted aryl C_{0-3}alkyl, and optionally substituted heterocyclyl C_{0-3}alkyl;

with the proviso, however, that the compound is not CAS Registry No. 439096-29-4, 439107-32-1 or 439107-34-3.

12. The method according to claim 1, wherein R^2 of Formula I(J) is



(g)

or



(e)

13. The method according to claim 1, wherein Z of Formula I(J) is 

, R^{26a} is $-C(O)R^{32}$, R^{26} is hydrogen, and R^{32} is selected from tetrahydrofuran, pyrrolidinyl or pryimidinyl, wherein R^{32} is optionally substituted with 1, 2, 3, 4 or 5 groups selected from hydroxyl, oxo, alkyl, alkoxy, amino, hydroxyalkyl and halo.

14. The method according to claim 13, wherein R^{32} of Formula I(J) is U or $-CH_2$-U, wherein U is selected from pyrolidinyl, thiazolidinyl, morpholinyl, azetidinyl, cyclobutyl, cyclopropyl, tetrahydofuranyl, pyrazinyl, imidazolyl, piperazinyl, thienyl, thienylmethyl, furanyl, phenyl, prolinamidyl, pyridinyl, tetrahydronaphthalene, tetrazolyl, isoindolinyl, pyranyl, cyclopentyl, and octahydro-1H-indolyl.

15. The method according to claim 1, wherein the JAK-2 compound has Formula IV(J):

16. The method according to claim 1, wherein the JAK-2 compound has Formula V(J):



wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

17. The method according to claim 1, wherein the JAK-2 compound has Formula VI(J):



wherein R^{28} and R^{28a}, together with the nitrogen atom to which they are attached, form a heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or two R^{31}.

18. The method according to claim 1, wherein the disease being treated is selected from prostate cancer, breast cancer, multiple myeloma, leukemia, lymphoma, lung cancer, colorectal cancer, renal cancer, melanoma, hepatocellular, gastric, GIST, pancreatic carcinoma, papillary thyroid cancer, myelofibrosis, thrombocythemia, polycythemia vera, essentia! thrombocythemia, agnogenic myeloid metaplasia, chronic myelogenous leukemia, and thrombocytosis.

19. The method according to claim 1, wherein the JAK-2 compound is selected from one or more of the following compounds:

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2,6-dichlorobenzamide;

2,6-dichloro-*N*-(3-{[4-(2,3-dihydro-1-benzofuran-6-yl)pyrimidin-2-yl]amino}propyl)benzamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2-fluoro-6-iodobenzamide;

N-(3-{[4-(4-aminophenyl)pyrimidin-2-yl]amino}propyl)-2,6-dichlorobenzamide;

N-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,6-dichlorobenzamide;

N-{4-[2-({3-[(4-ethylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[2-(dimethylamino)ethyl]benzamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2-fluorobenzamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2-fluoro-6-iodobenzamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,6-dimethylbenzamide;

N-(4-{2-[(3-aminophenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]pyridine-4-carboxamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,3,4,5,6-pentafluorobenzamide;

4-(4-chlorophenyl)-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,6-dichlorobenzamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

4-(2,4-dichlorophenyl)-*N*-{3-[(2-piperidin-1-ylethyl)oxy]phenyl}pyrimidin-2-amine;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2-chlorobenzamide;

N-(4-{2-[(3-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(3-piperidin-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2-bromobenzamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-3-fluorobenzamide;

N-[3-({4-[4-(acetylamino)phenyl]-5-methylpyrimidin-2-yl}amino)phenyl]-2,6-dichlorobenzamide;

N-(4-{2-[(3-{[(2,6-dichlorophenyl)sulfonyl]amino}phenyl)amino]-5-methylpyrimidin-4-yl}phenyl)acetamide;

2,6-dichloro-*N*-(3-{[4-(1*H*-indol-5-yl)pyrimidin-2-yl]amino}phenyl)benzamide;

N-[3-({4-[4-(acetylamino)phenyl]-5-fluoropyrimidin-2-yl}amino)phenyl]-2,6-dichlorobenzamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2-methylbenzamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,4-dichlorobenzamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,3-dichlorobenzamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,5-dichlorobenzamide;

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-(4-{2-[(4-piperidin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(2-methyl-4-piperazin-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(3-aminophenyl)amino]pyrimidin-4-yl}phenyl)thiophene-2-carboxamide;

N-(4-{5-methyl-2-[(3-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(3-aminophenyl)amino]pyrimidin-4-yl}phenyl)-2-(phenyloxy)acetamide;

N-(4-{6-methyl-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(3-aminophenyl)amino]pyrimidin-4-yl}phenyl)-2-morpholin-4-ylacetamide;

N-[4-(2-{[3-(methyloxy)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-[3-({4-[4-(acetylamino)-2-chlorophenyl]pyrimidin-2-yl}amino)phenyl]-2,6-dichlorobenzamide;

2,6-dichloro-*N*-{3-[(4-phenylpyrimidin-2-yl)amino]phenyl}benzamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,6-difluorobenzamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,4,5-trifluorobenzamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]benzamide;

N-(4-{6-morpholin-4-yl-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-3,5-difluorobenzamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2-chloro-6-fluoro-3-(methyloxy)benzamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2-chloro-6-fluoro-4-methylbenzamide;

N-(4-{2-[(3-{[(2,6-dimethylphenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

4-(2,4-dichlorophenyl)-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;

4-(2,4-dichlorophenyl)-*N*-{3-[(4-ethylpiperazin-1-yl)carbonyl]phenyl}pyrimidin-2-amine;

N-(3-{[4-(4-aminophenyl)pyrimidin-2-yl]amino}phenyl)-2,6-dichlorobenzamide;

4-(4-aminophenyl)-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;

4-[4-(ethylamino)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;

N-(4-{2-[(4-aminophenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[4-(2-{[4-(methyloxy)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-{4-[2-({3-[4-(pyridin-4-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-[5-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-2-morpholin-4-ylphenyl]-2,6-dichlorobenzamide;

N-(4-{5-fluoro-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{[2-(4-ethylpiperazin-1-yl)-2-oxoethyl]oxy}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[4-(2-{[3-(morpholin-4-ylcarbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-{3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-5-[(4-ethylpiperazin-1-yl)carbonyl]phenyl}-2,6-dichlorobenzamide;

4-[4-(dimethylamino)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;

2,6-dichloro-*N*-(3-{[4-(2,4-dichlorophenyl)pyrimidin-2-yl]amino}phenyl)benzamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]-5-(trifluoromethyl)pyrimidin-4-yl}phenyl)acetamide;

N-(3-{2-[(3-aminophenyl)amino]pyrimidin-4-yl}phenyl)thiophene-2-carboxamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-1-methylpiperidine-4-carboxamide;

N-{4-[2-({3-[(phenylmethyl)amino]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;
N-(4-{2-[(3-aminophenyl)amino]-5-methylpyrimidin-4-yl}phenyl)acetamide;
N-(4-{2-[(3-aminophenyl)amino]-5-fluoropyrimidin-4-yl}phenyl)acetamide;
3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(2-ethylphenyl)benzamide;
3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(phenylmethyl)benzamide;
N-{4-[2-({3-[(4-cyclopentylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;
N-{4-[2-({3-[(4-phenylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;
N-(3-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;
N-(2-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;
N-{4-[2-({3-[(4-pyrazin-2-ylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;
N-(4-{2-[(3-{[4-(3-chlorophenyl)piperazin-1-yl]carbonyl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;
3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(1-methyl-1*H*-benzimidazol-2-yl)methyl]benzamide;
3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-propylbenzamide;
3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-cyclopropylbenzamide;
3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(3-fluorophenyl)methyl]benzamide;
3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(naphthalen-1-ylmethyl)benzamide;
3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[2-(dimethylamino)ethyl]-*N*-methylbenzamide;
3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(2-methylphenyl)methyl]benzamide;
3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(3-chlorophenyl)methyl]benzamide;
3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(2-phenylethyl)benzamide;
N-{4-[2-({3-[(4-methylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;
3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(tetrahydrofuran-2-ylmethyl)benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(3s,5s,7s)-tricyclo[3.3.1.1~3,7~]dec-1-yl]benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[2-(methyloxy)ethyl]benzamide;

N-[4-(2-{[3-(1,3-thiazolidin-3-ylcarbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-{4-[2-({3-[(4-pyridin-2-ylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-{[2-(methyloxy)phenyl]methyl}benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-{[3-(methyloxy)phenyl]methyl}benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(2-fluorophenyl)methyl]benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(4-fluorophenyl)methyl]benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(3,3-dimethylbutyl)benzamide;

N-[4-(2-{[3-(thiomorpholin-4-ylcarbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(2-thienylmethyl)benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[3-(dimethylamino)propyl]benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-{[2-(trifluoromethyl)phenyl]methyl}benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-{[3-(trifluoromethyl)phenyl]methyl}benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-{[4-(trifluoromethyl)phenyl]methyl}benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(2,4-difluorophenyl)methyl]benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-ethyl-*N*-methylbenzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-({4-[(trifluoromethyl)oxy]phenyl}methyl)benzamide;

N-{4-[2-({3-[(4-acetylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(cyclopropylmethyl)benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[2-(2-fluorophenyl)ethyl]benzamide;

N-[4-(2-{[3-(pyrrolidin-1-ylcarbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-{4-[2-({3-[(4-pyrimidin-2-ylpiperazin-1-yl)carbonyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-methyl-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)benzamide;

N-[4-(2-{[3-(1,3-dioxan-2-yi)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-[4-(2-{[3-(morpholin-4-ylmethyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-{4-[2-({3-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-3-[(2-morpholin-4-ylethyl)oxy]benzamide;

4-[4-(methylamino)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;

N-[4-(2-{[4-(4-acetylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-(4-{2-[(3-amino-2,4,5,6-tetrafluorophenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(3-{[4-(2-fluorophenyl)piperazin-1-yl]carbonyl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[2-(phenyloxy)ethyl]benzamide;

methyl 1-{[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]carbonyl}piperidine-4-carboxylate;

N-[4-(2-{[3-({4-[3-(methyloxy)phenyl]piperazin-1-yl}carbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-{2-[2-(methyloxy)phenyl]ethyl}benzamide;

N-[4-(2-{[3-(1,3-dihydro-2*H*-isoindol-2-ylcarbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(biphenyl-4-ylmethyl)benzamide;

N-(4-{2-[(3-{[4-(phenylcarbonyl)piperazin-1-yl]carbonyl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[4-(2-{[3-({4-[4-(methyloxy)phenyl]piperazin-1-yl}carbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-methyl-*N*-{[2-(methyloxy)phenyl]methyl}benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(2-fluorophenyl)methyl]-*N*-methylbenzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(diphenylmethyl)benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(2-pyridin-2-ylethyl)benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(pyridin-2-ylmethyl)benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[2-(2-chlorophenyl)ethyl]benzamide;

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}-5-fluoropyrimidin-4-yl)phenyl]acetamide;

N^2-[3-(1*H*-imidazol-1-yl)propyl]-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)glycinamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)- N^2-(2-pyridin-3-ylethyl)glycinamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(pyridin-3-ylmethyl)benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(pyridin-4-ylmethyl)benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-methyl-*N*-(phenylmethyl)benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-cyclopentylbenzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(2-chlorophenyl)methyl]benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(4-chlorophenyl)methyl]benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-(furan-2-ylmethyl)benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-{[4-(methyloxy)phenyl]methyl}benzamide;

N-[4-(2-{[3-({4-[2-(methyloxy)phenyl]piperazin-1-yl}carbonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[3-(methyloxy)propyl]benzamide;

N-(4-{2-[(3-{[(2*R*,6*S*)-2,6-dimethylmorpholin-4-yl]carbonyl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-[(6-chloropyridin-3-yl)methyl]benzamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-butylbenzamide;

N-(4-{2-[(3-{[4-(2-chlorophenyl)piperazin-1-yl]carbonyl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-*N*-ethyl-*N*-[2-(methyloxy)ethyl]benzamide;

N-(4-(2-(3-(3-morpholinopropoxy)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(3-(2-(dimethylamino)ethoxy)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-[3-({4-[4-(acetylamino)phenyl]-5-methylpyrimidin-2-yl}amino)phenyl]-2,6-dimethylbenzamide;

N-[4-(2-{[4-(phenyloxy)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

4-(4-aminophenyl)-*N*-[4-(phenyloxy)phenyl]pyrimidin-2-amine;

N-{4-[2-({4-[(phenylmethyl)oxy]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

4-(4-aminophenyl)-*N*-[3-(morpholin-4-ylsulfonyl)phenyl]pyrimidin-2-amine;

N-(4-{2-[(3,5-dimorpholin-4-ylphenyl)amino]-5-fluoropyrimidin-4-yl}phenyl)acetamide;

N-{4-[2-({4-[4-(phenylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-(4-{2-[(4-{4-[(5-methyl-3-phenylisoxazol-4-yl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[(5-methyl-1-phenyl-1*H*-pyrazol-4-yl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[(2-phenyl-1,3-thiazol-4-yl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[4-(2-{[4-(4-{[6-(phenyloxy)pyridin-3-yl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-{4-[2-({4-[4-(cyclohexylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-(4-{2-[(4-{4-[(1*S*,4*S*)-bicyclo[2.2.1]hept-5-en-2-ylmethyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[4-(2-{[4-(4-pentylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-(4-{2-[(4-{4-[(2-chlorophenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[4-(2-{[4-(4-{[3,5-bis(methyloxy)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-(4-{2-[(4-{4-[(4-fluorophenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[(1-methyl-1*H*-pyrrol-2-yl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[(2,4-dichlorophenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-{4-[2-({4-[4-(9*H*-fluoren-2-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-(4-{2-[(4-{4-[(3-methyl-2-thienyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[(5-ethylfuran-2-yl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[(3-{[4-(1,1-dimethylethyl)phenyl]oxy}phenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-{4-[2-({4-[4-(3-thienylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

methyl 4-({4-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}methyl)benzoate;

N-(4-{2-[(4-{4-[3-(methylthio)propyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[(4-{[3-(dimethylamino)propyl]oxy}phenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[4-(2-{[4-(4-{2-[(phenylmethyl)oxy]ethyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-(4-{2-[(4-{4-[(2-chloroquinolin-3-yl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[(4-chloro-2,6-dimethylphenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-{1-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]pyrrolidin-3-yl}acetamide;

N^2-[3-(4-methylpiperazin-1-yl)propyl]-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)glycinamide;

N^2-(1-methylpiperidin-4-yl)-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)glycinamide;

N-{4-[2-({4-[(pyridin-4-ylmethyl)oxy]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-(4-{2-[(4-{[2-(methyloxy)ethyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

2-(dimethylamino)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)furan-2-carboxamide;

2-(methyloxy)-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)cyclobutanecarboxamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)azetidine-3-carboxamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)piperidine-2-carboxamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)piperidine-3-carboxamide;

N-[4-(2-{[4-(dimethylamino)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-(4-{2-[(4-chlorophenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(3-{[(2-fluorophenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)piperidine-4-carboxamide;

2-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)glycinamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)morpholine-2-carboxamide;

N^2-methyl-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)glycinamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-beta-alaninamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)phenylalaninamide;

N-[4-(2-{[4-(3-oxopiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-[4-(2-{[4-(4-{[5-(3-chlorophenyl)furan-2-yl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-[4-(2-{[4-(4-{[4-fluoro-2-(trifluoromethyl)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-[4-(2-{[4-(4-{[4-(1*H*-imidazol-1-yl)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-[4-(2-{[4-(4-{[2,5-bis(trifluoromethyl)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-(4-{2-[(4-{4-[(2,6-dimethylphenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[(2,3-dimethylphenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[4-(2-{[4-(4-{[2,4-bis(ethyloxy)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-[4-(2-{[4-(4-{[3-(ethyloxy)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-{4-[2-({4-[4-(2,2'-bithien-5-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-[4-(2-{[4-(4-{[4-(2-thienyl)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-(4-{2-[(4-{4-[(4-cyanophenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[4-(2-{[4-(4-{[2,5-bis(methyloxy)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-{4-[2-({4-[4-(2,2-diphenylethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({4-[4-(1*H*-pyrrol-2-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-(1*H*-indazol-6-ylamino)-5-methylpyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-(1*H*-indol-5-ylamino)-5-methylpyrimidin-4-yl]phenyl}acetamide;

N-[4-(2-{[4-(morpholin-4-ylmethyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-(4-{2-[(3-{[(3-fluorophenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(3-{[(4-fluorophenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

4-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-*N*-ethylpiperazine-1-carboxamide;

N-{4-[2-({4-[4-(ethylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-(1*H*-indazol-5-ylamino)-5-methylpyrimidin-4-yl]phenyl}acetamide;

N-[4-(2-{[4-(4-propylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-[4-(2-{[4-(4-butylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-{4-[2-({4-[4-(cyclopropylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

4-[4-(methylsulfonyl)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;

ethyl *N*-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-*N*-methylglycinate;

4-[3-(methylsulfonyl)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;

4-[4-(methylthio)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;

N-(4-{2-[(4-cyclohexylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-{4-[2-({4-[(tetrahydrofuran-2-ylmethyl)amino]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({4-[(phenylmethyl)amino]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-[4-(2-{[4-(acetylamino)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

methyl (4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)carbamate;

1-ethyl-3-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)urea;

ethyl 1-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]piperidine-3-carboxylate;

ethyl [4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]acetate;

4-[4-(methyloxy)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;

4-[3-(methyloxy)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;

4-(1*H*-indol-5-yl)-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;

2-[(2-amino-2-oxoethyl)amino]-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

2-morpholin-4-yl-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

2,6-dichloro-*N*-{3-[(4-{4-[(cyclopropylcarbonyl)amino]phenyl}pyrimidin-2-yl)amino]phenyl}benzamide;

N^2-(2-aminoethyl)- N^2-methyl-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)glycinamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)- N^2-1*H*-pyrazol-5-ylglycinamide;

phenylmethyl *N*-{2-[(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)amino]-2-oxoethyl}-L-alaninate;

4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}benzamide;

1,1-dimethylethyl [(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)methyl]carbamate;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)propanamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-phenylacetamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-3-phenylpropanamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)tetrahydrofuran-2-carboxamide;

5-methyl-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyrazine-2-carboxamide;

2-(ethyloxy)-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-(phenyloxy)acetamide;

N-[4-(2-{[4-(1*H*-pyrrol-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-[4-(2-{[4-(2,6-dimethylmorpholin-4-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

ethyl 1-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]piperidine-4-carboxylate;

2-cyclopentyl-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-3-pyridin-3-ylpropanamide;

6-(methyloxy)-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridine-3-carboxamide;

methyl 4-[(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)amino]-4-oxobutanoate;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)butanamide;

N-(4-{2-[(4-{bis[2-(methyloxy)ethyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[4-(2-{[4-(morpholin-4-ylsulfonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

4-(4-(aminomethyl)phenyl)-*N*-(4-morpholinophenyl)pyrimidin-2-amine;

N-[(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)methyl]acetamide;

N-(4-morpholin-4-ylphenyl)-4-{4-[(propylamino)methyl]phenyl}pyrimidin-2-amine;

N-(4-{2-[(4-piperidin-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(3,5-dimorpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

2-(2-methylphenyl)-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)cyclopentanecarboxamide;

N,*N*-dimethyl-*N'*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)butanediamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)- N^2-pyrimidin-4-ylglycinamide;

3-chloro-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridine-4-carboxamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-piperidin-1-ylacetamide;

N^2-ethyl-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)glycinamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-pyrrolidin-1-ylacetamide;

2-(1*H*-imidazol-1-yl)-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-piperazin-1-ylacetamide;

N-[4-(2-{[4-(4-phenylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-(4-{2-[(3-chloro-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-piperazin-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

'*N*-[6-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)pyridin-2-yl]-2,6-dichlorobenzamide;

'*N*-[6-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)pyrimidin-4-yl]-2,6-dichlorobenzamide;

'*N*-(4-{2-[(6-aminopyridin-2-yl)amino]pyrimidin-4-yl}phenyl)acetamide;

'*N*-(4-{2-[(6-aminopyrimidin-4-yl)amino]pyrimidin-4-yl}phenyl)acetamide;

'5-fluoro- N^4-[2-(methyloxy)phenyl]- N^2-[3-(methyloxy)phenyl]pyrimidine-2,4-diamine;

'2,6-dichloro-*N*-{3-[(4-{[3-chloro-4-(methyloxy)phenyl]oxy}pyrimidin-2-yl)amino]phenyl}benzamide;

'4-{[2-chloro-4-(methyloxy)phenyl]oxy}-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;

'*N*-[4-({2-[(4-morpholin-4-ylphenyl)amino]-7*H*-pyrrolo[2,3-d]pyrimidin-4-yl}amino)phenyl]acetamide;

'*N*-[4-({2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}oxy)phenyl]acetamide;

N-{4-[2-({4-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({4-[(2*R*,6*S*)-2,6-dimethylmorpholin-4-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-(4-{2-[(4-{4-[(2-methylphenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-{4-[2-({4-[4-(1*H*-pyrazol-4-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-(4-{2-[(3-piperazin-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[4-(2-{[3-(4-{[2-(methyloxy)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-{4-[2-({3-[4-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-(4-{2-[(3-bromo-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[4-(2-{[4-{[2-(diethylamino)ethyl]oxy}-3-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}benzoic acid;

4-(4-furan-2-ylphenyl)-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;

4-[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;

4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}benzonitrile;

methyl 4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}benzoate;

4-(4-fluorophenyl)-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;

N-[3-({2-[(4-morpholin-4-ylphenyl)amino]-7*H*-pyrrolo[2,3-d]pyrimidin-4-yl}amino)phenyl]acetamide;

N-(4-morpholin-4-ylphenyl)-4-[4-(pyridin-3-ylamino)phenyl]pyrimidin-2-amine;

N-(4-morpholin-4-ylphenyl)-4-[4-(pyridin-2-ylamino)phenyl]pyrimidin-2-amine;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)methanesulfonamide;

1-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-3-(phenylmethyl)urea;

4-(2,3-dihydro-1,4-benzodioxin-6-yl)-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]-7*H*-pyrrolo[2,3-d]pyrimidin-4-yl}phenyl)acetamide;

N-(4-morpholin-4-ylphenyl)-4-quinolin-6-ylpyrimidin-2-amine;

4-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]-*N*-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;

N-(4-morpholin-4-ylphenyl)-4-(4-pyrimidin-5-ylphenyl)pyrimidin-2-amine;

N-(4-morpholin-4-ylphenyl)-4-quinoxalin-6-ylpyrimidin-2-amine;

2-chloro-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)benzamide;

2-(2-fluorophenyl)-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyrimidine-5-carboxamide;

(2*S*)-*N*-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)azetidine-2-carboxamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)- N^2-phenylglycinamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-prolinamide;

N-(4-(2-(3-methoxy-4-morpholino-phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(4-(4-isobutyrylpiperazin-1-yl)phenylamino)-pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(4-(4-(3-methylbutanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(4-(4-(cyclopropanecarbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(4-(4-(cyclobutanecarbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(4-(4-(cyclopentanecarbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(4-(4-(2-methoxybenzoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(4-(4-pentanoylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(4-(4-picolinoylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(4-(4-isonicotinoylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(4-(4-(1-acetylpiperidine-4-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(4-(4-(2-cyclopropylacetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(4-(4-(2-(2-methoxyethoxy)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(4-(4-(2-(pyridin-3-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(4-(4-(3-(pyridin-3-yl)propanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide;

N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-2-(pyridin-3-yl)acetamide;

N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)isonicotinamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-prolinamide;

N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]-D-prolinamide;

O-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-serinamide;

(*S*)-3-hydroxy-*N*-(4-(2-(4-morpholino-phenylamino)-pyrimidin-4-yl)-phenyl)-butanamide;

(*R*)-3-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide;

(*R*)-2-amino-3-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide;

2-*H*ydroxy-2-methyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide;

2-methyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-*N*-(4-(2-(4-((*R*)-3-(dimethylamino)pyrrolidin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

4-amino-1,1-dioxo-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)tetrahydro-2*H*-thiopyran-4-carboxamide;

(*R*)-4-(4-aminophenyl)-*N*-(4-(3-(dimethylamino)-pyrrolidin-1-yl)phenyl)-pyrimidin-2-amine;

(*R*)-*N*-(4-(2-(4-(3-(dimethylamino)pyrrolidin-1-yl)phenylamino)-pyrimidin-4-yl)phenyl)-3-methoxy-propanamide;

N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)piperazine-2-carboxamide;

2-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-1,2,3,4-tetrahydronaphthalene-2-carboxamide;

4-(4-(1,1-dioxo-isothiazolidin-2-yl)phenyl)-*N*-(4-morpholinophenyl)-pyrimidin-2-amine;

4-(4-(1*H*-tetrazol-1-yl)phenyl)-*N*-(4-morpholinophenyl)-pyrimidin-2-amine;

(*R*)-*N*-(4-(2-(3-(benzyloxy)-4-morpholino-phenylamino)-pyrimidin-4-yl)phenyl)-pyrrolidine-2-carboxamide;

(*S*)-2-amino-3-hydroxy-*N*-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide;

N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-2-(1*H*-tetrazol-1-yl)acetamide;

(*R*)-*N*-(4-(2-(3-ethoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-pyrrolidine-2-carboxamide;

(*R*)-*N*-(4-(2-(1,2,3,4-tetrahydroquinolin-6-ylamino)-pyrimidin-4-yl)phenyl)-pyrrolidine-2-carboxamide;

3-hydroxy-*N*-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-3-methylbutanamide;

(3*S*,7*S*)-7-(hydroxymethyl)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)quinuclidine-3-carboxamide;

1-hydroxy-*N*-(4-(2-(4-morpholino-phenylamino)-pyrimidin-4-yl)phenyl)cyclopropanecarboxamide;

(*S*)-2-amino-*N*-(4-(2-(3-methyl-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide;

(*R*)-*N*-(4-(2-(3-methyl-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-*N*-(4-(2-(4-morpholino-3-(trifluoromethyl)-phenylamino)pyrimidin-4-yl)-phenyl)-pyrrolidine-2-carboxamide;

(*R*)-*N*-(4-(2-(4-(4-((*S*)-tetrahydrofuran-2-carbonyl)-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl)phenyl)-pyrrolidine-2-carboxamide;

(*R*)-*N*-(4-(2-(4-(4-((*R*)-tetrahydrofuran-2-carbonyl)-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl)phenyl)-pyrrolidine-2-carboxamide;

4-methyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)piperazine-1-carboxamide;

3-methoxy-*N*-(4-(2-(4-morpholino-3-(trifluoromethyl)phenylamino)pyrimidin-4-yl)phenyl)propanamide;

3-methoxy-*N*-(4-(2-(4-morpholino-phenylamino)pyrimidin-4-yl)phenyl)-propane-1-sulfonamide;

2-methoxy-*N*-(4-(2-(4-morpholino-phenylamino)pyrimidin-4-yl)phenyl)-ethanesulfonamide;

(*S*)-3-hydroxy-*N*-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide;

(*R*)-3-hydroxy-*N*-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide;

N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-2,5-dihydro-1*H*-pyrrole-2-carboxamide;

1-(3-(dimethylamino)propyl)-3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)urea;

(*R*)-*N*-(4-(2-(4-(4-((*S*)-pyrrolidin-2-ylmethyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-2-amino-*N*-(4-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)-5-methylpyrimidin-4-yl)phenyl)propanamide;

1-(3-methoxypropyl)-3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)urea;

(*R*)-*N*-(4-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)-5-methylpyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*S*)-*N*-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)-3-fluorophenylamino)pyrimidin-4-yl)phenyl)-5-oxopyrrolidine-2-carboxamide;

(*R*)-*N*-(4-(2-(3-chloro-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

1-(2-morpholinoethyl)-3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)urea;

1-(2-(dimethylamino)ethyl)-3-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)urea;

(*S*)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-2-(pyrrolidin-2-yl)acetamide;

2,3-dihydroxy-*N*-(4-(2-(4-morpholino-phenylamino)pyrimidin-4-yl)phenyl)-propanamide;

(*S*)-2-amino-4-methyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pentanamide;

(*R*)-2-amino-4-methyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pentanamide;

N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)isoindoline-1-carboxamide;

N-ethyl-4-(4-(4-(4-(tetrahydrofuran-2-carboxamido)phenyl)pyrimidin-2-ylamino)phenyl)piperazine-1-carboxamide;

N-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-2-carboxamide;

(*R*)-*N*-(4-(2-(4-(4-((*R*)-2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-*N*-(4-(2-(4-(4-((*S*)-2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

N-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide;

3-methoxy-*N*-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide;

N-(4-(2-(4-(4-pivaloylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide;

(*R*)-*N*-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-1-methylpyrrolidine-2-carboxamide;

(*R*)-*N*-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-4-(4-(4-(2-aminopropanamido)phenyl)-pyrimidin-2-ylamino)phenyl)-*N*-ethylpiperazine-1-carboxamide;

(*R*)-2-amino-*N*-(4-(2-(4-(4-((*R*)-pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide;

(*R*)-2-amino-*N*-(4-(2-(4-(4-((*S*)-pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide;

(*R*)-2-amino-*N*-(4-(2-(4-(4-((*S*)-2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide;

(*R*)-*N*-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*S*)-*N*-(4-(2-(4-(4-(pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide;

N-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide;

(*R*)-*N*-(4-(2-(4-(4-(pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide;

1-ethyl-3-(4-(5-methyl-2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)urea;

(*S*)-*N*-(4-(2-(4-(4-(2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide;

(*R*)-*N*-(4-(2-(4-(4-(2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-methoxypropanamide;

(*S*)-3-methoxy-*N*-(4-(2-(4-(4-(pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide;

(*R*)-*N*-(4-(2-(4-(4-(2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide;

N-(4-(2-(4-(4-(cyclobutanecarbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide;

N-(4-(2-(4-(4-isobutyrylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide;

N-(4-(2-(4-(1-butyryl-1,2,4-triazinan-4-yl)phenylamino)pyrimidin-4-yl)phenyl)butyramide;

1-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-ethylurea;

N-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-methoxypropanamide;

N-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide;

N-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)butyramide;

1-ethyl-3-(4-(2-(4-(4-pivaloylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)urea;

1-(4-(2-(4-(4-(cyclobutanecarbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-ethylurea;

1-ethyl-3-(4-(2-(4-(4-isobutyrylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)urea;

N-ethyl-4-(4-(4-(4-(3-ethylureido)phenyl)pyrimidin-2-ylamino)phenyl)piperazine-1-carboxamide;

(*S*)-1-ethyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-1-(2-hydroxyethyl)-*N*-(4-(2-(4-morpholinobenzyl)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-1-isopropyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*S*)-2-(dimethylamino)-*N*-(4-(2-(4-(4-(pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

1-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-ethylurea;

(*R*)-1-ethyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

4-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)tetrahydro-2*H*-pyran-4-carboxamide;

(*R*)-2-amino-*N*-(4-(2-(4-(4-isobutyrylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide;

(*R*)-2-amino-*N*-(4-(2-(4-(4-((*R*)-2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide;

(*R*)-*N*-(4-(5-methyl-2-(4-(4-((1-methyl-1*H*-imidazol-2-yl)methyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-2-amino-*N*-(4-(5-methyl-2-(4-(4-((1-methyl-1*H*-imidazol-2-yl)methyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide;

(*R*)-2-(dimethylamino)-*N*-(4-(2-(4-(4-(pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

(*R*)-*N*-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*S*)-*N*-(4-(5-methyl-2-(4-(4-((1-methyl-1*H*-imidazol-2-yl)methyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-2-amino-*N*-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide;

(2*R*)-*N*-(4-(2-(4-(4-(tetrahydrofuran-3-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*S*)-1-ethyl-3-(4-(2-(4-(4-(pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)urea;

(*S*)-1-(4-(2-(4-(4-(2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-ethylurea;

N-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)butyramide;

(*S*)-*N*-(4-(2-(4-(4-(2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)butyramide;

3-methoxy-*N*-(4-(5-methyl-2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide;

(*R*)-2-amino-*N*-(4-(5-methyl-2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide;

2-(dimethylamino)-*N*-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

1-ethyl-3-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)urea;

3-methoxy-*N*-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide;

(*R*)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-5-oxopyrrolidine-2-carboxamide;

(*S*)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-5-oxopyrrolidine-2-carboxamide;

(*S*)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-3-carboxamide;

(2*R*,3*S*)-2-amino-3-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide;

(*R*)-2-amino-*N*-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide;

N-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide;

N-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butyramide;

N-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)butyramide;

N-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide;

(*R*)-2-amino-*N*-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide;

(2*S*,3*R*)-2-amino-3-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide;

(*R*)-*N*-(4-(2-(4-((2*S*,6*R*)-2,6-dimethylmorpholino)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-*N*-(4-(2-(4-(4-(3-hydroxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

1-ethyl-3-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)urea;

(*R*)-1-ethyl-3-(4-(2-(4-(4-(pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)urea;

3,3,3-trifluoro-2-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide;

(*R*)-1-(4-(2-(4-(4-(2-aminopropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-ethylurea;

2-(dimethylamino)-*N*-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

(*R*)-2-amino-*N*-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide;

(*R*)-*N*-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-2-amino-*N*-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide;

N-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)-3-methoxypropanamide;

N-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)butyramide;

N-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide;

N-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide;

(*R*)-*N*-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-2-carboxamide;

2-(dimethylamino)-*N*-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

(*R*)-*N*-(4-(2-(4-(4-(piperidine-4-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

3-methoxy-*N*-(4-(2-(4-(4-(piperidine-4-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide;

1-ethyl-3-(4-(2-(4-(4-(piperidine-4-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)urea;

N-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropanoyl)piperazin-1-yl)benzyl)pyrimidin-4-yl)phenyl)acetamide;

(*S*)-*N*-(4-(2-(4-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-2-carboxamide;

(*R*)-*N*-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-2-carboxamide;

(4*S*)-4-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-*N*-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-2-carboxamide;

(*S*)-*N*-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-2-carboxamide;

N-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide;

N-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide;

(*S*)-*N*-(4-(2-(4-(4-(pyrrolidine-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)butyramide;

(2*R*)-*N*-(4-(2-(4-(4-(tetrahydrofuran-2-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-*N*-(4-(5-chloro-2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

N-(4-(2-(4-(4-(3-(diethylamino)propanoyl)piperazin-1-yl)benzyl)pyrimidin-4-yl)phenyl)acetamide;

(*S*)-1-(2-hydroxyethyl)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-3-carboxamide;

(*S*)-2-amino-*N*1-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pentanediamide;

(*R*)-2-amino-*N*1-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pentanediamide;

(*R*)-2-amino-*N*1-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)succinamide;

(*R*)-*N*-(4-(2-(4-(4-((4-chloro-1-methyl-1*H*-pyrazol-3-yl)methyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*S*)-1-ethyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-3-carboxamide;

(*R*)-*N*-(4-(2-(4-(4-(2-ethoxyacetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-*N*-(4-(2-(4-(4-(2-(pyrrolidin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-*N*-(4-(2-(4-(4-(2-morpholinoacetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-1*H*-imidazole-4-carboxamide;

2-(dimethylamino)-*N*-(4-(2-(4-(4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

(*S*)-*N*-(4-(2-(4-(4-(3-(dimethylamino)-2,2-dimethylpropyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-2-carboxamide;

(*R*)-2-hydroxy-2-methyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide;

(*S*)-2-hydroxy-2-methyl-*N*-(4-(2-(4-morpholinobenzyl)pyrimidin-4-yl)phenyl)butanamide;

(*R*)-2-methoxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide;

(*S*)-2-methoxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide;

(*R*)-*N*-(4-(2-(4-(4-(2-methoxyacetyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-*N*-(4-(2-(4-(4-acetylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*S*)-2-amino-*N*-(4-(5-methyl-2-(4-(4-((1-methyl-1*H*-imidazol-2-yl)methyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)propanamide;

N-(4-(2-(4-(4-(piperidine-4-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide;

(2*R*,4*S*)-4-hydroxy-*N*-(4-(2-(4-(4-(3-methoxypropanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

1-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)cyclopentanecarboxamide;

(*R*)-*N*-(4-(2-(4-(4-formylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-1-(2-hydroxyethyl)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-3-carboxamide;

1-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)cyclopropanecarboxamide;

N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-1*H*-pyrrole-2-carboxamide;

N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-1*H*-imidazole-2-carboxamide;

(*S*)-2-hydroxy-3,3-dimethyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide;

(*R*)-2-cyclohexyl-2-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)acetamide;

(*S*)-2-cyclohexyl-2-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)acetamide;

(*S*)-2-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide;

1-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)cyclobutanecarboxamide;

(*R*)-*N*-(4-(2-(6-morpholinopyridin-3-ylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*S*)-*N*-(4-(2-(3-chloro-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(2*R*,3*R*)-2-amino-3-methyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pentanamide;

1-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)cyclopentanecarboxamide;

(*R*)-*N*-(4-(2-(4-(4-(4-(dimethylamino)butanoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-*N*-(4-(2-(4-(2-methoxyethyl)-3,4-dihydro-2*H*-benzo[b][1,4]oxazin-7-ylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-2-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)butanamide;

(*R*)-2-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pentanamide;

(*R*)-2-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)hexanamide;

(*R*)-2-amino-3-methoxy-*N*-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide;

(2*S*,3*R*)-2-amino-3-methyl-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pentanamide;

(*R*)-*N*-(4-(2-(3-fluoro-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

N-(4-(2-(3-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)-2-(1*H*-tetrazol-1-yl)acetamide;

(*S*)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)indoline-2-carboxamide;

(*R*)-tert-butyl 2-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenylcarbamoyl)pyrrolidine-1-carboxylate;

1-acetyl-4-amino-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)piperidine-4-carboxamide;

(*R*)-2-amino-3-methoxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide;

(*S*)-*N*-(4-(2-(3-fluoro-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-2-amino-*N*-(4-(2-(3-fluoro-4-morpholinophenylamino)pyrimidin-4-yl)phenyl)propanamide;

2-hydroxy-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)acetamide;

(*R*)-*N*-(4-(2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-*N*-(4-(2-(4-(4-((1-methyl-1*H*-pyrrol-2-yl)methyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(*R*)-*N*-(4-(2-(4-(4-((*R*)-pyrrolidin-2-ylmethyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide;

(2*S*,3a*S*,7a*S*)-*N*-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)octahydro-1*H*-indole-2-carboxamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)cyclopropanecarboxamide;

N-(4-{5-methyl-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)cyclopropanecarboxamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)valinamide;

N-(4-{2-[(4-{4-[(1-methyl-1H-imidazol-2-yl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(3,5-dimorpholin-4-ylphenyl)amino]-5-methylpyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-alaninamide;

N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

2-amino-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-phenylacetamide;

N-(4-{5-methyl-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

3-(methyloxy)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)propanamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)prolinamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-alaninamide;

N-(4-{2-[(4-{4-[3-(dimethylamino)-2,2-dimethylpropyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[3-(methyloxy)propanoyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-1,3-thiazole-4-carboxamide;

N-(4-{2-[(2-methyl-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-pyrrolidin-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[4-(2-{[4-(diethylamino)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-(4-{2-[(4-azepan-1-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-{4-[2-({4-[methyl(2-phenylethyl)amino]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-[4-(2-{[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-[4-(2-{[4-(2-oxopiperidin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-[4-(2-{[4-(2-methylpiperidin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-valinamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-valinamide;

2-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)alaninamide

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)tryptophanamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamide;

O-(1,1-dimethylethyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-serinamide

3-amino-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)tetrahydrofuran-3-carboxamide;

bis(1,1-dimethylethyl) (2R)-2-{[(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)amino]carbonyl}piperazine-1,4-dicarboxylate;

N-(4-{2-[(4-{4-[2-(2-fluorophenyl)acetyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[2-(2-methylphenyl)acetyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[2-(3-fluorophenyl)acetyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-{4-[2-({4-[4-(3-thienylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-(4-{2-[(4-{4-[(6-chloropyridin-3-yl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[(3-methylfuran-2-yl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-(2-(4-(4-(3-fluoro-2-methylbenzoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(4-(4-(1H-imidazole-4-carbonyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(4-(4-(2-methoxynicotinoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-(4-(2-(4-(4-(4-fluoro-3-methylbenzoyl)piperazin-1-yl)phenylamino)pyrimidin-4-yl)phenyl)acetamide;

N-{4-[2-({4-[4-(naphthalen-2-ylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({4-[4-(quinolin-8-ylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-[4-(2-{[4-(4-{[4-(1,1-dimethylethyl)phenyl]sulfonyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-[4-(2-{[4-(4-{[5-bromo-2-(methyloxy)phenyl]sulfonyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-(4-{2-[(4-{4-[(phenylmethyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[4-(2-{[4-(4-{[3-(trifluoromethyl)phenyl]sulfonyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-(4-{2-[(4-{4-[(2-methylphenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[(3-fluorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[(2,4-difluorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-{4-[2-({3-[4-({4-[(trifluoromethyl)oxy]phenyl}methyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-(4-{2-[(3-{4-[(1-methyl-1H-imidazol-2-yl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-{4-[2-({3-[4-({2-[(trifluoromethyl)oxy]phenyl}methyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-(4-{2-[(3-{4-[(3-chlorophenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-{4-[2-({3-[4-(2,3-dihydroxypropyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({3-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({3-[4-(pyridin-2-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({3-[4-(pyridin-3-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({3-[4-(1H-pyrrol-2-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

4-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-N-(phenylmethyl)piperazine-1-carboxamide;

N-[4-(2-{[3-(4-{[2-(methyloxy)phenyl]carbonyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-{4-[2-({3-[4-(1H-pyrazol-4-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({3-[4-(3-pyridin-3-ylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-(4-{2-[(3-{4-[3-(methyloxy)propanoyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[4-(2-{[3-(4-{2-[(4-fluorophenyl)oxy]acetyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-{4-[2-({3-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({3-[4-(pyridin-4-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({3-[4-(pyridin-2-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-(4-{2-[(3-{4-[(2-methylphenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-{4-[2-({3-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({3-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({3-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-3-carboxamide;

(2R)-N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-2-carboxamide;

(2S)-N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-2-carboxamide;

N-(4-{2-[(4-{4-[(2-fluorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(3-{4-[(3,5-dichlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

ethyl 3-[(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)amino]-3-oxopropanoate;

N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}tetrahydrofuran-3-carboxamide;

N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}tetrahydrofuran-3-carboxamide;

N-ethyl-4-{4-[(4-{4-[(tetrahydrofuran-3-ylcarbonyl)amino]phenyl}pyrimidin-2-yl)amino]phenyl}piperazine-1-carboxamide;

N-[4-(2-{[4-(4-D-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-3-carboxamide;

N-[4-(2-{[4-(4-L-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-3-carboxamide;

N-[4-(2-{[4-(4-D-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-3-carboxamide;

N-[4-(2-{[4-(4-L-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-3-carboxamide;

N-{4-[2-(1H-benzimidazol-6-ylamino)-5-methylpyrimidin-4-yl]phenyl}acetamide;

4-(4-furan-2-ylphenyl)-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;

N-(4-morpholin-4-ylphenyl)-4-[4-(pyrimidin-2-ylamino)phenyl]pyrimidin-2-amine;

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}-5-methylpyrimidin-4-yl)phenyl]cyclopropanecarboxamide;

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]cyclopropanecarboxamide;

N-(4-{2-[(3,5-dimorpholin-4-ylphenyl)amino]-5-methylpyrimidin-4-yl}phenyl)- N^2, N^2-dimethylglycinamide;

N^2, N^2-dimethyl-N-(4-{5-methyl-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)glycinamide;

N-(4-{5-methyl-2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-prolinamide;

N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-prolinamide;

N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-prolinamide;

N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-prolinamide;

N-ethyl-4-[4-({4-[4-(D-prolylamino)phenyl]pyrimidin-2-yl}amino)phenyl]piperazine-1-carboxamide;

N-[4-(2-{[4-(4-D-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-D-prolinamide;

N-[4-(2-{[4-(4-L-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-D-prolinamide;

1-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)piperidine-2-carboxamide;

N-{4-[2-({4-[4-(piperidin-4-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

1-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-prolinamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-pyridin-4-ylacetamide;

2-(3-fluorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

3-(4-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)propanamide;

2-(3-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

2-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-3-phenylpropanamide;

(1R,2R)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-phenylcyclopropanecarboxamide;

2-(4-fluorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

3-(2-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)propanamide;

3-(3-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)propanamide;

3-(2-fluorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)propanamide;

Nalpha,Nalpha-dimethyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-phenylalaninamide;

2-(2-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-pyridin-2-ylacetamide;

2-(4-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-{4-[(trifluoromethyl)oxy]phenyl}acetamide;

2-[2-(methyloxy)phenyl]-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

2-[3-(methyloxy)phenyl]-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

2-[4-(methyloxy)phenyl]-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-D-alaninamide;

N-{4-[2-({4-[4-(N,N-dimethylglycyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-3-(methyloxy)propanamide;

(2R)-2-amino-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-phenylethanamide;

N^2, N^2-dimethyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-alaninamide;

1-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-prolinamide;

N^2, N^2-dimethyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-alaninamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-1-phenylcyclopropanecarboxamide;

2-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)butanamide;

(2S)-1-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)azetidine-2-carboxamide;

2,4,6-trichloro-N-(3-{[4-(4-methyl-2-thienyl)pyrimidin-2-yl]amino}propyl)benzamide;

N-[3-({4-[3,4-bis(methyloxy)phenyl]pyrimidin-2-yl}amino)propyl]-2,6-dichlorobenzamide;

2,6-dichloro-N-[3-({4-[(4-morpholin-4-ylphenyl)amino]pyrimidin-2-yl}amino)propyl]benzamide;

2,6-dichloro-N-(3-{[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-fluoropyrimidin-2-yl]amino}propyl)benzamide;

2,6-dichloro-N-{3-[(4-{3-[(dimethylamino)methyl]phenyl}pyrimidin-2-yl)amino]propyl}benzamide;

2,6-dichloro-N-[3-({4-[3-(1-methylethyl)phenyl]pyrimidin-2-yl}amino)propyl]benzamide;

2,6-dichloro-N-{3-[(4-{4-[(1-methylethyl)oxy]phenyl}pyrimidin-2-yl)amino]propyl}benzamide;

N-[3-({4-[3-(acetylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2,6-dichlorobenzamide;

2,6-dichloro-N-[3-({4-[(E)-2-phenylethenyl]pyrimidin-2-yl}amino)propyl]benzamide;

phenyl (4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)carbamate;

phenylmethyl (4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)carbamate;

N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-3-(methyloxy)propanamide;

N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}cyclopropanecarboxamide;

4-{4-[(4-{4-[(cyclopropylcarbonyl)amino]phenyl}pyrimidin-2-yl)amino]phenyl}-N-ethylpiperazine-1-carboxamide;

N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-3-(methyloxy)propanamide;

3-(methyloxy)-N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}propanamide;

N-ethyl-4-(4-{[4-(4-{[3-(methyloxy)propanoyl]amino}phenyl)pyrimidin-2-yl]amino}phenyl)piperazine-1-carboxamide;

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-2-phenylacetamide;

1-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyrrolidin-2-one;

N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-alaninamide;

N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-alaninamide;

(2S)-2-hydroxy-3-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)butanamide;

(2R)-2-hydroxy-3-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)butanamide;

N-{4-[2-({4-[4-(cyclopropylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-D-alaninamide;

(2S)-2-amino-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-2-phenylethanamide;

2-amino-2-(4-chlorophenyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)morpholine-3-carboxamide;

1-ethyl-3-[4-(2-{[4-(4-ethylpiperazin-1-yl)-3-(methyloxy)phenyl]amino}pyrimidin-4-yl)phenyl]urea;

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)-3-(methyloxy)phenyl]amino}pyrimidin-4-yl)phenyl]-D-prolinamide;

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)-3-(methyloxy)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

1-(2,6-dichlorophenyl)-3-(3-{[4-(4-methyl-2-thienyl)pyrimidin-2-yl]amino}propyl)urea;

1-[2-fluoro-5-(trifluoromethyl)phenyl]-3-(3-{[4-(4-methyl-2-thienyl)pyrimidin-2-yl]amino}propyl)urea;

2,6-dichloro-N-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]benzenesulfonamide;

N-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2,6-difluorobenzenesulfonamide;

N-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]naphthalene-2-sulfonamide;

N-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]-3,4-bis(methyloxy)benzenesulfonamide;

3-chloro-N-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]propane-1-sulfonamide;

N-[3-({4-[4-(dimethylamino)phenyl]pyrimidin-2-yl}amino)propyl]propane-1-sulfonamide;

methyl (3-{[4-(2,4-dichlorophenyl)pyrimidin-2-yl]amino}propyl)carbamate;

1-methylethyl (3-{[4-(2,4-dichlorophenyl)pyrimidin-2-yl]amino}propyl)carbamate;

phenylmethyl (3-{[4-(2,4-dichlorophenyl)pyrimidin-2-yl]amino}propyl)carbamate;

N-{4-[2-({[3-(3-chlorophenyl)isoxazol-5-yl]methyl}amino)pyrimidin-4-yl]phenyl}acetamide;

ethyl 4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)piperidine-1-carboxylate;

1,1-dimethylethyl 4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)piperidine-1-carboxylate;

N-(4-{2-[(4-cyanophenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyridin-4-yl}phenyl)acetamide;

1,1-dimethylethyl {1-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]piperidin-4-yl}carbamate;

N-{4-[2-({4-[4-(cyclopropylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}cyclopropanecarboxamide;

N-{1-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]piperidin-4-yl}acetamide;

4-(4-aminophenyl)-N-[4-(4-aminopiperidin-1-yl)phenyl]pyrimidin-2-amine;

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}-5-methylpyrimidin-4-yl)phenyl]-3-(methyloxy)propanamide;

N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}tetrahydrofuran-2-carboxamide;

N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}tetrahydrofuran-2-carboxamide;

N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}tetrahydrofuran-2-carboxamide;

N-cyclopropyl-4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}benzamide;

N-[2-(methyloxy)ethyl]-4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}benzamide;

2,6-dichloro-N-{3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]propyl}benzamide;

2,6-dichloro-N-(3-{[4-(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)pyrimidin-2-yl]amino}propyl)benzamide;

2,6-dichloro-N-(3-{[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-methylpyrimidin-2-yl]amino}propyl)benzamide;

N-(4-{2-[(3-{[(2,6-dichlorophenyl)carbonyl]amino}propyl)amino]pyrimidin-4-yl}phenyl)morpholine-4-carboxamide;

2,6-dichloro-N-{3-[(4-{4-[(cyclopropylcarbonyl)amino]phenyl}pyrimidin-2-yl)amino]propyl}benzamide;

N-(4-{2-[(3-{[(2,6-dichlorophenyl)carbonyl]amino}propyl)amino]pyrimidin-4-yl}phenyl)thiophene-2-carboxamide;

2,6-dichloro-N-(3-{[4-(4-{[N-(2-morpholin-4-ylethyl)glycyl]amino}phenyl)pyrimidin-2-yl]amino}propyl)benzamide;

1-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)ethanone;

(1E)-1-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)ethanone oxime;

N-{4-[2-({4-[4-(cyclopropylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-2-phenylacetamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2-bromobenzamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2-fluorobenzamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)propyl]-2-chlorobenzamide;

N-[4-(2-{[3-(morpholin-4-ylsulfonyl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-{4-[2-({3-[(cyclohexylmethyl)amino]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-(4-{2-[(3-{[(5-bromo-2-fluorophenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(3-{[(2,5-dimethylphenyl)methyl]amino}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(3,4-dimorpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-{4-[2-({4-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}cyclopropanecarboxamide;

N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}butanamide;

N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}butanamide;

N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}butanamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridine-2-carboxamide;

2-hydroxy-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)benzamide;

3-(methyloxy)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)benzamide;

4-(methyloxy)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)benzamide;

4-chloro-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)benzamide;

(2R)-N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-2-carboxamide;

(2S)-N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-2-carboxamide;

1-(2-hydroxyethyl)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-prolinamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)thiophene-2-carboxamide;

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-3-carboxamide;

2-phenyl-N-{4-[2-({4-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-N-(diphenylmethyl)benzamide;

N-[4-(2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-{4-[2-({4-[4-(phenylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({4-[4-(2-cyclopentylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({4-[4-(cyclohexylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-(4-{2-[(4-{4-[(2-chlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[(3-fluorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[(3-fluoro-4-methylphenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[(3,4-dichlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[(3,5-dichlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[4-(2-{[4-(4-{[3-(methyloxy)phenyl]carbonyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-(4-{2-[(4-{4-[(4-chlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[(4-methylphenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-{4-[2-({4-[4-(furan-2-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-[4-(2-{[4-(4-{2-[(4-fluorophenyl)oxy]acetyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)furan-3-carboxamide;

N-{4-[2-({4-[4-(phenylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({4-[4-(2-thienylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-(4-{2-[(4-{4-[(4-fluorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[4-(2-{[4-(4-{[4-(methyloxy)phenyl]sulfonyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-(4-{2-[(4-{4-[(4-chlorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-{4-[(3-chlorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-{4-[2-({4-[4-(biphenyl-4-ylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({4-[4-(naphthalen-1-ylsulfonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-(4-{2-[(3-{4-[(2-chlorophenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[4-(2-{[3-(4-{[3-(methyloxy)phenyl]methyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-{4-[2-({3-[4-(3-methylbutyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({3-[4-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({3-[4-(cyclopropylmethyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-(4-{2-[(3-{4-[3-(methylthio)propyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(3-{4-[(4-{[3-(dimethylamino)propyl]oxy}phenyl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-{4-[2-({3-[4-({3-[(trifluoromethyl)oxy]phenyl}methyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

4-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-N-phenylpiperazine-1-carboxamide;

N-[4-(2-{[3-(4-propanoylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-{4-[2-({3-[4-(phenylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({3-[4-(2-phenylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({3-[4-(cyclopentylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide

N-{4-[2-({3-[4-(2-pyridin-3-ylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({3-[4-(2-cyclopentylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-(4-{2-[(3-{4-[(2-chlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(3-{4-[(4-chiorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(3-{4-[(3,4-dichlorophenyl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(3-{4-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N^2, N^2-dimethyl-N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]glycinamide;

3-(methyloxy)-N-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]propanamide;

N-(4-{2-[(4-{4-[(2-chlorophenyl)sulfonyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-{4-[2-({3-[4-(cyclopropylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({3-[4-(2-cyclopropylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-[4-(2-{[3-(4-{[3-(methyloxy)phenyl]carbonyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

1-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]piperidine-3-carboxylic acid;

1,1-dimethylethyl methyl{2-[(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)amino]-2-oxoethyl}carbamate;

1,1-dimethylethyl [4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]carbamate;

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-N^2, N^2-dimethylglycinamide;

4-(4-aminophenyl)-N-[4-(4-ethylpiperazin-1-yl)phenyl]pyrimidin-2-amine;

Nalpha-{[(1,1-dimethylethyl)oxy]carbonyl}-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-phenylalaninamide;

Nalpha-{[(1,1-dimethylethyl)oxy]carbonyl}-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-phenylalaninamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-D-phenylalaninamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-L-phenylalaninamide;

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-L-valinamide;

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-D-valinamide;

1-ethyl-3-[4-(2-{[3-(methyloxy)-4-morpholin-4-ylphenyl]amino}pyrimidin-4-yl)phenyl]urea;

(2R)-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)piperidine-2-carboxamide;

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}-5-methylpyrimidin-4-yl)phenyl]acetamide;

4-{4-[(4-{4-[(N,N-dimethylglycyl)amino]phenyl}pyrimidin-2-yl)amino]phenyl}-N-ethylpiperazine-1-carboxamide;

N-{4-[2-({4-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-N^2, N^2-dimethylglycinamide;

N-{4-[2-({4-[4-(cyclobutylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-N^2, N^2-dimethylglycinamide;

N^2, N^2-dimethyl-N-{4-[2-({4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}glycinamide;

N-{4-[2-({4-[4-(cyclopropylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}-N^2,N^2-dimethylglycinamide;

N-[4-(2-{[4-(4-D-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-N^2, N^2-dimethylglycinamide;

N-[4-(2-{[4-(4-L-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-N^2, N^2-dimethylglycinamide;

N-(4-{2-[({1-[(2,6-dichlorophenyl)carbonyl]azetidin-3-yl}methyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(3-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-[3-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)cyclohexyl]-2,6-dichlorobenzamide;

N-{4-[2-({[4-(4-methylpiperazin-1-yl)phenyl]methyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-[4-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)phenyl]-2,6-dichlorobenzamide;

N-{4-[2-(piperidin-4-ylamino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({1-[(2,6-dichlorophenyl)carbonyl]piperidin-4-yl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-{4-[2-({4-[(2-hydroxyethyl)oxy]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

1-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-3-phenylurea;

N-[5-({4-[4-(acetylamino)phenyl]pyrimidin-2-yl}amino)-2-(4-ethylpiperazin-1-yl)phenyl]-2,6-dichlorobenzamide;

1-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-3-(phenylmethyl)urea;

N^2, N^2-dimethyl-N-{4-[2-({4-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}glycinamide;

N-(3-fluoro-4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)cyclopropanecarboxamide;

N-(4-{2-[(4-{4-[(1-methyl-1H-imidazol-2-yl)methyl]piperazin-1-yl}phenyl)amino]pyrimidin-4-yl}phenyl)cyclopropanecarboxamide;

N-[4-(2-{[4-(4-L-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-[4-(2-{[4-(4-L-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-[4-(2-{[4-(4-D-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-[4-(2-{[4-(4-D-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]acetamide;

N-{4-[2-({4-[4-(2-piperazin-1-ylacetyl)piperazin-1-yl]phenyl}amino)pyrimidin-4-yl]phenyl}acetamide;

N-[4-(2-{[4-(4-L-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-2-carboxamide;

N-[4-(2-{[4-(4-L-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-2-carboxamide;

N-[4-(2-{[4-(4-D-alanylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-2-carboxamide;

N-[4-(2-{[4-(4-D-prolylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]tetrahydrofuran-2-carboxamide;

1-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)-1H-pyrrole-2-carboxamide;

3-fluoro-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridine-4-carboxamide;

6-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridine-3-carboxamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridazine-4-carboxamide;

2-cyclopropyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)acetamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)isoxazole-5-carboxamide;

N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)pyridine-3-carboxamide;

4-methyl-N-(4-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}phenyl)benzamide;

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]-D-prolinamide;

N-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]butanamide; and

1-ethyl-3-[4-(2-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)phenyl]urea;

and the active agent is selected from one or more of the following compounds:

N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
7-({[(3aR,5r,6aS)-2-acetyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)quinazolin-4-amine;

N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-{[(3aR,5r,6aS)-octahydrocyclopenta[c]pyrrol-5-ylmethyl]oxy}quinazolin-4-amine;
ethyl (3aR,6aS)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3aR,5r,6aS)-2-(methylsulfonyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3aR,5r,6aS)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,5s,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3aR,5s,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-({[(3aR,5s,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-({[(3aR,5s,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3aR,5s,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-2,3-dichlorophenyl)-7-({[(3aR,5s,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-({[(3aR,5s,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3aR,5r,6aS)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(4-bromo-2,3-dichlorophenyl)-7-{[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-{[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-{[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(3-chloro-2,4-difluorophenyl)-7-{[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-{[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-{[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-{[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-[(hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl)oxy]-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-{[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-2,3-dichlorophenyl)-7-{[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-{[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-{[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-{[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(3R,8aR)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-{[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(3S,8aR)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(3R,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-{[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-{[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-{[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(4-bromo-2,3-dichlorophenyl)-7-{[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-{[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
(3S,9aS)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydro-2H-pyrido[1,2-a]pyrazin-1(6H)-one;
(3S,9aR)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydro-2H-pyrido[1,2-a]pyrazin-1(6H)-one;
(3S,8aS)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(3S,8aR)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(3S,8aS)-3-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(3S,8aS)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-methylhexahydropyrrolo[1,2-a]pyrazin-1(2H)-one;
N-(3,4-dichlorophenyl)-7-({2-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]ethyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(8aR)-tetrahydro-1H-[1,3]thiazolo[4,3-c][1,4]oxazin-6-ylmethyl]oxy}quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[2-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)ethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)oxy]-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-[(octahydro-2H-quinolizin-3-ylmethyl)oxy]quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
7-({[(3aR,6aS)-2-acetyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)quinazolin-4-amine;

N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-{[(3aR,6aS)-octahydrocyclopenta[c]pyrrol-5-ylmethyl]oxy}quinazolin-4-amine;
ethyl (3aR,5r,6aS)-5-[({4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl}oxy)methyl]hexahydrocyclopenta[c]pyrrole-2(1*H*)-carboxylate;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3aR,6aS)-2-(methylsulfonyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3aR,6aS)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-({[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-2,3-dichlorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-2,3-dichlorophenyl)-7-({[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;

N-(3,4-dichlorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-({[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3aR,6aS)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-[(2-{[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino}ethyl)oxy]-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-({2-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]ethyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-({[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]oxy}-6-(methyloxy)quinazolin-4-amine;
1,1-dimethylethyl (3aR,6aS)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyl-oxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate;
1,1-dimethylethyl (3aR,6aS)-5-({[4-[(4-bromo-5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta-[c]pyrrole-2(1H)-carboxylate;
N-(4-Bromo-5-chloro-2-fluorophenyl)-6-(methyloxy)-7-{[(3aR,5r,6aS)-octahydrocyclopenta-[c]pyrrol-5-ylmethyl]oxy}quinazolin-4-amine;
1,1-dimethylethyl (3aR,6aS)-5-({[4-[(3-chloro-2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta-[c]pyrrole-2(1H)-carboxylate;
N-(3-chloro-2,4-difluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-octahydrocyclopenta-[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
1,1-dimethylethyl (3aR,6aS)-5-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta-[c]pyrrole-2(1H)-carboxylate;
N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-{[[(3aR,5r,6aS)-octahydrocyclopenta[c]pyrrol-5-yl]methyl]oxy}quinazolin-4-amine;
1,1-dimethylethyl (3aR,6aS)-5-({[4-[(4,5-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta-[c]pyrrole-2(1H)-carboxylate;
N-(4,5-dichloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-octahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;

1,1-dimethylethyl (3aR,6aS)-5-({[4-[(4-bromo-2,3-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta-[c]pyrrole-2(1H)-carboxylate;
N-(4-bromo-2,3-dichlorophenyl)-7-({[(3aR,5r,6aS)-octahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
1,1-dimethylethyl (3aR,6aS)-5-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta-[c]pyrrole-2(1H)-carboxylate;
N-(3,4-dichlorophenyl)-7-({[(3aR,5r,6aS)-octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
7-{[(3-*endo*)-8-azabicyclo[3.2.1]oct-3-ylmethyl]oxy}-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine;
1,1-dimethylethyl (3-*endo*)-3-(2-{[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}ethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate;
7-({2-[(3-*endo*)-8-azabicyclo[3.2.1]oct-3-yl]ethyl}oxy)-*N*-(3,4-dichlorophenyl)-6-(methyloxy) quinazolin-4-amine;
N-{[(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)(methyl)amino]carbonothioyl}-2-phenylacetamide;
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl) imidazolidin-2-one;
N'-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N-methyl-N-(2-phenylethyl)sulfamide;
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)piperidin-2-one;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-4-phenyl-1,3-thiazol-2-amine;
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-N-(phenylmethyl) Benzenesulfonamide;
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-N-(2-phenylethyl) Benzenesulfonamide;
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-N-(3-phenylpropyl) Benzenesulfonamide;
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl (phenylmethyl)carbamate;
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-N-methyl-N-(3-phenylpropyl) Benzenesulfonamide;
N-[(Z)-[(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)amino](imino)methyl]-2-phenylacetamide;

N,N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-bis-(3-phenylpropane-1-sulfonamide);
N2-[(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)sulfonyl]-N1-phenylglycinamide;
N-{[(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)amino]carbonothioyl}-2-phenylacetamide;
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-1,3-benzothiazol-2-amine;
benzyl-{[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenylcarbamoyl]-methyl}-carbamic acid tert-butyl ester;
N2-acetyl-N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-(phenylmethyl)glycinamide;
benzyl-{[6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-ylcarbamoyl]-methyl}-carbamic acid tert-butyl ester;
N2-acetyl-N1-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-N2-(phenylmethyl)glycinamide;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-4-phenylbutanamide;
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-methyl-N2-(phenylmethyl)glycinamide;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-1,3-benzothiazol-2-yl)-3-phenylpropanamide;
N'-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N-(2-phenylethyl)-N-(phenylmethyl)sulfamide;
N-{[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenylcarbamoyl]-methyl}-benzamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N,N'-bis(phenylmethyl)sulfamide;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-(4-fluorophenyl)propanediamide;
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-3-[(4-methylphenyl)sulfonyl]-4-(phenylmethyl)imidazolidin-2-one;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-2-[3-(trifluoromethyl)phenyl]acetamide;
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-N-(2-piperidin-1-ylethyl)-1,3-benzothiazol-2-amine;

6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-N-(2-pyrrolidin-1-ylethyl)-1,3-benzothiazol-2-amine;
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-N-{2-[3-(trifluoromethyl)phenyl]ethyl}-1,3-benzothiazol-2-amine;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-1,3-benzothiazol-2-yl)-2-[3-(trifluoromethyl)phenyl]acetamide;
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-(2-phenylethyl)glycinamide;
benzyl-{[5-chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-ylcarbamoyl]-methyl}-carbamic acid tert-butyl ester;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-1,3-benzothiazol-2-yl)-2-[3,5-bis(trifluoromethyl)phenyl]acetamide;
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-methyl-N2-{[3-(trifluoromethyl)phenyl]methyl}glycinamide;
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-methyl-N2-(2-phenylethyl)glycinamide;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridazin-3-yl)-N'-(4-fluorophenyl)propanediamide;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-(3-chlorophenyl)propanediamide;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-(4-chlorophenyl)propanediamide;
(2E)-N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-2-[(ethyloxy)imino] propanamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-1-(phenylmethyl)prolinamide;
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-4-(phenylmethyl) imidazolidin-2-one;
6,7-bis(methyloxy)-4-({4-[4-(phenylmethyl)piperazin-1-yl]phenyl}oxy)quinoline;
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N2-(phenylmethyl)alaninamide;
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N2-(phenylmethyl)leucinamide;
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N2-(phenylmethyl)valinamide;
2-(Benzyl-methyl-amino)-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-3-methyl-butyramide;

2-Benzyloxyimino-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-2-phenyl-acetamide;
4-(4-{3-Chloro-5-[2-(4-fluoro-phenylcarbamoyl)-acetylamino]-pyridin-2-yloxy}-6-methoxy-quinolin-7-yloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester;
N-{5-Chloro-6-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-pyridin-3-yl}-N'-(4-fluoro-phenyl)-malonamide;
N-[5-Chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-N'-(2,4-difluoro-phenyl)-malonamide;
N-{5-Chloro-6-[6-methoxy-7-(3-piperidin-1-yl-propoxy)-quinolin-4-yloxy]-pyridin-3-yl}-N'-(4-fluoro-phenyl)-malonamide;
N-{5-Chloro-6-[7-(3-diethylamino-propoxy)-6-methoxy-quinolin-4-yloxy]-pyridin-3-yl}-N'-(4-fluoro-phenyl)-malonamide;
N-[5-Chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-N'-phenyl-malonamide;
1,1-dimethylethyl 4-(3-{[4-[(2-fluoro-4-{[(1-{[(4-fluorophenyl)amino]carbonyl}cyclopropyl)carbonyl]amino}phenyl)oxy]-6-(methyloxy)quinolin-7-yl]oxy}propyl)piperazine-1-carboxylate;
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(4-{[7-{[3-(4-acetylpiperazin-1-yl)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(3-fluoro-4-{[7-({3-[4-(1-methylethyl)piperazin-1-yl]propyl}oxy)-6-(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide;
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide;
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1-dicarboxamide;
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1-dicarboxamide;
N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1-dicarboxamide;
(1R,2R,3S)-N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide;

N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1-dicarboxamide;
N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1-dicarboxamide;
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1-dicarboxamide;
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide;
N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinazolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide;
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperazin-1-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide;
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide;
N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide;
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide;
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-{5-chloro-6-[(6-(methyloxy)-7-{[(1-methylpiperidin-4-yl)methyl]oxy}quinolin-4-yl)oxy]pyridin-3-yl}-N'-(4 fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-[5-chloro-6-({6-(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-yl}oxy)pyridin-3-yl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-[5-chloro-6-({6-(methyloxy)-7-[(phenylmethyl)oxy]quinolin-4-yl}oxy)pyridin-3-yl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;

N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide;
N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1-methylpiperidin-4-yl)methyl]oxy}quinazolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(4-fluorophenyl)-N'-[2-methyl-6-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)pyridin-3-yl]cyclopropane-1,1-dicarboxamide;
N-[3-fluoro-4-({7-(methyloxy)-6-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-[3-fluoro-4-({7-(methyloxy)-6-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-{3-fluoro-4-[(7-(methyloxy)-6-{[(1-methylpiperidin-4-yl)methyl]oxy}quinazolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-[5-fluoro-2-methyl-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(4-fluorophenyl)-N'-[2-methyl-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]cyclopropane-1,1-dicarboxamide;
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperazin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1-methylpiperidin-4-yl)methyl]oxy}quinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(4-fluorophenyl)-N'-[4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]cyclopropane-1,1-dicarboxamide;
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(4-{[6-{[3-(diethylamino)propyl]oxy}-7-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(4-{[6-{[2-(diethylamino)ethyl]oxy}-7-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
(1S,2R)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide;
(1R,2R)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide;

(1R,2R)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide;
(1R,2R)-N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide;
1,1-dimethylethyl 4-(3-{[4-[(2-fluoro-4-{[((1R,2R)-1-{[(4-fluorophenyl)amino] carbonyl}-2-methylcyclopropyl)carbonyl]amino}phenyl)oxy]-6-(methyloxy)quinolin-7-yl]oxy}propyl)piperazine-1-carboxylate;
(1R,2S)-N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide;
(1R,2R)-N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide;
(1R,2R)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperazin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide;
(1R,2R)-N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide;
(1R,2R)-N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide;
(1R,2S)-N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide;
(1R,2S)-N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide;
(1R,2S)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperazin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide;
(1R,2R,3S)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide;
(1R,2R,3S)-N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide;
(1R,2R,3S)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide;
(1R,2R,3S)-N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinazolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide;
(2R,3R)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide;
(2R,3R)-N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide;

(1R,2R,3S)-N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide;
(2R,3R)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide;
(1R,2R)-N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide;
(1R,2R)-N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinazolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide;
(2R,3R)-N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl) -N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide;
(2R,3R)-N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide;
(1R,2R)-N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperazin-1-ylpropyl) oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide;
(2R,3R)-N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide;
1-(4-{[6,7-bis (methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-3-(phenylmethyl)imidazolidin-2-one;
1-(4-{[6,7-bis (methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)3-(phenylacetyl)imidazolidin-2-one;
N-{[(4-{[6,7-bis(methyloxy)quinazolin-4-yl]amino}-3-fluorophenyl)amino] carbonothioyl}-2-phenylacetamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-1-phenylmethanesulfonamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-2-phenylethanesulfonamide;
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-N-methyl-N-(phenylmethyl) benzenesulfonamide;
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-N-methyl-N-(2-phenylethyl) benzenesulfonamide;

1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)pyrrolidin-2-one;
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl (2-phenylethyl)carbamate;
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-N-[2-(phenyloxy)ethyl] Benzenesulfonamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-3-phenylpropane-1-sulfonamide;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-2-phenylacetamide;
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-1,3-benzothiazol-2-amine;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-1,3-benzothiazol-2-yl)-2-phenylacetamide;
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-(phenylmethyl)glycinamide;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-1,3-benzothiazol-2-yl)-2-phenylacetamide;
N1-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-N2-(phenylmethyl)glycinamide;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-3-phenylpropanamide;
N1-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-N2-methyl-N2-(phenylmethyl)glycinamide;
4-[(2-amino-1,3-benzothiazol-6-yl)oxy]-6,7-bis(methyloxy)-1-(2-oxo-2-phenylethyl) quinolinium;
N-{[(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)amino]carbonothioyl}-2-phenylacetamide;
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-(trifluoroacetyl)glycinamide;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-N'-(4-fluorophenyl)propanediamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N,N'-bis(2-phenylethyl)sulfamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-[2-hydroxy-1-(phenylmethyl)ethyl]urea;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-3-oxo-4-phenylbutanamide;
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-N-[2-(phenyloxy)ethyl]-1,3-benzothiazol-2-amine;

6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-N-methyl-N-(2-phenylethyl)-1,3-benzothiazol-2-amine;
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-N-{[3-(trifluoromethyl)phenyl]methyl}-1,3-benzothiazol-2-amine;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-[3-(trifluoromethyl)phenyl]propanediamide;
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-{[3-(trifluoromethyl)phenyl]methyl}glycinamide;
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-{2-[3-(trifluoromethyl)phenyl]ethyl}glycinamide;
N1-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N2-(phenylmethyl)glycinamide;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-1,3-benzothiazol-2-yl)-2-[2-chloro-5-(trifluoromethyl)phenyl]acetamide;
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N2-methyl-N2-{2-[3-(trifluoromethyl)phenyl]ethyl}glycinamide;
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-4-(phenylmethyl)imidazolidin-2-one;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-(2-chlorophenyl)propanediamide;
N1-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N2-methyl-N2-(phenylmethyl)glycinamide;
(2E)-N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-2-[(methyloxy)imino]propanamide;
(2E)-N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-2-{[(phenylmethyl)oxy]imino}propanamide;
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-3-[(4-methylphenyl)sulfonyl]-4-(phenylmethyl)imidazolidin-2-one;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-4-(phenylmethyl)-4,5-dihydro-1,3-oxazol-2-amine;
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-4-(phenylmethyl)piperazin-2-one;
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N2-methyl-N2-(phenylmethyl) alaninamide;
N1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N2-methyl-N2-(phenylmethyl) Leucinamide;

4-benzyl-1-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-tetrahydro-pyrimidin-2-one;
N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-2-phenoxyimino-propionamide;
4-[4-(4-Benzyl-piperidin-1-yl)-phenoxy]-6,7-dimethoxy-quinoline;
N-{5-Chloro-6-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-pyridin-3-yl}-N'-(4-fluoro-phenyl)-malonamide;
N-[5-Chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-2,2-difluoro-N'-(4-fluoro-phenyl)-malonamide;
N-[5-Chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-N'-(4-fluoro-phenyl)-N'-methyl-malonamide;
N-{5-Chloro-6-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-pyridin-3-yl}-N'-(4-fluoro-phenyl)-malonamide;
N-[5-Chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-N'-(3-fluoro-phenyl)-malonamide;
N-[5-Chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-N'-(4-fluoro-phenyl)-2,2-dimethyl-malonamide;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-(phenylmethyl)cyclopropane-1,1-dicarboxamide;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-phenylcyclopropane-1,1-dicarboxamide;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-(2-phenylethyl)cyclopropane-1,1-dicarboxamide;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2-methylpyridin-3-yl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-{4-[(7-chloroquinolin-4-yl)oxy]-3-fluorophenyl} -N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-{4-[(7-chloroquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinazolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide;

N-(4-{[6,7-bis(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2-methylphenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloro-2-methylpyridin-3-yl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3,5-difluorophenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2,5-difluorophenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2,3,5-trifluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-2-methylphenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2-chloro-5-methylphenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(3-fluoro-4-{[6-hydroxy-7-(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2-chloro-5-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)-2-(methylthio)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(4-fluorophenyl)-N'-(4-{[2-methyl-6,7-bis(methyloxy)quinazolin-4-yl]oxy}phenyl) cyclopropane-1,1-dicarboxamide;
N-(4-{[2-amino-6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(3-fluoro-4-{[2-(methylamino)-6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)-1-(phenylmethyl)azetidine-3,3-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)azetidine-3,3-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[(4-fluorophenyl)methyl] cyclopropane-1,1-dicarboxamide;

N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(2-morpholin-4-ylethyl)cyclopropane-1,1-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[2-(piperidin-1-ylmethyl)phenyl]cyclopropane-1,1-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[2-(pyrrolidin-1-ylmethyl) phenyl]cyclopropane-1,1-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[3-(morpholin-4-ylmethyl) phenyl]cyclopropane-1,1-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[2-(morpholin-4-ylmethyl) phenyl]cyclopropane-1,1-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-phenylcyclopropane-1,1-dicarboxamide;
N-[3-(aminomethyl)phenyl]-N'-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl) cyclopropane-1,1-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[3-(piperidin-1-ylmethyl)phenyl]cyclopropane-1,1-dicarboxamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[3-(pyrrolidin-1-ylmethyl)phenyl]cyclopropane-1,1-dicarboxamide;
ethyl [(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl) amino](oxo)acetate;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(phenylmethyl)ethanediamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(2-phenylethyl)ethanediamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-phenylethanediamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(2-morpholin-4-ylethyl)ethanediamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-{2-[4-(methyloxy) phenyl]ethyl}ethanediamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(2,3-dihydro-1H-inden-1-yl)ethanediamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(2,3-dihydro-1H-inden-2-yl)ethanediamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(1,2,3,4-tetrahydronaphthalen-1-yl)ethanediamide;

N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-[(2S)-1,2,3,4-tetrahydronaphthalen-2-yl]ethanediamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-[2-(4-methylphenyl) ethyl]ethanediamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(2-phenylpropyl) Ethanediamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-[2-(4-chlorophenyl) ethyl]ethanediamide;
ethyl [(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)amino](oxo)acetate;
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-N'-(2-phenylethyl)ethanediamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(1,2,3,4-tetrahydronaphthalen-2-yl)ethanediamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-[2-(1-methylpyrrolidin-2-yl)ethyl]ethanediamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-[2-(phenyloxy) ethyl]ethanediamide;
N'-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N-methyl-N-(2-phenylethyl)ethanediamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-{[3-(trifluoromethyl)phenyl]methyl}ethanediamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-{2-[3-(trifluoromethyl)phenyl]ethyl}ethanediamide;
N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1-methylpiperidin-4-yl)methyl]oxy}quinolin-4-yl)oxy]phenyl}-N'-(2-phenylethyl)ethanediamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(1,2,3,4-tetrahydroisoquinolin-1-ylmethyl)ethanediamide;
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-[(2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]ethanediamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-phenethyl-oxalamide;
N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-N'-(2-isopropyl-1,2,3,4-tetrahydro-isoquinolin-1-ylmethyl)-oxalamide;
N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-N'-(2-ethyl-1,2,3,4-tetrahydro-isoquinolin-1-ylmethyl)-oxalamide;

N-{4-[7-(3-Diethylamino-propoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-N'-phenethyl-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-N'-phenethyl-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)-quinolin-4-yloxy]-phenyl}-N'-phenethyl-oxalamide;
N-{4-[7-(2-Diethylamino-ethoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-N'-phenethyl-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-methyl-N'-phenethyl-oxalamide;
2-(3,4-Dihydro-1H-isoquinolin-2-yl)-N-{3-fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-2-oxo-acetamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-2-oxo-2-(3-phenyl-pyrrolidin-1-yl)-acetamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-2-oxo-2-(2-phenyl-morpholin-4-yl)-acetamide;
N-(2-Dimethylamino-2-phenyl-ethyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-oxo-2-phenyl-ethyl)-oxalamide;
N-Benzyl-N'-{3-fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(2-fluoro-phenyl)-ethyl]-oxalamide;
N-[2-(3-Chloro-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(2-methoxy-phenyl)-ethyl]-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-pyridin-3-yl-ethyl)-oxalamide;
N-Benzyl-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(2,5-Dimethoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(2-trifluoromethyl-phenyl)-ethyl]-oxalamide;

N-[2-(2-Ethoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(2,4-Dimethyl-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1S -phenyl-2-p-tolyl-ethyl)-oxalamide;
N-[2-(4-Chloro-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamic acid;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(3-fluoro-phenyl)-ethyl]-oxalamide;
N-[2-(2-Chloro-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(3-methoxy-phenyl)-ethyl]-oxalamide;
N-(1,2-Diphenyl-ethyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(2,4-Dichloro-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(3,4-Dimethoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(4-Ethyl-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(4-Ethoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(4-Ethoxy-3-methoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(4-phenoxy-phenyl)-ethyl]-oxalamide;
N-[2-(3-Ethoxy-4-methoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-pyridin-2-yl-ethyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-pyridin-4-yl-ethyl)-oxalamide;

N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(4-fluoro-phenyl)-ethyl]-oxalamide;
N-[2-(2-Bromo-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2R-phenyl-propyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-indan-1-yl-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-isobutyl-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(3-methyl-butyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2R-phenyl-propyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-phenyl-propyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-indan-2-yl-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1R-phenyl-ethyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1S-phenyl-ethyl)-oxalamide;
N-[2-(3-Bromo-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(2,6-Dichloro-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(2,4-Dichloro-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-(2-Benzo[1,3]dioxol-5-yl-ethyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(3-Bromo-4-methoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(3,5-Dimethoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;

N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-o-tolyl-ethyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-m-tolyl-ethyl)-oxalamide;
N-[2-(3-Ethoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(3,4-Dimethyl-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(2,5-Dimethyl-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(3-Chloro-4-propoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(4-Butoxy-3-chloro-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(4-tert-Butyl-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(4-sulfamoyl-phenyl)-ethyl]-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(4-hydroxy-3-methoxy-phenyl)-ethyl]-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(3-hydroxy-4-methoxy-phenyl)-ethyl]-oxalamide;
N-(2,4-Dichloro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(4-fluoro-2-trifluoromethyl-benzyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1-p-tolyl-ethyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(3-fluoro-4-trifluoromethyl-benzyl)-oxalamide;
N-(3-Chloro-4-fluoro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[1-(3-methoxy-phenyl)-ethyl]-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1-naphthalen-2-yl-ethyl)-oxalamide;

N-(4-Chloro-3-trifluoromethyl-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1-p-tolyl-ethyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(6-trifluoromethyl-pyridin-3-ylmethyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-methyl-benzyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(3-methyl-benzyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(4-fluoro-3-trifluoromethyl-benzyl)-oxalamide;
N-(3,5-Dichloro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1R,2,3,4-tetrahydro-naphthalen-1-yl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1S,2,3,4-tetrahydro-naphthalen-1-yl)-oxalamide;
N-Cyclopentyl-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[1-(4-Bromo-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-(2-Fluoro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(3,4-Dichloro-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-(4-Fluoro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-(2,3-Difluoro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-phenoxy-ethyl)-oxalamide;
N-(2,2-Diphenyl-ethyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(4-methoxy-phenyl)-ethyl]-oxalamide;

N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-phenyl-propyl)-oxalamide;
N-[2-(4-Bromo-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{4-[7-(1-Ethyl-piperidin-4-ylmethoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-2-oxo-2-(2-phenyl-morpholin-4-yl)-acetamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(3-fluoro-5-trifluoromethyl-benzyl)-oxalamide;
N-(3,5-Difluoro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-(2-Chloro-5-trifluoromethyl-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-N'-(2-dimethylamino-2-phenyl-ethyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(4-methoxy-benzyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(4-trifluoromethyl-benzyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(3-methoxy-benzyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(3-trifluoromethyl-benzyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(3-trifluoromethoxy-benzyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-methoxy-benzyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-trifluoromethyl-benzyl)-oxalamide;
N-(3-Chloro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-trifluoromethoxy-benzyl)-oxalamide;
N-(2-Chloro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(4-trifluoromethoxy-benzyl)-oxalamide;

N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(4-methoxy-benzyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(4-trifluoromethyl-benzyl)-oxalamide;
N-{4-[7-(Azetidin-3-ylmethoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-N'-phenethyl-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-azetidin-3-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-phenethyl-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-hydroxy-2-phenyl-ethyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1R-phenyl-propyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(1R-phenyl-propyl)-oxalamide;
N-(3,4-Difluoro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-(2,6-Difluoro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[2-(4-fluoro-phenyl)-ethyl]-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-phenyl-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(3-fluoro-phenyl)-oxalamide;
N-(4-Chloro-3-fluoro-phenyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-(3,4-Dimethoxy-phenyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(3-methyl-butyl)-oxalamide;
N-(3,3-Dimethyl-butyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-(4-Chloro-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-(3,5-Dimethoxy-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;

N-(4-Butyl-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-p-tolyl-ethyl)-oxalamide;
N-(3,5-Bis-trifluoromethyl-benzyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-pyrazin-2-ylmethyl-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-pyridin-2-ylmethyl-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yloxy]-phenyl}-N'-phenethyl-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yloxy]-phenyl}-N'-phenethyl-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-fluoro-3-trifluoromethyl-benzyl)-oxalamide;
N-[2-(2-Bromo-6-methoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(3,4-Dimethoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N-methyl-oxalamide;
N-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-fluoro-5-trifluoromethyl-benzyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-[1-(4-fluoro-phenyl)-ethyl]-oxalamide;
N-(1S-Benzyl-2-oxo-2-pyrrolidin-1-yl-ethyl)-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-[2-(4-Amino-phenyl)-ethyl]-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
2-(4-Benzyl-piperidin-1-yl)-N-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-2-oxo-acetamide;
N-Ethyl-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-isopropyl-oxalamide;

N-Butyl-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-methoxy-ethyl)-oxalamide;
N-Cyclopropylmethyl-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N'-(2-morpholin-4-yl-ethyl)-oxalamide;
N-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-2-oxo-2-pyrrolidin-1-yl-acetamide;
N-Ethyl-N'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-N-methyl-oxalamide;
N-(4-{[(3-{[4-(methoxy)phenyl]amino}quinoxalin-2-yl) ami no]sulfonyl}phenyl) acetamide;
4-bromo-N-[3-(phenylamino)quinoxalin-2-yl] benzene sulfonamide;
4-bromo-N-{3-[(2-methylphenyl)amino]quinoxalin-2-yl}benzene sulfonamide;
4-bromo-N-(3-{[4-(methoxy)phenyl]amino}quinoxalin-2-yl) benzene sulfonamide;
4-chloro-N-{3-[(4-chlorophenyl)amino]-6-(methoxy)quinoxalin-2-yl}benzenesulfonamide;
N-(4-{[3-{[(4-chlorophenyl)sulfonyl]amino}-7-(methoxy)quinoxalin-2-yl]amino} phenyl) acetamide;
4-chloro-N-{6-(methoxy)-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-{4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl) amino]phenyl}acetamide;
N-(3-{[4-(ethyloxy) phenyl]amino}quinoxalin-2-yl)-4-methylbenzene sulfonamide;
N-{3-[(3,4-dimethylphenyl)amino]-6-methylquinoxalin-2-yl}-4-methylbenzene sulfonamide;
N-(3-{[3-(dimethylamino)phenyl]amino}quinoxalin-2-yl)-4-methylbenzene sulfonamide;
4-methyl-N-{6-methyl-3-[(4-methylphenyl)amino]quinoxalin-2-yl} benzene sulfonamide;

N-{3-[(4-hydroxyphenyl)amino]-6-methylquinoxalin-2-yl}-4-methylbenzene sulfonamide;
N-{3-[(2,5-dimethylphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide;
4-chloro-N-[3-(naphthalen-2-ylamino)quinoxalin-2-yl]benzenesulfonamide;
N-{3-[(3-aminophenyl)amino]quinoxalin-2-yl}-4-chlorobenzenesulfonamide;
N-(3-{[4-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide;
4-chloro-N-{3-[(4-chlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-chloro-N-{3-[(4-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-chloro-N-{3-[(2-methylphenyl)amino]quinoxalin-2-yl} benzenesulfonamide;
methyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino} quinoxalin-2-yl) amino]benzoate;
methyl 2-chloro-5-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl) amino]benzoate;
N-{4-[(7-methyl-3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl) amino]phenyl}acetamide;
4-methyl-N-(6-methyl-3-{[2-(methoxy)phenyl]amino} quinoxalin-2-yl)benzenesulfonamide;
N-{3-[(phenylmethyl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzoic acid;
3-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzenesulfonamide;
N-{3-[(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-{3-[(4-hydroxyphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-{3-[(4-hydroxyphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide;
N-(3-{[4-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-4-methylbenzenesulfonamide;
3-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid;
N-[4-({[3-(phenylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide;
N-(4-{[(3-{[4-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide;

N-[4-({[3-(naphthalen-1-ylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide;
N-{4-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}acetamide;
N-(3-{[3-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-4-bromobenzenesulfonamide;
N-{3-[(3-hydroxyphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide;
4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-2-hydroxybenzoic acid;
N-(3-{[4-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide;
3-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid;
N-(3-{[4-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-4-chlorobenzenesulfonamide;
N-(3-{[3-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-4-chlorobenzenesulfonamide;
N-[3-(naphthalen-2-ylamino)quinoxalin-2-yl]-4-nitrobenzenesulfonamide;
N-(3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-{3-[(4-bromophenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide;
3-[(3-{[(4-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid;
4-nitro-N-[3-(phenylamino)quinoxalin-2-yl]benzenesulfonamide;
4-chloro-N-[3-(phenylamino)quinoxalin-2-yl]benzenesulfonamide;
3-nitro-N-[3-(phenylamino)quinoxalin-2-yl]benzenesulfonamide;
4-[(3-{[(4-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid;
N-[3-(naphthalen-2-ylamino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide;
4-methyl-N-(3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-(3-{[3-chloro-4-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-{3-[(3-chloro-4-fluorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
methyl 2-chloro-5-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzoate;
4-chloro-N-{3-[(3-hydroxyphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-methyl-N-[6-methyl-3-(phenylamino)quinoxalin-2-yl]benzenesulfonamide;

N-{4-[({3-[(4-methylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide;
1-methylethyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}-7-methylquinoxalin-2-yl)amino]benzoate;
N-{3-[(4-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-{3-[(3-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-{3-[(4-bromophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide;
4-methyl-N-{3-[(3-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-methyl-N-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]benzenesulfonamide;
N-{4-[({3-[(4-chlorophenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide;
N-(4-{[(3-{[3-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide;
4-methyl-N-{3-[(phenylmethyl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-[(3-{[(4-bromophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-2-hydroxybenzoic acid;
4-bromo-N-{3-[(4-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-bromo-N-{3-[(3-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-{4-[({3-[(2-hydroxyethyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide;
4-bromo-N-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]benzenesulfonamide;
4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid;
3-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid;
N-{3-[(2-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzenesulfonamide;
N-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide;
N-(3-{[3-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide;
N-{3-[(4-bromophenyl)amino]quinoxalin-2-yl}-4-nitrobenzenesulfonamide;
4-chloro-N-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]benzenesulfonamide;

N-{4-[({3-[(phenylmethyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide;
N-[4-({[3-(butylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide;
N-[3-(butylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide;
N-[3-(cyclohexylamino)quinoxalin-2-yl]benzenesulfonamide;
1-(phenylsulfonyl)-3-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-2,3-dihydro-1H-imidazo[4,5-b]quinoxaline;
1-(phenylsulfonyl)-3-[4-(piperidin-1-ylsulfonyl)phenyl]-2,3-dihydro-1H-imidazo[4,5-b]quinoxaline;
2,5-dichloro-N-[3-(3,4-dihydroquinolin-1(2H)-yl)quinoxalin-2-yl]benzenesulfonamide;
ethyl 2-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate;
2,5-dichloro-N-{3-[(2-morpholin-4-ylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-{4-[({3-[(3-methylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide;
4-chloro-N-{3-[(3-chloro-4-piperidin-1-ylphenyl)amino]-6-methylquinoxalin-2-yl}benzenesulfonamide;
3-nitro-N-[3-(quinolin-6-ylamino)quinoxalin-2-yl]benzenesulfonamide;
butyl N-{[4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)phenyl]carbonyl}glycinate;
4-nitro-N-(3-{[3-(trifluoromethyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-[4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)phenyl]acetamide;
N-{3-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}acetamide;
ethyl 3,3,3-trifluoro-2-hydroxy-2-{4-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}propanoate;
N-{3-[(4-{[(2,6-dimethylpyrimidin-4-yl)amino]sulfonyl}phenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide;
4-chloro-N-{3-[(3,4-dimethylphenyl)amino]-6-methylquinoxalin-2-yl}benzenesulfonamide;
4-chloro-N-(6-methyl-3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;

butyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}-7-methylquinoxalin-2-yl)amino]benzoate;
4-chloro-N-{3-[(3-chloro-4-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
1-methylethyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoate;
N-{3-[(2,5-dimethylphenyl)amino]-6-nitroquinoxalin-2-yl}-4-methylbenzenesulfonamide;
N-[3-(cyclohexylamino)-6-nitroquinoxalin-2-yl]-4-methylbenzenesulfonamide;
N-{3-[(2,4-dimethylphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide;
N-(3-{[4-(ethyloxy)phenyl]amino}-6-methylquinoxalin-2-yl)-4-methylbenzenesulfonamide;
3-({3-[({4-[hydroxy(oxido)amino]phenyl}sulfonyl)amino]quinoxalin-2-yl}amino)benzoic acid;
N-{[4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)phenyl]carbonyl}glycine;
N-{3-[(3-{[(4-chlorophenyl)sulfonyl]amino}-7-methylquinoxalin-2-yl)amino]phenyl}acetamide;
4-chloro-N-{3-[(3,5-dimethyl-1H-pyrazol-4-yl)amino]-6-methylquinoxalin-2-yl}benzenesulfonamide;
4-bromo-N-{3-[(4'-nitrobiphenyl-3-yl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-bromo-N-{3-[(2-chlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-{3-[(4-butylphenyl)amino]-6-methylquinoxalin-2-yl}-4-chlorobenzenesulfonamide;
N-{4-[(3-{[(4-chlorophenyl)sulfonyl]amino}-7-methylquinoxalin-2-yl)amino]phenyl}acetamide;
4-chloro-N-{6-methyl-3-[(2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide;
propyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}-7-methylquinoxalin-2-yl)amino]benzoate;
4-chloro-N-{3-[(4-fluorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-[4-({[3-(naphthalen-2-ylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide;
4-bromo-N-(3-{[4-(phenylamino)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
2-hydroxy-4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzoic acid;

N-(3-{[3-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-4-methylbenzenesulfonamide;
4-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid;
N-(3-{[3-(butyloxy)phenyl]amino}quinoxalin-2-yl)-4-methylbenzenesulfonamide;
N-{3-[(4-fluorophenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide;
4-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-2-hydroxybenzoic acid;
N-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]-4-nitrobenzenesulfonamide;
4-[(3-{[(4-bromophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid;
N-{4-[({3-[(3-hydroxyphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide;
3-[(3-{[(4-bromophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid;
4-bromo-N-(3-{[3-(butyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
4-bromo-N-(3-{[3-(trifluoromethyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
4-methyl-N-{3-[(4'-nitrobiphenyl-3-yl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-chloro-N-{3-[(3-fluorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-{3-[(2-chlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-bromo-N-[3-(quinolin-5-ylamino)quinoxalin-2-yl]benzenesulfonamide;
N-{3-[(3-fluorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide;
N-{3-[(4-fluorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide;
3-nitro-N-(3-{[3-(trifluoromethyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
2-hydroxy-4-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid;
N-{3-[(3-chlorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide;
N-[3-(1,3-benzodioxol-5-ylamino)quinoxalin-2-yl]-4-bromobenzenesulfonamide;
N-{3-[(3-acetylphenyl)amino]quinoxalin-2-yl}-4-chlorobenzenesulfonamide;
3-nitro-N-(3-{[4-(9H-xanthen-9-yl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;

4-chloro-N-{3-[(4'-nitrobiphenyl-3-yl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]-4-tolylsulfonamide;
N-{3-[(2-methyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-methyl-N-[3-(quinolin-5-ylamino)quinoxalin-2-yl]benzenesulfonamide;
4-methyl-N-{3-[(1-oxo-1,3-dihydro-2-benzofuran-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-chloro-N-{3-[(2-chlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
2-hydroxy-5-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid;
N-(3-{[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-[3-({2-[(trifluoromethyl)thio]phenyl}amino)quinoxalin-2-yl]benzenesulfonamide;
N-{4-[({3-[(4-hydroxyphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide;
N-[3-(1,3-benzodioxol-5-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide;
N-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-{3-[(2,4-dichlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-[4-({[3-(2,3-dihydro-1,4-benzodioxin-6-ylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide;
4-chloro-N-{3-[(3,4-dimethylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide;
4-bromo-N-{3-[(3,4-dimethylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
5-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-2-hydroxybenzoic acid;
N-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-chlorobenzenesulfonamide;
N-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-methylbenzenesulfonamide;
N-{3-[(2,4-dichlorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide;
4-bromo-N-{3-[(3-fluorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide;

4-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}benzoic acid;
N-{3-[(2-fluorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide;
N-[3-(2,3-dihydro-1,4-benzodioxin-6-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide;
N-{3-[(3,4-dimethylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-methyl-N-(3-{[3-(trifluoromethyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
5-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-2-hydroxybenzoic acid;
3-nitro-N-{3-[(1-oxo-1,3-dihydro-2-benzofuran-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-{4-[({3-[(2-bromo-4-methylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide;
N-{3-[(2-fluorophenyl)amino]quinoxalin-2-yl}-4-nitrobenzenesulfonamide;
N-{3-[(2-methyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide;
4-chloro-N-{3-[(1-oxo-1,3-dihydro-2-benzofuran-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-{3-[(1-oxo-1,3-dihydro-2-benzofuran-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-{3-[(2-fluorophenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide;
N-[2-(butyloxy)-2-hydroxyethyl]-4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzamide;
3-nitro-N-(3-{[4-(phenylamino)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
4-bromo-N-{3-[(4-fluorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-methyl-N-[3-({2-[(trifluoromethyl)thio]phenyl}amino)quinoxalin-2-yl]benzenesulfonamide;
N-[4-({3-[2-(methoxy)phenyl]-2,3-dihydro-1H-imidazo[4,5-b]quinoxalin-1-yl}sulfonyl)phenyl]acetamide;
4-(3-{[4-(acetylamino)phenyl]sulfonyl}-2,3-dihydro-1H-imidazo[4,5-b]quinoxalin-1-yl)benzoic acid;
1-naphthalen-2-yl-3-[(3-nitrophenyl)sulfonyl]-2,3-dihydro-1H-imidazo[4,5-b]quinoxaline;

N-[4-({3-[4-(methoxy)phenyl]-2,3-dihydro-1H-imidazo[4,5-b]quinoxalin-1-yl}sulfonyl)phenyl]acetamide;
1-(3-methylphenyl)-3-[(4-methylphenyl)sulfonyl]-2,3-dihydro-1H-imidazo[4,5-b]quinoxaline;
N-(4-{[3-(4-methylphenyl)-2,3-dihydro-1H-imidazo[4,5-b]quinoxalin-1-yl]sulfonyl}phenyl)acetamide;
N-{4-[(3-phenyl-2,3-dihydro-1H-imidazo[4,5-b]quinoxalin-1-yl)sulfonyl]phenyl}acetamide;
N-(4-{[3-(3-methylphenyl)-2,3-dihydro-1H-imidazo[4,5-b]quinoxalin-1-yl]sulfonyl}phenyl)acetamide;
1-[4-(methoxy)phenyl]-3-[(4-methylphenyl)sulfonyl]-2,3-dihydro-1H-imidazo[4,5-b]quinoxaline;
N-(4-{[3-(2-methylphenyl)-2,3-dihydro-1H-imidazo[4,5-b]quinoxalin-1-yl]sulfonyl}phenyl)acetamide;
1-(3-methylphenyl)-3-[(3-nitrophenyl)sulfonyl]-2,3-dihydro-1H-imidazo[4,5-b]quinoxaline;
1-(4-methylphenyl)-3-[(3-nitrophenyl)sulfonyl]-2,3-dihydro-1H-imidazo[4,5-b]quinoxaline;
N-{3-[(4-methylphenyl)amino]quinoxalin-2-yl}-3-(1H-tetrazol-1-yl)benzenesulfonamide;
N-(3-{[2-(ethyloxy)phenyl]amino}quinoxalin-2-yl)-4-methylbenzenesulfonamide;
N-{4-[({3-[(4-ethylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide;
4-bromo-N-(3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide
N-(4-{[(3-{[4-(ethyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide;
N-{4-[({3-[(2-ethylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide;
N-(4-{[(3-{[2-(ethyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide;
N-{3-[(4-nitrophenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-(ethyloxy)-N-(3-{[4-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
methyl N-acetyl-N-[4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)phenyl]-beta-alaninate;
methyl N-acetyl-N-{4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}-beta-alaninate;

N-{3-[(3-chloro-5-methylphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide;
N-{3-[(3-acetylphenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide;
4-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-N-[4-(methoxy)phenyl]benzamide;
2-hydroxy-5-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzoic acid;
N-[3-(2,3-dihydro-1,4-benzodioxin-6-ylamino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide;
N-[4-(methoxy)phenyl]-4-[(3-{[(4-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzamide;
4-chloro-N-{3-[(2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-methyl-N-{3-[methyl(phenylmethyl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-[3-(3,4-dihydroisoquinolin-2(1H)-yl)quinoxalin-2-yl]-2-methylbenzenesulfonamide;
N-[4-({[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide;
4-bromo-N-{3-[(4-phenylquinolin-8-yl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-methyl-N-{3-[(4-phenylquinolin-8-yl)amino]quinoxalin-2-yl}benzenesulfonamide;
1-[(4-chlorophenyl)sulfonyl]-3-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-2,3-dihydro-1H-imidazo[4,5-b]quinoxaline;
1-(4-morpholin-4-ylphenyl)-3-(phenylsulfonyl)-2,3-dihydro-1H-imidazo[4,5-b]quinoxaline;
methyl 4,5-dimethyl-2-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)thiophene-3-carboxylate;
ethyl 6-methyl-2-[(3-{[(2-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate;
ethyl 2-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-6-phenyl-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate;
ethyl 6-methyl-2-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate;
propyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoate;
N-{3-[(4-butylphenyl)amino]quinoxalin-2-yl}-4-chlorobenzenesulfonamide;
N-{3-[(2-chlorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide;

N-{3-[(2,3-dimethylphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide;
N-{3-[(3,4-dimethylphenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide;
N-{4-[({3-[(2,3-dimethylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide;
4-chloro-N-{3-[(2,3-dimethylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
3-nitro-N-(3-{[3,4,5-tris(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
4-chloro-N-{3-[(2,4-dichlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-{3-[(2,3-dimethylphenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide;
N-{4-[({3-[(3,4-dimethylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide;
ethyl 2-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxylate;
4-chloro-N-(3-{[4-chloro-3-(morpholin-4-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
ethyl 2-[(3-{[(2-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate;
4-bromo-N-{3-[(2,4-dichlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
ethyl 5-ethyl-2-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]thiophene-3-carboxylate;
N-(3-{[3-(morpholin-4-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
ethyl 2-[(3-{[(4-bromophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate;
4-methyl-N-(3-{[3-(piperidin-1-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
4-chloro-N-(3-{[4-(morpholin-4-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
4-chloro-N-(3-{[3-(morpholin-4-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
4-methyl-N-[3-(quinolin-6-ylamino)quinoxalin-2-yl]benzenesulfonamide;
N-(3-{[3-(piperidin-1-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-(3-{[4-(phenylamino)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-bromobenzenesulfonamide;

ethyl 2-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxylate;
N-{3-[(4'-nitrobiphenyl-4-yl)amino]quinoxalin-2-yl}benzenesulfonamide;
ethyl 2-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate;
N-(3-{[4-chloro-3-(morpholin-4-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
ethyl 5-ethyl-2-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)thiophene-3-carboxylate;
N-[4-({[3-(quinolin-6-ylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide;
ethyl 2-[(3-{[(2-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxylate;
3,4-dichloro-N-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]benzenesulfonamide;
ethyl 2-{[3-({[4-(acetylamino)-3,5-dibromophenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate;
ethyl 2-[(3-{[(2-chloro-5-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate;
N-{3-[(3-fluorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-(3-{[4-(morpholin-4-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
ethyl 2-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate;
ethyl 2-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-5-ethylthiophene-3-carboxylate;
N,N-diethyl-4-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzenesulfonamide;
ethyl 2-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-5-ethylthiophene-3-carboxylate;
ethyl 2-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate;
ethyl 2-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate;
N-[4-(methoxy)phenyl]-4-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzamide;
N-[3-({4-[(4-aminophenyl)oxy]phenyl}amino)quinoxalin-2-yl]-4-chlorobenzenesulfonamide;

N-[4-({[3-({4-[(4-aminophenyl)oxy]phenyl}amino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide;
(2E)-3-{3-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}prop-2-enoic acid;
N-{3-[(9-ethyl-9H-carbazol-3-yl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide;
N-[3-({4-[(4-aminophenyl)oxy]phenyl}amino)quinoxalin-2-yl]benzenesulfonamide;
4-bromo-N-{3-[(9-ethyl-9H-carbazol-3-yl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-{3-[(9-ethyl-9H-carbazol-3-yl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-{3-[(2-iodophenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-{3-[(1-phenylethyl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-bromo-N-{3-[(4-bromophenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-bromo-N-{3-[(4-chlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-bromo-N-[3-(naphthalen-2-ylamino)quinoxalin-2-yl]benzenesulfonamide;
N-{3-[(2,3-dimethylphenyl)amino]-6-methylquinoxalin-2-yl}-4-methylbenzenesulfonamide;
4-chloro-N-{3-[(2-iodophenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-(3-{[4-(octyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide;
N-{3-[(2-bromo-4-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-[3-({4-[(3-aminophenyl)sulfonyl]phenyl}amino)quinoxalin-2-yl]-4-chlorobenzenesulfonamide;
N-[3-({2-[(difluoromethyl)oxy]phenyl}amino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide;
8-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]quinoline-2-carboxylic acid;
ethyl 3,3,3-trifluoro-2-hydroxy-2-{4-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}propanoate;
N-[3-(quinolin-6-ylamino)quinoxalin-2-yl]benzenesulfonamide ;
4-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}phenyl thiocyanate;
1-[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]-4-methylpyridinium;

N-{3-[(2-chlorophenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide;
4-methyl-N-[3-(phenylamino)quinoxalin-2-yl]benzenesulfonamide;
4-methyl-N-{3-[(2-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-methyl-N-{3-[(4-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-{3-[(4-chlorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide;
4-methyl-N-[3-(naphthalen-2-ylamino)quinoxalin-2-yl]benzenesulfonamide;
N-{4-[({3-[(4-bromophenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide;
N-{4-[({3-[(2-methylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]-phenyl}acetamide;
N-{3-[bis(phenylmethyl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid;
2-hydroxy-4-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid;
4-bromo-N-(3-{[2-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-{3-[(3-hydroxyphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]benzenesulfonamide;
3-methyl-1-(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)pyridinium;
N-(3-{[3-{[(4-chlorophenyl)sulfonyl]amino}-7-(methoxy)quinoxalin-2-yl]amino}phenyl)acetamide;
N-{3-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}acetamide;
N-{3-[(4-bromophenyl)amino]quinoxalin-2-yl}-4-chlorobenzenesulfonamide;
N-{3-[(2,4-dimethylphenyl)amino]-6-methylquinoxalin-2-yl}-4-methylbenzenesulfonamide;
N-{3-[(3,4-dimethylphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide;
N-{3-[(2,5-dimethylphenyl)amino]-6-methylquinoxalin-2-yl}-4-methylbenzenesulfonamide;
ethyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoate;
4-chloro-N-{3-[(4-ethylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
4-chloro-N-(6-methyl-3-{[4-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;

4-chloro-N-{3-[(4-chlorophenyl)amino]-6-methylquinoxalin-2-yl}benzenesulfonamide;
N-(3-{[4-chloro-2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-methylbenzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide;
N-(3-{[2-methyl-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-[3-(2-Chloro-5-methoxy-phenylamino)-quinoxalin-2-yl]-benzensulfonamide;
3-amino-N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-chlorobenzenesulfonamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide;
N-(3-{[4-chloro-3-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-(3-{[4-fluoro-3-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
3-amino-N-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-bromobenzenesulfonamide;
N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide;
3-amino-N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-,N-2-dimethylglycinamide;
N-(3-{[2,5-bis(methoxy)phenyl]amino}-7-methylquinoxalin-2-yl)benzenesulfonamide;
N-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-(methoxy)benzenesulfonamide;
N-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-bromobenzenesulfonamide;
N-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-fluorobenzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2-fluorobenzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-(methoxy)benzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-bromobenzenesulfonamide;

N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methylpiperidine-4-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-piperidin-1-ylpropanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-(dimethylamino)butanamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(hydroxyamino)benzenesulfonamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-morpholin-4-ylacetamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-N-2-methylglycinamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-L-alaninamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-2-methylalaninamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-N-2-,N-2-dimethylglycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-alaninamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-methylglycinamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-D-alaninamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-methylglycinamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-alaninamide ;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-alaninamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylalaninamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylalaninamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-N-2-,N-2-dimethylglycinamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-[2-(dimethylamino)ethyl]-N-2-methylglycinamide;

(2S)-2-amino-N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)butanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-[2-(dimethylamino)ethyl]-N-2-methylglycinamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-,N-2-dimethylglycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-methyl-L-alaninamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide;
N-(2-chloro-5-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-methylglycinamide;
2-(dimethylamino)-N-(3-(N-(3-(3-(2-(dimethylamino)acetamido)-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide;
N-(3-{[(3-{[2-acetyl-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-,N-2-dimethylglycinamide;
N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(formylamino)benzenesulfonamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-ethylglycinamide;
N-(5-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-2-methylphenyl)glycinamide;
2-azetidin-1-yl-N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-prolinamide;
N-(3-{[(3-{[2-bromo-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-methylglycinamide;
N-2-,N-2-dimethyl-N-(3-{[(3-{[6-(methoxy)quinolin-8-yl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-alaninamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-methyl-D-alaninamide;

N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-prolinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-serinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)azetidine-3-carboxamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-,2-dimethylalaninamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-methyl-D-alaninamide;
N-(3-{[(3-{[2-bromo-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-,N-2-dimethylglycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-propylglycinamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-methyl-L-alaninamide;
N-(5-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-2-methylphenyl)-beta-alaninamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)piperidine-3-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-methyl-1,4-diazepan-1-yl)acetamide;
(2S)-2-amino-N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)butanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(2-hydroxypropyl)glycinamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(2-fluoroethyl)glycinamide;
3-amino-N-(2-{[3,5-bis(methoxy)phenyl]amino}pyrido[2,3-b]pyrazin-3-yl)benzenesulfonamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-[(2-methylpropyl)oxy]glycinamide;
1-amino-N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopropanecarboxamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(formylamino)benzenesulfonamide;

N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(cyclopropylmethyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-prolinamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(dimethylamino)azetidin-1-yl]acetamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-prolinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)piperidine-2-carboxamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)morpholine-4-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyrrolidin-1-ylacetamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-6-,N-6-dimethyl-L-lysinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-ethyl-N-2-methylglycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(1H-imidazol-4-yl)acetamide;
1-amino-N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopentanecarboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(2-methylpropyl)glycinamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-ethyl-N-2-methylglycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(1H-imidazol-4-ylmethyl)azetidine-3-carboxamide;
N-(5-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-2-methylphenyl)-N-2-,N-2-dimethylglycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-ethylazetidine-3-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-methyl-N-2-(1-methylpyrrolidin-3-yl)glycinamide;
N-(3-{[(2-{[3,5-bis(methoxy)phenyl]amino}pyrido[2,3-b]pyrazin-3-yl)amino]sulfonyl}phenyl)-N-2-[2-(dimethylamino)ethyl]-N-2-methylglycinamide;

N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(3S)-3-hydroxypyrrolidin-1-yl]acetamide;
1-amino-N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclobutanecarboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-butylglycinamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-piperidin-1-ylazetidin-1-yl)acetamide;
3-[(aminocarbonyl)amino]-N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-hydroxycyclopropanecarboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2,2-dimethylhydrazino)acetamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-[({[2-(dimethylamino)ethyl]amino}carbonyl)amino]benzenesulfonamide;
N-(3-{[(3-{[3-fluoro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-methylglycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-hydroxyacetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyridazine-4-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(1-methylethyl)glycinamide;
1-amino-N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopentanecarboxamide;
1-amino-N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopropanecarboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(dimethylamino)pyrrolidin-1-yl]acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-[2-(dimethylamino)ethyl]glycinamide;
2-(dimethylamino)ethyl(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)carbamate;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(cyclopropylmethyl)azetidine-3-carboxamide;

N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(1,1-dimethylethyl)glycinamide;
N-2-methyl-N-(3-{[(3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1H-imidazole-2-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)isoxazole-5-carboxamide;
N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(2,2,2-trifluoroethyl)glycinamide;
3-amino-N-(3-{[2-methyl-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-oxocyclopentanecarboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-6-hydroxypyridine-2-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(3-fluoro-4-hydroxyphenyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(furan-2-ylmethyl)azetidine-3-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyrimidine-5-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1H-pyrrole-2-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-methyl-N-2-(1-methylethyl)glycinamide;
N-(3-{[(3-{[3-fluoro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-,N-2-dimethylglycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1H-imidazole-4-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-,N-2-diethylglycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-methylisoxazol-5-yl)acetamide;
N-2-,N-2-dimethyl-N-(3-{[(3-{[2-methyl-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide;

N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-[(3-hydroxyphenyl)methyl]glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methyl-1H-pyrrole-2-carboxamide;
4-amino-N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)tetrahydro-2H-pyran-4-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(methylamino)piperidin-1-yl]acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-piperidin-1-ylacetamide;
N-(4-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-,N-2-dimethylglycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methyl-L-prolinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)thiophene-3-carboxamide;
3-amino-N-{3-[(2-chloro-5-hydroxyphenyl)amino]quinoxalin-2-yl}benzenesulfonamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(cyclopropylcarbonyl)azetidine-3-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-methylpiperazin-1-yl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(phenylmethyl)azetidine-3-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-chloropyridine-3-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyridin-4-ylacetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-methyl-N-2-prop-2-en-1-ylglycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(phenylmethyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(methoxy)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-propanoylazetidine-3-carboxamide;

N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyridine-3-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-[2-(methoxy)ethyl]glycinamide;
1-acetyl-N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)piperidine-4-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-methylpyrrolidin-1-yl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)furan-3-carboxamide;
N-2-,N-2-dimethyl-N-(3-{[(3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-6-chloropyridine-3-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-chlorobenzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyridin-2-ylacetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(dimethylamino)azetidin-1-yl]acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyridin-3-ylacetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-chlorophenyl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-[3-(dimethylamino)propyl]-N-2-methylglycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-ethyl-N-2-(2-hydroxyethyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[2-(phenylmethyl)pyrrolidin-1-yl]acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)propanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)furan-2-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-chloropyridine-4-carboxamide;

N-2-acetyl-N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)butanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-chlorobenzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methylbenzamide;
1,1-dimethylethyl{2-[(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)amino]-2-oxoethyl}carbamate;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1,3-benzodioxole-5-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-({[2-(methoxy)phenyl]methyl}oxy)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyridine-4-carboxamide;
N-(3-{[(3-{[4-fluoro-3-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-,N-2-dimethylglycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(3,4-dichlorophenyl)piperazin-1-yl]acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-pyridin-3-ylpropanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)tetrahydrofuran-3-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-[(2-methylphenyl)methyl]glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylbutanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-fluorophenyl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(1-methyl-1-phenylethyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylcyclopropanecarboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methyl-4-(methoxy)benzamide;

N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylpyridine-3-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-(methoxy)benzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-ethylpiperazin-1-yl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)thiophene-2-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluoro-2-methylbenzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-bromothiophene-3-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-fluorobenzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-methylpiperidin-1-yl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylpropanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pentanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(ethyloxy)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(2-fluorophenyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-(dimethylamino)benzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-methylpiperidin-1-yl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(2-propylphenyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)benzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyrazine-2-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluoro-4-(methoxy)benzamide;

N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,2-dimethylbutanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(4-fluorophenyl)oxy]acetamide;
1-acetyl-N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)azetidine-3-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(4-methylphenyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-phenylglycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-prop-2-en-1-ylpiperazin-1-yl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylbenzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-(methoxy)propanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-methylfuran-2-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-[(phenylmethyl)oxy]glycinamide;
N-{3-[({3-[(2-chloro-5-hydroxyphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}-N-2-,N-2-dimethylglycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(3-chlorophenyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclobutanecarboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(methoxy)phenyl]acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methylcyclopropanecarboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluorobenzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-(dimethylamino)benzamide;

N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3,4-dichlorobenzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-{[2-(methylthio)phenyl]methyl}glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-fluorophenyl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-ethyl-N-2-(1-methylethyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1,3-thiazole-4-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-methyl-N-2-(phenylmethyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(2-thienylmethyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(pyridin-2-ylmethyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-(methoxy)benzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-[(3-chloro-4-methylphenyl)methyl]glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylpentanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-chlorophenyl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluoro-4-methylbenzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(2-methylphenyl)oxy]acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-cyclohexylacetamide;
(1R,2R)-N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-phenylcyclopropanecarboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-chlorobenzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[2-(methoxy)phenyl]acetamide;

N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-[3-(methoxy)phenyl]propanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(2-fluoro-4-methylphenyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-[(3-fluorophenyl)methyl]glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(methoxy)phenyl]acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-phenylacetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,4-dichlorobenzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-oxocyclohexanecarboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(3-fluorophenyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-chlorophenyl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(2-phenylpropyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-[(2,4-dimethylphenyl)methyl]glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-methylpiperidin-1-yl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-[2-(methoxy)phenyl]glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3,4-dihydroisoquinolin-2(1H)-yl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pent-4-enamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(2-methylphenyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-oxopiperidin-1-yl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-fluorobenzamide;

N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(1-phenylethyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-fluoro-6-(methoxy)benzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-[2-(1-methylethyl)phenyl]glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-[2-(methoxy)phenyl]propanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methylpentanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-phenylmorpholin-4-yl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-[4-(methoxy)phenyl]propanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-cyclopentyl-N-2-prop-2-en-1-ylglycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-methyl-N-2-[2-(methoxy)ethyl]glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-cyclopropyl-4-oxobutanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-[3-(1,1-dimethylethyl)phenyl]glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(cyclopropylmethyl)-N-2-propylglycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-oxocyclopentyl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(4-chlorophenyl)glycinamide;
2-(1,4'-bipiperidin-1'-yl)-N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-cyclopentylpiperazin-1-yl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-methylphenyl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-[(5-fluoro-2-methylphenyl)methyl]glycinamide;

N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3,3-dimethylbutanamide;
N-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N2-(2-chlorophenyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-5-fluoro-2-methylbenzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-fluoro-3-methylbenzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,3-dichlorobenzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(phenyloxy)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-(2,3-dimethylphenyl)glycinamide;
3-amino-N-(3-{[3,5-bis(methoxy)phenyl]amino}pyrido[2,3-b]pyrazin-2-yl)benzenesulfonamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-fluoro-5-methylbenzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-{[(4-methylphenyl)methyl]oxy}glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(1-methylethyl)piperazin-1-yl]acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-fluorophenyl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-methylbutanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methyl-2-(methoxy)benzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-propylpiperidin-1-yl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(3-methylphenyl)oxy]acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)tetrahydrofuran-2-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(hydroxymethyl)piperidin-1-yl]acetamide;

1,1-dimethylethyl2-{[(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)amino]carbonyl}piperidine-1-carboxylate;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-methyl-N-2-(pyridin-3-ylmethyl)glycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-ethyl-N-2-phenylglycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-{[2-(methoxy)ethyl]oxy}acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-cyclopentylpropanamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,5-dichlorobenzamide;
2-(4-acetylpiperazin-1-yl)-N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-5-fluoro-2-(methoxy)benzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-cyclohexyl-N-2-ethylglycinamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-5-methylisoxazole-3-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-methylpyridine-2-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(methoxy)pyridine-3-carboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3,5-dichlorobenzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(1,3-thiazolidin-3-yl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-formylpiperazin-1-yl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-pyridin-4-ylpiperidin-1-yl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(methoxy)benzamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N-2-methyl-N-2-(2-methylpropyl)glycinamide;

N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-formyl-1,4-diazepan-1-yl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-phenylcyclopropanecarboxamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2,6-dimethylmorpholin-4-yl)acetamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-phenylpyrrolidin-1-yl)acetamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[2-(dimethylamino)-1-methylethyl]benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[2-(dimethylamino)ethyl]benzamide;
5-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[2-(dimethylamino)ethyl]-2-fluorobenzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-pyrrolidin-3-ylbenzamide;
3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[2-(dimethylamino)ethyl]benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(2-pyrrolidin-1-ylethyl)benzamide;
N-(2-aminoethyl)-3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[2-(dimethylamino)ethyl]-N-methylbenzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(piperidin-2-ylmethyl)benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(1-methylazetidin-3-yl)benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(2-piperidin-1-ylethyl)benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[2-(diethylamino)ethyl]benzamide;
3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[2-(dimethylamino)ethyl]-N-methylbenzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(1-methylpiperidin-3-yl)benzamide;

3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-piperidin-3-ylbenzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[(1-methylpiperidin-2-yl)methyl]benzamide;
N-{2-[bis(2-hydroxyethyl)amino]ethyl}-3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(1-ethylpiperidin-3-yl)benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide;
3-[(3-aminopyrrolidin-1-yl)carbonyl]-N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
5-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[2-(dimethylamino)ethyl]-2-(methoxy)benzamide;
N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}benzenesulfonamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzoicacid;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(2-morpholin-4-ylethyl)benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[(1-ethylpyrrolidin-2-yl)methyl]benzamide;
3-[(4-amino-3-oxopyrazolidin-1-yl)carbonyl]-N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-methylbenzamide;
3-[(3-aminoazetidin-1-yl)carbonyl]-N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(pyridin-3-ylmethyl)benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(pyridin-2-ylmethyl)benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(2-hydroxyethyl)benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(3-oxopyrazolidin-4-yl)benzamide;

3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[2-(1H-imidazol-4-yl)ethyl]benzamide;
N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-{[3-(dimethylamino)pyrrolidin-1-yl]carbonyl}benzenesulfonamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(pyridin-4-ylmethyl)benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-methyl-N-(1-methylpyrrolidin-3-yl)benzamide;
N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-{[3-(diethylamino)pyrrolidin-1-yl]carbonyl}benzenesulfonamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-1H-pyrrol-1-ylbenzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(3-pyrrolidin-1-ylpropyl)benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(2-cyanoethyl)-N-methylbenzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[2-(methoxy)ethyl]benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(2-cyanoethyl)-N-ethylbenzamide;
3-[(3-aminopiperidin-1-yl)carbonyl]-N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzoicacid;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[3-(dimethylamino)propyl]benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-morpholin-4-ylbenzamide;
N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-[(2,2-dimethylhydrazino)carbonyl]benzenesulfonamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[3-(1H-imidazol-1-yl)propyl]benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[3-(diethylamino)propyl]benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(2-cyanoethyl)benzamide;

methylN-[(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)carbonyl]-beta-alaninate;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[2-(methylthio)ethyl]benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[2-(ethylthio)ethyl]benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[2-(dimethylamino)ethyl]-N-ethylbenzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[3-(2-oxopyrrolidin-1-yl)propyl]benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(2-pyridin-4-ylethyl)benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[3-(ethyloxy)propyl]benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(3-morpholin-4-ylpropyl)benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[3-(methoxy)propyl]benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[3-(dimethylamino)propyl]-N-methylbenzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[3-(propyloxy)propyl]benzamide;
ethylN-[(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)carbonyl]-beta-alaninate;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-{3-[(1-methylethyl)oxy]propyl}benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(1,1-dimethyl-2-piperidin-1-ylethyl)benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-methyl-N-propylbenzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-piperidin-1-ylbenzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[1-methyl-2-(methoxy)ethyl]benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(1,1-dimethyl-2-morpholin-4-ylethyl)benzamide;

N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-({2-[(dimethylamino)methyl]piperidin-1-yl}carbonyl)benzenesulfonamide;
N-[3-(butyloxy)propyl]-3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-[4-(diethylamino)-1-methylbutyl]benzamide;
3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-N-(1,1-dimethyl-2-oxo-2-piperidin-1-ylethyl)benzamide;
N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-[(4-methylpiperazin-1-yl)carbonyl]benzenesulfonamide;
N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-{[2-(piperidin-1-ylmethyl)piperidin-1-yl]carbonyl}benzenesulfonamide;
N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-6-oxo-1,6-dihydropyridine-3-sulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-6-oxo-1,6-dihydropyridine-3-sulfonamide;
3-amino-N-(3-{[6-(methoxy)quinolin-8-yl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)thiophene-2-sulfonamide;
N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-cyanobenzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(methylamino)benzenesulfonamide;
N-(2-{[3,5-bis(methoxy)phenyl]amino}pyrido[2,3-b]pyrazin-3-yl)-3-nitrobenzenesulfonamide;
N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(1-{[2-(dimethylamino)ethyl]amino}ethyl)benzenesulfonamide;
3-amino-N-(3-{[3-(methoxy)-5-nitrophenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
3-acetyl-N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
3-amino-N-(3-{[3-fluoro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-N'-[2-(dimethylamino)ethyl]benzene-1,3-disulfonamide;
N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-N'-[3-(dimethylamino)propyl]benzene-1,3-disulfonamide;

N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-6-chloropyridine-3-sulfonamide;
N-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-{5-[(dimethylamino)methyl]-1,3,4-oxadiazol-2-yl}benzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-6-{[2-(dimethylamino)ethyl]amino}pyridine-3-sulfonamide;
3-amino-N-(3-{[3-amino-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(dimethylamino)benzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-6-{[2-(dimethylamino)ethyl]oxy}pyridine-3-sulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-6-(dimethylamino)pyridine-3-sulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-cyanobenzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-fluorobenzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-fluoro-2-methylbenzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2-methylbenzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-cyanobenzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3,5-difluorobenzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2-chlorobenzenesulfonamide;
N-(4-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide;
N-(3-{[6-(methoxy)quinolin-8-yl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(2H-tetrazol-5-yl)benzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)naphthalene-1-sulfonamide;
N-{[(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)amino](dimethylamino)methylidene}-N-methylmethanaminium;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-fluorobenzenesulfonamide;

N-(3-{[2-bromo-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-[(difluoromethyl)oxy]benzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2-(trifluoromethyl)benzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-chloro-4-fluorobenzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-(trifluoromethyl)benzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(methylsulfonyl)benzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2,5-dichlorothiophene-3-sulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3,5-dichlorobenzenesulfonamide;
N-(3-{[2-methyl-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-[(trifluoromethyl)oxy]benzenesulfonamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(dimethylamino)piperidin-1-yl]acetamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-5-chloro-2-(methoxy)benzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(trifluoromethyl)benzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2,5-bis(methoxy)benzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3,5-dimethylisoxazole-4-sulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-5-bromo-2-(methoxy)benzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-fluoro-3-(trifluoromethyl)benzenesulfonamide;
N-(3-{[3-fluoro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide;

N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-fluoro-4-methylbenzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-chloro-4-methylbenzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2,5-dimethylthiophene-3-sulfonamide;
N-(3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide;
N-{3-[(2-chloro-5-hydroxyphenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide;
N-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methyl-3-(methoxy)benzamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-1-phenylmethanesulfonamide;
N-(3-{[3-(methoxy)-5-nitrophenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-1-(3-chlorophenyl)methanesulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4,5-dichlorothiophene-2-sulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-5-chloro-1,3-dimethyl-1H-pyrazole-4-sulfonamide;
N-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3,5-bis(trifluoromethyl)benzenesulfonamide;
8-ethyl-2-(ethylamino)-4-methyl-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-one;
6-bromo-8-ethyl-4-methyl-2-[(1-methylethyl)amino]pyrido[2,3-d]pyrimidin-7(8H)-one;
6-bromo-2-[(1,1-dimethylethyl)amino]-8-ethyl-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
6-biphenyl-4-yl-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
6-(2,4-difluorophenyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
6-(3-chloro-4-fluorophenyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-4-methyl-6-[4-(methyloxy)phenyl]pyrido[2,3-d]pyrimidin-7(8H)-one;
6-(2,4-dichlorophenyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
6-(3,4-difluorophenyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;

8-ethyl-2-(ethylamino)-4-methyl-6-[2-(methyloxy)phenyl]pyrido[2,3-d]pyrimidin-7(8H)-one;
6-bromo-2-{[3-(dimethylamino)propyl]amino}-8-ethyl-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-4-methyl-6-[4-(phenyloxy)phenyl]pyrido[2,3-d]pyrimidin-7(8H)-one;
6-[2,4-bis(methyloxy)phenyl]-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-6-(3-fluorophenyl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-6-(2-fluorophenyl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-4-methyl-6-[3-(trifluoromethyl)phenyl]pyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-6-(4-fluorophenyl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-4-methyl-6-(2-thienyl)pyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-4-methyl-6-[3-(methyloxy)phenyl]pyrido[2,3-d]pyrimidin-7(8H)-one;
6-(3-chlorophenyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
6-(4-chlorophenyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-4-methyl-6-(3-thienyl)pyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-4-methyl-6-(4-methyl-2-thienyl)pyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-4-methyl-6-(4-methyl-3-thienyl)pyrido[2,3-d]pyrimidin-7(8H)-one;
1,1-dimethylethyl 2-[8-ethyl-2-(ethylamino)-4-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl]-1H-pyrrole-1-carboxylate;
8-ethyl-2-(ethylamino)-4-methyl-6-(1H-pyrrol-2-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
6-(5-chloro-2-thienyl)-8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-4-methyl-6-pyrimidin-5-ylpyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-6-(3-fluoropyridiN-4-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-6-furan-3-yl-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;

8-ethyl-2-(ethylamino)-4-methyl-6-[1-(phenylmethyl)-1H-pyrazol-4-yl]pyrido[2,3-d]pyrimidin-7(8H)-one;
6-bromo-2-(ethylamino)-4-methyl-8-(1-methylethyl)pyrido[2,3-d]pyrimidin-7(8H)-one;
2-(ethylamino)-4-methyl-8-(1-methylethyl)-6-(2-thienyl)pyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-6-(1H-indol-6-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-4-methyl-6-(5-phenyl-2-thienyl)pyrido[2,3-d]pyrimidin-7(8H)-one;
2-(ethylamino)-6-furan-3-yl-4-methyl-8-(1-methylethyl)pyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-4-methyl-6-(1H-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
8-cyclohexyl-2-(ethylamino)-4-methyl-6-(2-thienyl)pyrido[2,3-d]pyrimidin-7(8H)-one;
6-bromo-2-(ethylamino)-4-methyl-8-[3-(methyloxy)propyl]pyrido[2,3-d]pyrimidin-7(8H)-one;
6-bromo-2-(ethylamino)-8-[2-(ethyloxy)ethyl]-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
6-bromo-2-(ethylamino)-4-methyl-8-(2-piperidin-1-ylethyl)pyrido[2,3-d]pyrimidin-7(8H)-one;
6-bromo-2-(ethylamino)-8-[3-(ethyloxy)propyl]-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
6-bromo-2-(ethylamino)-4-methyl-8-{3-[(1-methylethyl)oxy]propyl}pyrido[2,3-d]pyrimidin-7(8H)-one;
6-bromo-2-(ethylamino)-8-(3-hydroxypropyl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
6-bromo-2-(ethylamino)-8-(2-hydroxyethyl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
6-bromo-8-cyclopropyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-4-methyl-6-(1,3-thiazol-2-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
6-bromo-8-cyclopentyl-2-(ethylamino)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;

8-cyclopentyl-2-(ethylamino)-4-methyl-6-(1H-pyrazol-3-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
2-(ethylamino)-4-methyl-8-(1-methylethyl)-6-(1H-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-(ethylamino)-4-methyl-6-(1H-pyrazol-1-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
2-(ethylamino)-4-methyl-8-(1-methylethyl)-6-(1H-pyrazol-1-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
8-cyclopentyl-2-(ethylamino)-4-methyl-6-(1H-pyrazol-1-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-2-[(2,2,2-trifluoroethyl)amino]pyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
2-(ethylamino)-4-methyl-6-(1H-pyrazol-3-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-4-methyl-2-(methylamino)-6-(1H-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-cyclopentyl-4-methyl-6-(1H-pyrazol-3-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
8-ethyl-2-[(2-fluoroethyl)amino]-4-methyl-6-(1H-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-4-methyl-8-(1-methylethyl)-6-(1H-pyrazol-3-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-ethyl-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-4-methyl-8-(phenylmethyl)-6-(1H-pyrazol-3-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-ethyl-4-methyl-6-(4-methyl-3-thienyl)pyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-ethyl-4-methyl-6-(2-thienyl)pyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-ethyl-6-(4-fluorophenyl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-ethyl-6-(3-fluorophenyl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-ethyl-6-(2-fluorophenyl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-ethyl-4-methyl-6-(3-thienyl)pyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-ethyl-6-furan-3-yl-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;

2-amino-8-ethyl-4-methyl-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-ethyl-4-methyl-6-[4-(methyloxy)phenyl]pyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-6-(4-chlorophenyl)-8-ethyl-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-6-(3-chlorophenyl)-8-ethyl-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-ethyl-6-isoxazol-4-yl-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-ethyl-6-furan-2-yl-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-6-(2,4-dichlorophenyl)-8-ethyl-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
5-(2-amino-8-ethyl-4-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)thiophene-2-carbonitrile;
2-amino-8-ethyl-4-methyl-6-pyrimidin-5-ylpyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-ethyl-6-(1H-imidazol-5-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-ethyl-4-methyl-6-(1H-1,2,3-triazol-5-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-4-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-ethyl-4-methyl-6-(1,3-thiazol-2-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-ethyl-4-methyl-6-(1H-tetrazol-5-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-ethyl-4-methyl-6-(1-methyl-1H-pyrrol-2-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-6-bromo-8-cyclopentyl-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-4,8-diethyl-6-(1H-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;
2-amino-8-cyclopentyl-4-methyl-6-(1,3-thiazol-5-yl)pyrido[2,3-d]pyrimidin-7(8H)-one;

6-(2-butyl-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one;
6-[1-hydroxy-3-oxo-2-(2-phenylethyl)-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-(1-hydroxy-2-{[4-(methyloxy)phenyl]methyl}-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one;
6-(1-hydroxy-2-{[3-(methyloxy)phenyl]methyl}-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one;
6-{2-[(4-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
6-(1-hydroxy-3-oxo-2-phenyl-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one;
6-{2-[(3-bromophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
6-{2-[(4-bromophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
6-[1-hydroxy-3-oxo-2-(3-phenylpropyl)-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-{2-[(3,4-dichlorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
6-{1-hydroxy-2-[(4-methylphenyl)methyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
6-{2-[(4-chlorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
6-[1-hydroxy-2-(1-methylethyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
methyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
6-{2-[(3,4-dimethylphenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
6-(2-{[4-chloro-3-(trifluoromethyl)phenyl]methyl}-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one;
6-(2-{[4-(dimethylamino)phenyl]methyl}-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one;
6-[2-(3-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;

6-[2-(4-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-[2-(3,4-dichlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-[1-hydroxy-2-(4-methylphenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
3-(2-{[3,5-bis(methyloxy)phenyl]amino}-1H-benzimidazol-5-yl)-3-(methyloxy)-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one;
3-(2-{[3,5-bis(methyloxy)phenyl]amino}-1H-benzimidazol-5-yl)-2-(1-methylethyl)-3-(methyloxy)-2,3-dihydro-1H-isoindol-1-one;
3-(2-{[3,5-bis(methyloxy)phenyl]amino}-1H-benzimidazol-5-yl)-3-hydroxy-2-phenyl-2,3-dihydro-1H-isoindol-1-one;
3-(2-{[3,5-bis(methyloxy)phenyl]amino}-1H-benzimidazol-5-yl)-3-hydroxy-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one;
methyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1-methyl-1H-benzimidazol-2-yl}carbamate;
3-(1H-benzimidazol-5-yl)-3-hydroxy-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one;
5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-N-methyl-1H-benzimidazole-2-carboxamide;
3-hydroxy-3-(2-methyl-1H-benzimidazol-5-yl)-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one;
7-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-3,4-dihydroquinoxalin-2(1H)-one;
7-[2-(3-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-3,4-dihydroquinoxalin-2(1H)-one;
1,1-dimethylethyl 4-{[1-hydroxy-3-oxo-1-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-1,3-dihydro-2H-isoindol-2-yl]methyl}piperidine-1-carboxylate;
6-(1-hydroxy-2-{[2-(methyloxy)phenyl]methyl}-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one;
6-{2-[(3-chlorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
6-{2-[(2-chlorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
6-{2-[(3-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;

6-{2-[(2-bromophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
6-{2-[(2-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
6-[2-(3-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-[1-hydroxy-2-(3-iodophenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-[2-(3-bromophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-[1-hydroxy-2-(3-nitrophenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-{1-hydroxy-2-[3-(methyloxy)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
6-[1-hydroxy-2-(3-methylphenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
3-hydroxy-3-(1H-indol-5-yl)-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one;
methyl [6-(1-hydroxy-3-oxo-2-phenyl-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate;
6-[2-(2-aminophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-{[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]carbonyl}-2H-1,4-benzoxazin-3(4H)-one;
6-{[2-(1H-benzimidazol-2-yl)phenyl]carbonyl}-2H-1,4-benzoxazin-3(4H)-one;
6-(1-hydroxy-3-oxo-2-{[2-(trifluoromethyl)phenyl]methyl}-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one;
6-{2-[(5-bromo-2-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
6-{1-hydroxy-2-[(3-nitrophenyl)methyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
6-(1-hydroxy-3-oxo-2-{[3-(trifluoromethyl)phenyl]methyl}-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one;
6-(2-{[2,3-bis(methyloxy)phenyl]methyl}-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one;
6-{1-hydroxy-2-[(3-iodophenyl)methyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;

6-[1-hydroxy-3-oxo-2-({3-[(trifluoromethyl)oxy]phenyl}-methyl)-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-(1-hydroxy-2-{[2-(methylthio)phenyl]methyl}-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one;
6-[2-(3,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-{1-hydroxy-2-[3-(1-methylethyl)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
6-(1-hydroxy-3-oxo-2-{3-[(trifluoromethyl)oxy]phenyl}-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one;
6-{1-hydroxy-3-oxo-2-[3-(trifluoromethyl)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
3-[1-hydroxy-3-oxo-1-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-1,3-dihydro-2H-isoindol-2-yl]benzene-sulfonamide;
6-{2-[5-chloro-2-(methyloxy)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
6-{2-[4-fluoro-3-(trifluoromethyl)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
3-hydroxy-3-(1H-indol-6-yl)-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one;
6-[2-(3-fluoro-5-iodophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-[2-(3-aminophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-[2-(3,5-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-{1-hydroxy-2-[3-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
ethyl 3-[1-hydroxy-3-oxo-1-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-1,3-dihydro-2H-isoindol-2-yl]benzoate;
3-[1-hydroxy-3-oxo-1-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-1,3-dihydro-2H-isoindol-2-yl]benzonitrile;
6-[2-(2-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-[2-(3-amino-5-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;

6-[2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-[2-(3-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-[2-(3-ethylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-[2-(3-ethynylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-[1-hydroxy-2-(3-hydroxyphenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-{1-hydroxy-3-oxo-2-[3-(phenyloxy)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
6-(1-hydroxy-3-oxo-2-{3-[(phenylmethyl)oxy]phenyl}-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one;
3-[1-hydroxy-3-oxo-1-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-1,3-dihydro-2H-isoindol-2-yl]benzamide;
6-{1-hydroxy-2-[3-(hydroxymethyl)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-2H-1,4-benzoxazin-3(4H)-one;
6-[2-(2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
3-hydroxy-3-[2-(methylamino)-1H-benzimidazol-5-yl]-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one;
6-(2-biphenyl-3-yl-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one;
6-(2-{3-[(dimethylamino)methyl]phenyl}-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one;
6-[2-(3,5-dichlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-(1-hydroxy-3-oxo-2-piperidin-4-yl-2,3-dihydro-1H-isoindol-1-yl)-2H-1,4-benzoxazin-3(4H)-one;
6-[2-(3-{[2-(dimethylamino)ethyl]oxy}phenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
6-[1-hydroxy-2-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-2H-1,4-benzoxazin-3(4H)-one;
N-methyl-2-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)carbonyl]-N-phenylbenzamide;

methyl {5-[1-(ethyloxy)-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
Phenylmethyl 2-[(2-{[(methyloxy)carbonyl]-amino}-1H-benzimidazol-5-yl)carbonyl]-benzoate;
3-hydroxy-3-(1H-indazol-5-yl)-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one;
3-hydroxy-3-(1H-indazol-6-yl)-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one;
ethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-methylpropyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[1-hydroxy-3-oxo-2-(2-thienylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[1-hydroxy-3-oxo-2-(2-phenylethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
3-[2-amino-1-(1,1-dimethylethyl)-1H-benzimidazol-5-yl]-3-hydroxy-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one;
3-(2-amino-1H-benzimidazol-5-yl)-3-hydroxy-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one;
methyl [5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate;
3-(methyloxy)butyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl (5-{1-hydroxy-3-oxo-2-[(1R)-1-phenylethyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{1-hydroxy-3-oxo-2-[(1S)-1-phenylethyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
2-(methyloxy)ethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1-methyl-1H-benzimidazol-2-yl}carbamate;
prop-2-yn-1-yl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
but-2-yn-1-yl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
1-methylethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;

methyl {5-[2-(2,3-dihydro-1H-inden-2-yl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[1-hydroxy-3-oxo-2-(pyridin-4-ylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[1-hydroxy-3-oxo-2-(pyridin-3-ylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl (6-{2-[(3-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl {5-[1-hydroxy-2-(3-methylphenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl [5-(1-hydroxy-2-{[2-(methyloxy)phenyl]methyl}-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate;
methyl [5-(1-hydroxy-2-{[3-(methyloxy)phenyl]methyl}-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate;
methyl [5-(1-hydroxy-2-{[4-(methyloxy)phenyl]methyl}-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate;
methyl (6-{2-[(4-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (6-{2-[(3-bromophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{1-hydroxy-2-[(3-iodophenyl)methyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{2-[(3-chlorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{2-[(2-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl {5-[1-hydroxy-3-oxo-2-(pyridin-2-ylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
phenylmethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-fluoroethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
propyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl (5-{1-hydroxy-2-[4-(methyloxy)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;

methyl (5-{2-[(2-chlorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{2-[(2-bromophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{1-hydroxy-2-[(3-methylphenyl)methyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{1-hydroxy-2-[(4-methylphenyl)methyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{1-hydroxy-2-[(2-methylphenyl)methyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl {5-[2-(3-bromophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl (5-{1-hydroxy-2-[3-(methyloxy)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl {5-[2-(4-bromophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(4-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3,5-dimethylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(2-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[1-hydroxy-2-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl (5-{1-hydroxy-2-[2-(methyloxy)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl {5-[1-hydroxy-2-(4-methylphenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;

methyl (5-{1-hydroxy-3-oxo-2-[3-(trifluoromethyl)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
but-2-yn-1-yl (5-{1-hydroxy-3-oxo-2-[(1R)-1-phenylethyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
N-ethyl-N'-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}urea;
phenylmethyl (5-{1-hydroxy-3-oxo-2-[(1R)-1-phenylethyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl {6-[2-(3-amino-5-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
piperidin-4-ylmethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(cyclopropylmethyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(2,2-dimethylpropyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3,5-dichlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3,5-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
N-ethyl-N'-(5-{1-hydroxy-3-oxo-2-[(1R)-1-phenylethyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)urea;
N'-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-N,N-dimethylurea;
methyl {5-[2-(3-{[2-(dimethylamino)ethyl]oxy}phenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
3-(4-methylpiperazin-1-yl)propyl {6-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(cyclohexylmethyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[1-hydroxy-2-(2-methylpropyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[1-hydroxy-3-oxo-2-(1,3-thiazol-2-ylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;

methyl (5-{2-[1-(3,5-difluorophenyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{2-[1-(3-fluorophenyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl [5-(2-cyclohexyl-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate;
methyl {5-[2-(2,5-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-N'-(phenylmethyl)urea;
piperidin-4-yl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-N'-methylurea;
methyl (5-{2-[1-(2-fluorophenyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{1-hydroxy-3-oxo-2-[1-(2-thienyl)ethyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{2-[1-(3-chlorophenyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{1-hydroxy-2-[3-methyl-5-(trifluoromethyl)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}propanamide;
methyl {5-[2-(3,4-dichlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-ethylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-ethynylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(4-chloro-3-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl [5-(1-hydroxy-3-oxo-2-{1-[3-(trifluoromethyl)phenyl]ethyl}-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate;
methyl (5-{1-hydroxy-3-oxo-2-[(1R)-1-phenylpropyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;

methyl [5-(1-hydroxy-3-oxo-2-{2-[(trifluoromethyl)oxy]phenyl}-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate;
methyl {5-[2-(2,3-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
cyclohexyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
tetrahydrofuran-2-ylmethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
cyclopropylmethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}morpholine-4-carboxamide;
methyl {5-[2-(cyclopentylmethyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(2,3-dimethylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(2,3-dihydro-1H-inden-1-yl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl (2S)-cyclohexyl[1-hydroxy-1-(2-{[(methyloxy)carbonyl]amino}-1H-benzimidazol-5-yl)-3-oxo-1,3-dihydro-2H-isoindol-2-yl]ethanoate;
methyl {5-[2-(2,6-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-chloro-4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
but-3-en-1-yl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2,2,2-trifluoroethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(5-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl (5-{2-[1-(5-chloro-2-methylphenyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{1-hydroxy-3-oxo-2-[(1S)-1-phenylpropyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{2-[1-(3-chloro-2-methylphenyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;

methyl (5-{1-hydroxy-2-[1-(5-methyl-2-thienyl)ethyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{2-[1-(5-chloro-2-thienyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl {5-[1-hydroxy-2-(3-iodophenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl (5-{1-hydroxy-2-[3-(1-methylethyl)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl {5-[2-(furan-2-ylmethyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[1-hydroxy-3-oxo-2-(3-thienylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(cyclobutylmethyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
3,3,3-trifluoro-2-hydroxy-N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-2-(trifluoromethyl)propanamide;
methyl (5-{1-hydroxy-2-[1-(4-methyl-2-thienyl)ethyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{2-[1-(4-bromo-2-thienyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl {5-[1-hydroxy-2-(3-{[2-(methyloxy)ethyl]oxy}phenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
tetrahydrofuran-3-ylmethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}piperidine-1-carboxamide;
methyl {5-[2-(3-bromo-4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2,3-dihydroxypropyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[1-hydroxy-3-oxo-2-(tetrahydrofuran-2-ylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl (5-{2-[3-(aminocarbonyl)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
4,4,4-trifluoro-3-hydroxy-N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-3-(trifluoromethyl)butanamide;

methyl (5-{1-hydroxy-2-[3-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{1-hydroxy-3-oxo-2-[3-(phenyloxy)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl [5-(1-hydroxy-3-oxo-2-{3-[(phenylmethyl)oxy]phenyl}-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate;
methyl [5-(2-biphenyl-3-yl-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate;
2,2-dimethyl-3-[(phenylmethyl)oxy]propyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-cyanophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-ethynyl-4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(4-fluoro-3-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[2-(3,4-dichloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(5-bromo-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl (5-{2-[3-(acetylamino)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{1-hydroxy-3-oxo-2-[3-(phenylmethyl)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{2-[1-(4-chloro-2-thienyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{1-hydroxy-3-oxo-2-[3-(phenylcarbonyl)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl [5-(2-{3-[(dimethylamino)methyl]phenyl}-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate;
methyl (5-{2-[3-(aminosulfonyl)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;

methyl {5-[2-(3-acetylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-ethyl-4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-chloro-5-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
N-{6-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-2-methylpropanamide;
methyl (5-{2-[1-(3-chloro-2-thienyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl [5-(1-hydroxy-3-oxo-2-pyridin-3-yl-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate;
methyl (5-{1-hydroxy-3-oxo-2-[3-(phenylamino)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl {5-[2-(5-bromo-2,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(5-chloro-2,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3,5-dichloro-4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2,2-dimethyl-3-(methyloxy)propyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
3-hydroxy-2,2-dimethylpropyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl (5-{2-[1-(5-bromo-2-thienyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl {5-[2-(4,5-dichloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-bromo-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-chloro-2,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
N-{6-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}pent-4-ynamide;
methyl (6-{1-methyl-3-oxo-2-[3-(trifluoromethyl)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;

methyl [5-(1-hydroxy-3-oxo-2-{3-[(1,1,2,2-tetrafluoroethyl)oxy]phenyl}-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate;
methyl {5-[1-hydroxy-3-oxo-2-(3-piperidin-4-ylphenyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-ethenylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl (5-{2-[3-(dimethylamino)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
2,2-difluoro-N-{6-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}cyclopropanecarboxamide;
N-ethyl-N'-{6-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}urea;
methyl {5-[2-(3-aminophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-4-[(phenylmethyl)oxy]butanamide;
N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-4-piperidin-1-ylbutanamide;
N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-4-(4-methylpiperazin-1-yl)butanamide;
N-{6-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}butanamide;
methyl {6-[2-(3-bromophenyl)-5,6-dichloro-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl [5-(1-hydroxy-2-{3-[methyl(phenyl)amino]phenyl}-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate;
methyl {5-[1-hydroxy-3-oxo-2-(phenylsulfonyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[(2-{[(phenylamino)carbonyl]amino}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl (5-{[2-({[(phenylmethyl)oxy]carbonyl}amino)phenyl]carbonyl}-1H-benzimidazol-2-yl)carbamate;
methyl [5-({2-[(2-phenylhydrazino)carbonyl]phenyl}carbonyl)-1H-benzimidazol-2-yl]carbamate;
methyl {5-[(2-{[(phenyloxy)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;

but-2-yn-1-yl {5-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-3-piperidin-1-ylpropanamide;
N-{6-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}propanamide;
N-(4-fluorophenyl)-2-{[2-(pent-4-ynoylamino)-1H-benzimidazol-6-yl]carbonyl}benzamide;
4-(diethylamino)-N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}butanamide;
N-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-4-pyrrolidin-1-ylbutanamide;
3-piperidin-1-ylpropyl {6-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
3-(4-methylpiperazin-1-yl)propyl {6-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-bromophenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-ethynyl-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-piperidin-1-ylethyl {5-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
N-{6-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-2,2-dimethyl-3-piperidin-1-ylpropanamide;
N-{5-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-4-piperidin-1-ylbutanamide;
N-{5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-4-piperidin-1-ylbutanamide;
methyl [6-({2-[(phenylcarbonyl)amino]phenyl}carbonyl)-1H-benzimidazol-2-yl]carbamate;
methyl {5-[1-hydroxy-2-(3-morpholin-4-ylphenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;

2-(dimethylamino)ethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-(diethylamino)ethyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-piperidin-1-ylethyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
3-piperidin-1-ylpropyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-piperidin-1-ylethyl {6-[2-(3-bromophenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[2-(3-bromophenyl)-4,7-difluoro-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-[methyl(phenylmethyl)amino]ethyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[1-hydroxy-3-oxo-2-(3-pyrrolidin-1-ylphenyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(5-chloro-2,3-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[1-hydroxy-3-oxo-2-(pyrrolidin-2-ylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[1-hydroxy-3-oxo-2-(pyrrolidin-3-ylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
(1-methylpiperidin-2-yl)methyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
[(2S)-1-methylpyrrolidin-2-yl]methyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
octahydro-2H-quinolizin-1-ylmethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(5-bromo-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1,3-dihydro-2H-benzimidazol-2-one;
methyl {5-[2-(3-bromo-2,5-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-morpholin-4-ylethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;

(1-methylpiperidin-3-yl)methyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl (5-{2-[5-chloro-2-(methyloxy)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl [5-(2-{3-[cyclohexyl(methyl)amino]phenyl}-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate;
8-azabicyclo[3.2.1]oct-3-ylmethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[1-(3-bromophenyl)-5-oxopyrrolidin-2-yl]-1H-benzimidazol-2-yl}carbamate;
(1-methylpiperidin-4-yl)methyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
1,1-dimethylethyl 4-({[({5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}amino)carbonyl]oxy}methyl)piperidine-1-carboxylate;
(1-methylpiperidin-4-yl)methyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-(1-methylpiperidin-4-yl)ethyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl ({6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}amino)(oxo)acetate;
N-(5-{1-hydroxy-3-oxo-2-[3-(phenyloxy)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)-4-piperidin-1-ylbutanamide;
methyl {6-[2-(3-bromophenyl)-1-methyl-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
4-(diethylamino)but-2-yn-1-yl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-chloro-2,6-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-(2-oxopyrrolidin-1-yl)ethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-(2,5-dioxopyrrolidin-1-yl)ethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2,2,3,3-tetrafluorocyclobutyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
1-acetyl-N-{5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}piperidine-4-carboxamide;

N-{5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}cyclobutanecarboxamide;
methyl [5-(2-{3-[ethyl(phenyl)amino]phenyl}-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl]carbamate;
N-{6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-2,2-difluorocyclopropanecarboxamide;
cyclobutyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2,2-difluoroethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-[2-(pyridin-2-ylamino)-1H-benzimidazol-5-yl]-2,3-dihydro-1H-isoindol-1-one;
1-methylethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
cyclopropylmethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
N-{5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}cyclopropanecarboxamide;
2-(methyloxy)ethyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
tetrahydrofuran-2-ylmethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
N-{5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-2-(2-thienyl)acetamide;
methyl {6-[2-(3-chloro-2-fluorophenyl)-4,7-difluoro-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
ethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-fluoroethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl (5-{1-hydroxy-3-oxo-2-[2-(phenyloxy)phenyl]-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
N'-{5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}-N,N-diethylpentanediamide;
cyclobutylmethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;

2,2,2-trifluoroethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl (5-{2-[3-(1,1-dimethylethyl)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl {6-[2-(3-chloro-2-fluorophenyl)-7-fluoro-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-[2-(phenylamino)-1H-benzimidazol-5-yl]-2,3-dihydro-1H-isoindol-1-one;
methyl {6-[4,7-dichloro-2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
phenylmethyl 2-[(2-{[(ethyloxy)carbonyl]amino}-1,3-benzoxazol-5-yl)carbonyl]benzoate;
methyl {5-[2-(5-chloro-3-ethynyl-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(5-ethynyl-2,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-ethynyl-2,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-[2-(pyrimidin-2-ylamino)-1H-benzimidazol-5-yl]-2,3-dihydro-1H-isoindol-1-one;
methyl {5-[2-(3-ethynyl-2-fluorophenyl)-4,7-difluoro-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-[2-(1,3-thiazol-2-ylamino)-1H-benzimidazol-5-yl]-2,3-dihydro-1H-isoindol-1-one;
ethyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1,3-benzoxazol-2-yl}carbamate;
methyl {5-[2-(5-chloro-3-iodo-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-ethyl-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(5-ethynyl-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-[2-(pyrazin-2-ylamino)-1H-benzimidazol-5-yl]-2,3-dihydro-1H-isoindol-1-one;
methyl {5-[2-(2-fluoro-3-iodophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;

methyl {6-[2-(5-ethynyl-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-(3-ethynyl-2-fluorophenyl)-3-hydroxy-3-[2-(pyrimidin-2-ylamino)-1H-benzimidazol-5-yl]-2,3-dihydro-1H-isoindol-1-one;
methyl {5-[2-(2,5-dimethylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-ethenyl-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl (6-{2-[2-fluoro-3-(methyloxy)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{1-hydroxy-2-[2-methyl-5-(methyloxy)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl {5-[2-(3-ethynyl-2-fluorophenyl)-7-fluoro-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(2-fluoro-3-prop-1-yn-1-ylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(5-chloro-2-methylphenyl)-7-fluoro-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-ethynyl-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
3-hydroxy-2-[3-(methyloxy)phenyl]-3-[2-(pyrimidin-2-ylamino)-1H-benzimidazol-6-yl]-2,3-dihydro-1H-isoindol-1-one;
3-hydroxy-2-(3-methylphenyl)-3-[2-(pyrimidin-2-ylamino)-1H-benzimidazol-6-yl]-2,3-dihydro-1H-isoindol-1-one;
2-(5-chloro-2-methylphenyl)-3-hydroxy-3-[2-(pyrimidin-2-ylamino)-1H-benzimidazol-6-yl]-2,3-dihydro-1H-isoindol-1-one;
methyl {6-[2-(5-chloro-2-methylphenyl)-4,7-difluoro-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
methyl {5-[2-(3-ethynyl-2-fluorophenyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-(3-chloro-2-fluorophenyl)-3-{2-[(6-chloropyridazin-3-yl)amino]-1H-benzimidazol-5-yl}-3-hydroxy-2,3-dihydro-1H-isoindol-1-one;
2-(3-chloro-2-fluorophenyl)-4,7-difluoro-3-hydroxy-3-[2-(pyrimidin-2-ylamino)-1H-benzimidazol-5-yl]-2,3-dihydro-1H-isoindol-1-one;
methyl {5-[2-(2-fluoro-5-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;

methyl (5-{2-[2-fluoro-5-(methyloxy)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl (5-{1-hydroxy-2-[5-methyl-2-(methyloxy)phenyl]-3-oxo-2,3-dihydro-1H-isoindol-1-yl}-1H-benzimidazol-2-yl)carbamate;
methyl {5-[2-(3-ethynyl-5-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
2-(3-chloro-2-fluorophenyl)-3-{2-[(5-chloropyrimidin-2-yl)amino]-1H-benzimidazol-5-yl}-3-hydroxy-2,3-dihydro-1H-isoindol-1-one;
2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-{2-[(4-methylpyrimidin-2-yl)amino]-1H-benzimidazol-5-yl}-2,3-dihydro-1H-isoindol-1-one;
3-(2-{[4,6-bis(methyloxy)pyrimidin-2-yl]amino}-1H-benzimidazol-5-yl)-2-(3-chloro-2-fluorophenyl)-3-hydroxy-2,3-dihydro-1H-isoindol-1-one;
2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-(2-{[4-methyl-6-(methyloxy)pyrimidin-2-yl]amino}-1H-benzimidazol-5-yl)-2,3-dihydro-1H-isoindol-1-one;
3-hydroxy-2-(3-methylphenyl)-3-[2-(pyrazin-2-ylamino)-1H-benzimidazol-6-yl]-2,3-dihydro-1H-isoindol-1-one;
2-(5-chloro-2-methylphenyl)-3-hydroxy-3-[2-(pyrazin-2-ylamino)-1H-benzimidazol-6-yl]-2,3-dihydro-1H-isoindol-1-one;
methyl {6-[2-(2-fluoro-3-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate;
3-hydroxy-2-[3-(methyloxy)phenyl]-3-[2-(pyrazin-2-ylamino)-1H-benzimidazol-5-yl]-2,3-dihydro-1H-isoindol-1-one;
methyl {6-[(2-{[(2-thienylmethyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(3-methylphenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(3-bromophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(3-chlorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(3-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl (6-{[2-({[3-(methyloxy)phenyl]amino}carbonyl)phenyl]carbonyl}-1H-benzimidazol-2-yl)carbamate;
methyl (6-{[2-({[3-(trifluoromethyl)phenyl]amino}carbonyl)phenyl]carbonyl}-1H-benzimidazol-2-yl)carbamate;

methyl {6-[(2-{[(3-ethylphenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(3-ethynylphenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(3-chloro-4-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(5-chloro-2-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(3-iodophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl (6-{[2-({[3-(1-methylethyl)phenyl]amino}carbonyl)phenyl]carbonyl}-1H-benzimidazol-2-yl)carbamate;
methyl {6-[(2-{[(3-thienylmethyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(3-bromo-4-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(3-chloro-2-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(4-fluoro-3-methylphenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(5-bromo-2-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(5-bromo-2,4-difluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(5-chloro-2,4-difluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(3-bromo-2-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(3-ethenylphenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(3-ethynyl-2-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(5-chloro-2-methylphenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(5-bromo-2-methylphenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;

methyl {6-[(2-{[(2-fluoro-3-iodophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(3-ethenyl-2-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
methyl {6-[(2-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[3-(diethylamino)propyl]-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4,6-triamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[2-(diethylamino)ethyl]-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4,6-triamine;
N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(3S)-3-methylpiperazin-1-yl]pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-{[2-(dimethylamino)ethyl]oxy}-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
N4-[3-(1-methylethyl)-1H-pyrazol-5-yl]-6-[(1-methylpyrrolidin-3-yl)oxy]-N2-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-(3-cyclopropyl-1H-pyrazol-5-yl)-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(1-methylpyrrolidin-3-yl)oxy]pyrimidine-2,4-diamine;
N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[3-(1-methylethyl)-1H-pyrazol-5-yl]-6-[(1-methylpyrrolidin-3-yl)oxy]pyrimidine-2,4-diamine;
N4-[2-(diethylamino)ethyl]-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N6-[5-(1-methylethyl)-1H-pyrazol-3-yl]pyrimidine-2,4,6-triamine;
N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]pyrimidine-2,4-diamine;
N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]-N2-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine;
N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-2-{[(3-phenylisoxazol-5-yl)methyl]oxy}pyrimidin-4-amine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(4-phenyl-1H-imidazol-2-yl)methyl]pyrimidine-2,4-diamine;
6-{[2-(dimethylamino)ethyl]oxy}-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]pyrimidine-2,4-diamine;
N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(2-morpholin-4-ylethyl)oxy]pyrimidine-2,4-diamine;

N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(2-morpholin-4-ylethyl)oxy]-N2-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-[3-(1-methylethyl)-1H-pyrazol-5-yl]-N2-[(3-phenylisoxazol-5-yl)methyl]-6-[(2-piperidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;
N4-[3-(diethylamino)propyl]-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N6-[5-(1-methylethyl)-1H-pyrazol-3-yl]pyrimidine-2,4,6-triamine;
N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(3S)-3-methylpiperazin-1-yl]-N2-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-[2-(diethylamino)ethyl]-N6-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine;
N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-4-yl)oxy]-N2-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(2-morpholin-4-ylethyl)oxy]pyrimidine-2,4-diamine;
N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[3-(1-methylethyl)-1H-pyrazol-5-yl]-6-[(2-piperidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;
N4-(3-cyclopropyl-1H-pyrazol-5-yl)-6-[3-(diethylamino)propyl]-N2-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-(3-cyclopropyl-1H-pyrazol-5-yl)-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(2-piperidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine;
N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[3-(1-methylethyl)-1H-pyrazol-5-yl]-6-[(1-methylpiperidin-4-yl)oxy]pyrimidine-2,4-diamine;
N4-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methyl-N2-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-(3-cyclopropyl-1H-pyrazol-5-yl)-N2-[(3-methylisoxazol-5-yl)methyl]-6-morpholin-4-ylpyrimidine-2,4-diamine;
N4-(3-cyclopropyl-1H-pyrazol-5-yl)-N2-[(3-methylisoxazol-5-yl)methyl]-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(1-methylpiperidin-4-yl)oxy]pyrimidine-2,4-diamine;
N4-(3-cyclopropyl-1H-pyrazol-5-yl)-N2-{[3-(4-fluorophenyl)isoxazol-5-yl]methyl}-6-morpholin-4-ylpyrimidine-2,4-diamine;
N4-(3-cyclopropyl-1H-pyrazol-5-yl)-N2-{[3-(4-fluorophenyl)isoxazol-5-yl]methyl}-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine;

N4-(3-cyclopropyl-1H-pyrazol-5-yl)-N2-{[3-(4-fluorophenyl)isoxazol-5-yl]methyl}-6-[(2-morpholin-4-ylethyl)oxy]pyrimidine-2,4-diamine;
N2-{[3-(4-fluorophenyl)isoxazol-5-yl]methyl}-N4-[3-(1-methylethyl)-1H-pyrazol-5-yl]-6-morpholin-4-ylpyrimidine-2,4-diamine;
N2-{[3-(4-fluorophenyl)isoxazol-5-yl]methyl}-N4-[3-(1-methylethyl)-1H-pyrazol-5-yl]-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine;
N2-{[3-(4-fluorophenyl)isoxazol-5-yl]methyl}-N4-[3-(1-methylethyl)-1H-pyrazol-5-yl]-6-[(2-morpholin-4-ylethyl)oxy]pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(3-pyridin-3-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-N2-[(3-pyridin-2-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-morpholin-4-yl-N2-[(3-pyridin-2-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-piperazin-1-ylpyrimidine-2,4-diamine;
6-(4-acetylpiperazin-1-yl)-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[4-(methylsulfonyl)piperazin-1-yl]pyrimidine-2,4-diamine;
4-{6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-({[3-(1-methylethyl)isoxazol-5-yl]methyl}amino)pyrimidin-4-yl}piperazine-1-carbaldehyde;
N4-(3-methyl-1H-pyrazol-5-yl)-6-morpholin-4-yl-N2-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
6-(4-methylpiperazin-1-yl)-N4-(3-methyl-1H-pyrazol-5-yl)-N2-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-(3-methyl-1H-pyrazol-5-yl)-6-[(2-morpholin-4-ylethyl)oxy]-N2-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(3-pyridin-4-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-{[3-(3,4-difluorophenyl)isoxazol-5-yl]methyl}-6-methylpyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-{[3-(2,4-difluorophenyl)isoxazol-5-yl]methyl}-6-methylpyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(3-pyrazin-2-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;

5-chloro-N4-(3-cyclopropyl-1H-pyrazol-5-yl)-6-morpholin-4-yl-N2-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
5-chloro-N4-(3-cyclopropyl-1H-pyrazol-5-yl)-6-(4-methylpiperazin-1-yl)-N2-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N2-[(3-methylisoxazol-5-yl)methyl]-6-(4-methylpiperazin-1-yl)-N4-(3-methyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
N2-[(3-methylisoxazol-5-yl)methyl]-N4-(3-methyl-1H-pyrazol-5-yl)-6-morpholin-4-ylpyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-N2-[(3-pyrimidin-4-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-furan-3-ylisoxazol-5-yl)methyl]-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-N2-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)-N2-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
N4-bicyclo[2.2.1]hept-2-yl-N6-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4,6-triamine;
N4-bicyclo[2.2.1]hept-2-yl-N6-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methylisoxazol-5-yl)methyl]-6-[(1R,4R)-5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(1R,4R)-5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-morpholin-4-yl-N2-[(3-pyrimidin-4-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-{[2-(dimethylamino)ethyl]oxy}-N2-[(3-pyrimidin-4-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-{[3-(5-fluoropyridin-2-yl)isoxazol-5-yl]methyl}-6-methylpyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-N2-{[3-(2-thienyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-{[2-(dimethylamino)ethyl]oxy}-N2-[(3-pyridin-2-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;

N4-(3-cyclopropyl-1H-pyrazol-5-yl)-6-(4-methylpiperazin-1-yl)-N2-[(3-pyrimidin-5-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-(3-cyclopropyl-1H-pyrazol-5-yl)-6-morpholin-4-yl-N2-[(3-pyrimidin-5-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-{[2-(diethylamino)ethyl]oxy}-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(2-pyrrolidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-{[2-(diethylamino)ethyl]oxy}-N2-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methylisoxazol-5-yl)methyl]-6-[(2-pyrrolidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-N2-{[3-(1,3-thiazol-2-yl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
N4-(3-cyclopropyl-1H-pyrazol-5-yl)-6-[2-(dimethylamino)ethoxy]-N2-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
6-{[2-(dimethylamino)ethyl]oxy}-N2-[(3-methylisoxazol-5-yl)methyl]-N4-(3-methyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
6-{[2-(diethylamino)ethyl]oxy}-N2-[(3-methylisoxazol-5-yl)methyl]-N4-(3-methyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
N2-[(3-methylisoxazol-5-yl)methyl]-N4-(3-methyl-1H-pyrazol-5-yl)-6-[(2-pyrrolidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;
N4-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methyl-N2-[2-(3-phenylisoxazol-5-yl)ethyl]pyrimidine-2,4-diamine;
N4-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methyl-N2-[1-(3-phenylisoxazol-5-yl)ethyl]pyrimidine-2,4-diamine;
N4-(3-cyclopropyl-1H-pyrazol-5-yl)-N2-[(3-ethylisoxazol-5-yl)methyl]-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine;
N4-(3-cyclopropyl-1H-pyrazol-5-yl)-N2-[(3-ethylisoxazol-5-yl)methyl]-6-morpholin-4-ylpyrimidine-2,4-diamine;
N4-(3-cyclopropyl-1H-pyrazol-5-yl)-6-{[2-(dimethylamino)ethyl]oxy}-N2-[(3-ethylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-(3-cyclopropyl-1H-pyrazol-5-yl)-6-{[2-(diethylamino)ethyl]oxy}-N2-[(3-ethylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N4-(3-cyclopropyl-1H-pyrazol-5-yl)-N2-[(3-ethylisoxazol-5-yl)methyl]-6-[(2-pyrrolidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;

N2-{[3-(2-aminopyrimidin-4-yl)isoxazol-5-yl]methyl}-N4-(3-cyclopropyl-1H-pyrazol-5-yl)-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine;
N4-(3-cyclopropyl-1H-pyrazol-5-yl)-6-(4-ethylpiperazin-1-yl)-N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
2-(1-{6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-({[3-(1-methylethyl)isoxazol-5-yl]methyl}amino)pyrimidin-4-yl}piperidin-4-yl)ethanol;
2-(4-{6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-({[3-(1-methylethyl)isoxazol-5-yl]methyl}amino)pyrimidin-4-yl}piperazin-1-yl)ethanol;
NAME
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methyl-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~6~-methyl-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine;
6-methyl-N~4~-[3-(1-methylethyl)-1H-pyrazol-5-yl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-(methyloxy)-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-5-methyl-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-phenyl-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]-6-(propyloxy)pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~2~-[3,5-bis(methyloxy)phenyl]-5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine;
5-bromo-N~4~-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(4-morpholin-4-ylphenyl)pyrimidine-2,4-diamine;
N~4~-(3-cyclopentyl-1H-pyrazol-5-yl)-6-methyl-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;

5-bromo-N~4~-(3-methyl-1H-pyrazol-5-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~2~-[4-(aminomethyl)phenyl]-5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine;
N~2~-(2-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methylpyrimidine-2,4-diamine;
N-[3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-4-chlorophenyl]acetamide;
5-bromo-N~4~-(5-methylisoxazol-3-yl)-N~2~-(4-morpholin-4-ylphenyl)pyrimidine-2,4-diamine;
3-[4-({5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-[2-(diethylamino)ethyl]propanamide;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-(2,3-dihydro-1H-inden-1-yl)pyrimidine-2,4-diamine;
5-bromo-N~2~-(4-morpholin-4-ylphenyl)-N~4~-phenylpyrimidine-2,4-diamine;
3-[4-({5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-(1-methylethyl)propanamide;
4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-(1-methylpiperidin-4-yl)benzamide;
N~2~-(3-aminophenyl)-5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
3-[3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-[2-(diethylamino)ethyl]propanamide;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{[2-(methyloxy)phenyl]methyl}pyrimidine-2,4-diamine;
2-[4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-[2-(diethylamino)ethyl]acetamide;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrimidine-2,4-diamine;
3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl dimethylcarbamate;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-(1-phenylethyl)pyrimidine-2,4-diamine;

5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]phenyl}pyrimidine-2,4-diamine;
3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-[2-(diethylamino)ethyl]benzamide;
4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-[2-(diethylamino)ethyl]benzamide;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-methylpyrimidin-2-yl}amino)phenyl]-N-(2-pyrrolidin-1-ylethyl)propanamide;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~6~-[3-(diethylamino)propyl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-(4-methylpiperazin-1-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-(2-piperidin-1-ylethyl)propanamide;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~6~-[2-(diethylamino)ethyl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-morpholin-4-yl-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-(2-pyrrolidin-1-ylethyl)propanamide;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-methylpyrimidin-2-yl}amino)phenyl]-N-(3-pyrrolidin-1-ylpropyl)propanamide;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-methylpyrimidin-2-yl}amino)phenyl]-N-(3-piperidin-1-ylpropyl)propanamide;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-methylpyrimidin-2-yl}amino)phenyl]-N-[2-(diethylamino)ethyl]propanamide;
N~2~-[3,5-bis(methyloxy)phenyl]-5-bromo-N~4~-(5-methylisoxazol-3-yl)pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-{[2-(dimethylamino)ethyl]oxy}-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-(3-piperidin-1-ylpropyl)propanamide;
N-[3-({5-bromo-4-[(5-methylisoxazol-3-yl)amino]pyrimidin-2-yl}amino)-4-chlorophenyl]acetamide;
3-[4-({5-bromo-4-[(5-methylisoxazol-3-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-[2-(diethylamino)ethyl]propanamide;

5-bromo-N~4~-(3-methylisoxazol-5-yl)-N~2~-(4-morpholin-4-ylphenyl)pyrimidine-2,4-diamine;
3-[4-({5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-methylpropanamide;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[4-(dimethylamino)phenyl]pyrimidine-2,4-diamine;
4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-[(3R)-pyrrolidin-3-yl]benzamide;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
5-chloro-N~2~-(2-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~6~-[3-(diethylamino)propyl]pyrimidine-2,4,6-triamine;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-methylpyrimidin-2-yl}amino)phenyl]-N-(2-morpholin-4-ylethyl)propanamide;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-(3-pyrrolidin-1-ylpropyl)propanamide;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-[2-(diethylamino)ethyl]propanamide;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{4-[(3-morpholin-4-ylpropyl)oxy]phenyl}pyrimidine-2,4-diamine;
5-bromo-N~2~-[4-(dimethylamino)phenyl]-N~4~-phenylpyrimidine-2,4-diamine;
5-bromo-N~2~-[(3-bromoisoxazol-5-yl)methyl]-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)benzamide;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-methylpyrimidin-2-yl}amino)phenyl]-N-[3-(1H-imidazol-1-yl)propyl]propanamide;
4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-[3-(diethylamino)propyl]benzamide;
3-[4-({5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-[3-(diethylamino)propyl]propanamide;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
2-[4-({5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-[3-(diethylamino)propyl]acetamide;

5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(6-morpholin-4-ylpyridin-3-yl)pyrimidine-2,4-diamine;
N~2~-[(3-cyclohexylisoxazol-5-yl)methyl]-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methylpyrimidine-2,4-diamine;
5-bromo-N~2~-(2-bromophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{2-[(trifluoromethyl)oxy]phenyl}pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{4-[3-(4-methylpiperazin-1-yl)-3-oxopropyl]phenyl}pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-(2-methylphenyl)pyrimidine-2,4-diamine;
N~2~-(4-aminophenyl)-5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[4-(methyloxy)phenyl]pyrimidine-2,4-diamine;
3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-[(3S)-pyrrolidin-3-yl]benzamide;
5-bromo-N~4~-(3-methyl-1H-pyrazol-5-yl)-N~2~-phenylpyrimidine-2,4-diamine;
4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamide;
1,1-dimethylethyl {[4-({5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)phenyl]methyl}carbamate;
3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-4-chlorobenzamide;
5-bromo-N~2~-(2-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
5-bromo-N~2~-[2-chloro-5-(methyloxy)phenyl]-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
3-[3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-(1-methylethyl)propanamide;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{3-[3-(4-methylpiperazin-1-yl)-3-oxopropyl]phenyl}pyrimidine-2,4-diamine;
5-chloro-N~2~-(2-chlorophenyl)-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine;

5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[2-(methyloxy)phenyl]pyrimidine-2,4-diamine;
2-[4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-methylacetamide;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(2,3-dihydro-1,4-benzodioxin-6-yl)pyrimidine-2,4-diamine;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-(2-morpholin-4-ylethyl)propanamide;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-[3-(1H-imidazol-1-yl)propyl]propanamide;
3-[3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-[3-(diethylamino)propyl]propanamide;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(1S)-1-phenylethyl]pyrimidine-2,4-diamine;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-methylpyrimidin-2-yl}amino)phenyl]-N-(3-morpholin-4-ylpropyl)propanamide;
N~6~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~4~,N~4~-dimethyl-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-methylpyrimidin-2-yl}amino)phenyl]-N,N-dimethylpropanamide;
5-bromo-N~4~-(2-chlorophenyl)-N~2~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
2-[4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-(1-methylethyl)acetamide;
5-bromo-N~4~-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N~2~-phenylpyrimidine-2,4-diamine;
4-({5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)benzonitrile;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-(2-methylpropyl)pyrimidine-2,4-diamine;
N~2~-[2,5-bis(methyloxy)phenyl]-5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
5-bromo-N,N'-diphenylpyrimidine-2,4-diamine;
5-bromo-N~2~-(2-bromo-4-fluorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;

5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-phenylpyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[3-(methyloxy)phenyl]pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}pyrimidine-2,4-diamine;
3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-[3-(diethylamino)propyl]benzamide;
3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)benzamide;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{3-[(4-methylpiperazin-1-yl)carbonyl]phenyl}pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-naphthalen-1-ylpyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[2-(methylthio)phenyl]pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-1H-indol-5-ylpyrimidine-2,4-diamine;
5-bromo-N,N'-bis(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(2-methyl-1,3-thiazol-5-yl)methyl]pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(2,3-dichlorophenyl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(furan-2-ylmethyl)pyrimidine-2,4-diamine;
N~2~-(2-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-5-methylpyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[4-(morpholin-4-ylsulfonyl)phenyl]pyrimidine-2,4-diamine;
1,1-dimethylethyl (3S)-3-({[3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]carbonyl}amino)pyrrolidine-1-carboxylate;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(5-methylfuran-2-yl)methyl]pyrimidine-2,4-diamine;
5-bromo-N~2~-(4-bromo-2-chlorophenyl)-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine;

5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[2-(1H-pyrrol-1-yl)phenyl]pyrimidine-2,4-diamine;
1,1-dimethylethyl (3R)-3-({[4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]carbonyl}amino)pyrrolidine-1-carboxylate;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)phenyl]-N-(3-morpholin-4-ylpropyl)propanamide;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[5-methyl-2-(methyloxy)phenyl]pyrimidine-2,4-diamine;
ethyl 2-[(2-chlorophenyl)amino]-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-nitropyrimidine-4-carboxylate;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{[3-(methyloxy)phenyl]methyl}pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(1S)-1-phenylpropyl]pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(2-phenylethyl)pyrimidine-2,4-diamine;
3-[4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-methylpyrimidin-2-yl}amino)phenyl]-N-[3-(4-methylpiperazin-1-yl)propyl]propanamide;
5-bromo-N~2~-[(4-chlorophenyl)methyl]-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
N~2~-(2-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-5-(trifluoromethyl)pyrimidine-2,4-diamine;
4-[(3-amino-1H-pyrazol-5-yl)oxy]-5-bromo-N-(4-morpholin-4-ylphenyl)pyrimidin-2-amine;
4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-methylpyrimidin-2-yl}amino)-N-(1-methylpiperidin-4-yl)benzamide;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-(1-methylethyl)pyrimidine-2,4-diamine;
5-chloro-N~4~-(2-chlorophenyl)-N~6~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[3-(diethylamino)propyl]pyrimidine-2,4,6-triamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-(pyridin-3-ylmethyl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(2,4-dibromophenyl)pyrimidine-2,4-diamine;
4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-(1-methylpiperidin-4-yl)benzamide;

5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[2-methyl-5-(1-methylethyl)phenyl]pyrimidine-2,4-diamine;
4-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)benzonitrile;
4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-methylpyrimidin-2-yl}amino)-N-[2-(diethylamino)ethyl]benzamide;
N~2~-(2-chlorophenyl)-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-5-fluoropyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[2-(2-thienyl)ethyl]pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(2,5-dibromophenyl)pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[4-(dimethylamino)phenyl]-5-methylpyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[4-(methyloxy)phenyl]methyl}pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-(2,3-dihydro-1H-inden-5-yl)pyrimidine-2,4-diamine;
4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-methylpyrimidin-2-yl}amino)-N-[3-(diethylamino)propyl]benzamide;
N~2~-(2-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~6~-[3-(diethylamino)propyl]pyrimidine-2,4,6-triamine;
4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-[2-(diethylamino)ethyl]benzamide;
5-bromo-N~2~-[(2-chlorophenyl)methyl]-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{[4-(4-methylpiperazin-1-yl)phenyl]methyl}pyrimidine-2,4-diamine;
N~2~-{[3,5-bis(methyloxy)phenyl]methyl}-5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(phenylmethyl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-(3-phenylpropyl)pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-5-methyl-N~2~-(4-morpholin-4-ylphenyl)pyrimidine-2,4-diamine;

5-bromo-N~2~-(2-chlorophenyl)-N~4~-1H-pyrazol-3-ylpyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{[4-(dimethylamino)phenyl]methyl}pyrimidine-2,4-diamine;
4-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-N-[3-(diethylamino)propyl]benzamide;
3-({5-bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)benzonitrile;
5-bromo-N~2~-(4-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(piperidin-4-ylmethyl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(1R)-1-phenylethyl]pyrimidine-2,4-diamine;
N~2~-{[2,5-bis(methyloxy)phenyl]methyl}-5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N~2~-{[2-(methyloxy)phenyl]methyl}pyrimidine-2,4-diamine;
5-bromo-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-(2,4-dichlorophenyl)pyrimidine-2,4-diamine;
N~2~-(2-chlorophenyl)-N~6~-(3-cyclopropyl-1H-pyrazol-5-yl)-9H-purine-2,6-diamine;
N~2~-(2-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[2-(2-thienyl)-1,3-thiazol-4-l]methyl}pyrimidine-2,4-diamine;
N~2~-(2-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4,5-triamine;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-methyl-N~2~-phenylpyrimidine-2,4-diamine;
2-[(2-chlorophenyl)amino]-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-N-(2-morpholin-4-ylethyl)-5-nitropyrimidine-4-carboxamide;
5-bromo-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[2-(1-methylethyl)phenyl]pyrimidine-2,4-diamine;
5-bromo-N~2~-(3-chlorophenyl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;

N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]-7-(phenylmethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N~2~-({3-[4-(methyloxy)phenyl]isoxazol-5-yl}methyl)pyrimidine-2,4-diamine;
2-[(2-chlorophenyl)amino]-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-N-(1-methylethyl)-5-nitropyrimidine-4-carboxamide;
N~2~-[3,5-bis(methyloxy)phenyl]-N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methylpyrimidine-2,4-diamine;
N-[4-({4-(4-methylpiperazin-1-yl)-6-[(3-methyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}thio)phenyl]cyclopropanecarboxamide;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methyl-N~2~-[3-(methyloxy)-5-nitrophenyl]pyrimidine-2,4-diamine;
N-{[3-(4-amino-5-{3-[(phenylmethyl)oxy]phenyl}-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclobutyl]methyl}acetamide;
N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-morpholin-4-yl-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-methylpiperazin-1-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N~2~-[(3-pyridin-2-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(2-morpholin-4-ylethyl)oxy]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-({[(2S)-1-methylpyrrolidin-2-yl]methyl}oxy)-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(3S)-3-methylpiperazin-1-yl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(1-methylpiperidin-4-yl)oxy]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-morpholin-4-ylpyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]-6-[(2-piperidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;
N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~6~-[2-(4-methylpiperazin-1-yl)ethyl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine;

N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]-N~6~-(2-pyrrolidin-1-ylethyl)pyrimidine-2,4,6-triamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(3R)-3-methylpiperazin-1-yl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(3-phenylisoxazol-5-yl)methyl]-6-[(2-pyrrolidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(1-methylpyrrolidin-3-yl)oxy]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(1-methylpiperidin-3-yl)oxy]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
6-{[2-(dimethylamino)ethyl]oxy}-N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-morpholin-4-ylpyrimidine-2,4-diamine;
6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-{[(3-phenylisoxazol-5-yl)methyl]amino}-N-(2-pyrrolidin-1-ylethyl)pyrimidine-4-carboxamide;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methyl-N~2~-[(5-phenylisoxazol-3-yl)methyl]pyrimidine-2,4-diamine;
5-bromo-N~2~-(4-morpholin-4-ylphenyl)-N~4~-[4-(2-pyrrolidin-1-ylethyl)phenyl]pyrimidine-2,4-diamine;
6-methyl-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]pyrimidine-2,4-diamine;
5-bromo-N~2~-(4-morpholin-4-ylphenyl)-N~4~-[4-(2-piperidin-1-ylethyl)phenyl]pyrimidine-2,4-diamine;
6-chloro-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]pyrimidine-2,4-diamine;
N~2~-(2-amino-2,3-dihydro-1H-inden-5-yl)-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methylpyrimidine-2,4-diamine;
N~2~-[4-(2-aminoethyl)phenyl]-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methylpyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methyl-N~2~-[4-(2-pyrrolidin-1-ylethyl)phenyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methyl-N~2~-(4-piperidin-4-ylphenyl)pyrimidine-2,4-diamine;

N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(3R)-3-methylpiperazin-1-yl]pyrimidine-2,4-diamine;
N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N~6~-[2-(4-methylpiperazin-1-yl)ethyl]pyrimidine-2,4,6-triamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~6~-[2-(4-methylpiperazin-1-yl)ethyl]pyrimidine-2,4,6-triamine;
N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N~6~-[2-(4-methylpiperazin-1-yl)ethyl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~6~-[2-(diethylamino)ethyl]-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4,6-triamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-{[2-(dimethylamino)ethyl]oxy}-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
N~4~-[3-(1-methylethyl)-1H-pyrazol-5-yl]-6-[(1-methylpyrrolidin-3-yl)oxy]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(1-methylpyrrolidin-3-yl)oxy]pyrimidine-2,4-diamine;
N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[3-(1-methylethyl)-1H-pyrazol-5-yl]-6-[(1-methylpyrrolidin-3-yl)oxy]pyrimidine-2,4-diamine;
N~4~-[2-(diethylamino)ethyl]-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~6~-[5-(1-methylethyl)-1H-pyrazol-3-yl]pyrimidine-2,4,6-triamine;
N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine;
6-{[2-(dimethylamino)ethyl]oxy}-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]pyrimidine-2,4-diamine;
N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(2-morpholin-4-ylethyl)oxy]pyrimidine-2,4-diamine;
N~4~-[3-(1-methylethyl)-1H-pyrazol-5-yl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]-6-[(2-piperidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;
N~4~-[3-(diethylamino)propyl]-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~6~-[5-(1-methylethyl)-1H-pyrazol-3-yl]pyrimidine-2,4,6-triamine;
N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(3S)-3-methylpiperazin-1-yl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-4-yl)oxy]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(2-morpholin-4-ylethyl)oxy]pyrimidine-2,4-diamine;

N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[3-(1-methylethyl)-1H-pyrazol-5-yl]-6-[(2-piperidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-[3-(diethylamino)propyl]-N~2~-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(2-piperidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;
N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N~4~-[3-(1-methylethyl)-1H-pyrazol-5-yl]-6-[(1-methylpiperidin-4-yl)oxy]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-methyl-N~2~-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(3-methylisoxazol-5-yl)methyl]-6-morpholin-4-ylpyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(3-methylisoxazol-5-yl)methyl]-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(1-methylpiperidin-4-yl)oxy]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-{[3-(4-fluorophenyl)isoxazol-5-yl]methyl}-6-morpholin-4-ylpyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-N~2~-[(3-pyridin-2-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-morpholin-4-yl-N~2~-[(3-pyridin-2-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-piperazin-1-ylpyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[4-(methylsulfonyl)piperazin-1-yl]pyrimidine-2,4-diamine;
4-{6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-({[3-(1-methylethyl)isoxazol-5-yl]methyl}amino)pyrimidin-4-yl}piperazine-1-carbaldehyde;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N~2~-[(3-pyrazin-2-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~2~-[(3-methylisoxazol-5-yl)methyl]-6-(4-methylpiperazin-1-yl)-N~4~-(3-methyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine;
N~2~-[(3-methylisoxazol-5-yl)methyl]-N~4~-(3-methyl-1H-pyrazol-5-yl)-6-morpholin-4-ylpyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-N~2~-[(3-pyrimidin-4-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;

N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(3-furan-3-ylisoxazol-5-yl)methyl]-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~6~-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-N~2~-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)-N~2~-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
N~4~-bicyclo[2.2.1]hept-2-yl-N~6~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4,6-triamine;
N~4~-bicyclo[2.2.1]hept-2-yl-N~6~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(3-methylisoxazol-5-yl)methyl]-6-[(1R,4R)-5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(1R,4R)-5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-morpholin-4-yl-N~2~-[(3-pyrimidin-4-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-{[2-(dimethylamino)ethyl]oxy}-N~2~-[(3-pyrimidin-4-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-N~2~-{[3-(2-thienyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-{[2-(diethylamino)ethyl]oxy}-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(2-pyrrolidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-{[2-(diethylamino)ethyl]oxy}-N~2~-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-N~2~-[(3-methylisoxazol-5-yl)methyl]-6-[(2-pyrrolidin-1-ylethyl)oxy]pyrimidine-2,4-diamine;
N~4~-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-N~2~-{[3-(1,3-thiazol-2-yl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-{[2-(dimethylamino)ethyl]oxy}-N~2~-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(3-ethylisoxazol-5-yl)methyl]-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine;

N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(3-ethylisoxazol-5-yl)methyl]-6-morpholin-4-ylpyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-{[2-(dimethylamino)ethyl]oxy}-N~2~-[(3-ethylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine;
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-6-{[2-(diethylamino)ethyl]oxy}-N~2~-[(3-ethylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine; and
N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)-N~2~-[(3-ethylisoxazol-5-yl)methyl]-6-[(2-pyrrolidin-1-ylethyl)oxy]pyrimidine-2,4-diamine.

5